<SEC-DOCUMENT>0001048477-23-000009.txt : 20230227
<SEC-HEADER>0001048477-23-000009.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227172552
ACCESSION NUMBER:		0001048477-23-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		23676771

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bmrn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72,d:b1aad3959e884c01b6a07e04db98b99b--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:bmrn="http://www.bmrn.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bmrn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF8yLTEtMS0xLTc3NjM4_99b3a40a-0df8-4c79-b174-9088523ba171">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF8zLTEtMS0xLTgyOTQ2_f5bc20e5-6a2b-4c4d-8d26-42ce70fee556">2022</ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF80LTEtMS0xLTc3NjM4_11bb98dd-f125-46d7-bda8-ed964a68b179">FY</ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF81LTEtMS0xLTc3NjM4_9975fbf1-2caf-4463-af47-0049ac13ecea">0001048477</ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:SpanOfOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13">P24M</ix:nonNumeric><ix:nonNumeric contextRef="i529f551790304de7a1f979501912d7bf_D20220101-20221231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i94ae8ab120e1442b9b2b47f85170d9db_D20210101-20211231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="icc7acb734e7a46518521815a0e658880_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8yMTQyL2ZyYWc6ODIxNGVmOGVjMTJlNDk2Nzk3YTA2NjBlNTA3ZDhjMjEvdGV4dHJlZ2lvbjo4MjE0ZWY4ZWMxMmU0OTY3OTdhMDY2MGU1MDdkOGMyMV8zODQ4MjkwNjk3Njk1_57296b6e-53a2-4c5c-9419-0969537f7b00">0.0072743</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8yMTQyL2ZyYWc6ODIxNGVmOGVjMTJlNDk2Nzk3YTA2NjBlNTA3ZDhjMjEvdGV4dHJlZ2lvbjo4MjE0ZWY4ZWMxMmU0OTY3OTdhMDY2MGU1MDdkOGMyMV8xNjQ5MjY3NDQyMjI0_99103c13-7f7c-4daf-b139-d45fd58f77da">.0080212</ix:nonFraction><ix:nonNumeric contextRef="i529f551790304de7a1f979501912d7bf_D20220101-20221231" name="bmrn:IncomeTaxStatuteOfLimitationsPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NjY_b6dc29f0-a3a7-485e-8db1-2fd76231c141">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bmrn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide07883475384c4c80f688861264b837_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ice67fd0aa4d94423bd076cc3f7bfe365_I20230216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib246871d78d94c228e7dec2d91f453a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6babf135cae34564ae9f1313c802cf9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58108302281b46cebd5051fdc34011c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8381a40443874d71bf070c391e0c7639_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730600aac0774220b24184631d3ca45a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6cf6d8813654851864101d16af22c9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6719d1697cfe461fbe7e1476076d5020_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09dd10764f7419a9a4650c424edaaf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b42c69baf241b0b203d3fa4c47e397_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ebf8a2e2374a5abb965688a2d10d21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6098bafbae9d4819be0567307e54bb0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662d4660c31e4fe99f786fb1fb315bcb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia44e8bd9c9b746cfbddaca2a0eb336ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12190384e734edabd0ce99df1427a69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70ebaa31f544fe581553f2fab670db8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037d2ed2bca94a4db141fccb8f4098cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094472930d474e9db0bb25616669cfaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778dfb0b1c9b4191b55f82d31f87abfb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45678d32ad246c5bc437806356fe440_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff477083f4d346f6ac8e1fca2a77ac95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3fd3335b8041b9b3010fb2ffa6e213_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4626a538858248e5b6ffc8ab8d43cffc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb05616fee644133b5237b50cb6c2646_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0c42bea91a4dc2a7a17b7338db6938_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d7235bf19146b596b6df0be03b57f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d3e943b1074224a9e5025c4dcc0935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d353eb18df493b84f05bd498c9b00b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f810b0c8fb345f4bfb8bcbade131882_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4459fe0e1d3a4f18891f7db2ecc5a055_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436459593c174d1e9727d5e56761f15e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d3c22869c8421394b488a8626e5406_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808e908af0344804823d766893b68cc5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i104acad50b8a4571a58be492b9d7df86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54cd08c98774db68e3cb795308fff9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d01a3eb633442b8a24963b9a15b0f21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7875a67714c6452c84f63885164473d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id485da7dafae40ddabd0f37725dd651a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23b0b2b780d494282ba40678c605752_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02848a53e7a45cba266b90b81b13c5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba09bd3b78014fbfa684be4eb9247536_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb34c9bea594b0eabc679077dde1e28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02be9ecdb8dc4d27a02fe43f8746d284_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297dbbe3b39e4ab6a4b37e0a86515b1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4230919f8e50464c89c33c99ae0bba5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0c13891df446e79adeb971585c3cb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7c5b90e497444cab72b951983c3c835_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab00f1aa61d4a799d6596e92e9ea772_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b7329ecd8e4081bb41b08925e77b86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfee12a83d534677a3997b39f21b3db2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f07c323c9ed43ab9344a7d19cd1632a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd55ebfa48d4b8e91fb580564bc2ebf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52310aa2a3a247b697aa20cecbad91fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6c3ef715354e01be0ce46fef7ade7d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eedfe89ea9847a1b1177eebb3b74933_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b1e6d47d184565b72aec37b1bad113_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d169bd2b3f74f53a7bf1f5cccef2259_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bea8c595cc8498f897680fba3204460_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3293e8e2731d413a88a25a0d3bb69545_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623384117ca2486288e722c61f359369_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e5affca8dd4c6290c3e523c042ca61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44211095b6f4687bae28103060052c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4068777477954ecd9a0dcd931dbcab88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>bmrn:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bmrn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i4983aee6ed6f40a097f55f2b514fc899_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i301449ebc7e54567b1a8e9d3529a7296_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3429f515a1f74193939e9ed2c23c5c04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b853a38b944bfea4923c8120facacb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c8137f742a475fbc0a9c6d4094825e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41682380abc342c0a800728472affb1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i160b43862b4443b8b71abb1941361269_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7401b5a80acd48d992723aa4414c7abe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561448975fb740788726f49b7214216d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7dfd70a907429b878635ece7bc1fd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a7f65a195224b5d827cb975542f273c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df4ef5fd4294091833bfc00f71675ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a56284d386d47d5b5eb46c28db68c52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529f551790304de7a1f979501912d7bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ae8ab120e1442b9b2b47f85170d9db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465f964e015842ad9df73023d86585b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6c18d583ad4920abd1d0bcfedc9627_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6943ad4dcf614dd68d73dc3e5298e4f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:AcquiredIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c33f2a42d5842a59975b6b1c2729669_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:AcquiredIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f59e0944d0043aa8bbc9c5903fda1f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:TechnologyTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f772ec89c942a7a3e166b25c359f88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:TechnologyTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7317f10ceb0c4e0cb47f102d6347f258_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:RepurchasedRoyaltyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2619b7b15f451e8c6ceb0626894102_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:RepurchasedRoyaltyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b044b28769473fa1bf7da098b3d52e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:LicensePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596215e6117a4f52b5c0d7d97a1ef282_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:LicensePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41fa8108fc04c34b1787046ebcdad40_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674d0d14122b41c48b74ae0001c8fd9d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c89fa21a6740b4ae70eb14c57b4658_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd0df068ef64e57beb016ebea921ad8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04df3be9f9247e0a45ecf03bf54bdcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba77569d60840a79ea41ac5cfaf6073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a01c0ded34748d0bce2340302388477_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib586210770d7493e9072422b6c53e69d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9296d886772647e196d034a5c7da7e16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38d7d015d9641a2afccceaff3825715_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0f8b8eab5543b8a5874a2155f9b22e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a6bb5565934ac188f62eb1cf6acf5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a99600f7613497d89438354f0bada80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521cb957123a469e9a9db648b7ecd32d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ba21556ac84294bfa877f64bdd66f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3380a5d1065a44fe975fa8e9b0e091ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b02b6e13e842f682a38f22a659d47f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f45be8b0d354e1e8b7391f4a5dd0d20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079459cd9ea04678bb91caba28143414_D20221006-20221006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-06</xbrli:startDate><xbrli:endDate>2022-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>bmrn:employee</xbrli:measure></xbrli:unit><xbrli:context id="i9644565e09324c2bbebec177f02b7bc7_I20221006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23981085b84481d8fc2be75b9fbd5db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37f7a71be894ef6bba5307f5c4f92c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46791bdce16445e6898c45c3fd47dc0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb2e8fd98e264368a035b1b756757df5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474ce592912e4ee484fa06718d15d2fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i499a122963a44c19831951e9e567eaa7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed072224703463aac2c7d7482c6ffb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4446cd995b344e0ba108320ca62f991_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f9d3b26b0d4fe587d64e56b034ed55_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846fa6c590bb43c9b2c023bbeee9119a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id956bf9fc1b44873ab5ad29095686daa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ce1991d8464caba76b61ad0d0a2227_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d3183b154e44b52ba30e133758be6a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0827b42d3347d0afe4307d1f64a381_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1697a254339d443f8484e8d6d3c078e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef36079c8034aeb9d95e92fa8da0e7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b8aa0219e04f549a524810fe170d31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18e735b9eb6e4c1083bb535a258b00f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9bbb374233424ba61bcc6ed8300a30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2160a34a98f34909b7b6148fe186d3a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f15a50eebbd49b0a6ac560862776c4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffc1b1354b24fe9ba6f0f76f2c77735_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6b493cf9db47da80212141f81c1d71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f30189483c422fa011c8cb6d4922bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04dda45e829740f79226f6631d6049eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9c061692ee4459bfff0add9bcd50a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1808bc04910249a8a0f00222d3bf7e02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff430fafcf154f4e812f7d333d1d8d7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb05d919991b4e81a5d5ffacd7d4969b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd451bf195104b4fa89b348031fa3c06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4aad42990645598a710e3fdc875927_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fa5863ad174cd78a94e49878481b58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf63f31c217048c0b0893f82f7a57cc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361e100279e84b2abd489b481fc38b7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc636c5add94dcdb064bdd55b0154bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce35887d4b441e7903b44b39adba651_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1739c85dcaf415cacb59ea7ea04ca80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bbdcfdf6d7f44e98151b2323cc59a91_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4cc530299f847d189a72330922c67cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b156ee48534e11b0e4ec467c89f063_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6630e8205694223b373923bba0b4d10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5347e22ccf064748b88e50f6bd0c2161_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ad5d6c2ce54eb183ff3585f491d96e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8acf9e28afb48f9a9b97f6033ce470a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i049d9f5eac174d9e9fb8daaf63a40764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd631e0c0be404fbdac1dbda30f94fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5453050b0674bbfaf495fdbe38838bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78357676b9ad4a62990f8ad0e3be1b8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701ea9c137b743d5b8fbcf9a4516ee31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e05c8915f6d4424a51797377fec49d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81ef93ba75f4c7f9a65f2262abc826c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2949967682844b40b3939cf685911572_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120af3133b724435b609f48a754ddc28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id034c5704d704b1899e0fe63a9b16d85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0459695791c54a5c9470c16c53c5e1b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5945041fd04f8fa60d89c188909d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda7870ff3904fafa6c5f6898f8ea22b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc8c32dfdf364e6ebfeca0e2dbe52145_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7810729b64f4f81ab7e6d7951dd41db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2249a32749024298ac14d49e5abc5209_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535f35b9a823419bbd09b248cdd5f011_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9fcf787fd284d24881b86f72e6d9c06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i929eedfedb93483daed0c9feb18c8083_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aabd222ee0c445889bc6c55761ef645_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99c4348a7ed4696a2143a068c963e32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5daf35554b6a433a843510d389717d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib36660209faa4d7ab26ebb76638229b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ac5b26310a44ef85642267c702776c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7acb734e7a46518521815a0e658880_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97af8e39d55a45988666e9a615166ab0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3514162b114cccb5bd4903da892d79_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica62b7ca7a3f4aee8d2b64beac63adb6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76aebdd53eb84ceab8638e5fb1ff8e9b_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3efb3be452cd4b8cb7fea7f3c05ba63e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e306c702cbb420eac9580746df9ae30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i618baef4a9c943558fad300e0bb46e9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6872ed12f9164d05957167fd36693e24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec53576eff54be9aebf7078e363312e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0e209b4cba44c8841984717c05fdfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6451fcf8cc42d5bbe8a6ac07fa5fa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa7db8b29e9457f93217ca8c42e681e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d843487721d43b7a6cf7175f69e01fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5dbb579b5f418cb0577509240e9084_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ff2134016c43a48d2be70284677ab2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c36fee11624160a9a8777da81c0128_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd084d19fafe4eb08800335bbaa0fdb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7e67f5a5634503ad5879c8009f97f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d2704044e74eec86232f6b5bbfa0a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d540593f644f2cb082a24558b3f758_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107111d003394f429df9bc3b7e72083a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766158ee331f4b6dad23cc139f408d52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice70b2f98d8f46ee95e52f2e5d8735cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbfc39daa5e4e86b8925b3c91e0a20f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc10f3a93ae418882d57641c30e6fa2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a42714856349788ac98ef18c9c4eec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58bdf6d90d34e0e9c7db18bf1df4dc1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509d47fe3d174696acd23ae2feb9495e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6660ddacf84f446083b9e0ca5bce39fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef27eef923e434e862de91ae5beafca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7292c071f44cd4ba482c581dbba9e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2ca389fb2d47f3991717f9e5b9757c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b179a96cee8425daa243c6ec126fa90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieded801c64bf44adb38c0af09661c7f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6399581bf17e49c697410cb0a73c682c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0245c8a131434573a4579c1ffa6fe178_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a7a34d6b8446b19864867ebc10546d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff71e7217274546b0d948f39fc97420_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503208303f7343d68d5b53c7fb08f251_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7039784a43724956bd81fdb85ade56d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32233365d594b308746b274d89d9e5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae042974731b47fa8462f91e2b1ce268_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b2cd85806b4c09a10ee05befb288eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec738639a3694be7b566566f59fefda1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afae57055d2464bbca1472128e2dd4b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde566a1a304443a9740252495984863_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b889898bba94b54af9a9335b9b82b62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia344194268dd43fd989b6b04a378902f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826dd83d81b24084b26e5b5cc42493b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie581ba1d1b064e6986a21f9ea9fdc7a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31425f01f73430a9a3aec5dfc86da0d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id209fbaf4cd14f198010a1f4ff75159e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ed09d29aa1432fa6575525ede1e854_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0770f55d5c104f969b9acc886090f5fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacafee45f91e46ebb714c46c2ff89823_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f95dec71974a66bbde2f90b523281c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e42fce28b14ebbb8a5a4411c1433ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e7695ed7954a5fb9f808089e78a85d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5749604fcebc42ada76e2e1b582da09c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ade8d0054c45b997b2f2e5fb9e1490_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4553d6d08ef849c8a72048bc17b8ed75_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca4f3f8044a4465aad5cc36317e02b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692965d349e34f3ea4acc8a50f53276d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e7463435974d1d98101460b30a9c62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843ac21f80f24e97b5709f27f83dc60c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6558cc5ad3094460971e3ff939e6623a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe58d8557902475b9ecb613007413f59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aadf30296f940eeb46c2095e3ef8568_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5fa7ec2b1541f2a9aecd40ae5ca28b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fea8ab604b143e89c4c4066ac2d10d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05278f7e11d545918819b0e5fd3de8f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ede14dcb48b4252953a1349a4dcdcd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc3eff93ecba4e9ab0b751bba0479273_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d4996c3e9141c19bf5436bd1dfe088_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6853f1a77d1449f9e25fc0db6cfd462_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic617813345644c10af3fae918e7bce97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4183315e314d4360bb0502134885d9dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93e432edc5048a0ac3ab95326ff5424_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bmrn:IndependentDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1445253420474375b7efe62ace67131e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934a6fe3c5d2413c87067ea339f198cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9c60963aff483fa114c7b304603a7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e06e2017d4b477e9b69593553036531_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12938f6823a94b1c837db430e15262c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5dda00a8514dd59ad5007c3cd8c578_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b264f9c740640838312c3dbd938c92e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dfc5eb6e4d04a6390d4d537c078c61f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5359457de041eaba77b73a3803bcfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77524339bb424d85b4d57ae104a84f24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf62fa1ecfd497ea4311496211dd174_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1572514829d644a68de7022821a70b1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16e0033fc1948dc9e1fa09a786eaa23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2a458d9fee49c6a103d0f775c380d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a7c1018d1f4444a8560a5468103fba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardNonGAAPIncomeTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26584ec2b88147ebad7a6bf69b3d15d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardCoreOperatingMarginTargetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f49f0589db4d3fa2f9f5fb5d1f4355_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardStrategicGoalTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0260b6f7eb4a6fb48d30eb32daec80_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4d086842524837b758a134e20de2d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595951030a5d4e73a012f1be549c5e5a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b318a52937403fb847cf89e01b77ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca3a5fc58404fb58b979773eea67088_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933002237df241fbaa8a2f1845212112_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9a014bff6d4b1096c43e4334589a74_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b49962d5a640488eada80fa0f8ae01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7db90010f7454bb02b375d36208b18_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974da25672b24547a1fb86cd010d66a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae9719aaf7c4895bd6972ec9d5a1cdd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46fdf7486a84e9f90ef98b86432eb8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee705d880c0c46c7808d9be2b86c9f85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia481385bca9741cb9627136de2e3b7a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88d13cac03446da910f4bdda092a94d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba90d1418dc34fbcbca22b21986af64b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58aaac40a42b4a7fb111583b886ae23f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1866f0f98b4968a4a0b7d8ec1061c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d5c058dd7843b99ec211cfd4eaef44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45d9cb0ae984b8a895192c71ec4dc6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33b1905895a4c0d9c697f26aee83f66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64eb5ac7ff2c441b8532f7bcb1ddab8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0acf8a65e32646eda1218b113bbf892f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i501529bab97849e78084830bdba9baf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af5d8557d8a40ae8beee5eedec3c302_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba0e7db091b498bbec2338419da0c3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942bc095adee430bad3ee06049a4834a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7eeb745948249f9b5df95030b886512_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d2632b90814ba38f50774fec161236_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3436f033fc741c0ad3de97901f0af87_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5762589687004ef6b263f4cd981bf8cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c68988441f541e28fb1eef7917f2f8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:AAndRKuvanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i894b46e6d24741dca61467eef21c957a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:AAndRKuvanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e41e511f7c45fab191013826ff05c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:PegvaliaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bmrn:FirdapseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e08db3d4814a13a6b9f06ccc018757_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5349719ab5245ecb53681104dd48921_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062 id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ib1aad3959e884c01b6a07e04db98b99b_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF85Nw_276847f5-5792-4f3b-b379-75cc1b84358b">10-K</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:2.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6MTM2MGU0MTQwNDM0NDk4NWIyMGQ5OWNkZDJmMGMzZjIvdGFibGVyYW5nZToxMzYwZTQxNDA0MzQ0OTg1YjIwZDk5Y2RkMmYwYzNmMl8wLTAtMS0xLTc3NjM4_16776248-afe5-412c-930e-0883c5d917a3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTcyMTU_e0781f0c-f332-40de-985f-48281bead921"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTcyMTU_c76f428a-e7cf-4b63-8851-99628025ebb0">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.120%"><tr><td style="width:1.0%"></td><td style="width:2.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YmYzMDVhNjlkOGFiNDkyYWJlODc2ODFmZTNiNjA4YWMvdGFibGVyYW5nZTpiZjMwNWE2OWQ4YWI0OTJhYmU4NzY4MWZlM2I2MDhhY18wLTAtMS0xLTc3NjM4_d6f711e8-083f-469d-a2ac-adc446fcb10d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commission file number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yNzI_0bf0fe16-8884-424a-9d26-6c0c99cdac7e">000-26727</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yODg_51898ec6-27c6-45a6-9eb8-0581e8184ce8">BioMarin Pharmaceutical Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.241%"><tr><td style="width:1.0%"></td><td style="width:22.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8wLTAtMS0xLTc3NjM4_1be002b3-2809-4e0a-aabb-d66199a40bc7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8wLTMtMS0xLTc3NjM4_2ee5570d-7daa-4cc5-9c39-5c026f699d43">68-0397820</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTAtMS0xLTc3NjM4_238d48ae-a981-4d3f-9078-61243a84b074">770 Lindaro Street</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTEtMS0xLTc3NjM4_7e97e571-6fc8-4170-b4bd-4e23b3a78ffe">San Rafael</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTItMS0xLTc3NjM4_5012ffbb-94f7-43da-8fe2-97f80304fcdf">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTMtMS0xLTc3NjM4_f2783805-ff4b-4af8-959a-7edcf0e5add1">94901</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zNDk_b5148955-1ad6-40b9-991b-56c717f62f4b">415</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zNTM_8363cf33-0d34-4fb8-9b57-94a7940956c1">506-6700</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:32.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTAtMS0xLTc3NjM4_f618c5a5-1ed2-48db-b92c-cdfd39bae452">Common Stock, par value $.001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTItMS0xLTc3NjM4_bacd4558-6f84-4e01-81e5-5523a1985e7b">BMRN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTQtMS0xLTc3NjM4_ad858214-fbcc-4cf8-9434-a855fae4fda3">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Securities registered under Section&#160;12(g) of the Act:</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF82NjU_a3c66453-177d-4698-aa74-599ee783566a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. &#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF84MTg_af09ee6a-3250-4f96-bf71-c90849bf931a">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8xMTcy_bcc9651f-0d18-4fe5-996c-a75e66e77098">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;<ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8xNTAw_befd0847-e8c7-4195-9eef-682ace4a9b98">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:26.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8wLTAtMS0xLTc3NjM4_ca47bd2b-8c33-4522-aaf1-026841c92aa1">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8xLTUtMS0xLTc3NjM4_4bb89103-8208-4bfc-a776-a9a25546c80b">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging Growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8yLTUtMS0xLTc3NjM4_f3665aab-8848-412f-9506-c1d401aa5b19">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zMzAx_2793640a-621a-49d0-9b85-8a5e9f986de8">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.)&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTQyMjY3_aac0a125-7e5f-464a-8a6e-addc906a0c8c">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ide07883475384c4c80f688861264b837_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yNzMx_19babcc5-2373-4316-a3c3-85ebad6225b2">9.0</ix:nonFraction>&#160;billion, based on the closing price reported for such date on the Nasdaq Global Select Market.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of February&#160;16, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ice67fd0aa4d94423bd076cc3f7bfe365_I20230216" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yODY1_ebfb458f-f3d3-4f57-a59f-9b4b8c96451b">186,528,784</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">shares of common stock, par value $0.001, outstanding.&#160;&#160;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Documents Incorporated by Reference: <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zMzAy_e0ee86a4-01fa-488c-9405-0c9e0339c20f" escape="true">Specified portions of the registrant's definitive proxy statement for the registrant's 2023 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2022, are incorporated by reference under Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 FORM 10-K ANNUAL REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_13">Part I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_19">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_22">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_25">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_28">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_31">56</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_34">Part II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_37">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_40">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_43">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_64">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_64">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_64">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_67">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_67">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_70">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_70">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_70">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_73">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_73">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_73">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_76">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_76">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_76">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_79">Item 9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_79">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_79">73</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_82">Part III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_85">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_85">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_85">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_88">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_88">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_88">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_91">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_91">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_91">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_94">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_94">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_94">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_97">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_97">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_97">74</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_100">Part IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_103">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_103">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_103">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_109">Item&#160;16.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_109">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_109">79</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_112">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_112">80</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless the context suggests otherwise, references in this Annual Report on Form 10-K to &#8220;BioMarin,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to BioMarin Pharmaceutical Inc. and, where appropriate, its wholly owned subsidiaries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, BRINEURA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, KUVAN</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, NAGLAZYME</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, PALYNZIQ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, VIMIZIM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and VOXZOGO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are our registered trademarks. ROCTAVIAN&#8482; is a trademark of BioMarin Pharmaceutical Inc. ALDURAZYME</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this report are the property of their respective owners.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; as defined under securities laws. Many of these statements can be identified by the use of terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;projects,&#8221; &#8220;continues,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; &#8220;opportunity&#8221; or the negative versions of these terms and other similar expressions. You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of our management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that we may issue in the future as well as other cautionary statements we have made and may make. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in the section titled &#8220;Risk Factors&#8221; in Part I, Item&#160;1A of this Annual Report on Form 10-K as well as information provided elsewhere in this Annual Report on Form 10-K. You should carefully consider that information before you make an investment decision. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as required by law, we do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Annual Report on Form 10-K to reflect later events or circumstances or the occurrence of unanticipated events.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash flows or stock price. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business and Operational Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Because the target patient populations for our products are relatively small, we must achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenues could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The sale of generic versions of KUVAN by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in KUVAN revenues faster than expected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we do not achieve our projected development goals in the timeframes we announce or fail to achieve such goals, the commercialization of our product candidates may be delayed or never occur and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenues from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenues from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Gene Therapy Programs</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our gene therapy products and product candidates are based on a novel technology, which presents additional development, manufacturing, regulatory and treatment risks in relation to our other, more traditional drug development programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">As compared to our other, more traditional products, gene therapy products may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial and Financing Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to International Operations</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenues in these countries.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our international operations pose currency risks, which may adversely affect our operating results and net income.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Part I</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> Item&#160;1. Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Founded in 1997, BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a global biotechnology company dedicated to transforming lives through genetic discovery. We develop and commercialize targeted therapies that address the root cause of genetic conditions. Our robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. Our distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, we achieved nearly $2.1 billion in total revenues, including a significant contribution from our ongoing launch of VOXZOGO, and we continued making important advancements in our product development pipeline. Our key business developments since the beginning of 2022 include the conditional approval of ROCTAVIAN (formerly referred to as v</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">aloctocogene roxaparvovec)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the European Union (EU) for the treatment of severe hemophilia A in adult patients, our release of positive three-year data from our Phase 3 study of ROCTAVIAN, the acceptance by the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (FDA) of our resubmission of the Biologics License Application (BLA) for ROCTAVIAN, and approvals of VOXZOGO in Australia for patients with achondroplasia ages two and older and in Japan for children with achondroplasia of all ages. We also continued progress in our earlier stage clinical programs, BMN 255 for the treatment of hyperoxaluria in chronic liver disease and BMN 331, a gene therapy product candidate for Hereditary Angioedema (HAE). Please see the disclosures below in this Part I, Item 1 of this Annual Report on Form 10-K for further discussion of these recent developments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial Products</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of our commercial products is provided below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.695%"><tr><td style="width:1.0%"></td><td style="width:60.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Net Product Revenues</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products marketed by BioMarin:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM (elosulfase alpha)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> IVA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME (galsulfase)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ (pegvaliase-pqpz)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN (sapropterin dihydrochloride)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO (vosoritide)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achondroplasia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA (cerliponase alfa)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLN2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN (valoctocogene roxaparvovec)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe Hemophilia A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products not marketed by BioMarin:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME (laronidase) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS&#160;I</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Mucopolysaccharidosis </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;For the treatment of adult patients with phenylketonuria (PKU)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;For the treatment of achondroplasia in children aged five years and older for the U.S., aged two years and older for the EU and for various age ranges for other markets. For more information, see &#8220;VOXZOGO&#8221; below. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Neuronal ceroid lipofuscinosis type 2</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The European Commission (EC) conditionally approved ROCTAVIAN in the third quarter of 2022, but no sales occurred in 2022. For more information, see &#8220;ROCTAVIAN&#8221; below. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Marketed by Sanofi</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">VIMIZIM</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VIMIZIM is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. MPS IVA is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of certain complex carbohydrates known as glycosaminoglycans (GAGs), such as keratan sulfate and chondroitin sulfate. This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Malformation of the chest impairs respiratory function, and looseness of joints in the neck cause spinal instability and potentially spinal cord compression. Other symptoms may include hearing loss, corneal clouding, and heart disease. Initial symptoms often become evident in the first five years of life. The disease substantially limits both the quality and length of life of those affected. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VIMIZIM is approved for marketing in the U.S., the EU and other international markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">NAGLAZYME</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NAGLAZYME is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with MPS VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of GAGs. Patients with MPS VI typically become progressively worse and experience multiple severe and debilitating symptoms resulting from the build-up of carbohydrate residues in tissues in the body. These symptoms include: inhibited growth, spinal cord compression, enlarged liver and spleen, joint deformities and reduced range of motion, skeletal deformities, impaired cardiovascular function, upper airway obstruction, reduced pulmonary function, frequent ear and lung infections, impaired hearing and vision, sleep apnea, malaise and reduced endurance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NAGLAZYME is approved for marketing in the U.S., the EU and other international markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">PALYNZIQ</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PALYNZIQ is a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations. PALYNZIQ is our second approved treatment for PKU. PALYNZIQ is approved for marketing in the U.S. for adult patients with PKU who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management. PALYNZIQ is also approved for marketing in the EU and Australia for patients ages 16 and older who have inadequate blood Phe control (blood Phe concentrations greater than 600 micromol/L) despite prior management with available treatment options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., PALYNZIQ is only available through the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">prescribers must be certified by enrolling in the REMS program and completing training;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">prescribers must prescribe auto-injectable epinephrine with PALYNZIQ;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">pharmacies must be certified with the REMS program and must dispense PALYNZIQ only to patients who are authorized to receive it;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with PALYNZIQ; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">patients must have auto-injectable epinephrine available at all times while taking PALYNZIQ.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Please see &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of the risks posed by the REMS program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">KUVAN</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">KUVAN is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase (PAH), indicated for patients with PKU. KUVAN is the first drug for the treatment of PKU, which is an inherited metabolic disease that affects at least 50,000 diagnosed patients under the age of 40 in the developed world. We believe that approximately 30% to 50% of those with PKU could benefit from treatment with KUVAN. PKU is caused by a deficiency of activity of an enzyme, PAH, which is required for the metabolism of Phe. Phe is an essential amino acid found in all protein-containing foods. Without sufficient quantity or activity of PAH, Phe accumulates to abnormally high levels in the blood, resulting in a variety of serious neurological complications, including severe mental retardation and brain damage, mental illness, seizures and other cognitive problems. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially manufactured foods; however, it is difficult for most patients to adhere to the strict diet to the extent needed for achieving adequate control of blood Phe levels.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">KUVAN is approved for marketing in the U.S., the EU and other international markets (excluding Japan). In certain international markets, KUVAN is also approved for, or is only approved for, the treatment of primary BH4 deficiency, a different disorder than PKU.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic versions of KUVAN are available in several countries around the world, including multiple generic versions in the U.S. We are also aware that manufacturers are challenging our patent portfolio related to KUVAN in several jurisdictions, and several generic versions of KUVAN have been approved either centrally by the EMA or on a country-by-country basis throughout the EU. Please see &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of the risks posed by generic versions of KUVAN in the U.S. and international markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">VOXZOGO</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VOXZOGO is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia, the most common form of disproportionate short stature in humans. In patients with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 gene (FGFR3). VOXZOGO acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VOXZOGO is approved for marketing in the EU, Australia and Brazil for patients with achondroplasia ages two and older with open growth plates and in Japan for children with achondroplasia of all ages with open growth plates. The FDA granted accelerated approval for the use of VOXZOGO in the U.S. for patients with achondroplasia ages five and older with open growth plates. The FDA issued us a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with VOXZOGO&#8217;s accelerated approval, which confers priority review to a subsequent drug application that would not otherwise qualify for priority review. The PRV program is designed to encourage development of new drugs and biologics for the treatment of rare pediatric diseases. In the first quarter of 2022, we sold the PRV we obtained in connection with VOXZOGO&#8217;s accelerated approval for a gross lump sum payment of $110.0 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to research VOXZOGO&#8217;s safety and effectiveness in children with achondroplasia. On February 23, 2022, we announced results from our Phase 2 randomized, double-blind, placebo-controlled clinical trial of VOXZOGO in infants and young children up to five years of age with achondroplasia, and on June 13, 2022, we announced additional details from the analysis. Results at 52 weeks trended in favor of VOXZOGO compared to placebo on height (adjusted for age and gender) and annualized growth velocity, consistent with improvements previously observed after one year of treatment in children over five years of age and without significantly impacting upper-to-lower body segment ratio. The safety profile was generally consistent with older children from the Phase 3 study and product label population. Serious adverse events (SAEs) were higher in the placebo group (18%) compared to children treated with VOXZOGO (7%). All SAEs, including a fatal respiratory arrest (reported as a sudden infant death syndrome in a treated infant with pre-existing respiratory morbidity), were deemed by the study investigators to be unrelated to treatment. The most common adverse events were mild and self-limiting injection site reactions. As part of our efforts to expand access to VOXZOGO for younger children, on January 3, 2023, we announced that we submitted, and the EMA subsequently validated, our Type II Variation application to extend the indication for VOXZOGO in the EU to treat children with achondroplasia under the age of 2. We also announced that we submitted a supplemental New Drug Application (NDA) to the FDA to treat children with achondroplasia under the age of 5. Additionally, on August 3, 2022, we announced our interventional Phase 2 study with VOXZOGO for the treatment of infants under the age of two who are at risk for foramen magnum compression completed enrollment. The study is investigating the safety of VOXZOGO in infants at risk of requiring surgery to alleviate compression at the foramen magnum, the opening in the base of the skull through which the spinal cord passes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, we are evaluating VOXZOGO as a potential treatment for children with other genetic short stature conditions beyond achondroplasia. A 52-week investigator-initiated study sponsored by Children's National Hospital in Washington, D.C. to investigate VOXZOGO in children with selected genetic forms of short stature is ongoing and expected to complete in 2023. Preliminary 6-month results from 12 subjects demonstrated a positive response in all subgroups with interindividual variability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">BRINEURA</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BRINEURA is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease. CLN2 is an incurable, rapidly progressive disease that typically ends in patient death by 10-12 years of age. Patients are initially healthy but begin to decline at approximately the age of three. We estimate that up to 1,200 to 1,600 cases exist worldwide. BRINEURA is the first treatment approved to slow the progression of loss of ambulation in children with CLN2 disease and was one of the first therapies to go through an accelerated review procedure in the EU.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BRINEURA is administered via intracerebroventricular (ICV) infusion and intended to be used in combination with a delivery device, such as an injector or other delivery system. Please see &#8220;Government Regulation &#8211; Regulation of Product Marketing and Promotion &#8211; Combination Products&#8221; in this Annual Report on Form 10-K for additional information on combination products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BRINEURA is approved for marketing in the U.S. (for ages three and older) and in the EU (for all ages from birth) and in other international markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">ROCTAVIAN </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROCTAVIAN is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Hemophilia A, also called factor VIII deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. According to the World Federation of Hemophilia rankings of severity of hemophilia A, the normal range of factor VIII activity levels is between 50% and 150%, expressed as a percentage of normal factor activity in blood, the mild hemophilia A range of factor VIII activity levels is between 5% and 40%, the moderate hemophilia A range of factor VIII activity levels is between 1% and 5%, and the severe hemophilia range of factor VIII activity levels is less than 1%. People living with hemophilia A are not able to form blood clots efficiently and are at risk for excessive bleeding from modest injuries, potentially endangering their lives. People with severe hemophilia often bleed spontaneously into their muscles or joints. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our European launch of ROCTAVIAN is underway following ROCTAVIAN'S conditional approval for marketing in the EU in August 2022 for the treatment of severe hemophilia A in adult patients without a history of factor VIII inhibitors and without detectable antibodies to AAV5. We plan to provide the EMA further clinical data to convert our conditional </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">approval to a standard marketing authorization. Please see &#8220;Government Regulation &#8211; Adaptive Pathways&#8221; in this Annual Report on Form 10-K for additional information on conditional marketing authorizations. Moreover, we completed outcomes-based agreements (OBAs) for ROCTAVIAN with third-party payers in Germany, which make us subject to potential repayments if a patient does not respond to therapy or the therapeutic effect of the drug falls below specified thresholds. We continue to collaborate with other payers to secure additional OBAs for ROCTAVIAN, which are intended to assist payers with realizing the value and sharing the risk of a one-time treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 12, 2022, we announced that the FDA accepted for review our resubmission of the BLA for ROCTAVIAN for the treatment of adults with severe hemophilia A. The BLA resubmission incorporates our responses to all deficiencies identified in the FDA&#8217;s August 2020 Complete Response Letter to our original BLA submission. The Prescription Drug User Fee Act (PDUFA) target action date for the resubmitted BLA is March 31, 2023. Typically, BLA resubmissions are followed by a six-month review procedure. However, three additional months of review may be necessary in connection with our recent submission to the FDA of data from our three-year analysis of the global Phase 3 study of ROCTAVIAN, as discussed below. Additionally, the FDA completed a Pre-License Inspection of the ROCTAVIAN manufacturing facility in early December 2022. We have pr</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ovided responses to the FDA&#8217;s comments and observations received at the close of the inspection, and we believe all are addressable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 31, 2022, we announced an update to our previously reported results of an open-label Phase 1/2 study of ROCTAVIAN for the treatment of adults with severe hemophilia A. The six-year update for the 6e13 vg/kg and five-year update for the 4e13 vg/kg cohorts showed a sustained treatment benefit of ROCTAVIAN. All participants, except one in the 4e13 vg/kg cohort as discussed below, had remained off prophylactic factor VIII treatment since receiving their single dose of ROCTAVIAN. Six months prior to the data cut, one participant in the 4e13 vg/kg cohort temporarily resumed prophylactic factor VIII treatment for one month, after which he was bleed free through the last follow up. In addition, the mean annualized bleed rates (ABR) for the most recent year were less than one in both cohorts and below pre-treatment baseline levels.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 8, 2023, we announced topline results from our three-year analysis of the global Phase 3 study of ROCTAVIAN for the treatment of adults with severe hemophilia A. All 132 study participants received a single dose of ROCTAVIAN and had a minimum of 36 months of follow-up. For a pre-specified group of 112 participants (two of whom discontinued from the study prior to reaching three years of follow-up) in a non-interventional prospective baseline observational study after dosing with ROCTAVIAN (the Rollover Population), in year three the mean ABR was reduced by 80% from baseline, with a mean ABR for treated bleeds of 1.0 (median 0.0). For the Rollover Population, in year three the mean annualized factor VIII infusion rate was reduced by 94% from baseline, with a mean annualized infusion rate of 8.4 (median 0.0). As of the three-year data cut, 92% of the Rollover Population participants remained off factor VIII prophylactic therapy. At the end of the three year post-infusion with ROCTAVIAN, the population of 132 participants had a mean factor VIII activity level of 18.8 (median 8.4) IU/dL, as measured by the chromogenic substrate (CS) assay. In the 17 participants (one of whom discontinued from the study prior to reaching four years of follow-up) who had been dosed at least four years prior to the data cut, mean factor VIII activity was 15.2 (median 7.4) IU/dL by the CS assay at the end of year three. The mean ABR for treated bleeds in year four for this subpopulation was 0.8 (median 0.0) and the mean annualized infusion rate was 11.1 (median 0.0).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the ongoing Phase 1/2 and Phase 3 studies of ROCTAVIAN described above, we have multiple other clinical studies of ROCTAVIAN underway. We are conducting an ongoing Phase 3, single arm, open-label study to evaluate the efficacy and safety of ROCTAVIAN at a dose of 6e13 vg/kg with prophylactic corticosteroids in people with severe hemophilia A. We are also conducting an ongoing Phase 1/2 Study with the 6e13 vg/kg dose of ROCTAVIAN in people with severe hemophilia A with pre-existing AAV5 antibodies and a Phase 1/2 Study with the 6e13 vg/kg dose of ROCTAVIAN in people with severe hemophilia A with active or prior factor VIII inhibitors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Overall, ROCTAVIAN continues to have a favorable safety profile and has been generally well tolerated by participants across all doses in the Phase 1/2 and Phase 3 studies. No participants developed inhibitors to factor VIII, malignancy, or thromboembolic events. The most common adverse events associated with ROCTAVIAN across studies occurred early and included transient infusion-associated reactions and mild to moderate rise in liver enzymes with no long-lasting clinical sequelae. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During year three of the Phase 3 study, no new treatment-related SAEs or Grade 3 events attributed to ROCTAVIAN or corticosteroid use emerged.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">ALDURAZYME</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ALDURAZYME is a highly purified protein that is designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of GAGs. MPS I is a progressive and debilitating life-threatening genetic disease, for which no other drug treatment currently exists, that is caused by the deficiency of alpha-L-iduronidase. Patients with MPS I typically become progressively worse and experience multiple severe and debilitating symptoms resulting from the build-up of carbohydrate residues in all tissues in the body. These symptoms include: inhibited growth, delayed and regressed mental development (in the severe form of the disease), enlarged liver and spleen, joint deformities and reduced range of motion, impaired cardiovascular function, upper airway obstruction, reduced pulmonary function, frequent ear and lung infections, impaired hearing and vision, sleep apnea, malaise and reduced endurance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We developed ALDURAZYME through collaboration with Sanofi. Under our collaboration agreement with Sanofi, we are responsible for manufacturing ALDURAZYME and supplying it to Sanofi. We receive payments ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume. Sanofi and BioMarin are members of BioMarin/Genzyme LLC, a 50/50 limited liability company (the BioMarin/Genzyme LLC) that: (1) holds the intellectual property relating to ALDURAZYME and other collaboration products and licenses all such intellectual property on a royalty-free basis to Sanofi and BioMarin to allow us to exercise our rights and perform our obligations under the agreements related to the BioMarin/Genzyme LLC, and (2) engages in research and development activities that are mutually selected and funded by Sanofi and us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ALDURAZYME is approved for marketing in the U.S., the EU and other international markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Clinical Development Programs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of our clinical development programs is provided below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Clinical Development Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Indication</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe Hemophilia A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA regulatory review </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hyperoxaluria</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hereditary Angioedema (HAE)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">BMN 255</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BMN 255 is a small-molecule therapy that is designed to treat </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">hyperoxaluria in chronic liver disease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. We concluded the multiple-ascending dose phase of the first-in-human study with BMN 255. In January 2023, we shared early data that demonstrated a rapid and potent increase in plasma glycolate following treatment with BMN 255, which is predicted to have a profound reduction in oxalate excretion in patients. We plan to initiate and fully enroll an expanded study in patients with chronic liver disease and hyperoxaluria in 2023. We believe the availability of a potent, orally bioavailable, small molecule like BMN 255 may be able to significantly reduce disease and treatment burden in a patient population with significant unmet need.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">BMN 331</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BMN 331 is a gene therapy product candidate for HAE. Dosing continues in the Phase 1/2 HAERMONY study to evaluate BMN 331, an investigational AAV5-mediated gene therapy for people living with HAE, including dose escalation to the 6e13vg/kg dose, which our non-clinical studies project to provide therapeutic levels of C1-Inhibitor. In January 2023, we shared that the first participant treated with the 6e13vg/kg dose of BMN 331 demonstrated C1-Inhibitor levels that were approaching the normal range. A second participant is scheduled for dosing at the 6e13vg/kg dose level in the near term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manufacture the active pharmaceutical ingredients (API) for ALDURAZYME, NAGLAZYME, PALYNZIQ and VOXZOGO in our production facilities located in Novato, California. We manufacture the API for BRINEURA and VIMIZIM in our manufacturing facility in Shanbally, Cork, Ireland. These facilities have been inspected and have demonstrated compliance with current Good Manufacturing Practices (cGMPs) to the satisfaction of the FDA, the EC and health agencies in other countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We contract with third parties to manufacture KUVAN API. All our product manufacturing (which includes vials, syringes, tablets, and powder) and most packaging operations are performed by contract manufacturers. We expect to continue to contract with outside service providers for certain manufacturing services, including drug substance, drug product, and packaging operations for our products. All of our facilities and those of any third-party manufacturers will be subject to periodic inspections </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">confirming compliance with applicable law and must pass inspection before we can manufacture our drugs for commercial sales. Third-party manufacturers&#8217; facilities are subject to periodic inspections to confirm compliance with applicable law and must be cGMP certified. We believe that our current agreements with third-party manufacturers and suppliers provide for ample operating capacity to support the anticipated clinical and commercial demand for these products. In certain instances, there is only one approved contract manufacturer for certain aspects of the manufacturing process. In such cases, we attempt to prevent disruption of supplies through supply agreements, maintaining safety stock and other appropriate strategies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2017, we commissioned our commercial-scale gene therapy manufacturing facility, located in Novato, California, where we conduct cGMP production of ROCTAVIAN to support commercial sales in Europe, anticipated commercial demand in other markets and clinical development activities. The facility has been inspected and has demonstrated compliance with cGMPs to the satisfaction of the EC. This facility also supports cGMP production of BMN 331 to support clinical development activities. This facility has the potential to produce multiple gene therapy products to meet global commercial demand, depending on dose and production mix. The facility holds a GMP certificate and its production processes have been developed in accordance with International Conference on Harmonisation Technical Requirements for Registration of Pharmaceuticals for Human Use facilitating worldwide registration with health authorities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Raw Materials</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies required for the production of our products and product candidates are available in some instances from one supplier and in other instances from multiple suppliers. In those cases where raw materials are only available through one supplier, such supplier may be either a sole source (the only recognized supply source available to us) or a single source (the only approved supply source for us among other sources). We have adopted policies to attempt, to the extent feasible, to minimize our raw material supply risks, including maintenance of greater levels of raw materials inventory and implementation of multiple raw materials sourcing strategies, especially for critical raw materials. Although to date we have not experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have established a commercial organization, including a sales force, to support our product lines directly in the U.S., Europe, South America and certain other significant markets. For other selected markets, we have signed agreements with other companies to act as distributors of all our products, other than ALDURAZYME. Most of these agreements generally grant the distributor the right to market the product in the territory and the obligation to secure all necessary regulatory approvals for commercial or named patient sales. Additional markets are being assessed at this time and additional agreements may be signed in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sanofi has the exclusive right to distribute, market and sell ALDURAZYME globally and is required to purchase its requirements exclusively from us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., our products (other than ALDURAZYME) are marketed through our commercial teams, including sales representatives and supporting staff members, who promote our products directly to physicians in specialties appropriate for each product. Outside of the U.S., our sales representatives and supporting staff members market our products (other than ALDURAZYME). We believe that with moderate changes in 2023, the size of our sales force will be appropriate to effectively reach our target customers in markets where our products are directly marketed. The launch of any future products, if approved, will likely require expansion of our commercial organization, including our sales force, in the U.S. and international markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We utilize third-party logistics companies to store and distribute our products. Moreover, we use third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Customers</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customers for our products (other than ALDURAZYME) include a limited number of specialty pharmacies and end-users, such as hospitals and non-U.S. government agencies. We also sell our products (other than ALDURAZYME) to our authorized distributors and to certain larger pharmaceutical wholesalers globally, which act as intermediaries between us and end-users and generally do not stock significant quantities of our products. However, in certain countries, governments place large periodic orders for NAGLAZYME and VIMIZIM. The timing of these orders can be inconsistent and can create significant quarter to quarter variation in our revenue. PALYNZIQ is currently distributed in the U.S. pursuant to the REMS program through a limited number of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">certified specialty pharmacies. During 2022, 37% of our net product revenue was generated by three customers. Sanofi is our sole customer for ALDURAZYME and is responsible for marketing and selling ALDURAZYME to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The biopharmaceutical industry is rapidly evolving and highly competitive. Within the industry, there are many public and private companies, including pharmaceutical companies and biotechnology companies that have or may soon initiate programs for the same indications that our products and product candidates are intended to treat. Furthermore, universities and non-profit research organizations may have research programs, both early-stage and clinical, in the same disease areas. Our larger competitors may have advantages over us due to greater financial or scientific resources, lower labor and other costs, or higher headcount and more robust organizational structures, while smaller competitors may have advantages over us due to lower overhead costs, being more nimble, or being able to focus on a narrower set of indications or development programs. Our competitors have considerable experience in drug manufacturing, preclinical and clinical research and development, regulatory affairs, marketing, sales, and distribution. They pursue broad patent portfolios and other intellectual property to protect the products they are developing. Their products may outcompete ours due to one or more factors, including faster progress through preclinical and clinical development, lower manufacturing costs, superior safety and efficacy, lower pricing, stronger patent protection, and better marketing, sales, and distribution capabilities. In this event, our products and product candidates, if approved, could fail to gain significant market share, and as a result, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other than ROCTAVIAN and KUVAN, as described below, our products have no direct approved competition currently on the market in the U.S. or the EU; however, other companies are in the development phase with new and generic products. Our products and product candidates have potential competition from products under development either using similar technology to our programs or different treatment strategies. The following is a summary of some of the primary possible future competitors for our products and product candidates, but the information below may not include all potential competition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Commercial Products</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ALDURAZYME, NAGLAZYME, and VIMIZIM</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the mucopolysaccharidosis field, several companies are researching treatments using small molecules, gene therapy, and other novel technologies. ALDURAZYME, for the treatment of MPS I, has potential competition from clinical stage product candidates from ArmaGen, Inc., JCR Pharmaceuticals Co., Ltd (acquired by ArmaGen, Inc.)., Orchard Therapeutics Plc and RegenxBio Inc. and earlier stage product candidates, including product candidates from Denali Therapeutics Inc. and Immusoft Corporation. NAGLAZYME, for the treatment of MPS VI, has potential competition from clinical stage product candidates from Inventiva S.A. and Paradigm Biopharmaceuticals Limited and other potential candidates in earlier stages. VIMIZIM, for the treatment of MPS IVA, has potential competition from preclinical product candidates from Esteve Pharmaceuticals, S.A., and RegenxBio Inc. and other potential candidates in earlier stages.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BRINEURA</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BRINEURA, for the treatment of CLN2, has potential competition from preclinical product candidates from Lexeo Therapeutics, Inc., RegenxBio Inc. and the Roche Group.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KUVAN and PALYNZIQ</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are currently no other approved, non-generic drugs on the market in the U.S. or the EU for the treatment of PKU. However, generic versions of KUVAN are available in several countries around the world, including multiple generic versions in the U.S. We are also aware that manufacturers are challenging our patent portfolio related to KUVAN in several jurisdictions, and several generic versions of KUVAN have been approved either centrally by the EMA or on a country-by-country basis throughout the EU. Please see &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of the risks posed by generic versions of KUVAN in the U.S. and international markets. KUVAN and PALYNZIQ also have potential competition from clinical stage product candidates from Homology Medicines, Inc., Jnana Therapeutics Inc., Nestle Health Science, S.A., PTC Therapeutics, Inc. and Synlogic, Inc. and earlier stage product candidates, including product candidates from Codexis, Inc, Generation Bio Co., LogicBio Therapeutics, Inc., Moderna Therapeutics, Inc., Sangamo Therapeutics, Inc. and SOM Innovation Biotech, S.A. We and other companies are also developing gene therapy product candidates for PKU.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">VOXZOGO</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VOXZOGO, for the treatment of achondroplasia, could have competition from clinical stage products under development by Ascendis Pharma A/S, Pfizer, Inc., QED Therapeutics, Inc. (a subsidiary of BridgeBio Pharma, Inc.), Ribomic Inc. and Sanofi and preclinical product candidates from other companies, including Astellas Pharma Inc.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ROCTAVIAN</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROCTAVIAN, a gene therapy product candidate for severe hemophilia A, has potential competition from marketed recombinant factor VIII replacement therapies, a novel bispecific antibody marketed by the Roche Group, and clinical stage programs, including gene therapy product candidates under development by ASC Therapeutics, Inc., Bayer AG, Pfizer, Inc., the Roche Group and Sangamo Therapeutics, Inc. In addition, Novo Nordisk A/S, Pfizer, Inc., the Roche Group and Sanofi are developing novel non-factor replacement product candidates in the clinic for the treatment of hemophilia A.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development Programs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BMN 255</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BMN 255, a small-molecule product candidate for hyperoxaluria in chronic liver disease, has potential competition from marketed products from Alnylam Pharmaceuticals, Inc., clinical stage product candidates from BridgeBio Pharma, Inc., Chinook Therapeutics, Inc. and Dicerna Pharmaceuticals, Inc. (a subsidiary of Novo Nordisk A/S.) and preclinical product candidates from other companies, including Amarna Therapeutics and Intellia Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BMN 331</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BMN 331, a gene therapy product candidate for HAE, has potential competition from marketed products from BioCryst Pharmaceuticals, Inc., CSL Behring GmbH and Takeda Pharmaceutical Company Limited, clinical stage product candidates from Astria Therapeutics, Inc., CSL Behring GmbH, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Pharvaris N.V. and preclinical product candidates from other companies, including Orchard Therapeutics, Inc. and Spark Therapeutics, Inc. (a subsidiary of the Roche Group). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patents, Proprietary Rights and Regulatory Exclusivity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our success depends on an intellectual property portfolio that supports our future revenue streams and also erects barriers to our competitors. We are maintaining and building our patent portfolio through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent applications. Furthermore we seek to protect our ownership of know-how, trade secrets and trademarks through an active program of legal mechanisms including registrations, assignments, confidentiality agreements, material transfer agreements, research collaborations and licenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest application was filed. U.S. patents that were issued on applications filed before June 8, 1995, may be effective until 17 years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S. Patent and Trademark Office (USPTO) delays in prosecuting the application. In the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch-Waxman Act), a patent that covers a drug approved by the FDA may be eligible for patent term extension (for up to five years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies in accordance with local law. In the EU, Supplementary Protection Certificates, or SPCs, are available to extend a patent term up to five years to compensate for patent protection lost during regulatory review. Although all EU Member States must provide SPCs, SPCs must be applied for and granted on a country-by-country basis. Limited exceptions apply to the protection conferred by the SPC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below lists our outstanding patents and patent applications of primary importance for our products other than ALDURAZYME by territory, general subject matter (including composition, methods of treatment and approved use, methods of production and purification, pharmaceutical compositions and clinical formulations) and latest expiry date. With respect to ALDURAZYME, the last of our patents expired in November 2020. One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately in the table below. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend patent exclusivity beyond the expiration dates listed in the table below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:12.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent No(s).</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">General Subject Matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BRINEURA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,029,781</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Method of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 7, 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,044,473</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Method of treatment by administration into the cerebrospinal fluid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 18, 2032</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,279,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Formulation; kit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 5, 2036</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1673104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical composition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 30, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16793229.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 5, 2036</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">KUVAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3138566; 3977999</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Use for treating with once daily dosing regimen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 17, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2545939; </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Use for treating once daily after a meal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 11, 2028</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3461503; 4029519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Use for treating after a meal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 11, 2028</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NAGLAZYME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,713,709</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Antibody assays</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 20, 2028</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1565209; 2327414</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions; pharmaceutical compositions; use to treat an enzyme deficiency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 7, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PALYNZIQ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,534,595</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Composition; method of treating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 16, 2027 / May 24, 2032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,221,408</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 3, 2031</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,557,340</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Antibody detection assay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 30, 2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,505,790</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regimen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 3, 2031</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2152868</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Composition; pharmaceutical composition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 23, 2028 / May 23, 2033</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2531209; 3025728</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Formulation; purification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 03, 2031</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,504,762; 10,463,718; 11,406,690<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions, Methods of Treatment, Production</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 10, 2034</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,512,675</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Formulation, Clinical Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 23, 2036</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3044231</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions, Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 30, 2034</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VIMIZIM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,128,925</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions; methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 10, 2030</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,765,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purification; formulation; methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 10, 2032</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2245145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Composition; use for treating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 30, 2029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2595650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purification; composition; use for treating; formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 22, 2031</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VOXZOGO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,198,242</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions, Methods of Treatment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 11, 2030</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,907,834</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 1, 2036</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,646,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 1, 2036</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2432489</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compositions, Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 20, 2030</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Under a patent term extension (PTE) that has been granted </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Patent application</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;We filed for a PTE for this patent, and if granted, the patent expiration will extend to May 24, 2032.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;We applied for SPCs for this patent, and we have to date received SPC to extend the patent expiration to May 23, 2033 in certain European countries, including Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland France, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Slovenia and Sweden.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;We filed for a PTE for these patents, and if granted, the patents&#8217; expirations will extend to September 10, 2039.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;We applied for SPCs for this patent, and we have to date received SPC to extend the patent expiration to September 10, 2037 in certain European countries, including Austria, Belgium, Bulgaria, Cyprus, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden and Slovakia.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;We applied for SPCs for this patent, and we have to date received SPC to extend the patent expiration to April 30, 2029 in certain European countries, including Austria, Bulgaria, Cypress, Czech Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;We filed for a PTE for this patent, and if granted, the patent expiration will extend to May 20, 2035.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;We applied for SPCs for this patent in Hungary, Germany, Poland, Netherlands, Norway, Denmark, Czech Republic, Italy, France, Spain, Greece, Belgium, Finland, Sweden, Ireland, Croatia, Austria and the United Kingdom, and have been granted SPCs so far in Italy and Austria extending the patent expiration to May 30, 2035.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the EU through the dates set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.001%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Orphan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Drug</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exclusivity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">United</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Biologic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exclusivity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">European</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Union</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Orphan Drug</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exclusivity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;See &#8220;Government Regulation&#8212;Other Regulation&#8212;Orphan Drug Designation&#8221; in this Annual Report on Form 10-K for further discussion.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;See &#8220;Government Regulation&#8212;Other Regulation&#8212;Exclusivity for Biologics in the U.S.&#8221; in this Annual Report on Form 10-K for further discussion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to our clinical product candidates, we believe we have the necessary intellectual property rights to allow us to undertake the development of these candidates. Certain of our product candidates are in therapeutic areas that have been the subject of many years of extensive research and development by academic organizations and third parties who may control patents or other intellectual property that they might assert against us, should one or more of our product candidates in these therapeutic areas succeed in obtaining regulatory approval and thereafter be commercialized. We continually evaluate the intellectual property rights of others in these areas in order to determine whether a claim of infringement may be made by others against us. Should we determine that a third party has intellectual property rights that could impact our ability to freely market a compound we consider a number of factors in determining how best to prepare for the commercialization of any such product candidate. In making this determination we consider, among other things, the stage of development of our product candidate and whether we and our outside counsel believe the intellectual property rights of others are valid, whether we infringe the intellectual property rights of others, whether a license is available upon commercially reasonable terms, whether we will seek to challenge the intellectual property rights of others, and the likelihood of and liability resulting from an adverse outcome should we be found to infringe the intellectual property rights of others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulation by governmental authorities in the U.S., European countries and other countries is a significant factor in the development, manufacture, commercialization, pricing and reimbursement of our products. Our industry is subject to significant federal, state, local and non-U.S. regulation. Our products require approval from the FDA, the EC (on the basis of the scientific opinions issued by the EMA) and corresponding agencies in other countries before they can be marketed. Failure to comply with applicable U.S. and foreign requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension or withdrawal of marketing, production or distribution authorizations, injunctions, fines, civil penalties, and criminal prosecution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Approval Process in the U.S. and EU</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Satisfaction of FDA and EU pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Pharmaceutical product development in the U.S. and the EU typically involves preclinical laboratory and animal tests, the submission to the applicable regulatory agency of an application (e.g., an IND in the U.S. or a CTA in the EU), which must become effective before clinical testing may commence, and adequate and well-controlled human clinical trials to establish the safety and effectiveness of the drug for each indication for which marketing approval is sought. On January 31, 2022, Regulation EU No 536/2014 (CTR) became fully applicable in the EU. The CTR established a centralized application procedure where one of the National Competent Authorities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(NCA) of the Member States where the trial will take place takes the lead in reviewing certain aspects of the application, while the other NCAs have a lesser involvement than they had under the previous regime established by Directive 2001/20/EC (CTD). The CTD indeed introduced the first set of harmonized rules on clinical trials in the EU but resulted in a patchwork of different national regimes. The CTR was adopted with a view to introducing a more uniform set of the rules across the EU for the authorization of clinical trials. Such authorization still involves the national regulatory authorities and Ethics Committees of each of the EU Member States where the trial is to be conducted. However, the relevant procedures have now been streamlined with a view to facilitating a swifter and more seamless authorization and deployment of multi-center trials occurring in more than one EU Member State. More specifically, the CTR allows sponsors to rely on one single submission for CTAs regardless of the number of Member States where the trial takes place and based on a single harmonized application. Furthermore, under the CTR, deadlines for regulatory approvals are shortened with a view to accelerating the authorization process. The CTR also established an EU Portal which will act as a single-entry point for submission of data and information relating to clinical trials. Until January 30, 2025, the CTD will continue to apply in parallel to the CTR for a transitional period. From January 31, 2025 all trials will have to comply with the CTR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluation, as well as animal studies, to assess the characteristics and potential pharmacology, pharmacokinetics and toxicity of the product. The conduct of the preclinical tests must comply with FDA and/or EU and national regulations and requirements, including good laboratory practices (GLP). The results of preclinical testing, along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol are reviewed by the applicable regulatory agency as part of an IND or CTA. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND or CTA is submitted. Until the CTA or IND is approved, or becomes effective following a waiting period, and appropriate reviews have been satisfactorily completed by the applicable Institutional Review Boards (IRBs) or Ethics Committees, we may not start the clinical trial in the relevant jurisdiction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with applicable regulations, good clinical practices (GCP), as well as under protocols detailing the objectives of the trial and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on patients and subsequent protocol amendments must be submitted to the FDA as part of the IND and to the relevant regulatory agency in the EU as part of a new CTA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The regulatory agencies may order the temporary halt or permanent discontinuation of a clinical trial at any time or impose other sanctions if they believe that the clinical trial is not being conducted in accordance with applicable requirements or presents an unacceptable risk to the clinical trial patients. An IRB/Ethics Committee may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB/Ethics Committee&#8217;s requirements, or may impose other conditions. Clinical trials that are deployed to support NDAs, BLAs or Marketing Authorization Applications (MAAs) for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. Typically, we undertake a three-phase human clinical testing program as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Phase 1 - the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Phase 2 - usually involves trials in a limited patient population, to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Phase 3 - undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an application is prepared and submitted to the applicable regulatory agency. Approval of the application by the applicable regulatory agency is required before marketing of the product may begin. In the European Economic Area (i.e., the EU as well as Iceland, Liechtenstein and Norway) (the EEA), there are two types of marketing authorizations (MA), namely: (i) the &#8220;Union&#8221; MA, which is issued by the EC through the so-called &#8220;centralized procedure&#8221;, based on the positive opinion of the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP), and results in a single marketing authorization that is valid across the EEA; and (ii) &#8220;National MAs,&#8221; which are issued by the competent NCAs and only cover their respective territory. The centralized procedure is mandatory for certain types of products such as: (i) medicinal products derived from certain biotechnology processes, (ii) designated orphan medicinal products, (iii) medicinal products containing a new active substance indicated for the treatment of certain diseases such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other auto-immune dysfunctions, viral diseases; and (iv) Advanced Therapy Medicinal Products (ATMPs) (such as gene therapy, somatic cell therapy or tissue-engineered medicines). The NDA, BLA or MAA must include the results of all preclinical, clinical and other testing, a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls and proposed labeling, among other things. In the U.S., each NDA or BLA is subject to a significant user fee at the time of submission, unless a waiver is granted by the FDA. Similarly, in the EU, the submission of an MAA is subject to the payment of fees, a waiver of which may be obtained only under limited circumstances. The FDA and the EMA initially review the applications for a threshold determination that it is sufficiently complete to permit substantive review. The regulatory agency </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may request additional information rather than accepting an application for filing or validation. Once the submission is accepted, the applicable agency begins an in-depth review. For the FDA, the review period for standard review applications is typically an additional ten months and, for priority review of drugs, that is, drugs that the FDA determines address a significant unmet need and represent a significant improvement over existing therapy, the review period is typically an additional six months in duration. The review process may be extended by the FDA for three additional months to consider new information submitted during the review or clarification regarding information already provided in the submission. The FDA may also refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. After the FDA evaluates the information provided in the NDA/BLA, it issues an approval letter, or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed and the NDA/BLA has been resubmitted, the FDA will re-initiate review. If it is satisfied that the deficiencies have been addressed, the FDA will issue an approval letter.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. At the end of the review period, the CHMP provides an opinion to the EC. If the opinion is favorable, the EC may then adopt a decision to grant marketing authorization. In the event of a negative opinion, the company may request a re-examination of the application within 15 days of receipt of the negative opinion. The company then has 60 days to provide the CHMP with detailed grounds for requesting the re-examination. Within 60 days of providing this information, the CHMP must re-examine its opinion. The EC follows the recommendation of the CHMP in almost all cases. In exceptional cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days. This is usually when the product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the review period, the FDA and/or the European authorities may typically inspect one or more clinical sites and/or the sponsor to assure compliance with GCP regulations and may equally inspect the facility or the facilities at which the drug is manufactured to ensure compliance with cGMPs regulations. Neither the FDA nor the EC will approve the product unless compliance is satisfactory and the application contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fast Track Designation and Accelerated Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA is required to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and that demonstrate the potential to address unmet medical needs for the condition. Under the FDA&#8217;s fast track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with the FDA, the FDA may initiate review of sections of a fast track drug&#8217;s NDA or BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA or BLA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the fast track program and the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of a Phase 4 or post-approval clinical trial to confirm the effect on the clinical endpoint. Failure to conduct a required post-approval study or confirm a clinical benefit through a post-marketing study will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. The Food and Drug Omnibus Reform Act (FDORA) was recently enacted, which included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">termination of the study. FDORA enables the FDA to initiate criminal prosecutions for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Adaptive Pathways</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EMA has an adaptive pathways approach which allows for early and progressive patient access to a medicine in cases of high medical need. To achieve this goal, several approaches are envisaged including for example identifying small populations with severe disease where a medicine&#8217;s benefit-risk balance could be favorable or making more use of real-world data where appropriate to support clinical trial data. The adaptive pathways concept applies primarily to treatments in areas of high medical need where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine. The approach builds on regulatory processes already in place within the existing EU legal framework. These include: scientific advice; compassionate use; the conditional MA; patient registries and other pharmacovigilance tools that allow collection of real-life data and development of a risk-management plan for each medicine.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A conditional MA may be granted prior to the submission of comprehensive clinical data if the benefit of the immediate availability on the market of the product is deemed to outweigh the risk inherent in the fact that additional data are still required. In emergency situations, a MA for such medicinal products may be granted also where comprehensive pre-clinical or pharmaceutical data have not been provided. Under this procedure a MA can be granted as soon as sufficient data becomes available to demonstrate that the drug's benefits outweigh its risks, with safeguards and controls in place post-authorization. This procedure can also be combined with a rolling review of data during the development of a promising medicine, to further expedite its evaluation. Conditional MAs are typically subject to obligations that are reviewed annually. These include the obligation to complete ongoing studies, or to conduct new studies, with a view to confirming that the risk-benefit balance is favorable. Conditional MAs are valid for one year and are renewable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PRIME Program</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EMA launched its PRIME regulatory program to enhance support for the development of therapies that target an unmet medical need. The initiative focuses on drugs that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options. These therapies are considered priority medicines within the EU. Through PRIME, the EMA offers early, proactive and enhanced support to drug developers to optimize the generation of robust data on a therapy&#8217;s benefits and risks and enable accelerated assessment of drug applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Product Marketing and Promotion</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A marketing approval authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA or BLA approval, the FDA may require a REMS, to help ensure that the benefits of the drug outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, such as special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Similar rules apply outside of the U.S. For example, products approved in the EU may be subject to post-authorization requirements such as the obligation to perform post-authorization efficacy studies (PAES) or post-authorization safety studies (PASS) imposed as conditions to the MA, or other Risk Minimization Measures (RMMs), such as educational programs or controlled access programs, which may sometimes vary from one EU Member State to another. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Regulation of Manufacturing Standards</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA as well as other regulatory agencies around the world, regulate and inspect the equipment, facilities, laboratories and processes used in the manufacturing and testing of products prior to granting approval to market products. If after receiving approval from the FDA and other agencies such as the EC we make a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to cGMP regulations and product-specific regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. The FDA and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">other regulatory agencies around the world conduct regular, periodic visits to reinspect our equipment, facilities, laboratories and processes following an initial approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Combination Products</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combination products are defined by the FDA as products composed of two or more regulated components (e.g., a biologic and/or drug and a device). Biologics/drugs and devices each have their own regulatory requirements, and combination products may have additional requirements. For example, in the EU, if a device intended to administer a medicinal product is sold together with such medicinal product in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product is regulated as a medicinal product. In addition, the relevant general safety and performance requirements established for medical devices by EU medical devices legislation apply to the device component of such combination products. A number of our products qualify as combination products and are regulated under the applicable framework, and we expect that a number of our pipeline product candidates will be evaluated for regulatory approval under such framework as well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Post-Approval Regulatory Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Following approval, the FDA and the regulatory authorities around the world will impose certain post-approval requirements related to a product. For instance, the FDA and European authorities closely regulate the post-approval marketing and promotion of approved products, including standards and regulations for direct-to-consumer advertising (which is prohibited in the EU for prescription products such as our products), off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Moreover, if a company obtains original approval for a product via an accelerated approval pathway, the company will be typically required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of the marketing approval for a product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approved products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, may require a submission to and approval by the FDA or the EC, as applicable, before the change can be implemented. An NDA/BLA or MAA supplement for a new indication typically requires clinical data similar to that in the original application, and similar procedures and actions in reviewing NDA/ BLA or MAA supplements as in reviewing NDAs/BLAs and MAAs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following marketing approval. Either the FDA or the EC/EMA may also require post-marketing testing, known as Phase 4 testing, a risk evaluation and mitigation strategy, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as the manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug and biological product manufacturers and certain of their subcontractors are subject to periodic unannounced inspections by the FDA, the EMA/NCAs, during which the inspectors audit manufacturing facilities to assess compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, prescription drug manufacturers in the U.S. must comply with applicable provisions of the Drug Supply Chain Security Act and provide and receive product tracing information, maintain appropriate licenses, ensure they only work with other properly licensed entities and have procedures in place to identify and properly handle suspect and illegitimate products. Similarly, in the EU, stringent rules have been introduced to fight medicine falsifications and to ensure that the trade in medicines is subject to rigorous controls. Measures required to ensure that include: a unique identifier and an anti-tampering device on the outer packaging of drugs, stringent rules on import of active pharmaceutical ingredients and record-keeping requirements for wholesale distributors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Approval Regulation Outside of the U.S. and the EU</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For marketing outside the U.S. and the EU, we are subject to non-U.S. regulatory requirements governing human clinical testing and marketing approval for our products. These requirements vary by jurisdiction, can differ from those in the U.S. and the EU and may require us to perform additional preclinical or clinical testing. The amount of time required to obtain necessary approvals may be longer or shorter than that required for FDA or EC approval. In many countries outside of the U.S., approvals for pricing, coverage and reimbursement offered by third-party payers, including government payers and private insurance plans, are also required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Exclusivity for Biologics in the U.S.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (BPCIA), which was enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (as amended, the PPACA), created an abbreviated approval pathway for biological products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-licensed product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical studies, animal studies, and at least one clinical study, absent a waiver from the Secretary of the U.S. Department of Health and Human Services. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The first biosimilar product was approved under the BPCIA in 2015, and the first interchangeable product was approved in 2021. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) eighteen months after the first interchangeable biosimilar is approved if there is not patent challenge, (iii) eighteen months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Data Exclusivity and Market Exclusivity in the EU</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EU provides opportunities for market and data exclusivity for all products containing a New Active Substance, or NAS (such as a chemical, biological or radiopharmaceutical substance not previously authorized as a medicinal product in the EU), which have been granted an MA. These products receive eight years of data exclusivity and an additional two years of market exclusivity. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Orphan drug designation is granted by the FDA and the EC to drugs intended to treat a rare disease or condition, which in the U.S. is defined as having a prevalence of less than 200,000 individuals in the U.S. In the EU, orphan drug designation is available if a sponsor can establish: that the medicine is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, which is equivalent to around 250,000 people or fewer, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives derived from the orphan status, it is unlikely that the marketing of the medicinal product in the EU would generate sufficient return to justify the necessary investment. For either of these criteria, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. Orphan drug designation must be requested before submitting a marketing application and, in the EU, it must be maintained until the time of the granting of the MA. Orphan designation is indeed lost in the EU if it is established that the product no longer meets the orphan criteria at the time a MA is granted for such product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Orphan drug designation does not shorten the regulatory review and approval process. However, if an orphan drug later receives approval for the indication for which it has designation, the relevant regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years in the U.S. and ten years in the EU (extendable to twelve years for medicines that have complied with an agreed Pediatric Investigation Plan (PIP) pursuant to Regulation 1901/2006) and, in addition, a range of other benefits during the development and regulatory review process are available in the EU, including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. Among the benefits of orphan drug designation in the U.S. are tax credits for certain research and a waiver of the NDA/BLA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">application user fee. Orphan drug exclusive marketing rights may be lost under certain conditions, such as if the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In the EU, a MA may be granted to a similar medicinal product with the same orphan indication during the regulatory exclusivity period with the consent of the MA holder for the original orphan medicinal product or if the MA holder of the original orphan medicinal product is unable to supply sufficient quantities. A MA may also be granted to a similar medicinal product with the same orphan indication if the second applicant can establish that its medicinal product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the healthcare industry, including legislation that seeks to directly or indirectly regulate pharmaceutical drug pricing. For more information, see Item 1A. Risk Factors &#8220;Government healthcare reform could increase our costs and adversely affect our revenue and results of operations.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback, false claims, patient data privacy and security, and transparency statutes and regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. The PPACA amended the intent requirement of the federal Anti-Kickback and certain other criminal healthcare fraud statutes such that a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. The PPACA amended the statute so that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn are used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the federal Anti-Kickback Statute and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to individual physicians in these states while other states prohibit various other marketing-related activities. Other states require submission or disclosure of certain pricing information. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, states including California, Connecticut, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nevada and Massachusetts require pharmaceutical companies to implement compliance programs or marketing codes. Currently, several additional states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Sanctions under these federal and state laws may include significant penalties, including administrative and criminal sanctions, civil monetary penalties, damages, monetary fines, disgorgement, exclusion of a company from federal healthcare programs, integrity oversight and reporting obligations, criminal fines, contractual damages, reputational harm, diminished profits and future earnings, curtailment of operations and imprisonment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act (FCPA), to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any non-U.S. government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Similar laws exist in other countries, such as the U.K., that restrict improper payments to public and private parties. Many countries have laws prohibiting these types of payments within the respective country. In the EU, for example, harmonized rules prohibit gifts, pecuniary advantages or benefits in kind to Health Care Professionals (HCPs) unless they are inexpensive and relevant to the practice of medicine or pharmacy. Similarly, strict rules apply to hospitality at sales promotion events. Based on these rules, a body of industry guidelines and sometimes national laws in force in individual EU Member States has been introduced to fight improper payments or other transfers of value to HCPs, and in general inducements that may have a broadly promotional character. Historically, pharmaceutical companies have been the target of FCPA and other anti-corruption and similar investigations, as well as of wide media attention, sometimes resulting in significant penalties, image and other costs for such companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because the course of treatment for patients using our products is expensive, sales of our products depend, in significant part, on the availability and extent of coverage and reimbursement offered by third-party payers, including government payers and private insurance plans. Governments may regulate access to, prices of or reimbursement levels for our products to control costs or to affect levels of use of our products, and private insurers may be influenced by government reimbursement methodologies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-party payers carefully review and increasingly challenge the prices charged for drugs, examine their medical necessity, and review their cost effectiveness. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. One payer&#8217;s determination to provide coverage for a product does not assure that other payers will also provide coverage for the product. Moreover, the process for determining whether a third-party payer will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payer will pay for the product. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. A payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain high enough price levels to realize sufficient revenues from our investment in product development. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S. our products are paid for by a variety of payers, with governments being the primary source of payment. Reimbursement in the EU and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until pricing and/or reimbursement is approved. In many countries the government closely regulates drug pricing and reimbursement and often has a significant discretion in determining whether a product will be reimbursed at all and, if it is, how much will be paid. Negotiating prices with governmental authorities can delay commercialization of our products. Payers in many countries use a variety of cost-containment measures that can include referencing prices in other countries and using those reference prices to set their own price, mandatory price cuts and rebates. This international patchwork of price regulation has led to different prices across countries and some cross-border trade in our products from markets with lower prices. Even after a price is negotiated, countries frequently request or require adjustments to the price and other concessions over time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Medicaid, the 340B Drug Pricing Program, and Medicare</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal law requires that a pharmaceutical manufacturer, as a condition of having its products receive federal reimbursement under Medicaid and Medicare Part B, must pay rebates to state Medicaid programs for all units of its covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program under either a fee-for-service arrangement or through a managed care organization. This federal requirement is effectuated through a Medicaid drug rebate agreement between the manufacturer and the Secretary of Health and Human Services. CMS administers the Medicaid drug rebate agreements, which provide, among other things, that the drug manufacturer will pay rebates to each state Medicaid agency </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">on a quarterly basis and report certain price information on a monthly and quarterly basis. The rebates are based on prices reported to CMS by manufacturers for their covered outpatient drugs. For non-innovator products, generally generic drugs marketed under abbreviated new drug applications (referred to as ANDAs), the rebate amount is 13% of the average manufacturer price (AMP) for the quarter. The AMP is the weighted average of prices paid to the manufacturer (1) directly by retail community pharmacies and (2) by wholesalers for drugs distributed to retail community pharmacies. For innovator products (i.e., drugs that are marketed under NDAs or BLAs), the rebate amount is the greater of 23.1% of the AMP for the quarter or the difference between such AMP and the best price for that same quarter. The best price is essentially the lowest price available to non-governmental entities. Innovator products may also be subject to an additional rebate that is based on the amount, if any, by which the product&#8217;s AMP for a given quarter exceeds the inflation-adjusted baseline AMP, which for most drugs is the AMP for the first full quarter after launch. Since 2017, non-innovator products are also subject to an additional rebate. To date, the rebate amount for a drug has been capped at 100% of the AMP; however, effective January 1, 2024, this cap will be eliminated, which means that a manufacturer could pay a rebate amount on a unit of the drug that is greater than the average price the manufacturer receives for the drug.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The terms of participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in additional or lesser rebate liability, depending on the direction of the correction. In addition to retroactive rebates, if a manufacturer were found to have knowingly submitted false information to the government, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A manufacturer must also participate in a federal program known as the 340B drug pricing program in order for federal funds to be available to pay for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. Under this program, the participating manufacturer agrees to charge certain safety net healthcare providers no more than an established discounted price for its covered outpatient drugs. The formula for determining the discounted price is defined by statute and is based on the AMP and the unit rebate amount as calculated under the Medicaid drug rebate program, discussed above. Manufacturers are required to report pricing information to the Health Resources and Services Administration (HRSA) on a quarterly basis. HRSA has also issued regulations relating to the calculation of the ceiling price as well as imposition of civil monetary penalties for each instance of knowingly and intentionally overcharging a 340B covered entity.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal law also requires that manufacturers report data on a quarterly basis to CMS regarding the pricing of drugs that are separately reimbursable under Medicare Part B. These are generally drugs, such as injectable products, that are administered &#8220;incident to&#8221; a physician service and are not generally self-administered. The pricing information submitted by manufacturers is the basis for reimbursement to physicians and suppliers for drugs covered under Medicare Part B. As with the Medicaid drug rebate program, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Medicare Part D provides prescription drug benefits for seniors and people with disabilities. Medicare Part D enrollees once had a gap in their coverage (between the initial coverage limit and the point at which catastrophic coverage begins) where Medicare did not cover their prescription drug costs, known as the coverage gap. However, beginning in 2019, Medicare Part D enrollees paid 25% of brand drug costs after they reached the initial coverage limit - the same percentage they were responsible for before they reached that limit - thereby closing the coverage gap from the enrollee&#8217;s point of view. Most of the cost of closing the coverage gap is being borne by innovator companies and the government through subsidies. Each manufacturer of drugs approved under NDAs or BLAs is required to enter into a Medicare Part D coverage gap discount agreement and provide a 70% discount on those drugs dispensed to Medicare Part D enrollees in the coverage gap, in order for its drugs to be reimbursed by Medicare Part D. Beginning in 2025, the Inflation Reduction Act (IRA) eliminates the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. Although these discounts represent a lower percentage of enrollees&#8217; costs than the current discounts required below the out-of-pocket maximum (that is, in the coverage gap phase of Part D coverage), the new manufacturer contribution required above the out-of-pocket maximum could be considerable for very high-cost patients and the total contributions by manufacturers to a Part D enrollee&#8217;s drug expenses may exceed those currently provided.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IRA will also allow the U.S. Department of Health and Human Services (HHS) to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in October 2022 for Medicare Part D and January 2023 for Medicare Part B, the IRA will also penalize drug manufacturers that increase prices of Medicare Part D and Part B drugs at a rate greater than the rate of inflation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">U.S. Federal Contracting and Pricing Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturers are also required to make their covered drugs, which are generally drugs approved under NDAs or BLAs, available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration. The law also requires manufacturers to offer deeply discounted FSS contract pricing for purchases of their covered drugs by the Department of Veterans </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Affairs, the Department of Defense, the Coast Guard, and the Public Health Service (including the Indian Health Service) in order for federal funding to be available for reimbursement or purchase of the manufacturer&#8217;s drugs under certain federal programs. FSS pricing to those four federal agencies for covered drugs must be no more than the Federal Ceiling Price (FCP), which is at least 24% below the Non-Federal Average Manufacturer Price (Non-FAMP) for the prior year. The Non-FAMP is the average price for covered drugs sold to wholesalers or other middlemen, net of any price reductions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accuracy of a manufacturer&#8217;s reported Non-FAMPs, FCPs, or FSS contract prices may be audited by the government. Among the remedies available to the government for inaccuracies is recoupment of any overcharges to the four specified federal agencies based on those inaccuracies. If a manufacturer were found to have knowingly reported false prices, in addition to other penalties available to the government, the law provides for significant civil monetary penalties per incorrect item. Finally, manufacturers are required to disclose in FSS contract proposals all commercial pricing that is equal to or less than the proposed FSS pricing, and subsequent to award of an FSS contract, manufacturers are required to monitor certain commercial price reductions and extend commensurate price reductions to the government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is recoupment of any FSS overcharges that may result from such omissions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA-regulated products, including drugs and biologics, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial are then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. In certain circumstances, disclosure of the results of these trials can be delayed for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. In the EU there is an increasing trend requiring public disclosure of development data, in particular clinical trial data. These data were traditionally regarded as Confidential Commercial Information (CCI); however, under policies adopted in the EU, clinical study data submitted to the EMA in MAAs, including preclinical data, and patient level data, may be subject to public disclosure. This is confirmed in the CTR, the new EU legislation on clinical trials, according to which clinical trial applications and all the related documentation are uploaded and stored in the Clinical Trials Information System (CTIS) which is managed by the EMA. Confirming the transparency principle, the CTR provides that the information stored in such system is publicly accessible unless confidentiality is justified on the basis of a limited set of exceptions. These exceptions, which are to be interpreted narrowly in the EU, include the protection of CCI, in particular through taking into account the status of the MA for the applicable product; however, CCI is overridden in those cases where the authorities conclude that there is an overriding public interest in disclosure. Case law of the Court of Justice of the EU has also confirmed the absence of a general presumption of confidentiality over documents containing clinical and preclinical data provided to the EMA in support of a MAA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Indications</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., under the Pediatric Research Equity Act of 2007 (PREA), NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the drug for the claimed indication(s) in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by statute or regulation, PREA does not apply to any drug for an indication for which orphan drug designation has been granted. The Best Pharmaceuticals for Children Act (BPCA) provides sponsors of NDAs with an additional six-month period of market exclusivity for all unexpired patent or non-patent exclusivity on all forms of the drug containing the active moiety if the sponsor submits results of pediatric studies specifically requested by the FDA under BPCA within required timeframes. The BPCIA provides sponsors of BLAs an additional six-month extension for all unexpired non-patent market exclusivity on all forms of the biological containing the active moiety pursuant to the BPCA if the conditions under the BPCA are met.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, companies developing a new medicinal product must agree to a PIP with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver is granted by the EMA on request by the applicant (e.g., because the relevant disease or condition occurs only in adults). The PIP requirement also applies when a MA holder intends to add a new indication, pharmaceutical form or route of administration for a medicinal product that has already been authorized. The MAA for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Once all the studies and measures agreed have been conducted in accordance with the PIP, products are eligible for a six -month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two -year extension of the orphan market exclusivity. This pediatric reward is granted subject to specific conditions. These conditions include that the applicant demonstrates having complied with all the measures contained in the PIP, that the summary of product characteristics, and if appropriate the package leaflet, reflects the results of studies conducted in compliance with such PIP, and that the product is authorized in all Member States. The rewards for conducting studies in the pediatric population can be granted irrespective of the fact that the information generated in compliance with the agreed PIP fails to lead to the authorization of a pediatric indication.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Legislation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may process personal or sensitive data. Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy, security, and protection. Such obligations may include, without limitation, the Federal Trade Commission Act, the California Consumer Privacy Act of 2018 (CCPA), the Canadian Personal Information Protection and Electronic Documents Act, the European Union&#8217;s General Data Protection Regulation 2016/679 (EU GDPR), the EU GDPR as it forms part of United Kingdom (UK) law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (UK GDPR).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The legislative and regulatory environments regarding privacy and data protection are continually evolving and developing, in response to increasing global attention. In the U.S., for example, we are subject to the CCPA along with the California Privacy Rights Act of 2020 (CPRA). The CCPA imposes obligations on covered businesses to provide specific disclosures related to a business&#8217;s collecting, using, and disclosing personal data and to respond to certain requests from California residents related to their personal data (for example, requests to know of the business&#8217;s personal data processing activities, to delete the individual&#8217;s personal data, and to opt out of certain personal data disclosures). Also, the CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. In addition, the CPRA, effective January 1, 2023, expanded the CCPA. The CPRA, among other things, gives California residents the ability to limit use of certain sensitive personal data, establish restrictions on personal data retention, expands the types of data breaches that are subject to the CCPA&#8217;s private right of action, and establishes a new California Privacy Protection Agency to implement and enforce the new law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. Several states within the United States have enacted or proposed data privacy laws. Additionally, we are, or may become, subject to various U.S. federal and state consumer protection laws which require us to publish statements that accurately and fairly describe how we handle personal data and choices individuals may have about the way we handle their personal data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are also subject to the EU&#8217;s General Data Protection Regulation GDPR, which requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the EEA (unless certain steps are taken to ensure an adequate level of protection), and must not be retained for longer than necessary for the purposes for which it was collected. The GDPR also requires companies processing personal data to implement adequate technical measures in order to ensure the most appropriate level of security which may vary depending on different factors such as the categories of processed personal data, the state of the art, the costs of implementation and the nature, scope, context and purposes of processing as well as the risk of varying likelihood and severity for the rights and freedoms of natural persons. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure the protection of data subject rights, including as required to respond to complaints and requests from data subjects. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, provides for conditions under which a valid consent for processing can be obtained, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, imposes mandatory data breach notification throughout the EEA and imposes additional obligations when contracting with service providers or partners. In addition, to the extent a company processes, controls or otherwise uses &#8220;special category&#8221; of personal data (including patients&#8217; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure to comply with these laws could result in significant penalties, including, under GDPR, fines of up to 20 million Euro or 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. The CCPA and EU GDPR are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing that may increase compliance obligations and exposure for any noncompliance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 3,082 full-time employees worldwide, of whom 1,343 were in operations, 736 were in research and development, 495 were in sales and marketing and 508 were in administration. Of the 3,082 full-time employees as of December&#160;31, 2022, 2,066 employees were in the U.S. and Canada, and 1,016 employees were in other non-U.S. countries, including 818 in Europe and the Middle East, 129 in Latin America and 69 in Asia Pacific. We also leverage temporary workers to fill short-term positions for our business and manufacturing needs. A significant portion of our employee base in the U.S. and Ireland works onsite supporting manufacturing and laboratory operations. As restrictions from the COVID-19 pandemic have eased, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a significant portion of our global workforce who worked remotely during the pandemic has made a return to their respective office locations on a hybrid basis, with a small number of employees continuing to fully work remotely.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 6, 2022, we announced a plan to simplify our organization, which included a planned reduction in headcount of approximately 120 employees (representing approximately 4% of the Company&#8217;s global workforce), </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">most of whom were from the Company's U.S. operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At BioMarin, prejudice, racism and intolerance are unacceptable. We are committed to diversity, equity and inclusion (DEI) across all aspects of our organization, including hiring, promotion and development practices. At the direction of BioMarin's senior leadership team, our human resources department has implemented policies and programs to foster DEI at all levels of the organization. In addition, the Corporate Governance and Nominating and Compensation Committees of our Board of Directors regularly receive reports on our DEI policies and programs and offer valuable insights and recommendations to management in addition to providing appropriate oversight. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2022, racial and ethnic minorities represented 47% of our employees in the U.S. Globally, 50% of our workforce were women and 47% of our positions at director-level and above were held by women. We are committed to continuing our ongoing efforts to ensure diversity in all positions, including leadership. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We remain steadfast in our commitment to fostering a community that reflects equality and inclusiveness and working towards making BioMarin a place where every employee feels heard, respected and valued. This commitment is a cultural value, and we believe incorporating and encouraging different perspectives from employees of varied backgrounds and experiences helps us better serve our patients, achieve our business goals and objectives and provide employees with a fulfilling work experience. Since 2020, BioMarin&#8217;s DEI Employee Advisory Committee has helped to define our DEI roadmap and ensure that perspectives from employees of different age, gender, sexual orientation, race, ethnicity, tenure, level and location are considered in how we build the most inclusive environment. We also continue to support and increase the number of our employee resource groups that build community for employees from underrepresented groups. In addition, our foundational DEI training is required for all employees, with a 100% global participation rate in 2022, and we offer opportunities for advanced DEI training as well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are honored to be recognized as a company of choice. In 2022, we were recognized for the second year in a row as a Best Place to Work for lesbian, gay, bisexual, transgender and queer (LGBTQ+) equality by the Human Rights Campaign, scoring 100% on their Corporate Equality Index, one of the foremost benchmarking surveys and reports in the U.S. measuring corporate policies and practices related to LGBTQ+ workplace equality. In JUST Capital&#8217;s America&#8217;s Most JUST Companies 2023 rankings, our overall rank was eight out of 41 in our industry, and our &#8220;Workers&#8221; rank, which is intended to measure how a company invests in its employees, was 29 out of 951 companies across all industries and 4 out of 41 pharmaceutical and biotechnology companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Compensation, Benefits and Well-being</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We offer competitive compensation and benefits in order to attract and retain excellent employees and support their overall well-being. Our total rewards compensation package includes market-competitive salary, the potential to earn bonuses or sales commissions, equity, healthcare benefits, retirement savings plans, paid time off and family leave, wellness programs, free flu vaccinations and an Employee Assistance Program and other mental health services. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe employees should be paid for the value of their work, regardless of race, ethnicity, gender or other protected characteristics. To this end, we benchmark and tie compensation to market data as well as to an employee&#8217;s experience, function, and performance. We regularly review our workforce compensation practices and strive for equity. Specifically, we partner with independent, third-party experts to conduct a regular and detailed pay equity assessment to determine whether gender and race/ethnicity have a significant impact on pay levels across the organization. This pay equity analysis is conducted on an employee&#8217;s total compensation, including base pay, bonus and equity. If we identify any pay gap across the organization, we typically make adjustments to mitigate such gaps. Our managers also receive training in how to recognize and prevent discrimination in hiring, performance management and compensation decisions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional Growth and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We help our employees develop the skills and capabilities to support BioMarin&#8217;s growth and innovation. We continually invest in our employees&#8217; career growth and provide them with a wide range of development opportunities, including face-to-face, virtual and self-directed learning, mentoring, mobile coaching and external development. We offer our employees career-specific training and resources and support development opportunities through company sponsored programs in addition to our tuition </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">reimbursement program. We also provide our high-potential employees with a variety of leadership coaching and management programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Patient and Community Connections</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are striving to support our local communities around the world by developing programs that inspire and enrich both our patient populations and the areas where we live and work. We actively engage with underrepresented populations through a variety of outreach and programs. We collaborate with Biotech Partners, a non-profit organization in the San Francisco Bay Area focused on helping students who are underrepresented in the biotechnology field to gain experience through classroom instruction and paid internships. We also partner with Health Career Connection, a national non-profit that prepares the next generation of diverse, transformational health, equity and racial justice leaders by providing promising undergraduate college students from underrepresented backgrounds and under-resourced communities with paid internship programs, health equity scholars programs and alumni professional development initiatives. In addition, we award annual scholarships to students living with rare disease through our Rare Scholars program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were incorporated in Delaware in October 1996. Our principal executive offices are located at 770 Lindaro Street, San Rafael, California 94901 and our telephone number is (415) 506-6700. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) are available free of charge at www.bmrn.com as soon as reasonably practicable after electronically filing such reports with the Security and Exchange Commission (the SEC). Such reports and other information may be accessed through the SEC&#8217;s website at www.sec.gov. Information contained in our website is not part of this or any other report that we file with or furnish to the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The course of treatment for patients using our products is expensive. For all our products except ROCTAVIAN, we expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenues and gross margin will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reimbursement in the European Union (EU) and many other territories must be negotiated on a country-by-country basis, and in many countries the product cannot be commercially launched until pricing and/or reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margin may be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Because the target patient populations for our products are relatively small, we must achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All of our products target diseases with relatively small patient populations. Our two newest products, VOXZOGO and ROCTAVIAN, address potentially larger patient populations than most of our other products; however, their market sizes are considerably smaller than many drugs marketed by other pharmaceutical and biotechnology companies. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve and maintain profitability. For BRINEURA, NAGLAZYME and VIMIZIM in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenues could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely) or commercialize their products before we do. With respect to ROCTAVIAN, which has been conditionally approved in the EU and may be approved in the U.S. and other markets in the future, we face a highly developed and competitive market for hemophilia A treatments. As we commercialize ROCTAVIAN, we may face intense competition from large pharmaceutical companies with extensive resources and established relationships in the hemophilia A community. If we do not compete successfully, our revenues would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as ALDURAZYME, NAGLAZYME, and VIMIZIM in MPS diseases, could be greatly reduced. Changes in treatment method can be caused by the introduction of other companies&#8217; products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future growth and development depend in part on our ability to successfully develop new products from our research and development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals, are inherently uncertain and may not result in the commercialization of any products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as ALDURAZYME, KUVAN and NAGLAZYME. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which may target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The sale of generic versions of KUVAN by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in KUVAN revenues faster than expected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic versions of KUVAN are available in several countries around the world, including multiple generic versions in the U.S. This generic competition has adversely affected and will continue to adversely affect our revenues from KUVAN, and we cannot accurately predict the rate of decline of KUVAN revenues in these countries. We are also aware that manufacturers are challenging our patent portfolio related to KUVAN in several jurisdictions, and several generic versions of KUVAN have been approved either centrally by the European Medicines Agency (EMA) or on a country-by-country basis throughout the EU. If these patent challenges are successful, or if a manufacturer chooses to offer a generic version of KUVAN, notwithstanding our existing patents, our revenues from KUVAN may decline faster than expected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce or fail to achieve such goals, the commercialization of our product candidates may be delayed or never occur and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates or the milestones may never be achieved, in many cases for reasons beyond our control. For example, in 2021 and early 2022, we announced that we planned to resubmit our Biologics License Application (BLA) for ROCTAVIAN to the Food and Drug Administration (FDA) in the first half of 2022; however, we did not file the BLA until the third quarter of 2022 due to the additional time we needed to include supplemental information and analyses of data requested by the FDA. If we do not meet development milestones as publicly announced, the commercialization of our products may be delayed or never occur and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have in the past and may in the future enter into licensing arrangements, and we may not realize the benefits of such licensing arrangements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have in the past and may in the future enter into licensing arrangements with third parties. It is possible that we may not achieve financial or strategic benefits that justify a specific license, or we may otherwise not realize the benefits of such licensing arrangement. Further, licensing arrangements impose various diligence, milestone and royalty payment and other obligations on us. If we fail to comply with our obligations under any current or future licenses, our licensors may have the right to terminate these license agreements, which could harm our business prospects, financial condition and results of operations. Additionally, counterparties to our license agreements have in the past alleged and may in the future allege that we have breached a license agreement, which can result in litigation or other disputes that can divert management&#8217;s attention away from our business and require us to expend resources, as well as potentially having to negotiate new or reinstated licenses with less favorable terms. Any such situation could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenues from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We must obtain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain FDA approval for each product candidate that we intend to commercialize, and in the EU, we must obtain approval from the European Commission (EC), based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The FDA and EC approval processes are typically lengthy and expensive, and approval is never certain. To obtain regulatory approval, we must first show that our product candidates are safe and effective for target indications through preclinical studies and clinical trials. Preclinical studies and clinical development are long, expensive and uncertain processes. Completion of clinical trials may take several years, and failure may occur at any stage of development. The length of time required varies substantially according to the type, complexity, novelty and intended use of a product candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory authority will mean that other authorities will also approve the same product candidate. For example, the EC&#8217;s conditional approval of ROCTAVIAN in August 2022 does not guarantee that the FDA will approve the same drug. Similarly, in the EU, a positive CHMP opinion for approval of a product candidate does not guarantee that the EC will approve a drug. Moreover, regulatory authorities may approve a product candidate for fewer or more limited indications than requested. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have had fewer interactions with regulatory authorities outside the U.S. and the EU as compared to our interactions with the FDA and EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EC approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EC does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by regulatory authorities in other non-U.S. countries or by the FDA or EC. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA or EC approval. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also rely on independent third-party CROs to file some of our non-U.S. marketing applications, and while we keep a close oversight on the activities we delegate to CROs, important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although the FDA and the EMA have programs to facilitate expedited development and accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. Accordingly, even if any of our applications receives a designation to facilitate expedited development and accelerated approval processes, these designations may not result in faster review or approval for our product candidates compared to product candidates considered for approval under conventional procedures and, in any event, do not assure ultimate approval of our product candidates by regulatory authorities. In addition, the FDA, the EMA and other comparable international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy to grant approval and may require, and in the past have required, additional data. If we fail to obtain regulatory approval for our product candidates, we will be unable to market and sell those product candidates, which would have a negative effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our treatment candidate or lead to significant post-approval studies, limitations or restrictions. For example, on August 18, 2020, the FDA issued a Complete Response Letter (CRL) to our BLA for ROCTAVIAN for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for two-year follow-up safety and efficacy data on all study participants from our ongoing Phase 3 study of ROCTAVIAN. In January 2022, we announced results from the requested two-year data analysis from our Phase 3 study. In the third quarter of 2022, we resubmitted our BLA, and the FDA subsequently accepted our submission with a Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2023. Typically, BLA resubmissions are followed by a six-month review procedure. However, we anticipate three additional months of review may be necessary based on the data read-out we announced on January 8, 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, some of our product candidates are intended to be used in combination with a medical device, such as an injector or other delivery system or companion diagnostic. Such products may be regulated as &#8220;combination products&#8221; in the U.S. and the EU, which are generally defined as products consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). In the U.S., each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. In the EU, if a device intended to administer a medicinal product is sold together with such medicinal product in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product is regulated as a medicinal product. In addition, the relevant general safety and performance requirements established for medical devices by EU medical devices legislation apply to the device component of such combination products. Our product candidates intended for use with separately regulated devices, or expanded indications that we may seek for our products used with such devices, may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug or biologic product and device is sought under a single application, the increased complexity of the review process may delay approval. The FDA review process and criteria are not well-established areas, which could also lead to delays in the approval process. In addition, because these devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time during the development and regulatory approval process for our products and product candidates, we engage in discussions with the FDA, the EMA and other comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory agencies globally, but we do not always follow such guidance. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. Moreover, sometimes different regulatory agencies provide different or conflicting advice. While we attempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA, the EMA and other comparable international regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenues from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and VIMIZIM have received regulatory approval to be commercially marketed and sold in the U.S., the EU and certain other countries, PALYNZIQ has received regulatory approval to be commercially marketed in the U.S., the EU, and Australia. VOXZOGO has received regulatory approval to be commercially marketed in the U.S., the EU, and Brazil. ROCTAVIAN has received conditional approval to be commercially marketed in the EU. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and/or other comparable international and national regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An example of the ongoing regulatory requirements our products are subject to is the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., PALYNZIQ is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">prescribers must be certified by enrolling in the REMS program and completing training;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">prescribers must prescribe auto-injectable epinephrine with PALYNZIQ;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">pharmacies must be certified with the REMS program and must dispense PALYNZIQ only to patients who are authorized to receive it;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with PALYNZIQ; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">patients must have auto-injectable epinephrine available at all times while taking PALYNZIQ.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of PALYNZIQ. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the PALYNZIQ REMS program, or whether the FDA will permit modifications to the PALYNZIQ REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute PALYNZIQ in the U.S., impair the safety profile of PALYNZIQ, disrupt continuity of care for PALYNZIQ patients and/or negatively affect sales of PALYNZIQ.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. In particular, a product may not be promoted for uses that are not approved by the FDA or the EC as reflected in the product&#8217;s approved labeling. Although the FDA and other comparable international and national regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. The FDA and other national competent authorities or international regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we are not able to promote any products we develop for indications or uses for which they are not approved. Additionally, in the EU, it is prohibited to promote prescription drugs to the general public and we are therefore limited to promote our products exclusively to healthcare professionals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, if original FDA approval for one of our product candidates is granted via the accelerated approval pathway, we will be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of the FDA&#8217;s marketing approval for a product candidate. For example, VOXZOGO is approved in the U.S. under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies. To fulfill this post-marketing requirement, we intend to use our ongoing open-label extension studies compared to available natural history. In addition, the FDA and the EC often require post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on product manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on the marketing of a product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on product distribution;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to conduct post-marketing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">untitled or warning letters or other adverse publicity;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory authorities withdraws its approval of a product, we will be unable to generate revenues from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the drug development process we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early-stage product candidates, we may need to perform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial will be favorable. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">slow or insufficient patient enrollment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">slow recruitment of, and completion of necessary institutional approvals at, clinical sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">budgetary constraints or prohibitively high clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">longer treatment time required to demonstrate efficacy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">lack of sufficient supplies of the product candidate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse medical events or side effects in treated patients, including immune reactions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">lack of effectiveness of the product candidate being tested;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">availability of competitive therapies to treat the same indication as our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory requests for additional clinical trials or preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">deviations in standards for Good Clinical Practice (GCP); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has been under scrutiny for many years and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected. For example, in the EU, governments influence the price of medicinal products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. An EU Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. Other EU Member States allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payers. There is also no assurance that an adequate level of reimbursement will be established even if coverage is available or that the third-party payers&#8217; reimbursement policies will not adversely affect our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. In the U.S., there have been several recent congressional inquiries, proposed and enacted federal and state legislation and executive action designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. Recently, healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (IRA) in August 2022, which will, among other things, allow U.S. Department of Health and Human Services (HHS) to negotiate the selling price of certain drugs and biologics that the CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the IRA, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. Since its enactment, there have been executive, judicial and congressional challenges to certain aspects of the PPACA. Although the PPACA has generally been upheld thus far, it is unclear how continued challenges to the law may impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, price disclosure and reporting requirements, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Likewise, in many EU Member States, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU Member States and other non-U.S. countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. If the price of one of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">products decreases substantially in a reference price country, it could impact the price for that product in other countries. Consequently, a downward trend in prices of our products in some countries could contribute to similar downward trends elsewhere, which would have a material adverse effect on our revenues and results of operations. Moreover, in order to obtain reimbursement for our products in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our products to other available therapies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We anticipate that the IRA, PPACA and other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Recently there has been heightened governmental scrutiny in countries worldwide over the manner in which manufacturers set prices for their marketed products. Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. In the EU, pursuant to the Orphan Regulation, orphan drug designation is available if a sponsor can establish that: (1) the medicine is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU at the time the application is made, or, (2) that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives derived from the orphan status, it is unlikely that the marketing of the medicine in the EU would generate sufficient return to justify the necessary investment. In both cases, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicine will be of significant benefit to those affected by that condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity (extendable to twelve years for orphan drugs that have complied with an agreed Pediatric Investigation Plan (PIP) pursuant to Regulation 1901/2006), during which similar medicines for the same indication cannot be placed on the market, is granted. MAs may also be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior to the orphan medicinal product already authorized; (ii) the MA holder for the first orphan medicinal product grants its consent; or (iii) if the MA holder of the orphan medicinal product is unable to supply sufficient quantities. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act and/or the Orphan Regulation, as applicable, to maintain a competitive position. If we do not obtain orphan drug exclusivity for our products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor product&#8217;s orphan drug exclusivity period expires. Moreover, with respect to certain biologics and gene therapies, there may be some uncertainty regarding how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidates&#8217; orphan drug exclusivities. For biologics and gene therapies, the FDA&#8217;s determination of whether a drug is the same drug or a different drug will be based on the principal molecular structural features of the products. For gene therapy products, the FDA has stated in guidance that it generally intends to consider certain key features such as transgenes and vectors used in gene therapy products to be principal molecular structural features. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ and VIMIZIM products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated approval of biological products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-approved biological product. A similar abridged MA process is available to biosimilar products in the EU. In particular, applicants for MAs of biosimilars are required to demonstrate through comprehensive comparability studies with the reference biological medicine that: a) their biological medicine is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines; and b) there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., in order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of exclusivity for reference products. In the EU, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or as a result of Marketing Authorization Applications (MAAs) in the EU, as well as our product candidates that may be approved in the future, could be reference products for biosimilar marketing applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in funding for the FDA, the EMA, other comparable international regulatory authorities and other government agencies or government shutdowns could hinder the ability of such agencies to hire and retain key leadership and other personnel or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in funding levels of government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA or the EMA to timely review and approve INDs or MAAs for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government shutdowns could also impact the ability of government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory agencies, such as the FDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Gene Therapy Programs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our gene therapy products and product candidates are based on a novel technology, which presents additional development, manufacturing, regulatory and treatment risks in relation to our other, more traditional drug development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the risks set forth in this Risk Factors section associated with more traditional pharmaceutical drugs, there are additional, unique development, manufacturing, regulatory and treatment risks associated with gene therapy products and product candidates like ROCTAVIAN and BMN 331. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The goal of gene therapy is to be able to correct an inborn genetic defect through administration of therapeutic genetic material containing non-defective gene copies. The gene copies are designed to reside permanently in a patient, allowing the patient to produce an essential protein or ribonucleic acid (RNA) molecule that a healthy person would normally produce. There is a risk, however, that the new gene copies will produce too little or too much of the desired protein or RNA. Although administration of a gene therapy product like ROCTAVIAN is intended to correct an inborn genetic defect for at least several years, there is a risk that the therapeutic effect will not be durable and production of the desired protein or RNA will decrease more quickly or cease entirely earlier than expected. If the therapeutic effect decreases significantly or ceases entirely, it is uncertain whether redosing is possible or would be effective. Furthermore, because gene therapy treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential overproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Additionally, because </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, gene therapy products are relatively novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the gene therapy manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all, or commercializing our gene therapy products on a profitable basis, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, we may experience regulatory challenges specific to gene therapy that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials, the FDA has only approved a very small number of vector-based gene therapy products thus far. Moreover, there are very few approved gene therapy products outside the U.S. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our gene therapy product candidates in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. For example, in October 2020, it was reported that the Director of the Center for Biologics Evaluation and Research, the center of the FDA responsible for reviewing marketing applications for gene therapies, stated that the FDA will assess the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Additionally, in September 2021, the FDA held a Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) to discuss toxicity risks of adeno-associated virus (AAV) vectors for gene therapy and to seek the CTGTAC&#8217;s insight into strategies to evaluate and mitigate risks in the context of AAV vector-based product design and quality, preclinical studies, and clinical trials. ROCTAVIAN and BMN 331 are AAV vector-based product candidates. Further, the FDA continues to develop and publish new guidance and policies, such as the publication of four draft or final gene therapy-specific guidance documents in 2022. These guidance documents and other recent policy statements demonstrate that the FDA&#8217;s regulatory requirements for gene therapies are likely to continue to evolve based upon factors such as the intended disease or class of diseases, product type or mechanism of action, as well as broader considerations such as the kinds of evidence that will be required for gene therapy products to take advantage of expedited development programs. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring our gene therapy product candidates to market could have a negative effect on our business and financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As compared to our other, more traditional products, gene therapy products may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the risks set forth in this Risk Factors section associated with commercializing more traditional pharmaceutical drugs, there are additional, unique commercial risks associated with gene therapy products like ROCTAVIAN. Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we face uncertainty with respect to the pricing, coverage and reimbursement of these products. In order to recover our research and development costs and commercialize one-time treatments on a profitable basis, the cost of a single administration of ROCTAVIAN is substantial, and it is likely other gene therapy products would also require relatively high prices. Therefore, coverage and reimbursement by governments and other third-party payers is essential for the vast majority of patients to be able to afford ROCTAVIAN or other gene therapy products that we may commercialize in the future. Accordingly, sales of our gene therapy products will depend substantially on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of our gene therapy products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to ROCTAVIAN specifically, we have entered into, and plan to enter into additional, outcomes-based agreements for the product with third-party payers to assist with realizing the value and sharing the risk of a one-time treatment, which make us subject to potential repayments if a patient does not respond to therapy or the therapeutic effect of the drug falls below specified thresholds. Although we will record reserves for potential refunds under the outcomes-based agreements for ROCTAVIAN in the same period as sales, our revenues and financial results could be adversely affected if our assumptions underlying our refund reserves differ from actual experience or otherwise underestimate refund obligations. Additionally, the increased complexity of reimbursement with outcomes-based arrangements heightens the risk that our price reporting may be inaccurate or delayed, which may result in fines and liability.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. The commercial success of ROCTAVIAN or any other gene therapy product candidate that may be approved in the future will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">product in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of one of our gene therapy treatments until the product has been on the market for a certain amount of time. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, ROCTAVIAN or future gene therapy products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have implemented data access plans for our main clinical trials of ROCTAVIAN, which restrict our management&#8217;s review of emerging key efficacy data from these trials. Without access to this ongoing data, management does not have the ability to adjust the trials based on such emerging data, which could adversely impact the ultimate outcome of these trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to preserve the scientific integrity of our main ROCTAVIAN clinical trials and to allow us to only report on data at intervals that we believe will be meaningful to investors, we have implemented data access plans related to these ongoing open-label trials, which plans are designed to significantly mirror blinded trials. Pursuant to the plans, the ongoing emerging data for key endpoints are generally not accessed by us, with the exception that certain specific data points are reviewed by a small group of medical personnel monitoring and managing the trials, and then, only to the extent necessary to allow them to perform their monitoring responsibilities. As we disclose and publicly discuss prior data from one of these trials, such discussions do not incorporate any of the currently emerging data that are being collected and reviewed by personnel monitoring the trial and, accordingly, this prior data may differ significantly from more recent data that are only available to such personnel. Further, because our management does not have access to any of the ongoing key efficacy data and does not have the ability to adjust the trials based on such emerging data, the data access plans could adversely impact the ultimate outcome of the trials.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial and Financing Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for each year since our inception, with the exceptions of 2008, 2010, 2020 and 2022. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we fail to become profitable or are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents and investments totaling $1.6 billion and debt obligations of $1.1 billion (undiscounted), which consisted of our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes) and our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes). The 2024 Notes and the 2027 Notes (collectively, the Notes), if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may require additional financing to fund the repayment of the Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully market and sell our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, number, size and scope of our preclinical studies and clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress of research programs carried out by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Sanofi&#8217;s ability to continue to successfully commercialize ALDURAZYME; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">whether our convertible debt is converted to common stock in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional licenses and collaborative agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional contracts for product manufacturing; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional financing facilities or arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional equity and/or equity-linked securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $1.1 billion (undiscounted) principal amount of indebtedness, including $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes and $600.0 million (undiscounted) principal amount of indebtedness under the 2027 Notes. In October 2018, we entered into an unsecured credit agreement (the 2018 Credit Agreement) with Bank of America, N.A., as the administrative agent, swingline lender and a lender, Citibank, N.A. as letter of credit issuer and each of Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, Citibank, N.A. and Wells Fargo Securities, LLC as joint lead arrangers and joint bookrunners, providing up to $200.0&#160;million in revolving loan commitments (the 2018 Credit Facility). In May 2021, we amended the 2018 Credit Facility to, among other things, extend the maturity date of the 2018 Credit Facility from October 19, 2021 to May 28, 2024. Our indebtedness may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">require us to use a substantial portion of our cash flow from operations to make debt service payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our flexibility to plan for, or react to, changes in our business and industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">place us at a competitive disadvantage compared to our less leveraged competitors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">increase our vulnerability to the impact of adverse economic and industry conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the 2018 Credit Facility contains, and any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full. If we default under the 2018 Credit Facility, the outstanding borrowings thereunder could become immediately due and payable, the 2018 Credit Facility lenders could refuse to permit additional borrowings under the facility, or it could lead to defaults under agreements governing our current or future indebtedness, including the indentures governing the Notes. If we default under any series of the Notes, such series of Notes could become immediately due and payable and it could lead to defaults under the other series of Notes and/or the 2018 Credit Facility.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our outstanding indebtedness consists primarily of the 2024 Notes and 2027 Notes, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon maturity of the Notes, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we also may borrow up to $200.0&#160;million in revolving loans under the 2018 Credit Facility, which would be required to be repaid in cash at maturity on May 28, 2024.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Manufacturing Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Before we can begin commercial manufacture of our products, regulatory authorities must approve marketing applications that identify authorized manufacturing facilities operated by us or our contract manufacturers that have passed regulatory inspection and manufacturing processes that are acceptable to the regulatory authorities. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced inspection by the FDA, and other comparable EU and other national and international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facility in the U.S. has </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">received a good manufacturing practice certificate from the EMA for the manufacture and distribution of ROCTAVIAN in the EU, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">been approved by the FDA and the EC for the manufacture of PALYNZIQ, and been approved by the FDA, the EC, and health agencies in other countries for the manufacture of ALDURAZYME, BRINEURA, NAGLAZYME, VIMIZIM and VOXZOGO.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our manufacturing facility in Shanbally, Cork, Ireland has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of VIMIZIM and BRINEURA. In addition, our third-party manufacturers&#8217; facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal or international regulatory inspection.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our product candidates and products, we may not be able to manufacture sufficient quantities. Our inability to produce enough of our product candidate at acceptable costs may result in the delay or termination of development programs. With respect to our commercial portfolio, we may not be able to manufacture our products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We currently rely on third parties for portions of the manufacture of each of our products. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our manufacturing processes subject us to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We depend on single-source suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">labor interruptions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in our sources for manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing and delivery of shipments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">conditions affecting the cost and availability of raw materials, including inflation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If our Manufacturing, Marketing and Sales Agreement with Sanofi were terminated, we could be prevented from continuing to commercialize ALDURAZYME or our ability to successfully commercialize ALDURAZYME would be delayed or diminished.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Sanofi and us related to ALDURAZYME for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching party&#8217;s interest in ALDURAZYME and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to ALDURAZYME and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating party&#8217;s interest in ALDURAZYME and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to ALDURAZYME will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to ALDURAZYME is to be sold to the highest bidder, with the proceeds to be split between Sanofi and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to ALDURAZYME exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offeree&#8217;s interest in ALDURAZYME and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating party&#8217;s interest in ALDURAZYME and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to ALDURAZYME. The Amended and Restated Collaboration Agreement between us and Sanofi will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we were obligated or given the option to buy out Sanofi&#8217;s interest in ALDURAZYME and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to ALDURAZYME, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Sanofi&#8217;s interest, we may be held in breach of the agreement and may lose any claim to the rights to ALDURAZYME and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing ALDURAZYME. If this happened, not only would our product revenues decrease, but our share price would also decline.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to International Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the sales of our products are generated from countries other than the U.S., and we expect international markets will continue to be important for the sales of any products approved in the future. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the increased complexity and costs inherent in managing international operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">political and economic instability, such as the instability caused by Russia&#8217;s invasion of Ukraine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property in some countries outside of the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">trade protection measures and import or export licensing requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulty in staffing and managing international operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">differing labor regulations and business practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">potentially negative consequences from changes in or interpretations of tax laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in international medical reimbursement policies and programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by non-U.S. governments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; and service providers&#8217; activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russia&#8217;s invasion of Ukraine and the related impacts to Ukraine&#8217;s infrastructure and healthcare system has significantly impacted our ability to provide our therapies to patients in Ukraine. Sanctions issued by the U.S. and other countries against Russia and Belarus in response to the attack on Ukraine and related counter-sanctions issued by Russia have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia and Belarus. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenues and profitability.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenues in these countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We make a significant portion of our initial international sales of newly launched products through early access, special access or &#8220;named patient sales&#8221; programs in markets where we are not required to obtain regulatory approval. For example, a significant portion of our international sales of VOXZOGO since the product&#8217;s launch have been made through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained to initiate such programs, and in some cases, special approval must be obtained for each patient. The approval normally requires an application or a lawsuit accompanied by evidence of medical need.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These programs are not well defined in some countries and are subject to changes in requirements, funding levels, unmet medical need and classification of the disease treated by our product. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders, requiring additional in-country testing and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Without the special access programs, we would need to seek full product approval or official reimbursement to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek, obtain and maintain a full product approval or official reimbursement, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our international operations pose currency risks, which may adversely affect our operating results and net income.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant and growing portion of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the Canadian Dollar, the Colombian Peso, the Argentine Peso and several other currencies, changes in those currencies relative to the U.S. Dollar (USD) will impact our revenues and expenses. If the USD were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the USD were to strengthen against another currency (as was the case for many currencies in 2022), assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. In addition, because our financial statements are reported in USD, changes in currency exchange rates between the USD and other currencies have had, and will continue to have, an impact on our results of operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">U.S. export control and economic sanctions may adversely affect our business, financial condition and operating results. Moreover, compliance with such regulatory requirements may increase our costs and negatively impact our ability to sell our products and collect cash from customers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or hinder our ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. For example, sanctions issued by the U.S. and other jurisdictions against Russia and Belarus in response to the invasion of Ukraine have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia and Belarus. Moreover, if we fail to comply with these laws and regulations, we could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges and fines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, the general license will be renewed in the future or we will remain in compliance with the general license. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, U.S. export control and economic sanctions may make operating in certain countries more difficult and expensive. For example, we may be unable to find distributors or financial institutions willing to facilitate the sale of our products and collection of cash from such sales in a cost-effective manner, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the U.S. and other similar laws in other countries in which we do business. We operate in a number of countries that are recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered non-U.S. government officials for purposes of applicable anti-corruption laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party independent charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of ALDURAZYME, NAGLAZYME and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in KUVAN) has also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Patents have limited duration and expire. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, and the implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is also unclear whether our trade secrets are adequately protected. Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, materials we submit to the EMA in connection with our clinical trials that were traditionally regarded as confidential, proprietary information, such as study protocols, information regarding manufacturing methods and controls, and intermediate data analyses, are now subject to public disclosure. Moreover, clinical trial data submitted to the EMA in our MAAs are also available to the public. We are only permitted to redact from public disclosures commercially confidential information, a standard which is construed narrowly and subject to the interpretation and final decision of the EU regulatory authorities. EU regulations have resulted and will continue to result in the EMA&#8217;s public disclosure of certain of our proprietary information related to recently completed and future clinical trials and MAA submissions. The move toward public disclosure of such development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">information could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, increasing scrutiny of our product candidates and products, and enabling competitors to use our clinical trial information and data to gain approvals for their own products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Competitors may interfere with our patent process in a variety of ways. Competitors may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, a competitor could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent. Moreover, generic manufacturers may use litigation and regulatory means to obtain approval for generic versions of our products notwithstanding our filed patents or patent applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenues and financial results generally.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, such as ROCTAVIAN, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. If someone else claims we infringe their intellectual property, we would face a number of issues, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Defending a lawsuit takes significant executive resources and can be very expensive.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If a court decides that our product infringes a competitor&#8217;s intellectual property, we may have to pay substantial damages.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may need to redesign our product so it does not infringe the intellectual property rights of others. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Redesigning our product so it does not infringe the intellectual property rights of competitors may not be possible or could require substantial funds and time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our stock price has been and may in the future be volatile, and an investment in our stock could suffer a decline in value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our stock price has been and may in the future be volatile. Our valuation and stock price may have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock will fluctuate due to factors including: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">product sales and profitability of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturing, supply or distribution of our product candidates and products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">results of clinical trials, announcements of technological innovations or new products by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">generic competition to KUVAN tablets and powder described above in this Risk Factors section or potential generic competition from future competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">government regulatory action affecting our product candidates, our products or our competitors&#8217; product candidates and products in both the U.S. and non-U.S. countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments or disputes concerning patent or proprietary rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">economic conditions in the U.S. or abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative publicity about us or the pharmaceutical industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">cybersecurity incidents experienced by us or others in our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">broad market fluctuations in the U.S., the EU or in other parts of the world;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">actual or anticipated fluctuations in our operating results, including due to timing of large periodic orders for our products by governments in certain countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in company assessments or financial estimates by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">acquisitions of products, businesses, or other assets; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, the stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In some cases, these fluctuations have been unrelated or disproportionate to the operating performance of those companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. For example, in September 2020, after a substantial drop in our stock price that followed an announcement providing a regulatory update regarding ROCTAVIAN, we and certain of our officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. In addition, in October 2021, after a drop in our stock price that followed an announcement providing a regulatory update regarding BMN 307, we and certain of our current and former officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. We may be the target of additional litigation of this type in the future as well. Securities litigation against us could result in substantial costs and divert our management&#8217;s time and attention from other business concerns, which could harm our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Conversion of the Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take us over.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The terms of the Notes require us to offer to repurchase the Notes in the event of a fundamental change (as defined in each indenture governing the Notes). A takeover of us would trigger options by the respective holders of the applicable Notes to require us to repurchase such Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the Notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholders&#8217; meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the U.S. as the exclusive forums for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any derivative claim or cause of action brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action for breach of a fiduciary duty owed by any director, officer or other employee of BioMarin to us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action against us or any of our directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate of incorporation or our amended and restated bylaws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction to the Court of Chancery of the State of Delaware; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. In addition, our amended and restated bylaws provide that the federal district courts of the U.S. of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either of our exclusive forum provisions to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. Our amended and restated bylaws further provide that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provisions.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We depend upon our key personnel and our ability to attract and retain qualified employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of a significant portion of our workforce or any member of our senior management or the inability to hire or retain qualified personnel could adversely affect our ability to execute our business plan and harm our operating results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the specialized nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officers&#8217; ability to compete with us after their employment is terminated. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. This competition was exacerbated during the COVID-19 pandemic, and we have recently experienced increased employee turnover like many other employers in the U.S. during the &#8220;great resignation.&#8221; Due to the intense competition for talent, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. If we are unsuccessful in our recruitment and retention efforts, our business may be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our success depends on our ability to manage our growth.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our two newest products, VOXZOGO and ROCTAVIAN, address potentially larger patient populations than most of our other products, and product candidates that we are currently developing or may license or acquire in the future may be intended for similarly larger patient populations than we have historically targeted. In order to continue development of such product candidates and marketing of products with larger markets, we will need to continue expanding our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory, competitive, and corruption risks and our management may be unable to manage successfully current or future market opportunities or our relationships with customers and other third parties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">New tax laws or regulations that are enacted or existing tax laws and regulations that are interpreted, modified or applied adversely to us or our customers may have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, the Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Any future tax legislation could increase our U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, changes in the tax laws of jurisdictions in which we conduct business could arise, including as a result of the base erosion and profit shifting (BEPS) project that is being led by the Organization for Economic Co-operation and Development (OECD), and other initiatives led by the OECD or the EC. For example, the OECD, which represents a coalition of member countries including the U.S. and other countries in which we have operations, is working on proposals, commonly referred to as &#8220;BEPS 2.0&#8221;, which, if implemented, would make important changes to the international tax system. These proposals are based on two &#8220;pillars&#8221;, Pillar One focuses on the allocation of taxing rights in respect of certain profits of multinational enterprises with annual global revenue above 20 billion euros and profitability above 10% to the jurisdictions within which they carry on business (based on the thresholds, we currently expect to be outside the scope of the Pillar One proposals) and Pillar Two imposes a minimum effective tax rate of 15% on certain multinational enterprises that have consolidated revenues of at least 750 million euros in at least two out of the last four years (based on the thresholds, we currently expect that we could fall within the scope of the Pillar Two </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">proposals). The EU has adopted a Council Directive requiring aspects of the Pillar Two proposal to be transposed into the national laws of EU Member States by December 31, 2023, and a number of other countries in which we conduct business are also planning to enact such rules. The implementation of such rules may increase the amount of tax we have to pay, increase tax uncertainty and may adversely affect our provision for income taxes, results of operations and cash flows. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#8217;s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, resulting in a higher tax liability. In addition, if a country from which income is reallocated does not agree with the reallocation, both that country and the other country to which the income was allocated could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, reputation, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase, order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state false claims laws, including the civil False Claims Act and the Civil Monetary Penalties Law, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, recent healthcare reform legislation has strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and non-U.S. laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the U.S., California enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California consumers expanded rights to access and delete their personal information, opt out of certain personal information sales, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA was expanded substantially on January 1, 2023 when the California Privacy Rights Act of 2020 (CPRA) took effect and amended the CCPA. Following the CPRA amendments, the CCPA, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, expands an individual&#8217;s private right of action and establishes the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to California, other U.S. states have recently adopted consumer data protection and privacy laws, and more U.S. states may do so in the future. This creates the potential for a patchwork of overlapping but different state laws and could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business, financial condition, and results of operations. Many other states are considering proposed comprehensive data privacy legislation and all 50 states have passed some form of legislation relating to privacy or cybersecurity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aspects of the CCPA, CPRA and similar laws in other states and their interpretation and enforcement remain uncertain. The potential effects of these laws are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Complying with these or other similar laws, regulations, amendments to or re-interpretations of existing laws and regulations, and contractual or other obligations relating to privacy, data protection, data transfers, data localization, or information security may require us to make changes to our services to enable us or our customers to meet new legal requirements, incur substantial operational costs, modify our data practices and policies, and restrict our business operations. Any actual or perceived failure by us to comply with these laws, regulations, or other obligations may lead to significant fines, penalties, regulatory investigations, lawsuits, significant costs for remediation, damage to our reputation, or other liabilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EEA Member State legislations supplementing such regulation, apply to the processing of personal data of individuals located in the EEA, including health-related information, by companies located in the EEA, or in certain circumstances, by companies located outside of the EEA. These laws impose strict obligations on the ability to collect, record, store, disclose, use and transmit personal data, including health-related information. These include several requirements relating to (i) obtaining, in some situations, the informed consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). Switzerland has adopted similar restrictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The GDPR and other European data protection laws generally restrict the transfer of personal information from Europe, including the EEA and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from the EEA has been the EC&#8217;s Standard Contractual Clauses (SCCs). However, the Court of Justice of the EU (CJEU) issued a decision that called into question whether the SCCs can lawfully be used for transfers of personal information from Europe to the United States or most other countries. At present, there are few, if any, viable alternatives to the SCCs, on which we have relied for personal information transfers from Europe to the United States and other &#8220;third countries.&#8221; After the mentioned CJEU judgment, new sets of SCCs were published on June 4, 2021. Most importantly, the use of SCCs does not any longer automatically ensure compliance with the GDPR. Instead, companies remain required to conduct a data transfer impact assessment for each transfer, which adds a compliance burden.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential pecuniary fines for noncompliance with the GDPR may be up to the greater of &#8364;20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process and has increased our compliance costs. The EU regulations that make certain materials we submit to the EMA in connection with our clinical trials subject to public disclosure have increased the risk that we may unintentionally disclose personal information protected under the GDPR and thereby incur associated penalties and suffer reputational damage.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the U.S. and European countries, other countries in which we operate have also enacted data privacy laws or may do so in the future. For example, Brazil&#8217;s General Data Protection Law (LGPD), which is modeled on the GDPR, took effect on August 16, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Substantial new laws and regulations affecting compliance have also been adopted in the U.S. and certain non-U.S. countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as investment and ownership interests held by such physicians and their immediate family members during the preceding calendar year. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many non-U.S. countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted non-U.S. legislation creates reporting obligations on payments, gifts and benefits made to these professionals. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement agencies in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to significant criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercialization of our product programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively and have a material adverse effect on our business, reputation, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely significantly on our information technology systems to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse (whether intentional or inadvertent) of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively. Our ability to manage and maintain our operations, inventory and internal reports, to manufacture and ship our products to customers and timely invoice them depends significantly on our enterprise resource planning, production management and other information systems. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, cyberattack and other disruptions. Potential problems and interruptions associated with the implementation of new or upgraded technology systems or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations and expose us to greater risk of security breaches. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access or unavailability of these systems or those of any third parties in our supply chain or on whom we otherwise depend, have occurred in the past and may affect our ability in the future to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of our business, we collect, store, and transmit large amounts of confidential information, proprietary data, intellectual property, and personal data. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties on whom we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation. Data security breaches may be the result of unauthorized or unintended activity (or lack of activity) by our employees, contractors, or others with authorized access to our network or malware, hacking, business email compromise, phishing, ransomware or other cyberattacks directed by third parties. While we have implemented measures to protect our information and data stored in our technology systems and those of the third parties that we rely on, our efforts may not be successful.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have experienced and may continue to experience cybersecurity incidents, although to our knowledge we have not experienced any material incident or interruption to date. If such a significant event were to occur, it could result in a material disruption of our development programs and commercial operations, including due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information. Further, these cybersecurity incidents can lead to the public disclosure of personal information (including sensitive personal information) of our employees, clinical trial patients and others and result in demands for ransom or other forms of blackmail. Such attacks, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems, are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#8220;hacktivists&#8221;, nation states and others. Moreover, the costs to us to investigate and mitigate cybersecurity incidents could be significant. For example, the loss of clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security breach that results in the unauthorized access, use or disclosure of personal data may require us to notify individuals, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">governmental authorities, credit reporting agencies, or other parties pursuant to privacy and security laws and regulations or other obligations. Such a security compromise could harm our reputation, erode confidence in our information security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, proprietary or personal information, we could be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims, litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not all our contracts contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If a natural disaster, terrorist or criminal activity or other unforeseen event caused significant damage to our facilities or those of our third-party manufacturers and suppliers or significantly disrupted our operations or those of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair the ability for us or our third-party manufacturers to manufacture our products and product candidates. Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for ALDURAZYME, NAGLAZYME, VOXZOGO and PALYNZIQ and is one of two manufacturing facilities for BRINEURA and VIMIZIM. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support ROCTAVIAN clinical development activities, commercial demand for ROCTAVIAN in the EU, and anticipated commercial demand for ROCTAVIAN to the extent it receives approval by the FDA or other regulatory authorities. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely, impaired, and our commercialization efforts and revenues could be seriously impaired. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, other unforeseen events, such as power outages, could significantly disrupt our operations or those of our third-party manufacturers and suppliers, which could result in significant delays in the manufacture of our products and adversely impact our commercial operations and revenues. Pacific Gas and Electric Company, the electric utility in the San Francisco Bay Area where many of our facilities are located, commenced widespread blackouts during the fall of 2019 to avoid and contain wildfires sparked during strong wind events by downed power lines or equipment failures. While we have not experienced damage to our facilities or material disruption to our operations as a result of these power outages, ongoing blackouts, particularly if prolonged or frequent, could impact our business going forward. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our business is affected by macroeconomic conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates, foreign currency exchange rates, natural disasters, lasting effects of the COVID-19 pandemic or other global public health threats and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets and volatility and disruptions in the equity and debt markets. For instance, COVID-19 previously adversely affected our ability to source materials and supplies. If inflation (such as that recently observed in the U.S. and elsewhere) or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counterparties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenues would be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products, which could limit our ability to obtain sufficient materials and supplies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">necessary for production of our therapies. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, the lasting effects of the COVID-19 pandemic could continue to adversely affect our business, results of our operations, and financial condition. The COVID-19 pandemic impacted our global revenue sources and overall business operations by, for example, presenting challenges to our ability to find adequate resources to staff clinical trials, impacting patients&#8217; ability to participate in trials, affecting our ability to source materials and supplies for trials and otherwise delaying trials, and the pandemic could continue to adversely impact our financial results and our business generally in 2023. Ongoing and future effects of the COVID-19 pandemic (or any future pandemic or other global public health threat) on all aspects of our business and operations and the duration of such effects are highly uncertain and difficult to predict. Moreover, while the long-term economic impact and the duration of the COVID-19 pandemic may be difficult to predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and Notes. In addition, a recession, further market correction or depression resulting from the COVID-19 pandemic or other global public health threat could materially adversely affect our business and the value of our common stock and Notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the extent macroeconomic conditions continue to adversely affect our business and financial results, they may also have the effect of heightening many of the other risks described in this Risk Factors section, such as those relating to our conducting a significant amount of our sales and operations outside of the U.S., exposure to changes in foreign exchange rates, our need to generate sufficient cash flows to service our indebtedness and finance our operations and the volatility of our stock price.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;2. Properties</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table contains information about our significant owned and leased properties as of December&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:35.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Square Feet</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Rafael facility, San Rafael, California</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407,300&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate headquarters, laboratory and office</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned&#160;<br/>property</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Several facilities in Novato, California</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical&#160;and&#160;commercial manufacturing, laboratory and office</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned&#160;<br/>property</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Several leased facilities in Novato, California</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,000&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office and warehouse</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanbally facility, Cork, Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing, laboratory and office</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned&#160;<br/>property</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that these properties, together with our other smaller leased office facilities in various countries, will be adequate for our operations for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 25, 2020, a purported shareholder class action lawsuit was filed against us, our Chief Executive Officer, our President of Worldwide Research and Development and our Chief Financial Officer in the United States District Court in the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act). The complaint alleges that we made materially false or misleading statements regarding the clinical trials and Biologics License Application (BLA) for ROCTAVIAN (formerly known as valoctocogene roxaparvovec) by purportedly failing to disclose that differences between the Company&#8217;s Phase 1/2 and Phase 3 clinical studies limited the ability of the Phase 1/2 study to support ROCTAVIAN&#8217;s durability of effect and, as a result, that it was foreseeable that the Food and Drug Administration (FDA) would not approve the BLA without additional data. The complaint seeks an unspecified amount of damages, prejudgment and post-judgment interest, attorneys&#8217; fees, expert fees, and other costs. The lead plaintiff filed an amended complaint in February 2021, dropping our Chief Financial Officer as a defendant, and asserting that the Company misled investors about the progress of the FDA's review of our BLA for ROCTAVIAN. On April 22, 2021, we moved to dismiss the amended complaint. On January 6, 2022, the court denied our motion to dismiss. We answered the amended complaint on February 15, 2022. Plaintiff filed a motion for class certification on October 17, 2022. We filed an opposition to Plaintiff&#8217;s motion for class certification on January 27, 2023. Trial is scheduled to begin on May 20, 2024. We believe that the claims have no merit and we intend to vigorously defend this action.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 22, 2021, a purported securities class action lawsuit was filed against us, our Chief Executive Officer, our current and prior Chief Financial Officers, and our President of Worldwide Research &amp; Development in the United States District Court for the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Exchange Act. The complaint alleges that we made materially false or misleading statements regarding BMN 307 by purportedly failing to disclose information about BMN 307&#8217;s safety profile, and by purportedly overstating BMN 307&#8217;s clinical and commercial prospects. The complaint seeks an unspecified amount of damages, pre-judgment and post-judgment interest, attorneys&#8217; fees, expert fees, and other costs. The Court appointed lead plaintiffs and lead counsel on January 10, 2022. Lead plaintiffs filed an amended complaint on March 25, 2022. We filed a motion to dismiss the amended complaint on May 25, 2022. On January 19, 2023, the Court granted our motion to dismiss the complaint without prejud</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ice. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 21, 2023, the court dismissed the complaint with prejudice at plaintiffs&#8217; request. Plaintiffs filed a notice indicating that they plan to appeal the court&#8217;s January 19, 2023 order.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> We believe that the claims have no merit and we intend to vigorously defend this action.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 19, 2023, certain of our officers and directors were named as defendants in a shareholder derivative action filed in the Delaware Court of Chancery. The complaint asserts, inter alia, breach of fiduciary duty claims arising from the facts underlying the securities class action related to ROCTAVIAN. The complaint seeks unspecified monetary damages, internal governance reforms by the Company, attorneys fees and costs, and any other relief the court may deem just and proper. W</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e believe that the claims have no merit and we intend to vigorously defend this action.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 23, 2023, purported shareholders filed a lawsuit against us, our Chief Executive Officer, and our President of Worldwide Research and Development in the United States District Court in the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Exchange Act and a common law fraud claim. The complaint is similar to the ROCTAVIAN putative class action and largely premised on the same underlying facts. The complaint seeks an unspecified amount of compensatory damages, punitive damages, prejudgment and post-judgment interest, attorneys&#8217; fees and other costs, and any further relief the court may deem just and proper. We believe that the claims have no merit and we intend to vigorously defend this action.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Part II</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_37"></div><div style="margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our common stock is listed under the symbol &#8220;BMRN&#8221; on the Nasdaq Global Select Market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have never paid any cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We did not sell any unregistered securities during the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;16, 2023, there were 35 holders of record of 186,528,784 outstanding shares of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission and is not to be incorporated by reference into any filing we make under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation by reference language in such filing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graph shows the value of an investment in BioMarin common stock, the Nasdaq Composite Index, the Nasdaq Biotechnology Index, and the Standard and Poor's (S&amp;P) Depository Receipts S&amp;P Biotech Exchange-traded Funds Index (SPDR S&amp;P Biotech ETF), assuming the investment of $100.00 at the beginning of the period and the reinvestment of dividends, if any. Our common stock is traded on the Nasdaq Global Select Market and is a component of the Nasdaq Composite Index, the Nasdaq Biotechnology Index and the SPDR S&amp;P Biotech ETF. The comparisons shown in the graph are based upon historical data and we caution that the stock price performance shown in the graph is not indicative of, nor intended to forecast, the potential future performance of our stock.</span></div><div style="margin-top:12pt;text-align:center"><img src="bmrn-20221231_g1.jpg" alt="bmrn-20221231_g1.jpg" style="height:416px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="margin-top:12pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* $100 invested on December&#160;31, 2017 in stock or index, including reinvestment of dividends</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nasdaq Biotechnology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SPDR S&amp;P Biotech ETF</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;6. [Reserved]</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited Consolidated Financial Statements and the accompanying notes to the Consolidated Financial Statements and other disclosures included in this Annual Report on Form 10-K, including the disclosures under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled &#8220;Forward-Looking Statements&#8221; that appears at the beginning of this Annual Report on Form 10-K. These statements, like all statements in this report, speak only as of the date of this Annual Report on Form 10-K (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) and are presented in U.S. Dollars (USD).</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Founded in 1997, we are a global biotechnology company dedicated to transforming lives through genetic discovery. We develop and commercialize targeted therapies that address the root cause of genetic conditions. Our robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. Our distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. A summary of our commercial products, as of December&#160;31, 2022, is provided below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Indication</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products marketed by BioMarin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM (elosulfase alpha)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;IVA&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME (galsulfase)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS&#160;VI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ (pegvaliase-pqpz)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN (sapropterin dihydrochloride)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO (vosoritide)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achondroplasia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA (cerliponase alfa)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLN2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN (valoctocogene roxaparvovec)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe Hemophilia A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products not marketed by BioMarin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME (laronidase) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS I</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Mucopolysaccharidosis</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of adult patients with phenylketonuria (PKU)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of achondroplasia in children aged five years and older for the U.S., aged two years and older for the European Union (EU) and for various age ranges for other markets</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of neuronal ceroid lipofuscinosis type 2</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">ROCTAVIAN (formerly known as valoctocogene roxaparvovec) for the treatment of adults with severe hemophilia A was conditionally approved by the European Commission (EC) in August 2022</span></div><div style="margin-top:6pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of our clinical development programs as of December&#160;31, 2022, is provided below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Clinical Development Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe Hemophilia A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> regulatory review </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hyperoxaluria</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hereditary Angioedema (HAE)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;U.S. Food and Drug Administration </span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2022 Financial Highlights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Key components of our results of operations include the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:62.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development (R&amp;D) expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative (SG&amp;A) expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See &#8220;Results of Operations&#8221; below for discussion of our results for the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty Relating to Macroeconomic Environment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could impact our global revenue sources and our overall business operations. The extent and duration of such effects remain uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor, &#8220;Our business is affected by macroeconomic conditions.&#8221; described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Business Developments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continued to grow our commercial business and advance our product candidate pipeline during 2022. We believe that the combination of our internal research programs, acquisitions and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Below is a summary of key business developments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Continued Emphasis on Research and Development </span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">New Product Launches, Approvals and Mid-stage Product Life Cycle Expansion Opportunities</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">VOXZOGO: The global expansion of VOXZOGO continues, with market access and reimbursement activities progressing as anticipated. As of December&#160;31, 2022, we have seen worldwide increases in the number of children being treated with commercial VOXZOGO and in the number of active markets contributing to VOXZOGO sales. </span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the fourth quarter, we submitted supplemental marketing applications in the U.S. and EU to expand VOXZOGO access to younger age groups, based on favorable results from a Phase 2 study in infants and young </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">children. In January 2023, the European Medicines Agency (EMA) validated our application for extension of indications for VOXZOGO for the treatment of children under the age of two. We expect action by U.S. and EU health authorities on the applications in the second half of 2023, and if accepted, this will increase the number of children eligible for VOXZOGO treatment in the U.S. and Europe. </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">ROCTAVIAN: Following conditional EMA approval in the third quarter of 2022, the European launch of ROCTAVIAN is underway. Since approval, we continue to collaborate with German health insurers to secure novel Outcomes Based Agreements (OBAs) to enable access to ROCTAVIAN treatment. The first OBA has been completed, allowing for a significant percentage of people in Germany affected by severe hemophilia A to pursue treatment with ROCTAVIAN. Patient testing to determine eligibility for ROCTAVIAN treatment is ongoing throughout Germany.</span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our Biologics License Application (BLA) for ROCTAVIAN is currently under review by the FDA with a current Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2023, subject to a potential three-month extension, if deemed necessary during the review procedure. We recently submitted to the FDA results from three or more years of follow up from our ongoing global Phase 3 GENEr8-1 study of ROCTAVIAN, the largest and longest global Phase 3 study to date for any gene therapy in hemophilia with 134 participants. As part of the ongoing review, the FDA completed the Pre-License Inspection of our dedicated gene therapy facility in December 2022. We have provided responses to the comments and observations received at the close of the FDA inspection, and believe all are addressable. Also in the U.S., the Premarket Approval application is under review at the Center for Devices and Radiological Health to support contemporaneous approval of a companion diagnostic (CDx) along with the ROCTAVIAN BLA.</span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product expansion opportunities with ROCTAVIAN are supported by a number of clinical studies currently underway. Two additional studies are ongoing, one investigating ROCTAVIAN treatment in those with active or prior inhibitors, as well as one study investigating ROCTAVIAN in people with pre-existing antibodies against AAV5.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Select Earlier-stage Development Portfolio</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">BMN 255 for hyperoxaluria in chronic liver disease: We have concluded the multi-ascending dose phase of the First-in-Human study with BMN 255. In January 2023, we shared early data that demonstrated a rapid and potent increase in plasma glycolate following treatment with BMN 255, which is predicted to have a profound reduction in oxalate excretion in patients. We now plan to initiate and fully enroll an expanded study in patients with chronic liver disease and hyperoxaluria in 2023. We believe the availability of a potent, orally bioavailable, small molecule like BMN 255 may be able to significantly reduce disease and treatment burden in a patient population with significant unmet need. </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">BMN 331 gene therapy product candidate for HAE: Dosing continues in the Phase 1/2 HAERMONY study to evaluate BMN 331, an investigational AAV5-mediated gene therapy for people living with HAE. In January 2023, we shared that the first participant treated with the 6e13vg/kg dose demonstrated C1-Inhibitor levels that were approaching the therapeutically relevant range.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 6, 2022, we announced our decision to redesign and simplify the organization to focus our resources on investments that advance our R&amp;D pipeline, maximize recent commercial launch success, prepare for commercial launch of ROCTAVIAN in the EU and potential U.S. launch, if approved by the FDA, and drive core infrastructure optimization. As a result, there was a planned reduction in force of approximately 120 employees (representing approximately 4% of our global workforce), most of whom are from our U.S. operations, and we incurred pre-tax severance and employee termination benefit charges of $23.0 million in 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2023 Outlook</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that our product pipeline investments and supporting our commercial infrastructure will enable us to execute on our 2023 operating objectives. From an R&amp;D perspective, we expect to continue to invest in our various ongoing clinical studies which support both our commercial products and research and early development pipeline. We expect to move forward on our late and early-stage clinical studies for new product candidates, including supporting the review of our BLA submission of ROCTAVIAN by the FDA. From a commercial perspective, we expect to continue to support our global business as it grows, including support of the global commercialization of VOXZOGO and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROCTAVIAN in the EU.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to experience growth in Net Product Revenues with respect to our new and other existing commercial products, with the exception of KUVAN due to its loss of market exclusivity. We continue to monitor conditions in the macroeconomic environment that could affect our ability to achieve our goals, such as changes in the reimbursement and payer landscape, changes in economic conditions in certain key markets throughout the world, market competition and the launch of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">generic competitors, international government pricing pressures and the potential volatility in foreign currency exchange rates. We will adjust our business processes, as appropriate, to attempt to mitigate these risks to our business.</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In preparing our Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. Historically, our assumptions, judgments and estimates relative to our critical accounting policies have not differed materially from actual results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements included in this Annual Report on Form 10-K. We believe the critical accounting policies below reflect the most critical judgments and estimates used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Related Allowances</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For ALDURAZYME revenues, we receive a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues in our Consolidated Statements of Operations. We recognize our best estimate of the entire revenue that we expect to receive when the product is released and control is transferred to Sanofi. We record ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from our estimates, we will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Sales Adjustments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We record product sales net of estimated mandatory and supplemental discounts to government payers, discounts to private payers and other related charges. Rebates, cash discounts and distributor fees represent the majority of our gross-to-net deductions and are recorded in the same period the related sales occur.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rebates may include amounts paid to Medicaid or other U.S. or foreign government programs, certain managed care providers, or other payers. Rebates, branded co-pay assistance programs, cash discounts and distributor fees are estimates based on contractual arrangements or statutory obligations, which may vary by product and payer. Estimation requires</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">evaluation of our actual historical experience,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">customer mix,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">current contractual and statutory obligations, patient outcomes, specific known market events and trends and industry data.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We evaluate our customer mix to estimate which sales will be subject to these revenue dilutive items and consider changes to government program guidelines or contractual obligations that would impact the actual rebates and/or our estimates of which sales qualify for such rebates. Any necessary adjustments to our reserves are made each quarter to reflect current information. We believe the methodologies that we use to estimate allowances are reasonable and appropriate given the facts and circumstances. However, actual results may differ significantly from our estimates.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the consolidated activities and ending balances of all our gross-to-net sales adjustments: </span></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for Current Period <br/>Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and we expect to realize economic benefit in the future, we capitalize pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, management considers a number of factors based on the information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In applying the lower of cost or net realizable value to pre-launch inventory, we estimate a range of likely commercial prices based on our comparable commercial products and consider the product candidate&#8217;s stability data for all of the pre-approval production to date to determine whether there is adequate expected shelf life for the capitalized pre-launch production costs. If additional requirements are subsequently presented by the regulatory authorities prior to their final decision, thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, as occurred in the third quarter of 2020 with ROCTAVIAN, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to R&amp;D. As of December&#160;31, 2022 and 2021, there were no pre-launch inventory costs on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We calculate and provide for income taxes in each of the tax jurisdictions in which we operate. Our Consolidated Balance Sheets reflect net deferred tax assets and liabilities, which are measured using enacted tax rates. The net deferred tax assets primarily represent the tax benefit of tax credits and timing differences between book and tax recognition of certain revenue and expense items, net of a valuation allowance. When it is more likely than not that all or some portion of deferred tax assets may not be realized, we establish a valuation allowance for the amount that may not be realized. We utilize financial projections to support our net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our net deferred tax assets. Changes in our valuation allowance will result in a change to tax expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We establish liabilities or reduce assets for certain tax positions when we believe those certain tax positions are not more likely than not to be sustained if challenged. Each quarter, we evaluate these uncertain tax positions and adjust the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and various foreign jurisdictions, including Ireland. Due to economic and political conditions, various countries are actively considering changes to existing tax laws. We cannot predict the form or timing of potential legislative changes that could have a material adverse impact on our results of operations. Management is not aware of any potential changes that would have a material effect on our Consolidated Financial Statements. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_187">15</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for additional discussion.</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for a full description of recent accounting pronouncements and our expectation of their impact, if any, on our results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net Product Revenues consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FIRDAPSE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by us</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in Net Product Revenues in 2022 as compared to 2021 was primarily attributed to the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">VOXZOGO: ramp up of commercial sales due to new patients initiating therapy globally following regulatory approvals in late 2021 and 2022;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">NAGLAZYME and VIMIZIM: new patients initiating therapy and the timing of orders in countries that place large government orders, particularly in Latin America, the Middle East and Europe; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">BRINEURA: higher sales primarily due to new patients initiating therapy globally; partially offset by</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">KUVAN: lower sales primarily attributed to increasing generic competition over time as a result of the loss of exclusivity in the U.S. that occurred in October 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In certain countries, governments place large periodic orders for our products. We expect that the timing of these large government orders will continue to be inconsistent, which has created and may continue to create significant period to period variation in our revenues. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See the risk factor &#8220;The sale of generic versions of KUVAN by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in KUVAN revenues faster than expected&#8221; in &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report for additional information on risks we face.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We face exposure to movements in foreign currency exchange rates, primarily the Euro, which we expect to continue in future periods. We use foreign currency exchange forward contracts to hedge a percentage of our foreign currency exposure. The following table shows our Net Product Revenues denominated in USD and foreign currencies:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales denominated in USD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales denominated in foreign currencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable (unfavorable) impact of foreign currency exchange rates on product sales denominated in currencies other than USD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relative to the USD, the unfavorable impact in 2022 was primarily driven by weakening of the Euro, currencies from certain Latin American markets, Japanese Yen and Turkish Lira. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in Part II, Item 7A of this Annual Report on Form 10-K and the risk factor &#8220;Our international operations pose currency risks, which may adversely affect our operating and net income&#8221; in &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report for information on currency exchange rate risk related to our Net Product Revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Royalty and Other Revenues include royalties earned on net sales of products sold by third parties, up-front licensing fees, milestones achieved by licensees or sublicensees and rental income associated with the tenants in our facilities.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in Royalty and Other Revenues in 2022 as compared to 2021 was primarily due to the absence of license revenues earned from a third party due to their achievement of a regulatory milestone in the first quarter of 2021. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to continue to earn royalties from third parties in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales and Gross Margin</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Sales includes raw materials, personnel, facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, amortization of technology transfer intangible assets and internal and external final formulation and packaging costs. Cost of Sales also includes royalties payable to third parties based on sales of our products and charges for inventory valuation reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our Cost of Sales and gross margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Sales increased for 2022 compared to 2021 primarily due to increased sales volumes. Gross margin for 2022 increased compared to 2021 primarily due to lower per unit manufacturing costs, lower inventory reserves and higher sales volume of products with higher margins.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect gross margin to range between 77.5% and 79% over the next twelve months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our approved products. R&amp;D expense primarily includes preclinical and clinical studies, personnel </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our R&amp;D expense by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continuously evaluate the recoverability of costs associated with pre-launch or pre-qualification manufacturing activities, and capitalize the costs incurred related to those activities if we determine that recoverability is highly likely and therefore future revenues are expected. If the related product candidate's marketing application is rejected by the applicable regulators and the likelihood of future revenues for a product candidate become uncertain, the related manufacturing costs are expensed as R&amp;D expenses. We did not have any pre-launch or pre-qualification manufacturing activities capitalized in inventory as of December&#160;31, 2022 and 2021. See "Critical Accounting Estimates &#8212; Inventory Produced Prior to Regulatory Approval" above for additional discussion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expense consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and early development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other approved products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expense increased for 2022 compared to 2021 primarily due to the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">higher spend in research and early development programs due to increased costs associated with manufacturing clinical product, Investigational New Drug (IND)-enabling studies for planned IND filings and pre-clinical activities; partially offset by</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">a decrease in VOXZOGO related expenses due to capitalization of manufacturing costs and lower regulatory activity costs following the regulatory approvals in the third and fourth quarters of 2021. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect R&amp;D expense to increase in future periods compared to 2022, primarily due to higher spend on early research and clinical programs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing (S&amp;M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and administrative (G&amp;A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A expenses consisted of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;M expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G&amp;A expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S&amp;M expenses by product were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU Products (Kuvan and Palynziq)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS Products (Aldurazyme, Naglazyme and Vimizim)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total S&amp;M expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in S&amp;M expense for 2022 compared to 2021 was primarily a result of increased activities in 2022 in support of the VOXZOGO commercial launch following EU and U.S. regulatory approvals in the latter half of 2021 and an increase in ROCTAVIAN commercial launch preparation activities in connection with its conditional approval in the EU in August 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in G&amp;A expense was primarily due to increased severance, employee termination benefits and external costs related to our reorganization plan and higher legal expenses, partially offset by lower idle plant time related to maintaining our gene therapy manufacturing facility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect SG&amp;A expense to increase in future periods as we prepare to launch new products and support the expansion of our global brands.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes during the periods presented for Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible asset amortization and contingent consideration</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: the expense in 2022 as compared to 2021 was relatively flat. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: the 2022 decrease in expense as compared to 2021 was attributable to the attainment of milestones during the year equal to &#8364;45.0&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of Nonfinancial Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: the increase in 2022 as compared to 2021 was due to the sale in the first quarter of 2022 of the Priority Review Voucher (PRV) that we received in connection with the FDA approval of VOXZOGO in 2021. In exchange for the PRV, we received a gross lump sum payment of $110.0 million. This amount, net of broker fees, was recognized as a gain on the sale of intangible assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in Interest Income during 2022 compared to 2021 was primarily due to higher interest rates and total portfolio returns.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect Interest Income to be higher over the next 12 months due to anticipated higher interest rates and yields on our cash equivalents and investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We incur interest expense primarily on our convertible debt. Interest Expense for the periods presented was as follows:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Expense in 2022 was relatively flat compared to 2021. We do not expect Interest Expense to fluctuate significantly over the next 12 months as the rates on our convertible debt are fixed. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_172">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for additional information regarding our convertible debt.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Income (Expense), Net for the periods presented was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Income (Expense), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in Other Income (Expense), Net in 2022 compared to 2021 was primarily due to the absence of insurance proceeds received in 2021 that were in excess of direct costs incurred as well as attributed to the loss on the fair value of assets held in our nonqualified deferred compensation (NQDC) plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for (Benefit from) Income Taxes for the periods presented was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021&#160;vs.&#160;2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for (Benefit from) Income Taxes in 2022 increased compared to 2021, primarily due to taxes on higher income recognized, which includes income recognized in the first quarter of 2022 from the sale of the PRV. Our Provision for (Benefit from) Income Taxes in 2022 and 2021 consisted of state, federal and foreign current tax expense which was offset by tax benefits related to stock option exercises, foreign tax credits, and deferred tax benefits from federal orphan drug credits and federal R&amp;D credits. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_187">15</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations 2021 Compared to 2020</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a discussion of our results of operations pertaining to 2021 as compared to 2020 see Item </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_43">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our cash, cash equivalents, and investments were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,625.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe our cash generated from sales of our commercial products, in addition to our cash, cash equivalents and investments, will be sufficient to satisfy our liquidity requirements for at least the next 12 months. We believe we will meet longer-term expected future cash requirements and obligations through a combination of cash flows from operating activities, available cash and investments balances and available revolving loan balances. We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. For example, we may require additional financing to fund the repayment of our convertible debt, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. The timing and mix of our funding alternatives could change depending on many factors, including how much we elect to spend on our development programs, potential licenses and acquisitions of complementary technologies, products and companies or if we settle our convertible debt in cash. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could affect our ability to achieve our goals. In addition, we sell our products in certain countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. We will continue to monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our cash flows for each of the years ended December&#160;31, 2022 and 2021 were as follows: </span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022&#160;vs.&#160;2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(366.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in net cash provided by operating activities in 2022 compared to 2021 was primarily attributed to the timing of cash receipts from our customers and the absence of a tax refund received in 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in net cash used in investing activities in 2022 compared to 2021 was primarily attributable to lower net purchases of investments and the $110.0 million gross proceeds from the sale of PRV in the first quarter of 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in net cash used by financing activities in 2022 compared to 2021 was primarily attributed to payments to a third party related to PKU sales milestones that were achieved in 2022, partially offset by higher exercises of awards under our equity incentive plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing and Credit Facilities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our $1.1 billion (undiscounted) of total convertible debt as of December&#160;31, 2022 will impact our liquidity due to the semi-annual cash interest payments as well as the repayment of the principal amount, if not converted. As of December&#160;31, 2022, our indebtedness consisted of our 1.250% senior subordinated convertible notes due in 2027 (the 2027 Notes) and our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes and together with the 2027 Notes, the Notes), which, if not converted, will be required to be repaid in cash at maturity in May 2027 and August 2024, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, we entered into an unsecured revolving credit facility of up to $200.0 million that included a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. Dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">other general corporate purposes. In May 2021, we amended the credit facility agreement, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes. The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of December&#160;31, 2022, there were no outstanding amounts due on nor any usage of the credit facility and we were in compliance with all covenants.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_172">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for additional discussion on our convertible debt and credit facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Funding Commitments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our investment in our research and early development of product candidates and continued development of our existing commercial products has a major impact on our operating performance. R&amp;D expenses for our commercial products and certain product candidates for the period since inception as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:79.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Since Program</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inception</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROCTAVIAN</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other approved products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,489.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot estimate with certainty the cost to complete any of our product development programs. We may need or elect to increase our spending above our current long-term plans to be able to achieve our long-term goals. This may increase our capital requirements, including: costs associated with the commercialization of our products&#894; additional clinical trials; investments in the manufacturing of our commercial products&#894; preclinical studies and clinical trials for our product candidates&#894; potential licenses and other acquisitions of complementary technologies, products and companies&#894; and general corporate purposes. Additionally, we cannot precisely estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K, for a discussion of the reasons we are unable to estimate such information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase and Lease Obligations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had purchase obligations of approximately $225.5&#160;million, of which $188.7 million is expected to be paid in 2023. Our purchase obligations are primarily related to firm purchase commitments entered into in the normal course of business to procure active pharmaceutical ingredients, certain inventory-related items, certain third-party R&amp;D services, production services and facility construction services. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had lease payment obligations of $42.3 million, of which $12.0 million is payable within the next 12 months. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_169">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for details on our lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Obligations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $15.9&#160;million of acquisition-related contingent consideration on our Consolidated Balance Sheets related to our achievement of a PKU sales milestone during the fourth quarter of 2022. The December 31, 2022 balance was subsequently paid in cash in the first quarter of 2023. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_193">17</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for details on this arrangement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were subject to contingent payments considered reasonably possible of $762.5 million, including $381.5 million and $210.0 million for two early-stage development programs licensed from third parties. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_196">18</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for additional discussion on our contingent obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Unrecognized Tax Benefits</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our liability for unrecognized tax benefits was $232.9 million. Due to their nature, we cannot reasonably estimate the timing of future payments. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_187">15</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our accompanying Consolidated Financial Statements for a full discussion on our income taxes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;7A. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in foreign currency exchange rates, interest rates and credit risks. To reduce certain of these risks, we enter into foreign currency derivative hedging transactions, follow investment guidelines and monitor outstanding trade receivables as part of our risk management program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations include manufacturing activities in the U.S. and Ireland and sales activities in the U.S. as well as in regions outside the U.S, including Europe, Latin America and Asia Pacific. As a result, our financial results may be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we sell our products. Our operating results are exposed to changes in foreign currency exchange rates between the U.S. Dollar (USD) and various foreign currencies, primarily the Euro. When the USD strengthens against these currencies, the relative value of the sales and operating expenses made in the respective foreign currency decreases. Conversely, when the USD weakens against these currencies, the relative value of such sales and operating expenses increases. Overall, we are a net receiver of foreign currencies and, therefore, benefit from a weaker USD and are adversely affected by a stronger USD relative to those foreign currencies in which we transact significant business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2022, approximately 51% of our net product sales were denominated in foreign currencies and 19% of our operating expenses, excluding Cost of Sales, were denominated in foreign currencies. To partially mitigate the impact of changes in currency exchange rates on net cash flows from our foreign currency denominated sales and operating expenses, we may enter into foreign currency exchange forward contracts (forward contracts). We also hedge certain monetary assets and liabilities, primarily those denominated in Euros, using forward contracts, which reduces but does not eliminate our exposure to currency fluctuations between the date the transaction is recorded and the date the cash is collected or paid. Generally, the market risks of these contracts are offset by the corresponding gains and losses on the transactions being hedged.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the effects of changes in foreign currency exchange rates. The counterparties to these forward contracts are creditworthy multinational commercial banks, which minimizes the risk of counterparty nonperformance. We regularly review our hedging program and may, as part of this review, make changes to the program.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had open forward contracts with net notional amounts of $843.4&#160;million. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the USD relative to exchange rates as of December&#160;31, 2022 would have resulted in a reduction in the value received over the remaining life of these contracts by approximately $83.2&#160;million on this date and, if realized, would negatively affect earnings during the remaining life of the contracts. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. This analysis does not consider the impact of the hypothetical changes in foreign currency rates would have on the forecasted transactions that these foreign currency sensitive instruments were designated to offset. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on our overall foreign currency denominated exposures as of December&#160;31, 2022, we believe that a near-term 10% fluctuation of the USD exchange rate could result in a potential change in the fair value of our net foreign currency denominated assets and liabilities, excluding our investments and open forward contracts, by approximately $20.6&#160;million. We expect to continue to enter into transactions based in foreign currencies that could be impacted by changes in exchange rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Market Risk</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio, which includes our cash equivalents and marketable debt securities. By policy, we place our investments with highly rated credit issuers and limit the amount of credit exposure to any one issuer. As stated in our investment policy, we seek to improve the safety and likelihood of preservation of our invested funds by limiting default risk and market risk.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We mitigate default risk by investing in high credit quality securities and by positioning our portfolio to respond appropriately to a significant reduction in a credit rating of any investment issuer or guarantor. The portfolio includes only marketable securities with active secondary or resale markets to ensure portfolio liquidity.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have outstanding $495.0 million (undiscounted) of the 2024 Notes and $600.0 million (undiscounted) of the 2027 Notes. The interest rates on these notes are fixed and therefore they do not expose us to risk related to rising interest rates. As of December&#160;31, 2022, the fair value of our convertible debt was $1.2 billion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our investment portfolio did not include any investments with significant exposure to countries that face economic volatility and weakness. Although not predictive in nature, based on our investment portfolio and interest rates for the period ending December&#160;31, 2022, we believe a 100 basis point increase in interest rates could result in a potential loss in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fair value of our investment portfolio of approximately $6.3&#160;million. Changes in interest rates may affect the fair value of our investment portfolio. However, we will not recognize such gains or losses in our Consolidated Statements of Operations unless the investments are sold or we determine that the declines in the investment&#8217;s fair values below the cost basis are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below summarizes the expected maturities and average interest rates of our interest-generating investments as of December&#160;31, 2022 (in millions of U.S. Dollars):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:31.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.510%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Credit Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our financial instruments, including derivatives, are subject to counterparty credit risk that we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by requiring transactions to be with institutions with minimum credit ratings of A- or equivalent by Standards &amp; Poor&#8217;s, Moody's or Fitch. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required to be filed in this item appears under &#8220;Exhibits, Financial Statement Schedules&#8221; in Part IV, Item 15 of this Annual Report on Form 10-K</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining an adequate internal control structure and procedures for financial reporting. Under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, our management has assessed the effectiveness of our internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act as of December&#160;31, 2022. Our management&#8217;s assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), Internal Control-Integrated Framework (2013).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on the COSO criteria, our management has concluded that our internal control over financial reporting as of December&#160;31, 2022 was effective at the reasonable assurance level.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, KPMG LLP, has audited the financial statements included in this Annual Report on Form 10-K and has issued a report on the effectiveness of our internal control over financial reporting. The report of KPMG LLP is incorporated by reference to Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We continue to utilize the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Scope of the Effectiveness of Controls</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our board of directors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9B. Other Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Part III</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding our directors, executive officers and corporate governance is incorporated into this section by reference to the sections captioned &#8220;Election of Directors&#8221; and &#8220;Executive Officers&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation</span></div><div style="margin-top:12pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding executive compensation is incorporated into this section by reference to the section captioned &#8220;Executive Compensation&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:33.75pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding security ownership of our beneficial owners, management and related stockholder matters is incorporated into this section by reference to the section captioned &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding the securities authorized for issuance under our equity compensation plans is incorporated into this section by reference to the section captioned &#8220;Equity Compensation Plan Information&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding certain relationships, related transactions and director independence is incorporated into this section by reference to the sections captioned &#8220;Other Board Governance Information &#8212; Transactions with Related Persons, Promoters and Certain Control Persons,&#8221; &#8220;Other Board Governance Information &#8212; Review, Approval and Ratification of Transactions with Related Parties&#8221; and &#8220;Director Independence&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accountant Fees and Services</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item regarding our principal accountant fees and services is incorporated into this section by reference to the section captioned &#8220;Independent Registered Public Accounting Firm&#8221; in the proxy statement for our 2023 annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Part IV</span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits, Financial Statement Schedules</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_106">Exhibit Index</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_106">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_121">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (KPMG LLP, San Francisco, CA, Auditor Firm ID: <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMDMvZnJhZzpmYTBjODZlYTkwYmQ0OGIwYjc4NjQ3MTFlZmFiZDFlYi90YWJsZTpkZWYzZGMxOWZjNjk0Zjk1YTdlMDMxNzhlMWRlNTQ4OC90YWJsZXJhbmdlOmRlZjNkYzE5ZmM2OTRmOTVhN2UwMzE3OGUxZGU1NDg4XzQtMC0xLTEtODM2ODcvdGV4dHJlZ2lvbjpkMzc0MjkzNTA3NzY0ZDg5YWNlNDFlMmQ3MDIwY2ZjOF8xMTU0NDg3MjA5MTc2Nw_3edb11b0-593c-41f9-ad36-341cd1057a7f">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_121">83</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated Financial Statements as of December&#160;31, 2022 and 2021, and for the three years ended December&#160;31, 2022:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_127">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_127">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_130">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_130">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_133">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_133">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_136">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_136">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_139">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_139">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_142">91</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit&#160;Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312516423476/d117941dex21.htm">Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312516423476/d117941dex23.htm">Termination and Transition Agreement, dated as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.3 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459017002483/bmrn-ex26_494.htm">First Amendment, dated as of December 12, 2016, to the Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015 and effective as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on February 27, 2017 as Exhibit 2.6 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex32.htm">Restated Certificate of Incorporation of BioMarin Pharmaceutical Inc., previously filed with the SEC on June 12, 2017 as Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001048477/000119312522310054/d440213d8k.htm">Amended and Restated Bylaws of BioMarin Pharmaceutical Inc., previously filed with the SEC on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001048477/000119312522310054/d440213d8k.htm">21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001048477/000119312522310054/d440213d8k.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001048477/000119312522310054/d440213d8k.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001048477/000119312522310054/d440213d8k.htm"> as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517255963/d439703dex41.htm">Base Indenture, dated August 11, 2017, between the Company and Wilmington Trust, National Association, as Trustee, previously filed with the SEC on August 11, 2017 as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517255963/d439703dex42.htm">First Supplemental Indenture, dated August 11, 2017, between the Company and Wilmington Trust, National Association, as Trustee (including the form of 0.599% Senior Subordinated Convertible Note due 2024), previously filed with the SEC on August 11, 2017 as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000119312520142808/d901226dex41.htm">Indenture, dated as of May 14, 2020, between BioMarin Pharmaceutical Inc. and U.S. Bank National Association, as trustee, including the Form of Global Note representing BioMarin Pharmaceutical, Inc.&#8217;s 1.25% Senior Subordinated Convertible Notes due 2027 as Exhibit A thereto, previously filed with the SEC on May 14, 2020 as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847720000009/bmrn-20191231xexx46.htm">Description of Capital Stock, previously filed with the SEC on February 27, 2020 as Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459016030328/bmrn-ex101_7.htm">Form of Indemnification Agreement for Directors and Officers, previously filed with the SEC on December 19, 2016 as Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000007/exhibit102.htm">BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan, as amended and restated April 12, 2019, previously filed with the SEC on August 2, 2019 as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312515223487/d942811dex101.htm">BioMarin Pharmaceutical Inc. Amended and Restated 2006 Share Incentive Plan, as adopted on May 2, 2006 and as amended and restated on April 16, 2015, previously filed with the SEC on June 15, 2015 as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312513224274/d540417dex101.htm">Form of Agreement Regarding Restricted Share Units for the BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan, previously filed with the SEC on May 16, 2013 as Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459016030078/bmrn-ex101_6.htm">Form of Amendment to Agreement Regarding Restricted Share Units for the BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan, previously filed with the SEC on December 9, 2016 as Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312514370098/d804203dex102.htm">Amended and Restated BioMarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan, as adopted on December 1, 2005 and as amended and restated on January 1, 2009 and further amended and restated on December 19, 2013 and October 7, 2014, previously filed with the SEC on October 14, 2014 as Exhibit 10.2 to the Company&#8217;s Current Report on Form&#160;8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459016030328/bmrn-ex102_6.htm">Amended and Restated Employment Agreement with Jean-Jacques Bienaim&#233; effective December 13, 2016 previously filed with the SEC on December 19, 2016 as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312505052825/dex1025.htm">License Agreement dated July&#160;30, 2004, between BioMarin Pharmaceutical Inc. and Daiichi Suntory Pharma Co., Ltd., as amended by Amendment No. 1 to License Agreement dated November&#160;19, 2004, previously filed with the SEC on March&#160;16, 2005 as Exhibit 10.25 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000101287099002193/0001012870-99-002193.txt">Operating Agreement with Genzyme Corporation, previously filed with the SEC on July&#160;6, 1999 as Exhibit 10.30 to the Company&#8217;s Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-77701), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312508040467/dex1030.htm">Manufacturing, Marketing and Sales Agreement dated as of January 1, 2008, by and among BioMarin Pharmaceutical Inc., Genzyme Corporation and BioMarin/Genzyme LLC previously filed with the SEC on February 28, 2008 as Exhibit 10.30 to the Company&#8217;s Annual Report on Form&#160;10-K (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312508040467/dex1031.htm">Amended and Restated Collaboration Agreement dated as of January 1, 2008, by and among BioMarin Pharmaceutical Inc., Genzyme Corporation and BioMarin/Genzyme LLC previously filed with the SEC on February 28, 2008 as Exhibit 10.31 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312508040467/dex1032.htm">Members Agreement dated as of January 1, 2008 by and among BioMarin Pharmaceutical Inc., Genzyme Corporation, BioMarin Genetics Inc., and BioMarin/Genzyme LLC previously filed with the SEC on February 28, 2008 as Exhibit 10.32 to the Company&#8217;s Annual Report on Form&#160;10-K (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312512219454/d352214dex102.htm">BioMarin Pharmaceutical Inc. 2012 Inducement Plan, adopted May 8, 2012, previously filed with the SEC on May 9, 2012 as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312512331653/d370421dex1011.htm">Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan. (as Amended and Restated 2010), previously filed with the SEC on August 2, 2012 as Exhibit 10.11 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312512331653/d370421dex1013.htm">Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2012 Inducement Plan, previously filed with the SEC on August 2, 2012 as Exhibit 10.13 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312514070025/d657861dex1068.htm">Contract of Purchase and Sale and Joint Escrow Instructions, dated December 17, 2013, for the San Rafael Corporate Center, by and among BioMarin Pharmaceutical Inc., through its wholly-owned subsidiary, California Corporate Center Acquisition, LLC, SR Corporate Center Phase One, LLC, and SR Corporate Center Phase Two, previously filed with the SEC on February 26, 2014 as Exhibit 10.68 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312514452963/d841715dex101.htm">BioMarin Pharmaceutical Inc. 2014 Inducement Plan, adopted December 17, 2014, previously filed with the SEC on December&#160;23, 2014 as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459015001140/bmrn-ex1060_201412311266.htm">Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2014 Inducement Plan, previously filed with the SEC on March 2, 2015 as Exhibit 10.60 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459015001140/bmrn-ex1061_201412311267.htm">Form of Agreement Regarding Restricted Share Units for the BioMarin Pharmaceutical Inc. 2014 Inducement Plan, previously filed with the SEC on March 2, 2015 as Exhibit 10.61 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312515223487/d942811dex102.htm">Form of Amended and Restated Employment Agreement for the Company&#8217;s Executive Officers (other than the Company&#8217;s Chief Executive Officer) previously filed with the SEC on June 15, 2015 as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459015009051/bmrn-ex102_235.htm">Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck &amp; Cie, Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd., dated September 14, 2015, previously filed with the SEC on November 2, 2015 as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459017023407/bmrn-ex101_6.htm">Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck &amp; Cie and Par Pharmaceutical, Inc., dated as of April 12, 2017, previously filed with the SEC on November 13, 2017 as Exhibit 10.1 to the Company&#8217;s Amendment No. 1 to Quarterly Report on Form 10-Q/A (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex104.htm">Form of Agreement Regarding Performance Stock Award in the Form of Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan, previously filed with the SEC on February 27, 2017 as Exhibit 10.50 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000119312522045513/d295143ds8.htm">BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as adopted April 10, 2017 and amended April 5, 2021, previously filed with the SEC on February 17, 2022 as Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-262824), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex102.htm">Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, previously filed with the SEC on June 12, 2017 as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex103.htm">Form of Agreement Regarding Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, previously filed with the SEC on June 12, 2017 as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex104.htm">Form of Agreement Regarding Performance Stock Award in the Form of Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, previously filed with the SEC on June 12, 2017 as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation, previously filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">28</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">22</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm"> as Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit_102.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459019005033/bmrn-ex1048_577.htm">Credit Agreement by and among BioMarin Pharmaceutical Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender and a Lender, and Citibank N.A. as L/C Issuer, and the Lenders party thereto, dated as of October 19, 2018, previously filed with the SEC on February 28, 2019 as Exhibit 10.48 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is herein incorporated by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847721000025/exhibit101.htm">First Amendment, dated May 28, 2021, to the Credit Agreement by and among BioMarin Pharmaceutical Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender and a Lender, and Citibank N.A. as L/C Issuer, and the Lenders party thereto, previously filed with the SEC on July 30, 2021 as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000007/exhibit101.htm">First Amendment to the Amended and Restated BioMarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan, as adopted June 4, 2019, previously filed with the SEC on August 2, 2019 as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm">Second amendment to the Amended and Restated BioMarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan, as adopted on October 5, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm">, previously filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm">February 25, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm"> as Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm">32</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000012/bmrn-20211221xexx1032.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">Asset Purchase Agreement by and between Eli Lilly and Company, BioMarin Pharmaceutical Inc., and BioMarin International Ltd., dated February 8, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">previously filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">April</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">22</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm"> as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 000-26727), which is incorporated herein by reference.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm"> Portions of this exhibit have been omitted because they are not material and the type that the registrant treats as private or confidential</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1048477/000104847719000017/exhibit101-30sep19x10q.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.34&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">Th</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">ird</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm"> Amendment to the Amended and Restated BioMarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan, as adopted October 4, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">previously filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm"> 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">, 2022 as Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm"> to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm"> Report on Form 10-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1048477/000104847722000033/exhibit-101.htm"> (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.35&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_35.htm">Form of Agreement Regarding </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_35.htm">Non-Employee Director </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_35.htm">Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_35.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.36&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_36.htm">Form of Agreement Regarding Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_37.htm">Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10_37.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="bmrn-2022xexx211.htm">Subsidiaries of BioMarin Pharmaceutical Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="bmrn-20221231xexx231.htm">Consent of KPMG LLP, Independent Registered Public Accounting Firm for BioMarin Pharmaceutical Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_115">Power of Attorney (Included in Signature Page to this Report)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="bmrn-20221231xexx311.htm">Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="bmrn-20221231xexx312.htm">Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="bmrn-20221231xexx321.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Certification accompanies this report and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL tags for the cover page from the Company&#8217;s Quarterly Report on Form 10-K for the year ended December&#160;31, 2022, are embedded within the Inline XBRL document.</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets as of December&#160;31, 2022 and December&#160;31, 2021, (ii)&#160;Consolidated Statements of Operations for the years ended December&#160;31, 2022, 2021 and 2020, (iii)&#160;Consolidated Statements of Comprehensive Income (Loss) for the years ended December&#160;31, 2022, 2021 and 2020, (iv) Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2022, 2021 and 2020, (v)&#160;Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022, 2021 and 2020, and (vi)&#160;Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:44.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: February 27, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;BRIAN R. MUELLER</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Brian R. Mueller<br/>Executive Vice&#160;President, Finance &amp; Chief&#160;Financial&#160;Officer</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 24.1</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jean-Jacques Bienaim&#233; and Brian R. Mueller, his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to the Report on Form&#160;10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;JEAN-JACQUES BIENAIM&#201;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jean-Jacques Bienaim&#233;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;BRIAN R. MUELLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Finance &amp; Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Brian R. Mueller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/ ERIN BURKHART</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Group Vice President, Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Erin Burkhart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/ MARK J. ALLES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mark J. Alles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;ELIZABETH MCKEE ANDERSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Elizabeth McKee Anderson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;WILLARD H. DERE, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Willard H. Dere, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;ELAINE J. HERON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Elaine J. Heron</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/ MAYKIN HO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maykin Ho</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;ROBERT J. HOMBACH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Robert J. Hombach</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/ V. BRYAN LAWLIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">V. Bryan Lawlis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;RICHARD A. MEIER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lead Independent Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Richard A. Meier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;DAVID PYOTT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">David Pyott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;DENNIS J. SLAMON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dennis J. Slamon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_121">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (KPMG LLP, San Francisco, CA, Firm ID: 185)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_121">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated Financial Statements as of December&#160;31, 2022 and 2021, and for the three years ended December&#160;31, 2022:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_127">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_127">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_130">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_130">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_133">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_133">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_136">Consolidated&#160;Statements&#160;of&#160;Stockholders&#8217;&#160;Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_136">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_139">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_139">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib1aad3959e884c01b6a07e04db98b99b_142">91</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc.:</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries (the Company) as of December&#160;31, 2022 and December&#160;31, 2021, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December&#160;31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and December&#160;31, 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February&#160;27, 2023 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of variable consideration relating to ALDURAZYME product sales</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As described in Notes 1 and 12 to the consolidated financial statements, during the year ended December&#160;31, 2022 the Company recognized $128 million in ALDURAZYME net product revenue. Under its arrangement with Sanofi, the Company receives payments ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi, depending on Sanofi&#8217;s sales volume. The Company estimates this variable consideration based on the amount that it expects to be entitled to from Sanofi&#8217;s sales of ALDURAZYME. The Company recognizes this revenue upon satisfying the product performance obligation, which is when the product is shipped to Sanofi and all required quality control certificates are complete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We identified the evaluation of variable consideration relating to ALDURAZYME net product revenue as a critical audit matter. Evaluating the key assumptions of forecasted Sanofi sales volume and average price per vial involved a high degree of subjective auditor judgment due to the nature of available supporting evidence being limited to Sanofi sales forecasts and historical sales and price data. Changes in these key assumptions could have had a significant impact on ALDURAZYME net product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s process for recognizing ALDURAZYME net product revenue. This included controls over forecasting Sanofi&#8217;s sales volume and average price per vial used to estimate variable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">consideration. We evaluated the Company&#8217;s ability to estimate the variable consideration by comparing historical estimates of sales volume and price per vial to actual sales volume and price per vial of product sold by Sanofi. We also compared the Company&#8217;s current-period forecasts of future Sanofi sales volume and average price per vial to Sanofi&#8217;s historical sales volume and price per vial. We performed a sensitivity analysis to assess the impact of changes in these key assumptions on the Company&#8217;s estimate of variable consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjEvZnJhZzpmYjJjMjg2ZjhkYmM0NmQ4ODRkZGRmZmI1ZTkyYTllOS90ZXh0cmVnaW9uOmZiMmMyODZmOGRiYzQ2ZDg4NGRkZGZmYjVlOTJhOWU5XzEwMjkw_88ba79ac-9b2e-4435-9d8c-a3d92d175101">KPMG LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjEvZnJhZzpmYjJjMjg2ZjhkYmM0NmQ4ODRkZGRmZmI1ZTkyYTllOS90ZXh0cmVnaW9uOmZiMmMyODZmOGRiYzQ2ZDg4NGRkZGZmYjVlOTJhOWU5XzEwMjkx_feffa6d2-5301-4391-bd3d-6655fed18528">San Francisco, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;27, 2023</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc.:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have audited BioMarin Pharmaceutical Inc. and subsidiaries' (the Company) internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2022 and December&#160;31, 2021, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December&#160;31, 2022, and the related notes (collectively, the consolidated financial statements), and our report dated February&#160;27, 2023 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">San Francisco, California</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;27, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_127"></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December&#160;31, 2022 and 2021 </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021 &#8317;&#185;&#8318;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMS0xLTEtNzc3OTc_50374629-7d8b-4092-b7a6-7f56add573b3">724,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMS0xLTEtNzc3OTc_ddc3fd21-9233-4c05-b9ef-9889d8f22efb">567,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMS0xLTEtNzc3OTc_4025b165-f693-4c0a-a6a5-a1f8a480d891">461,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792">373,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMS0xLTEtNzc3OTc_c7ece4dc-f922-46b5-a131-f2af92d394bc">894,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4">776,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMS0xLTEtNzc3OTc_b6988fc5-62a3-4f2b-8bc1-d6492f166abe">104,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7">110,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMS0xLTEtNzc4NDk_a90077cf-2fc7-4c9d-b8ef-97d31b00fbda">2,751,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f">2,274,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTEtMS0xLTc3ODQ5_55168085-6de2-4c5e-bd25-eb488bb71bb0">333,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTEtMS0xLTc3ODQ5_9ffb949b-c0c0-4bd1-8cfe-857ce9a4a9cc">1,073,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c">1,035,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTEtMS0xLTc3ODQ5_e312e60c-625e-413b-9a34-64987c9185bd">338,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563">388,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTEtMS0xLTc3ODQ5_eb83e6a7-2f99-41be-99e5-e79a077cbf17">196,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd">196,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTEtMS0xLTc3ODQ5_d60f7829-7fa5-4b27-9fc9-802c479dd042">1,505,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c">1,450,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTEtMS0xLTc3ODQ5_295b3ad8-f4eb-4828-929a-35df815481c2">176,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d">152,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTEtMS0xLTc3ODQ5_e31c416c-d505-4b8b-8b29-1e56583fd28c">6,375,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889">6,004,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTEtMS0xLTc3ODQ5_df65dbd7-b6b7-4a31-97d9-2b378455edf4">572,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee">498,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTEtMS0xLTc3ODQ5_56535373-e5ee-49a6-bfe2-2d608757d6bf">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTEtMS0xLTc3ODQ5_bb72c213-1632-480c-b2af-f6811a7587d9">588,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571">546,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term convertible debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTEtMS0xLTc3ODQ5_f939d0c8-d2d5-44df-8c03-8d0a36fd153e">1,083,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0">1,079,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTEtMS0xLTc3ODQ5_2d5352ff-0c09-4e1b-a5d4-3fe18ed78f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTEtMS0xLTc3ODQ5_b339e999-fb3d-46ba-b04c-83c8217c610e">100,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee">98,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTEtMS0xLTc3ODQ5_896aef71-3a20-4c48-ad8b-49b10f3e39da">1,771,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da">1,739,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk4Mg_66900386-1fa5-40cb-b877-e6099b28e0c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk4Mg_a8b20e8c-6b96-4830-8743-b88bacd3c371">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5MA_0c6a31e8-8fd3-444f-bf91-974ee21fb33b"><ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5MA_ef4148a1-6004-4654-8a6b-2a7f7e022b0e">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5NQ_245740a9-be8a-47af-a538-13e28fb5872f"><ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5NQ_28422acb-db26-440a-b799-c8746f3ef14e">186,250,719</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyODAwMg_d77ed93f-0d83-4136-8f34-78a0a9301fd9"><ix:nonFraction unitRef="shares" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyODAwMg_e028824f-f3d0-4961-9c7a-29f279931fa8">183,912,514</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTEtMS0xLTc3ODQ5_343b1f3d-21e4-4d71-923a-efbe385f61c1">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTEtMS0xLTc3ODQ5_5b32d9ba-a4de-46bf-94cd-d375360b286a">5,404,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565">5,191,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company common stock held by the Nonqualified Deferred Compensation Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:CommonStockIssuedEmployeeStockTrust" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTEtMS0xLTc3ODQ5_a2251964-78f2-4fc1-91ef-a7397dd49586">8,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CommonStockIssuedEmployeeStockTrust" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2">9,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTEtMS0xLTc3ODQ5_a99205bc-f8cd-41c6-809f-453bc40af43c">3,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTEtMS0xLTc3ODQ5_f0109836-0b96-4942-8e76-89e3d595927c">789,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db">930,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTEtMS0xLTc3ODQ5_83e56efc-8f91-46b0-ad94-fc4aa0099875">4,603,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d">4,265,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTEtMS0xLTc3ODQ5_74582a0b-d6b3-487b-895f-8935c4c92ba9">6,375,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224">6,004,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts)</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">REVENUES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItMS0xLTEtNzc4ODg_3707e77b-520b-4c87-99f4-a8f54d528bab">2,042,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItMy0xLTEtNzc4ODg_5c4431a0-eaf6-4669-9251-8db91d826ae2">1,783,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941">1,805,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtMS0xLTEtNzc4ODg_534dbf48-e1d2-4c32-92e5-5e66c1080fb9">54,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtMy0xLTEtNzc4ODg_df991375-653d-464c-acbc-98a39f8e53f8">62,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd">54,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtMS0xLTEtNzc4ODg_71c78a97-07f7-403c-b3bf-a0996e1b9271">2,096,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtMy0xLTEtNzc4ODg_653675b8-3901-46b2-9fb5-86d46185abbe">1,846,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a">1,860,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtMS0xLTEtNzc4ODg_f02dd3e6-6438-4ab2-bc6e-96ab54cf5f8c">483,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtMy0xLTEtNzc4ODg_6126fcfd-51b4-48c8-87e5-159fddef79be">470,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78">524,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctMS0xLTEtNzc4ODg_b7befc02-d917-48d0-8911-37ab77d321c4">649,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctMy0xLTEtNzc4ODg_72d60f1e-58c4-4162-bc5e-6133924fdc6b">628,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a">628,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtMS0xLTEtNzc4ODg_d1a24c13-7fd4-4de2-a130-d2dfd3e6ea3b">854,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtMy0xLTEtNzc4ODg_1f80de7a-0045-4bcf-be90-2d0e4064a62f">759,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408">737,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset amortization and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:IntangibleAssetAmortizationAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktMS0xLTEtNzc4ODg_c96c56aa-cf5c-423c-a6e6-f0f75890c450">67,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:IntangibleAssetAmortizationAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktMy0xLTEtNzc4ODg_9fc3d78a-5d2d-43f5-a9f0-1e9bccfbac72">69,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:IntangibleAssetAmortizationAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df">66,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTEtMS0xLTc3ODg4_9de99928-fb9f-46d5-9482-7bc8de10ec8a">108,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTMtMS0xLTc3ODg4_fcb915ba-9808-4855-8205-d1be901664a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de">52,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTEtMS0xLTc3ODg4_31d1dada-473c-4b0e-97f9-d7864e87bfd8">1,946,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTMtMS0xLTc3ODg4_8c25245f-d971-4d6e-bed2-fe6e7115238b">1,928,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02">1,903,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME (LOSS) FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTEtMS0xLTc3ODg4_9537b582-9846-4995-81d4-4170a382a00f">149,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTMtMS0xLTc3ODg4_1260145f-b706-442b-863e-2cfdd2fdb1ac">82,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7">43,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTEtMS0xLTc3ODg4_1f310a23-fd3d-4b5e-ba58-b9fdde6c2fef">18,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTMtMS0xLTc3ODg4_8486fe8a-b5fd-4e3a-9348-097fd85e1299">10,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67">16,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTEtMS0xLTc3ODg4_be8f7be3-933e-4b12-96fd-59a038bebedb">15,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTMtMS0xLTc3ODg4_9044248f-aa5d-425f-ba46-98788ba70339">15,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c">29,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTEtMS0xLTc3ODg4_3780955c-b848-4587-a07f-0b2559a9bac0">2,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTMtMS0xLTc3ODg4_fb7604de-e686-48e3-974a-8fc1edbddadf">11,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de">7,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME (LOSS) BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTEtMS0xLTc3ODg4_9635c08b-9666-4ece-9ab3-db57927ca89d">149,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTMtMS0xLTc3ODg4_a9231661-f46f-4755-9b93-964748c4db87">75,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251">48,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTEtMS0xLTc3ODg4_8e13ad60-34c7-4941-82e0-962718b2997c">8,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTMtMS0xLTc3ODg4_a82d66c7-a485-46ad-9745-c5bab963da77">11,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7">903,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME (LOSS)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTEtMS0xLTc3ODg4_1a2738a7-b941-4b01-acb7-5d4a6daf1c90">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTMtMS0xLTc3ODg4_cf8fe135-b45c-438b-93c1-1666935a0e27">64,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8">854,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EARNINGS (LOSS) PER SHARE, BASIC</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTEtMS0xLTc3ODg4_2022af65-b355-41a7-a119-1612c8109092">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTMtMS0xLTc3ODg4_df4a8e30-c193-457d-8397-1651395f1153">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb">4.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EARNINGS (LOSS) PER SHARE, DILUTED</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTEtMS0xLTc3ODg4_4096be7e-5d38-4cc7-8139-d43f3b28eac3">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTMtMS0xLTc3ODg4_55eeba34-96a3-4236-a4b2-83bb3360cfe4">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTEtMS0xLTc3ODg4_de549fdc-42fc-448e-8fa9-5e76a6c5b30f">185,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTMtMS0xLTc3ODg4_617068be-fd3a-496a-bfa2-80c43f6e6bc4">182,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8">180,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTEtMS0xLTc3ODg4_73ffc4ac-ca09-43c6-8daa-ba3c03bb7386">188,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTMtMS0xLTc3ODg4_126619be-8942-45a2-bfba-cb77ba5f3d4c">182,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b">191,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars)</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME (LOSS)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtMi0xLTEtNzkyNDE_7a9de89a-90ae-40f9-b132-8d12978e8f45">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNC0xLTEtNzkyNDE_29871c29-014b-4bf6-b5fc-185d1e2529ba">64,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398">854,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gain (loss) arising during the period, net</span></div><div style="padding-left:21.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160; of tax impact of $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1Njg2_8b6e46b3-5005-4225-91ac-f781b32cb349">3,247</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1Njk1_b079e72f-4e14-4f98-94aa-bd310ec1c2b2">1,596</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1NzA2_1485d52f-39ec-46f0-9a47-33159da4c86c">227</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMi0xLTEtNzkyNDE_51c7e0e4-050b-4369-a9b0-02934bc333d9">10,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNC0xLTEtNzkyNDE_5b727b3c-3104-4749-92cc-6f8a376ec402">5,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: reclassifications to net income (loss), net of tax impact of</span></div><div style="padding-left:21.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;$<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1NjYx_dc36df92-2476-4f97-84a4-6b93fa022625">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1Njcw_3dec9f4d-bb11-4abb-a5c4-eca5d0f74d56">0</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1Njc1_cb17eb7e-a5cf-4b6f-a5d8-96d97b1c842e">127</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMi0xLTEtNzkyNDE_8b1a779d-e8cd-4b7e-a3cc-920fe270ecf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNC0xLTEtNzkyNDE_33b6b852-c550-43e5-8f8f-37dc1617b0e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in unrealized holding gain (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtMi0xLTEtNzkyNDE_692283a1-15cc-4f58-9954-1a894ccd89a4">10,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNC0xLTEtNzkyNDE_b58cc42f-6e0f-41a8-b44a-739e92210195">5,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gain (loss) arising during the period, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_445f57b8-0b76-4e9c-8e0d-0f1bc25d36fe"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_4f5a1fa0-e9dd-4b1a-9a03-5ecf85e2523b"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_a4c98ba8-cdc9-4d65-b7a1-97b0b7dc343e">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods presented</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMi0xLTEtNzkyNDE_cddf0bed-c669-4407-80d4-2eadb3ade80f">29,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNC0xLTEtNzkyNDE_60958c4c-c2d1-4cf1-b404-e794aa06371e">34,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd">23,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: reclassifications to net income (loss), net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_489d7cad-1b15-4807-879d-a0da393add8f"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_7ad5e0a9-ec3f-47b0-a5ca-067d8ec62ee2"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_9c8253db-aa03-4f10-87bf-a4bcb2298a73">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods presented</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMi0xLTEtNzkyNDE_7db4d784-81f7-4dd7-9a78-a647820e5eab">36,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNC0xLTEtNzkyNDE_de4e75e9-7a5e-4904-8efb-8debe7f486e7">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363">13,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in unrealized holding gain (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTItMS0xLTc5MjQx_fd5d018c-4092-4de2-9323-9595f8722758">7,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTQtMS0xLTc5MjQx_00085046-f7c2-4b09-b4ac-086a991771fe">35,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61">36,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:OtherComprehensiveIncomeLossOtherNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTItMS0xLTc5MjQ5_8ebc107c-8762-4625-911e-31932e7743cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:OtherComprehensiveIncomeLossOtherNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTQtMS0xLTc5MjQ5_5a22f0f4-8073-45a8-94d9-2d65fc3e44b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:OtherComprehensiveIncomeLossOtherNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTItMS0xLTc5MjQ5_2d937cb7-7a2c-4d54-93df-cdb2eb2a0abf">18,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTQtMS0xLTc5MjQ5_3ab16787-5784-4fa5-9eb5-a76686f41309">30,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a">36,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COMPREHENSIVE INCOME (LOSS)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTItMS0xLTc5MjQ5_0190d1f5-e7f9-44d1-9633-10d41ab4068d">123,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTQtMS0xLTc5MjQ5_4d73f081-cbbc-41f0-9271-193cebc4abc5">33,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177">817,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_136"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:1pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands of U.S. Dollars and share amounts in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of Common Stock, beginning balances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItMS0xLTEtNzc5Mzc_704b7ded-acf3-4d1f-9490-6a83fcd08a0d">183,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItMy0xLTEtNzc5Mzc_a4a4a3ed-f076-4a14-aa60-03714d3e907d">181,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib09dd10764f7419a9a4650c424edaaf4_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItNS0xLTEtNzk0MDk_2e95c066-bc56-4208-bdda-823b803aaa7c">179,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtMS0xLTEtNzc5NzM_335ebde4-f67a-4ab9-9617-54c27035eaf3">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtMy0xLTEtNzc5NzM_53c7ff7b-be2f-4d3e-8092-5f0ab492a59f">2,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtNS0xLTEtNzk0MDk_d762a4b0-4a3d-4ed4-bd47-e1580e6a4e56">2,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtMS0xLTEtNzkzMTQ_ee673289-3ebc-409c-8e46-b49262c4d9fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtMy0xLTEtNzc5NDA_83ca7caa-15ad-43eb-9751-b5fde6e9e95d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtNS0xLTEtNzk0MDk_f64ea1af-ab80-41c2-ac51-93d02e00b074">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of Common Stock, ending balances</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10b42c69baf241b0b203d3fa4c47e397_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtMS0xLTEtNzc5NDQ_0b263f01-106f-4d74-890e-6fe9bd5260fb">186,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtMy0xLTEtNzc5NDQ_1fdfccc7-0712-407c-b4cc-37a95e82e2c1">183,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtNS0xLTEtNzk0MDk_aafc4542-1a19-4aee-9a21-4d7f2a9276a9">181,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity, beginning balances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ebf8a2e2374a5abb965688a2d10d21_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtMS0xLTEtNzc5NDk_2c043f7c-f298-41da-8cbd-d9f253ecdc35">4,270,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6098bafbae9d4819be0567307e54bb0b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtMy0xLTEtNzc5NDk_dbce3999-dc1a-4b38-a1be-f483151f5dc4">4,106,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662d4660c31e4fe99f786fb1fb315bcb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtNS0xLTEtNzk0MDk_312bb075-9e56-4baf-9619-003c3d15440f">3,122,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment related to correction of immaterial error </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c">5,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065">5,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44e8bd9c9b746cfbddaca2a0eb336ac_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted beginning balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTEtMS0xLTc3OTU0_c417c0fa-7a87-480a-aa07-4c53c55b2d04">4,265,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12190384e734edabd0ce99df1427a69_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTMtMS0xLTc3OTU0_96754669-c138-4427-8fb3-ba283d34f462">4,100,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ebaa31f544fe581553f2fab670db8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTUtMS0xLTgyOTcy_a2b3b693-0a31-45c2-845d-276684ede287">3,122,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTEtMS0xLTc3OTc3_3aafa8db-bf6a-4a19-9a7b-b05c8085d450">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTMtMS0xLTc3OTc3_640560e9-30c4-4ada-96e0-447659cd2657">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09dd10764f7419a9a4650c424edaaf4_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTUtMS0xLTc5NDA5_da951ede-3bb2-441d-9f86-f2e6357f0bfc">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTEtMS0xLTc3OTc3_52f13e60-59e3-488c-8bee-20964b55dcb5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTMtMS0xLTc3OTc3_ed49788c-aada-47b4-9b70-70441a526c5d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTUtMS0xLTc5NDA5_f8b0da66-2d3d-4c27-8993-5f518b8b0623">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balances</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b42c69baf241b0b203d3fa4c47e397_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTEtMS0xLTc3OTgx_44286ebe-63cf-4d13-8ea0-241952933bdc">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTMtMS0xLTc3OTgx_1fc85ec3-3feb-41c1-9aa5-4ae8529b5e33">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTUtMS0xLTc5NDA5_396d3c03-605d-4ea4-80a9-a81378e1f840">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037d2ed2bca94a4db141fccb8f4098cf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTEtMS0xLTc3OTg1_412828e4-af9f-49b8-a288-4676f4fe38b4">5,191,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094472930d474e9db0bb25616669cfaf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTMtMS0xLTc3OTg1_a0741258-731e-4053-8d7e-80cd9c597727">4,993,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778dfb0b1c9b4191b55f82d31f87abfb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTUtMS0xLTc5NDA5_033909fb-d5b9-4991-8fed-87f39e1c739c">4,832,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTEtMS0xLTc3OTg5_1f7cf5c9-2898-42f4-818b-dd73bca9e216">14,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTMtMS0xLTc3OTg5_c28712fb-cfc4-4cfe-b239-13b67bcda7b0">3,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTUtMS0xLTc5NDA5_337ad288-e0ff-490d-afd6-a110f50b75ff">27,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTEtMS0xLTc3OTkz_27e89f60-8913-4fd9-80f3-1472ffd5b56e">199,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTMtMS0xLTc3OTkz_be6f77be-1eab-48af-9f26-051736b014a0">194,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTUtMS0xLTc5NDA5_570f3d02-4234-4fa2-8718-7cf93a67dab6">183,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTEtMS0xLTc5NDA5_b0015f9b-6d8c-432b-a582-68535e192283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTMtMS0xLTc5NDA5_ffe9d073-31d9-4fad-907f-7443ce08e66a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTUtMS0xLTc5NDA5_2a3559f6-643e-4937-a290-9d451cfb5218">50,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231" decimals="-3" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTEtMS0xLTc3OTk5_a66599ea-ec5a-4cce-ae76-a5205bcfe95a">830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231" decimals="-3" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTMtMS0xLTc3OTk5_ed8154c9-87db-4d3c-8a78-ccf502c01944">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231" decimals="-3" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTUtMS0xLTc5NDA5_8743f32a-64ff-4584-b549-dbfffc36a281">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balances</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45678d32ad246c5bc437806356fe440_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTEtMS0xLTc4MDAz_f6f93b89-27a8-4127-847b-ab17a64df02d">5,404,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037d2ed2bca94a4db141fccb8f4098cf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTMtMS0xLTc4MDAz_83c8fc29-b968-47dc-80be-a6ff5bd65028">5,191,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094472930d474e9db0bb25616669cfaf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTUtMS0xLTc5NDA5_2f0f7e14-0e77-4eed-8f2d-1c8606c1eb8a">4,993,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTEtMS0xLTc5NDA5_978150d1-5a61-40ab-84ed-e36f00091f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff477083f4d346f6ac8e1fca2a77ac95_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTMtMS0xLTc5NDA5_97968232-95a5-4058-a2e7-529b94da23c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3fd3335b8041b9b3010fb2ffa6e213_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTUtMS0xLTc5NDA5_4281c9cb-414a-45c1-99b7-6be3eb5b2b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTEtMS0xLTc5NDA5_cf7dca7d-c349-4525-8602-e501da3bb00a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTMtMS0xLTc5NDA5_c3b47d3b-4248-468c-a892-c203a791faa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTUtMS0xLTc5NDA5_5358d692-f8ff-412f-acf5-31e69a1923a0">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTEtMS0xLTc5NDA5_a1c93f90-c9b2-43fd-a2cd-dbaeae3bd30f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTMtMS0xLTc5NDA5_70b89ad7-b188-407f-a3b9-6af78e27a43d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTUtMS0xLTc5NDA5_5c55159d-17bf-4635-b3d1-3c538a52095a">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4626a538858248e5b6ffc8ab8d43cffc_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTEtMS0xLTc5NDA5_3042e569-b811-4ae6-a5e6-655b0c9bfa64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTMtMS0xLTc5NDA5_c2642529-6e60-49b0-affc-34205f7ba76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff477083f4d346f6ac8e1fca2a77ac95_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTUtMS0xLTc5NDA5_d4044c09-925f-490c-9459-9b2d9747cc55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company common stock held by the NQDC:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTEtMS0xLTc4MDEz_943586ba-5405-4b8d-a067-37c065f65935">9,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb05616fee644133b5237b50cb6c2646_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTMtMS0xLTc4MDEz_eb17fddd-9478-49af-a1e5-35bc7a12a446">9,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d0c42bea91a4dc2a7a17b7338db6938_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTUtMS0xLTc5NDA5_8079440b-2a5f-4851-a9aa-05b0a1625e75">9,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d7235bf19146b596b6df0be03b57f7_D20220101-20221231" decimals="-3" sign="-" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTEtMS0xLTc4MDEz_ab44c8a2-ce32-4bca-8668-1538979d92ec">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d3e943b1074224a9e5025c4dcc0935_D20210101-20211231" decimals="-3" sign="-" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTMtMS0xLTc4MDEz_dfb281c9-88ac-4b42-91bb-a5c989fa0dab">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d353eb18df493b84f05bd498c9b00b_D20200101-20201231" decimals="-3" sign="-" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTUtMS0xLTc5NDA5_326d1293-4569-496b-88ee-f32e456306c4">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balances</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f810b0c8fb345f4bfb8bcbade131882_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTEtMS0xLTc4MDE3_fc56ee9b-890b-41f8-adce-fedceca821fd">8,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTMtMS0xLTc4MDE3_29d74c19-321a-498a-ba6b-15e9891fc0bf">9,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb05616fee644133b5237b50cb6c2646_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTUtMS0xLTc5NDA5_37cf9b36-d6b4-4c0f-925d-69dd254b4eba">9,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4459fe0e1d3a4f18891f7db2ecc5a055_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTEtMS0xLTc4MDI2_5fc52b32-2ce2-4605-95a1-bc348ebca612">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436459593c174d1e9727d5e56761f15e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTMtMS0xLTc4MDI2_85685170-679d-4eb5-baa8-bed89cadcf3c">16,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d3c22869c8421394b488a8626e5406_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTUtMS0xLTc5NDA5_40586205-45c8-49a5-89d7-cfd11039adb9">20,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808e908af0344804823d766893b68cc5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTEtMS0xLTc4MDMw_e2faaf52-8d21-4adc-a7fa-4cba3a808d95">18,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104acad50b8a4571a58be492b9d7df86_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTMtMS0xLTc4MDMw_aad35db4-4fab-4ec5-8d46-ed6aa8672069">30,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib54cd08c98774db68e3cb795308fff9f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTUtMS0xLTc5NDA5_14e0f96a-03f4-4c52-84db-aff0f66e737b">36,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balances</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d01a3eb633442b8a24963b9a15b0f21_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTEtMS0xLTc4MDMw_c584c672-f2ce-46a6-a38f-e9bf865593e8">3,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875a67714c6452c84f63885164473d3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTMtMS0xLTc4MDMw_ada6355a-ef4a-42ac-b9f3-9cd005aa3ff9">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id485da7dafae40ddabd0f37725dd651a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTUtMS0xLTc5NDA5_d4018978-482d-436d-b75e-01323696791c">16,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia23b0b2b780d494282ba40678c605752_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTEtMS0xLTc4MDM0_6f4bd12d-9ec5-4728-aedb-f12d8b3fc020">925,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02848a53e7a45cba266b90b81b13c5a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTMtMS0xLTc4MDM0_2bdb21c9-e548-441e-8bb5-7959bc2b47b9">861,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba09bd3b78014fbfa684be4eb9247536_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTUtMS0xLTc5NDA5_afa8509a-74eb-431c-83be-2f80a0bcf568">1,720,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment related to correction of immaterial error</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fb34c9bea594b0eabc679077dde1e28_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTg3Mzgw_1ff60593-9663-42af-bc09-e04b3029c0a4">5,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02be9ecdb8dc4d27a02fe43f8746d284_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTg3Mzgw_a4abb31b-9e16-4ed5-ab3a-359d486f990e">5,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297dbbe3b39e4ab6a4b37e0a86515b1c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTg3Mzgw_8c601828-61e3-4d2c-88a4-dd8b9ae8b398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted beginning balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4230919f8e50464c89c33c99ae0bba5d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTEtMS0xLTg3Mzgw_5d8e3bc7-c1e1-4d0d-a8d3-2af9dc030e9c">930,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba0c13891df446e79adeb971585c3cb5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTMtMS0xLTg3Mzgw_b9a9ae8d-ba6c-4568-8e88-2d50f3843393">866,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7c5b90e497444cab72b951983c3c835_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTUtMS0xLTg3Mzgw_c28ee63e-bb3e-47e6-bf2b-0f0e394ce12f">1,720,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab00f1aa61d4a799d6596e92e9ea772_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84b7329ecd8e4081bb41b08925e77b86_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b">64,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee12a83d534677a3997b39f21b3db2_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96">854,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balances</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f07c323c9ed43ab9344a7d19cd1632a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTEtMS0xLTc4MDQ0_65318ea5-427c-4653-9b44-d58e06846735">789,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4230919f8e50464c89c33c99ae0bba5d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTMtMS0xLTc4MDQ0_260a5e36-1323-4016-af29-3a660dc2945b">930,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba0c13891df446e79adeb971585c3cb5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTUtMS0xLTc5NDA5_7d829830-bcbd-4950-808c-07e761cf9d40">866,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity, ending balances</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTEtMS0xLTc4MDQ0_b81bc193-58d8-4b60-a045-e8a5c2b7b958">4,603,156</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTMtMS0xLTc4MDQ0_81d4aaa7-efb9-45b8-a24d-f552a3d2eb75">4,265,669</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12190384e734edabd0ce99df1427a69_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTUtMS0xLTc5NDA5_3710c1a7-d309-4ebb-a816-c54da7a35b0a">4,100,931</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The years ended December 31, 2021 and 2020 have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.<br/></span></ix:footnote></div><div style="text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Contents</a></span></div></div><div style="margin-top:1pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands of U.S. dollars)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItMS0xLTEtNzgwNjc_a9f3800b-0002-4b60-a1ad-994df6fe3f70">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItMy0xLTEtNzgwNjc_7250722d-989b-47a6-8988-46a90ff53a94">64,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa">854,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtMS0xLTEtNzgwNjc_2a87fbee-fe37-48df-906d-8bed21379491">101,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtMy0xLTEtNzgwNjc_f84b1a59-1037-4090-b8f3-224867437f4e">108,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9">105,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtMS0xLTEtNzgwNjc_8c33bef5-fcdc-4257-a26f-59fd40366b6d">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtMy0xLTEtNzgwNjc_4395c075-2597-4d5e-b562-2b8eecb7e5a1">4,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8">16,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premium on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtMS0xLTEtNzgwNjc_1edfe25e-23f9-4afb-8bec-1348a1012da1">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtMy0xLTEtNzgwNjc_81ac69cf-9868-4b87-a28a-f3423c57d928">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctMS0xLTEtNzgwNjc_67a8f1e8-1228-45eb-ab88-a14631d311d5">196,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctMy0xLTEtNzgwNjc_8d0056ea-832c-42d1-8cb2-b182214b1a69">197,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae">189,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtMS0xLTEtNzgwNjc_796c5ab1-6c96-4a3d-b600-6a36fdff657e">108,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtMy0xLTEtNzgwNjc_03543073-9f00-4be8-944a-485004f04b37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d">52,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory reserves, net of stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktMS0xLTEtNzgwNjc_2cd456dd-17e7-4a94-8df4-e6fabe509688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktMy0xLTEtNzgwNjc_c7569333-8f43-4faf-bc53-c11bed922648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051">75,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTEtMS0xLTc4MDY3_7b373c6d-9e84-4812-afea-d02594643c7d">52,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTMtMS0xLTc4MDY3_1f859630-8c89-45a9-ab4a-7ead0cae1288">15,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e">889,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTEtMS0xLTc4MDY3_58ccd9ac-70b9-41c2-9004-517c4cf5a644">14,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTMtMS0xLTc4MDY3_cb7e9239-efdc-4190-9474-38cd7417a745">1,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5">8,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTEtMS0xLTc4MDY3_404e12f5-9c01-4afb-bbf3-287b4808fc29">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTMtMS0xLTc4MDY3_21cb5172-6db9-464e-8e2e-2e6c53e0f952">8,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTEtMS0xLTc4MDY3_44b4cca4-abdd-4052-a8e5-d78f198f3bad">2,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTMtMS0xLTc4MDY3_76194aa8-7d61-463c-a01e-6c92a264dcb7">2,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd">997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTEtMS0xLTc4MDY3_61d78bc4-81a7-4c1a-af00-7c33016890af">82,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTMtMS0xLTc4MDY3_7e7e341e-28f6-4479-a6bd-c945d5c3f99b">65,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e">59,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTEtMS0xLTc4MDY3_2f6a56ee-e6f6-414f-9504-4dcb4f3c5a99">68,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTMtMS0xLTc4MDY3_ab7eb697-5b64-489f-9344-c6b86e4c97a8">35,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605">61,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTEtMS0xLTc4MDY3_09ffecb3-84e8-4a30-8d3e-e9002aaa847d">7,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTMtMS0xLTc4MDY3_125d4cf3-7986-4669-bf7d-7d24ec3f885c">29,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTEtMS0xLTc4MDY3_369b5cda-9bb3-43fb-b7d8-df874b439d4d">19,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTMtMS0xLTc4MDY3_ef653303-0223-4cfd-b978-cf0848285e66">6,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94">29,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and other short-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTEtMS0xLTc4MDY3_53082fab-d7ba-4ad3-9b22-4cd21c49d175">59,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTMtMS0xLTc4MDY3_b3c697b9-ae84-49cb-b9d1-1d1decb9ddbe">15,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57">87,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTEtMS0xLTc4MDY3_addf8fc2-347a-41f7-b9ea-1ab579036347">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTMtMS0xLTc4MDY3_48a4180a-e520-40e0-993e-c2f59bc54906">3,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62">7,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTEtMS0xLTc4MDY3_f8408e0c-6100-48ae-bc56-b3acdf583049">175,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTMtMS0xLTc4MDY3_bc4288e3-81d7-4e54-98a4-b32dde778d6c">304,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7">85,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTEtMS0xLTc4MDcz_7d295b32-c395-4d68-8d40-39d81e402d02">120,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTMtMS0xLTc4MDcz_a107d964-b25e-424e-9d48-544979c0d38e">95,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274">114,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTEtMS0xLTc4MDcz_32bffd50-f04f-4be7-829c-640e61d063e5">619,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTMtMS0xLTc4MDcz_8648e345-4d1e-4857-859c-26f7f919db63">691,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608">555,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTEtMS0xLTc4MDcz_2696ba18-d076-4b79-bd04-40c2254bb937">611,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTMtMS0xLTc4MDcz_06f74c2d-2997-45a4-b880-4c61dcb46f06">937,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea">529,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of nonfinancial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:ProceedsFromSaleOfNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTEtMS0xLTc4MDcz_5aab6e1c-482e-424d-bb22-2d7b4a2fd18d">103,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:ProceedsFromSaleOfNonfinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTMtMS0xLTc4MDcz_d821f955-48c3-4ae3-af02-2504d8ae3f2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:ProceedsFromSaleOfNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66">67,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTEtMS0xLTc4MDcz_632d0db3-a134-4a3f-91f4-c8ac1c5ff1f7">10,581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTMtMS0xLTc4MDcz_98044676-00f2-4347-b1df-6f3bf44de5b8">23,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f">23,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTEtMS0xLTc5NTY3_7c55e330-15a2-4d1f-9b61-9c6711617c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTMtMS0xLTc5NTY3_5eda4fe5-5918-445d-915a-0db4b642287b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06">8,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTEtMS0xLTc4MDgw_470253c0-9136-471e-a301-8a2cfbab2f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTMtMS0xLTc4MDgw_8483a985-7e7e-4e30-ac7a-f336607114c9">994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTEtMS0xLTc4MDgw_d0245b0b-51d6-48ac-bcb5-6d12169fe457">20,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTMtMS0xLTc4MDgw_e8714e9f-d36f-4ba0-b726-159d7a805e00">366,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e">53,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercises of awards under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTEtMS0xLTc4MDg0_c81a2081-1950-477c-accc-a92dca14c497">69,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTMtMS0xLTc4MDg0_584324d6-d88b-46ba-aa22-66a7a79b57e1">49,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d">71,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTEtMS0xLTc4MDg0_b53bae34-6b0f-443e-a1a2-08ee3fdd91fc">54,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTMtMS0xLTc4MDg0_036b2fc4-8701-4d8e-9681-d2ec7bb7edfd">45,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657">44,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTEtMS0xLTc5NTg4_4106be7c-7c83-4507-93ec-65f965fc85d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTMtMS0xLTc5NTg4_18f4d5b7-c0bf-40a9-8cf9-f13fe856a62a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f">50,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from convertible senior subordinated note offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTEtMS0xLTc5NTg4_9e011a17-daa8-4afe-ab2e-ff9b5a614c67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTMtMS0xLTc5NTg4_42f9f089-ad78-4001-a334-32c766a8004d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4">585,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTEtMS0xLTc5NTg4_2f491944-019a-43b5-829a-c7937b2f8573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTMtMS0xLTc5NTg4_4933a0ba-aecb-4d2d-9438-456e22c893e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52">374,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTEtMS0xLTk4Mjg1_ab8f910d-2621-4c49-a821-c392c5affd8e">31,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTMtMS0xLTk4Mjg1_900c306e-647d-4fa6-b953-5518664559e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of financing leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTEtMS0xLTc4MDk2_f55d3784-59b7-40ef-ad8b-e6dbeb2faa8e">2,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTMtMS0xLTc4MDk2_3d1a3dd3-82d7-4a6d-ac36-42a0f67f6f61">3,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4">6,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTEtMS0xLTc4MTA1_28a705c2-4d0d-493f-aaf2-d644e5125d45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTMtMS0xLTc4MTA1_ffd42b38-0baa-4ed3-93bf-347af53dfec5">398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTEtMS0xLTc4MTA5_9584cdff-13e9-4fb8-8123-5a57d5eddcf4">18,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTMtMS0xLTc4MTA5_e1522c4e-7537-4109-b3ed-a10f7bcb8375">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d">181,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTEtMS0xLTc4MTA5_421b8d07-56ca-4578-8621-764bbd2b1ce4">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTMtMS0xLTc4MTA5_5767a4d9-41f3-4bff-82a5-bb822a776a13">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053">1,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTEtMS0xLTc4MTEz_155df6a3-dd48-420b-9681-4d14e40dbd7d">137,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTMtMS0xLTc4MTEz_daa74b43-8133-459b-94ea-94d1f52d3b9f">61,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc">211,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTEtMS0xLTc4MTE3_52f6c83e-f7c2-49f3-9725-23c5a20a4586">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12190384e734edabd0ce99df1427a69_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTMtMS0xLTc4MTE3_b2f96b26-6e87-4d9e-a31f-256aaf278b6d">649,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ebaa31f544fe581553f2fab670db8_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802">437,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTEtMS0xLTc4MTE3_da30b457-081b-46d4-a2b6-940526c07eac">724,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTMtMS0xLTc4MTE3_3fca0474-f2c9-44b8-9cbc-9d89649adae3">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12190384e734edabd0ce99df1427a69_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3">649,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SUPPLEMENTAL CASH FLOW DISCLOSURES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTEtMS0xLTc4MTI1_856e6c32-90bc-4523-af8c-f227128f0505">10,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTMtMS0xLTc4MTI1_04b85eaa-b9af-48ee-9dad-b788fae3af2d">10,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6">12,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTEtMS0xLTc4MTIx_e81eada0-67cc-4ff1-82e4-608eb47d2059">54,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTMtMS0xLTc4MTIx_fb532296-9125-4bb9-9991-005929f74eed">18,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d">8,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities related to fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTEtMS0xLTc4MTMy_59c54177-e89a-4a16-8173-0e599656ea57">1,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTMtMS0xLTc4MTMy_27b30699-d306-4bc3-b3a1-213d75f9e38f">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83">5,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTEtMS0xLTc4MTMy_6a353117-411f-4180-8563-69e10fdb71a9">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTMtMS0xLTc4MTMy_abc0a1c7-f48f-4c26-aab9-3829f10fa517">9,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></ix:footnote></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_142"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA0_286ce116-4034-4f3c-ba88-3a6ac30021be" continuedAt="ib1b3221d70ff458e95c0a0654246c9c4" escape="true">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ib1b3221d70ff458e95c0a0654246c9c4" continuedAt="i41999113c0044d49a0ca6c0957c5a84f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Founded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. ROCTAVIAN (formerly known as valoctocogene roxaparvovec) was granted conditional marketing approval in the European Union (EU) on August 24, 2022.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA4_28e11c15-3ad8-4e5d-99d8-e9328ccb8ac7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Correction of Immaterial Error </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company became aware of an unrecorded amount due to a third party following the January 2020 sale of the worldwide rights of FIRDAPSE, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. The Company evaluated the materiality of the previously described error from a qualitative and quantitative perspective. Based on such evaluation, the Company concluded that the error was not material to any individual current or prior period, nor did it have an effect on the Company&#8217;s trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 108, C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">onsidering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Although the effect of the error was not material to the current or previously issued financial statements, the Company has corrected the accompanying Consolidated Balance Sheets, Statement of Operations, Statement of Comprehensive Income and Statements of Stockholders Equity. As a result, the correction decreased 2020 Net Income and increased the 2020 Accumulated Deficit balance by $<ix:nonFraction unitRef="usd" contextRef="iadd55ebfa48d4b8e91fb580564bc2ebf_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNDUz_acbdeaea-fdc3-4bca-bad3-25b70d08c27a"><ix:nonFraction unitRef="usd" contextRef="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNDUz_cacf18ce-4fbd-4ba4-8048-7e3b8f01055b">5.1</ix:nonFraction></ix:nonFraction>&#160;million. Consequently, this had the following impact on certain December 31, 2021 balances: an increase to Accounts Payable and Accrued Liabilities of $<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3ODA_4c0a2e89-de40-41da-b3af-3751a953343f">6.7</ix:nonFraction>&#160;million, a decrease to Total Stockholders&#8217; Equity of $<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNzI1_98f39301-6122-412c-ac54-c11d5664580f">5.1</ix:nonFraction>&#160;million, an increase to Deferred Tax Assets of $<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3OTA_c4795e1f-0205-40c0-9e65-afad76672d18">1.1</ix:nonFraction>&#160;million, an increase to Other Assets of $<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3OTg_6fbcfdcc-964c-416c-9d41-487172e02f3c">0.4</ix:nonFraction>&#160;million and a decrease to Other Long-term Liabilities of $<ix:nonFraction unitRef="usd" contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231" decimals="-5" sign="-" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM4MDY_92efc5b5-24fb-46be-ac88-708a72bd01c6">0.1</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTIw_c20ad5d8-357e-44b2-80bd-a5676da181d3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company&#8217;s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEy_3a7beb78-d062-4aee-8c99-99a86bcecbd8" continuedAt="ib55ab6bc77584080bef159773af6053d" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ib55ab6bc77584080bef159773af6053d">The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i41999113c0044d49a0ca6c0957c5a84f" continuedAt="i3a09d7c9e31f47ae8037e43ee0ced3c9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTIz_b12d5600-6a00-4012-995e-42d447fb03e5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument&#8217;s underlying contractual maturity date and its availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company&#8217;s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment&#8217;s amortized cost and fair value at such date.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SecuritiesOwnedNotReadilyMarketablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEw_7e587eda-be69-455d-9d0a-cd0513c9981e" continuedAt="i08a0a9c91231410195c1ca2a5768aa97" escape="true">Non-Marketable Equity Securities</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i08a0a9c91231410195c1ca2a5768aa97">The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.</ix:continuation> </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEz_5d6d98a2-4933-416c-a602-50e7ce29d2ae" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Inventory </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;D).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE2_04293c2e-8033-4711-b66f-c828b62f39fb" continuedAt="iaacbd2d1e0ac4bcb8935f0de07f2c1b9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;D and Selling, General and Administrative (SG&amp;A), as appropriate, in the Consolidated </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i3a09d7c9e31f47ae8037e43ee0ced3c9" continuedAt="i6a0544f0be8c4c88bfc2ca1ce4bd26a5"><ix:continuation id="iaacbd2d1e0ac4bcb8935f0de07f2c1b9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Statements of Operations. Property and equipment purchased for specific R&amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;D in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE3_9861096f-67f1-433e-af9d-9f1023a442d4" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzAtMS0xLTEtNzc2Mzg_b58d615d-8961-4800-9f69-ab3c39ead3a4">Shorter of life of asset or lease term</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52310aa2a3a247b697aa20cecbad91fd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzEtMS0xLTEtNzk2NzQvdGV4dHJlZ2lvbjowNTc2NWUxN2JkN2I0YTFiOWEzYjA4ZWNkZjYwM2M4YV8yMTk5MDIzMjU1NTcy_0d219c1b-d77a-4672-9766-13c39375855c">20</ix:nonNumeric> to <ix:nonNumeric contextRef="i1f6c3ef715354e01be0ce46fef7ade7d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzEtMS0xLTEtNzk2NzQvdGV4dHJlZ2lvbjowNTc2NWUxN2JkN2I0YTFiOWEzYjA4ZWNkZjYwM2M4YV8yMTk5MDIzMjU1NTgz_b6485c54-ef4b-4781-9f47-a8fc606f49e1">50</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing&#160;and&#160;laboratory&#160;equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6eedfe89ea9847a1b1177eebb3b74933_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzItMS0xLTEtNzk2OTQvdGV4dHJlZ2lvbjo4N2RhN2NkZWY4NWE0YzJjOGJmODU5ZWQzZjI4ZTU3MF8xMDk5NTExNjI3ODA1_65d305c8-7e4a-4b57-8d68-266ca16d1d74">5</ix:nonNumeric> to <ix:nonNumeric contextRef="ia8b1e6d47d184565b72aec37b1bad113_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzItMS0xLTEtNzk2OTQvdGV4dHJlZ2lvbjo4N2RhN2NkZWY4NWE0YzJjOGJmODU5ZWQzZjI4ZTU3MF8yMTk5MDIzMjU1NTc3_94dc0a7c-a93f-4f04-824d-cf62b6a0dc34">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d169bd2b3f74f53a7bf1f5cccef2259_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzMtMS0xLTEtNzk3MDAvdGV4dHJlZ2lvbjplZDA5MGQ4ZWU1NGQ0OTAyYjhiNzk1Y2RlODhkNzhkZV8xMDk5NTExNjI3ODAz_8ca1ae17-24e3-49d8-918f-516c1c0e5e71">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i6bea8c595cc8498f897680fba3204460_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzMtMS0xLTEtNzk3MDAvdGV4dHJlZ2lvbjplZDA5MGQ4ZWU1NGQ0OTAyYjhiNzk1Y2RlODhkNzhkZV8yMTk5MDIzMjU1NTc1_56034320-0419-4872-b07d-29cfe2aacaf4">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3293e8e2731d413a88a25a0d3bb69545_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzQtMS0xLTEtNzk3MDcvdGV4dHJlZ2lvbjo1ZDFiMmMxYzg5MzQ0ZTE2YjJiM2I2M2M5YWNkZGZiMV8xMDk5NTExNjI3Nzg2_570f1011-f395-43ae-a75a-ab6c547c9c3e">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i623384117ca2486288e722c61f359369_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzUtMS0xLTEtNzk3MTQvdGV4dHJlZ2lvbjozMGUxMzExMzI4MjI0MmQ1ODQ0NGI2ZTcyZTU1NmMwNl8yMTk5MDIzMjU1NTcy_af3c58e7-10ad-4b5b-837c-926c608c1ca3">10</ix:nonNumeric> to <ix:nonNumeric contextRef="i71e5affca8dd4c6290c3e523c042ca61_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzUtMS0xLTEtNzk3MTQvdGV4dHJlZ2lvbjozMGUxMzExMzI4MjI0MmQ1ODQ0NGI2ZTcyZTU1NmMwNl8xMDk5NTExNjI3ODA3_dd48bbbd-3528-4e2b-8242-3359184ea8ea">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table></ix:nonNumeric></div></ix:continuation><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE0_de99fd27-a9eb-4a28-a899-e44fb93cb8f7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&amp;D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company&#8217;s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company&#8217;s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE4_95511990-5194-4855-8a5d-08b2b046a7b2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA1_9de343b0-2f92-4536-86e2-a83a52ec7d96" continuedAt="i5edb2b9d3a7b495da4b8b22f82d34c05" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment by comparing the fair value of the Company&#8217;s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i6a0544f0be8c4c88bfc2ca1ce4bd26a5" continuedAt="i791d3ffb74844d198328cdd0e52c1001"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:continuation id="i5edb2b9d3a7b495da4b8b22f82d34c05" continuedAt="i0510a4d54ca24f7285a423de19fa4682">Long-lived Asset Impairment</ix:continuation></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i0510a4d54ca24f7285a423de19fa4682">The Company&#8217;s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify a manufacturing facility for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzE2NDkyNjc1MTA2ODA_9e78373a-f459-4542-be4c-16ee7908aa03" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capitalized Software</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE5_9a59d895-3a97-4bae-b8f6-d67071b2c3ce" continuedAt="i446612781e794bfda8909a41d9626373" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt">identification of the promised goods or services in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt">measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt">allocation of the transaction price to the performance obligations based on estimated selling prices; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Company&#8217;s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company&#8217;s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzMxODg1ODM3Mjc1MDIw_4d7e0edd-76ca-43ab-8828-b205ba67be61">one year</ix:nonNumeric> after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzMxODg1ODM3Mjc1MDM3_7394e31b-a823-4c9a-9fa6-f956cc39016b">one year</ix:nonNumeric> or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company&#8217;s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For ALDURAZYME revenues, the Company receives a payment ranging from <ix:nonFraction unitRef="number" contextRef="id44211095b6f4687bae28103060052c4_I20221231" decimals="3" name="bmrn:PaymentReceivedAsPercentageOfNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgxODA2NjM_a4cf237f-7302-4e9a-bfa4-478d24e6d05b">39.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4068777477954ecd9a0dcd931dbcab88_I20221231" decimals="2" name="bmrn:PaymentReceivedAsPercentageOfNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgxODA2NzA_409762ad-7d4b-4873-979d-77a14faff54d">50</ix:nonFraction>% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company&#8217;s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company&#8217;s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i791d3ffb74844d198328cdd0e52c1001" continuedAt="if2814f42d3024d82b4c1a55366ec66a6"><ix:continuation id="i446612781e794bfda8909a41d9626373" continuedAt="ia9ede232afe34693b10ed2b493e9bc39"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Reserves</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. Such variable consideration includes rebates, chargebacks, sales returns and other incentives. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Government and Commercial Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company&#8217;s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers&#8217; limited return rights and the Company&#8217;s historical experience with returns. Because of the pricing of the Company&#8217;s commercial products, the limited number of patients and the customers&#8217; limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Other incentives include fees paid to the Company&#8217;s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient&#8217;s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:&#160;For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="if2814f42d3024d82b4c1a55366ec66a6" continuedAt="i984cb473db4b40ed90e1b97438ed1c0a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ia9ede232afe34693b10ed2b493e9bc39">attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</ix:continuation></span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI1_8fcb2939-6707-4851-b113-267851aad0df" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D costs are generally expensed as incurred. These expenses include contract R&amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs and R&amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgyMDQ3Nzc_a1abb3be-c572-46ea-9fbf-e855d37411b9" continuedAt="id9e1319cda7f4a52833dab63fb92376f" escape="true">Advertising Expenses</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="id9e1319cda7f4a52833dab63fb92376f">The costs of advertising are presented in SG&amp;A in the Consolidated Statements of Operations and are expensed as incurred.</ix:continuation> Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyMzI_518919bc-4382-4997-b554-d4ab2569074f">25.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyNTM_f2016ac7-77a9-47ef-8454-c926f7ae3a38">30.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyNzM_65b9257f-3477-43b7-814e-4ea8738d97e5">29.3</ix:nonFraction>&#160;million in 2022, 2021 and 2020, respectively. </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA2_96d58678-cd7e-4cfa-83b3-e6a94c164374" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Earnings (Loss) Per Common Share</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI2_bf50f0dd-c8e7-4bf0-8b2f-71404388330d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;D or SG&amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company&#8217;s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of each stock option award and purchase rights under the Company&#8217;s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is <ix:nonFraction unitRef="tranche" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="bmrn:NumberOfTranchesInOfferingPeriod" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTQ0_962ad8ff-d6e1-415e-9715-373b8d6de6aa">four</ix:nonFraction> tranches in a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13">twenty-four</span>-month period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company&#8217;s stock price and may use assumptions regarding a number of complex and subjective variables.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i984cb473db4b40ed90e1b97438ed1c0a" continuedAt="ida827c253ba241be9e5324c1fc5e5f0e"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE1_00a05946-6472-460b-8600-7a4b15a1da40" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company&#8217;s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI3_284fb459-5a71-4788-841d-05429a4e5f98" continuedAt="i52a6cf94040945ed866e617975c3b0e4" escape="true">Foreign Currency</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i52a6cf94040945ed866e617975c3b0e4">For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates.</ix:continuation> Foreign currency transaction losses resulting from remeasurement recognized in SG&amp;A in the Consolidated Statements of Operations totaled $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc0ODk_d4bdf9f6-69a7-40f4-9a80-9961606f11c6">11.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc1MDk_e8bfec8b-5b67-42a3-aa63-03e78494479b">11.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc1Mjg_9aa18948-237a-447b-ac35-edac143efbe3">9.9</ix:nonFraction>&#160;million in 2022, 2021 and 2020, respectively. </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA3_6634a213-a25d-46dd-8cfc-00e496f85895" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;A in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTAy_69974d1b-4cb1-4060-a70e-a099254cfe3b" continuedAt="i4938fae977fa414c82bfdc4b7b2485c5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Income approach, which is based on the present value of a future stream of net cash flows</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ida827c253ba241be9e5324c1fc5e5f0e"><ix:continuation id="i4938fae977fa414c82bfdc4b7b2485c5"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Notes</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_148"> 2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_163">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_166">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_172">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_193">17</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further information on the nature of these financial instruments.</span></div></ix:continuation><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTAz_5b887a7c-69aa-4101-9ae0-fe7b80270fcf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzExNTQ0ODcyMTM3NTM5_a823dd32-fbac-4325-bfc5-7b620f018333">one</ix:nonFraction> segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in <ix:nonFraction unitRef="segment" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM4NTM_19399624-7682-48cd-9a8b-94cecf20d8a9">one</ix:nonFraction> operating segment because the majority of the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as <ix:nonFraction unitRef="segment" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzExNTQ0ODcyMTM3NTQz_44b500bf-dc7c-4e59-99e4-479bb9eab1f7">one</ix:nonFraction> business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEx_f12a708a-9a3a-4ca6-a896-6c9f1400926c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during 2022 that the Company believes are of significance or potential significance to the Company.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_148"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzE1MDA_d4524f72-b1e5-4b97-9559-558b9d434c03" continuedAt="ia7ddf0693111455bac4a0a0b701ecd04" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ia7ddf0693111455bac4a0a0b701ecd04" continuedAt="iaa5804b6526a4701a3717df34d27d83a"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzE1MDE_3a70a4ba-3101-4839-a981-32a4a7516124" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMS0xLTEtNzgyMzk_c1cff2ec-ce62-4cef-9eb8-6633b8a00007">463,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMy0xLTEtNzgyMzk_5728c60c-11cc-4d0d-8885-18d1703808ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtNS0xLTEtNzgyMzk_5adbd487-e9a8-4942-84ff-63b2c8835e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtNy0xLTEtNzgyMzk_dc661c83-9e4d-4aee-9616-c03dd1b5eed9">463,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtOS0xLTEtNzgyMzk_e68587f5-6720-46dd-82af-4fcb644b8456">463,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMTEtMS0xLTc4MjM5_5025a846-c663-49e5-ab7d-b0f175e59cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMTMtMS0xLTc4MjM5_d463bb5e-0020-4388-a780-916a4204d280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMS0xLTEtNzgyMzk_cd16884a-ef2d-432e-99ed-cc694eee38f6">248,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMy0xLTEtNzgyMzk_daba6354-5010-423c-9ebc-f47feaa41498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtNS0xLTEtNzgyMzk_9b2d48ee-98e3-4804-8c7e-019d36421b45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtNy0xLTEtNzgyMzk_279a8daf-1563-4617-a1d4-c928338712b4">248,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtOS0xLTEtNzgyMzk_2c2d0cbe-c71d-4f8b-9f6a-b324916b7d6a">248,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMTEtMS0xLTc4MjM5_c9a758d1-3edd-4eee-8da0-cbeb2583bcd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMTMtMS0xLTc4MjM5_84c33241-976d-41ad-875d-78f7ae4dbb11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMS0xLTEtNzgyMzk_7faa8f6b-4cb3-496b-b644-b35a16dec0df">504,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMy0xLTEtNzgyMzk_3322aa67-ed88-43cb-a6c0-2e3b1ac7a19e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctNS0xLTEtNzgyMzk_83fe0783-437e-4c2d-8589-ce3f6a8c9944">11,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctNy0xLTEtNzgyMzk_be08a9af-c582-4d33-a96d-ba0dded53c81">493,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctOS0xLTEtNzgyMzk_d61996fd-8f4d-454d-b697-9bcfb6a1eb14">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMTEtMS0xLTc4MjM5_126e40fb-94ab-4831-b0c2-df44dcbb7b3b">299,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMTMtMS0xLTc4MjM5_987e0f76-7842-44f4-aaf0-e050b9af028a">192,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMS0xLTEtNzgyMzk_402b7a7e-4a2e-4bf6-8317-9fdb1db14020">312,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMy0xLTEtNzgyMzk_45bbb7ce-1473-4d76-b994-867eed8aa35a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtNS0xLTEtNzgyMzk_35bc6468-9419-457c-bc5b-326229b7b23c">3,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtNy0xLTEtNzgyMzk_e5f4ee18-5a1a-4d80-ba8c-d5faced0cb9a">308,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtOS0xLTEtNzgyMzk_54db5706-3e64-4f8f-b981-6a411ad8c1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMTEtMS0xLTc4MjM5_b9f6c353-69fc-4d12-b6a4-9a545e1db39f">229,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b853a38b944bfea4923c8120facacb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMTMtMS0xLTc4MjM5_9264d5e7-d55a-4aa4-8eb6-f91aa27a9d27">79,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMS0xLTEtNzgyMzk_e501054b-606a-4a3f-bf94-9b4c2b1119b3">48,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMy0xLTEtNzgyMzk_0b43db0b-2cde-4bed-85e8-bde2a3adb429">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktNS0xLTEtNzgyMzk_b85e2608-0b6c-4a8f-b838-c8e317d406d4">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktNy0xLTEtNzgyMzk_9e52f236-90d8-4162-a592-a0eea102ad77">48,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktOS0xLTEtNzgyMzk_c4e834f2-576e-4fcc-bbb2-f95948411529">10,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMTEtMS0xLTc4MjM5_32db3bef-d9a2-4497-9a5d-e246c83decbb">37,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMTMtMS0xLTc4MjM5_c4ec990b-0df6-48a8-b928-b7a4898c9058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTEtMS0xLTc4MjM5_c870f924-d0a2-4635-913a-0fdf132d9656">63,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTMtMS0xLTc4MjM5_856cac44-f9e0-45b5-b140-ff6e01a56028">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTUtMS0xLTc4MjM5_c3ead0ee-8578-4a43-bdb9-ded0067078f9">592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTctMS0xLTc4MjM5_741daf1c-c523-46f5-a375-c04ec21d41ac">62,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTktMS0xLTc4MjM5_be9c39ce-c90f-4c4f-9b5a-c8d221332394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTExLTEtMS03ODIzOQ_1a76dbbb-19ef-4565-b16d-7fe04fd447f1">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41682380abc342c0a800728472affb1d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTEzLTEtMS03ODIzOQ_d2496c9c-b325-45c1-b29e-5277bed4386c">62,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTEtMS0xLTc4MjM5_69366646-fe90-4b13-8687-42ef333807d8">1,177,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTMtMS0xLTc4MjM5_9156fcf4-7eaf-41dd-8009-a3a4aba1da03">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTUtMS0xLTc4MjM5_64341c0b-d5e5-4de7-bedc-d6e231d33d88">15,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTctMS0xLTc4MjM5_f4f6bf24-b499-4ffe-8ec6-05bd058d88c9">1,162,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTktMS0xLTc4MjM5_d1082d9f-94f4-4dbc-b761-6b9be26aad01">261,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTExLTEtMS03ODIzOQ_5117b9fa-31e2-4e52-9500-8210e48dd032">567,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160b43862b4443b8b71abb1941361269_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTEzLTEtMS03ODIzOQ_0d5e2343-2ef0-4799-b254-ccada03a3b80">333,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTEtMS0xLTc4MjM5_0c4d42d7-6e1d-4ef5-861f-80eda1040cd9">1,641,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTMtMS0xLTc4MjM5_7f9bb847-54b4-4cc6-b23a-381727889fb0">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTUtMS0xLTc4MjM5_8801df6a-a2ee-4463-95d5-91bd8760084d">15,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTctMS0xLTc4MjM5_c90a3e29-fb08-4f00-80d0-bb5e810acf8d">1,625,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTktMS0xLTc4MjM5_52104b13-fc5d-499b-b046-ae3b6dfff082">724,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTExLTEtMS03ODIzOQ_8cb330de-7801-492f-aa84-7d033e95265b">567,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTEzLTEtMS03ODIzOQ_c4000a2f-ee21-44d8-a7f4-050834ba7d22">333,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMS0xLTEtNzgyMjU_e2bf2379-3cc8-422a-a876-3a5e09b893e2">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMy0xLTEtNzgyMjU_7f13f05a-35d8-4939-82a2-2dd354eb18c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtNS0xLTEtNzgyMjU_19d3a5d4-6b52-4e94-ac02-a950fa7e48f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtNy0xLTEtNzgyMjU_aa1597cf-6d02-438e-8b3e-e6a4468eaaf3">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtOS0xLTEtNzgyMjU_1ffe7034-7c11-4fd8-bf06-8c51521819d3">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMTEtMS0xLTc4MjI1_a7368777-217c-4a2f-bfa0-e61539924895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMTMtMS0xLTc4MjI1_c301eaf8-d8e7-4763-89e3-446b75ccab8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMS0xLTEtNzgyMjU_0492c504-e780-476f-843d-ae00ad772e30">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMy0xLTEtNzgyMjU_7f4f8692-1e38-425c-94f8-8a2685840c79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtNS0xLTEtNzgyMjU_025c4648-2de2-4f9d-a7aa-991b79702e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtNy0xLTEtNzgyMjU_35e75732-7470-4deb-9d5a-81e35e42c8ce">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtOS0xLTEtNzgyMjU_969ffd6a-f7f9-497e-a6bd-cbf90fa2192c">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMTEtMS0xLTc4MjI1_6576fb5b-5701-4d25-af94-c657bc5c04f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561448975fb740788726f49b7214216d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMTMtMS0xLTc4MjI1_66b2fa99-ca35-4ada-b600-2d6d891ae887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMS0xLTEtNzgyMjU_8ec7b737-76f4-470a-b6da-3f4022000bd2">584,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMy0xLTEtNzgyMjU_0740cbb6-8617-443e-941e-14db220893af">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctNS0xLTEtNzgyMjU_055d1f85-4d84-4b22-a949-a34dc7328d4b">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctNy0xLTEtNzgyMjU_6f82671c-bdc1-4020-afac-e7a1c25cdec9">582,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctOS0xLTEtNzgyMjU_b8bef2c0-0d37-4046-afe0-b22359f5a196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMTEtMS0xLTc4MjI1_481a392f-6012-4f6b-b0be-89394be23018">200,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMTMtMS0xLTc4MjI1_4ccec112-0814-4b1b-abc4-9e4e2bd608d3">381,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMS0xLTEtNzgyMjU_561e61ad-6aeb-4fa9-a5e5-e03bf594f1e2">224,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMy0xLTEtNzgyMjU_0802825f-d92e-4714-bd27-5785de1bf98a">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtNS0xLTEtNzgyMjU_b0fbe87b-18ad-44fb-ad1a-811477039b90">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtNy0xLTEtNzgyMjU_b0e102f8-1d2b-45df-bfbf-0476fe9a4364">224,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtOS0xLTEtNzgyMjU_72d7d67c-7550-4e4d-92f1-9d9ba35ac580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMTEtMS0xLTc4MjI1_e2c436ba-91a1-46ae-92eb-5b28f49462b0">146,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMTMtMS0xLTc4MjI1_8b807c1e-a136-4ca8-9d88-db563bd7afb8">78,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMS0xLTEtNzgyMjU_0f117f6b-c83a-432d-9ff3-4613e0a85df7">68,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMy0xLTEtNzgyMjU_71d9ec41-cb95-49d1-8c7d-171fcab417cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktNS0xLTEtNzgyMjU_895a415f-f7ca-4602-9964-fb2dee6e23ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktNy0xLTEtNzgyMjU_dee48deb-d7cf-47b4-8e2e-aa54f57ba82c">68,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktOS0xLTEtNzgyMjU_a62167ed-1b6b-4fc2-a7a0-4d9e0e462500">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMTEtMS0xLTc4MjI1_f741dd6c-2262-4092-8b7c-43d7b06e4df2">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMTMtMS0xLTc4MjI1_3878964c-b8d6-4722-b8ac-858ef65be121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTEtMS0xLTc4MjI1_67697c26-5938-4bd4-8035-aa3c28e2d3a4">56,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTMtMS0xLTc4MjI1_c8260d6a-e19f-42b4-b1eb-5cb1068d7067">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTUtMS0xLTc4MjI1_679127c8-35b6-4d69-bab1-e5de04631a8e">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTctMS0xLTc4MjI1_504251ff-e7d5-4855-af1f-5f46f1d23dcf">56,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTktMS0xLTc4MjI1_5d606491-a5ca-45e1-a2be-e0a9453ec372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTExLTEtMS03ODIyNQ_70434e00-ada2-4b5f-a153-1e2b4f6135d1">9,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTEzLTEtMS03ODIyNQ_c5833148-a895-49ea-be7d-fca13e3b62e5">47,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTEtMS0xLTc4MjI1_874fe1aa-2a2d-4aea-8324-8969996a891c">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTMtMS0xLTc4MjI1_db593d61-edee-4fc6-9099-96687c42cbd4">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTUtMS0xLTc4MjI1_d9182335-fed5-42a5-bf73-20dd2136d6b5">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTctMS0xLTc4MjI1_7975babe-ba3b-4ebd-93bb-ae597e38ae5e">3,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTktMS0xLTc4MjI1_09b0958c-fbc1-4245-98e5-a68a16e14e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTExLTEtMS03ODIyNQ_ac4ccc85-f0cd-439b-9ed5-d103461fdb42">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTEzLTEtMS03ODIyNQ_7dd8ba60-6cf9-4b21-8050-8fd6089a12b2">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTEtMS0xLTc4MjI1_f15b61e0-8b51-45b1-9242-afb6b196bfd3">1,222,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTMtMS0xLTc4MjI1_b058392e-e448-4be6-8a0e-f91b0e8a92a5">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTUtMS0xLTc4MjI1_f98c49d2-0a32-40a4-859c-03b0e911b83d">2,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTctMS0xLTc4MjI1_31ef0561-8d23-441a-a5c1-02e5e74d1a64">1,220,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTktMS0xLTc4MjI1_4b4d6864-85ea-46c7-8ed1-75245aec8e34">286,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTExLTEtMS03ODIyNQ_272b8af3-a17d-4972-8c01-f54ce2ad372e">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTEzLTEtMS03ODIyNQ_d462a307-6e01-4ba0-a240-5c9780c893c4">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTEtMS0xLTc4MjM0_d31c855a-8693-4284-b368-9bdec1d7c277">1,523,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTMtMS0xLTc4MjM0_ef76e889-756f-4114-9c88-abd5af9a9eea">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTUtMS0xLTc4MjM0_dd05e864-4c98-4639-87be-3781d5318288">2,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTctMS0xLTc4MjM0_b8babb2a-3c07-45bb-a825-de83976d8aa5">1,521,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTktMS0xLTc4MjM0_2eff9a73-a4a2-4dbf-a405-3714971e9f91">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTExLTEtMS03ODIzNA_6b002ce3-4c1f-4a6d-9e60-0d3fa2078715">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTEzLTEtMS03ODIzNA_7b448c40-aee5-4a93-a54d-bb7ebe5cd30e">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231" name="bmrn:ShortTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzI3NA_2bc8d19a-bc02-4c0e-89b7-6598b66504b2"><ix:nonNumeric contextRef="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231" name="bmrn:ShortTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzI3NA_d51c0764-9d3d-4382-aecd-379dff38fb6f">one year</ix:nonNumeric></ix:nonNumeric> or less.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9">one</span></span> and <ix:nonNumeric contextRef="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM1NA_5c680365-ea9d-48d3-bb1e-8cc5df185cca"><ix:nonNumeric contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM1NA_fc5a033e-2452-4048-bd3c-301773429213">five years</ix:nonNumeric></ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#8217;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="iaa5804b6526a4701a3717df34d27d83a"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#8217;s strategic investments was $<ix:nonFraction unitRef="usd" contextRef="i465f964e015842ad9df73023d86585b8_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzEwOTk1MTE2MjkzMzk_7f8be9ff-f596-4168-8621-0289213b10fa">23.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c6c18d583ad4920abd1d0bcfedc9627_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzEwOTk1MTE2MjkzNTU_71b9ded6-ef74-4697-a47e-a21a20e13c6a">16.5</ix:nonFraction> million, respectively. These investments were recorded in Other Assets on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div id="ib1aad3959e884c01b6a07e04db98b99b_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzc_3677754e-8f28-4f94-873b-ca6ae1142ea1" continuedAt="i210413162d144565963f1517f941ee51" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i210413162d144565963f1517f941ee51"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzM_cbf66aae-f35d-416c-bb63-d2d203ecf83f" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzItMS0xLTEtNzgyNzA_aeacafc9-a41a-48fc-9511-e0e5796d5c5e">690,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzItMy0xLTEtNzgyNzA_0b4fd5e0-0113-402d-9641-c2f603401d03">677,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzUtMS0xLTEtNzgyNzQ_7c2a6369-e57c-47c7-9db8-0f14caf97b4f">352,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzUtMy0xLTEtNzgyNzQ_21446ee9-0ef5-4102-b3f2-b2f01592a3b4">288,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzYtMS0xLTEtNzgyNzg_ae1349e6-a611-4fb4-a30a-74e499e34cea">338,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzYtMy0xLTEtNzgyNzg_37ae75e7-a5f2-465a-a032-87ca34190591">388,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzQ_e7923c0f-0ca5-449a-8315-a270ed697eaf" continuedAt="iab81f855e36f41c4adaa37db1f63bf5e" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the carrying value and estimated remaining life of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Remaining Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intellectual property</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6943ad4dcf614dd68d73dc3e5298e4f7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzEtMS0xLTEtNzg4ODE_44e2bd54-6a54-49fb-80cb-84545fe51bcf">240,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c33f2a42d5842a59975b6b1c2729669_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzEtMy0xLTEtNzg4ODE_721d49b1-cbae-447f-a058-2c7f0957e2a1">5.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology transfer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f59e0944d0043aa8bbc9c5903fda1f9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzItMS0xLTEtNzg4ODE_635812c4-6d83-492a-9d30-6451ec762b08">86,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47f772ec89c942a7a3e166b25c359f88_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzItMy0xLTEtNzg4ODEvdGV4dHJlZ2lvbjowMzY4ZmIyMDUzNDA0NTExYjkwM2NiOTI0NWI2Yzk3Ml8xMDk5NTExNjI3ODQw_eeecc721-7ebc-4fed-bf12-3e95989cdaf6">5.4</ix:nonNumeric> years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchased royalty rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7317f10ceb0c4e0cb47f102d6347f258_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzMtMS0xLTEtNzg4ODE_a3122a1b-6a0f-43c6-b9fd-0cbbc5079902">6,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff2619b7b15f451e8c6ceb0626894102_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzMtMy0xLTEtNzg4ODE_72e9ad52-51be-4366-b72d-9b5dbcfbcc1c">0.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b044b28769473fa1bf7da098b3d52e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzQtMS0xLTEtNzg4ODE_2ee19bc2-0456-4fb5-a9d1-23e63184ed28">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i596215e6117a4f52b5c0d7d97a1ef282_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzQtMy0xLTEtNzg4ODE_e0c1f583-36bf-4f26-938e-0b267606da48">7.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41fa8108fc04c34b1787046ebcdad40_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzUtMS0xLTEtNzg4ODE_17b775a8-384d-4374-9d85-8be30b7fe12a">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i674d0d14122b41c48b74ae0001c8fd9d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzUtMy0xLTEtNzg4ODE_697ce589-dd91-426b-b0ac-86d2f0bd8234">0.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzYtMS0xLTEtNzg4ODE_82024598-8b19-45c5-9360-98b3672845bd">338,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="iab81f855e36f41c4adaa37db1f63bf5e" continuedAt="if77610b164844f1a8f13cea615cb464d">(1)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"><ix:continuation id="if77610b164844f1a8f13cea615cb464d">Certain technology transfer intangible assets have not yet been placed into service. The average remaining life presented is only for those placed into service.</ix:continuation> </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzU_faa9f821-fe46-4adb-8218-93f23eee7544" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the estimated future amortization expense associated with the Company&#8217;s finite-lived intangible assets that have been placed into service, was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzEtMi0xLTEtNzk5ODI_7a01ff8d-58df-47d4-89e0-0e9c66b15e7a">63,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzItMi0xLTEtNzk5ODI_7da308ab-0a95-4be7-9650-bbacf8096b6d">57,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzMtMi0xLTEtNzk5ODI_72830fe2-9661-4cfb-816c-f0b381e501b4">38,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzQtMi0xLTEtNzk5ODI_1f32f76e-890b-4000-917a-670a7ee74ea8">38,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzUtMi0xLTEtNzk5ODI_ccd41a1e-ec8d-47ac-835b-57704b302dfd">38,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzYtMi0xLTEtNzk5ODI_88f32d68-ca86-43e9-a9b2-74c694f9fc91">25,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzctMi0xLTEtNzk5ODI_b4d7d818-99b7-4636-8143-598fdd3e62b8">261,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022 the Company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzEwOTk1MTE2MzA4MDc_83fa78e7-5a78-4ce1-99f2-bf12f3608b31">108.0</ix:nonFraction> million net gain on sale of nonfinancial assets in the first quarter of 2022 on the Company's Consolidated Statement of Operations.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_154"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzI4Nw_0bf51c69-8961-44a3-8e86-7ee47e8d4113" continuedAt="i731bd8aac8154a40a0f70b9e44d536be" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i731bd8aac8154a40a0f70b9e44d536be"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzI4OA_7ae33e01-590e-4ae6-bc6c-c020958f93e0" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c89fa21a6740b4ae70eb14c57b4658_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzItMS0xLTEtODAwNTY_d224f1c0-413a-43d7-bbb1-8d500629b105">819,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd0df068ef64e57beb016ebea921ad8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzItMy0xLTEtODAwNTY_a98cff15-d6b4-4b86-9c9a-0e5e08966d90">774,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04df3be9f9247e0a45ecf03bf54bdcf_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzMtMS0xLTEtODAwNTY_c27027a0-90bd-4b63-8488-88a36be10000">475,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba77569d60840a79ea41ac5cfaf6073_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzMtMy0xLTEtODAwNTY_9f0496fb-b673-4179-81de-d7b439fbb87d">444,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01c0ded34748d0bce2340302388477_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzQtMS0xLTEtODAwNTY_f28d2506-f963-4f96-9c74-1ea106692642">214,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib586210770d7493e9072422b6c53e69d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzQtMy0xLTEtODAwNTY_ea6a9f21-eb8d-4e3b-9c7b-e54b45fe45bc">201,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9296d886772647e196d034a5c7da7e16_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzUtMS0xLTEtODAwNTY_93935c0c-93f1-4a0e-a647-4059b1312e62">90,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38d7d015d9641a2afccceaff3825715_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzUtMy0xLTEtODAwNTY_c7036177-a14c-4729-b72b-736e03adcf31">90,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0f8b8eab5543b8a5874a2155f9b22e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzYtMS0xLTEtODAwNTY_63957c67-11d1-42e1-a169-3bef17a6f3a1">59,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a6bb5565934ac188f62eb1cf6acf5c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzYtMy0xLTEtODAwNTY_1766502c-2bb0-4410-b09b-857bf5d3cca5">55,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a99600f7613497d89438354f0bada80_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzctMS0xLTEtODAwNTY_c5801199-502e-4e24-974d-06c2be7d38db">45,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521cb957123a469e9a9db648b7ecd32d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzctMy0xLTEtODAwNTY_7c246ea4-2c57-4d26-8cb7-dd88eefda4c9">42,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ba21556ac84294bfa877f64bdd66f8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzgtMS0xLTEtODAwNTY_93d989b8-f53b-4018-bb9d-db842d05234e">26,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3380a5d1065a44fe975fa8e9b0e091ca_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzgtMy0xLTEtODAwNTY_350be046-6860-4162-8ef6-2e462ab48b21">10,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b02b6e13e842f682a38f22a659d47f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzktMS0xLTEtODAwNTY_171436e4-8073-4b21-bb0d-e36735368b11">143,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f45be8b0d354e1e8b7391f4a5dd0d20_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzktMy0xLTEtODAwNTY_e97dc3ee-cbd1-49a5-a568-d6d139843bb6">136,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEwLTEtMS0xLTgwMDU2_603187d2-222f-46cf-8693-0a3c430bf936">1,875,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEwLTMtMS0xLTgwMDU2_f003d21e-0ae6-43b5-9b4c-b2277a8f08d8">1,756,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzExLTEtMS0xLTgwMDU2_dbf8790b-b62b-4baf-becb-350ebde2c720">802,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzExLTMtMS0xLTgwMDU2_d8cff892-7da7-4adb-844a-948f60d00acf">720,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEyLTEtMS0xLTgwMDU2_d0110fa2-35d7-450f-9d8b-019819763e4a">1,073,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEyLTMtMS0xLTgwMDU2_b59c7147-56d3-4c6b-9298-217aad61368c">1,035,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense, net of amounts capitalized into inventory, was $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzU0OTc1NTgxNDI3MA_abbd7783-fd5c-49b6-81de-8dfee6128e37">38.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzU0OTc1NTgxNDI3Nw_0160d0c0-caf7-4c02-8027-25d845b02c9d">46.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzIxOTkwMjMyNTU5NTE_4246df6a-dc8f-468c-a552-f501c0bf7506">43.0</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="ib1aad3959e884c01b6a07e04db98b99b_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90ZXh0cmVnaW9uOjQwMzEyODZkNGJjMjRjNjNhMmY4NTY5NWVjMjBmZDg3XzExOTQ_7f7dd52c-1e5d-4335-8541-ca8ba0be1b34" continuedAt="iab05af47f5b5410b93477ceec2522caa" escape="true">INVENTORY</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><ix:continuation id="iab05af47f5b5410b93477ceec2522caa"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90ZXh0cmVnaW9uOjQwMzEyODZkNGJjMjRjNjNhMmY4NTY5NWVjMjBmZDg3XzExOTU_1bb01089-fed4-469b-9a62-e6e2fb15f008" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzItMS0xLTEtNzgyODk_bf2baa8c-e26b-4815-b58b-a060ab8aaeb0">131,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzItMy0xLTEtNzgyODk_8fef3005-5450-4f52-becd-ab93930b8d9b">80,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzMtMS0xLTEtNzgyODk_f36314b2-8708-4518-ad69-735e349fb902">410,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzMtMy0xLTEtNzgyODk_4e6baf52-6e66-49e0-8e29-39b2f64f019c">415,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzQtMS0xLTEtNzgyODk_16889cf0-485b-4815-97cd-d05c75f430ee">352,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzQtMy0xLTEtNzgyODk_db683369-01c8-40ba-9af6-8dec600a5282">281,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzUtMS0xLTEtNzgyODk_c5ec9630-92fc-4107-9ca6-5a088ce9a866">894,083</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzUtMy0xLTEtNzgyODk_283b77d4-1728-4c85-84cb-22e764edb995">776,669</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_160"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI4MQ_02e1cb5e-12e4-412c-a25a-00c463db645e" continuedAt="icb135a25846949b5b0242665e54885f2" escape="true">SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="icb135a25846949b5b0242665e54885f2"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI4Mg_ee7257e1-69fa-4423-81d8-84946758f89e" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzItMS0xLTEtNzgzMTA_608db194-31df-4720-a476-4dd8a5005be0">231,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzItMy0xLTEtNzgzMTA_3b161f54-79b7-4133-8801-32554f05a70f">199,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzMtMS0xLTEtNzgyOTU_72e33ae5-1164-4610-b768-51f8c848a3fd">207,573</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzMtMy0xLTEtNzgyOTU_93f4722b-5f8d-44a8-81f3-b26cb025857b">204,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzQtMS0xLTEtNzgyOTk_389f4f7d-3dc6-49d1-b0ce-5afccba1c420">72,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzQtMy0xLTEtNzgyOTk_74554278-86ae-4e76-89f9-b8879e9887e7">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzUtMS0xLTEtNzgzMDY_e6d51b29-03a7-4853-84c3-d29387e06c0b">16,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzUtMy0xLTEtNzgzMDY_1a39bd8d-ca0d-45ca-a035-b1d66d1f5171">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzYtMS0xLTEtNzgzMTc_7ca0063f-d3d3-4258-a0a0-7b59fcb45eb8">13,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzYtMy0xLTEtNzgzMTc_1bb06c13-cfed-4546-bf72-ba167ec495dd">15,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzctMS0xLTEtNzgzMjE_54adf032-5979-4079-af99-f42ee4e4d1ce">12,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzctMy0xLTEtNzgzMjE_383a203e-f49e-48c5-9c52-7607041de473">6,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzgtMS0xLTEtNzgzMjU_d0e478c9-8175-43e6-a343-2a556d5e2425">10,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzgtMy0xLTEtNzgzMjU_eea7dc7f-f449-4c8b-9d3c-e669e85b9f26">10,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEwLTEtMS0xLTc4MzI5_1241f209-2188-4501-b13e-08dd407dd9ed">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEwLTMtMS0xLTc4MzI5_2dffbd8c-c38b-427b-bf29-3b893ac968a4">6,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzExLTEtMS0xLTc4MzMz_abc6ac0f-1725-40ad-a597-44381b4267d9">8,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzExLTMtMS0xLTc4MzMz_cb28f66e-8f00-4458-a868-5318b5685515">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEyLTEtMS0xLTc4MzM3_9eb64dfc-5721-4b59-b435-0195f79f4cb5">572,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEyLTMtMS0xLTc4MzM3_dd91c8f0-cf51-4ac9-afdb-f951e9d65404">498,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The balance as of December 31, 2021 has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Plan Costs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 6, 2022, the Company announced a plan to simplify its organizational design, which included a planned reduction in headcount of approximately <ix:nonFraction unitRef="employee" contextRef="i079459cd9ea04678bb91caba28143414_D20221006-20221006" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzM4NDgyOTA3MDE4NjU_3e2fbbcc-ef33-4182-bd0d-818680d722b7">120</ix:nonFraction> employees (representing approximately <ix:nonFraction unitRef="number" contextRef="i9644565e09324c2bbebec177f02b7bc7_I20221006" decimals="2" name="bmrn:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzM4NDgyOTA3MDE4NzA_bd1b15cb-713c-4a1f-9520-fc419a2ec46a">4</ix:nonFraction>% of the Company&#8217;s global workforce), </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">most of whom were from the Company's U.S. operations. The reduction in headcount was substantially completed as of December 31, 2022. In 2022, the Company recorded costs of $<ix:nonFraction unitRef="usd" contextRef="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzEwNDQ1MzYwNDY2OTgw_6cb79a8d-b044-44ba-8752-a5d891521531">23.0</ix:nonFraction> million related to one-time termination severance and employee termination benefits within SG&amp;A expense, of which</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzEwOTk1MTE2MzI2NzM_5f66bc0f-d1aa-4c75-aaad-246491a319dd">11.9</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has been paid as of December 31, 2022. The Company does not expect to incur any significant incremental costs in future periods. The unpaid balance at December 31, 2022 is recorde</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d to Accounts Payable and Accrued Liabilities on the Consolidated Balance Sheet and is expected to be paid within the next 12 months. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Revenue Rebates and Reserves for Cash Discounts</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI3OQ_e7183f35-b187-46a1-ad1a-6941e8905117" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December&#160;31, 2022, 2021 and 2020, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision for Current Period Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23981085b84481d8fc2be75b9fbd5db_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItMS0xLTEtODAyODM_d055a7a3-1851-461b-84d8-18edba4ed332">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItMy0xLTEtODAyODM_d2b235f5-3756-4f77-9fc3-5173adcb595c">140,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItNS0xLTEtODAyODM_c2f238c2-de46-46ea-a414-e38cdd35bd8b">115,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37f7a71be894ef6bba5307f5c4f92c2_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItNy0xLTEtODAyODM_2bd0e94c-b552-402d-9455-7381001357a1">72,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46791bdce16445e6898c45c3fd47dc0b_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtMS0xLTEtODAyODM_d4faece4-873e-4f68-ac12-aff21d4cfeaf">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtMy0xLTEtODAyODM_a135ad49-cd96-4733-8f1d-ceb5eec18d62">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtNS0xLTEtODAyODM_7d9d87b2-3583-4049-9bd0-c8a6f484ac5c">18,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2e8fd98e264368a035b1b756757df5_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtNy0xLTEtODAyODM_19371d7e-9ba9-41a0-9cf1-95cde3d85b91">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474ce592912e4ee484fa06718d15d2fe_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtMS0xLTEtODAyNzU_de0ba51f-8c63-4447-8653-245f425f5690">65,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499a122963a44c19831951e9e567eaa7_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtMy0xLTEtODAyNzU_3d377648-426f-4d3f-b1ed-295e9f9007f5">116,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i499a122963a44c19831951e9e567eaa7_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtNS0xLTEtODAyNzU_043f62c0-5887-46c1-8b23-4d2a7a85d827">134,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23981085b84481d8fc2be75b9fbd5db_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtNy0xLTEtODAyNzU_9cfaae13-ea8f-491e-b8f4-bbc8debfa242">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed072224703463aac2c7d7482c6ffb3_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctMS0xLTEtODAyNzU_23000340-fab7-4655-8151-663b22b316bf">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctMy0xLTEtODAyNzU_065ed687-0b6e-4de3-9198-b08c8635f1f4">16,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctNS0xLTEtODAyNzU_9c4ea245-a999-4561-8522-f2059a59fe74">15,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46791bdce16445e6898c45c3fd47dc0b_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctNy0xLTEtODAyNzU_b20b3c01-c2e2-4dde-baa6-72306e64f384">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4446cd995b344e0ba108320ca62f991_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTEtMS0xLTgwMjU5_03b134c3-e886-42a8-a787-0cd435638778">57,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTMtMS0xLTgwMjU5_6015357b-4fab-4fd9-9406-60ffe1825591">113,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTUtMS0xLTgwMjY3_54375337-cb8b-4fcc-bc92-7961622f4f89">104,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474ce592912e4ee484fa06718d15d2fe_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTctMS0xLTgwMjY3_c688f990-d255-4278-872f-81de0c3b2f81">65,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f9d3b26b0d4fe587d64e56b034ed55_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTEtMS0xLTgwMjU5_a120920f-6cec-46e3-a031-ec6b88c85b95">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTMtMS0xLTgwMjU5_a756cb06-9bc2-48db-8ee4-0b6ae6a8d7bc">17,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTUtMS0xLTgwMjY3_062a7614-dee3-4e92-9f83-8bd18dd2710c">17,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed072224703463aac2c7d7482c6ffb3_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTctMS0xLTgwMjY3_d066c277-264a-48b2-af01-2a14b7bcb12f">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_163"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExNzc_99f2696c-436c-4de1-a9f7-269e13f7fc54" continuedAt="i17d0fbfef4e44d179d3c75452a409d9b" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i17d0fbfef4e44d179d3c75452a409d9b" continuedAt="i4de03de8e4f14f8489b94df0bbe2319c"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements. </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExNzk_1d5eec3b-b6d7-49c4-b5fe-6d0620a0bcf1" continuedAt="i8157fac77e0b41dd8159196e9bda5594" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December&#160;31, 2022 and 2021. Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_172">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements, there were <ix:nonFraction unitRef="usd" contextRef="i846fa6c590bb43c9b2c023bbeee9119a_I20211231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_24b5a826-de49-44aa-a266-6794e4fc4d84"><ix:nonFraction unitRef="usd" contextRef="id956bf9fc1b44873ab5ad29095686daa_I20221231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_4351849a-6a3a-401a-bcbc-ca7ea7c8e287"><ix:nonFraction unitRef="usd" contextRef="i846fa6c590bb43c9b2c023bbeee9119a_I20211231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_643a5c4c-8a52-43fe-8f91-10d0f7336ba1"><ix:nonFraction unitRef="usd" contextRef="id956bf9fc1b44873ab5ad29095686daa_I20221231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_d3043ea1-229b-4a43-b92c-6be52bdc4ea7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December&#160;31, 2022 and 2021. Refer to Notes </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_148">2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_166">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:54.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ce1991d8464caba76b61ad0d0a2227_I20221231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtMi0xLTEtNzgzNTI_44ade62b-44d7-448c-b3e9-134cdf02fbd5">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3183b154e44b52ba30e133758be6a3_I20221231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtNC0xLTEtNzgzNTI_d30fe09b-8e11-4ca1-beb3-410c2006e89a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0827b42d3347d0afe4307d1f64a381_I20221231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtNi0xLTEtNzgzNTI_c560961f-df2f-4878-82ca-0589f3d4a680">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ce1991d8464caba76b61ad0d0a2227_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtMi0xLTEtNzgzNTI_c69fc197-cae9-4144-9f3e-a6a34e73004d">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3183b154e44b52ba30e133758be6a3_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtNC0xLTEtNzgzNTI_2f21d71c-f76a-4dc2-8cdf-85ef3b368c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0827b42d3347d0afe4307d1f64a381_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtNi0xLTEtNzgzNTI_24d3514d-676d-4edb-a922-063db10dae09">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1697a254339d443f8484e8d6d3c078e1_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctMi0xLTEtNzgzNTI_e68fc1a3-61ed-46c5-9b08-a7a5e971b324">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef36079c8034aeb9d95e92fa8da0e7a_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctNC0xLTEtNzgzNTI_04fa9fa5-fca8-444a-8bb1-e94b2f8b202c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b8aa0219e04f549a524810fe170d31_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctNi0xLTEtNzgzNTI_2fd19954-2bed-49cd-8d4e-9e604cdc9f27">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtMi0xLTEtNzgzNTI_e50535de-baa2-4f1c-ae3f-c155b88c293f">22,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtNC0xLTEtNzgzNTI_6f3420b9-6542-4975-be3d-c2cc7928f707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtNi0xLTEtNzgzNTI_0602344c-97d2-4b45-b01f-5c1038b0db75">22,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktMi0xLTEtNzgzNTI_7d1b5fb1-d92e-4a1a-b589-375a1fbc3e01">24,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktNC0xLTEtNzgzNTI_29c78530-ff7a-463b-8948-ab01d701d1b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktNi0xLTEtNzgzNTI_1903f4f8-73a3-497f-9626-a3c384992cab">24,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e735b9eb6e4c1083bb535a258b00f8_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTItMS0xLTc4MzUy_02232120-f764-445b-bebf-cfe5f49e2f5a">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9bbb374233424ba61bcc6ed8300a30_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTQtMS0xLTc4MzUy_34db202c-ea3f-4bbf-af57-e4e5af3242b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2160a34a98f34909b7b6148fe186d3a7_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTYtMS0xLTc4MzUy_c95b8c2f-0393-4a48-b048-4ff24f82f8d6">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f15a50eebbd49b0a6ac560862776c4b_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTItMS0xLTc4MzUy_83459f31-c29c-4662-bd3f-f75f75f79c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffc1b1354b24fe9ba6f0f76f2c77735_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTQtMS0xLTc4MzUy_d3281c87-e359-442e-800e-e43176b3f8a3">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6b493cf9db47da80212141f81c1d71_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTYtMS0xLTc4MzUy_698bb1ed-c005-45e3-bb7e-3b3bf778ed65">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTItMS0xLTc4MzUy_ac14dcdb-8cf2-43d2-8597-9e98a8fee25b">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTQtMS0xLTc4MzUy_534ca1e6-2e2d-472a-a28a-b60199cb36ba">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTYtMS0xLTc4MzUy_ac1cfb29-6e1a-4782-b992-ea5adf6285ba">18,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e735b9eb6e4c1083bb535a258b00f8_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTItMS0xLTc4MzUy_5a060e37-a292-41a9-9c08-d020a9b159d3">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9bbb374233424ba61bcc6ed8300a30_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTQtMS0xLTc4MzUy_ee3f8603-baf6-4f2b-a599-7c340c1db24b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2160a34a98f34909b7b6148fe186d3a7_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTYtMS0xLTc4MzUy_27b4e8d2-26d6-4e13-b3bd-82a3510a84d9">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTItMS0xLTc4MzUy_15e1f17c-10dc-42e8-8a1d-2cca5d7487d2">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTQtMS0xLTc4MzUy_c3d914ca-5ebf-42d5-8dc1-39e9c22d0f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTYtMS0xLTc4MzUy_2c1bf2cf-a0ce-426f-9b7f-735cd4b3be29">19,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTItMS0xLTc4MzUy_d1168e39-d6fa-4437-b234-67e897c0d870">22,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTQtMS0xLTc4MzUy_ce28573c-aad7-499e-b29e-c85cda2a9bce">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTYtMS0xLTc4MzUy_d41e4ea3-ab8d-41d9-949a-1a2047c867ca">38,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i4de03de8e4f14f8489b94df0bbe2319c"><ix:continuation id="i8157fac77e0b41dd8159196e9bda5594"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:53.907%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f30189483c422fa011c8cb6d4922bf_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtMy0xLTEtNzgzOTk_f52bc71d-c913-4e45-924c-462e23291148">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04dda45e829740f79226f6631d6049eb_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtNS0xLTEtNzgzOTk_c1f64e28-f448-48e4-a78a-8ea89862f8ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9c061692ee4459bfff0add9bcd50a4_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtNy0xLTEtNzgzOTk_6f2a2314-dfa2-4a00-b656-89819a1bb419">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f30189483c422fa011c8cb6d4922bf_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtMy0xLTEtNzgzODI_82d3db21-9697-44ee-9fa4-7e67b498b0c3">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04dda45e829740f79226f6631d6049eb_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtNS0xLTEtNzgzODI_adc59dc1-ade6-4e9c-966c-5a35593f1f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9c061692ee4459bfff0add9bcd50a4_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtNy0xLTEtNzgzODI_4d0e59ad-cc70-41eb-b9ae-62a70b53143c">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1808bc04910249a8a0f00222d3bf7e02_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktMy0xLTEtNzgzODc_ade5a9bc-5c66-4869-baa3-79309ca2b5b8">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff430fafcf154f4e812f7d333d1d8d7c_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktNS0xLTEtNzgzODc_df5037c1-cabc-41a5-b095-ff5ed26c4e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb05d919991b4e81a5d5ffacd7d4969b_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktNy0xLTEtNzgzODc_8d7c24f6-1111-49a8-9cc7-6d9b3e6749f7">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTMtMS0xLTc4Mzkx_465876e3-d052-4309-a805-e9e413f065b9">26,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTUtMS0xLTc4Mzkx_83be11c2-d2d7-40d5-9c1b-9b8e19bf1212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTctMS0xLTc4Mzkx_6f938a50-60c0-40fc-a931-b667d924ccc7">26,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTMtMS0xLTc4Mzk1_e2078e16-e8e4-4bf4-a688-cc156cf7defd">28,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTUtMS0xLTc4Mzk1_02728962-2557-4f64-8d93-d6a18f584652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTctMS0xLTc4Mzk1_4f4ce096-8af8-4838-b836-5a7c596ccedd">28,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4aad42990645598a710e3fdc875927_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTMtMS0xLTc4NDAz_8b486137-8fdd-486d-85d6-09739a294cae">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fa5863ad174cd78a94e49878481b58_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTUtMS0xLTc4NDAz_368dd167-359b-488b-935c-8888ac74a64f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf63f31c217048c0b0893f82f7a57cc6_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTctMS0xLTc4NDAz_8c16ea5f-9a06-4989-8c7e-3d241d02a07c">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTMtMS0xLTc4NDIx_82e182d6-6694-4bd4-b91d-685140b1cd00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361e100279e84b2abd489b481fc38b7e_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTUtMS0xLTc4NDIx_1c5484a9-b5ef-4bcb-a143-4c2f18fdf186">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc636c5add94dcdb064bdd55b0154bb_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTctMS0xLTc4NDIx_f4bf67cd-6a3e-48e5-967b-ac74177730ba">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTMtMS0xLTc4NDI1_50145aae-6df3-4e85-a8a7-41f7cead78af">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTUtMS0xLTc4NDI1_88ef38fd-3468-43bf-8b2b-58e1c77f0198">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTctMS0xLTc4NDI1_2de5eec7-9b86-48c7-8a8b-094d1c9b4444">50,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4aad42990645598a710e3fdc875927_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTMtMS0xLTc4NDA3_172c2260-c6c4-481b-a2ca-7b84e93bbe47">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fa5863ad174cd78a94e49878481b58_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTUtMS0xLTc4NDA3_94523555-829d-40bf-b5e1-44bc9ab88392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf63f31c217048c0b0893f82f7a57cc6_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTctMS0xLTc4NDA3_51ab78d2-b9f7-4694-8506-c594fddd3479">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTMtMS0xLTc4NDA3_75e2e5f8-6fff-463c-b589-648ea1235fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361e100279e84b2abd489b481fc38b7e_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTUtMS0xLTc4NDA3_9527676e-4fa8-466a-b180-3c9a7bbe25fd">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc636c5add94dcdb064bdd55b0154bb_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTctMS0xLTc4NDA3_67fadc20-dc24-44fb-8da8-c1bc5569e21e">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTMtMS0xLTc4NDEx_0766f969-65ab-4df0-ae0b-244454161d5c">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTUtMS0xLTc4NDEx_f2001252-076e-4904-9e60-1a6d8e676e0b">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTctMS0xLTc4NDEx_b52b90ce-de3e-4ceb-961b-975e77a87d66">39,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTMtMS0xLTc4NDEx_6fa02887-383a-41d5-8d55-671497fc1129">25,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTUtMS0xLTc4NDEx_b6a8bb64-2536-4deb-a49d-fe66e448f730">63,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTctMS0xLTc4NDEx_e8a97115-b631-4c66-9457-f8cd22e40b15">89,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The restricted investments as of December&#160;31, 2022 and 2021 secure the Company&#8217;s irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExODE_180965c2-918c-4654-9c69-307825d54449" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzAtMS0xLTEtNzg0NDU_c2668843-dee5-4704-872b-e4b02875ed0b">63,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payments to Ares Trading S.A. (Merck Serono)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzEtMS0xLTEtNzg0NzA_1ebbe1b4-3e57-4312-95a9-b125440bf7a0">47,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzMtMS0xLTEtNzg0NDk_d81b2b2a-a64c-429f-a3d5-c65bc0bcc125">4,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized foreign exchange gain on settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231" decimals="-3" name="bmrn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzQtMS0xLTEtNzg0NzQ_652a0144-ab10-475b-987b-5f3807b84089">2,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231" decimals="-3" sign="-" name="bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzUtMS0xLTEtNzg0NTM_6ec6436f-4f84-4e16-bdbe-a42309ef8bb0">1,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1739c85dcaf415cacb59ea7ea04ca80_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzYtMS0xLTEtNzg0Nzg_320dc3be-1801-4b7f-9928-7d3da69c353e">15,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_166"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzExOTE_6e327736-53a2-48ba-8a7c-dad1e9ca8fe3" continuedAt="ia0b9ccb3ef914f4081e74cb72b76980f" escape="true">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</ix:nonNumeric></span></div><ix:continuation id="ia0b9ccb3ef914f4081e74cb72b76980f" continuedAt="ib2cbf6e5a2674c35b05f5a9677158679"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's forward contracts designated as hedging instruments have maturities up to <ix:nonNumeric contextRef="i1bbdcfdf6d7f44e98151b2323cc59a91_D20220101-20221231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzE3NTkyMTg2MDQ1NzM2_cc0cf263-5e7f-45a1-a22b-c3497c5a876c">1 year, 9 months</ix:nonNumeric>. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to <ix:nonNumeric contextRef="ia4cc530299f847d189a72330922c67cd_D20220101-20221231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzE3NTkyMTg2MDQ1NzQw_8422ba71-dd2e-4fe4-a7a9-75d9636b5186">3</ix:nonNumeric> months. </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzExOTI_6152da71-0084-493e-8f3b-cceb532b930a" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b156ee48534e11b0e4ec467c89f063_I20221231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzItMS0xLTEtNzg0ODY_46b3ae97-0acc-4865-a490-0e18dd0314f9">808,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6630e8205694223b373923bba0b4d10_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzItMy0xLTEtNzg0ODY_4e08a4ca-f5b7-4887-bba5-96ba27370c52">740,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5347e22ccf064748b88e50f6bd0c2161_I20221231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzMtMS0xLTEtNzg0ODY_0c50a37c-2b26-445a-aa18-9e2a10feb700">177,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ad5d6c2ce54eb183ff3585f491d96e_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzMtMy0xLTEtNzg0ODY_e2d31e4d-3bfc-4a79-9a68-2cccbc32cafd">183,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8acf9e28afb48f9a9b97f6033ce470a_I20221231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzYtMS0xLTEtNzg0ODY_25703082-8c77-468f-bb91-b7ebe56a222a">218,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d9f5eac174d9e9fb8daaf63a40764_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzYtMy0xLTEtNzg0ODY_96ff48e9-a367-4a84-a1f9-ae7c8467f5a2">113,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd631e0c0be404fbdac1dbda30f94fa_I20221231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzctMS0xLTEtNzg0ODY_7db1ada9-0a57-49bf-b63a-ef55c25fe124">6,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5453050b0674bbfaf495fdbe38838bb_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzctMy0xLTEtNzg0ODY_d5d296e2-ea98-49b4-8685-da3ba8330850">31,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzU0OTc1NTgxNDYxNDc_cd2e1aed-da78-48a5-8795-7155d9907b71" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:67.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78357676b9ad4a62990f8ad0e3be1b8c_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzMtMS0xLTEtMTA0MTAx_c9b2c1ce-5422-444a-9953-b537947e6ab2">19,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701ea9c137b743d5b8fbcf9a4516ee31_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzMtMy0xLTEtMTA0MTAx_4179b2d8-2370-4b88-9cb4-edd7a3de2f5b">17,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e05c8915f6d4424a51797377fec49d4_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzQtMS0xLTEtMTA0MTAx_1d2236e5-3a9c-40df-8620-633ec1c0c452">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81ef93ba75f4c7f9a65f2262abc826c_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzQtMy0xLTEtMTA0MTAx_cdaea01d-cec1-4b20-ba16-928df0560775">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzUtMS0xLTEtMTA0MTAx_7a47e927-cdba-4cc9-bc9f-463569e61b42">21,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2949967682844b40b3939cf685911572_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzUtMy0xLTEtMTA0MTAx_9fbe327c-8417-4304-954d-29e40793d48c">22,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120af3133b724435b609f48a754ddc28_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzgtMS0xLTEtMTA0MTAx_3c5c6f4a-f001-405f-822c-3093c8e06818">12,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id034c5704d704b1899e0fe63a9b16d85_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzgtMy0xLTEtMTA0MTAx_c7ffc0f1-193a-44e0-902b-21d834242fe4">5,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0459695791c54a5c9470c16c53c5e1b4_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzktMS0xLTEtMTA0MTAx_8eb0cc53-d7a7-42d7-826b-48a38ccfd9b4">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5945041fd04f8fa60d89c188909d74_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzktMy0xLTEtMTA0MTAx_91a3da32-0f75-4987-89e7-416cd52b16cc">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzEwLTEtMS0xLTEwNDEwMQ_17f5dddc-54af-47e5-8f19-eee8bdeebeae">13,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2949967682844b40b3939cf685911572_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzEwLTMtMS0xLTEwNDEwMQ_78b67f90-7cca-4d52-a771-11caa78b89a4">6,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda7870ff3904fafa6c5f6898f8ea22b_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE0LTEtMS0xLTEwNDEwMQ_a8ee207d-2085-4d37-8ef9-304472e568fa">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc8c32dfdf364e6ebfeca0e2dbe52145_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE0LTMtMS0xLTEwNDEwMQ_bf352c6c-8b34-4d83-8bab-e0fd1e40d75a">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7810729b64f4f81ab7e6d7951dd41db_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE5LTEtMS0xLTEwNDEwMQ_6ff2beb2-25b0-4768-bb11-91b30ab90e2e">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2249a32749024298ac14d49e5abc5209_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE5LTMtMS0xLTEwNDEwMQ_cd4aaeda-a1cb-4a70-b371-122a8dd195a7">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzIzLTEtMS0xLTEwNDEwMQ_94344e9a-444b-4844-aba5-eb180be316b3">22,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzIzLTMtMS0xLTEwNDEwMQ_56570220-fb5d-4b14-b85c-5979ff30a90b">22,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzI0LTEtMS0xLTEwNDEwMQ_868c114e-8661-4b64-a180-e7058e1df241">13,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzI0LTMtMS0xLTEwNDEwMQ_ffb0e3d5-fd44-48e0-80f2-f5aafcb5174f">7,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Refer to Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional information related to the Company&#8217;s fair value measurements.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ib2cbf6e5a2674c35b05f5a9677158679"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzU0OTc1NTgxNDYxNDg_c9b78bbe-eb54-434f-b96d-bbebce4014d9" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535f35b9a823419bbd09b248cdd5f011_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzQtMy0xLTEtMTA0MTAx_36e5acab-73f0-4b7d-bd13-a2a97f070117">48,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9fcf787fd284d24881b86f72e6d9c06_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzQtNy0xLTEtMTA0MTAx_ad760256-8e60-45cb-8ed8-bbbe578f178a">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzUtMy0xLTEtMTA0MTAx_a59c3e6b-cbb2-4a20-9034-e83390e90762">11,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i929eedfedb93483daed0c9feb18c8083_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzUtNy0xLTEtMTA0MTAx_a7c015ba-4860-4e79-be1a-e7de9f8e457d">1,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4cc530299f847d189a72330922c67cd_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzgtMy0xLTEtMTA0MTAx_91a30c21-0df6-4390-9257-e1a4943ba727">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aabd222ee0c445889bc6c55761ef645_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzgtNy0xLTEtMTA0MTAx_75c28c16-b919-4adb-b33d-8cd9d63d0e37">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company expects to reclassify unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzEwOTk1MTE2MzMzNDc_4f002b46-e63f-43ed-8991-fac18c8c9764">7.2</ix:nonFraction> million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_175">11</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_169"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1NA_79090c65-bdb3-4cb8-afba-c43313e5bc6e" continuedAt="iba6ab3c7886a4a41823f9f4bffd98dcf" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="iba6ab3c7886a4a41823f9f4bffd98dcf" continuedAt="ifebb4b1a06094fc4a2daa8d32707364a"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1NQ_11ae744a-22d4-4b8b-ab74-2e197a1ee165" escape="true"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s ROU assets and lease liabilities for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtNC0xLTEtODA2MjQ_54d42f55-cfe3-4242-a251-d84450aa713e">34,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtNi0xLTEtODA2MjQ_6b983b2d-096e-45c1-a09c-ba1bc96faab3">38,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtNC0xLTEtODA2MjQ_a8684dae-4e83-4d58-b751-1820480763db">6,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtNi0xLTEtODA2MjQ_36b993f5-72fa-40f9-b945-af5586de5e6e">8,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzUtNC0xLTEtODA2MjQ_00773891-c13e-49f1-85c8-9190d8598804">40,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzUtNi0xLTEtODA2MjQ_c2c54bb0-5910-4f1f-9c7f-e879ef18cb7d">46,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtNC0xLTEtODA2MjQ_17e79932-cb7b-41db-93d2-144b7cf68e47">8,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtNi0xLTEtODA2MjQ_affbea0d-5a91-4e80-a60f-8e3f631b673f">8,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktNC0xLTEtODA2MjQ_a0c7f529-9a2d-409b-94ff-a4c3fdcc3cff">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktNi0xLTEtODA2MjQ_28207ce1-40a4-4c74-a1ba-5f491c9d141f">2,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTQtMS0xLTgwNjI0_6ba59258-1b56-4e5d-abf4-68dda549ae99">26,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTYtMS0xLTgwNjI0_866dd75a-f5f7-49d2-ac10-6baccaf791d2">31,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTQtMS0xLTgwNjI0_6e872df4-e5a4-47fa-a132-e45d330b1767">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTYtMS0xLTgwNjI0_7e885337-efd1-4e27-8c6c-bafdcb4c7f77">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEzLTQtMS0xLTgwNjI0_653e843e-b1fb-4d69-9069-f666aaad3eaa">36,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEzLTYtMS0xLTgwNjI0_2e5e2aef-6222-4c59-84e6-2cb8b6720949">44,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1OQ_7e6c9af7-41eb-45d1-8b71-4792b8454c00" escape="true"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1OQ_b59f4dc9-0a9c-4b93-b914-2727dd611a69" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:59.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtMi0xLTEtODA2NDE_6a0dc89d-7805-431e-a9e4-365a31cd3c9e">9,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtNC0xLTEtODA2NDE_8968daff-6ab2-4bc1-9fb4-90d4265b4f61">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtNi0xLTEtODA2NDE_fd7bbb30-5015-4747-8b00-f36be10ef121">12,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItMi0xLTEtODA2NDE_5e522b10-bb17-48f7-932e-70ba75126ff2">7,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItNC0xLTEtODA2NDE_3035a4ca-8bd0-4acb-a979-a8971bf663f8">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItNi0xLTEtODA2NDE_65a4f641-18f7-4a31-86ad-775ab635cd21">7,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtMi0xLTEtODA2NDE_32ca9667-a6a4-463e-b79d-50df0cff261d">5,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtNC0xLTEtODA2NDE_19c5bf37-be24-4b16-a3ed-af88279b671d">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtNi0xLTEtODA2NDE_5655b9d7-eb70-42de-b6db-bc4dce29eede">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtMi0xLTEtODA2NDE_503a92c0-bbbe-4e8c-a760-8f0acc60b041">4,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtNC0xLTEtODA2NDE_0d54ca24-5b94-49fc-9f45-7f3850c7d54a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtNi0xLTEtODA2NDE_e6ca3e7e-b434-4a8d-b163-5ea55362be53">4,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtMi0xLTEtODA2NDE_659591a2-deb1-4661-b142-b2d2158cf32b">4,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtNC0xLTEtODA2NDE_5b17ebb6-f51d-4ebc-8eee-fa09fa535948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtNi0xLTEtODA2NDE_945abc84-bc92-440e-9d08-06357d287ef2">4,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtMi0xLTEtODA2NDE_1428e068-c1d0-40ab-a75f-77975af4fdf8">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtNC0xLTEtODA2NDE_eca6187b-7ea2-4ff7-9859-c7b255d8dc15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtNi0xLTEtODA2NDE_b32b282e-8eaa-473b-b7c7-272ef1dcf683">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctMi0xLTEtODA2NDE_e1ad6051-31ad-46da-961b-77611828bc2e">39,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctNC0xLTEtODA2NDE_36ed00f3-3c9a-4376-b9be-0c74c5e8ce01">2,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctNi0xLTEtODA2NDE_4c9eade2-fdee-496e-97af-b3c35a8be452">42,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtMi0xLTEtODA2NDE_5fb68e56-4a31-4c06-acdc-d0b4f0e81cb6">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtNC0xLTEtODA2NDE_aaf5517e-b6b8-452b-90cd-d98289f8dfe0">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtNi0xLTEtODA2NDE_1ecc9146-d0a4-43da-9702-1147b034fa3a">5,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktMi0xLTEtODA2NDE_fac8a46c-b742-4dbc-af58-e3a154cbe144">34,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktNC0xLTEtODA2NDE_d8812ec8-6a75-4433-8941-ec850f9ffe0d">2,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktNi0xLTEtODA2NDE_5a8d4ecf-538b-4890-9931-bfdda9768858">36,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc2MA_9587ec0e-2bde-472a-bf94-e0acf5da89cb" continuedAt="i13bd74853ea24c5ab513e592f89e0f59" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company&#8217;s leases for the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzItNC0xLTEtODA2OTk_456860c5-e381-4345-afac-088e9b3bd40b">13,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzItNi0xLTEtODA2OTk_b26a7d26-25ed-4cf9-b46a-dbc0fc5a67d2">13,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzQtNC0xLTEtODA2OTk_9ee98503-b1c6-4f5b-9aac-8283a0e58713">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzQtNi0xLTEtODA2OTk_f3bb7f60-c826-420c-a82b-ebdbf80ce188">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzUtNC0xLTEtODA2OTk_ce3c6240-2c7d-4ad1-a18a-70837c83aa96">163</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzUtNi0xLTEtODA2OTk_45d6cff8-154e-438d-ab1a-7f716e74d2bc">283</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzYtNC0xLTEtODA2OTk_ef2a8e15-3b4d-4864-bd8f-105512a3831e">16,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzYtNi0xLTEtODA2OTk_42870677-04a4-4427-aa2d-29e55cc3a79e">17,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ifebb4b1a06094fc4a2daa8d32707364a"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc2Mg_a9ed4532-0d1e-46ed-8641-3567e713e3bf" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company&#8217;s lease liabilities:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzMtMi0xLTEtODA3NTM_17839275-bb4d-419c-829c-9098f5415ad0">5.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzMtNC0xLTEtODA3NTM_0102566e-32cc-4a96-a0da-c02790bc1fcf">6.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzQtMi0xLTEtODA3NTM_d00f8545-8334-46a0-8875-6fe8c0672958">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzQtNC0xLTEtODA3NTM_1ba8c9c4-6cb9-4eb7-8d6d-a48f6b153893">1.9</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzctMi0xLTEtODA3NTM_f009d76e-c02d-46a7-8fa3-bda25c87da6c">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzctNC0xLTEtODA3NTM_0a6b7cee-a403-4c13-be44-33af512f8952">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzgtMi0xLTEtODA3NTM_bbac41ff-7e22-4200-a68b-27212799aad5">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzgtNC0xLTEtODA3NTM_323ea9c3-8ae1-4dba-86eb-70c837e3347a">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, no </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">leases were expected to commence that would create significant rights and obligations for the Company.</span></div><div style="margin-top:12pt"><ix:continuation id="i13bd74853ea24c5ab513e592f89e0f59"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzQtMi0xLTEtODA3OTM_19d4cc95-f146-4975-8aa6-78369fe441ef">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzQtNC0xLTEtODA3OTM_d8ce56ed-08f3-4245-bdb7-3ceab5af8cf2">10,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzUtMi0xLTEtODA3OTM_84dee11a-f763-4d55-b40f-9724976035e8">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzUtNC0xLTEtODA3OTM_55d9f39c-ee23-4f58-9c8a-cfd25be5f7cb">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzctMi0xLTEtODA3OTM_ebd98f48-9a70-4560-ab23-9c50943b217e">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzctNC0xLTEtODA3OTM_5736e09b-6a51-4cbb-a228-0000c041a689">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzktMi0xLTEtODA3OTM_148e50d6-cf5e-48f6-b66a-a17dfa51d908">5,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzktNC0xLTEtODA3OTM_594d8b6d-3449-49c3-8e48-16000b1e3e79">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzEwLTItMS0xLTgwNzkz_b4dfcd79-214b-4700-972b-14dc80178ab8">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzEwLTQtMS0xLTgwNzkz_7143565c-637a-4065-8970-eac4f4504ffe">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDY_c4c43b34-b918-4ebf-a04d-796e96f8f4ad" continuedAt="ic32ba91c321b45eda191ebf090082ffa" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="ic32ba91c321b45eda191ebf090082ffa" continuedAt="ica7273ce89544b5c9af3aa0b3ca29e98"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzU0OTc1NTgyMTIwOQ_9e059330-6c76-4f04-8919-7ba777d4f2df">1.1</ix:nonFraction> billion (collectively the Notes). <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDM_3d3ea7e8-b13f-4dff-9d41-eceeb06c2591" continuedAt="i9e6c0276d33d42e5b6de1e103851e352" escape="true">The Notes are senior subordinated convertible obligations, and </ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ica7273ce89544b5c9af3aa0b3ca29e98" continuedAt="i8897ccce0c7b4682b1ff96e5c2e2de35"><ix:continuation id="i9e6c0276d33d42e5b6de1e103851e352"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#8217;s convertible debt:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjphYTIzZTE1NTUxZjA0ZDg2ODY0MzNhODkwMDgzMDE2NF8xNjQ5MjY3NDQxNzY1_7f8c9fe1-855b-4d9c-9340-50c9e9633995"><ix:nonFraction unitRef="number" contextRef="i5daf35554b6a433a843510d389717d6b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjphYTIzZTE1NTUxZjA0ZDg2ODY0MzNhODkwMDgzMDE2NF8xNjQ5MjY3NDQxNzY1_8a3c2193-03f5-4095-8dd7-c40e87c94d5d">1.250</ix:nonFraction></ix:nonFraction>% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMS0xLTEtNzg1NDM_94c6aa71-db10-4dcb-aca3-0dafe4aff759">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5daf35554b6a433a843510d389717d6b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMy0xLTEtNzg1NDM_8cc47798-f790-41f7-9096-2ed589392286">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzMtMS0xLTEtNzg1NDM_f8f9ab73-2301-4642-ab4a-ec48a98bf093">8,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5daf35554b6a433a843510d389717d6b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzMtMy0xLTEtNzg1NDM_2845d8f4-b52e-4443-be33-89d4471b685a">10,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzQtMS0xLTEtNzg1NDM_62a8effa-a364-4032-9c4e-82641cd96dcb">591,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5daf35554b6a433a843510d389717d6b_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzQtMy0xLTEtNzg1NDM_ec6d44e7-6b57-474f-8809-96ea32694236">589,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjozNWFkODEwYTg4NzA0ODRjOWFiZmNjZGU4YjhmODY4ZF8xNjQ5MjY3NDQxNzcw_c72942a5-1702-4c33-a4e3-dd507088c7fa"><ix:nonFraction unitRef="number" contextRef="i86ac5b26310a44ef85642267c702776c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjozNWFkODEwYTg4NzA0ODRjOWFiZmNjZGU4YjhmODY4ZF8xNjQ5MjY3NDQxNzcw_cedf81b9-5247-4373-9488-efabbd6c9e13">0.599</ix:nonFraction></ix:nonFraction>% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMS0xLTEtNzg1NDM_b1d4176b-dd4d-44be-a622-bee94b27c1d2">495,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ac5b26310a44ef85642267c702776c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMy0xLTEtNzg1NDM_84999a08-de68-4ae6-b875-b0ce897882e7">495,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzctMS0xLTEtNzg1NDM_06b8dbcb-e904-44b9-9d72-5e2586ca7d36">3,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ac5b26310a44ef85642267c702776c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzctMy0xLTEtNzg1NDM_515657f8-a697-4be3-9f9f-a8dcae445adb">4,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzgtMS0xLTEtNzg1NDM_a8ff704d-99c9-4e22-b873-e3385844535f">491,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ac5b26310a44ef85642267c702776c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzgtMy0xLTEtNzg1NDM_d79871f1-ff3d-4c08-a0b5-d15aaadff520">490,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEwLTEtMS0xLTc4NTQz_b3d59e83-55d0-4a90-adfb-1f5dd5835110">1,083,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEwLTMtMS0xLTc4NTQz_7447a477-e863-438e-ba53-4740bdd25853">1,079,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEzLTEtMS0xLTc4NTQz_2d1edd81-bd96-419b-9517-6686f8ca1607">647,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5daf35554b6a433a843510d389717d6b_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEzLTMtMS0xLTc4NTQz_d67193d4-c92a-41a4-89ce-7a8b21f8a2f8">625,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE0LTEtMS0xLTc4NTQz_77fd4300-6b15-427d-966f-6a19f4ebc9df">526,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ac5b26310a44ef85642267c702776c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE0LTMtMS0xLTc4NTQz_d98dded9-8ed9-4b8f-ae53-35719bb1f741">521,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE1LTEtMS0xLTc4NTQz_46d5eba2-f07b-4f99-b509-3dcda66846fe">1,173,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE1LTMtMS0xLTc4NTQz_4c951053-bb6d-4cf0-b838-b0000bbbfd82">1,146,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The fair value of the Company&#8217;s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional discussion of fair value measurements.</span></div></ix:continuation><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDQ_5adecdba-6881-4de6-90ab-090e48eab528" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s fixed-rate convertible debt consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItMS0xLTEtNzg1NTY_e0f858a3-14a2-46f4-9fbc-8ff05d8eefe2">10,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItMy0xLTEtNzg1NTY_3e910b31-e5ed-48f9-8706-0b1b1269735a">10,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItNS0xLTEtODEzNzI_f4fa4acc-27f9-4c1a-8aba-2a6cb7e2bac6">12,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtMS0xLTEtNzg1NTY_80a05c36-8a5b-48e8-b940-a43f8eeecf6d">3,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtMy0xLTEtNzg1NTY_725e5aed-68c7-4a80-aa4c-039868de6aa0">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtNS0xLTEtODEzNzI_dc04d0e9-9080-4b2b-b8fa-06fe73ed404d">14,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtMS0xLTEtNzg1NTY_15a36d7a-d9d7-4bf2-ae29-c019d48a26c9">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtMy0xLTEtNzg1NTY_b6723e88-6c3e-4f24-8c82-0f262a2051af">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtNS0xLTEtODEzNzI_fc601cf3-7ac1-465f-aa16-af92d9966296">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtMS0xLTEtNzg1NTY_3d6cc2f3-cbaa-43dd-af34-bad96224a3ba">14,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtMy0xLTEtNzg1NTY_41714b57-68f1-415d-b659-8a28cbde8718">14,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtNS0xLTEtODEzNzI_93d39da6-c179-44e5-ad03-eea203957316">28,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2027 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNTk_3b3d620f-6fd4-4cb4-9387-13c46f3d3055">600.0</ix:nonFraction> million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNjk_ac276b66-f29c-4741-b93b-a7504b698618">1.25</ix:nonFraction>% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company&#8217;s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzE0MTk_6b8f1e97-76b5-44ab-8d2b-7398432fc6b4">137.47</ix:nonFraction> per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company&#8217;s common stock. A holder may convert fewer than all of such holder&#8217;s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="icc7acb734e7a46518521815a0e658880_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzE5NjA_9a4d1145-1db7-41a4-af72-416f455a2447">585.8</ix:nonFraction>&#160;million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $<ix:nonFraction unitRef="usd" contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNzg_d7653fbd-b1ba-4e79-8f29-fe603f7461d0">13.5</ix:nonFraction> million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company&#8217;s existing and future senior debt, (ii) equal in right of payment with the Company&#8217;s existing and future senior subordinated debt, (iii) senior in right of payment to the Company&#8217;s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i8897ccce0c7b4682b1ff96e5c2e2de35"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">preferred equity, if any, of the Company&#8217;s subsidiaries. Upon the occurrence of a &#8220;fundamental change,&#8221; as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder&#8217;s 2027 Notes for cash at <ix:nonFraction unitRef="number" contextRef="i97af8e39d55a45988666e9a615166ab0_D20220101-20221231" decimals="INF" name="bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzMyMjk_3df3184a-f75f-4880-ab2f-3cd98a24ca3a">100</ix:nonFraction>% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The offer and sale of the 2027 Notes and the shares of the Company&#8217;s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2024 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzM3MDE_766410d3-a8bd-4653-a1e0-010b2480cb0c">495.0</ix:nonFraction> million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at <ix:nonFraction unitRef="number" contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831" decimals="INF" name="bmrn:DebtInstrumentPercentageOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzM4NDc_09544a3a-ec19-4a1e-9ac4-ae8661b27592">98</ix:nonFraction>% of face value and bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwOTM_753aa417-45d4-4b76-aa26-ace9848f21d2">0.599</ix:nonFraction>% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company&#8217;s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQyODI_638d2e08-a38a-4b29-a42c-761d4ce0ca86">124.67</ix:nonFraction> per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company&#8217;s common stock. A holder may convert fewer than all of such holder&#8217;s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQ4MTk_c1a7c584-a995-43e4-9d0e-6e86bc9787ce">481.7</ix:nonFraction> million. In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $<ix:nonFraction unitRef="usd" contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQ5Mjc_9d278928-704f-49f4-99a5-98c1f776210a">9.9</ix:nonFraction>&#160;million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company&#8217;s existing and future senior debt, (ii) equal in right of payment to any of the Company&#8217;s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company&#8217;s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company&#8217;s subsidiaries. Upon the occurrence of a &#8220;fundamental change,&#8221; as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder&#8217;s 2024 Notes for cash at <ix:nonFraction unitRef="number" contextRef="ica62b7ca7a3f4aee8d2b64beac63adb6_D20220101-20221231" decimals="INF" name="bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzYwOTk_0d227f83-afb3-4cc7-8452-e779f22d7c2f">100</ix:nonFraction>% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_190">16</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on earnings (loss) per common share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="i76aebdd53eb84ceab8638e5fb1ff8e9b_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzY0OTQ_a8260f94-e996-4bbc-8e47-aa94273edc1c">200.0</ix:nonFraction> million, which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="i3efb3be452cd4b8cb7fea7f3c05ba63e_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcwNDQ_dc597146-602a-48fb-8e30-6a4bf1680b7a">no</ix:nonFraction> amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_175"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90ZXh0cmVnaW9uOmFiZDQwOWI2MjgyYTQwNWU4NTk0YWVmMDYxNDJmMGRkXzI3Mw_48199ab9-00e8-447e-b041-346b58217e55" continuedAt="i5e6aa56e41ba40e3a3ffa54419a48095" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</ix:nonNumeric></span></div><ix:continuation id="i5e6aa56e41ba40e3a3ffa54419a48095"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90ZXh0cmVnaW9uOmFiZDQwOWI2MjgyYTQwNWU4NTk0YWVmMDYxNDJmMGRkXzI3NA_0e37f1b6-41d6-4cc5-bcce-603dee130fd3" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e306c702cbb420eac9580746df9ae30_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtMS0xLTEtODEzNzU_8a7c76f8-0521-4b98-b8d9-39e00d882ee1">16,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618baef4a9c943558fad300e0bb46e9e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtMy0xLTEtODEzNzU_e8647f69-eb7b-412f-95e8-fc77c8fd11dd">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6872ed12f9164d05957167fd36693e24_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtNS0xLTEtODEzNzU_13151765-568f-4aa8-b914-1d1d3eecb74e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec53576eff54be9aebf7078e363312e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtNy0xLTEtODEzNzU_143f7aef-7c82-4908-b60a-455b5a586cb3">20,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItMS0xLTEtODEzNzU_d856469b-1f68-49ba-8cf7-96c9d2e9435c">23,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItMy0xLTEtODEzNzU_5b4966c2-504b-4ba1-a650-d499f959e7e7">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItNS0xLTEtODEzNzU_40846f52-f53f-43df-9f31-0d4fd06fb226">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItNy0xLTEtODEzNzU_8dc97e9a-4bea-4ddd-8120-84f8b84108e3">22,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtMS0xLTEtODEzNzU_7f8f1859-45d1-44ad-82e2-11c2c477e562">13,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtMy0xLTEtODEzNzU_9e16e203-7319-4ad6-9b30-fdd581e4c75b">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtNS0xLTEtODEzNzU_f087c6dc-8a8f-484d-8b0b-12ff1319ccbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtNy0xLTEtODEzNzU_de736716-e8b4-4aa5-b807-a9e65f716209">13,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtMS0xLTEtODEzNzU_7989a01f-13eb-46d9-85bb-e0cb26b43435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtMy0xLTEtODEzNzU_d642bad5-55d7-4663-8ec5-4c180063ac41">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtNS0xLTEtODEzNzU_a17780ff-43ba-433b-89c7-7db2af5fce3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtNy0xLTEtODEzNzU_38aff9dc-4f2c-4bff-9c2d-176e3ad0fefe">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtMS0xLTEtODEzNzU_656f37db-afc6-4556-9880-e8e4754d5959">36,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtMy0xLTEtODEzNzU_9077a8ec-fb90-47e1-a34f-edb1141ed2f2">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtNS0xLTEtODEzNzU_bc68eab7-db64-4d36-b754-f97879908afb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtNy0xLTEtODEzNzU_e6ec1286-ca60-4044-9ec6-84041c7c52fd">36,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d0e209b4cba44c8841984717c05fdfd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtMS0xLTEtNzg1Njg_0f303696-3047-4c85-aa84-f27b547ca3d2">20,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6451fcf8cc42d5bbe8a6ac07fa5fa8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtMy0xLTEtNzg1Njg_ab5bb3c3-aa74-474d-9313-1b76109505a7">3,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa7db8b29e9457f93217ca8c42e681e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtNS0xLTEtNzg1Njg_52251862-0b13-4358-860a-81f717b3c85c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id485da7dafae40ddabd0f37725dd651a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtNy0xLTEtNzg1Njg_a6003c3c-b2be-48a5-9ca3-080b8a9bd1bf">16,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctMS0xLTEtNzg1Njg_6aef68b1-708b-415a-8b36-e29c2a26f405">34,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctMy0xLTEtNzg1Njg_369db5b1-af88-44fc-b531-e2d74259e745">6,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctNS0xLTEtNzg1Njg_e0527b53-28bd-47d3-a4f8-da45fcac3720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctNy0xLTEtNzg1Njg_33790656-82b4-47c1-a1d2-c6c5c235f3e0">27,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtMS0xLTEtNzg1Njg_65dbc19b-7d76-4935-ad4c-1abf49cb8683">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtMy0xLTEtNzg1Njg_58f7aeb5-70fa-4fe3-853d-f778e7704891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtNS0xLTEtNzg1Njg_94fbb4f6-bf4f-49b2-bbae-daa504371594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtNy0xLTEtNzg1Njg_1ea7c100-77c7-48ce-83f6-b0de5afbe8da">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktMS0xLTEtNzg1Njg_018f3965-23c5-44c2-8035-28b77f4c8354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktMy0xLTEtNzg1Njg_9360679d-e2eb-4599-92a3-e3aa651629fc">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktNS0xLTEtNzg1Njg_4fd3dc75-1be5-43f5-94ff-dfa5d6f0f50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktNy0xLTEtNzg1Njg_65ceef1e-3318-440a-8b13-73af38b13875">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTEtMS0xLTc4NTY4_8cd637cd-e472-4a23-9793-aee145282b64">35,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTMtMS0xLTc4NTY4_aa6983e4-86f5-47a0-916f-2a4b4de527e3">5,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTUtMS0xLTc4NTY4_6e33a06d-77f1-4156-9dd2-2301956be3f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTctMS0xLTc4NTY4_c4686175-b8f5-4ecb-857c-f92bc5e19008">30,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d843487721d43b7a6cf7175f69e01fa_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTEtMS0xLTc4NTY4_c11cadbe-d185-409a-b13e-58aefbc163ac">15,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd5dbb579b5f418cb0577509240e9084_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTMtMS0xLTc4NTY4_6d0ae9ca-533a-4d5c-a8db-659dae8128da">1,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ff2134016c43a48d2be70284677ab2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTUtMS0xLTc4NTY4_c59f9e02-bf97-4ea5-a53b-5eac7b576c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875a67714c6452c84f63885164473d3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTctMS0xLTc4NTY4_8295a61b-4ac2-45ed-a93f-5032bfdb32b0">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTEtMS0xLTc4NTc0_d9baf702-afe9-48a3-80c5-ed93ce383631">29,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTMtMS0xLTc4NTc0_fe18b44c-8733-4220-aa3f-6978348b0fcf">13,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTUtMS0xLTc4NTc0_015bd02d-dcea-4c94-bdbf-d2979f305a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTctMS0xLTc4NTc0_91839bd4-0da5-4583-bece-df0369c3b201">15,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTEtMS0xLTc4NTc0_8e7cfd26-2f6d-4135-a1bf-fb2166d16ac5">36,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTMtMS0xLTc4NTc0_d00b555a-addd-4f9f-9820-6c74db797247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTUtMS0xLTc4NTc0_98677808-be35-4e34-ba3b-baf0f31cd475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTctMS0xLTc4NTc0_bc76c5c2-9cce-4f79-86da-e64fb9e29eb5">36,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTEtMS0xLTc4NTc0_40d326c0-03a4-4e71-92a4-0482c26a343c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTMtMS0xLTc4NTc0_fa9f95e3-717e-4e25-9245-939745ad2c75">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTUtMS0xLTc4NTc0_4b3846ea-91c6-46cc-bb17-7a14e228c377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTctMS0xLTc4NTc0_b5284cf4-1629-41f3-a68f-e848f090c56a">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTEtMS0xLTc4NTc0_77b8a673-152a-476d-9481-edfdf3c81607">7,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTMtMS0xLTc4NTc0_bfaf29f2-83e1-47a8-b3e0-5250060f57d5">10,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTUtMS0xLTc4NTc0_8c52187e-faf8-4792-a80e-38c6de0fab33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTctMS0xLTc4NTc0_175cd4bb-ef6e-4d2f-88d2-f85fc593ab50">18,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd084d19fafe4eb08800335bbaa0fdb3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTEtMS0xLTc4NTc0_6062c8a1-cd3f-43a1-a2ea-af756f2b67f7">8,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied7e67f5a5634503ad5879c8009f97f2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTMtMS0xLTc4NTc0_5ca857e8-1d8f-4788-9ac0-565a98ddbb42">12,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d2704044e74eec86232f6b5bbfa0a0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTUtMS0xLTc4NTc0_4582e111-d985-4ad3-9c89-277fc8df785d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d01a3eb633442b8a24963b9a15b0f21_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTctMS0xLTc4NTc0_89600720-78fa-477a-a4f3-b12d9e7be08e">3,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="ib1aad3959e884c01b6a07e04db98b99b_178"></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1Nzk_2bbb0546-4f3e-476a-bdde-2f1afa689fc7" continuedAt="idb359f2489424492ac98c61eee1cbd1e" escape="true">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</ix:nonNumeric></span></div><ix:continuation id="idb359f2489424492ac98c61eee1cbd1e" continuedAt="iad4def29158d4220b057e2b9d9314a89"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODE_7dbd14dd-50ea-4001-bde1-6bb7653a09cd" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents Total Revenues and disaggregates Net Product Revenues by product.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d540593f644f2cb082a24558b3f758_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtMS0xLTEtNzg1Nzk_13fe4095-4bab-44e9-935d-b989ce87d1d3">663,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107111d003394f429df9bc3b7e72083a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtMy0xLTEtNzg1Nzk_0108bdd1-57a7-4e7c-b711-2165ae6d213b">623,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766158ee331f4b6dad23cc139f408d52_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtNS0xLTEtODEzNzg_bd18c21c-3c51-4d17-adf2-b8c479fc5fc9">544,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice70b2f98d8f46ee95e52f2e5d8735cd_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtMS0xLTEtNzg1Nzk_5a7eb51a-d33d-4d92-9886-6c136dd93663">443,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbfc39daa5e4e86b8925b3c91e0a20f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtMy0xLTEtNzg1Nzk_20785189-a31c-4385-a03f-01ae4bd798bb">380,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc10f3a93ae418882d57641c30e6fa2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtNS0xLTEtODEzNzg_2fd43839-aaa1-4915-9e45-182db32923a6">391,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a42714856349788ac98ef18c9c4eec_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtMS0xLTEtNzg1Nzk_b7a223c1-1fb5-40ca-ac12-188ecfffdf51">255,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58bdf6d90d34e0e9c7db18bf1df4dc1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtMy0xLTEtNzg1Nzk_3c4fcce8-3bfd-4e71-80d5-545e9129e75d">237,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509d47fe3d174696acd23ae2feb9495e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtNS0xLTEtODEzNzg_767538e1-5a19-48ab-99c7-f74c10c6761d">170,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6660ddacf84f446083b9e0ca5bce39fb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtMS0xLTEtNzg1Nzk_d8353f25-2cac-4adf-a51f-88e76ae74d62">227,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef27eef923e434e862de91ae5beafca_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtMy0xLTEtNzg1Nzk_58495325-c25a-4c44-b241-8014194b31d5">285,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7292c071f44cd4ba482c581dbba9e1_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtNS0xLTEtODEzNzg_a2527c02-110f-48d0-8f3a-5c2d361932c8">457,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2ca389fb2d47f3991717f9e5b9757c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctMS0xLTEtNzg1Nzk_12cde75a-dff4-4ecf-b9d8-e55539d520e1">169,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b179a96cee8425daa243c6ec126fa90_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctMy0xLTEtNzg1Nzk_c38fe649-e26a-4e10-8386-0ac622ae95cf">5,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieded801c64bf44adb38c0af09661c7f4_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctNS0xLTEtODEzNzg_a4aa5e68-702d-4583-bb28-230788f13054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6399581bf17e49c697410cb0a73c682c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtMS0xLTEtNzg1Nzk_8543b5f6-12b8-4131-80a6-a93e2652a542">154,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0245c8a131434573a4579c1ffa6fe178_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtMy0xLTEtNzg1Nzk_5663ec8f-2776-494a-aec1-795c8bb374e9">128,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a7a34d6b8446b19864867ebc10546d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtNS0xLTEtODEzNzg_6f8945f9-00ad-4513-b250-bebe5cf86cfd">110,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FIRDAPSE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff71e7217274546b0d948f39fc97420_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktMS0xLTEtNzg1Nzk_f0c360e2-f7cd-4a35-bd22-15321306c744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503208303f7343d68d5b53c7fb08f251_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktMy0xLTEtNzg1Nzk_42f4d8c4-f2b7-49f1-867a-c14ea0b9e7d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7039784a43724956bd81fdb85ade56d5_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktNS0xLTEtODEzODA_fb4bdc22-a5ab-4a50-a14d-c4f3985d3ab6">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTEtMS0xLTc3NjM4_6f66abfa-062c-4727-950c-163644a2debd">1,913,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTMtMS0xLTc3NjM4_f42ce139-ac21-44b0-b89c-934e07d4c709">1,660,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTUtMS0xLTc3NjM4_61211306-5807-4db2-aa25-f8dce53433d8">1,675,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTEtMS0xLTc4NTc5_e4c9ee71-753c-4107-9d6b-1c918c32a67f">128,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32233365d594b308746b274d89d9e5f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTMtMS0xLTc4NTc5_ceebd3b9-6434-4864-b145-b4af07121248">122,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTUtMS0xLTgxMzc4_3022dd1e-0bbe-48b9-b629-899ce16d6ef3">130,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTEtMS0xLTc4NTc5_8087b13a-82ac-436d-87fa-4ce4b106f7eb">2,042,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTMtMS0xLTc4NTc5_4697472d-e093-4080-aded-5371fae6e582">1,783,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTUtMS0xLTgxMzc4_09f3add0-b1dd-4939-877c-507de6345025">1,805,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTEtMS0xLTc3NjM4_cc57e559-840c-4ce1-bc0b-a9c5b7ee1e8e">54,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTMtMS0xLTc3NjM4_b5552547-a0a7-479c-9edf-869da6e55498">62,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTUtMS0xLTc3NjM4_fc951521-6717-4bed-80af-cbfb60e12b05">54,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTEtMS0xLTc3NjM4_baf86be7-64f5-4a84-85a8-4d99b8fd8191">2,096,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTMtMS0xLTc3NjM4_81912af7-eefa-4dd8-ad67-38f68aa59ed9">1,846,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTUtMS0xLTc3NjM4_140f687f-0658-47a6-9816-55d0839f1d0b">1,860,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#8217;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#8217;s revenues and results of operations if sales in the respective regions experience difficulties. <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODI_18b82673-e6ee-4d4b-8c3c-f130c2df654c" continuedAt="iaec417ea3f56449c8b5f3373db771cda" escape="true">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="iaec417ea3f56449c8b5f3373db771cda"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae042974731b47fa8462f91e2b1ce268_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtMS0xLTEtNzg2MDk_81dc2cca-0e3c-4015-b965-c19762dce15c">684,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b2cd85806b4c09a10ee05befb288eb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtMy0xLTEtNzg2MDk_ab3ec98c-2c86-4ba5-9a87-9add1be173d8">657,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec738639a3694be7b566566f59fefda1_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtNS0xLTEtODEzODI_1d3b4521-92a7-4a73-8429-4e77e33c972e">756,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afae57055d2464bbca1472128e2dd4b_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtMS0xLTEtNzg2MDk_0461751b-036f-45f4-b7d6-23068c144833">650,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde566a1a304443a9740252495984863_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtMy0xLTEtNzg2MDk_d21334a7-0dac-4e05-8033-40903ef8dd04">558,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b889898bba94b54af9a9335b9b82b62_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtNS0xLTEtODEzODI_b6f8b3fa-4abc-468e-8ecc-ae0d461566ed">498,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia344194268dd43fd989b6b04a378902f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtMS0xLTEtNzg2MDk_769d81ea-acc9-4f65-a08d-794603ec5e37">266,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826dd83d81b24084b26e5b5cc42493b1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtMy0xLTEtNzg2MDk_5cb3f5e4-e373-48af-9789-d5d5840bbbe8">191,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie581ba1d1b064e6986a21f9ea9fdc7a2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtNS0xLTEtODEzODI_7fe20336-8fc6-4dcb-a1ba-9767f835231f">205,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31425f01f73430a9a3aec5dfc86da0d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtMS0xLTEtNzg2MDk_cfb93059-d3c1-4575-984a-7a3287158e84">311,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id209fbaf4cd14f198010a1f4ff75159e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtMy0xLTEtNzg2MDk_0ed467aa-30a1-4697-9a54-5a0eb6133f97">252,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ed09d29aa1432fa6575525ede1e854_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtNS0xLTEtODEzODI_09f9d8a0-8e79-41ab-ac95-9c36aa92385f">214,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctMS0xLTEtNzg2MDk_f9128ae4-cbe0-4b54-b2ab-ca24b638aca4">1,913,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctMy0xLTEtNzg2MDk_ea20dffd-a707-4782-b760-07e31f22a5d4">1,660,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctNS0xLTEtODEzODI_2f566046-fdaf-4c76-ad8f-1b662c306ac1">1,675,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtMS0xLTEtNzg2MDk_f69c0821-6d3f-4acd-b3e7-ede906fb9860">128,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32233365d594b308746b274d89d9e5f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtMy0xLTEtNzg2MDk_a15224a0-e590-4b8f-8d4e-2726317fc84f">122,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtNS0xLTEtODEzODI_150e732e-d056-48ee-a2de-78f6041624be">130,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktMS0xLTEtODMwMzU_74b55167-001b-4e58-b52b-a7892e57a248">2,042,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktMy0xLTEtODMwMzU_4b34d552-f9bc-443a-acf6-89fcf32a4c7d">1,783,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktNS0xLTEtODMwMzU_691dab07-2e00-4ff7-8711-9c306887ef4c">1,805,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODM_f77eda1a-ad01-4c92-a3ec-d0343c814cc5" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0770f55d5c104f969b9acc886090f5fb_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItMS0xLTEtNzg2MTc_c18894e7-5566-45d6-a036-1972ec3ca625">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacafee45f91e46ebb714c46c2ff89823_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItMy0xLTEtNzg2MTc_d3193bdd-f089-41cf-a01c-02a015f307a5">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59f95dec71974a66bbde2f90b523281c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItNS0xLTEtODEzODU_0f5dc176-2bda-4f9c-a141-d77216d15713">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9e42fce28b14ebbb8a5a4411c1433ba_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtMS0xLTEtNzg2MTc_9306b490-4c72-4ec3-8a43-0fd04faa9dc4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94e7695ed7954a5fb9f808089e78a85d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtMy0xLTEtNzg2MTc_67810924-4e03-41dd-be16-6b62a317dce5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5749604fcebc42ada76e2e1b582da09c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtNS0xLTEtODEzODU_629a4f90-b4b7-4d85-903b-bc982ed2f512">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40ade8d0054c45b997b2f2e5fb9e1490_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtMS0xLTEtNzg2MTc_92e88698-579f-499c-b96a-f0a2602dd388">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4553d6d08ef849c8a72048bc17b8ed75_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtMy0xLTEtNzg2MTc_076ad239-3722-4677-b24a-e35148239703">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca4f3f8044a4465aad5cc36317e02b0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtNS0xLTEtODEzODU_fb5ef194-20fc-48de-95d6-197cf2fa3da5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtMS0xLTEtNzg2MjE_d088d574-7db0-40e8-a82c-47bab01815c1">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i692965d349e34f3ea4acc8a50f53276d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtMy0xLTEtNzg2MjE_cfe72d93-d562-4e7b-a6d4-caf7bcd90357">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63e7463435974d1d98101460b30a9c62_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtNS0xLTEtODEzODU_29597aa6-2eb4-454e-861a-9b3059e756e9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for <ix:nonFraction unitRef="number" contextRef="i843ac21f80f24e97b5709f27f83dc60c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzEzNzQ_d0dafad0-9a92-4569-9c3a-8061221467c5">22</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6558cc5ad3094460971e3ff939e6623a_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzEzODA_0e55accc-946c-4243-9630-5daa61584cc2">15</ix:nonFraction>% of the Company&#8217;s December&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021 when two customers accounted for <ix:nonFraction unitRef="number" contextRef="ibe58d8557902475b9ecb613007413f59_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0MzY_698ab8ca-09a2-4d1a-adae-76423918468b">28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2aadf30296f940eeb46c2095e3ef8568_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0NDQ_0e640ce9-e71f-4ba6-bfe0-3ce1c20617d7">16</ix:nonFraction>% of the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="iad4def29158d4220b057e2b9d9314a89"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accounts receivable balance, respectively. As of December&#160;31, 2022 and 2021, the accounts receivable balance for Sanofi included $<ix:nonFraction unitRef="usd" contextRef="i7b5fa7ec2b1541f2a9aecd40ae5ca28b_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0OTk_4c0eb78e-7412-4d50-8ac4-15b94091bdb2">68.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fea8ab604b143e89c4c4066ac2d10d3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE1MDc_2fc8e1c6-f3d3-4be5-8206-6f8f56387ae6">67.9</ix:nonFraction> million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#8217; financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the year ended December&#160;31, 2022, 2021, and 2020, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients. While the extent and duration of such effects remain uncertain and difficult to predict, the Company does not expect significant impacts to its operating results and financial condition as a result of the COVID-19 pandemic in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could affect the Company&#8217;s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company&#8217;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODQ_b2e2c24b-5d07-4dcb-acf7-016fcd696c3d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-lived assets by geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05278f7e11d545918819b0e5fd3de8f3_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzMtMS0xLTEtODA4Nzg_a63d3b3a-182f-45c9-909e-18de8895c955">786,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ede14dcb48b4252953a1349a4dcdcd0_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzMtMy0xLTEtODA4Nzg_c1ee43b5-c0bd-4eec-900b-1b5b2dd7fe0b">763,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3eff93ecba4e9ab0b751bba0479273_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzQtMS0xLTEtODA4Nzg_56bc2bef-ce17-49d1-b212-1a5f9a0ffac7">309,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d4996c3e9141c19bf5436bd1dfe088_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzQtMy0xLTEtODA4Nzg_8bac3867-c99b-4ae1-87a0-d7853e1acac6">304,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6853f1a77d1449f9e25fc0db6cfd462_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzUtMS0xLTEtODA4Nzg_d633a65f-5310-402c-906d-7a91a5cb538e">18,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic617813345644c10af3fae918e7bce97_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzUtMy0xLTEtODA4Nzg_714bc0a5-9d8a-4f47-b76a-f2b93207d01f">13,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzYtMS0xLTEtODA4Nzg_1a766187-8871-49ed-9cab-6792d68fc40b">1,114,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzYtMy0xLTEtODA4Nzg_fa0836d1-1f6f-4234-a2d2-8dce5005cb24">1,081,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib1aad3959e884c01b6a07e04db98b99b_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzU0OTc1NTgxNTMyNzQ_ff8d59ed-b9af-4dc4-b268-3439933faee3" continuedAt="i7fca78c831684e70b90d626c6346d9a9" escape="true">EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i7fca78c831684e70b90d626c6346d9a9" continuedAt="i057e6e8316954669b25fc64e8444ed10"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Shares Available Under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NDkw_525151e2-4bce-4181-bd56-6340e61f8b2c">41.5</ix:nonFraction> million unissued shares was authorized for future issuance under the Company&#8217;s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan (2017 EIP) and the ESPP. Under the 2017 EIP, shares issued and outstanding under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company&#8217;s stock-based compensation plans are administered by the Company&#8217;s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2017 EIP provides for awards of RSUs and stock options as well as other forms of equity compensation. RSUs granted to employees generally vest annually over a straight-line <ix:nonNumeric contextRef="i4183315e314d4360bb0502134885d9dc_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk3MTA_a5673e6a-1eb9-4506-b01a-1ad4ecc4704c">four-year</ix:nonNumeric> period after the grant date. RSU Awards with Performance-based Vesting Conditions (PRSUs) generally vest over a <ix:nonNumeric contextRef="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk3MTc_c6b1acec-512f-466e-956c-904989a66dfe">three-year</ix:nonNumeric> period on a cliff basis <ix:nonNumeric contextRef="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzMDQ_473fce67-0e6f-442e-8f6a-12ac480890d2">three years</ix:nonNumeric> after the grant date. Stock option awards granted to employees generally vest over a <ix:nonNumeric contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzU0OTc1NTgxNjI1MjY_dccf587d-2d95-47a7-9f05-dc34ac1b60a2">four-year</ix:nonNumeric> period on a cliff basis <ix:nonNumeric contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NDM5NjE3_697b29f6-106f-41f6-b08c-67189fee0343">12</ix:nonNumeric> months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally <ix:nonNumeric contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NDM5NzI4_6677fc99-b6dc-46d7-bfd1-ab1011129568">10</ix:nonNumeric> years from the grant date. As of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><ix:continuation id="i057e6e8316954669b25fc64e8444ed10" continuedAt="ib6fc6830e7ed4149ad8ccefd19fcd30c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="ia93e432edc5048a0ac3ab95326ff5424_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NTA1_e6a54363-57b3-4123-b292-0524596b3fe6">27.7</ix:nonFraction> million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ESPP was initially approved in June&#160;2006, replacing the Company&#8217;s previous plan, and was most recently amended in June 2019. Under BioMarin&#8217;s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of <ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzNjA_7aed1458-7c8d-4386-ba27-e386b90e1845">85</ix:nonFraction>% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to <ix:nonNumeric contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" name="bmrn:SpanOfOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzNzM_c9703287-db5b-4890-8ba9-0444d88e3a95">two years</ix:nonNumeric>. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to <ix:nonFraction unitRef="number" contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzODA_52b8afd5-6a22-471a-80e6-b060bc09c74c">10</ix:nonFraction>% of qualified compensation, up to an annual limit of $<ix:nonFraction unitRef="usd" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="INF" name="bmrn:MaximumPayrollDeductions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzOTE_a077db13-0d18-47e5-a93c-c8cb64b10eff">25,000</ix:nonFraction>. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Internal Revenue Code. During the year ended December&#160;31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE1ODQ4_fd650b14-e453-47e7-91cf-07351db8b280">0.3</ix:nonFraction>&#160;million shares under the ESPP. As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDUw_9c11836c-7a8d-4c2d-8d4f-9961ca411d83">7.0</ix:nonFraction>&#160;million shares were authorized and <ix:nonFraction unitRef="shares" contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NDk3_76f3448f-7331-4e0f-aaa1-7bd3d9cf522b">2.8</ix:nonFraction> million shares reserved for future issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Board of Director Grants</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the date of the Company&#8217;s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $<ix:nonFraction unitRef="usd" contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMyOTE_9732d238-76f4-4f02-9011-6866003832e8">400,000</ix:nonFraction>, with the number of RSUs to be granted calculated based on the <ix:nonNumeric contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919" name="bmrn:AverageClosingPriceTrailingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDIw_1224987d-cd1d-40dd-a501-20141e43494c">thirty-day</ix:nonNumeric> trailing average closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market. The annual RSU grant for a director who has served for less than a year is prorated to the nearest quarter of the calendar year. The RSUs subject to the annual award vest in full on the <ix:nonNumeric contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDE5_d646c500-ccab-47ff-9205-a2076f9ed70d">one-year</ix:nonNumeric> anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company&#8217;s next annual meeting of stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDIx_08513b76-c4ff-4ddd-aa5a-e9758030392c" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense included on the Company&#8217;s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:62.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1445253420474375b7efe62ace67131e_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItMS0xLTEtNzg2NjE_ccfad749-404b-4451-8597-bc7d10965c4d">17,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934a6fe3c5d2413c87067ea339f198cc_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItMy0xLTEtNzg2NjE_a16a583d-72c1-40ef-b94e-bebe6d95c5bc">22,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9c60963aff483fa114c7b304603a7d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItNS0xLTEtODEzODg_c540f210-c4e9-4ea1-9b68-717d8fa0a90a">26,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e06e2017d4b477e9b69593553036531_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtMS0xLTEtNzg2NjE_32e01376-1ead-4af8-bdee-f0b2b2397a4e">61,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12938f6823a94b1c837db430e15262c0_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtMy0xLTEtNzg2NjE_bb361d5a-9aca-4531-83d0-b08e4318904e">67,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5dda00a8514dd59ad5007c3cd8c578_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtNS0xLTEtODEzODg_a68706cd-38a7-42e5-a752-1829c6e147f0">61,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b264f9c740640838312c3dbd938c92e_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtMS0xLTEtNzg2NjE_59d79352-02eb-4d25-bc48-92ff552bfdb1">116,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dfc5eb6e4d04a6390d4d537c078c61f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtMy0xLTEtNzg2NjE_e2e4e7e4-9b2b-47af-ad1d-8b2d686c0b5b">107,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5359457de041eaba77b73a3803bcfe_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtNS0xLTEtODEzODg_a1b17c31-5181-4a86-bdcc-1f5e413b929c">101,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtMS0xLTEtNzg2NjE_46eddf62-3fec-43f1-b680-3daf90231e98">196,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtMy0xLTEtNzg2NjE_37183703-1fc1-45cf-83a0-51f77d77b242">197,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtNS0xLTEtODEzODg_37ee6b51-41e8-4c60-a92d-fcab1775bbdb">189,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDk1_ea2b582b-2e69-464f-8f53-b6846c7200f4">21.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTA2_1dc8c9ef-441a-48ff-9007-3b7eafaea2a9">20.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTE4_81f04b85-c9bc-4ae7-9a84-39f27590bedb">20.1</ix:nonFraction>&#160;million was capitalized into inventory for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><ix:continuation id="ib6fc6830e7ed4149ad8ccefd19fcd30c" continuedAt="ibd5a37b5cf8a460794b77d14ab41465a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Service-Based Vesting Conditions</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI0_202eee35-c8e1-47a0-afe8-2c096eecee28" continuedAt="i66d271a7d419426eade025325f2fdfc9" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with service-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzEtMS0xLTEtODIyNjI_26f632e2-07e7-40b2-99a7-be3877ae9920">4,437,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzEtMy0xLTEtODIyNjI_6887ca93-920e-4c85-bd3d-a1a83084b21f">80.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzItMS0xLTEtODIyNjI_57116bb4-dbc8-4b74-b8d3-00fb2522d82a">2,266,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzItMy0xLTEtODIyNjI_777058bd-8ae5-425c-80ed-8af83e3b5a0e">79.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzMtMS0xLTEtODIyNjI_c8213142-ecfa-451a-941d-0b9c67fd920f">1,609,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzMtMy0xLTEtODIyNjI_a17a1f10-9f11-4be0-8c3d-128e1f440893">81.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzQtMS0xLTEtODIyNjI_90d76632-9042-4408-8165-9626e3392fa7">574,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzQtMy0xLTEtODIyNjI_f9d17de3-e8ba-4677-b610-c5a0ff87f2ca">79.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzUtMS0xLTEtODIyNjI_b8cae14e-5903-48c5-85b5-37853274b481">4,519,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzUtMy0xLTEtODIyNjI_50c1d903-b670-4d98-805a-5765b1b0de4d">79.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2MzU_2ea87c9f-00f1-4eeb-8d59-e226fe47dd71">79.43</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2NDQ_5a911fde-c5e5-4b80-b801-fb0ae176ad77">78.46</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2NTM_c8751c49-2e31-48cb-b0fd-51d5a54cf48d">77.13</ix:nonFraction>, respectively. The total intrinsic value of restricted stock that vested and released in the years ended December&#160;31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTQ2_67df4760-c264-47e8-b299-47fe048401ce">130.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk5MDE_1594d50a-b8eb-44c9-898f-460815a6e502">117.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk5MTc_2706b002-13c3-4c25-a5c4-3f415b7efa48">109.9</ix:nonFraction>&#160;million respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $<ix:nonFraction unitRef="usd" contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTg5_a5ca1f0e-50bb-4164-a21b-e9c01652bf02">251.2</ix:nonFraction> million was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk3ODQ_153830ad-d3a0-4626-97b9-ddd2a4c6ea06">2.5</ix:nonNumeric> years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Performance-based Vesting Conditions</span></div><ix:continuation id="i66d271a7d419426eade025325f2fdfc9" continuedAt="i3042d9c0dce64e949a2565b02b661a4a"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with vesting conditions based on performance targets under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cf62fa1ecfd497ea4311496211dd174_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzEtMS0xLTEtODIyOTQ_48885ff3-4d0f-4ded-aaa7-efa7f52b2685">437,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cf62fa1ecfd497ea4311496211dd174_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzEtMy0xLTEtODIyOTQ_75ea2f61-54fd-4171-8ae5-01ac435b5e6b">78.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzItMS0xLTEtODIyOTQ_89181765-6670-4bf9-8771-5a23fa88b9ec">147,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzItMy0xLTEtODIyOTQ_8859c914-70bb-4519-8af6-67877cb34e72">78.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzMtMS0xLTEtODIyOTQ_d57f716e-f63b-40ac-a9bd-c474688fbf6e">102,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzMtMy0xLTEtODIyOTQ_69d68e89-f44d-42fc-832f-42b5ee00489b">82.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzQtMS0xLTEtODIyOTQ_bd1dfc78-5e5b-4155-a593-343e34fcb163">34,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzQtMy0xLTEtODIyOTQ_e08be090-9540-46b2-8c58-1aa2466a2bad">65.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1572514829d644a68de7022821a70b1d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzUtMS0xLTEtODIyOTQ_de036510-0807-4d0a-85fe-772c58b00981">447,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1572514829d644a68de7022821a70b1d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzUtMy0xLTEtODIyOTQ_1f85e6d9-24ab-4e5a-b62b-a7c85889a686">78.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the PRSUs for the years ended December&#160;31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMDU_8859c914-70bb-4519-8af6-67877cb34e72">78.27</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="id16e0033fc1948dc9e1fa09a786eaa23_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMTQ_6857ae3b-08b1-4ad3-9325-106b9d8b6815">78.09</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0f2a458d9fee49c6a103d0f775c380d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMjM_7f64b7c5-259c-4335-8bbf-4b30c9e6a804">84.17</ix:nonFraction>, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-vested PRSUs included grants with vesting contingent upon the achievement of a <ix:nonNumeric contextRef="i77a7c1018d1f4444a8560a5468103fba_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMxODg1ODM3MjI4MTM1_96232c56-06ab-4312-a5d7-c19e98a3da64">three-year</ix:nonNumeric> Non-GAAP income target, upon the achievement of a <ix:nonNumeric contextRef="i26584ec2b88147ebad7a6bf69b3d15d6_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMxODg1ODM3MjI4MTM2_9d17748e-ddf1-456f-8f0e-43d32f2b140c">three-year</ix:nonNumeric> Core Operating margin target, vesting contingent upon achievement of a <ix:nonNumeric contextRef="i27f49f0589db4d3fa2f9f5fb5d1f4355_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NTYwNjk_b9b5c56d-b3b3-4bca-a258-0062246c244d">three-year</ix:nonNumeric> strategic goal target and vesting contingent upon achievement of certain regulatory milestones. The awarded PRSUs generally vest over a <ix:nonNumeric contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI2_45469910-0618-4278-b4b6-e18742ac6363">three-year</ix:nonNumeric> service period on a cliff basis. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the quarter granted. The number of shares that may be earned range between <ix:nonFraction unitRef="number" contextRef="ied0260b6f7eb4a6fb48d30eb32daec80_D20220101-20221231" decimals="INF" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzc1Njc_caec9f38-a95d-4999-ba6f-07db0ca19cee">50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iee4d086842524837b758a134e20de2d5_D20220101-20221231" decimals="INF" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzc1NzQ_6e9bf3d0-2e27-4e15-8cea-aac85a91aa4a">200</ix:nonFraction>% of the base PRSUs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense related to non-vested PRSUs of $<ix:nonFraction unitRef="usd" contextRef="i1572514829d644a68de7022821a70b1d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2ODcz_4b1f4f02-80d7-4f9d-9012-6eab22d82af8">12.8</ix:nonFraction>&#160;million was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDYwNjY5_7c53ae17-ceb6-4c29-a15b-5ddf6a1ad248">1.2</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><ix:continuation id="ibd5a37b5cf8a460794b77d14ab41465a" continuedAt="i31e0d27ff6a549e6aca768d1da442c6b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Market-based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a <ix:nonNumeric contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDMz_f336eca7-8333-4a47-83b2-15062835e9a3">three-year</ix:nonNumeric> service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between <ix:nonFraction unitRef="number" contextRef="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231" decimals="INF" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg2NjU_d81f6b29-fe6d-4cb2-b857-9e765723572a">zero</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i595951030a5d4e73a012f1be549c5e5a_D20220101-20221231" decimals="INF" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg2ODA_92929492-0e09-4608-a7fb-2c8532b8a868">200</ix:nonFraction>% of the base TSR-RSUs with a ceiling achievement level of <ix:nonFraction unitRef="number" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="INF" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg3NDA_a65044fb-2028-4109-b5be-50c7f5c1694d">100</ix:nonFraction>% of the base TSR-RSUs in the event the Company&#8217;s TSR is above the <ix:nonFraction unitRef="number" contextRef="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231" decimals="INF" name="bmrn:AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg4MDg_ddf34464-96e1-472a-ac3e-e559f9308861">50</ix:nonFraction>th percentile but negative on an absolute basis. </span></div><ix:continuation id="i3042d9c0dce64e949a2565b02b661a4a"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2b318a52937403fb847cf89e01b77ea_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzEtMS0xLTEtODI0NjQ_9e420e19-74f4-4fb9-a994-ad6765d76dc9">350,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2b318a52937403fb847cf89e01b77ea_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzEtMy0xLTEtODI0NjQ_276a6c01-281d-4e64-acb9-35ca098ec77a">123.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzItMS0xLTEtODI0NjQ_7a5c5786-38aa-4f08-9ce0-afb789ae8434">147,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzItMy0xLTEtODI0NjQ_3bbc7cfa-6750-4c78-8763-d4d8c64d2bee">124.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzMtMS0xLTEtODI0NjQ_5182a651-bfa7-4d58-8f52-ea19fa95a691">89,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzMtMy0xLTEtODI0NjQ_89364ff4-d9c3-4861-89ec-a4d617d941a1">143.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzQtMS0xLTEtODI0NjQ_a9e38e8c-1a78-4cf4-8a23-50477f74f8ff">12,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzQtMy0xLTEtODI0NjQ_1f91f952-1a3b-4fdf-b43a-288891380e77">120.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzUtMS0xLTEtODI0NjQ_f377e2c2-8d2a-4529-8bc1-c05c8caac296">396,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzUtMy0xLTEtODI0NjQ_1171fd3a-5548-418d-b706-6efdd3a0dc1c">119.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI4_c13f578b-8ba8-4013-b2be-a111d7fdddef" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The grant date fair values and assumptions used to determine the grant date fair value of TSR-RSUs granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItMS0xLTEtODI1OTI_869b41be-0ab7-42d1-b77a-aec3445ca30d">124.67</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItMy0xLTEtODI1NTE_aa4c673b-1c06-4a46-8981-6f8f3f1cd762">117.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItNS0xLTEtODI0ODAvdGV4dHJlZ2lvbjpkNTk0NzdlZTdlYWU0Y2MyOTcyYzcxNjRkYzQzMDAxMF8xMDk5NTExNjI3ODM2_3acdb66a-a472-49b8-989d-6bec82942958">112.12</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="usdPerShare" contextRef="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItNS0xLTEtODI0ODAvdGV4dHJlZ2lvbjpkNTk0NzdlZTdlYWU0Y2MyOTcyYzcxNjRkYzQzMDAxMF8xMDk5NTExNjI3ODI2_a00d623f-0607-4778-929b-89785d4c8b01">217.65</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMS0xLTEtODI1OTkvdGV4dHJlZ2lvbjplMjVkNDdmMTFkMjM0ZGFjYjlkOWU2ZjdiNjRiNDg5ZF8xMDk5NTExNjI3OTIw_f5bf0907-44d4-4b97-962f-f8ed8495a8e0">24.5</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMS0xLTEtODI1OTkvdGV4dHJlZ2lvbjplMjVkNDdmMTFkMjM0ZGFjYjlkOWU2ZjdiNjRiNDg5ZF8xMDk5NTExNjI3OTMw_c9c1d281-7df0-4cd9-adbb-3ce8158b2a1d">157.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMy0xLTEtODI1NTgvdGV4dHJlZ2lvbjpkNjNlOTViOTliYzE0NWM3YmJkZjNkNjNjYmRkZjY3ZV8xMDk5NTExNjI3ODAw_d7337124-d1cb-44f6-ae1f-a9e875ef5f95">24.7</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMy0xLTEtODI1NTgvdGV4dHJlZ2lvbjpkNjNlOTViOTliYzE0NWM3YmJkZjNkNjNjYmRkZjY3ZV8xMDk5NTExNjI3ODA5_26debe5b-5366-4826-adb9-d0a0d2131926">161.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtNS0xLTEtODI0ODcvdGV4dHJlZ2lvbjphNDg3ZTY5MGJiNTI0OTlmYTgxNjJkNWNkYjNjYzhiZV8xMDk5NTExNjI3ODAw_eca22dba-f291-496b-87f1-ba2acbed1ceb">21.3</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtNS0xLTEtODI0ODcvdGV4dHJlZ2lvbjphNDg3ZTY5MGJiNTI0OTlmYTgxNjJkNWNkYjNjYzhiZV8xMDk5NTExNjI3ODA5_674fb47e-f818-4dd8-9eb8-0f6c1e64e085">159.9</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtMS0xLTEtODI2MTI_e755d1e0-1913-428c-97f1-5a63bc3882fc">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtMy0xLTEtODI1NzA_616c2e0f-50f6-45b4-a8a7-ba94c049e817">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtNS0xLTEtODI1MDA_d98d7f12-5c7e-4a42-aaf3-fca5ad6db59a">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtMS0xLTEtODI2MjA_777d603b-23d9-4238-9cbd-860c2c887120">2.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtMy0xLTEtODI1NzYvdGV4dHJlZ2lvbjozZjU0Y2Q2ZjY4ZTE0NjExOTA2ZjU1ZTBmMTVmNDBjZl8xMDk5NTExNjI3Nzk5_a89c847f-8fc2-4fb9-b10c-beefdfce50d7">2.8</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtNS0xLTEtODI1MDcvdGV4dHJlZ2lvbjo4MDg2M2Q1ODU2NmQ0YjVhODBiNDkyOWE4Yzk5MTMwNF8xMDk5NTExNjI3Nzg4_fdb93834-6c4b-4e5a-b832-3520444f73ae">2.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtNS0xLTEtODI1MDcvdGV4dHJlZ2lvbjo4MDg2M2Q1ODU2NmQ0YjVhODBiNDkyOWE4Yzk5MTMwNF8xMDk5NTExNjI3ODA1_68a9064b-811e-4bb4-8fad-0f2d71fbaafc">2.8</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtMS0xLTEtODI2MjgvdGV4dHJlZ2lvbjplYWUxZWE5ZWY4Njk0MzdkYTNlNzA3MmJlZDM5OGE5NV8xMDk5NTExNjI3Nzky_74840420-3d43-4108-8829-23fa332629f9">2.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtMy0xLTEtODI1ODQ_2a2c2987-c4f7-40c2-8ea1-2725d1740c9d">0.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtNS0xLTEtODI1MjAvdGV4dHJlZ2lvbjo5YmJlODU3MDQ5NGI0N2U0OGZjZWZjYjQwNTRlZDczYl8xMDk5NTExNjI3Nzg1_505296a0-d6e4-40de-a7a6-b7f3e1996f2a">0.2</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtNS0xLTEtODI1MjAvdGV4dHJlZ2lvbjo5YmJlODU3MDQ5NGI0N2U0OGZjZWZjYjQwNTRlZDczYl8xMDk5NTExNjI3Nzk2_89ae44e2-7432-4ff5-b409-d3447780ab30">0.4</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2OTE1_219bb420-704d-4d23-8abd-637eee93b1b7">17.1</ix:nonFraction>&#160;million related to base TSR-RSUs was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyNDI_6c882108-ac7f-46fb-8e35-161287d2858c">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><ix:continuation id="i31e0d27ff6a549e6aca768d1da442c6b" continuedAt="i4a3407b8aaf146f0b52ddbc1bcf23391"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM0_ae09ba06-bdad-466a-b18b-9b4b6c56a75c" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes activity under the Company&#8217;s stock option plans for the year ended December&#160;31, 2022. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:50.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtMS0xLTEtODI3MDQ_5fc89d4b-2b6e-447d-a892-7e2088651ae7">6,449,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtMy0xLTEtODI3MTI_0026bf53-4f4d-4d44-a9b3-0ce7b8121d69">78.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtNy0xLTEtODI3MzY_2a541680-e016-4d9f-8fa6-19e1f691ef75">80,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzItMS0xLTEtODI3MDQ_13ae0636-4e8e-4912-b3c6-9aedd268949b">695,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzItMy0xLTEtODI3MTI_ab676fd3-b553-4c60-9434-b68b5f8917e4">78.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzMtMS0xLTEtODI3MDQ_e275a445-2c14-4d5a-88fa-40ae1b0322dc">943,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzMtMy0xLTEtODI3MTI_a0c6df37-efa2-49d2-afe1-ae000b13aeae">55.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzQtMS0xLTEtODI3MDQ_c5988b81-7178-4d3b-a478-1d3de77772d4">258,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzQtMy0xLTEtODI3MTI_559e49a9-d27c-468c-85dc-8d0166dc6e9d">79.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtMS0xLTEtODI3MDQ_844427e7-98f8-4f43-a830-605d59849da4">5,943,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtMy0xLTEtODI3MTI_434c4f0a-0e6d-42cc-9e60-1b1b6804029e">82.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtNS0xLTEtODI3MjA_22588f32-050a-41e1-bd60-4a822b98b4f9">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtNy0xLTEtODI3Mjg_2ebbe414-f38a-4f0b-ab6f-fd73531696fd">132,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtMS0xLTEtODI3MDQ_3ca09746-6468-49bf-b1d1-ef8313f95859">1,255,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="2" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtMy0xLTEtODI3MTI_54b6f81f-5b66-4d71-b78d-f20a35b5e7aa">78.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtNS0xLTEtODI3MjA_b2a5aa82-ce36-4678-a647-d226676255e2">8.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtNy0xLTEtODI3Mjg_be017f18-4665-44dd-b581-a3769859bd67">31,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctMS0xLTEtODI3MDQ_8328825e-3b98-4dde-ad84-2d0e43bd3e3b">4,687,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctMy0xLTEtODI3MTI_65e2f397-58e5-4c82-9dc8-ca7d722d29f1">83.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctNS0xLTEtODI3MjA_4d8d6194-7591-4599-b5fd-021aa5df1f4c">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctNy0xLTEtODI3Mjg_ffc52bc3-f260-4f98-8485-bda3f45fc246">101,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f9a014bff6d4b1096c43e4334589a74_I20221230" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwMDU4_7b82ac29-c8f5-4e24-b592-64c52331e6f9">103.49</ix:nonFraction>, the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on December&#160;30, 2022.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average fair value per stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDEw_7488cce1-fc24-4097-acd4-479f519854cd">32.45</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDIx_de864c81-5cf3-47f5-af88-55e4d6472631">31.61</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEzMDY0_229384b6-4bb0-4cc5-898a-58f3bb01372c">27.47</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDI1_5da8bf60-841b-4106-bc14-6baf00e2c494">32.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAwOTg_ea2b402a-4d18-4638-85d1-bcd0d0f0e24c">40.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAwODI_06313d30-95b0-40cc-a058-1abc834e0591">71.9</ix:nonFraction>&#160;million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM1_00dfdae1-2fc1-414d-9873-ae610eef8ec0" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMS0xLTEtOTQ4NTAvdGV4dHJlZ2lvbjo0NzkwN2NhYzU1YTE0MDY3YWJmZDBiNWUwNzVmYzk3NV8xNTk0MjkxODYwMjc5OA_9ca4581c-21cc-4f7d-87ef-1925d61e42e9">38.1</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMS0xLTEtOTQ4NTAvdGV4dHJlZ2lvbjo0NzkwN2NhYzU1YTE0MDY3YWJmZDBiNWUwNzVmYzk3NV8xNTk0MjkxODYwMjc5MQ_875a49f0-5113-4e95-bc3c-88b07b3fbc3c">40.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMy0xLTEtOTA1MzkvdGV4dHJlZ2lvbjowMTEzZDg0OTE0YTQ0OTdkOTYyNzM2Y2Y5ZjYwOTE4ZV8xMDk5NTExNjI3Nzk2_e59d6881-30ad-4a2e-927d-d9c3c742b80e">39.4</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMy0xLTEtOTA1MzkvdGV4dHJlZ2lvbjowMTEzZDg0OTE0YTQ0OTdkOTYyNzM2Y2Y5ZjYwOTE4ZV8xMDk5NTExNjI3ODA1_44d22daa-6870-4079-acbf-55639f7b8eb0">41.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItNS0xLTEtOTA0OTcvdGV4dHJlZ2lvbjphYWVlNTE3Zjc5MDc0MmQ5YWNjOTVmYzdhYzAxOGQ2ZV8xMDk5NTExNjI3Nzk2_bf166038-4d1b-4682-9d01-0a9f55ef5345">36.5</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItNS0xLTEtOTA0OTcvdGV4dHJlZ2lvbjphYWVlNTE3Zjc5MDc0MmQ5YWNjOTVmYzdhYzAxOGQ2ZV8xMDk5NTExNjI3ODA3_3587c88c-2092-41cb-bc2f-44fd46ed8765">42.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtMS0xLTEtODQwNzY_3b55140b-b725-48d2-9759-fd89ce88e3b0">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtMy0xLTEtODQwNzY_7882fec9-27c6-4058-b4d1-c1454c0b02b9">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtNS0xLTEtODQwNzY_d866bdce-7d7c-4eb3-8821-683a74ae44d8">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47b49962d5a640488eada80fa0f8ae01_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMS0xLTEtOTQ4MTgvdGV4dHJlZ2lvbjo2N2QyNWI3MzY4ZTY0MDNlYmYyNTM1NDYyODZmZWMwMF8xNTk0MjkxODYwMjc5Mg_ab9c8ec6-75cb-406d-ba03-b78be69be31f">4.7</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i7b7db90010f7454bb02b375d36208b18_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMS0xLTEtOTQ4MTgvdGV4dHJlZ2lvbjo2N2QyNWI3MzY4ZTY0MDNlYmYyNTM1NDYyODZmZWMwMF8xNTk0MjkxODYwMjc4Ng_b3bc3bde-3693-44b2-aef9-fdf0f156d1a4">6.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i974da25672b24547a1fb86cd010d66a4_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMy0xLTEtOTA1NTcvdGV4dHJlZ2lvbjoxYmE2OTBkNWViOTM0NWZlOGJiNzkwNjBmZGI0ZDNmMl8xMDk5NTExNjI3Nzk4_d9f451da-410c-45f5-a97e-5e2cee943434">4.7</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="ifae9719aaf7c4895bd6972ec9d5a1cdd_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMy0xLTEtOTA1NTcvdGV4dHJlZ2lvbjoxYmE2OTBkNWViOTM0NWZlOGJiNzkwNjBmZGI0ZDNmMl8xMDk5NTExNjI3ODEx_3eb99b79-807f-4095-9995-5c2ba8062377">6.0</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia46fdf7486a84e9f90ef98b86432eb8a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtNS0xLTEtOTA1MTUvdGV4dHJlZ2lvbjplZDE3NzMzNTAyYWY0YzhiOWZjN2ZjZTE3ZjA1ZDZlY18xMDk5NTExNjI3Nzk4_eb420a79-97f8-4172-a7b2-0cf8d3b5aea3">4.6</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="iee705d880c0c46c7808d9be2b86c9f85_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtNS0xLTEtOTA1MTUvdGV4dHJlZ2lvbjplZDE3NzMzNTAyYWY0YzhiOWZjN2ZjZTE3ZjA1ZDZlY18xMDk5NTExNjI3ODEx_eb841b8a-e2ca-44aa-a366-fe7f5ca56e81">5.9</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMS0xLTEtOTQ4NDQvdGV4dHJlZ2lvbjozNGFiNTk2YmExZTc0NWQ4ODZhMzM4M2NjYTZjMTE5Nl8xNTk0MjkxODYwMjc5MA_1dd28d01-a58e-42f6-86d6-8b391b363898">2.1</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMS0xLTEtOTQ4NDQvdGV4dHJlZ2lvbjozNGFiNTk2YmExZTc0NWQ4ODZhMzM4M2NjYTZjMTE5Nl8xNTk0MjkxODYwMjc4NA_6a7c0b93-6865-402e-a77c-7884839f27c2">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMy0xLTEtOTA1NjkvdGV4dHJlZ2lvbjo2NTllNDg1NDI0OWY0MGM5YTE4MmZmMDY2NDhhNWNmZV8xMDk5NTExNjI3Nzkz_8ff09834-1ef3-419a-ba3c-14ee52eadc0a">0.7</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMy0xLTEtOTA1NjkvdGV4dHJlZ2lvbjo2NTllNDg1NDI0OWY0MGM5YTE4MmZmMDY2NDhhNWNmZV8xMDk5NTExNjI3ODAx_74a550d5-a020-4378-8b3b-f2eb88d48902">1.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtNS0xLTEtOTA1MjcvdGV4dHJlZ2lvbjpkZjViYTZjMDk5NWQ0ZmRjYjMwYzJlYTVmZmJlZTY2ZF8xMDk5NTExNjI3Nzkz_65393904-6f44-4418-8d59-8f9d02a3a2e4">0.3</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtNS0xLTEtOTA1MjcvdGV4dHJlZ2lvbjpkZjViYTZjMDk5NWQ0ZmRjYjMwYzJlYTVmZmJlZTY2ZF8xMDk5NTExNjI3ODAx_162c5580-8ef8-4570-9c81-6c8003b10d62">1.7</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options of $<ix:nonFraction unitRef="usd" contextRef="ia481385bca9741cb9627136de2e3b7a5_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDMz_56683b75-8083-4ff5-8a7d-08dd58a7f98d">31.5</ix:nonFraction>&#160;million was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDQ0_f0a92ce1-9fe7-4102-b6f6-450feda1bdc9">2.5</ix:nonNumeric> years.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net tax expense from stock options exercised during the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAxMTQ_082f3383-3dbe-4951-9a8c-d4df37739c3b">0.2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div><div><span><br/></span></div></div><ix:continuation id="i4a3407b8aaf146f0b52ddbc1bcf23391"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Purchase Rights</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM2_86c07155-a4af-4241-89be-4000791875fb" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMS0xLTEtMTA0NzIyL3RleHRyZWdpb246YzczYjdkYzJlNDYwNGFhODljNzJlYmExMjM0YzM2ZmRfMTA5OTUxMTYyNzc5Ng_3fe95ea5-5406-414a-946f-7e1933f7a79c">28.6</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMS0xLTEtMTA0NzIyL3RleHRyZWdpb246YzczYjdkYzJlNDYwNGFhODljNzJlYmExMjM0YzM2ZmRfMTA5OTUxMTYyNzgwNQ_66f2dbae-bc25-4af3-b2a6-6ac13b43b2bf">69.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMy0xLTEtOTA2OTMvdGV4dHJlZ2lvbjo4NDRjYjc1MTRkNTA0N2YxYWRjM2RiNTNkMDJlNmFjNV8xMDk5NTExNjI3Nzk2_81825b5a-5c2d-466e-a293-474781e15eeb">23.7</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMy0xLTEtOTA2OTMvdGV4dHJlZ2lvbjo4NDRjYjc1MTRkNTA0N2YxYWRjM2RiNTNkMDJlNmFjNV8xMDk5NTExNjI3ODA1_3cf67de0-b86c-400a-9810-da77452d96ce">69.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItNS0xLTEtOTA2NDkvdGV4dHJlZ2lvbjphNTZjZGE5ZWUwMzc0NmM0OWEzZjRmOThiOTNiYzUzNV8xMDk5NTExNjI3Nzk2_a64b84eb-99b6-43b9-add8-c5e480c4ad37">30.6</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItNS0xLTEtOTA2NDkvdGV4dHJlZ2lvbjphNTZjZGE5ZWUwMzc0NmM0OWEzZjRmOThiOTNiYzUzNV8xMDk5NTExNjI3ODA1_83505e9a-9c99-4e92-a179-6d8257cfff3e">69.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtMS0xLTEtODQwNzQ_1ea16e3b-2be2-43bb-b53e-04ba919cb09c">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtMy0xLTEtODQwNzQ_ff8ff33f-11bb-489c-b6c6-c41e855401ec">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtNS0xLTEtODQwNzQ_596591ac-1ee0-43ec-af42-1428889cb37c">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia88d13cac03446da910f4bdda092a94d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMS0xLTEtMTA0NzQwL3RleHRyZWdpb246NWU5NjM4ZDEwZTFhNDllZTg1MzlkZGM0ZmNkNzUwZGFfMTA5OTUxMTYyNzc5OA_d72cd69a-7d7a-47e7-ab62-5b0d9eb61c85">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="iba90d1418dc34fbcbca22b21986af64b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMS0xLTEtMTA0NzQwL3RleHRyZWdpb246NWU5NjM4ZDEwZTFhNDllZTg1MzlkZGM0ZmNkNzUwZGFfMTA5OTUxMTYyNzgxMQ_3e89b504-e0e8-4c15-a49a-798f6b066485">2.0</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58aaac40a42b4a7fb111583b886ae23f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMy0xLTEtOTA3MTEvdGV4dHJlZ2lvbjozY2YyN2EyYmJkYTc0NmJjOTllNGJkOGM3ZGJlZTAyYV8xMDk5NTExNjI3Nzk4_fa88bc7a-0f2d-4d27-bc1a-14d79c632dc8">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i4f1866f0f98b4968a4a0b7d8ec1061c9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMy0xLTEtOTA3MTEvdGV4dHJlZ2lvbjozY2YyN2EyYmJkYTc0NmJjOTllNGJkOGM3ZGJlZTAyYV8xMDk5NTExNjI3ODEx_48c13b05-cad3-42a3-9b70-ecb2aa7f41b1">2.0</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94d5c058dd7843b99ec211cfd4eaef44_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtNS0xLTEtOTA2NjkvdGV4dHJlZ2lvbjo1YjI1M2I3ZWI2NDI0NjJkOWE5MjI1NmU5YWExOGQ2Y18xMDk5NTExNjI3Nzk4_f9cb0464-ca01-4882-9b40-adb8b3c63f78">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="id45d9cb0ae984b8a895192c71ec4dc6a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtNS0xLTEtOTA2NjkvdGV4dHJlZ2lvbjo1YjI1M2I3ZWI2NDI0NjJkOWE5MjI1NmU5YWExOGQ2Y18xMDk5NTExNjI3ODEx_7a1498d0-f8d8-43b5-ab7c-750e22ca8d40">2.0</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMS0xLTEtMTA0NzUyL3RleHRyZWdpb246ODE0ZDBiMmFkNjVlNDFhZmI4ZDkyNTBkZGY4ZjJiMTVfMTA5OTUxMTYyNzc5Ng_3f6e3377-aff4-4098-af22-495b0664a52d">0.04</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMS0xLTEtMTA0NzUyL3RleHRyZWdpb246ODE0ZDBiMmFkNjVlNDFhZmI4ZDkyNTBkZGY4ZjJiMTVfMTA5OTUxMTYyNzgwNQ_813ebe65-534e-4f77-aade-ef796fa011e3">4.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMy0xLTEtOTA3MjMvdGV4dHJlZ2lvbjpkN2YwOGRjODBlNjc0MjkxYjNkY2FkZTM4NzliM2Y1Ml8xMDk5NTExNjI3Nzk3_c90ea1c7-08ea-406d-b605-462ba6ec6056">0.04</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMy0xLTEtOTA3MjMvdGV4dHJlZ2lvbjpkN2YwOGRjODBlNjc0MjkxYjNkY2FkZTM4NzliM2Y1Ml8xMDk5NTExNjI3ODA1_3490f49a-4e61-47c2-b06e-0d534ec24617">2.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtNS0xLTEtOTA2ODEvdGV4dHJlZ2lvbjoxOTQ5MmJiNWQ4ZjM0YzNjOTY5MzhkMDJjOWYyODBkM18xMDk5NTExNjI3Nzkz_eb976dfd-c489-4442-b6d4-4b2c1301fc3c">0.1</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtNS0xLTEtOTA2ODEvdGV4dHJlZ2lvbjoxOTQ5MmJiNWQ4ZjM0YzNjOTY5MzhkMDJjOWYyODBkM18xMDk5NTExNjI3ODAx_7ff998df-ec17-434f-9f9a-e211908877d5">2.8</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $<ix:nonFraction unitRef="usd" contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2OTUx_711c64d5-bb4c-4760-a2d5-52cfb68011bf">14.0</ix:nonFraction>&#160;million was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDYwOTAy_a33f0e38-6b0b-43c8-bfe9-aaeaf5a9ba5d">1.3</ix:nonNumeric> years.</span></div></ix:continuation><div id="ib1aad3959e884c01b6a07e04db98b99b_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzE2NTc_3011ed68-8e20-4a4b-9e93-a6e76bc49a88" continuedAt="i4469fd65435443fe8c92eb7dbdc44ed5" escape="true">OTHER EMPLOYEE BENEFITS</ix:nonNumeric></span></div><ix:continuation id="i4469fd65435443fe8c92eb7dbdc44ed5" continuedAt="i4fc6bbca75ed4d2e9b68538bf9eec173"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">401(k) Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan) for eligible U.S. employees. The Company pays the direct expenses of the 401(k) Plan and matches <ix:nonFraction unitRef="number" contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MTQ_17615ee3-7a04-4dc1-a10f-15bcd6ac29b0">100</ix:nonFraction>% of each participating employee&#8217;s eligible contributions, up to a maximum of the lesser of <ix:nonFraction unitRef="number" contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk0Mzc_895fbacb-a46d-4493-b224-ee1fb02e7af1">6</ix:nonFraction>% of the employee&#8217;s annual compensation or the annual statutory contribution limit. The Company&#8217;s matching contribution vests immediately and was approximately $<ix:nonFraction unitRef="usd" contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MzM_a94ac67c-b28e-46ca-be69-d000c337288a">30.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if33b1905895a4c0d9c697f26aee83f66_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MjY_051e5961-207f-4ec1-b20d-dc65463e4a95">31.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64eb5ac7ff2c441b8532f7bcb1ddab8b_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MTk_35c368af-e39b-48d3-b6c5-fcfeb5067f7e">26.4</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains the Nonqualified Deferred Compensation (NQDC) plan under which eligible directors and key employee may defer compensation. The NQDC prohibits the diversification of deferrals of Company stock. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity with no changes in the fair value of Company stock held in the NQDC recognized in earnings. Other contributions held in the NQDC are classified as trading securities, recorded at fair value with the corresponding deferred compensation obligation classified as a liability and subsequent changes in the fair value of these non-BioMarin investments are recognized in earnings in the period they occur. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i4fc6bbca75ed4d2e9b68538bf9eec173" continuedAt="i896e5e6bcc8d40339b8f784c68faa632"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_163">7</a></span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i896e5e6bcc8d40339b8f784c68faa632"> to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities.</ix:continuation> </span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_187"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(15) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDY_5ad1a690-1c26-465b-afce-a6340f4a6f15" continuedAt="i46b32580a7a2443da062c07b254dc92f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i46b32580a7a2443da062c07b254dc92f" continuedAt="i39180f16bca440db9084818bbc511583"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDA_31425f7a-cbf2-47ca-9ac2-1035859af407" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Source</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItMS0xLTEtODEwMDA_ad4f4cee-98a9-4617-8b39-0020d4768d8e">299,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItMy0xLTEtODEwMDA_d5789a7b-c8aa-4fb1-b411-51ca22902592">259,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItNS0xLTEtODEwMDA_43996f61-7129-4a6d-b6e4-76e2be8ec2cb">169,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Source</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtMS0xLTEtODEwMDA_1491387a-0282-46c4-ab64-1f10879f974f">448,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtMy0xLTEtODEwMDA_daa1b128-2873-468d-b797-9023f8ad1934">183,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtNS0xLTEtODEwMDA_b217b917-62ec-4d63-8781-1757b76af427">120,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtMS0xLTEtODEwMDA_6d212634-dcce-4014-b361-b0fa36565c99">149,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtMy0xLTEtODEwMDA_3897047e-ee9e-4cbe-a814-9c18e12634fb">75,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtNS0xLTEtODEwMDA_257b5847-2f2b-44c1-a772-b6e2bf555f3b">48,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i39180f16bca440db9084818bbc511583" continuedAt="i2da981b2f4ec4a2997f67228b6b31a91"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MTA_023e42cd-088b-4374-a478-4141c27178d4" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtMS0xLTEtODEwMTE_bc3582d4-702d-4aac-a24c-6e7afd3dadca">12,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtMy0xLTEtODEwMTE_41a1ddd4-c40d-46de-94a0-e64f55cdec01">2,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtNS0xLTEtODEwMTE_8b5b2c76-f32f-4497-bfcb-868bc03b679c">15,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtMS0xLTEtODEwMTE_c500f4b8-b591-4593-8b37-43ddb67075b1">5,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtMy0xLTEtODEwMTE_9ef80f53-8961-4d4a-830b-e264ef9dec39">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtNS0xLTEtODEwMTE_b27f1ca8-d944-45bc-847b-b7a325e6c2f0">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtMS0xLTEtODEwMTE_1d57b5a9-2c56-45f5-98e6-63ed04c3d822">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtMy0xLTEtODEwMTE_82d52ed6-9378-450b-b8dc-cf48375ff77e">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtNS0xLTEtODEwMTE_c6c6c9e3-a855-4d90-941b-5d2772a2c7ef">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtMS0xLTEtODEwMTE_8408c95f-2468-46ee-b447-ad42384c6fcc">60,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtMy0xLTEtODEwMTE_8c0fa173-adba-4c2e-a711-975b77667dbd">4,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtNS0xLTEtODEwMTE_aa625030-516f-49aa-a21d-5b708c41719f">13,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtMS0xLTEtODEwMTE_51c5e3f0-86c7-42bb-86f3-e984df40d0e8">79,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtMy0xLTEtODEwMTE_4bcbe171-9615-46d3-bdce-0bffc8d350ee">29,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtNS0xLTEtODEwMTE_aa91d5a3-8380-44fb-8846-a1c0c8c4a71c">46,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktMS0xLTEtODEwMTE_4f853032-fc20-49dc-b11c-bc1636057c40">5,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktMy0xLTEtODEwMTE_c18b6966-6acb-4aa8-bf83-a923bb48404c">1,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktNS0xLTEtODEwMTE_49151722-c6c7-4cbf-8df6-0545281d99d7">5,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTEtMS0xLTgxMDEx_eff5c1bc-25da-42b9-8a17-a390a38b4f18">32,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTMtMS0xLTgxMDEx_6282486d-779e-497f-b6d6-6919b405e673">15,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTUtMS0xLTgxMDEx_a7b89f80-59a0-444f-9875-47907fa965f1">838,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTEtMS0xLTgxMDEx_34ba5e42-e266-4500-8540-b514e1e979b3">52,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTMtMS0xLTgxMDEx_a4cf6242-4a12-4760-aef7-527171c2a181">15,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTUtMS0xLTgxMDEx_92a85515-3ed4-486c-a77f-fa58dd0d9df9">889,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTEtMS0xLTgxMDEx_d5675946-ec68-4a36-9951-548e1b2a99a8">8,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTMtMS0xLTgxMDEx_2e38b7ea-190a-4b89-aabb-34b373f9dd65">11,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTUtMS0xLTgxMDEx_a2f9848c-e9cd-4efe-aac3-b5dcc46c6eaa">903,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights from a wholly owned foreign subsidiary (tax resident in the Bahamas) to its wholly owned Irish subsidiary. The rights were sold to the Company&#8217;s Irish subsidiary where its ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The intra-entity transfer did not result in a taxable gain in 2020 in any jurisdiction including the U.S. as the transaction was disregarded for U.S. tax purposes. The Company filed an election to treat the Irish subsidiary as a disregarded entity for U.S. income tax purposes in 2011. The transaction resulted in a step-up in the tax basis in the transferred intellectual property rights and the Company&#8217;s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i0acf8a65e32646eda1218b113bbf892f_I20200930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEyNzQ_f0179dac-564c-454e-b558-16f295347d2a">835.1</ix:nonFraction>&#160;million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The fair value of the transferred intellectual property rights was determined utilizing the income approach which relied on projections of product-specific revenues and the inclusion or exclusion of a terminal value for each product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The tax deductions related to the amortization of these transferred intellectual property rights will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2022 and 2021.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i2da981b2f4ec4a2997f67228b6b31a91" continuedAt="if2c90e2b549b42b0b842ae562347d062"><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MTE_40ab1e03-d946-478b-8c4c-90d45984577d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a reconciliation of the statutory federal income tax benefit to the Company&#8217;s effective tax rate:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItMS0xLTEtODEwMzA_1a2b7db4-c9ee-4832-9f49-df67db2a4982">31,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItMy0xLTEtODEwMzA_8834530f-3d10-4a12-b8d1-dda569f8c43e">15,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItNS0xLTEtODEwMzA_ee4b5499-54ea-49e8-96a6-eba584baa2ed">10,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtMS0xLTEtODEwMzA_4111b07b-a5bc-45cb-bcf1-33d05d0dd2ff">1,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtMy0xLTEtODEwMzA_b40aa29a-9d11-47b5-b1e2-50c97319aeae">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtNS0xLTEtODEwMzA_da34a35a-0468-47b3-8329-39b3a5e05f38">3,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan Drug &amp; General Business Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtMS0xLTEtODEwMzA_0ea1d62a-2e7c-49fd-9682-eda98f21234a">35,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtMy0xLTEtODEwMzA_8c09000c-973b-418f-94b9-3f07de3e361d">29,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtNS0xLTEtODEwMzA_e1fc58b5-dee4-493e-809a-a9a81ffe4c73">44,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtMS0xLTEtODEwNDE_22b06f6a-7687-4ae9-ad7b-5933c7f1f436">6,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtMy0xLTEtODEwNDE_4d86de12-6e27-433c-91d9-bf077426394b">7,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtNS0xLTEtODEwNDE_e523ddd7-6481-4581-b007-8e6815552d35">1,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Source Income Subject to US Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctMS0xLTEtODEwNDE_5d517ebd-744a-4fdc-862d-58654eaf0164">5,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctMy0xLTEtODEwNDE_40360778-640a-450f-b750-83a044f5f741">16,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctNS0xLTEtODEwNDE_3cf3317b-70f9-4e57-a995-0ce6fa5c473c">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax rate differential </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtMS0xLTEtODEwNTU_8e222ac5-848f-4dfd-9aa8-d25ce8ccfffd">4,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtMy0xLTEtODEwNTU_9914a459-eb06-4b24-887a-13c8bd81856e">16,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtNS0xLTEtODEwNTU_a5e0c160-d371-415b-b507-0b6ca4c66402">16,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationSection162Limitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktMS0xLTEtODEwNTU_f1c829c8-448d-468d-bfd1-d0cc1725d712">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationSection162Limitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktMy0xLTEtODEwNTU_d6487a2f-9876-4518-a02f-c4ab67a48814">6,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationSection162Limitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktNS0xLTEtODEwNTU_ae4c7122-dd1b-492d-b740-fea25eb1697b">9,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationTaxReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTEtMS0xLTgxMDU1_a1f74eef-8d76-4944-85d6-1d0a8079ca5a">18,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationTaxReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTMtMS0xLTgxMDU1_2ba96631-bef4-4ac0-9978-4f329fca8bac">15,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:IncomeTaxRateReconciliationTaxReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTUtMS0xLTgxMDU1_f170f7b6-97da-4352-be7d-7b7688bc76f7">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfer of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" sign="-" name="bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTEtMS0xLTgxMDgw_6c11beb8-4d9f-4415-8789-e47826d14dcf">18,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTMtMS0xLTgxMDgw_f738b030-629a-42ec-bfc8-b6dc5a68485d">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTUtMS0xLTgxMDgw_07f9125f-e747-4492-a087-64d03c1e6eb9">852,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CARES act carryback claim</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTEtMS0xLTgxMDkx_dc5253d7-0cf7-4d86-9262-cefe10bb946e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTMtMS0xLTgxMDkx_478e28c6-c732-4302-821f-988de0cd54a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTUtMS0xLTgxMDkx_3b6bd164-9b7e-447e-b501-c171a305eb08">2,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance/deferred benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTEtMS0xLTgxMTAy_a5229e53-e221-4db9-9050-d3785e621265">7,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTMtMS0xLTgxMTAy_76de24f5-fbd2-440f-92e1-2e5c9449abfc">6,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTUtMS0xLTgxMTAy_49a17676-ae32-4a39-b87f-49bf4306adc6">6,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTEtMS0xLTgxMTEz_ff71b079-4dba-4773-9bbd-31cb7b5271fe">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTMtMS0xLTgxMTEz_33156384-ea94-4cb4-96b0-c64cd9c87f48">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTUtMS0xLTgxMTEz_e267c236-e5c1-4d5d-8da5-ddedbf31168b">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTEtMS0xLTgxMTI0_2f106b23-0a9c-41ae-80d0-629874be43bf">8,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTMtMS0xLTgxMTI0_db3a5085-85a1-4434-80fa-7397aab358dc">11,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTUtMS0xLTgxMTI0_85b094e1-acc2-4bbb-afb1-6eab9d300afc">903,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and is offset by the PRV income taxed at a higher tax rate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company&#8217;s Dutch subsidiary of $<ix:nonFraction unitRef="usd" contextRef="i501529bab97849e78084830bdba9baf9_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2Mzk0MjY_ea37a49d-edc7-4c74-90fc-72db2cddd4ad">9.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDE_2b5dbfd4-aba4-44f3-beb9-46d408d4f195" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s net deferred tax assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzMtMS0xLTEtODExNDc_fb64ce8a-5807-4e26-8d3a-85aabb81101f">20,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzMtMy0xLTEtODExNDc_ccdf65bb-b637-479a-8841-bbbd1f9448ac">25,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryforwards </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzQtMS0xLTEtODExNDc_95babdd3-a5be-440f-8866-fd0c2ff824fc">555,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzQtMy0xLTEtODExNDc_9ad65c44-c57a-4c0c-9430-e904de633862">564,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, reserves, and prepaids</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzUtMS0xLTEtODExNDc_2e41d0b5-1cea-4517-8223-2b28c23c443b">88,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzUtMy0xLTEtODExNDc_4eb13355-e555-46ea-a77d-1e90d3b2fd94">72,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzYtMS0xLTEtODExNDc_0cbbf5ae-7616-4330-b8b4-7948f7d3397e">836,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzYtMy0xLTEtODExNDc_71785437-ffa4-4f42-a523-3e8034fccb62">875,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMS0xLTEtMTA3NDc0_371900bc-7a37-46a1-bb0e-373159564dce">103,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMy0xLTEtMTA3NDY2_ad7f3692-910b-493c-be25-ccec3371b242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMS0xLTEtODExNDc_45d8a60c-863a-497c-8123-bdad60a8d2ad">49,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMy0xLTEtODExNDc_10127c7a-d1a9-4672-86f3-c0a1cfb09703">50,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzgtMS0xLTEtODExNDc_1392141d-8c50-4992-96a9-14d9a68d67e5">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzgtMy0xLTEtODExNDc_764d4f77-ff85-4679-ad84-9d5a788e755c">7,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzktMS0xLTEtODExNDc_e73bfb74-9160-49ed-8947-83df1db046d9">22,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzktMy0xLTEtODExNDc_33eb6bde-d808-4b4f-9562-80449f7136d1">25,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEwLTEtMS0xLTgxMTQ3_23b3db66-5f87-4207-9dd0-7187c7c2a20e">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEwLTMtMS0xLTgxMTQ3_1356cdcc-eefe-4e1c-9e5b-8dc75404cbf2">1,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzExLTEtMS0xLTgxMTQ3_881680c3-2794-4ce4-9d28-08ea1d923df2">116,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzExLTMtMS0xLTgxMTQ3_b20728f9-bea8-4fe2-ae6a-da73917ff1b0">109,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEyLTEtMS0xLTgxMTQ3_72f74ce9-085a-4528-98e7-bfd75e35f3ff">1,571,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEyLTMtMS0xLTgxMTQ3_53359af9-2f7a-4bab-9e04-7832b488fee9">1,514,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joint venture basis difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE0LTEtMS0xLTgxMTYx_de466e59-cf0a-472e-bed4-b7f55e26dd7b">745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE0LTMtMS0xLTgxMTYx_02c38373-8810-4e1c-98d7-59e25171580b">1,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE1LTEtMS0xLTgxMTYx_1e09ffce-86eb-4d32-a57c-967f8af93889">1,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE1LTMtMS0xLTgxMTYx_4a00abef-0900-4741-ab7b-20b7a2d31737">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="bmrn:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE3LTEtMS0xLTgxMTcy_9f6e050a-17cb-40cc-94d6-b575f03d7b90">5,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="bmrn:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE3LTMtMS0xLTgxMTcy_30aef316-f0b5-4b68-90d6-e4af8a2f6222">6,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE4LTEtMS0xLTgxMTcy_7c41fbb2-954c-4240-ba4a-56bb6d31b8d4">58,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE4LTMtMS0xLTgxMTcy_9d3f691c-e73b-495b-b79e-f49dafd4d819">54,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE5LTEtMS0xLTgxMTcy_08b6ca98-dd60-49ad-85fe-8f15843bf277">66,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE5LTMtMS0xLTgxMTcy_548152a4-4471-4e6d-a284-9c580286db55">64,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzIwLTEtMS0xLTgxMTcy_7c35ba77-75ea-462d-be5c-ccfa0d38afc2">1,505,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzIwLTMtMS0xLTgxMTcy_efd75052-5c1c-4b64-86c4-64196d172c40">1,450,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="if2c90e2b549b42b0b842ae562347d062" continuedAt="ida60f549bfce4120b481e3aad3de6e39"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in net deferred tax assets is primarily related to capitalization of research and development expenses offset by a decrease in intangible assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, the Company renegotiated a license agreement that resulted in lower royalty projections for its Dutch subsidiary. The revised royalty projections required establishment of a valuation allowance on net operating loss deferred tax assets that were no longer expected to be realizable. The valuation allowance also increased in 2021 due to the Company&#8217;s expectation that state R&amp;D credits will not be utilized.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDI_9aaff22c-c593-42e2-87a3-23dbcf6c513d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af5d8557d8a40ae8beee5eedec3c302_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzEtMi0xLTEtODEyMDM_8335b993-59cc-4b9a-be9f-d6d490baba6a">3,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2030-2033 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal R&amp;D and orphan drug credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af5d8557d8a40ae8beee5eedec3c302_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzItMi0xLTEtODEyMDM_0b40d98c-7fd5-411a-abc1-e49163448c16">585,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2024-2042 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0e7db091b498bbec2338419da0c3c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzMtMi0xLTEtODEyMDM_9ac89d23-1c72-411f-9567-f2d5452323d9">186,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2023-2042 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i942bc095adee430bad3ee06049a4834a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzQtMi0xLTEtODEyMDM_ab351c23-f096-4a44-ba50-aa757929b2a7">38,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Indefinite </span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not included in the table above are $<ix:nonFraction unitRef="usd" contextRef="iaba0e7db091b498bbec2338419da0c3c_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1ODE_58c21ab5-b175-4263-98f9-ba4cd0aa6828">152.7</ix:nonFraction> million of state research credit carryovers that will carry forward indefinitely.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.</span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDQ_c0199f59-de5c-4742-bd5a-71991f8ad618" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&#160;31, 2022 and 2021, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzItMS0xLTEtODEyMzU_bc108fc7-33e1-41f5-afa6-56712092bd3d">205,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12190384e734edabd0ce99df1427a69_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzItMy0xLTEtODEyMzU_6f414cba-41a4-4147-b5b5-4e355921de3d">182,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzMtMS0xLTEtODEyMzU_d641c169-ca9c-4376-828c-67fa22f5d461">26,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzMtMy0xLTEtODEyMzU_e6566e77-7716-4e18-b6c0-62192390e9a6">23,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Deletions) Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzQtMS0xLTEtODEyMzU_5e06b6e8-9231-4651-9e25-ec4349e12f2e">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzQtMy0xLTEtODEyMzU_46dc71c2-19d6-4c1e-8ecc-4f7dd1ef4b43">786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzUtMS0xLTEtODEyMzU_23f1b5eb-8e62-4b9e-95df-8fe81f1ac1da">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzUtMy0xLTEtODEyMzU_5be1b69a-bca4-438b-aa2b-df451ae260c3">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzYtMS0xLTEtODEyMzU_2505e96e-1ce3-46d2-a8ff-03e97bc66a5e">232,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzYtMy0xLTEtODEyMzU_619de8e7-ce2f-4cbb-b390-5abbc5e5549d">205,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31, 2022 were potential benefits of $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NzY_47369083-4089-4c01-8c21-f49d19e3ebbf">223.3</ix:nonFraction> million that, if recognized, would affect the effective tax rate. The Company&#8217;s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December&#160;31, 2022. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NjY_b6dc29f0-a3a7-485e-8db1-2fd76231c141">three</span> to <ix:nonNumeric contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231" name="bmrn:IncomeTaxStatuteOfLimitationsPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NzE_4778a348-a2a4-448a-bcfb-3cbe32738db9">five years</ix:nonNumeric>. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ida60f549bfce4120b481e3aad3de6e39">U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.&#160;This excess totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzIxOTkwMjMyNjcxODM_54333664-56cf-4ad0-825d-8e8d0305eb38">17.3</ix:nonFraction> million as of December&#160;31, 2022, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.</ix:continuation></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(16) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzM_c50b81c0-bf2b-48bb-93e8-d4b73bfa1283" continuedAt="ibfbe1067397f4852965bfa84d4815b35" escape="true">EARNINGS (LOSS) PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="ibfbe1067397f4852965bfa84d4815b35"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#8217;s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt. </span></div><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzQ_1c073087-6f45-4dfc-92f5-b3cf250385bf" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:62.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtMS0xLTEtNzg2NjY_791857fe-2d33-452b-9f7c-01cda0dc52e6">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtMy0xLTEtNzg2NjY_6ff5a5ea-a18f-418b-b3ef-feb4f2d762e2">64,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtNS0xLTEtODE0MDc_8654fbd5-d8c1-4404-8192-c74d30f4534a">854,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtMS0xLTEtNzg2NjY_f937bcea-8407-4fdb-8265-07fe604d54d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtMy0xLTEtNzg2NjY_ef156ca5-77a2-4d8d-8251-15521933c0bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtNS0xLTEtODE0MDc_474b112a-cf26-4c3b-b2d5-4aea5078ba53">8,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income/(loss), diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtMS0xLTEtNzg2NjY_0ebbee98-ecda-4e2f-8126-bc45b89a4a17">141,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtMy0xLTEtNzg2NjY_542abff6-3913-4f82-9560-ae465a585caa">64,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtNS0xLTEtODE0MDc_f7a11a23-faa0-40d9-95b8-352f6871f5d5">862,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctMS0xLTEtNzg2NzA_ab56a505-bbe8-4fd2-b606-15a847ecc625">185,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctMy0xLTEtNzg2NzA_7d33bf5e-3d97-4c54-8b8c-72521de5ed0d">182,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctNS0xLTEtODE0MDc_fce1efe0-96cf-4c62-81f8-ca518bd56409">180,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktMS0xLTEtODE0MDc_90e19a73-8c62-4699-909f-ff06edafc195">3,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7eeb745948249f9b5df95030b886512_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktMy0xLTEtODE0MDc_0005b75c-98f0-465f-a014-499805329c47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55d2632b90814ba38f50774fec161236_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktNS0xLTEtODE0MDc_5114ee5b-f616-4808-885a-a51721aee4e8">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTEtMS0xLTgxNDA3_ceb4cd81-ad0b-47f8-b5dc-80f8e0ed94e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTMtMS0xLTgxNDA3_8c95cd07-d3db-4535-83a5-c4d55c170e74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTUtMS0xLTgxNDA3_6567d1fe-d3f8-4a3f-bf0c-416750dfe41e">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTEtMS0xLTc4Njk1_1d8bc4fe-1a4c-4ad7-9c7d-0199e983104c">188,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTMtMS0xLTc4Njk1_f550de96-02e0-498d-a9fb-f0c9ccd2733b">182,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTUtMS0xLTgxNDA3_33ada0ea-0269-4570-bcdd-f53e7f72d025">191,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTEtMS0xLTc4Njk1_2280cea6-8e78-4084-8ffd-39632ca4bdc2">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTMtMS0xLTc4Njk1_e86ddd43-12d1-48b8-8bc1-b81cfd25f873">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTUtMS0xLTgxNDA3_d2648b6d-d016-47b8-b4be-5ca29403d482">4.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTEtMS0xLTc4Njk1_15a27b92-a607-4338-912b-49b347492301">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTMtMS0xLTc4Njk1_19e20015-7cf1-4709-b44c-c5a8305fda32">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTUtMS0xLTgxNDA3_5550976f-c86e-49d8-825e-e51ae4da4e4f">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzU_f4f57840-db4e-4ae1-8829-49966b609f15" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted earnings (loss) per common share as they were anti-dilutive (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:62.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItMS0xLTEtODE0MDQ_0b1c4101-d720-4ace-80a2-f27614232bc9">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7eeb745948249f9b5df95030b886512_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItMy0xLTEtODE0MDQ_7e2d55ab-0c09-4883-a658-993259a2b93b">12,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55d2632b90814ba38f50774fec161236_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItNS0xLTEtODE0MDQ_be4e05df-cacd-4d7c-8758-cdbe25964f58">7,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtMS0xLTEtODE0MDQ_4b6203dd-3047-47be-acfa-ccd4a8d0f8e4">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtMy0xLTEtODE0MDQ_695a25e3-ad8d-4434-8780-9bf9aa9f4e1d">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtNS0xLTEtODE0MDQ_41fca5e8-cfc9-40d1-999a-8a84df57c99e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktMS0xLTEtODE0MDQ_732eae5c-7438-4927-9db6-580237920bfa">16,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktMy0xLTEtODE0MDQ_c564c678-f655-459b-9e35-970fcacd024a">20,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktNS0xLTEtODE0MDQ_14671491-97c4-44be-bf15-4992e9ef333a">7,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_172">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for information on the Notes.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="ib1aad3959e884c01b6a07e04db98b99b_193"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(17) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzQzMzE_0c58c2a9-0541-4aa0-87c8-1bd5f7514deb" continuedAt="i17c367920d364825a4d537f5db25778a" escape="true">LICENSE AND COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i17c367920d364825a4d537f5db25778a" continuedAt="i8d674a19525a4308a1b82d92ef8e1d97">In October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id3436f033fc741c0ad3de97901f0af87_D20191001-20191031" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzM1Mw_65cdf701-a08b-4a07-ad33-23e928e80a0e">3.0</ix:nonFraction>&#160;million, a minority <ix:nonFraction unitRef="number" contextRef="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzM2OA_4edb1a35-b087-4e53-aa0c-4e04bce240d8">15</ix:nonFraction>% equity ownership interest in the licensee, and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and </ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i8d674a19525a4308a1b82d92ef8e1d97"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sales milestones are met by the licensee. Subsequently, the third party licensee raised additional funding and issued the Company incremental shares to maintain its <ix:nonFraction unitRef="number" contextRef="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzE2NDkyNjc0NTAwNTI_99c8eb95-f241-4aaf-a8fa-34982b500ef9">15</ix:nonFraction>% minority interest. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee&#8217;s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December&#160;31, 2022. As a result, the Company's loss exposure is limited to the value of the equity investment of $<ix:nonFraction unitRef="usd" contextRef="i5762589687004ef6b263f4cd981bf8cd_I20221231" decimals="-5" name="bmrn:CollaborativeArrangementMinorityEquityInvestmentInLicense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzIzMTI_cd71ee6f-900b-4b6a-8d77-7793d84e156f">12.6</ix:nonFraction>&#160;million which is included in Other Assets on the Company&#8217;s Consolidated Balance Sheets as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2017, the Company executed a license agreement with Sarepta Therapeutics (Sarepta) that provides Sarepta with global exclusive rights to the Company&#8217;s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under the license agreement, Sarepta pays the Company royalties and may pay the Company certain milestone payments for exons 51, 45, 53 and possibly other exon-skipping products. In the fourth quarter of 2021, the Company and Sarepta amended the license agreement to, among other things, make the license co-exclusive at a future date and reduce future royalty rates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan. Previously, the Company had exclusive rights to KUVAN in the U.S. and Canada and PALYNZIQ in the U.S. and Japan. Pursuant to the amended and restated KUVAN Agreement, if future sales milestones were met, the Company was obligated to pay Merck Serono up to a maximum of &#8364;<ix:nonFraction unitRef="eur" contextRef="i7c68988441f541e28fb1eef7917f2f8f_I20221231" decimals="-5" name="bmrn:BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzI2NDI_37f742b2-eb15-4cc2-90db-a1429d682aa2">60.0</ix:nonFraction> million, all of which were met as of December&#160;31, 2022, &#8364;<ix:nonFraction unitRef="eur" contextRef="i894b46e6d24741dca61467eef21c957a_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzQ4MDg_9d4aeb56-94fe-43f3-b15c-8e113caba7d1">15.0</ix:nonFraction> million of which was unpaid as of December&#160;31, 2022. Pursuant to the Pegvaliase Agreement, the Company also paid Merck Serono &#8364;<ix:nonFraction unitRef="eur" contextRef="i69e41e511f7c45fab191013826ff05c7_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzI4Nzk_239d5df3-b589-4fc4-a9f2-4e3ae033b8bd">125.0</ix:nonFraction>&#160;million in cash when the PALYNZIQ development milestones were achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market FIRDAPSE, the Company's former commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to FIRDAPSE, commencing in the first quarter of 2019 the Company receives royalties of <ix:nonFraction unitRef="number" contextRef="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331" decimals="2" name="bmrn:RoyaltyRateLowerLimit" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzMzMjA_698441f5-6fb7-4e7c-8f24-393419ca9302">7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331" decimals="2" name="bmrn:RoyaltyRateUpperLimit" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzMzMjY_d8ac46e1-0f60-4b63-aed1-dd6e63d42c45">10</ix:nonFraction>% on net product sales of FIRDAPSE in North America. In January 2020, the Company completed the sale of worldwide rights to FIRDAPSE to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_145">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further information about the FIRDAPSE sale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the KUVAN New Drug Application. The Company receives royalties on net sales of the product in Japan.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is engaged in R&amp;D collaborations with various other entities. These provide for sponsorship of R&amp;D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.</span></div></ix:continuation><div id="ib1aad3959e884c01b6a07e04db98b99b_196"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18) <ix:nonNumeric contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzE3NDA_7695b355-9f6c-463d-911d-b8e944f91ba9" continuedAt="i68889cd51ccd4bff90b85f8f2422ec6c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i68889cd51ccd4bff90b85f8f2422ec6c" continuedAt="ie03c41dacd1c4359b6f164deb5e5ca85"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#8217;s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:82.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1aad3959e884c01b6a07e04db98b99b_7">Table of Content</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ie03c41dacd1c4359b6f164deb5e5ca85"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various purported shareholder class action and derivative lawsuits filed against the Company and certain officers and directors. For example, there are shareholder class actions alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act) for making materially false or misleading statements regarding information for two of its clinical products. The estimated long-term loss contingency recorded on the Company's Consolidated Balance Sheets was $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzM4NDgyOTA3MDg5OTE_dbe47af6-030d-43c1-af48-2b835bfb53b8">13.0</ix:nonFraction>&#160;million as of December&#160;31, 2022. The same amount was recorded for expected insurance recoveries. Legal proceedings may occur that may result in a change in the estimated loss accrued by the Company. While it is not feasible to predict the outcome of such proceedings and exposures with certainty, management believes this should not have a material adverse effect on the Company&#8217;s Consolidated Balance Sheets, Statement of Operations or Statement of Cash Flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $<ix:nonFraction unitRef="usd" contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1NTM_26531034-c321-4b88-8ce5-8e5c9979f87f">762.5</ix:nonFraction> million, which included $<ix:nonFraction unitRef="usd" contextRef="i35e08db3d4814a13a6b9f06ccc018757_D20220101-20221231" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1NzE_73788096-a8ca-4a51-89bf-d7ce0658664e">381.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5349719ab5245ecb53681104dd48921_D20220101-20221231" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1ODk_fa720ee6-60b7-4b5d-83d3-2ff227ed2d9b">210.0</ix:nonFraction> million for two early stage development programs licensed from third parties. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;D activities. These amounts are included as R&amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services, production services and facility construction services. As of December&#160;31, 2022, such commitments were estimated at approximately $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk2MjY_c43ccb62-cb0a-4c0c-ac5a-29ccdd01321f">225.5</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzExNTQ0ODcyMTA1MDQz_4791e535-51bc-47c4-971f-5de382ac880a">188.7</ix:nonFraction> million is expected to be paid in 2023. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>2
<FILENAME>exhibit10_35.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i02f2c51bffb2472f879aca6728b14b59_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.35</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017 EQUITY INCENTIVE PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) hereby grants you a number of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) in the amount set forth below (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  The Award is subject to all of the terms and conditions set forth in this Restricted Stock Unit Award Agreement, including the exhibits, appendices and addenda attached hereto (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) and the Plan.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:31pt;text-decoration:underline">NOTICE OF AWARD OF RSUs</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Terms of the Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  You have been granted RSUs, each of which represents the right to receive one share of Common Stock of the Company (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), subject to the terms and conditions of the Plan and this Agreement, as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:27.58pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.301%"><tr><td style="width:1.0%"></td><td style="width:48.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Participant Name (&#8220;you&#8221;)&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total Number of RSUs Granted&#58;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;The RSUs will be adjusted in the event if changes in capital structure and similar events, as provided in Section 9 of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Vesting Schedule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  The RSUs will vest in full immediately prior to the first annual meeting of the Company&#8217;s stockholders following the Grant Date, conditioned on your Continuous Service through such date. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Settlement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Subject to Section V, each RSU will be settled by delivery to you of one Share within thirty (30) days following vesting.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Termination of Continuous Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  All unvested RSUs will be forfeited upon your termination of Continuous Service.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">MISCELLANEOUS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  You will not be deemed to be the holder of, or have any of the rights of a stockholder with respect to, the RSUs (including, without limitation, any voting rights or any right to dividends paid with respect to the Shares underlying the RSUs) unless and until the RSUs vest and the Company has issued and delivered Shares to you and your name has been entered as a stockholder into the books and records of the Company.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  In no event will the Company deliver Shares upon vesting and settlement of the RSUs unless the Shares are then registered under the Securities Act, and applicable state or non-U.S. securities law or, if not registered, the Committee has determined that the issuance of the Shares would be exempt from the registration requirements of the Securities Act and applicable state securities laws.  The issuance of Shares also must comply with all other applicable laws and regulations governing the RSUs, including the requirements of any stock exchange on which the Shares may be listed, and you may not be issued Shares if the Committee determines that such issuance would not be in material compliance with such laws, regulations and listing requirements.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Transferability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Except as permitted in the Plan, the RSUs are not transferable except by will or by the laws of descent and distribution.  Without limiting the generality of the foregoing, the RSUs may not be sold, assigned, transferred or otherwise disposed of, or pledged or hypothecated in any manner (whether by operation of law or otherwise), and shall not be subject to execution, attachment or other process.  Any assignment, transfer, sale, pledge, hypothecation or other disposition of the RSUs or any attempt to make any such levy of execution, attachment or other process will cause the RSUs to terminate immediately.  </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to you at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Data Privacy Notice and Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, the Company and is Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and its Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Common Stock or directorships held in the Company, details of all RSUs or any other entitlement to shares of Common Stock </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.35</font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">awarded, canceled, vested, unvested or outstanding in your favor, for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  You understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in your country, or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Common Stock received upon vesting of the RSUs may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. You understand, however, that refusal or withdrawal of consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23.51pt">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. The interpretation, performance, and enforcement of this Agreement shall be governed by the internal laws of the State of Delaware without regard to that state&#8217;s conflict-of-laws rules.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26.5pt">Integration.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26pt;text-decoration:underline">MODIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">This Agreement may be modified or amended at any time in accordance with the Plan&#59; provided that you must consent in writing to any modification that adversely or materially affects your rights or obligations under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">NO RIGHT TO CONTINUOUS SERVICE </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neither the Company nor any of its Affiliates is obligated by or as a result of the Plan or this Agreement to continue your service with the Company or any Affiliate, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company and its Affiliates to terminate your Continuous Service at any time. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">ACKNOWLEDGMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In acknowledging the Award, you agree that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:28.03pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:26.04pt">the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of RSUs even if RSUs have been awarded repeatedly in the past&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:24.05pt">all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">your participation in the Plan is voluntary&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:25.52pt">the Award is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculation of any overtime, severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">the grant of the Award will not be interpreted to form an employment contract or relationship with the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.54pt">the future value of the underlying Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:19.55pt">if you receive the shares of Common Stock upon settlement of the RSUs, the value of such shares may increase or decrease in value&#59;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">in consideration of the grant of the Award, no claim or entitlement to compensation or damages arises from termination of the Award or diminution in value of the shares of Common Stock received upon vesting and settlement of the RSUs resulting from termination of your Continuous Service (for any reason whatsoever and whether or not in breach of local labor laws) and you irrevocably release the Company and its Affiliates from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, you shall be deemed irrevocably to have waived your entitlement to pursue such claim.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.35</font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By executing this Agreement, you agree to be bound by all of the provisions of the Plan applicable to the Award, the provisions of which are hereby made a part of this Agreement and incorporated herein by reference, and all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  You hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan and this Agreement.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">TAX WITHHOLDING&#59; TAX IMPLICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee and the Company assume no responsibility for individual income taxes, penalties or interest related to grant, vesting or settlement of the RSUs.  Neither the Committee, the Company nor any Affiliate makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant, vesting or settlement of the RSUs.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">You should consult with your personal tax advisor regarding the tax ramifications, if any, which result from receipt of the RSUs, the subsequent issuance, if any, of Shares on vesting and settlement of the RSUs, and subsequent disposition of any such Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">It is the Board&#8217;s, the Committee&#8217;s and the Company&#8217;s intent that the RSUs and this Agreement be exempt from Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) to the extent applicable, and that this Agreement be administered accordingly.  Notwithstanding anything to the contrary, to the extent that any payment or benefit under this Agreement is determined by the Committee to constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and is payable to you by reason of termination of your Continuous Service, then (a) such payment or benefit shall be made or provided to you only upon a &#8220;separation from service,&#8221; as defined for purposes of Section 409A under applicable regulations, from the Company and (b) if you are a &#8220;specified employee&#8221; (within the meaning of Section 409A and as determined by the Committee), such payment or benefit shall not be made or provided to you until first day of the seventh month following the date of your separation from service from the Company and its Affiliates (or, if earlier, on the date of your death).  Each payment under this Agreement shall be treated as a separate payment under Section 409A.  You hereby agree that the Committee and the Company do not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities.  You will not make any claim against the Board, the Committee and the Company or any of its officers, directors, employees or Affiliates related to tax liabilities arising from the RSUs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You may request a copy of the Plan by contacting our General Counsel at (415) 506-6307 or BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, Attention&#58; General Counsel.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">You should carefully review the Plan and this Agreement before acknowledging this Award.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:125%">&#91;Remainder of the page intentionally left blank.&#93;</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i02f2c51bffb2472f879aca6728b14b59_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.35</font></div></div><div style="margin-bottom:9pt;margin-top:30pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By acknowledging this award of RSUs, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Committee or another third party designated by the Committee.</font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#91;NAME&#93;</font></div><div style="margin-bottom:30pt;padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  </font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Participant&#58;</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">             &#91;Signed Electronically&#93;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;NAME&#93;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgment Date&#58; </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>3
<FILENAME>exhibit10_36.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibdf57129551d4626b275a0dfccd32d75_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017 EQUITY INCENTIVE PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) hereby grants you a number of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) in the amount set forth below (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  The Award is subject to all of the terms and conditions set forth in this Restricted Stock Unit Award Agreement, including the exhibits, appendices and addenda attached hereto (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) and the Plan.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:31pt;text-decoration:underline">NOTICE OF AWARD OF RSUs</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Terms of the Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  You have been granted RSUs, each of which represents the right to receive one share of Common Stock of the Company (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), subject to the terms and conditions of the Plan and this Agreement, as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:27.58pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.301%"><tr><td style="width:1.0%"></td><td style="width:48.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Participant Name (&#8220;you&#8221;)&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total Number of RSUs Granted&#58;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;The RSUs will be adjusted in the event if changes in capital structure and similar events, as provided in Section 9 of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Vesting Schedule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  The RSUs will vest pursuant to the schedule set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, which is attached hereto and incorporated herein in its entirety. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Settlement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Subject to Section V, each RSU will be settled by delivery to you of one Share within thirty (30) days following vesting.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Termination of Continuous Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Unless otherwise provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, all unvested RSUs will be forfeited upon your termination of Continuous Service.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">MISCELLANEOUS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  You will not be deemed to be the holder of, or have any of the rights of a stockholder with respect to, the RSUs (including, without limitation, any voting rights or any right to dividends paid with respect to the Shares underlying the RSUs) unless and until the RSUs vest and the Company has issued and delivered Shares to you and your name has been entered as a stockholder into the books and records of the Company.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  In no event will the Company deliver Shares upon vesting and settlement of the RSUs unless the Shares are then registered under the Securities Act, and applicable state or non-U.S. securities law or, if not registered, the Committee has determined that the issuance of the Shares would be exempt from the registration requirements of the Securities Act and applicable state securities laws.  The issuance of Shares also must comply with all other applicable laws and regulations governing the RSUs, including the requirements of any stock exchange on which the Shares may be listed, and you may not be issued Shares if the Committee determines that such issuance would not be in material compliance with such laws, regulations and listing requirements.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Transferability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Except as permitted in the Plan, the RSUs are not transferable except by will or by the laws of descent and distribution.  Without limiting the generality of the foregoing, the RSUs may not be sold, assigned, transferred or otherwise disposed of, or pledged or hypothecated in any manner (whether by operation of law or otherwise), and shall not be subject to execution, attachment or other process.  Any assignment, transfer, sale, pledge, hypothecation or other disposition of the RSUs or any attempt to make any such levy of execution, attachment or other process will cause the RSUs to terminate immediately.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.51pt">Recovery of Compensation&#59; Insider Trading Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Agreement, the Shares issued on settlement of an RSU under this Agreement and all amounts that may be received by you in connection with any disposition of any such Shares shall be subject to applicable recoupment, &#8220;clawback&#8221; and similar provisions under applicable law, as well as the Company&#8217;s clawback policy in accordance with Section 8(l) of the Plan.  In addition, you may not be able to sell the Shares issued on settlement due to the restrictions of the Company&#8217;s insider trading policy.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to you at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23.51pt">Data Privacy Notice and Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, the Company and is Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and its Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Common Stock or directorships held in the Company, details of all RSUs or any other entitlement to shares of Common Stock awarded, canceled, vested, unvested or outstanding in your favor, for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  You understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in your country, or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Common Stock received upon vesting of the RSUs may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. You understand, however, that refusal or withdrawal of consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22pt">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. The interpretation, performance, and enforcement of this Agreement shall be governed by the internal laws of the State of Delaware without regard to that state&#8217;s conflict-of-laws rules.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Integration.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26pt;text-decoration:underline">MODIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">This Agreement may be modified or amended at any time in accordance with the Plan&#59; provided that you must consent in writing to any modification that adversely or materially affects your rights or obligations under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">NO RIGHT TO CONTINUOUS SERVICE </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neither the Company nor any of its Affiliates is obligated by or as a result of the Plan or this Agreement to continue your employment or other service with the Company or any Affiliate, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company and its Affiliates to terminate your Continuous Service at any time, subject to applicable law. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">ACKNOWLEDGMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In acknowledging the Award, you agree that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:28.03pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:26.04pt">the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of RSUs even if RSUs have been awarded repeatedly in the past&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:24.05pt">all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">your participation in the Plan is voluntary&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:25.52pt">the Award is outside the scope of your employment contract, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">the Award is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculation of any overtime, severance, resignation, termination, redundancy, end of service payments, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">bonuses, long-service awards, pension or retirement benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.54pt">in the event that you are not an Employee, the grant of the Award will not be interpreted to form an employment contract or relationship with the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:19.55pt">the future value of the underlying Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">if you receive the shares of Common Stock upon settlement of the RSUs, the value of such shares may increase or decrease in value&#59;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:25.52pt">in consideration of the grant of the Award, no claim or entitlement to compensation or damages arises from termination of the Award or diminution in value of the shares of Common Stock received upon vesting and settlement of the RSUs resulting from termination of your Continuous Service (for any reason whatsoever and whether or not in breach of local labor laws) and you irrevocably release the Company and its Affiliates from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, you shall be deemed irrevocably to have waived your entitlement to pursue such claim.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By executing this Agreement, you agree to be bound by all of the provisions of the Plan applicable to the Award, the provisions of which are hereby made a part of this Agreement and incorporated herein by reference, and all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  You hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan and this Agreement.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">NON-U.S. APPENDIX</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Notwithstanding any provisions in this Agreement, the grant of RSUs may be subject to the special terms and conditions set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%"> to this Agreement (including all addenda) for your country.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">, including its addenda, constitute part of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.5pt;text-decoration:underline">TAX WITHHOLDING&#59; TAX IMPLICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regardless of any action the Company or your employer (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Employer. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting, and settlement of the Award, the issuance of shares of Common Stock upon settlement of the Award, the subsequent sale of Common Stock acquired pursuant to such issuance and the receipt of any dividends and&#47;or any dividend equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, you will pay or make adequate arrangements satisfactory to the Committee (in the Committee&#8217;s sole discretion) to satisfy all withholding obligations. Unless the Committee expressly authorizes otherwise, you shall satisfy all tax withholding obligations arising in connection with the vesting of RSUs by automatically having withheld, effective as of each Vesting Date (as defined on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">), such number of shares of Common Stock underlying the RSUs that vest on such Vesting Date as have a Fair Market Value (calculated in accordance with the Plan) equal to the amount of the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.  The Company will withhold only the number of shares required to satisfy your obligations for Tax-Related Items at the statutory minimum (or such higher amount as is acceptable without adverse accounting consequences).  You are deemed to have been issued the full number of shares of Common Stock at vesting, notwithstanding that a number of the shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You shall pay to the Employer any amount of Tax-Related Items that the Employer may be required to withhold as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to issue or deliver the Shares, if you fail to comply with your obligations in connection with the Tax-Related Items. Further, in consideration of the grant of the Award, no claim or entitlement to compensation or damages arises if, in satisfying your (and&#47;or the Employer&#8217;s) obligation for Tax-Related Items, the Company and&#47;or the Employer withholds an amount in excess of the amount legally required to be withheld, you irrevocably release the Company and the Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, you shall be deemed irrevocably to have waived your entitlement to pursue such claim or damages.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee and the Company assume no responsibility for individual income taxes, penalties or interest related to grant, vesting or settlement of the RSUs.  Neither the Committee, the Company nor any Affiliate makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant, vesting or settlement of the RSUs.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">You should consult with your personal tax advisor regarding the tax ramifications, if any, which result from receipt of the RSUs, the subsequent issuance, if any, of Shares on vesting and settlement of the RSUs, and subsequent disposition of any such Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">It is the Board&#8217;s, the Committee&#8217;s and the Company&#8217;s intent that the RSUs and this Agreement be exempt from Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) to the extent applicable, and that this Agreement be administered accordingly.  Notwithstanding anything to the contrary, to the extent that any payment or benefit under this Agreement is determined by the Committee to constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and is payable to you by reason of termination of your Continuous Service, then (a) such payment or benefit shall be made or provided to you only upon a &#8220;separation from service,&#8221; as defined for purposes of Section 409A under applicable regulations, from the Company and (b) if you are a &#8220;specified employee&#8221; (within the meaning of Section 409A and as determined by the Committee), such payment or benefit shall not be made or provided to you until first day of the seventh month following the date of your separation from service from the Company and its Affiliates (or, if earlier, on the date of your death).  Each payment under this Agreement shall be treated as a separate payment under Section 409A.  You hereby agree that the Committee and the Company do not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities.  You will not make any claim against the Board, the Committee and the Company or any of its officers, directors, employees or Affiliates related to tax liabilities arising from the RSUs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You may request a copy of the Plan by contacting our General Counsel at (415) 506-6307 or BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, Attention&#58; General Counsel.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">You should carefully review the Plan and this Agreement before acknowledging this Award.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:125%">&#91;Remainder of the page intentionally left blank.&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="ibdf57129551d4626b275a0dfccd32d75_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-bottom:9pt;margin-top:30pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By acknowledging this award of RSUs, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Committee or another third party designated by the Committee.</font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#91;NAME&#93;</font></div><div style="margin-bottom:30pt;padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  </font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Participant&#58;</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">             &#91;Signed Electronically&#93;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;NAME&#93;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgment Date&#58; </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>exhibit10_37.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idda672890450472ea6d5071477b90f5d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">STOCK OPTION AWARD AGREEMENT</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) hereby grants you an option to purchase the number of shares of Common Stock in the amount set forth below (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  The Option is subject to all of the terms and conditions set forth in this Stock Option Award Agreement, including the exhibits, appendices and addenda attached hereto (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) and the Plan.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:31pt;text-decoration:underline">NOTICE OF STOCK OPTION GRANT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt">Terms of the Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  You have been granted an Option to purchase shares of Common Stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Option Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), subject to the terms and conditions of the Plan and this Agreement, as follows&#58;</font></div><div style="margin-bottom:0.08pt;padding-left:67.69pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"><tr><td style="width:1.0%"></td><td style="width:45.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Participant Name (&#8220;you&#8221;)&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Exercise Price per Share&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total Number of Shares Granted&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Type of Option&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Nonstatutory Stock Option</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Term&#47;Expiration Date&#58;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">10 years after the Grant Date</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Options will be adjusted in the event if changes in capital structure and similar events, as provided in Section 9 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt">Vesting Schedule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  The Option will vest pursuant to the schedule set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, which is attached hereto and incorporated herein in its entirety. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Termination of Continuous Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Unless otherwise provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, all unvested Option Shares will be forfeited upon your termination of Continuous Service.  Unless otherwise provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, any vested Option Shares may be exercisable following the termination of Continuous Service until the earliest of the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:19.03pt">three months following the termination of your Continuous Service other than for Cause, due to your death or Disability or after attaining Retirement Eligibility Status&#59;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:17.04pt">the Expiration Date set forth above following a termination of Continuous Service after attaining Retirement Eligibility Status.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement Eligibility Status</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221; shall mean that you (a) have the Company title of Vice President or a title more senior than Vice President&#59; and (b) have a combined age and years of Continuous Service equal to or more than 65 years&#59;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:15.05pt">12 months following a termination of Continuous Service as a result of your Disability&#59;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.53pt">12 months following the date of your death&#59;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:16.52pt">immediately upon a termination of Continuous Service for Cause&#59; or </font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.53pt">the Expiration Date set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If, after your termination of Continuous Service, you do not exercise the Option within the applicable time frame above, the Option will terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Exercise.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You may exercise the vested portion of the Option prior to the Expiration Date by (i) delivering a notice of exercise (in a form designated by the Committee) or completing such other documents and&#47;or procedures designated by the Committee for exercise and (ii) paying the Exercise Price and any applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">withholding taxes to the Company, stock plan administrator, or such other person as the Committee may designate, together with such additional documents as the Committee may then require.   To the extent permitted by applicable law and as determined by the Committee in its sole discretion, as set forth in a notice of exercise designated by the Committee, the Exercise Price may be paid (A) by cash, check, bank draft or money order payable to the Company&#59; (B) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate Exercise Price to the Company from the sales proceeds&#59; (C) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock&#59; or (D) by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate Exercise Price, provided that the Company will accept a cash or other payment from you to the extent of any remaining balance of the aggregate Exercise Price not satisfied by such reduction in the number of whole shares to be issued.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You may exercise the Option only for whole shares of Common Stock. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt">Stockholder Rights.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  You will not be deemed to be the holder of, or have any of the rights of a stockholder with respect to, the Option (including, without limitation, any voting rights or any right to dividends paid with respect to the Option Shares) unless and until the Option vests and you exercise the Option in accordance with this Agreement and the Company has issued and delivered Common Stock to you and your name has been entered as a stockholder into the books and records of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt">Securities Law Compliance.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  In no event may you exercise the Option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act, and applicable state securities law or, if not registered, the Committee has determined that the exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act and applicable state or non-U.S. securities laws.  The exercise of the Option also must comply with all other applicable laws and regulations governing the Option, including the requirements of any stock exchange on which the Stock may be listed, and you may not exercise your option if the Committee determines that such exercise would not be in material compliance with such laws, regulations and listing requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Transferability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Except as permitted in the Plan, the Option is not be transferable except by will or by the laws of descent and distribution, and is exercisable during your life only by you.  Without limiting the generality of the foregoing, the Option may not be sold, assigned, transferred or otherwise disposed of, or pledged or hypothecated in any manner (whether by operation of law or otherwise), and shall not be subject to execution, attachment or other process.  Any assignment, transfer, sale, pledge, hypothecation or other disposition of the Option or any attempt to make any such levy of execution, attachment or other process will cause the Option to terminate immediately.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Recovery of Compensation&#59; Insider Trading Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Agreement, the Common Stock issued under this Agreement and all amounts that may be received by you in connection with any disposition of any such Common Stock shall be subject to applicable recoupment, &#8220;clawback&#8221; and similar provisions under applicable law, as well as the Company&#8217;s clawback policy in accordance with Section 8(l) of the Plan.  In addition, you may not be able to sell the shares of Common Stock issued on exercise due to the restrictions of the Company&#8217;s insider trading policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to you at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:28.01pt">Data Privacy Notice and Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, the Company and is Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.  You understand that the Company and its Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Common Stock or directorships held in the Company, details of all Options or any other entitlement to shares of Common Stock awarded, canceled, vested, unvested or outstanding in your favor, for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).  You understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in your country, or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Common Stock received upon exercise of the Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">herein, in any case without cost, by contacting in writing your local human resources representative. You understand, however, that refusal or withdrawal of consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26.5pt">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. The interpretation, performance, and enforcement of this Agreement shall be governed by the internal laws of the State of Delaware without regard to that state&#8217;s conflict-of-laws rules.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.01pt">Integration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. This Agreement constitutes the entire agreement between the parties with respect to this Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26pt;text-decoration:underline">MODIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Agreement may be modified or amended at any time in accordance with the Plan&#59; provided that you must consent in writing to any modification that adversely or materially affects your rights or obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">NO RIGHT TO CONTINUOUS SERVICE </font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Neither the Company nor any of its Affiliates is obligated by or as a result of the Plan or this Agreement to continue your employment or other service with the Company or any Affiliate, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company and its Affiliates to terminate your Continuous Service at any time, subject to applicable law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">ACKNOWLEDGMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In acknowledging the Option, you agree that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:28.03pt">the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:26.04pt">the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of options even if options have been awarded repeatedly in the past&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:24.05pt">all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">your participation in the Plan is voluntary&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:25.52pt">the Option is outside the scope of your employment contract, if any&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">the Option is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculation of any overtime, severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.54pt">in the event that you are not an Employee, the grant of the Option will not be interpreted to form an employment contract or relationship with the Company or its Affiliates&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:19.55pt">the future value of the underlying Option Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.53pt">if you receive the shares of Common Stock upon exercise of the Option, the value of such shares may increase or decrease in value&#59;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:25.52pt">in consideration of the grant of the Option, no claim or entitlement to compensation or damages arises from termination of the Option or diminution in value of the Option shares of Common Stock received upon exercise of the Option resulting from termination of your Continuous Service (for any reason whatsoever and whether or not in breach of local labor laws) and you irrevocably release the Company and its Affiliates from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, you shall be deemed irrevocably to have waived your entitlement to pursue such claim.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By executing this Agreement, you agree to be bound by all of the provisions of the Plan applicable to the Option, the provisions of which are hereby made a part of this Agreement and incorporated herein by reference, and all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  You hereby agree to accept as binding, conclusive and final all decisions or interpretations of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Committee upon any questions relating to the Plan and this Agreement.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25pt;text-decoration:underline">NON-U.S. APPENDIX</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Notwithstanding any provisions in this Agreement, the grant of the Option may be subject to the special terms and conditions set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%"> to this Agreement (including all addenda) for your country.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">, including its addenda, constitute part of this Agreement.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.5pt;text-decoration:underline">TAX WITHHOLDING&#59; TAX IMPLICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regardless of any action the Company or your employer (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Employer. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting, and exercise of the Option, the issuance of shares of Common Stock upon exercise of the Option, the subsequent sale of Common Stock acquired pursuant to such issuance and the receipt of any dividends and&#47;or any dividend equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, you will pay or make adequate arrangements satisfactory to the Committee (in the Committee&#8217;s sole discretion) to satisfy all withholding obligations. In this regard, in those cases where no such prior arrangement has been made (or where the amount of money provided is insufficient to satisfy the applicable obligations) you authorize the Company and&#47;or the Employer, in their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you&#59; (ii) withholding from proceeds of the sale of shares of Common Stock acquired upon exercise of the Option through a sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon exercise of the Option. If your obligation is satisfied as described in (ii), the Company will endeavor to only sell only the number of shares required to satisfy your obligations for Tax-Related Items&#59; however, you agree that the Company may sell more shares than necessary to cover the Tax-Related Item, and that in such event, the Company will reimburse you for the excess amount withheld, in cash and without interest.  If your obligations are satisfied as described in (iii), the Company shall withhold a number of shares otherwise deliverable at exercise having a Fair Market Value sufficient to satisfy the statutory minimum (or such higher amount as is acceptable without adverse accounting consequences) of your estimated tax obligations. You are deemed to have been issued the full number of shares of Common Stock subject to the exercise, notwithstanding that a number of the shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You shall pay to the Employer any amount of Tax-Related Items that the Employer may be required to withhold as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the shares or the proceeds of the sale of shares, if you fail to comply with your obligations in connection with the Tax-Related Items. Further, in consideration of the grant of the Option, no claim or entitlement to compensation or damages arises if, in satisfying your (and&#47;or the Employer&#8217;s) obligation for Tax-Related Items, the Company and&#47;or the Employer withholds an amount in excess of the amount legally required to be withheld, you irrevocably release the Company and the Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, you shall be deemed irrevocably to have waived your entitlement to pursue such claim or damages.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee and the Company assume no responsibility for individual income taxes, penalties or interest related to grant or exercise of the Option.  Neither the Committee, the Company nor any Affiliate makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or exercise of the Option.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">You should consult with your personal tax advisor regarding the tax ramifications, if any, which result from receipt of the Option, the subsequent issuance, if any, of Common Stock on exercise of the Option, and subsequent disposition of any such Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">It is the Board&#8217;s, the Committee&#8217;s and the Company&#8217;s intent that the Option and this Agreement be exempt from Section 409A of the Code to the extent applicable, and that this Agreement be administered accordingly.  You hereby agree that the Committee and the Company do not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities.  You will not make any claim against the Board, the Committee and the Company or any of its officers, directors, employees or Affiliates related to tax liabilities arising from the Option.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You may request a copy of the Plan by contacting our General Counsel at (415) 506-6307 or BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, Attention&#58; General Counsel.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">You should carefully review the Plan and this Agreement before acknowledging this Option.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#91;Remainder of the page intentionally left blank.&#93;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="idda672890450472ea6d5071477b90f5d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit 10.37</font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">By acknowledging the Option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Committee or another third party designated by the Committee.</font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#91;NAME&#93;</font></div><div style="margin-bottom:30pt;padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  </font></div><div style="margin-bottom:3pt;margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Participant&#58;</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">             &#91;Signed Electronically&#93;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;NAME&#93;</font></div><div style="padding-left:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgement Date&#58; </font></div><div style="padding-left:2.9pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>bmrn-2022xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0bd80a5d105a43238a84a76ce7430d9b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subsidiaries of BioMarin Pharmaceutical Inc. as of December&#160;31, 2022</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Direct Parent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ownership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Commercial Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin International Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Commercial Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>bmrn-20221231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5db6c62bbbd84a29babb353f7ddd3073_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (No. 333-136963, 333-168552, 333-181697, 333-188620, 333-197759, 333-201504, 333-206094, 333-218695, 333-234231, 333-262824) on Form S-8 and in the registration statement (No. 333-212974) on Form S-3 of our reports dated February&#160;27, 2023, with respect to the consolidated financial statements of BioMarin Pharmaceutical Inc. and the effectiveness of internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">San Francisco, California</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;27, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>bmrn-20221231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7f5014f69fc3421ea6423839c00d5eef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Jean-Jacques Bienaim&#233;, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of BioMarin Pharmaceutical Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.51pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; February 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;S&#47; JEAN-JACQUES BIENAIM&#201;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jean-Jacques Bienaim&#233;<br>Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>bmrn-20221231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i745862c73a3d4da18e4ce8d9d87d83d3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Brian R. Mueller certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of BioMarin Pharmaceutical Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.51pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:47.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; February 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;S&#47; BRIAN R. MUELLER</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian R. Mueller<br>Executive Vice President, Finance &#38;<br>Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>bmrn-20221231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iadc78fc729e346059644a1907dc3f2d3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of BioMarin Pharmaceutical Inc. (the Company) for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Jean-Jacques Bienaim&#233;, and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:34.02pt">the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:34.02pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.536%"><tr><td style="width:1.0%"></td><td style="width:48.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#47;S&#47; JEAN-JACQUES BIENAIM&#201;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Jean-Jacques Bienaim&#233;<br>&#160;Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Date&#58; February&#160;27, 2023</font></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.536%"><tr><td style="width:1.0%"></td><td style="width:48.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;S&#47; BRIAN R. MUELLER</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian R. Mueller<br>Executive Vice President, Finance &#38;<br>Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Date&#58; February&#160;27, 2023</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bmrn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.bmrn.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bmrn.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.bmrn.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.bmrn.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTS">
        <link:definition>0000011 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETS" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETS">
        <link:definition>0000012 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT">
        <link:definition>0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://www.bmrn.com/role/INVENTORY">
        <link:definition>0000014 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETINFORMATION" roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION">
        <link:definition>0000015 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000016 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES">
        <link:definition>0000017 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bmrn.com/role/LEASES">
        <link:definition>0000018 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.bmrn.com/role/DEBT">
        <link:definition>0000019 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION">
        <link:definition>0000021 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION">
        <link:definition>0000022 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREMPLOYEEBENEFITS" roleURI="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS">
        <link:definition>0000023 - Disclosure - OTHER EMPLOYEE BENEFITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bmrn.com/role/INCOMETAXES">
        <link:definition>0000024 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERCOMMONSHARE" roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE">
        <link:definition>0000025 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDCOLLABORATIONAGREEMENTS" roleURI="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS">
        <link:definition>0000026 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000028 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000029 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>0000030 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSTables" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSTables">
        <link:definition>0000031 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://www.bmrn.com/role/INVENTORYTables">
        <link:definition>0000033 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETINFORMATIONTables" roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables">
        <link:definition>0000034 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables">
        <link:definition>0000036 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.bmrn.com/role/LeasesTables">
        <link:definition>0000037 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.bmrn.com/role/DEBTTables">
        <link:definition>0000038 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables">
        <link:definition>0000039 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables">
        <link:definition>0000040 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables">
        <link:definition>0000041 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.bmrn.com/role/INCOMETAXESTables">
        <link:definition>0000042 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERCOMMONSHARETables" roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables">
        <link:definition>0000043 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>0000044 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000045 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
        <link:definition>0000046 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails">
        <link:definition>0000047 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails">
        <link:definition>0000048 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails">
        <link:definition>0000049 - Disclosure - INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails">
        <link:definition>0000050 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails">
        <link:definition>0000052 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTNarrativeDetails" roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails">
        <link:definition>0000053 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYScheduleofInventoryDetails" roleURI="http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails">
        <link:definition>0000054 - Disclosure - INVENTORY - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails" roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails">
        <link:definition>0000056 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails" roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails">
        <link:definition>0000057 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>0000058 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails">
        <link:definition>0000059 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails">
        <link:definition>0000060 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails">
        <link:definition>0000061 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails">
        <link:definition>0000062 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails">
        <link:definition>0000063 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails" roleURI="http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails">
        <link:definition>0000064 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000065 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000065 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2" roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2">
        <link:definition>0000065 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofLeaseCostDetails" roleURI="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails">
        <link:definition>0000066 - Disclosure - LEASES - Schedule of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOtherInformationDetails" roleURI="http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails">
        <link:definition>0000067 - Disclosure - LEASES - Schedule of Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofSupplementalCashFlowInformationDetails" roleURI="http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>0000068 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/DEBTAdditionalInformationDetails">
        <link:definition>0000069 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" roleURI="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails">
        <link:definition>0000070 - Disclosure - DEBT - Schedule of Senior Subordinated Convertible Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofInterestExpenseonDebtDetails" roleURI="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails">
        <link:definition>0000071 - Disclosure - DEBT - Schedule of Interest Expense on Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails">
        <link:definition>0000072 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails">
        <link:definition>0000073 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails">
        <link:definition>0000074 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails">
        <link:definition>0000075 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails">
        <link:definition>0000076 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails">
        <link:definition>0000077 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails">
        <link:definition>0000078 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>0000079 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails">
        <link:definition>0000080 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails">
        <link:definition>0000081 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>0000082 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
        <link:definition>0000083 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails" roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails">
        <link:definition>0000084 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREMPLOYEEBENEFITSAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails">
        <link:definition>0000085 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>0000086 - Disclosure - INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails">
        <link:definition>0000087 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>0000088 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000089 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails">
        <link:definition>0000090 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails">
        <link:definition>0000091 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000092 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails">
        <link:definition>0000093 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>0000094 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDCOLLABORATIONAGREEMENTSDetails" roleURI="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails">
        <link:definition>0000095 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bmrn_ScheduleOfInterestExpensesLineItems" abstract="true" name="ScheduleOfInterestExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ProductTwoMember" abstract="true" name="ProductTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_SpanOfOfferingPeriod" abstract="false" name="SpanOfOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_AAndRKuvanAgreementMember" abstract="true" name="AAndRKuvanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bmrn_AverageClosingPriceTrailingPeriod" abstract="false" name="AverageClosingPriceTrailingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_IncomeTaxStatuteOfLimitationsPeriod" abstract="false" name="IncomeTaxStatuteOfLimitationsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" abstract="false" name="RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_StrategicInvestmentMember" abstract="true" name="StrategicInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" abstract="true" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ProductFourMember" abstract="true" name="ProductFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseRightOfUseAsset" abstract="false" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" abstract="false" name="DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RoyaltyRateLowerLimit" abstract="false" name="RoyaltyRateLowerLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" abstract="false" name="EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductOneMember" abstract="true" name="ProductOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" abstract="true" name="TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" abstract="true" name="NonqualifiedDeferredCompensationPlanAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherAssetsNoncurrentFairValueDisclosure" abstract="false" name="OtherAssetsNoncurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" abstract="true" name="ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" abstract="false" name="SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_NumberOfTranchesInOfferingPeriod" abstract="false" name="NumberOfTranchesInOfferingPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_LicensePaymentsMember" abstract="true" name="LicensePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossOtherNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_CustomerOneTwoAndThreeMember" abstract="true" name="CustomerOneTwoAndThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" abstract="true" name="ShareBasedPaymentAwardCoreOperatingMarginTargetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_MaximumPayrollDeductions" abstract="false" name="MaximumPayrollDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RoyaltyAndOtherMember" abstract="true" name="RoyaltyAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" abstract="true" name="TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_IncomeTaxRateReconciliationTaxReserves" abstract="false" name="IncomeTaxRateReconciliationTaxReserves" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductFiveMember" abstract="true" name="ProductFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndGeographicInformationLineItems" abstract="true" name="ConcentrationRiskAndGeographicInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_A2022RestructuringPlanMember" abstract="true" name="A2022RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_LeasesLiabilitiesAbstract" abstract="true" name="LeasesLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_TechnologyTransferMember" abstract="true" name="TechnologyTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bmrn_ContingentPaymentMember" abstract="true" name="ContingentPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" abstract="false" name="ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RoyaltyRateUpperLimit" abstract="false" name="RoyaltyRateUpperLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_EarlyStageDevelopmentProgramTwoMember" abstract="true" name="EarlyStageDevelopmentProgramTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_IndependentDirectorMember" abstract="true" name="IndependentDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_AcquiredIntellectualPropertyMember" abstract="true" name="AcquiredIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" abstract="false" name="PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_BiomarinRetirementSavingsPlanMember" abstract="true" name="BiomarinRetirementSavingsPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SupplementalBalanceSheetInformationTable" abstract="true" name="SupplementalBalanceSheetInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_MaturityOfLeaseLiabilitiesAbstract" abstract="true" name="MaturityOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" abstract="true" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CustomersMember" abstract="true" name="CustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProductThreeMember" abstract="true" name="ProductThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" abstract="false" name="ConcentrationRiskAndSegmentReportingDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_ProductEightMember" abstract="true" name="ProductEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" abstract="true" name="RestrictedStockWithServiceBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" abstract="false" name="SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_SupplementalCashFlowLeaseInformationAbstract" abstract="true" name="SupplementalCashFlowLeaseInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndGeographicInformationTable" abstract="true" name="ConcentrationRiskAndGeographicInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_LeaseRightOfUseAssetsAbstract" abstract="true" name="LeaseRightOfUseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_AccumulatedGainLossFromOtherMember" abstract="true" name="AccumulatedGainLossFromOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_PaymentReceivedAsPercentageOfNetProductSales" abstract="false" name="PaymentReceivedAsPercentageOfNetProductSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_FirdapseMember" abstract="true" name="FirdapseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_PegvaliaseAgreementMember" abstract="true" name="PegvaliaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" abstract="false" name="OtherLiabilitiesNoncurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_LongTermMarketableSecuritiesMaturityPeriod" abstract="false" name="LongTermMarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_EarlyStageDevelopmentProgramOneMember" abstract="true" name="EarlyStageDevelopmentProgramOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ShortTermMarketableSecuritiesMaturityPeriod" abstract="false" name="ShortTermMarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" abstract="false" name="SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" abstract="false" name="ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_AllowancesForReserveForCashDiscountsMember" abstract="true" name="AllowancesForReserveForCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_IntangibleAssetAmortizationAndContingentConsideration" abstract="false" name="IntangibleAssetAmortizationAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RestrictedInvestmentsMember" abstract="true" name="RestrictedInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" abstract="false" name="ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" abstract="false" name="ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_ProductsExcludingProductOneMember" abstract="true" name="ProductsExcludingProductOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ScheduleOfInterestExpensesTable" abstract="true" name="ScheduleOfInterestExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" abstract="true" name="A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SupplementalBalanceSheetInformationLineItems" abstract="true" name="SupplementalBalanceSheetInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_MerckSeronoMember" abstract="true" name="MerckSeronoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_IncomeTaxRateReconciliationSection162Limitation" abstract="false" name="IncomeTaxRateReconciliationSection162Limitation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductSixMember" abstract="true" name="ProductSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" abstract="false" name="ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" abstract="true" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" abstract="true" name="ExclusiveLicensingAgreementForTralesinidaseAlfaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" abstract="false" name="CollaborativeArrangementMinorityEquityInvestmentInLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" abstract="true" name="CommonStockIssuableUnderTheConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" abstract="false" name="OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_RepurchasedRoyaltyRightsMember" abstract="true" name="RepurchasedRoyaltyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" abstract="false" name="SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" abstract="false" name="OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherLiabilitiesCurrentFairValueDisclosure" abstract="false" name="OtherLiabilitiesCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_OtherInformationLeaseLiabilityAbstract" abstract="true" name="OtherInformationLeaseLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" abstract="true" name="OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" abstract="false" name="AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_ProductSevenMember" abstract="true" name="ProductSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ThirdPartyMember" abstract="true" name="ThirdPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_AccruedRebatesMember" abstract="true" name="AccruedRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_DebtInstrumentPercentageOfFaceValue" abstract="false" name="DebtInstrumentPercentageOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" abstract="true" name="ShareBasedPaymentAwardStrategicGoalTargetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" abstract="true" name="TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" abstract="true" name="SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" abstract="true" name="NonqualifiedDeferredCompensationPlanLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" abstract="true" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" abstract="true" name="ShareBasedPaymentAwardNonGAAPIncomeTargetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProceedsFromSaleOfNonfinancialAssets" abstract="false" name="ProceedsFromSaleOfNonfinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" abstract="true" name="ForeignGovernmentAndOtherDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bmrn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cca2ead2-b1cf-4b0f-8f47-8e99cd43238c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:to="loc_us-gaap_CommonStockValue_cca2ead2-b1cf-4b0f-8f47-8e99cd43238c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2afe9e31-5501-4051-91aa-abc19e695643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2afe9e31-5501-4051-91aa-abc19e695643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_83a06378-7f7b-4025-bb2b-63ca8b46dda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:to="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_83a06378-7f7b-4025-bb2b-63ca8b46dda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebadaebd-fb89-49e1-858e-be63b8a09b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebadaebd-fb89-49e1-858e-be63b8a09b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33082d51-1940-4725-bc85-393c0088ba35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ba51343-a77b-46b9-b7f9-dea320828a2b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33082d51-1940-4725-bc85-393c0088ba35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b4eff40-1873-47be-a059-b326f9b2a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8f46b6f6-b9df-4a94-b365-016046ba4e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b4eff40-1873-47be-a059-b326f9b2a31d" xlink:to="loc_us-gaap_Liabilities_8f46b6f6-b9df-4a94-b365-016046ba4e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf71bee7-7f9d-405c-ab74-a5e16f9f1c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b4eff40-1873-47be-a059-b326f9b2a31d" xlink:to="loc_us-gaap_StockholdersEquity_bf71bee7-7f9d-405c-ab74-a5e16f9f1c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3bc3a106-b233-49f1-9877-e324c8b8597a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_AssetsCurrent_3bc3a106-b233-49f1-9877-e324c8b8597a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65b87ffc-cd3c-4157-a482-ab58098d6607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65b87ffc-cd3c-4157-a482-ab58098d6607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a6de0c47-d27d-4759-b8b7-32be569a15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a6de0c47-d27d-4759-b8b7-32be569a15e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_28b1ebd5-0245-4f5d-bfa4-351463f34e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_28b1ebd5-0245-4f5d-bfa4-351463f34e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_58e101e1-e33b-4f88-ba56-20e290a3cc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_Goodwill_58e101e1-e33b-4f88-ba56-20e290a3cc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75adafcb-6844-474f-aca8-8e9f0cc5a538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75adafcb-6844-474f-aca8-8e9f0cc5a538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_75cfbb79-8afb-4424-a4f3-924ec1d3cbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4bb53703-934a-4150-89a9-f55275ad8083" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_75cfbb79-8afb-4424-a4f3-924ec1d3cbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4a6bac1f-6d21-409d-b583-8d3c58dc53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_54980b80-35a0-45b1-9550-601d0e8c453f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a6bac1f-6d21-409d-b583-8d3c58dc53a0" xlink:to="loc_us-gaap_LiabilitiesCurrent_54980b80-35a0-45b1-9550-601d0e8c453f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_5f30ef27-d45a-4daf-bf96-70ab27d68c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a6bac1f-6d21-409d-b583-8d3c58dc53a0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_5f30ef27-d45a-4daf-bf96-70ab27d68c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2fbadb5e-975e-4163-90d7-05fc5ee116d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a6bac1f-6d21-409d-b583-8d3c58dc53a0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2fbadb5e-975e-4163-90d7-05fc5ee116d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_444bf19a-44d7-42ed-913e-b513dd836e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a6bac1f-6d21-409d-b583-8d3c58dc53a0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_444bf19a-44d7-42ed-913e-b513dd836e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_12991447-a927-4e16-b20c-6459afa3cec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ece50942-54d8-490c-9cb5-d6adf20a1320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12991447-a927-4e16-b20c-6459afa3cec2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ece50942-54d8-490c-9cb5-d6adf20a1320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fc4059ed-78d6-4f40-9d1c-216a1576e14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12991447-a927-4e16-b20c-6459afa3cec2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fc4059ed-78d6-4f40-9d1c-216a1576e14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5367d8bf-9bb4-4a7b-8aa8-842fa228397d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5367d8bf-9bb4-4a7b-8aa8-842fa228397d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b165490c-32d9-4c3b-b6a1-2176ad808eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b165490c-32d9-4c3b-b6a1-2176ad808eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bc9ea076-fd54-4c4a-be64-15a3f9c34234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bc9ea076-fd54-4c4a-be64-15a3f9c34234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1321e737-0c4f-4467-a344-f2a4f6bf126a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:to="loc_us-gaap_InventoryNet_1321e737-0c4f-4467-a344-f2a4f6bf126a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6d85334e-9d1c-400b-854a-61483a11dd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f15b1a3-e5b8-4e88-9848-3c957b96e810" xlink:to="loc_us-gaap_OtherAssetsCurrent_6d85334e-9d1c-400b-854a-61483a11dd5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a48f28e6-7269-4f09-aa8b-7643477c1115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_63289778-580e-4144-be79-846b22617851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a48f28e6-7269-4f09-aa8b-7643477c1115" xlink:to="loc_us-gaap_OperatingIncomeLoss_63289778-580e-4144-be79-846b22617851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0508e611-f37a-42f2-a2ba-5472c96ca4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a48f28e6-7269-4f09-aa8b-7643477c1115" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0508e611-f37a-42f2-a2ba-5472c96ca4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4c54ac92-e749-44a0-a9a2-9a110bb112a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a48f28e6-7269-4f09-aa8b-7643477c1115" xlink:to="loc_us-gaap_InterestExpense_4c54ac92-e749-44a0-a9a2-9a110bb112a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_c99059ef-2108-4f11-930b-a626a234823f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a48f28e6-7269-4f09-aa8b-7643477c1115" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_c99059ef-2108-4f11-930b-a626a234823f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_5b2106ae-665d-4cec-a9fb-1d0dfe3aa4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:to="loc_us-gaap_CostOfRevenue_5b2106ae-665d-4cec-a9fb-1d0dfe3aa4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3620aa73-d630-4732-8d20-00892490f2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3620aa73-d630-4732-8d20-00892490f2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7359e4f3-cd22-42c4-b82b-ddb61e143469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7359e4f3-cd22-42c4-b82b-ddb61e143469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_8d4ace75-9196-433d-ae9d-cf728632929c" xlink:href="bmrn-20221231.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_8d4ace75-9196-433d-ae9d-cf728632929c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6e2e8b66-8d55-4305-a69b-713849c5363b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97ceb31d-4018-4135-9322-137fa2dac371" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6e2e8b66-8d55-4305-a69b-713849c5363b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bd181088-fe42-41f2-817d-2029e353e0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ebc5252-96ac-48c2-b3f7-10ad1af3d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bd181088-fe42-41f2-817d-2029e353e0fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ebc5252-96ac-48c2-b3f7-10ad1af3d58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d9abee10-210c-43bc-ab27-62c767aaf952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bd181088-fe42-41f2-817d-2029e353e0fc" xlink:to="loc_us-gaap_CostsAndExpenses_d9abee10-210c-43bc-ab27-62c767aaf952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7092f55c-ea6a-445e-ba5b-ae6941f8d0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e70ec5ae-0209-4063-8791-2e8fe3353095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7092f55c-ea6a-445e-ba5b-ae6941f8d0fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e70ec5ae-0209-4063-8791-2e8fe3353095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_512d01fc-c77e-4eea-a6d9-5891ec7ba3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7092f55c-ea6a-445e-ba5b-ae6941f8d0fe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_512d01fc-c77e-4eea-a6d9-5891ec7ba3d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_15fb1203-1520-4a84-a668-055be41f5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_79e1f8fa-5553-40cb-828f-6702c0f158ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_15fb1203-1520-4a84-a668-055be41f5d87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_79e1f8fa-5553-40cb-828f-6702c0f158ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7913bd17-d2eb-4f28-b5eb-eb5d67f9e3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_15fb1203-1520-4a84-a668-055be41f5d87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7913bd17-d2eb-4f28-b5eb-eb5d67f9e3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d0e0d2f3-2e93-4858-99f6-7563da6efbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_053741a6-5dcf-451a-8840-48dca3bbf57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d0e0d2f3-2e93-4858-99f6-7563da6efbc2" xlink:to="loc_us-gaap_NetIncomeLoss_053741a6-5dcf-451a-8840-48dca3bbf57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1790991f-ee63-4771-a8d4-ee9413284746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d0e0d2f3-2e93-4858-99f6-7563da6efbc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1790991f-ee63-4771-a8d4-ee9413284746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd844774-9be2-4118-a05a-53448553928c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7bdd7af4-2398-4cc8-a577-5e479b32eb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd844774-9be2-4118-a05a-53448553928c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7bdd7af4-2398-4cc8-a577-5e479b32eb64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_833025cf-563b-4ae4-8965-cf78c33c472e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd844774-9be2-4118-a05a-53448553928c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_833025cf-563b-4ae4-8965-cf78c33c472e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_a5f39b2c-c195-456c-9b30-587a13804023" xlink:href="bmrn-20221231.xsd#bmrn_OtherComprehensiveIncomeLossOtherNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd844774-9be2-4118-a05a-53448553928c" xlink:to="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_a5f39b2c-c195-456c-9b30-587a13804023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_402209f2-c20b-44c6-a002-dbfe3f9c6229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0ee37cad-6ea9-4d1f-93dc-f1605daa14fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_402209f2-c20b-44c6-a002-dbfe3f9c6229" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0ee37cad-6ea9-4d1f-93dc-f1605daa14fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_022b296c-d709-47ef-8a40-29dc0a627b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_402209f2-c20b-44c6-a002-dbfe3f9c6229" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_022b296c-d709-47ef-8a40-29dc0a627b66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ae473fc-50a1-4dda-b985-a8b32b0d9a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_NetIncomeLoss_3ae473fc-50a1-4dda-b985-a8b32b0d9a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_52a97456-1be9-4766-a124-b2727893c9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_52a97456-1be9-4766-a124-b2727893c9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_877d6dd4-bcd7-4ee9-9d7a-187ebd6c246b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_877d6dd4-bcd7-4ee9-9d7a-187ebd6c246b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4d4209dc-4d3c-4df9-8cea-2da2c688ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4d4209dc-4d3c-4df9-8cea-2da2c688ac43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_81f26c80-8288-4909-a167-070dd69fcc79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_ShareBasedCompensation_81f26c80-8288-4909-a167-070dd69fcc79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_4a7d404d-eae0-46a2-9f6c-d5be26f966e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_4a7d404d-eae0-46a2-9f6c-d5be26f966e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_39340929-59db-4c1c-9d3f-98084b4afebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_39340929-59db-4c1c-9d3f-98084b4afebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f6be6252-7f76-43d8-8eda-080a726dd1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f6be6252-7f76-43d8-8eda-080a726dd1ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35b0baee-8e16-44a1-9198-375aafa8b407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35b0baee-8e16-44a1-9198-375aafa8b407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_191ea6b2-4d2b-4c77-8309-ca2060398cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_191ea6b2-4d2b-4c77-8309-ca2060398cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bca5fef3-b9bb-4ea3-88cc-7c064498d576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bca5fef3-b9bb-4ea3-88cc-7c064498d576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_35e54996-8c60-4557-94b3-8bab32759018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_35e54996-8c60-4557-94b3-8bab32759018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_fc165050-4ae7-410d-b289-444514313341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_fc165050-4ae7-410d-b289-444514313341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d37de926-6785-48b1-849d-807673ca0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d37de926-6785-48b1-849d-807673ca0a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_198c627d-a5cd-4497-aadb-df7adb7e257c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_198c627d-a5cd-4497-aadb-df7adb7e257c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4f7d659f-1c2d-424b-9a15-5c506151e2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4f7d659f-1c2d-424b-9a15-5c506151e2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b34b5645-da4b-4c0e-8024-d9efec8ffd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9160d6-514f-4323-8af3-5c11e76dc989" xlink:to="loc_us-gaap_InventoryWriteDown_b34b5645-da4b-4c0e-8024-d9efec8ffd49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce7d017e-7d76-45f5-ae6c-97519828d15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_487abb30-465c-43c9-99c8-2705b7bd97c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce7d017e-7d76-45f5-ae6c-97519828d15e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_487abb30-465c-43c9-99c8-2705b7bd97c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a20db0fe-b785-4fcd-a317-abccc887b244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce7d017e-7d76-45f5-ae6c-97519828d15e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a20db0fe-b785-4fcd-a317-abccc887b244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d85db33-c509-4f9c-a222-72f3ad7f3937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce7d017e-7d76-45f5-ae6c-97519828d15e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d85db33-c509-4f9c-a222-72f3ad7f3937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3e723b77-9211-4bdd-9c92-cf2a7936d435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce7d017e-7d76-45f5-ae6c-97519828d15e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3e723b77-9211-4bdd-9c92-cf2a7936d435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9df44b01-8f94-4927-a721-bce0cbbfae08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9df44b01-8f94-4927-a721-bce0cbbfae08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c2140049-89f4-4b7a-b031-6d245af2b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c2140049-89f4-4b7a-b031-6d245af2b63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_bcd14aff-7abf-4374-903c-1723da1da8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_bcd14aff-7abf-4374-903c-1723da1da8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_f2264f27-7a72-408f-820c-eb873eceb3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_f2264f27-7a72-408f-820c-eb873eceb3fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_579408df-c9b8-47a4-a58c-1218b02b8358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_579408df-c9b8-47a4-a58c-1218b02b8358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a288ad37-d43d-45f7-afbf-8ac20f9a51a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a288ad37-d43d-45f7-afbf-8ac20f9a51a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f18f3d78-3a14-419b-a7b0-dd6564a543d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f18f3d78-3a14-419b-a7b0-dd6564a543d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_07da138b-a089-45dc-8417-c3987d0d6758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7b0b1ea-f4e3-4079-8e4e-132756b62443" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_07da138b-a089-45dc-8417-c3987d0d6758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_855a8f65-73dc-43ad-aae6-d0116c14c310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_855a8f65-73dc-43ad-aae6-d0116c14c310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c38c000d-253a-4407-a323-38fb2d996964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c38c000d-253a-4407-a323-38fb2d996964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_feb38e0a-80da-4c4d-bace-08b534638f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_feb38e0a-80da-4c4d-bace-08b534638f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2759fd1e-090f-41b3-800e-b7d3ff34e798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2759fd1e-090f-41b3-800e-b7d3ff34e798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cad4081-89a5-4b2a-a037-9693f06ae949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cad4081-89a5-4b2a-a037-9693f06ae949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_70468732-56d1-45d1-a7a6-b2682961d118" xlink:href="bmrn-20221231.xsd#bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_70468732-56d1-45d1-a7a6-b2682961d118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_fcb5ad0f-d857-4255-b566-dd9068da94dc" xlink:href="bmrn-20221231.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b2daf9c-0265-4147-a343-a23775e79670" xlink:to="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_fcb5ad0f-d857-4255-b566-dd9068da94dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3446418a-4a68-4993-a985-0429c75a7ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_602d634c-78ff-4ff1-b55e-36db1e2455bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3446418a-4a68-4993-a985-0429c75a7ff9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_602d634c-78ff-4ff1-b55e-36db1e2455bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635331cd-5425-4130-b7ff-18035292f23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3446418a-4a68-4993-a985-0429c75a7ff9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635331cd-5425-4130-b7ff-18035292f23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5951bbd5-81ef-41ca-8cdf-0f2680f4e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3446418a-4a68-4993-a985-0429c75a7ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5951bbd5-81ef-41ca-8cdf-0f2680f4e9c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e4d82766-f5bc-42c6-893c-6f78b33c1daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6262a968-8be1-42b8-a7ed-4b710528e0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e4d82766-f5bc-42c6-893c-6f78b33c1daf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6262a968-8be1-42b8-a7ed-4b710528e0c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04025534-2b80-4dbc-b1cd-76380fd95d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e4d82766-f5bc-42c6-893c-6f78b33c1daf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04025534-2b80-4dbc-b1cd-76380fd95d00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:href="bmrn-20221231.xsd#bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2c96a844-097b-41bd-8b38-7036c6b00ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2c96a844-097b-41bd-8b38-7036c6b00ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_048292a8-cf69-409b-a9f9-5c7eb7c3ee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_048292a8-cf69-409b-a9f9-5c7eb7c3ee74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b27ab865-20b2-4df8-8a19-7d8cce6165ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b27ab865-20b2-4df8-8a19-7d8cce6165ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8244c1d1-c78b-4ebb-9e85-852443aca9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8244c1d1-c78b-4ebb-9e85-852443aca9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c9a8010-d4fd-4d40-82f6-7660b4800f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c9a8010-d4fd-4d40-82f6-7660b4800f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9bd0413d-2a24-469c-8c7a-2b86f7bb46da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_98ab31a3-3607-403a-aaeb-8a9e9c9ae7ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9bd0413d-2a24-469c-8c7a-2b86f7bb46da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4429e2fc-033c-4c86-9d5d-de1c89aca596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_601913dc-1a29-4f1a-b488-f127d4c5c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4429e2fc-033c-4c86-9d5d-de1c89aca596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_601913dc-1a29-4f1a-b488-f127d4c5c5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1678da34-9c72-4b12-a88a-5b8903672653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4429e2fc-033c-4c86-9d5d-de1c89aca596" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1678da34-9c72-4b12-a88a-5b8903672653" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INVENTORYScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2d57a1ac-496a-4987-ba9a-fb292daec231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3968dbb2-fb38-482b-928c-38406a6afa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d57a1ac-496a-4987-ba9a-fb292daec231" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3968dbb2-fb38-482b-928c-38406a6afa4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_236ff1ca-c7cf-4e6b-be8c-be241f55e124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d57a1ac-496a-4987-ba9a-fb292daec231" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_236ff1ca-c7cf-4e6b-be8c-be241f55e124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2ea36ba3-4b66-4ea3-8b54-d2e99c42159a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d57a1ac-496a-4987-ba9a-fb292daec231" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2ea36ba3-4b66-4ea3-8b54-d2e99c42159a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_71a04a6c-8d64-4678-a6a2-dd43900263fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_71a04a6c-8d64-4678-a6a2-dd43900263fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_61f2d97f-aadb-41f1-87b3-3325eedc06df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_61f2d97f-aadb-41f1-87b3-3325eedc06df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_72f93d2a-d7e6-41a3-ae2b-45a8a6c90d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_72f93d2a-d7e6-41a3-ae2b-45a8a6c90d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_04aa897f-bb92-45a0-9340-b0a615759bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_04aa897f-bb92-45a0-9340-b0a615759bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_2894890c-1e95-4cc0-bd3f-4a48d3106eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_2894890c-1e95-4cc0-bd3f-4a48d3106eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_81de964f-54bf-4f54-bbba-3ce53558ce7d" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_81de964f-54bf-4f54-bbba-3ce53558ce7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_547dd6d2-bf53-4eef-99ac-574f30ff203d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_547dd6d2-bf53-4eef-99ac-574f30ff203d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates_c7d4d661-2a0a-4f8c-8842-07f81053480d" xlink:href="bmrn-20221231.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_bmrn_AccruedGovernmentAndOtherRebates_c7d4d661-2a0a-4f8c-8842-07f81053480d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_35c952c2-45a8-4e03-b160-2632b97cb947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aab6e43-e449-4642-85c8-0bee2716e845" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_35c952c2-45a8-4e03-b160-2632b97cb947" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f70dcd59-c752-4f20-9582-553c00c5194b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_7b14b21f-b9d1-42d8-b106-c226c33787ba" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f70dcd59-c752-4f20-9582-553c00c5194b" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_7b14b21f-b9d1-42d8-b106-c226c33787ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_19ce97ff-9f76-4113-8df4-7a80444737b3" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f70dcd59-c752-4f20-9582-553c00c5194b" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_19ce97ff-9f76-4113-8df4-7a80444737b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fafed85d-8850-4b1b-b8a2-24a96c1cef3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_f911e351-ab43-4709-a3b6-94952594838a" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fafed85d-8850-4b1b-b8a2-24a96c1cef3e" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_f911e351-ab43-4709-a3b6-94952594838a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_06033afb-3a43-4eb5-947b-ef8de6a223af" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fafed85d-8850-4b1b-b8a2-24a96c1cef3e" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_06033afb-3a43-4eb5-947b-ef8de6a223af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_bc813b17-ea3d-40eb-8aba-93fe879201b8" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_60567e08-3686-4f39-ab10-d8732f8ed099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_bc813b17-ea3d-40eb-8aba-93fe879201b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_60567e08-3686-4f39-ab10-d8732f8ed099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_babfd27b-1a93-488d-a668-6f7caa3b8553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_bc813b17-ea3d-40eb-8aba-93fe879201b8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_babfd27b-1a93-488d-a668-6f7caa3b8553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability_d888f4be-a0fa-4ba2-a254-d006172bcd29" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f95d7113-4d3e-4a33-9fc2-d9a5aca04672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_d888f4be-a0fa-4ba2-a254-d006172bcd29" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f95d7113-4d3e-4a33-9fc2-d9a5aca04672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b090aeec-ec87-434f-8de3-fb8fe9bf51e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_d888f4be-a0fa-4ba2-a254-d006172bcd29" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b090aeec-ec87-434f-8de3-fb8fe9bf51e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_179d6671-b2bf-420a-8c8f-09613e45fb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_d888f4be-a0fa-4ba2-a254-d006172bcd29" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_179d6671-b2bf-420a-8c8f-09613e45fb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4771163-c5e1-4a8b-9f08-454725238922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_d888f4be-a0fa-4ba2-a254-d006172bcd29" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4771163-c5e1-4a8b-9f08-454725238922" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d00513d7-1676-42ba-9d20-1adeccd2d19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d00513d7-1676-42ba-9d20-1adeccd2d19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_eab0837b-13d0-47e0-b52f-ffb87dbb0c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_eab0837b-13d0-47e0-b52f-ffb87dbb0c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f017a8b1-2870-4aa2-908c-fd8581f255a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f017a8b1-2870-4aa2-908c-fd8581f255a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b64d5bd7-82bb-4faf-808c-85406f7531ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b64d5bd7-82bb-4faf-808c-85406f7531ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b1c1c3c3-041e-4a15-86ed-4d6356c9b589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b1c1c3c3-041e-4a15-86ed-4d6356c9b589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2a55fc65-035d-4a30-a3a8-63cc9b88f977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b32adca8-8fdd-40b7-a238-dc75457fd87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2a55fc65-035d-4a30-a3a8-63cc9b88f977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52250ab8-bbe7-49a4-9402-9d075a9fca37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cab8e753-9068-4ff1-b149-334835eb2891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52250ab8-bbe7-49a4-9402-9d075a9fca37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cab8e753-9068-4ff1-b149-334835eb2891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8f3ff39f-14f8-4502-a40b-48423bd23a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52250ab8-bbe7-49a4-9402-9d075a9fca37" xlink:to="loc_us-gaap_OperatingLeaseLiability_8f3ff39f-14f8-4502-a40b-48423bd23a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_56d3879a-51ce-4733-b808-4f1c86b8ef0a" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b10e99de-a4f7-40bd-9d60-76332a246c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_56d3879a-51ce-4733-b808-4f1c86b8ef0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b10e99de-a4f7-40bd-9d60-76332a246c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_65f33327-1b8c-489f-877f-d593eff946f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_56d3879a-51ce-4733-b808-4f1c86b8ef0a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_65f33327-1b8c-489f-877f-d593eff946f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_b40b1f15-254b-4291-81d2-0908c205887e" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_98644e4f-637f-4e97-a64b-301a249a07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_b40b1f15-254b-4291-81d2-0908c205887e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_98644e4f-637f-4e97-a64b-301a249a07b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3bf3ec9d-66d7-4e8e-b59b-b921f1140142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_b40b1f15-254b-4291-81d2-0908c205887e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3bf3ec9d-66d7-4e8e-b59b-b921f1140142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_932b9fb7-4583-47dc-aa49-ece62cf1a2d9" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a5de52e0-e146-4dd6-aa48-5b36a9935ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_932b9fb7-4583-47dc-aa49-ece62cf1a2d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a5de52e0-e146-4dd6-aa48-5b36a9935ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_50e26667-8867-4f04-90bf-54362c743fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_932b9fb7-4583-47dc-aa49-ece62cf1a2d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_50e26667-8867-4f04-90bf-54362c743fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_93601389-c84a-43dd-b47a-b8555164b546" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_93601389-c84a-43dd-b47a-b8555164b546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_87bb5e1a-844e-4285-bc39-6cbc99132270" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_87bb5e1a-844e-4285-bc39-6cbc99132270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_4640e72c-da42-495f-a521-6f446f32d374" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_4640e72c-da42-495f-a521-6f446f32d374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_766e4af9-4846-4841-be6d-1b519fe4199e" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_766e4af9-4846-4841-be6d-1b519fe4199e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_6f20465d-0f50-4d4a-b1ee-03089009a696" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_6f20465d-0f50-4d4a-b1ee-03089009a696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_4b9bbec2-7d49-4a30-9f7b-362d3a24a7a5" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_e7a59cfb-6338-4e99-b1c2-594a95e9d611" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_4b9bbec2-7d49-4a30-9f7b-362d3a24a7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_9752693d-5e3f-4e1a-b1eb-6de9b8a2e7af" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bad05296-3729-4dd8-9d7b-80d868a36758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_9752693d-5e3f-4e1a-b1eb-6de9b8a2e7af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bad05296-3729-4dd8-9d7b-80d868a36758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_43bafa9c-6d6a-40a2-84e1-c2e6120f66d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_9752693d-5e3f-4e1a-b1eb-6de9b8a2e7af" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_43bafa9c-6d6a-40a2-84e1-c2e6120f66d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_3d1e785d-8c2b-42ba-8d39-b9bea4964472" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e00ef86-c5b4-4d6a-ba2a-0e1bff7130b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_3d1e785d-8c2b-42ba-8d39-b9bea4964472" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e00ef86-c5b4-4d6a-ba2a-0e1bff7130b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_84d021a8-3427-4bcb-90b6-e10c7167dafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_3d1e785d-8c2b-42ba-8d39-b9bea4964472" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_84d021a8-3427-4bcb-90b6-e10c7167dafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_02c66215-1520-45f0-8652-a9aec30fcaad" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f3b16eab-2609-4c40-86cb-078e3e828142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_02c66215-1520-45f0-8652-a9aec30fcaad" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f3b16eab-2609-4c40-86cb-078e3e828142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8faec71-1fd4-489c-b52f-0d10c77380ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_02c66215-1520-45f0-8652-a9aec30fcaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8faec71-1fd4-489c-b52f-0d10c77380ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability_44e978b3-bf00-4fb7-8d9f-ae3cc30156ab" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f1cdc885-cfbc-4a68-aa35-1f2354d9ebd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_44e978b3-bf00-4fb7-8d9f-ae3cc30156ab" xlink:to="loc_us-gaap_FinanceLeaseLiability_f1cdc885-cfbc-4a68-aa35-1f2354d9ebd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_99842ee4-27cd-4796-8be8-62c1cedf0548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability_44e978b3-bf00-4fb7-8d9f-ae3cc30156ab" xlink:to="loc_us-gaap_OperatingLeaseLiability_99842ee4-27cd-4796-8be8-62c1cedf0548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5bc3080f-c03a-4198-86d6-40c312889cfb" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f32769fc-ecf9-4274-a817-5c133928673f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5bc3080f-c03a-4198-86d6-40c312889cfb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f32769fc-ecf9-4274-a817-5c133928673f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5b0311be-fe30-4526-aac8-0be0f73235ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5bc3080f-c03a-4198-86d6-40c312889cfb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5b0311be-fe30-4526-aac8-0be0f73235ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_93bfee89-bfe2-4ed0-8711-26715f6ac1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_93bfee89-bfe2-4ed0-8711-26715f6ac1a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f7cc402-6341-4101-b195-7f273ab5e3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f7cc402-6341-4101-b195-7f273ab5e3af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9d8592cd-6e65-49cf-9a8b-849c89934b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9d8592cd-6e65-49cf-9a8b-849c89934b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ea9eb7ce-e8dd-4a55-a881-0221b2e4f125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ea9eb7ce-e8dd-4a55-a881-0221b2e4f125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_34a34024-66fb-46a6-9407-e670596f87d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_34a34024-66fb-46a6-9407-e670596f87d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d398ce1-122d-4283-a8fa-3ed1899f6d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18db9d5f-b53e-4d5d-8bec-8f2bbe5e95ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d398ce1-122d-4283-a8fa-3ed1899f6d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_bf0ad417-8759-40b7-9f91-29b9dcc8b483" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cb2a9d8b-430e-4a01-8968-5fc1d291425e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_bf0ad417-8759-40b7-9f91-29b9dcc8b483" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cb2a9d8b-430e-4a01-8968-5fc1d291425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d38c7e4b-9d6c-4377-93ba-a4640cf79310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_bf0ad417-8759-40b7-9f91-29b9dcc8b483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d38c7e4b-9d6c-4377-93ba-a4640cf79310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_051e099c-5b82-40ea-9fc9-0d3cdc91c638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_40fee3f0-1c83-408e-ab0c-a9a4b71886e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_051e099c-5b82-40ea-9fc9-0d3cdc91c638" xlink:to="loc_us-gaap_FinanceLeaseLiability_40fee3f0-1c83-408e-ab0c-a9a4b71886e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_740f7997-5f43-418b-8309-caac57a3e7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_051e099c-5b82-40ea-9fc9-0d3cdc91c638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_740f7997-5f43-418b-8309-caac57a3e7c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_31f4ad03-a97e-4c5c-9ec3-565f255bb3f7" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability_a5c15067-94e6-4407-997d-fcf3981bfe60" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_31f4ad03-a97e-4c5c-9ec3-565f255bb3f7" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiability_a5c15067-94e6-4407-997d-fcf3981bfe60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_251503a0-bb4f-4c26-a6a3-1bcacf12a2a9" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_31f4ad03-a97e-4c5c-9ec3-565f255bb3f7" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_251503a0-bb4f-4c26-a6a3-1bcacf12a2a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_033dc0d8-5906-4bd9-91bc-51f9d3fe4eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6d713868-da4e-4569-9f4c-c549b21acc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_033dc0d8-5906-4bd9-91bc-51f9d3fe4eeb" xlink:to="loc_us-gaap_OperatingLeaseCost_6d713868-da4e-4569-9f4c-c549b21acc41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_14119560-04e7-40c6-a1f3-2db0d5713388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_033dc0d8-5906-4bd9-91bc-51f9d3fe4eeb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_14119560-04e7-40c6-a1f3-2db0d5713388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3ab13de1-d3ef-42eb-ac6f-8d7686bb3aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_033dc0d8-5906-4bd9-91bc-51f9d3fe4eeb" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3ab13de1-d3ef-42eb-ac6f-8d7686bb3aa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_1b0bd0f8-da9d-40c1-91bf-ebaef854d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3faac095-c408-49dc-9531-0054bf3ad14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_1b0bd0f8-da9d-40c1-91bf-ebaef854d6a6" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_3faac095-c408-49dc-9531-0054bf3ad14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3fca77eb-9e0e-4aea-a715-2d9bda8bf484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d79a9597-d54c-4a26-8f24-9399d862bb03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_3fca77eb-9e0e-4aea-a715-2d9bda8bf484" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d79a9597-d54c-4a26-8f24-9399d862bb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_fae1b964-e0cb-45fb-9abd-b11b2641cfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_3fca77eb-9e0e-4aea-a715-2d9bda8bf484" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_fae1b964-e0cb-45fb-9abd-b11b2641cfd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofInterestExpenseonDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3362b11e-7f29-4467-9611-eafd5cfe390d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ee246efb-8c21-422c-80d3-cc84a15d2f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_3362b11e-7f29-4467-9611-eafd5cfe390d" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ee246efb-8c21-422c-80d3-cc84a15d2f74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a568486f-bd99-48e6-bc35-9d3280fe9156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_3362b11e-7f29-4467-9611-eafd5cfe390d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a568486f-bd99-48e6-bc35-9d3280fe9156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_20ca34a5-ed7c-40bf-a2cb-22c8a28c2a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_3362b11e-7f29-4467-9611-eafd5cfe390d" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_20ca34a5-ed7c-40bf-a2cb-22c8a28c2a4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76a63331-3fb2-444e-96a5-30f7c5182407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e45ff339-b825-42af-b555-80c08fda0275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76a63331-3fb2-444e-96a5-30f7c5182407" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e45ff339-b825-42af-b555-80c08fda0275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0cd5c70d-cd0b-4a75-a105-f9620bfae19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76a63331-3fb2-444e-96a5-30f7c5182407" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0cd5c70d-cd0b-4a75-a105-f9620bfae19a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_54e264fb-bbf4-4643-ae17-88a40895c796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76a63331-3fb2-444e-96a5-30f7c5182407" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_54e264fb-bbf4-4643-ae17-88a40895c796" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5475226-1855-4c95-affb-576153365508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8b9ba957-e3ca-4bb4-9825-58353ceb3264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5475226-1855-4c95-affb-576153365508" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8b9ba957-e3ca-4bb4-9825-58353ceb3264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a2954883-b017-4611-a9c0-301b6c5ea192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5475226-1855-4c95-affb-576153365508" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a2954883-b017-4611-a9c0-301b6c5ea192" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab479472-e6a4-4f07-906c-e4f5ab67ff35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_33cf508f-4c8b-40e2-bc4f-3c2e5564e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab479472-e6a4-4f07-906c-e4f5ab67ff35" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_33cf508f-4c8b-40e2-bc4f-3c2e5564e5f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a10832a9-b3c5-4177-a7fb-13839da319a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab479472-e6a4-4f07-906c-e4f5ab67ff35" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a10832a9-b3c5-4177-a7fb-13839da319a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ef8b12b9-a7a9-4edd-8b69-b5ab4212a004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab479472-e6a4-4f07-906c-e4f5ab67ff35" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ef8b12b9-a7a9-4edd-8b69-b5ab4212a004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7c213cb1-6a1e-4e3c-aece-5f14d691a032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_81152392-dc7d-495d-be34-23a520e3ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7c213cb1-6a1e-4e3c-aece-5f14d691a032" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_81152392-dc7d-495d-be34-23a520e3ea3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fbe82d4e-601e-4558-937e-f2d62c48d098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7c213cb1-6a1e-4e3c-aece-5f14d691a032" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fbe82d4e-601e-4558-937e-f2d62c48d098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b35dc1c0-a093-49b9-90ec-9d071dcc5be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7c213cb1-6a1e-4e3c-aece-5f14d691a032" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b35dc1c0-a093-49b9-90ec-9d071dcc5be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52b11f49-8d1f-4272-b849-959451029e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b90d7930-3de3-40c9-b770-973fa6a4c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52b11f49-8d1f-4272-b849-959451029e14" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b90d7930-3de3-40c9-b770-973fa6a4c26e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0d4342c9-2ac2-418b-9a2f-597910f5821d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52b11f49-8d1f-4272-b849-959451029e14" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0d4342c9-2ac2-418b-9a2f-597910f5821d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_667ef3af-96a7-4ba7-aa8a-32331e5c6e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_667ef3af-96a7-4ba7-aa8a-32331e5c6e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_fc7b919b-673e-491c-a825-95a0e806189b" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationSection162Limitation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_fc7b919b-673e-491c-a825-95a0e806189b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b667f700-053b-43e6-bbca-d73c48f1fa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b667f700-053b-43e6-bbca-d73c48f1fa75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e6ca28d5-4ba4-4072-9a9d-aec19ecaef65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e6ca28d5-4ba4-4072-9a9d-aec19ecaef65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_13ab80fc-e891-40e1-957e-7a8f1926a623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_13ab80fc-e891-40e1-957e-7a8f1926a623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_391888cf-5308-488a-bcfe-54982cb6051e" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationTaxReserves"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_391888cf-5308-488a-bcfe-54982cb6051e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f4b42eeb-eef6-4807-a800-dd831f479aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f4b42eeb-eef6-4807-a800-dd831f479aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_c658d7a0-5882-4c2b-850d-11403e97f202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_c658d7a0-5882-4c2b-850d-11403e97f202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_51d006dd-c9b3-455e-afc3-5e13d6e144a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_51d006dd-c9b3-455e-afc3-5e13d6e144a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_96bbb4b7-4a71-4279-bb76-8f31a872e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_96bbb4b7-4a71-4279-bb76-8f31a872e91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_f0077d83-ea89-4a02-addf-59f1033e436d" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_f0077d83-ea89-4a02-addf-59f1033e436d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_165fb573-b10e-4b4d-8d9b-917f99112334" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f7995f10-93a5-4e5a-8b25-4a8ce74daa09" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_165fb573-b10e-4b4d-8d9b-917f99112334" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_718ee0e6-cec5-4a18-86e1-e354d2c4b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_04d4a6ce-ee82-4457-80b0-a99c9598c38e" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_718ee0e6-cec5-4a18-86e1-e354d2c4b4ae" xlink:to="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_04d4a6ce-ee82-4457-80b0-a99c9598c38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e45cc8d5-cd68-43de-b98b-37a6d3c958ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_718ee0e6-cec5-4a18-86e1-e354d2c4b4ae" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e45cc8d5-cd68-43de-b98b-37a6d3c958ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_148cf327-6b58-42fb-988d-c821d22b7873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_718ee0e6-cec5-4a18-86e1-e354d2c4b4ae" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_148cf327-6b58-42fb-988d-c821d22b7873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_5ee50b13-1bdb-4bab-8e6d-28f92631fd69" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_718ee0e6-cec5-4a18-86e1-e354d2c4b4ae" xlink:to="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_5ee50b13-1bdb-4bab-8e6d-28f92631fd69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41de53d8-fd1e-4dd8-b764-1fbf767d9423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41de53d8-fd1e-4dd8-b764-1fbf767d9423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e546d193-66b5-4277-aa30-5e3e3c49583d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e546d193-66b5-4277-aa30-5e3e3c49583d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_67d4c1ce-ed16-42c5-b939-4e3faf76dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_67d4c1ce-ed16-42c5-b939-4e3faf76dbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_07909389-df61-4be6-b30f-4f357f9e9038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_07909389-df61-4be6-b30f-4f357f9e9038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_82daee0b-08df-4b0c-a775-c9d24e76b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_82daee0b-08df-4b0c-a775-c9d24e76b94a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_4db9dee4-50fc-452d-b058-17baef5de23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_4db9dee4-50fc-452d-b058-17baef5de23b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c3b0f26d-c9ed-441d-ae14-f119b00497a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c3b0f26d-c9ed-441d-ae14-f119b00497a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a492289-5cd3-4582-a501-3dbeddb928cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a492289-5cd3-4582-a501-3dbeddb928cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxAssetsLeaseLiabilities_68a81bf9-2398-447c-b28d-2ed961c564d7" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_bmrn_DeferredTaxAssetsLeaseLiabilities_68a81bf9-2398-447c-b28d-2ed961c564d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_79201745-0476-4056-9009-46d82ecb3ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6878941f-ac9f-4b88-b5ea-3cc67acb9914" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_79201745-0476-4056-9009-46d82ecb3ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b06c654-9bc2-4bd8-858c-da52cba7b619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_85730de4-c15f-4a4a-91a5-42d07b8ca39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b06c654-9bc2-4bd8-858c-da52cba7b619" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_85730de4-c15f-4a4a-91a5-42d07b8ca39a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1c820938-90d9-4d08-a55e-bb9c507c268d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b06c654-9bc2-4bd8-858c-da52cba7b619" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1c820938-90d9-4d08-a55e-bb9c507c268d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ffe22c7e-3691-4d14-8c5e-94eee4388ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_dea40771-5236-4b7b-bfdf-bb2d697c283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ffe22c7e-3691-4d14-8c5e-94eee4388ff8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_dea40771-5236-4b7b-bfdf-bb2d697c283b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b61f0eda-fa00-4bea-9194-88e8ebdfb51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ffe22c7e-3691-4d14-8c5e-94eee4388ff8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b61f0eda-fa00-4bea-9194-88e8ebdfb51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_93e633a7-abae-454e-9a3e-6e0cc4760245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b85158f-1aa0-4128-9d07-2c59fdc7ad0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_93e633a7-abae-454e-9a3e-6e0cc4760245" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b85158f-1aa0-4128-9d07-2c59fdc7ad0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_96e1c588-8a9f-46b7-87fd-24a5210594f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_93e633a7-abae-454e-9a3e-6e0cc4760245" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_96e1c588-8a9f-46b7-87fd-24a5210594f8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bmrn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="icb365b81ee1e48d3b00e51d5214a7145_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb81f786-2847-4f0b-bc20-fb0152b4f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb81f786-2847-4f0b-bc20-fb0152b4f6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_77101799-70aa-4b20-9ba1-03c37c75a0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_CostOfRevenue_77101799-70aa-4b20-9ba1-03c37c75a0a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1b6ad50-197e-47c7-af73-06c449ff3a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1b6ad50-197e-47c7-af73-06c449ff3a40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d3520859-0e42-42c1-b57c-8fabf1cd5284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d3520859-0e42-42c1-b57c-8fabf1cd5284" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_0f0504d5-a681-43da-84fd-1f83ffe21034" xlink:href="bmrn-20221231.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_0f0504d5-a681-43da-84fd-1f83ffe21034" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b8d76461-cb6c-4487-8b98-d3a0b03d094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b8d76461-cb6c-4487-8b98-d3a0b03d094f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed2519e0-4171-4327-9276-c01963fefc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_CostsAndExpenses_ed2519e0-4171-4327-9276-c01963fefc65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29639c83-c57c-4eca-8e96-72aac3aa228a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_OperatingIncomeLoss_29639c83-c57c-4eca-8e96-72aac3aa228a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4b765e61-085d-4afa-b21a-4828f7f189a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4b765e61-085d-4afa-b21a-4828f7f189a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ba572ef5-6a11-4be5-841b-65d64eafa6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_InterestExpense_ba572ef5-6a11-4be5-841b-65d64eafa6a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a498331a-2ce4-4090-972c-623e15c121a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a498331a-2ce4-4090-972c-623e15c121a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_751495f7-2ea4-48e0-9f47-9c6c855d8b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_751495f7-2ea4-48e0-9f47-9c6c855d8b1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4044b08a-b734-447b-b4c1-090c9d8e2435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4044b08a-b734-447b-b4c1-090c9d8e2435" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3fdc40d0-8ddb-410e-91a6-1a69c3328c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_NetIncomeLoss_3fdc40d0-8ddb-410e-91a6-1a69c3328c93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2fb30acd-b873-46c5-9dab-f7921012736b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_EarningsPerShareBasic_2fb30acd-b873-46c5-9dab-f7921012736b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d9cfd9d5-1429-47c8-8e28-78466e6c2d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d9cfd9d5-1429-47c8-8e28-78466e6c2d8f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_295beedf-5f79-4468-8a1a-c34474c63a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_295beedf-5f79-4468-8a1a-c34474c63a60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bed8de59-916b-485b-8381-6e2073f2c5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bed8de59-916b-485b-8381-6e2073f2c5ca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:to="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd515ec9-30cf-4880-89ca-b92d3a4fc14d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:to="loc_srt_ProductsAndServicesDomain_fd515ec9-30cf-4880-89ca-b92d3a4fc14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:to="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_92de3438-cd18-410b-bba6-19e792f22500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:to="loc_us-gaap_ProductMember_92de3438-cd18-410b-bba6-19e792f22500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_93023b8d-04db-4cc8-a63b-a799dc7b66e5" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:to="loc_bmrn_RoyaltyAndOtherMember_93023b8d-04db-4cc8-a63b-a799dc7b66e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i94d3c2074bdf447a87b248ff5b6b925a_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_234105fa-8d92-4fdb-a608-8a2e1a7567f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_234105fa-8d92-4fdb-a608-8a2e1a7567f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_0f0f6691-8929-48f1-9fee-533f072106e4" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_0f0f6691-8929-48f1-9fee-533f072106e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_74f0cee0-a71a-4185-8e52-de89fa353e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_74f0cee0-a71a-4185-8e52-de89fa353e9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4e177c3c-2236-4b77-ab3b-4ce4b997cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a671e965-fd14-4db3-908b-d96c13277c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockholdersEquity_a671e965-fd14-4db3-908b-d96c13277c45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_556e0cfe-a74d-4255-88c6-a4d10f86387b" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_556e0cfe-a74d-4255-88c6-a4d10f86387b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2431e09a-632c-4745-b8b9-03e33945b3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2431e09a-632c-4745-b8b9-03e33945b3e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccfc29e9-9155-46a3-bc28-9cbf7d5a6b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccfc29e9-9155-46a3-bc28-9cbf7d5a6b3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_cc3d5511-e23a-43c5-af7d-fefd0beffe88" xlink:href="bmrn-20221231.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_cc3d5511-e23a-43c5-af7d-fefd0beffe88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c4625d39-9b9c-434b-9d61-0f8760340d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c4625d39-9b9c-434b-9d61-0f8760340d47" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d93fc37d-01eb-403b-9b96-3986e926c039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d93fc37d-01eb-403b-9b96-3986e926c039" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3fd8f088-5363-4ed1-90b5-436b433703a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_NetIncomeLoss_3fd8f088-5363-4ed1-90b5-436b433703a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a651e10-da49-4e67-a5d4-a38febb9cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:to="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a44181e-2edc-454d-8180-57dd74ec2d5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:to="loc_us-gaap_EquityComponentDomain_8a44181e-2edc-454d-8180-57dd74ec2d5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:to="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c45fcb4e-630f-4fb3-a9b3-3bd3324e2ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_CommonStockMember_c45fcb4e-630f-4fb3-a9b3-3bd3324e2ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1f628c64-d464-4858-be72-1dc9c40a0770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1f628c64-d464-4858-be72-1dc9c40a0770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_aa7ba89f-6f1a-4fbe-8510-923b4ed99ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_TreasuryStockCommonMember_aa7ba89f-6f1a-4fbe-8510-923b4ed99ec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_4d91a327-41b5-45c1-a2fe-90e1dd755b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_4d91a327-41b5-45c1-a2fe-90e1dd755b23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c42f17-aaf2-4d2e-bdf8-e746389474fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c42f17-aaf2-4d2e-bdf8-e746389474fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04d829fe-4806-4a2b-8969-14bb255c54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_RetainedEarningsMember_04d829fe-4806-4a2b-8969-14bb255c54bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:to="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_4051bce8-ffcb-4afc-8ece-4cecb978f656_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:to="loc_srt_RestatementDomain_4051bce8-ffcb-4afc-8ece-4cecb978f656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:to="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4f31af94-55e9-47ad-99a9-d02a1458795c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4f31af94-55e9-47ad-99a9-d02a1458795c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_6e584236-7735-42c6-ab03-4a281d250a88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_6e584236-7735-42c6-ab03-4a281d250a88" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended" id="ifda840052f1c46f5bdb19c0e9db3fa31_BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d8b8bc8-ed9d-4c2c-adf3-b1f2bf755ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NetIncomeLoss_6d8b8bc8-ed9d-4c2c-adf3-b1f2bf755ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109aef9c-44cc-4e0f-8f87-bd271624dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109aef9c-44cc-4e0f-8f87-bd271624dbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_85b6f6dd-8132-4040-8fe9-e8df28d32ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_85b6f6dd-8132-4040-8fe9-e8df28d32ab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd1d3506-0138-46d9-b4d1-9654a1e0c33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_StockholdersEquity_dd1d3506-0138-46d9-b4d1-9654a1e0c33f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7197f570-0820-4ae3-b25a-eac4b575a474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7197f570-0820-4ae3-b25a-eac4b575a474" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9e50487b-8fbe-4004-8848-fbbe3dc47013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9e50487b-8fbe-4004-8848-fbbe3dc47013" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_533652cd-bdb6-40da-8118-a9f483d1f806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_533652cd-bdb6-40da-8118-a9f483d1f806" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_eb475bfe-bb18-4391-b979-071cec8a08a2" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_eb475bfe-bb18-4391-b979-071cec8a08a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_f6cb1a58-193d-45dc-bb1c-e927d405f6a9" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_f6cb1a58-193d-45dc-bb1c-e927d405f6a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales_ff4f5738-3269-47de-aaae-2055eeeb371b" xlink:href="bmrn-20221231.xsd#bmrn_PaymentReceivedAsPercentageOfNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales_ff4f5738-3269-47de-aaae-2055eeeb371b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_b073604c-6c11-4d05-8484-f2d82ba704c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_AdvertisingExpense_b073604c-6c11-4d05-8484-f2d82ba704c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NumberOfTranchesInOfferingPeriod_228b1d19-ecf6-4455-aecc-3a78fdff2e1a" xlink:href="bmrn-20221231.xsd#bmrn_NumberOfTranchesInOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_NumberOfTranchesInOfferingPeriod_228b1d19-ecf6-4455-aecc-3a78fdff2e1a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SpanOfOfferingPeriod_eb272a06-88c9-473d-8368-bfad05ed6c05" xlink:href="bmrn-20221231.xsd#bmrn_SpanOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_SpanOfOfferingPeriod_eb272a06-88c9-473d-8368-bfad05ed6c05" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_774c6dfe-80f9-44ed-a353-bdbfcb3e0f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_774c6dfe-80f9-44ed-a353-bdbfcb3e0f3d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_14e616b3-5571-42d1-ad24-61147a462439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NumberOfReportableSegments_14e616b3-5571-42d1-ad24-61147a462439" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_508ded30-54fb-460e-bfd5-41eedc93ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_508ded30-54fb-460e-bfd5-41eedc93ecef" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_490f81e0-a870-45ca-8243-fe7248ebe356_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:to="loc_srt_RestatementDomain_490f81e0-a870-45ca-8243-fe7248ebe356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:to="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_66eb022b-0c9f-4fc0-82df-9642b91bcdcf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_66eb022b-0c9f-4fc0-82df-9642b91bcdcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:to="loc_srt_ProductsAndServicesDomain_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:to="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_b6c65edc-76e6-48a8-b7f9-5d05be43ef64" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:to="loc_bmrn_ProductOneMember_b6c65edc-76e6-48a8-b7f9-5d05be43ef64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f335a823-e742-4641-a677-eceea3d9c388_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:to="loc_srt_RangeMember_f335a823-e742-4641-a677-eceea3d9c388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:to="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_753cc667-0cdc-4161-9879-4b10ae82989a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:to="loc_srt_MinimumMember_753cc667-0cdc-4161-9879-4b10ae82989a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d110864d-92bd-4d42-92f8-656482fd2430" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:to="loc_srt_MaximumMember_d110864d-92bd-4d42-92f8-656482fd2430" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i8db04bdde58c4c1d8c8af79f275d92e5_BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_8a8736c5-be78-4101-b800-7d52fcc27d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_8a8736c5-be78-4101-b800-7d52fcc27d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_80c56da0-fe1e-4f43-bb4f-d70c1a12f500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_80c56da0-fe1e-4f43-bb4f-d70c1a12f500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_257998eb-cd9d-47d6-a9a0-e5b9180dd96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_257998eb-cd9d-47d6-a9a0-e5b9180dd96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb384e63-8b48-422b-bd9c-45c2b0d25ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb384e63-8b48-422b-bd9c-45c2b0d25ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_77e7174b-02e1-44cf-b4a1-c4dcf7fb71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_EquipmentMember_77e7174b-02e1-44cf-b4a1-c4dcf7fb71d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cbec0bef-0e93-4294-adad-8b388000adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_ComputerEquipmentMember_cbec0bef-0e93-4294-adad-8b388000adf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_2f84c522-2ccf-45c0-b4ef-b76960a2d697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_OfficeEquipmentMember_2f84c522-2ccf-45c0-b4ef-b76960a2d697" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_a9581449-4231-47d4-a4d6-1ede2ef5865b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_LandImprovementsMember_a9581449-4231-47d4-a4d6-1ede2ef5865b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:to="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdeca991-b703-4596-94b7-f04bb84eb50e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:to="loc_srt_RangeMember_fdeca991-b703-4596-94b7-f04bb84eb50e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:to="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64300487-dfaf-474c-8620-bfe20700b5a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:to="loc_srt_MinimumMember_64300487-dfaf-474c-8620-bfe20700b5a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69f66fe2-502e-47a6-974b-2ff4e24e5553" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:to="loc_srt_MaximumMember_69f66fe2-502e-47a6-974b-2ff4e24e5553" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended" id="i7b2dee80e02d4dae97127d19cdd9fdfd_FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_bff083c0-f810-479f-92b4-b059c86197f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_Cash_bff083c0-f810-479f-92b4-b059c86197f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02a85835-e98a-42b2-8995-4240f81be3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02a85835-e98a-42b2-8995-4240f81be3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e562fa5a-f15e-45b5-b4d3-49eb7122eac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e562fa5a-f15e-45b5-b4d3-49eb7122eac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fb23a0b-42e3-4d57-86c2-0309673905b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fb23a0b-42e3-4d57-86c2-0309673905b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b345c8ab-d27b-4d64-8f8c-4cb697e7f952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b345c8ab-d27b-4d64-8f8c-4cb697e7f952" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae7d2431-facd-41b3-b488-6acc17bc0af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae7d2431-facd-41b3-b488-6acc17bc0af5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_868cbeba-7fb9-430e-9367-ad8c1301105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_868cbeba-7fb9-430e-9367-ad8c1301105e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7c56dd12-4b89-4087-8efb-d06807c7dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7c56dd12-4b89-4087-8efb-d06807c7dc73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_0fdaa7b7-38d0-41ae-9356-d76fe0c9358d" xlink:href="bmrn-20221231.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_0fdaa7b7-38d0-41ae-9356-d76fe0c9358d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_2311a072-04a9-4202-a0e2-9cc28fe7ee78" xlink:href="bmrn-20221231.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_2311a072-04a9-4202-a0e2-9cc28fe7ee78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35b41a98-4ba9-4af3-bac3-4cd56f93341a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:to="loc_srt_RangeMember_35b41a98-4ba9-4af3-bac3-4cd56f93341a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:to="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24e98aa0-2434-446b-819b-9a271fc947a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:to="loc_srt_MaximumMember_24e98aa0-2434-446b-819b-9a271fc947a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0232582a-81cb-4cc9-a0b3-a9c9f525c522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:to="loc_srt_MinimumMember_0232582a-81cb-4cc9-a0b3-a9c9f525c522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44a6b268-0360-40d5-8a6b-fbb838921cb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44a6b268-0360-40d5-8a6b-fbb838921cb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e360377a-c9c5-40bb-b5ef-c0b7562a0414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e360377a-c9c5-40bb-b5ef-c0b7562a0414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4baf5b01-4588-4ab5-90d0-6b63c28cb13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4baf5b01-4588-4ab5-90d0-6b63c28cb13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d7a93e71-8430-479f-b2f1-a25b4da51dbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d7a93e71-8430-479f-b2f1-a25b4da51dbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_104bdc4c-77b5-4e31-8355-e4b0c876d2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CashMember_104bdc4c-77b5-4e31-8355-e4b0c876d2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d0b8194-a305-438d-87bf-aaf2debceddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d0b8194-a305-438d-87bf-aaf2debceddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5d6eb5d8-8a72-4c08-8a7f-8887806d8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5d6eb5d8-8a72-4c08-8a7f-8887806d8db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fe3e2e24-9385-4672-b375-fb5b36496106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fe3e2e24-9385-4672-b375-fb5b36496106" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_43ffba4a-af55-43f7-923e-ece099c5127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CommercialPaperMember_43ffba4a-af55-43f7-923e-ece099c5127c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2c7da80-13f2-446b-b93b-80df4f1cb4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2c7da80-13f2-446b-b93b-80df4f1cb4b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_ed57082a-b098-4717-8410-cd6ee2601b6f" xlink:href="bmrn-20221231.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_ed57082a-b098-4717-8410-cd6ee2601b6f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="ibe84bcf1b0a24e04a987d593ec5a9de5_FINANCIALINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_90b11305-5a59-45aa-bc57-6b156ea95b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_90b11305-5a59-45aa-bc57-6b156ea95b49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af8a02d7-fc46-4642-8f4c-07505fbc1fdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af8a02d7-fc46-4642-8f4c-07505fbc1fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ee9bfd24-e06e-433d-9e71-8095c91c2044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ee9bfd24-e06e-433d-9e71-8095c91c2044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe9a90fe-f2b4-4980-af67-e839f0e07a1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe9a90fe-f2b4-4980-af67-e839f0e07a1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember_651025ed-0827-4e52-9e77-867737a7ea9a" xlink:href="bmrn-20221231.xsd#bmrn_StrategicInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:to="loc_bmrn_StrategicInvestmentMember_651025ed-0827-4e52-9e77-867737a7ea9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails" xlink:type="extended" id="i56dd36a29d2b47c48c46e8bfdd319838_INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5ffc8d7-88f6-4ff3-b824-23c7d1c5400a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5ffc8d7-88f6-4ff3-b824-23c7d1c5400a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1ab6b6d5-3233-49f8-9c12-e2a1b1a539aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1ab6b6d5-3233-49f8-9c12-e2a1b1a539aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8f21183-6487-49b7-8daa-f76c9d2854d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8f21183-6487-49b7-8daa-f76c9d2854d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AcquiredIntellectualPropertyMember_0df10198-84b1-49be-827f-21b17bcf4d6e" xlink:href="bmrn-20221231.xsd#bmrn_AcquiredIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_AcquiredIntellectualPropertyMember_0df10198-84b1-49be-827f-21b17bcf4d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TechnologyTransferMember_5daa780e-2b2b-4436-9009-faf4917f3aef" xlink:href="bmrn-20221231.xsd#bmrn_TechnologyTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_TechnologyTransferMember_5daa780e-2b2b-4436-9009-faf4917f3aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RepurchasedRoyaltyRightsMember_3d1295db-4662-4f3c-adc6-c368b7e50bac" xlink:href="bmrn-20221231.xsd#bmrn_RepurchasedRoyaltyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_RepurchasedRoyaltyRightsMember_3d1295db-4662-4f3c-adc6-c368b7e50bac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LicensePaymentsMember_ebd01e0a-51b9-4c2a-b598-60e8e04dbb09" xlink:href="bmrn-20221231.xsd#bmrn_LicensePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_LicensePaymentsMember_ebd01e0a-51b9-4c2a-b598-60e8e04dbb09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_9e208351-27bd-4130-8e66-9736f6fd68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_9e208351-27bd-4130-8e66-9736f6fd68a0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended" id="ib906b05c30ad4f1b91d866808907c8bb_PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9c0b1658-3345-4666-9dc8-1010672a86b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9c0b1658-3345-4666-9dc8-1010672a86b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f916376-0176-450f-8343-847c28c704e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f916376-0176-450f-8343-847c28c704e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9959b863-8254-429e-a7f9-fa8d3ae339bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9959b863-8254-429e-a7f9-fa8d3ae339bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64ababaf-606b-4323-8388-8128f414c812_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64ababaf-606b-4323-8388-8128f414c812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fd617d8a-8948-4df9-9bf8-c4088c3d8b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fd617d8a-8948-4df9-9bf8-c4088c3d8b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_35eb2a48-c501-4c90-953d-51c18836d017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_EquipmentMember_35eb2a48-c501-4c90-953d-51c18836d017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a1d9b25e-acbf-44d9-9fa4-0cc491d58c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_ComputerEquipmentMember_a1d9b25e-acbf-44d9-9fa4-0cc491d58c5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ce6d6706-3a56-469a-a19f-5561a0380a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LandMember_ce6d6706-3a56-469a-a19f-5561a0380a74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_18484871-89c2-4a35-baec-1f354eee26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_18484871-89c2-4a35-baec-1f354eee26e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eee471cf-939f-4579-9791-1d8f8454d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eee471cf-939f-4579-9791-1d8f8454d9d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_1a28b03d-9a07-4cda-8a48-3bbf7d53ab20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LandImprovementsMember_1a28b03d-9a07-4cda-8a48-3bbf7d53ab20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b6d2664e-daf4-4719-9855-3f3d962dbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_ConstructionInProgressMember_b6d2664e-daf4-4719-9855-3f3d962dbe25" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails" xlink:type="extended" id="i8141e8690594410596f6873065b604a3_SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_1ba48048-dc41-438a-9f74-2b02a885b189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_1ba48048-dc41-438a-9f74-2b02a885b189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_5eaaf566-d59f-4b63-afa9-2fc84cc7a9d0" xlink:href="bmrn-20221231.xsd#bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_5eaaf566-d59f-4b63-afa9-2fc84cc7a9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_40ddcf4a-031e-4919-b3e8-9278c8df9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_RestructuringCharges_40ddcf4a-031e-4919-b3e8-9278c8df9b88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_37297e9d-f065-40ab-be8a-74c2ce7fdfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_PaymentsForRestructuring_37297e9d-f065-40ab-be8a-74c2ce7fdfb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:to="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:to="loc_us-gaap_RestructuringPlanDomain_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:to="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A2022RestructuringPlanMember_4faf3117-e369-4d9f-92ab-0bb9c73945cb" xlink:href="bmrn-20221231.xsd#bmrn_A2022RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:to="loc_bmrn_A2022RestructuringPlanMember_4faf3117-e369-4d9f-92ab-0bb9c73945cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails" xlink:type="extended" id="i215456962b62460c9ab1d8ccb39c1e71_SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a299dfe5-46bf-43be-a750-e7e6e08e23c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a299dfe5-46bf-43be-a750-e7e6e08e23c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f6a272c5-8797-4e8e-9578-a2ef14e54cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f6a272c5-8797-4e8e-9578-a2ef14e54cd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fd279882-9b9e-42d3-8127-10a7bc362f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fd279882-9b9e-42d3-8127-10a7bc362f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_50c99cb3-cbdc-4c74-ac4e-8f2c83a8a417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3afdf40-1dee-420e-9df2-21a59f3673f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3afdf40-1dee-420e-9df2-21a59f3673f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedRebatesMember_31e8d0b0-0fbb-4d30-8890-b2f67f46e7c1" xlink:href="bmrn-20221231.xsd#bmrn_AccruedRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:to="loc_bmrn_AccruedRebatesMember_31e8d0b0-0fbb-4d30-8890-b2f67f46e7c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AllowancesForReserveForCashDiscountsMember_44f0f44b-787c-42ef-accd-3dd61dfd8ea6" xlink:href="bmrn-20221231.xsd#bmrn_AllowancesForReserveForCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:to="loc_bmrn_AllowancesForReserveForCashDiscountsMember_44f0f44b-787c-42ef-accd-3dd61dfd8ea6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="i357091cd3a9f42bd951950b886803484_FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_55f782ea-47d9-4f31-a39d-00b0eff3711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_55f782ea-47d9-4f31-a39d-00b0eff3711b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3a0e05b-abe4-41cf-93f3-d9310997ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3a0e05b-abe4-41cf-93f3-d9310997ec5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_165fe999-d3f3-46f2-ad4a-4d695bff89e5" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_165fe999-d3f3-46f2-ad4a-4d695bff89e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c30b5a7d-b008-4b0b-b855-e2435ed44895" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c30b5a7d-b008-4b0b-b855-e2435ed44895" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5f3482b4-8494-409e-9102-7fdf1ebef73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5f3482b4-8494-409e-9102-7fdf1ebef73a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_af88b4a0-122d-4632-a4e4-f27474de581f" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_af88b4a0-122d-4632-a4e4-f27474de581f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_644c3cdc-4bda-4537-9784-309c2557c336" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_644c3cdc-4bda-4537-9784-309c2557c336" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8288a5a7-3e11-4d3e-8a96-d614537088cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8288a5a7-3e11-4d3e-8a96-d614537088cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28feb6a0-47cf-4a8c-ad09-273fced02358_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28feb6a0-47cf-4a8c-ad09-273fced02358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4b59f94b-978e-4cf0-8183-411b86a0d717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4b59f94b-978e-4cf0-8183-411b86a0d717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_41cf8941-9910-4097-9328-7da7607ca7ac" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_41cf8941-9910-4097-9328-7da7607ca7ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember_ea0cf8f1-9879-44d7-8349-42dfa8d449f7" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:to="loc_bmrn_RestrictedInvestmentsMember_ea0cf8f1-9879-44d7-8349-42dfa8d449f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f2dcc98-de62-4334-827e-79ad0bccc3b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f2dcc98-de62-4334-827e-79ad0bccc3b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_335d0afe-b7ed-41a8-9e7a-03c7754b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_335d0afe-b7ed-41a8-9e7a-03c7754b4506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5aae0ec9-b325-4396-9000-cba86500fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5aae0ec9-b325-4396-9000-cba86500fbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bd2ca838-11fa-4c69-a0c6-0b1341b0830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bd2ca838-11fa-4c69-a0c6-0b1341b0830e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1739c53d-7191-4386-8930-f475340ad7e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1739c53d-7191-4386-8930-f475340ad7e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_b2c2d809-b95b-4d87-8dc9-f57bd2bf19b5" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_b2c2d809-b95b-4d87-8dc9-f57bd2bf19b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember_9916483d-10b7-454f-a393-eee306920901" xlink:href="bmrn-20221231.xsd#bmrn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:to="loc_bmrn_ContingentConsiderationMember_9916483d-10b7-454f-a393-eee306920901" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended" id="i58a4dfc3b9aa4922b722b5793ba1e002_FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_057e1c25-f3f8-4054-bb5a-ac3c4e269d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_057e1c25-f3f8-4054-bb5a-ac3c4e269d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9aec4766-6f36-42c4-978d-22b995e6375a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9aec4766-6f36-42c4-978d-22b995e6375a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c262241e-cc35-4b0c-8fa9-927b3f57e869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c262241e-cc35-4b0c-8fa9-927b3f57e869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_397ad7ba-842e-40e4-a55e-2000d33cc08e" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_397ad7ba-842e-40e4-a55e-2000d33cc08e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_b42bb249-60bc-42ea-8d4b-495429211b77" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_b42bb249-60bc-42ea-8d4b-495429211b77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf940cd5-c0a8-4b29-a499-bc518e6aa5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ca601c65-20d8-49a0-81dc-ea49dabaec36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ca601c65-20d8-49a0-81dc-ea49dabaec36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember_0643fe0a-75fa-4932-a15b-d3e1acd0a837" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:to="loc_bmrn_ContingentPaymentMember_0643fe0a-75fa-4932-a15b-d3e1acd0a837" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails" xlink:type="extended" id="i520ec2bfbd084e37b0d4094bde60cd7c_DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_bccccc7e-d3e2-48bb-8a1f-9740214bae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_bccccc7e-d3e2-48bb-8a1f-9740214bae6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0b7c8062-a52b-4d05-8d06-563c52fc06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0b7c8062-a52b-4d05-8d06-563c52fc06b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:to="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:to="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e854d3cd-45a2-4a3e-8263-b04f87f119b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_e854d3cd-45a2-4a3e-8263-b04f87f119b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6adcf57d-6384-47c8-8f66-aee98f563d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6adcf57d-6384-47c8-8f66-aee98f563d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0eda57d9-6a0b-4dab-aab7-e4c9c9f382d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:to="loc_us-gaap_NondesignatedMember_0eda57d9-6a0b-4dab-aab7-e4c9c9f382d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended" id="icc243b3d75d74fd9856627a39c185cb0_DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8719c462-d8ce-4ea6-97e1-3aae8bcefcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8719c462-d8ce-4ea6-97e1-3aae8bcefcc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:to="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d8397af2-e408-4c7c-80e8-220390b606f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:to="loc_us-gaap_HedgingDesignationDomain_d8397af2-e408-4c7c-80e8-220390b606f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:to="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254f801e-bc3a-4f83-ad68-010b9314cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254f801e-bc3a-4f83-ad68-010b9314cf13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a1aee908-1f2b-4e61-992d-6604d7817c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:to="loc_us-gaap_NondesignatedMember_a1aee908-1f2b-4e61-992d-6604d7817c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf51c110-1651-489d-8283-b56690862e69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf51c110-1651-489d-8283-b56690862e69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d13ca8a8-b02b-4dab-b978-9fcb3a845ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d13ca8a8-b02b-4dab-b978-9fcb3a845ef6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_8bb4b70e-3d36-46bb-a5ac-73e151c44120_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:to="loc_us-gaap_PositionDomain_8bb4b70e-3d36-46bb-a5ac-73e151c44120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:to="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_ba8f9f19-e5fc-47d0-bf4d-0db6d06638d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:to="loc_us-gaap_ShortMember_ba8f9f19-e5fc-47d0-bf4d-0db6d06638d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_0f39a80c-c5ab-4d50-9ccf-d2b48811890d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:to="loc_us-gaap_LongMember_0f39a80c-c5ab-4d50-9ccf-d2b48811890d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails" xlink:type="extended" id="i26d131d4a7d44ef8b875a92a58e73467_DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_92c7c71f-3cca-4980-bb10-289d418ca246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_92c7c71f-3cca-4980-bb10-289d418ca246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0962f8c0-187e-4dd8-b8f7-f6d091dfaaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0962f8c0-187e-4dd8-b8f7-f6d091dfaaf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:to="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_58ad430c-9217-48c3-9347-96283797af60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:to="loc_us-gaap_HedgingDesignationDomain_58ad430c-9217-48c3-9347-96283797af60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:to="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1ae45e07-3bb4-42f0-b31c-d6a8b76a3383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1ae45e07-3bb4-42f0-b31c-d6a8b76a3383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_fc55856b-ea5c-4f12-ac32-c83b690fff7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:to="loc_us-gaap_NondesignatedMember_fc55856b-ea5c-4f12-ac32-c83b690fff7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8822d6b-6114-4ed6-aeae-760110a5fde7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8822d6b-6114-4ed6-aeae-760110a5fde7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7feb0458-5cbe-4e80-894c-e48f8884b21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7feb0458-5cbe-4e80-894c-e48f8884b21c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6b85dab3-567f-441f-a9dc-37d67566bbd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6b85dab3-567f-441f-a9dc-37d67566bbd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22b7a568-685f-4565-8bcd-c0a2b10f3d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22b7a568-685f-4565-8bcd-c0a2b10f3d6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2f069ff8-7c98-4b0b-9cb3-b858d25e3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2f069ff8-7c98-4b0b-9cb3-b858d25e3bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_203680b8-ed98-42fe-87d0-1e63f7a0a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_203680b8-ed98-42fe-87d0-1e63f7a0a8ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ad51bb1a-ca09-4f7a-b0fe-422380285b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ad51bb1a-ca09-4f7a-b0fe-422380285b1f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails" xlink:type="extended" id="i8999c0ca01644da5892ed6c597ac5430_DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4e11aa24-e647-4248-a7a7-919dbf8eedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4e11aa24-e647-4248-a7a7-919dbf8eedd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2b0b3da8-8489-4772-bad7-fe9a5bc589b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2b0b3da8-8489-4772-bad7-fe9a5bc589b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a9826e28-8ad9-4b45-93b7-f26cd70ccad4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:to="loc_us-gaap_HedgingDesignationDomain_a9826e28-8ad9-4b45-93b7-f26cd70ccad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:to="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2197e4e4-208e-4858-b514-a9883e22b5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2197e4e4-208e-4858-b514-a9883e22b5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e6a4266-d485-40e9-8c72-7dce18fbd188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:to="loc_us-gaap_NondesignatedMember_8e6a4266-d485-40e9-8c72-7dce18fbd188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_84ca5b1e-b05e-48f6-bbe6-b1c672c75874_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:to="loc_srt_ProductsAndServicesDomain_84ca5b1e-b05e-48f6-bbe6-b1c672c75874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:to="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a1f4db74-807d-48c8-89a6-fe03c57d218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:to="loc_us-gaap_ProductMember_a1f4db74-807d-48c8-89a6-fe03c57d218a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70b6e86c-ef8b-456f-89b8-21c69024d0eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70b6e86c-ef8b-456f-89b8-21c69024d0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_4bd076c2-3b60-44ee-a0ff-da9b4bbcdca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:to="loc_us-gaap_OperatingExpenseMember_4bd076c2-3b60-44ee-a0ff-da9b4bbcdca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3c3d15ae-55df-4162-b949-08ab9d87dbe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:to="loc_us-gaap_EquityComponentDomain_3c3d15ae-55df-4162-b949-08ab9d87dbe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:to="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e6b3b170-4054-4c74-922a-63c9849c025f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e6b3b170-4054-4c74-922a-63c9849c025f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="extended" id="i1dd9efe53dfc464486f36218efb5c99f_LEASESScheduleofLeaseCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:to="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bf0ae6c1-feed-4fde-9758-a0055026ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_OperatingLeaseCost_bf0ae6c1-feed-4fde-9758-a0055026ee6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5600978e-2338-4c70-a3d2-471f6bafa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5600978e-2338-4c70-a3d2-471f6bafa31a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ac7c2a9f-b96a-43f0-a61c-011e098a98bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ac7c2a9f-b96a-43f0-a61c-011e098a98bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fe558d44-421c-40bd-b357-a7787c5b89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_LeaseCost_fe558d44-421c-40bd-b357-a7787c5b89d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e0f89bd-82ac-4162-a574-7341187f1d4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e0f89bd-82ac-4162-a574-7341187f1d4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_9e9ef336-3488-455f-ad88-aee190e814ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:to="loc_us-gaap_OperatingExpenseMember_9e9ef336-3488-455f-ad88-aee190e814ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DEBTAdditionalInformationDetails" xlink:type="extended" id="i0d682f1ec59d4c8d91c7525ad287c5b2_DEBTAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_05e7e26f-4345-4b3c-b59b-8c2e46718400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_05e7e26f-4345-4b3c-b59b-8c2e46718400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1f63974c-caf2-4917-a9de-677320bd1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1f63974c-caf2-4917-a9de-677320bd1d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa3a248f-33ab-4151-a764-8ebfeb6c6b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa3a248f-33ab-4151-a764-8ebfeb6c6b47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_eb60891a-2277-4471-9b75-8b3cbaa4bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_eb60891a-2277-4471-9b75-8b3cbaa4bfa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_189160f3-a009-40e1-be81-af2d3df41c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_189160f3-a009-40e1-be81-af2d3df41c34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0016d17e-1d18-4214-8027-3b48f5cf4ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0016d17e-1d18-4214-8027-3b48f5cf4ece" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c0cfb120-61bd-4aba-83d7-611491e1b6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c0cfb120-61bd-4aba-83d7-611491e1b6c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_3cd46cba-ccd0-4c4e-b1bf-73fec3900559" xlink:href="bmrn-20221231.xsd#bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_3cd46cba-ccd0-4c4e-b1bf-73fec3900559" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DebtInstrumentPercentageOfFaceValue_aa84575c-5035-40eb-a5e7-780bf856fb25" xlink:href="bmrn-20221231.xsd#bmrn_DebtInstrumentPercentageOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_bmrn_DebtInstrumentPercentageOfFaceValue_aa84575c-5035-40eb-a5e7-780bf856fb25" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b34ff168-e52c-4a75-aafc-3b644ac71fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b34ff168-e52c-4a75-aafc-3b644ac71fbc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d4072ba8-d093-42c6-a2ee-fa1d309a34e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d4072ba8-d093-42c6-a2ee-fa1d309a34e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2948939f-a72f-4fcc-83ea-16afc7727617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_LineOfCredit_2948939f-a72f-4fcc-83ea-16afc7727617" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:to="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_817e21df-0754-46d0-9e8a-361ce85b0371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_817e21df-0754-46d0-9e8a-361ce85b0371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_3657e71f-f733-402b-a79a-e4471386bcb4" xlink:href="bmrn-20221231.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_3657e71f-f733-402b-a79a-e4471386bcb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_ffea594c-b555-422c-9c38-62c9d72f4093" xlink:href="bmrn-20221231.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_ffea594c-b555-422c-9c38-62c9d72f4093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_122808b7-fe8d-446b-9906-8ca1f29a60e4" xlink:href="bmrn-20221231.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_122808b7-fe8d-446b-9906-8ca1f29a60e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_7195c22e-612c-40fb-9f45-918db9f3a729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorSubordinatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_7195c22e-612c-40fb-9f45-918db9f3a729" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="extended" id="ie9c6a791d1b0456ab9b04f73c7d3f180_DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc10ab4e-688f-4c5c-880c-77ff74211f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc10ab4e-688f-4c5c-880c-77ff74211f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec02f68c-fcce-42c3-8a16-1311accaf7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec02f68c-fcce-42c3-8a16-1311accaf7b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eb08383-5622-48e1-999b-47aee7873fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eb08383-5622-48e1-999b-47aee7873fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_155d5282-7282-4107-a395-9a85659aaa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_155d5282-7282-4107-a395-9a85659aaa6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_3bac7a6a-b4a8-49b9-bcf3-17f5746dadbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebt_3bac7a6a-b4a8-49b9-bcf3-17f5746dadbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e571575-4f29-460f-b163-98730a08bb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e571575-4f29-460f-b163-98730a08bb50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:to="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_949dca8b-0a28-44d9-b4db-8aa71a287c7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_949dca8b-0a28-44d9-b4db-8aa71a287c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_84bdebca-1831-470e-b11d-54991f1030fe" xlink:href="bmrn-20221231.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_84bdebca-1831-470e-b11d-54991f1030fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_29e2f82f-6d36-459a-a83c-1ee51189260a" xlink:href="bmrn-20221231.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_29e2f82f-6d36-459a-a83c-1ee51189260a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofInterestExpenseonDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="extended" id="i036f295c72b642299098e596ee31c0ab_DEBTScheduleofInterestExpenseonDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f6bf4a7d-41a0-48e0-bf7e-82e5aad7dfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f6bf4a7d-41a0-48e0-bf7e-82e5aad7dfb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7468c2c3-a0a1-4bbd-920d-ce0a54faeff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7468c2c3-a0a1-4bbd-920d-ce0a54faeff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c9954a01-b5d6-40b7-a042-1849a88ec874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c9954a01-b5d6-40b7-a042-1849a88ec874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_478dea76-81bd-42e6-8800-620109200518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_InterestExpense_478dea76-81bd-42e6-8800-620109200518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5f8fa94-9114-4210-b4b6-43ff9528610f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5f8fa94-9114-4210-b4b6-43ff9528610f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_211b2289-85d3-4065-8edf-c886c6908a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_211b2289-85d3-4065-8edf-c886c6908a7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="extended" id="id0878dd4abe5435aadec3711def42595_ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45b15422-8ba8-4350-bbea-f53928ee057e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_StockholdersEquity_45b15422-8ba8-4350-bbea-f53928ee057e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_7de45780-3185-4dee-b8e2-c74871109975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_7de45780-3185-4dee-b8e2-c74871109975" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d3414581-9fd5-414d-917f-fe5680fd2261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d3414581-9fd5-414d-917f-fe5680fd2261" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_9aa11ca9-fa2a-4407-b5c8-24b0a9dca885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_9aa11ca9-fa2a-4407-b5c8-24b0a9dca885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abe88927-e28e-44e6-83ff-36e5f25add2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abe88927-e28e-44e6-83ff-36e5f25add2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6fac9ba-edba-4378-b25a-2b351d82ecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1710b49a-98a1-416f-93d3-c186216fd489_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:to="loc_us-gaap_EquityComponentDomain_1710b49a-98a1-416f-93d3-c186216fd489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:to="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_0babb432-399b-4c7b-ae3b-864d3a0c5696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_0babb432-399b-4c7b-ae3b-864d3a0c5696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2f0f9363-96fa-4719-9932-b9b99a390e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2f0f9363-96fa-4719-9932-b9b99a390e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccumulatedGainLossFromOtherMember_557a8e61-61bc-4ece-8b41-03ae6abf00cf" xlink:href="bmrn-20221231.xsd#bmrn_AccumulatedGainLossFromOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_bmrn_AccumulatedGainLossFromOtherMember_557a8e61-61bc-4ece-8b41-03ae6abf00cf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails" xlink:type="extended" id="i660fef9d875e49738b5e26eea38cbc61_REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_990e89a3-28a3-4de9-9abe-c30b02c6a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_990e89a3-28a3-4de9-9abe-c30b02c6a918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:to="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3da1ead4-213b-44da-a22e-bb6c87d5c2c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:to="loc_srt_ProductsAndServicesDomain_3da1ead4-213b-44da-a22e-bb6c87d5c2c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:to="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:to="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember_078b1537-5c3a-44eb-a261-f5856738ee45" xlink:href="bmrn-20221231.xsd#bmrn_ProductTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductTwoMember_078b1537-5c3a-44eb-a261-f5856738ee45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember_9ee8d979-cc61-4b7b-97e3-df639cbb3d4c" xlink:href="bmrn-20221231.xsd#bmrn_ProductThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductThreeMember_9ee8d979-cc61-4b7b-97e3-df639cbb3d4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember_dd4f9c15-0b03-421d-b9bf-5df96aee8969" xlink:href="bmrn-20221231.xsd#bmrn_ProductFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductFourMember_dd4f9c15-0b03-421d-b9bf-5df96aee8969" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFiveMember_4e4f2ec5-aa9a-479c-aa80-652f6104049a" xlink:href="bmrn-20221231.xsd#bmrn_ProductFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductFiveMember_4e4f2ec5-aa9a-479c-aa80-652f6104049a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember_0f52d0a9-7300-4e5a-b88b-8faee4b44e0b" xlink:href="bmrn-20221231.xsd#bmrn_ProductSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductSixMember_0f52d0a9-7300-4e5a-b88b-8faee4b44e0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember_7a25aec1-505d-40cd-9c40-9341c5f8ac35" xlink:href="bmrn-20221231.xsd#bmrn_ProductSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductSevenMember_7a25aec1-505d-40cd-9c40-9341c5f8ac35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember_2325d4ab-4d20-4b3b-a5b9-95633a260021" xlink:href="bmrn-20221231.xsd#bmrn_ProductEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductEightMember_2325d4ab-4d20-4b3b-a5b9-95633a260021" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_74ab0838-52a0-4d74-9c65-102f35417533" xlink:href="bmrn-20221231.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_74ab0838-52a0-4d74-9c65-102f35417533" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_a56d573e-b582-4c44-bdba-efee3e887805" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductOneMember_a56d573e-b582-4c44-bdba-efee3e887805" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_11b50faf-3c97-4f8f-bcab-c8e726daa4fd" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:to="loc_bmrn_RoyaltyAndOtherMember_11b50faf-3c97-4f8f-bcab-c8e726daa4fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_72e79ec7-f543-4ba4-b948-4d3180fcf2f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_72e79ec7-f543-4ba4-b948-4d3180fcf2f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_8e77079d-bdbf-429f-9fc2-71133dac87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_8e77079d-bdbf-429f-9fc2-71133dac87ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_fbc94d76-af72-4257-88bf-f784d87ae516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_fbc94d76-af72-4257-88bf-f784d87ae516" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails" xlink:type="extended" id="i7e718f64645741ac9176283cce47b9dd_REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53f99a28-0e67-4aa1-9a57-4786625914f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53f99a28-0e67-4aa1-9a57-4786625914f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_62f36e2d-5ff0-4339-9406-1add3306a0cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_62f36e2d-5ff0-4339-9406-1add3306a0cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_39aec0b9-72c6-4dd8-8b51-3a7f7c2bf3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_39aec0b9-72c6-4dd8-8b51-3a7f7c2bf3ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_3892fa39-8de1-44ea-97b5-9c3556727d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_3892fa39-8de1-44ea-97b5-9c3556727d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14bf9cb9-b343-4f82-bfa1-94f13254f814_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:to="loc_srt_ProductsAndServicesDomain_14bf9cb9-b343-4f82-bfa1-94f13254f814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:to="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:to="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_570cf04e-2277-446d-bf5e-8afeb87eef25" xlink:href="bmrn-20221231.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_570cf04e-2277-446d-bf5e-8afeb87eef25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_64ac0382-1ba3-4aff-9b19-ad86d0025599" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:to="loc_bmrn_ProductOneMember_64ac0382-1ba3-4aff-9b19-ad86d0025599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f72d904-fccd-46a3-9d46-6bdf28ae62a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:to="loc_srt_SegmentGeographicalDomain_8f72d904-fccd-46a3-9d46-6bdf28ae62a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:to="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5303c340-8ef4-4031-9910-eab8f6721abb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_country_US_5303c340-8ef4-4031-9910-eab8f6721abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2133cc4f-923a-4f17-9b73-c1e574ceb538" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_srt_EuropeMember_2133cc4f-923a-4f17-9b73-c1e574ceb538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_ced2b891-7070-408b-985e-e37202e1058c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_srt_LatinAmericaMember_ced2b891-7070-408b-985e-e37202e1058c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_4db99373-bddd-4a69-b485-fec939c99eaa" xlink:href="bmrn-20221231.xsd#bmrn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_bmrn_RestOfWorldMember_4db99373-bddd-4a69-b485-fec939c99eaa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails" xlink:type="extended" id="ie8913b0c6d3845e2ba5256a55ca2592d_REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f549328-d20e-4a4a-9e5f-3a765804d866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f549328-d20e-4a4a-9e5f-3a765804d866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:to="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44361f8a-a35e-4c03-82fb-de650c31c64a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44361f8a-a35e-4c03-82fb-de650c31c64a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a9abf78-d7ec-4270-bf1d-2f3e4778ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a9abf78-d7ec-4270-bf1d-2f3e4778ee61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_354e2254-453a-444a-95df-4ce0b858688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:to="loc_us-gaap_SalesRevenueNetMember_354e2254-453a-444a-95df-4ce0b858688b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_819bb07b-f509-489d-9fcb-f4c01baacd96_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:to="loc_srt_NameOfMajorCustomerDomain_819bb07b-f509-489d-9fcb-f4c01baacd96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:to="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneTwoAndThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:to="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_f0bde07d-fdaa-44bf-9d9d-83416efe24b9" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerOneMember_f0bde07d-fdaa-44bf-9d9d-83416efe24b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_2ad24fbc-0eba-4b36-b9ce-d0714ba65c8a" xlink:href="bmrn-20221231.xsd#bmrn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerTwoMember_2ad24fbc-0eba-4b36-b9ce-d0714ba65c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember_44838ad8-ea07-4c57-8848-b803aec2334f" xlink:href="bmrn-20221231.xsd#bmrn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerThreeMember_44838ad8-ea07-4c57-8848-b803aec2334f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails" xlink:type="extended" id="ice867a2a7b5843768ed5079653debfd8_REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26601492-decd-4938-9adc-ef0b9883f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26601492-decd-4938-9adc-ef0b9883f549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d370d997-bd34-4b2b-9734-e9f647da4f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d370d997-bd34-4b2b-9734-e9f647da4f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_13629be9-cc4f-4131-9cd8-0a709bc2f46d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_13629be9-cc4f-4131-9cd8-0a709bc2f46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_be062292-cf85-46c9-a192-f9a576248218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_be062292-cf85-46c9-a192-f9a576248218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a716428d-4ea0-4af9-b02f-11a266a59fbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a716428d-4ea0-4af9-b02f-11a266a59fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e46d48fb-4001-4c31-a602-ab533abf9dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:to="loc_us-gaap_AccountsReceivableMember_e46d48fb-4001-4c31-a602-ab533abf9dfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:to="loc_srt_NameOfMajorCustomerDomain_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:to="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_0f184854-2752-49b8-8d2e-5ef05ef41a7e" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomerOneMember_0f184854-2752-49b8-8d2e-5ef05ef41a7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_68c6c424-7ba4-418b-83b4-73def509b76b" xlink:href="bmrn-20221231.xsd#bmrn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomerTwoMember_68c6c424-7ba4-418b-83b4-73def509b76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember_28e460bd-2d18-41f9-84ab-99f354bc2e16" xlink:href="bmrn-20221231.xsd#bmrn_CustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomersMember_28e460bd-2d18-41f9-84ab-99f354bc2e16" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails" xlink:type="extended" id="ifa7fefb97eec45c38dad638163aac4d4_REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_5629404e-7ca7-4129-b0e6-e5327a5739d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:to="loc_us-gaap_NoncurrentAssets_5629404e-7ca7-4129-b0e6-e5327a5739d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:to="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_45f63661-0525-4445-9ed9-42f746851f97_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:to="loc_srt_SegmentGeographicalDomain_45f63661-0525-4445-9ed9-42f746851f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:to="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b2eb6be0-ae17-461a-ab59-13d5979bd39f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_country_US_b2eb6be0-ae17-461a-ab59-13d5979bd39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_b22323e5-d14e-4a61-a154-c60c454212bd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_country_IE_b22323e5-d14e-4a61-a154-c60c454212bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_39cca9ea-0fda-422f-a0fa-f7b20cb03ff1" xlink:href="bmrn-20221231.xsd#bmrn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_bmrn_RestOfWorldMember_39cca9ea-0fda-422f-a0fa-f7b20cb03ff1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="extended" id="id3ad6e9f12014c588a80c47de589522f_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e158c375-110a-4a34-aaa2-5cd538e68d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e158c375-110a-4a34-aaa2-5cd538e68d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01869e6e-2876-4985-b7b9-9c2ac7bb2b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01869e6e-2876-4985-b7b9-9c2ac7bb2b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_d6b0a9bc-348a-4d38-884e-e5e3801b9fd5" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_d6b0a9bc-348a-4d38-884e-e5e3801b9fd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d5f6a63a-c061-478c-8e1a-db9435a8e8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d5f6a63a-c061-478c-8e1a-db9435a8e8da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d44acd29-dca6-4980-98ce-d65bea6e07f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d44acd29-dca6-4980-98ce-d65bea6e07f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63385a54-518d-47a9-a1b0-788c63cca8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63385a54-518d-47a9-a1b0-788c63cca8f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SpanOfOfferingPeriod_e7909496-b115-49a5-b944-898d9e0fb5b3" xlink:href="bmrn-20221231.xsd#bmrn_SpanOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_SpanOfOfferingPeriod_e7909496-b115-49a5-b944-898d9e0fb5b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4f5d4dd6-25fa-407a-bb35-a00664758605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4f5d4dd6-25fa-407a-bb35-a00664758605" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MaximumPayrollDeductions_6841495c-a73b-47a5-9aa1-04e1fc2682e2" xlink:href="bmrn-20221231.xsd#bmrn_MaximumPayrollDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_MaximumPayrollDeductions_6841495c-a73b-47a5-9aa1-04e1fc2682e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7fadd38d-647f-4303-a08b-441366657e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7fadd38d-647f-4303-a08b-441366657e6f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_e65cb837-06cb-4cda-9f8d-279adad6c279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_e65cb837-06cb-4cda-9f8d-279adad6c279" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AverageClosingPriceTrailingPeriod_61def96f-1bc0-458b-8425-b0f4e88b567a" xlink:href="bmrn-20221231.xsd#bmrn_AverageClosingPriceTrailingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_AverageClosingPriceTrailingPeriod_61def96f-1bc0-458b-8425-b0f4e88b567a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4906c018-c202-4c8f-8628-935b2550c91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4906c018-c202-4c8f-8628-935b2550c91f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0f3fcfa-b0b2-41ef-a73f-effaaf7b3307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0f3fcfa-b0b2-41ef-a73f-effaaf7b3307" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_0c47716f-3666-4b41-b6e6-7868f7b94253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_0c47716f-3666-4b41-b6e6-7868f7b94253" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21bdc13e-1837-4ec8-9153-8890a1ce7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21bdc13e-1837-4ec8-9153-8890a1ce7f8b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ca18aa5-bd66-48f8-aeb1-7e76df923bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ca18aa5-bd66-48f8-aeb1-7e76df923bf4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fb6ba99d-51db-4c9f-a5bd-726d0afb485d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fb6ba99d-51db-4c9f-a5bd-726d0afb485d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_af959582-2b62-44a7-be46-7fddccf03fcb" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_af959582-2b62-44a7-be46-7fddccf03fcb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_0939f929-c2f7-4551-981c-2c294dfd8432" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_0939f929-c2f7-4551-981c-2c294dfd8432" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_f31da968-3f23-4964-9732-e090086e88f7" xlink:href="bmrn-20221231.xsd#bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_f31da968-3f23-4964-9732-e090086e88f7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7db4021f-7d6d-4a1f-9bbe-011f9fb78a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7db4021f-7d6d-4a1f-9bbe-011f9fb78a53" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5baf4c37-f34c-4214-bff0-1ad1fb6768bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5baf4c37-f34c-4214-bff0-1ad1fb6768bd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_280de73a-1d0d-4cd7-a2bc-6ee47108920e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_280de73a-1d0d-4cd7-a2bc-6ee47108920e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa481307-23cd-4c4e-bc21-ca4be165de42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:to="loc_us-gaap_PlanNameDomain_aa481307-23cd-4c4e-bc21-ca4be165de42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:to="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_1c152e65-1510-4fea-a568-d820d8b93caf" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:to="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_1c152e65-1510-4fea-a568-d820d8b93caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8200e42-1e77-4c5d-a25a-428c3c5bd272_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8200e42-1e77-4c5d-a25a-428c3c5bd272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_1be5d834-dae8-4ea2-b2f6-c8aeaccc88fe" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedStockWithServiceBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_1be5d834-dae8-4ea2-b2f6-c8aeaccc88fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_82709c4e-bcc7-4817-9eaa-ab857a6d5614" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_82709c4e-bcc7-4817-9eaa-ab857a6d5614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4ce445f4-b57f-41ba-83e6-c7f405e14d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4ce445f4-b57f-41ba-83e6-c7f405e14d4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d140fe87-5861-4ce2-b258-067919dfada1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_us-gaap_RestrictedStockMember_d140fe87-5861-4ce2-b258-067919dfada1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_df0745e8-8d5d-4edf-905f-63db0c61802f" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_df0745e8-8d5d-4edf-905f-63db0c61802f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_d2493bac-b0e0-47d4-8818-8417605b586e" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_d2493bac-b0e0-47d4-8818-8417605b586e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ebfe39d-eb49-4075-98dc-521459c693bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ebfe39d-eb49-4075-98dc-521459c693bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IndependentDirectorMember_750f9d5b-9767-430d-8ceb-bd733d244a86" xlink:href="bmrn-20221231.xsd#bmrn_IndependentDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:to="loc_bmrn_IndependentDirectorMember_750f9d5b-9767-430d-8ceb-bd733d244a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd819998-3956-45f6-bb14-721bc0722b14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd819998-3956-45f6-bb14-721bc0722b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51637d60-f0d7-46d2-a8d6-89dd2750fb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:to="loc_us-gaap_EmployeeStockMember_51637d60-f0d7-46d2-a8d6-89dd2750fb54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c60f1aa-eabc-42d8-a251-870747b7be93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:to="loc_us-gaap_EquityComponentDomain_7c60f1aa-eabc-42d8-a251-870747b7be93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:to="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c23e483-8b4f-4c6f-aab8-6da1e0e5fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:to="loc_us-gaap_CommonStockMember_0c23e483-8b4f-4c6f-aab8-6da1e0e5fcb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ff48049-b772-4302-8c6a-cf16daea032e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:to="loc_srt_RangeMember_8ff48049-b772-4302-8c6a-cf16daea032e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:to="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3db159e0-975f-4824-81a1-7a1bfb43718f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:to="loc_srt_MinimumMember_3db159e0-975f-4824-81a1-7a1bfb43718f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_102f22d7-0f53-4c21-8b6a-6562d66c882a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:to="loc_srt_MaximumMember_102f22d7-0f53-4c21-8b6a-6562d66c882a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:to="loc_us-gaap_VestingDomain_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:to="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_837277ef-69ea-4292-a466-8001510aa36b" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_837277ef-69ea-4292-a466-8001510aa36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_db120dda-879c-4eb0-8691-042857502feb" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_db120dda-879c-4eb0-8691-042857502feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_4e4d44ba-6042-409b-a989-39f722aab6e4" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_4e4d44ba-6042-409b-a989-39f722aab6e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i9d1dfc73049b44a49f840a4d1c23b922_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_df883d21-786c-4be8-8da1-2e3923614273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_df883d21-786c-4be8-8da1-2e3923614273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ad4c06c-35c8-4c19-9745-48c6de56cfad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ad4c06c-35c8-4c19-9745-48c6de56cfad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7007800c-657d-4ecb-bca2-63bd4429136f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_CostOfSalesMember_7007800c-657d-4ecb-bca2-63bd4429136f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be25ee3-4682-40ea-b0c9-a10ba87a835f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be25ee3-4682-40ea-b0c9-a10ba87a835f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_74b78b64-3f3c-45cf-90ab-17b4726ea834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_74b78b64-3f3c-45cf-90ab-17b4726ea834" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended" id="i41960b84bef34ec59c5a4a36a8636f3d_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f7fc553-f369-4007-94fd-72e42df5e0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f7fc553-f369-4007-94fd-72e42df5e0fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06ddc64a-d9ef-49f8-bfff-e94fdf86a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06ddc64a-d9ef-49f8-bfff-e94fdf86a59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1fb06e6-fa5f-464b-8e37-160535e88ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1fb06e6-fa5f-464b-8e37-160535e88ffa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15634d89-ea0b-4c53-ae39-68df9e8ea0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15634d89-ea0b-4c53-ae39-68df9e8ea0e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee573772-5fe3-41c4-bb0b-37d4c7647df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c121abc-b468-4551-9e5d-f88727e5e735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c121abc-b468-4551-9e5d-f88727e5e735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d26ecbe-80f1-4664-8f8b-9ced8d9eb685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d26ecbe-80f1-4664-8f8b-9ced8d9eb685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94ebd2d4-09f6-4336-bf56-eeb2007d0499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94ebd2d4-09f6-4336-bf56-eeb2007d0499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc2df80a-42f1-4eab-83fb-2bfca4a2250e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc2df80a-42f1-4eab-83fb-2bfca4a2250e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cdce99f9-4247-4c72-a298-0b57f8baf3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:to="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:to="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_071467f2-ea1e-43f5-b67e-8834cd160c09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_071467f2-ea1e-43f5-b67e-8834cd160c09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_2152df84-de33-4616-a535-0b0733ffcee6" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedStockWithServiceBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_2152df84-de33-4616-a535-0b0733ffcee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_d5607166-a60f-4829-8f96-18dab00cb7df" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_d5607166-a60f-4829-8f96-18dab00cb7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_df0d4e73-fdc6-4653-be29-f082ebbb05f1" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_df0d4e73-fdc6-4653-be29-f082ebbb05f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails" xlink:type="extended" id="i6fa7d8707cc64372b4ed2c3608e3ded6_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eeb86b04-7a7a-4335-85be-a9f313e7be79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eeb86b04-7a7a-4335-85be-a9f313e7be79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1e7a8f25-3596-4bd0-b41a-ec2a0aaeccda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1e7a8f25-3596-4bd0-b41a-ec2a0aaeccda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2b0ba4d7-0d37-4d98-9810-dc870edc4b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2b0ba4d7-0d37-4d98-9810-dc870edc4b0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6f1e245-5fab-4696-9e4e-b98e200a64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6f1e245-5fab-4696-9e4e-b98e200a64d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_530942cb-1741-4ecd-b57b-26e8eb10dd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_530942cb-1741-4ecd-b57b-26e8eb10dd28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ecbc6bc9-1b4e-4bb0-9880-f2cf2ac008ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ecbc6bc9-1b4e-4bb0-9880-f2cf2ac008ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_795eb568-09d7-4c09-8f63-83706bd256f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_795eb568-09d7-4c09-8f63-83706bd256f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_304613de-8bae-4122-b13d-bbe36e280a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_304613de-8bae-4122-b13d-bbe36e280a42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:to="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5e82113-2eca-4dae-a7fa-266bafb73826_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:to="loc_srt_RangeMember_b5e82113-2eca-4dae-a7fa-266bafb73826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:to="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ded0678e-da14-4467-883d-d10be7f99252" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:to="loc_srt_MinimumMember_ded0678e-da14-4467-883d-d10be7f99252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70e612c2-b85e-4647-aba3-5773839d3d4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:to="loc_srt_MaximumMember_70e612c2-b85e-4647-aba3-5773839d3d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:to="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d60832e-18f6-49aa-8244-e48b681a5a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d60832e-18f6-49aa-8244-e48b681a5a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_a92775b8-23f7-415a-b9c8-8511ef56d085" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_a92775b8-23f7-415a-b9c8-8511ef56d085" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended" id="i91ea0af7750642858727ca615ae2db14_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5edea640-64d3-40b0-85f6-75c0dfb7dbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5edea640-64d3-40b0-85f6-75c0dfb7dbad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a6f7dbc4-f672-42a2-8596-11cb569dd446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a6f7dbc4-f672-42a2-8596-11cb569dd446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30cb1a20-1d21-465e-b8b7-b5d89884b1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30cb1a20-1d21-465e-b8b7-b5d89884b1ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f8494ed0-8219-4154-9ae5-12a6975a8ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f8494ed0-8219-4154-9ae5-12a6975a8ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_85105867-60c5-46cf-8070-4463ad292c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_85105867-60c5-46cf-8070-4463ad292c85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0903d37b-ca83-4e14-bb78-625f5ef81b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0903d37b-ca83-4e14-bb78-625f5ef81b06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:to="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_707df0e8-87f5-4eba-b1b7-4c5843258fe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_707df0e8-87f5-4eba-b1b7-4c5843258fe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6314148d-6e3c-4b5d-a080-78eadd9cfbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6314148d-6e3c-4b5d-a080-78eadd9cfbd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:to="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a421d12-856c-4723-98a9-88c7fa68715d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:to="loc_srt_RangeMember_1a421d12-856c-4723-98a9-88c7fa68715d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:to="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_064b6352-bc57-4883-867f-9803a47fdc65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:to="loc_srt_MinimumMember_064b6352-bc57-4883-867f-9803a47fdc65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7f205a3-4303-4520-8a5c-ec3de41dc348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:to="loc_srt_MaximumMember_c7f205a3-4303-4520-8a5c-ec3de41dc348" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="extended" id="i1ec68824dbca4b83a641b9cc7146c6ac_EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37a328dd-4416-4d4a-adde-e9922303ca39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37a328dd-4416-4d4a-adde-e9922303ca39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc4ad749-fcac-4a89-b998-363db08930e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc4ad749-fcac-4a89-b998-363db08930e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36f8495a-bb95-4956-a5a2-9544de14a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36f8495a-bb95-4956-a5a2-9544de14a7bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_04f4a0d9-ec56-49e0-81f4-b699c9ef211e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_04f4a0d9-ec56-49e0-81f4-b699c9ef211e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_771a30f0-60ae-4694-8f4a-46d6efae1ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_771a30f0-60ae-4694-8f4a-46d6efae1ed4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_35931aa5-7907-4a6f-bda9-dbb411218112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_35931aa5-7907-4a6f-bda9-dbb411218112" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b889bd5-5370-4ac0-8e3d-c6c46c798953_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b889bd5-5370-4ac0-8e3d-c6c46c798953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_03d42f05-dea1-43dc-a4d3-31ea84b7d711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:to="loc_us-gaap_EmployeeStockMember_03d42f05-dea1-43dc-a4d3-31ea84b7d711" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:to="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ac74853-2f4e-411c-a71a-ae55ee95fa3d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:to="loc_srt_RangeMember_4ac74853-2f4e-411c-a71a-ae55ee95fa3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:to="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6289e20c-02df-4f6a-8051-d85afd3d7ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:to="loc_srt_MinimumMember_6289e20c-02df-4f6a-8051-d85afd3d7ef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95d1068a-c3ea-459b-b391-bd5c43c2402e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:to="loc_srt_MaximumMember_95d1068a-c3ea-459b-b391-bd5c43c2402e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails" xlink:type="extended" id="i0ca875192c8a42d58fa4efc9209a0930_OTHEREMPLOYEEBENEFITSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6422745f-19f6-46ff-869d-e0f455a46eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6422745f-19f6-46ff-869d-e0f455a46eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d3526ec-f7ae-4696-91f1-07cc9fc804c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d3526ec-f7ae-4696-91f1-07cc9fc804c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_72ebd411-4674-4a21-a036-f97b1404eece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_72ebd411-4674-4a21-a036-f97b1404eece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:to="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ecce9e67-a11e-4dad-b89d-0d8633f4887d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:to="loc_us-gaap_PlanNameDomain_ecce9e67-a11e-4dad-b89d-0d8633f4887d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:to="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BiomarinRetirementSavingsPlanMember_e23e4d6d-b52e-41b7-8e10-b50421c3803c" xlink:href="bmrn-20221231.xsd#bmrn_BiomarinRetirementSavingsPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:to="loc_bmrn_BiomarinRetirementSavingsPlanMember_e23e4d6d-b52e-41b7-8e10-b50421c3803c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended" id="id7301f32738c4ca3a6796f833760ecae_INCOMETAXESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_15302752-0670-43eb-af27-aecd3a906dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_15302752-0670-43eb-af27-aecd3a906dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d89ba96d-3e19-4a66-b5f4-b9b246040584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d89ba96d-3e19-4a66-b5f4-b9b246040584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77e49351-94ff-4ada-ba03-1fe1b286e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77e49351-94ff-4ada-ba03-1fe1b286e79b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod_ceb2d030-8201-41cb-9bf2-6eeb682401f7" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxStatuteOfLimitationsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod_ceb2d030-8201-41cb-9bf2-6eeb682401f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_b8edd203-7975-4203-bda3-0eea59362319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_b8edd203-7975-4203-bda3-0eea59362319" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_73a39367-1111-4a35-9fb3-a46114cd3cc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_73a39367-1111-4a35-9fb3-a46114cd3cc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2d3c196d-f1a6-4363-84ea-a7ef25aaff84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2d3c196d-f1a6-4363-84ea-a7ef25aaff84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_157a6774-f483-4394-b0e6-c5002c41d18c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:to="loc_srt_SegmentGeographicalDomain_157a6774-f483-4394-b0e6-c5002c41d18c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:to="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_5506e022-16e2-4efd-aedd-79a2bfdcee38" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:to="loc_country_IE_5506e022-16e2-4efd-aedd-79a2bfdcee38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbc2f0d2-0354-4dd1-bcd4-242d2750415a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:to="loc_srt_RangeMember_fbc2f0d2-0354-4dd1-bcd4-242d2750415a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:to="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4fc68661-5c78-469f-b2e8-da9ad055208e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:to="loc_srt_MinimumMember_4fc68661-5c78-469f-b2e8-da9ad055208e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_862539ad-b4cc-4c72-8a4d-ad9ba44cdb4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:to="loc_srt_MaximumMember_862539ad-b4cc-4c72-8a4d-ad9ba44cdb4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" id="i596625247d4c45838f8ca60487821f54_INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fedf2f27-63b2-4037-9dcb-42643af56a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fedf2f27-63b2-4037-9dcb-42643af56a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8551b19f-ec8f-47eb-a353-c08e8ece19ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8551b19f-ec8f-47eb-a353-c08e8ece19ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7f45334b-19cc-480e-9be0-2ca5930a60d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7f45334b-19cc-480e-9be0-2ca5930a60d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_222a694d-b80e-4785-9e2b-8c370ea17578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_222a694d-b80e-4785-9e2b-8c370ea17578" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_48c9c9bd-cd0c-4d15-8712-c3696b4a8686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_48c9c9bd-cd0c-4d15-8712-c3696b4a8686" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_41162703-8c57-40c1-9f92-d08f459ddf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_41162703-8c57-40c1-9f92-d08f459ddf6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_953e5f95-34d2-4923-9e93-72781580ae49" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationSection162Limitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_953e5f95-34d2-4923-9e93-72781580ae49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_d33d33ff-7a9b-458a-b688-3a0db097f49f" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationTaxReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_d33d33ff-7a9b-458a-b688-3a0db097f49f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_98e46bb2-5bfe-4848-ade8-0200996ac42f" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_98e46bb2-5bfe-4848-ade8-0200996ac42f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_415886fa-7b8c-458a-a873-c3ffb0799bb0" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_415886fa-7b8c-458a-a873-c3ffb0799bb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ae03ca7-2474-4fdd-af64-704105e071b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ae03ca7-2474-4fdd-af64-704105e071b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91deb923-7901-4a88-8ceb-9af26772281a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91deb923-7901-4a88-8ceb-9af26772281a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78ca88fa-bd8c-42e1-b371-aa519073eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78ca88fa-bd8c-42e1-b371-aa519073eb87" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f9ea15d9-81f4-4a52-bbd8-10cb061c11de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f9ea15d9-81f4-4a52-bbd8-10cb061c11de" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:to="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:to="loc_srt_SegmentGeographicalDomain_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:to="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_7a9dbc73-1f25-42d7-af2b-287d47adb93f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:to="loc_country_NL_7a9dbc73-1f25-42d7-af2b-287d47adb93f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails" xlink:type="extended" id="id02b58db15224c0cbbfb8c2ae0adedb4_INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_290ed945-2748-4f90-ba8e-12ce2e6874d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_290ed945-2748-4f90-ba8e-12ce2e6874d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8a614b3c-fe61-4237-93c8-66390e2ae765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8a614b3c-fe61-4237-93c8-66390e2ae765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_4168b330-a93b-489b-84ec-0daad71ac3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_4168b330-a93b-489b-84ec-0daad71ac3c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:to="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c9c748d3-1497-4edd-a14b-6f83bc465961_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:to="loc_srt_SegmentGeographicalDomain_c9c748d3-1497-4edd-a14b-6f83bc465961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:to="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_fe390f26-8ad1-47b2-bdc8-52fa8c87cbb8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:to="loc_country_NL_fe390f26-8ad1-47b2-bdc8-52fa8c87cbb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2355a6d3-1d66-41ea-8594-caf25ab260f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2355a6d3-1d66-41ea-8594-caf25ab260f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a87f8f11-862d-4405-a448-a51be0281f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_DomesticCountryMember_a87f8f11-862d-4405-a448-a51be0281f2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3fc8fa92-12c1-4e1d-9997-5211a3780bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3fc8fa92-12c1-4e1d-9997-5211a3780bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9c8caea2-f7c5-41c4-ab76-daaefbc278c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_ForeignCountryMember_9c8caea2-f7c5-41c4-ab76-daaefbc278c5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="extended" id="i06ce42fbc6584214bc6661dbd572f324_EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d7a03e1-cb4c-414a-9795-0a39fd472142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d7a03e1-cb4c-414a-9795-0a39fd472142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_e6e521d3-51c5-46ad-b499-cddd12d66fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_e6e521d3-51c5-46ad-b499-cddd12d66fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1bb29458-8497-46d2-b38d-688a96517e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1bb29458-8497-46d2-b38d-688a96517e43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0658377e-a86d-4bd5-94f5-64da6fb78dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0658377e-a86d-4bd5-94f5-64da6fb78dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7083be14-f799-4c02-8de7-055e0b340eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7083be14-f799-4c02-8de7-055e0b340eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_124256d4-ed15-4ff6-a114-c427a35e462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_124256d4-ed15-4ff6-a114-c427a35e462a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7275ab80-1afc-4d11-b939-4cde74edee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_EarningsPerShareBasic_7275ab80-1afc-4d11-b939-4cde74edee7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9c345f39-4634-4b78-86d0-b990b0fdaa46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9c345f39-4634-4b78-86d0-b990b0fdaa46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7bb91265-7fa6-475b-8c8b-390bb3d23a79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7bb91265-7fa6-475b-8c8b-390bb3d23a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_6979d0a8-78df-4663-8916-4464bf764ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:to="loc_us-gaap_StockCompensationPlanMember_6979d0a8-78df-4663-8916-4464bf764ea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_c4682738-67ed-4a03-9113-85214ee0345b" xlink:href="bmrn-20221231.xsd#bmrn_CommonStockIssuableUnderTheConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:to="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_c4682738-67ed-4a03-9113-85214ee0345b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended" id="i0e23527473eb4eae867307dda6a632cb_EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8eed26-ef6f-4940-8a75-0a48def7cb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8eed26-ef6f-4940-8a75-0a48def7cb3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45826837-1160-4a46-932b-542037ae1869_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45826837-1160-4a46-932b-542037ae1869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_58084918-52b5-4e17-8cf0-1b778026c6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:to="loc_us-gaap_StockCompensationPlanMember_58084918-52b5-4e17-8cf0-1b778026c6b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_2d76bd9c-784b-4c3e-96fc-bfee11f4a23a" xlink:href="bmrn-20221231.xsd#bmrn_CommonStockIssuableUnderTheConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:to="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_2d76bd9c-784b-4c3e-96fc-bfee11f4a23a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LICENSEANDCOLLABORATIONAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails" xlink:type="extended" id="id17e5c1085234238a86c56a5df213275_LICENSEANDCOLLABORATIONAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edc5a134-b94b-4cb8-b431-2d55f779c216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edc5a134-b94b-4cb8-b431-2d55f779c216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_64d3dca8-00f4-4adf-a0c2-88737fd42035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_64d3dca8-00f4-4adf-a0c2-88737fd42035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_cb9e6708-1c7e-4fc4-9774-e223b06f3322" xlink:href="bmrn-20221231.xsd#bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_cb9e6708-1c7e-4fc4-9774-e223b06f3322" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_856c3c5b-206d-4fb1-8f78-4e9f2dc548a0" xlink:href="bmrn-20221231.xsd#bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_856c3c5b-206d-4fb1-8f78-4e9f2dc548a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b9b9b643-c892-4ff5-8f14-4244ff6f8262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b9b9b643-c892-4ff5-8f14-4244ff6f8262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_22eb7553-7820-4fae-a3ab-61ad5fc5ae0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_22eb7553-7820-4fae-a3ab-61ad5fc5ae0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateLowerLimit_c7e48706-2e36-476a-a28d-9b01671235cc" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateLowerLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_RoyaltyRateLowerLimit_c7e48706-2e36-476a-a28d-9b01671235cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateUpperLimit_88edc1e4-4b1b-4460-9218-db0f32cfbaaf" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateUpperLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_RoyaltyRateUpperLimit_88edc1e4-4b1b-4460-9218-db0f32cfbaaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c73b518b-6ee9-4846-841a-b1fa5223d922_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c73b518b-6ee9-4846-841a-b1fa5223d922_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_2d8b97ca-0b91-4ba8-9eed-5665088ed952" xlink:href="bmrn-20221231.xsd#bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_2d8b97ca-0b91-4ba8-9eed-5665088ed952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AAndRKuvanAgreementMember_9b435393-56b9-44f3-b596-49fd7d95488c" xlink:href="bmrn-20221231.xsd#bmrn_AAndRKuvanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_AAndRKuvanAgreementMember_9b435393-56b9-44f3-b596-49fd7d95488c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PegvaliaseAgreementMember_92f25207-32e2-4a86-83b0-f889663f646b" xlink:href="bmrn-20221231.xsd#bmrn_PegvaliaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_PegvaliaseAgreementMember_92f25207-32e2-4a86-83b0-f889663f646b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1dc81f73-bf8c-4016-b04d-8fa78eb2abac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1dc81f73-bf8c-4016-b04d-8fa78eb2abac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MerckSeronoMember_02d07600-dec1-4af4-a461-9c3c24b3db1c" xlink:href="bmrn-20221231.xsd#bmrn_MerckSeronoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:to="loc_bmrn_MerckSeronoMember_02d07600-dec1-4af4-a461-9c3c24b3db1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c094e547-3bbf-4033-8821-60ad88138ba7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:to="loc_srt_RangeMember_c094e547-3bbf-4033-8821-60ad88138ba7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:to="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e74ba42-ffd9-45b2-af58-4078765b1dea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:to="loc_srt_MaximumMember_2e74ba42-ffd9-45b2-af58-4078765b1dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f3bcb759-2a04-4507-beb4-7f77d02710ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f3bcb759-2a04-4507-beb4-7f77d02710ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FirdapseMember_9b7e4fd2-c86d-4d39-8ec4-eb0bd516589b" xlink:href="bmrn-20221231.xsd#bmrn_FirdapseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:to="loc_bmrn_FirdapseMember_9b7e4fd2-c86d-4d39-8ec4-eb0bd516589b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6954982e-c3fd-49b5-99aa-7e553e6ea1f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6954982e-c3fd-49b5-99aa-7e553e6ea1f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4ca924e4-9a8e-4209-a9af-7e08dc409925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4ca924e4-9a8e-4209-a9af-7e08dc409925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4b449edd-ca00-439a-a171-e3ac18e93ada_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4b449edd-ca00-439a-a171-e3ac18e93ada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:to="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ad83ba8c-2f4e-4c73-bf1f-88631fb6f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ad83ba8c-2f4e-4c73-bf1f-88631fb6f7fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i754001b765fa49c888795d4514bb65bb_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_89b327e2-7773-4e7e-88a0-e84295ab71f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_89b327e2-7773-4e7e-88a0-e84295ab71f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_51c373f0-171e-4ede-8b25-f140eae1fe90" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_51c373f0-171e-4ede-8b25-f140eae1fe90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_41635e2e-67e9-48d9-ba06-577341e1340f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_PurchaseObligation_41635e2e-67e9-48d9-ba06-577341e1340f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0592279f-9880-4f59-8f2d-1e696a37b604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0592279f-9880-4f59-8f2d-1e696a37b604" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c6bf1dd9-089c-4333-bee8-1a1ddb669b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c6bf1dd9-089c-4333-bee8-1a1ddb669b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramOneMember_1858d52f-51da-4349-abfa-88ca2f506b6a" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramOneMember_1858d52f-51da-4349-abfa-88ca2f506b6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramTwoMember_3aebdb51-0068-4845-bde0-301b7ae79578" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramTwoMember_3aebdb51-0068-4845-bde0-301b7ae79578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cd3e994-d37b-4dc9-a93d-b3cb62619015_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cd3e994-d37b-4dc9-a93d-b3cb62619015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember_f893d00c-396a-4157-8976-8963c56301bf" xlink:href="bmrn-20221231.xsd#bmrn_ThirdPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:to="loc_bmrn_ThirdPartyMember_f893d00c-396a-4157-8976-8963c56301bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bmrn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ca51e156-0fcc-4269-a4a9-3c3833bb0bbb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_013b68ac-685a-49ce-bdb3-edcc69636b78_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due After Year Five</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_47f82e62-f5eb-4434-be53-f067d6ccc326_terseLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability, Current</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_0c93f0ff-1d18-433b-9797-001205b77448_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ec10463c-d7bc-4519-bbea-435ab55eff7c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3958fb28-3ab4-4122-8340-408c922b7815_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_b562cf2d-c41f-494d-86c0-b01e72f0dbff_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EMPLOYEE BENEFITS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_17839044-084c-40ec-aac0-fd7f84c594a3_verboseLabel_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net product revenues marketed by the Company</link:label>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_label_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Excluding Product One [Member]</link:label>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_documentation_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products excluding product one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductsExcludingProductOneMember" xlink:to="lab_bmrn_ProductsExcludingProductOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_dee786d4-cbb7-4cc1-9e89-c00f6cb9c685_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_49febaee-64f0-4a6e-a3ad-4c2ac0da9c83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_39e292ab-b1cb-492d-a26e-99037db7c427_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_497e4a49-3894-424b-a69d-3225c263a8a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_dfc06346-057b-4b0d-9702-70b1c30d21b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_979cb1eb-61e6-4b7e-b64e-aba6b85b942e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) deferred income taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_39330c54-8635-47ef-be85-08d099ea0e7b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Subordinated Notes</link:label>
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Subordinated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorSubordinatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorSubordinatedNotesMember" xlink:to="lab_us-gaap_SeniorSubordinatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e0878988-13fb-45e9-932a-27eab561b4b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7c0be840-9d7b-4486-b44e-cd7cb26ae6e9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_41f74964-0424-4aeb-a23e-8650045a4683_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_e4d2c25c-4581-4002-8604-d897c5d525db_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment Estimated Useful Lives</link:label>
    <link:label id="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Life Table [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:to="lab_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_c4123126-d61c-4644-9826-824d2f58de69_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_77e75add-b9b5-4f65-ad5a-10da2fcd6b7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesTable_ae574b8f-0fce-478e-8a9b-e021f7df35c6_terseLabel_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesTable" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable" xlink:to="lab_bmrn_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1be7723-9f08-4bd5-9eef-a686e073ea15_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8a536f91-abd4-44c0-824c-4e556058ce0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ccf1f48e-baf9-4f50-b8a4-3156dae95658_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f53ce82-70b2-47b6-bd9e-66631cc46f08_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_095a484d-687d-4501-9297-cd1d3f510641_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_80262517-98aa-42fb-ac47-7f1010cc3df0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage, per annum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5e2bf8dd-d3b0-4708-a425-7d698e5905bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d785fb12-b4b8-4672-ae16-d3d3c9693519_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_e83db18e-cc1c-4117-b2b4-50616077e1ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;current&#160;assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_72bfa08b-609c-4b75-bbbd-36ff56981d54_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_label_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_documentation_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:to="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ed92dc02-c8a5-420d-8550-8f11da0f19d0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3cfd6a47-97bb-4628-8661-7274781b0f25_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_07f1670f-284b-4c0b-b611-a3ac074a84ec_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial time period vesting requirements</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Initial Time Period Vesting Requirement</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award initial time period vesting requirement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3a56574a-b1b8-405e-b4b6-7ec28cd69d82_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_0e26c405-2113-4024-853c-c3165d8994d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c55ae0a6-5c6c-4ad1-ae03-f2332f4de099_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_205977fe-7761-4afa-b44d-0963faabc8f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11b52c2d-2ec4-4e01-b372-85157608ec12_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a55bcad2-455b-43ac-8269-cbfc9239eb03_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductFiveMember_2c19e821-c1f2-4e24-beb7-412e04043850_terseLabel_en-US" xlink:label="lab_bmrn_ProductFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KUVAN</link:label>
    <link:label id="lab_bmrn_ProductFiveMember_label_en-US" xlink:label="lab_bmrn_ProductFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Five [Member]</link:label>
    <link:label id="lab_bmrn_ProductFiveMember_documentation_en-US" xlink:label="lab_bmrn_ProductFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 5 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFiveMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductFiveMember" xlink:to="lab_bmrn_ProductFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_313ff0cb-2734-4472-ba86-368e9421c81a_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Income Target</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_label_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Non-GAAP Income Target [Member]</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_documentation_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Non-GAAP Income Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:to="lab_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8868ab7f-462f-42ce-bdaf-5f84dd3885f3_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_703debba-7e40-4d33-913b-6632c4683429_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: reclassifications to net income (loss), net of tax impact of &#160;&#160;$0, $0 and $(127), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1baab1a0-1db9-40db-bd29-f7975793a077_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f6a330b8-127c-4683-aefa-2f8a480fcffe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_1545fdfd-dd77-4ac6-a969-3207277a09dc_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Segment Reporting Disclosure [Text Block]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and segment reporting disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:to="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_44cf017c-c7e9-49da-9a07-492853022984_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b53df993-d1c7-489c-ad22-999d733857d7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_838de3fb-23a5-41ec-ba88-1d5510fc675e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated long-term loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c05ef9fa-60b3-4def-89c1-7932a2c66f00_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8ab27a70-f1b2-4bd0-962d-80735e1c6f8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8024f6c-23c8-4f83-a387-3b07ec2aa3ee_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_8a8c0a4c-f91b-4d51-8754-8f60e9d60fa8_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options unvested</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_176a6889-0743-427c-81eb-b80f729bfd51_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_851d1e30-d788-402a-893a-79012e36d463_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cc317f35-5b76-4ea1-860c-561b2f26dced_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_26230553-ae5b-401c-8cdb-046a11b37ac3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_d3544ae3-e830-4f96-8ed0-db049100fc10_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding amount</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c44d228-29e3-4ee5-8d2a-ee4aae14cfb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f05e2aae-e7f8-4bed-a1e5-f272909499f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5a2be181-43c0-4e9f-a1c0-dfac5e458c0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19ab5a47-913f-4340-bfb1-38fa76a7bc65_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Years, Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_54ce3d1a-0937-4e0c-a1ff-1e93fe37411d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_63cbfbe7-d594-43a9-bd6f-1c198bdff51c_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of TSR-RSU Valuation Assumptions</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5581074a-0ba1-4d87-b955-a5a0c3115f42_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_01d39b9d-cb27-4299-b656-213093331f32_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIssuedEmployeeStockTrust_15cd40c2-b638-48c6-8b42-3ce5b53056db_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company common stock held by the Nonqualified Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_CommonStockIssuedEmployeeStockTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued, Employee Stock Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:to="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_736b78eb-d160-4c23-9c3a-751e4a17e546_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomersMember_01841115-f58a-4f67-affd-f8983c3635c2_terseLabel_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_bmrn_CustomersMember_label_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers [Member]</link:label>
    <link:label id="lab_bmrn_CustomersMember_documentation_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember" xlink:href="bmrn-20221231.xsd#bmrn_CustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomersMember" xlink:to="lab_bmrn_CustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales_fb8e3616-140b-4c12-b3ca-671bcc39dc85_terseLabel_en-US" xlink:label="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received as percentage of net product sales</link:label>
    <link:label id="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales_label_en-US" xlink:label="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Received As Percentage Of Net Product Sales</link:label>
    <link:label id="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales_documentation_en-US" xlink:label="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received from sale of a product as percentage of worldwide net product sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:href="bmrn-20221231.xsd#bmrn_PaymentReceivedAsPercentageOfNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:to="lab_bmrn_PaymentReceivedAsPercentageOfNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2c1f450d-482c-4f7d-9486-988d69b9d6d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0504fdf6-1ce9-4614-a04b-a7bb4b61ab7f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_54934b3a-ac73-46bc-ba28-57e08f477b7c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_8fd4345e-edc0-4c5a-8eb3-1ddbc193fc22_terseLabel_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of nonfinancial assets</link:label>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_label_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Nonfinancial Assets</link:label>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_documentation_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Nonfinancial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:href="bmrn-20221231.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:to="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_551546c8-e17e-436f-86b8-aa3361b33d5a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_293f4908-8a0a-4954-be0c-7922e4311f76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e75ef026-ea93-4c08-8c7d-822476633c71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62f6a2c0-f243-4248-8e11-fb1484736bff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PositionAxis_d8bfef8e-b99b-40e8-8157-be8315aa73b9_terseLabel_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position</link:label>
    <link:label id="lab_us-gaap_PositionAxis_label_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionAxis" xlink:to="lab_us-gaap_PositionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_70c2604f-1b2c-460d-b712-888f3e823565_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total intrinsic value of restricted stock vested and released</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3c50a298-ffe1-41ff-bd24-338e0a17e362_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ee243dc-1857-4435-abd3-76a5cbcedcce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_f180cb66-1506-4d5e-92e5-246f99f94ecc_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_2a00d216-075c-4d97-8243-a38baa9b652c_verboseLabel_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other current liabilities</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Current Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities current fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e42842ba-089f-464e-9544-419ec50010e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_566c777d-382f-450c-a1f6-c3f750bd00df_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c9dca013-519d-4dd5-80cf-a82a820e3eea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_00ffb919-dc2c-4b93-bda0-427adb24c864_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_28934b6b-9eec-4935-bceb-8db8444bf287_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_80c964ed-8451-4b34-8849-364d17ac7467_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life, (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_9a572991-6ede-486b-9fca-db98847cece2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c72b909a-acf6-4493-869a-67915d43a98e_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7faad3fa-45a5-4b4c-ac3e-d4cb2e21c3a9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_2f158a58-82d5-4789-b28a-4e7dfa789ee6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts&#160;payable&#160;and accrued&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2ccb4d9d-e0fb-47f4-9f06-b0fab7974c6f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81f9cad1-e97c-49b7-8c27-ae877dba274d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55493391-9c24-4cc3-b184-e05b760160d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_41e19fc4-b4f0-4651-a7fa-79a13ff66dd4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0f2c515a-f540-4a78-983d-941ae028bda4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_53112a92-f3b5-4f65-b044-676c0e9f2322_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit), total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationTable_4a2ebd5a-686d-444c-af53-5fac50974b81_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Table]</link:label>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationTable_label_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Table]</link:label>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationTable_documentation_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental balance sheet information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationTable" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable" xlink:to="lab_bmrn_SupplementalBalanceSheetInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_c4b2f4ac-b5ac-4999-acb1-29a80d39a1ea_terseLabel_en-US" xlink:label="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of note principal amount</link:label>
    <link:label id="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Subordinated Notes Repurchased Percentage Of Principal Amount</link:label>
    <link:label id="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior subordinated notes repurchased percentage of principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:href="bmrn-20221231.xsd#bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:to="lab_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_da4e174d-1fd8-4627-8693-53e409602487_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7bee373f-d429-41d4-8b18-9045c7cfd7a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_15b14081-2984-40a5-be51-827ade707b7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_11c9fd35-6bd2-4886-8a0f-4d7a73d0e39e_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_f17d7225-1757-4f74-be08-1933e47a5a91_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_8447f821-bb05-4f0f-be5e-67200aba6f3d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_befcb52d-d1e9-4d7d-b794-3e475852bf3d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5275dab7-54ce-414c-918b-8237249042b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7a591106-2952-42bc-b9f8-e40cb2d9de61_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a86587d0-9fba-4bbd-bf2d-8e05f875b019_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SpanOfOfferingPeriod_a412024c-3e83-4514-8ceb-817fbe95e91c_verboseLabel_en-US" xlink:label="lab_bmrn_SpanOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Span of offering period</link:label>
    <link:label id="lab_bmrn_SpanOfOfferingPeriod_22fe6eb8-f75f-4960-a7db-f0ea57915346_terseLabel_en-US" xlink:label="lab_bmrn_SpanOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Span of offering period, in years</link:label>
    <link:label id="lab_bmrn_SpanOfOfferingPeriod_label_en-US" xlink:label="lab_bmrn_SpanOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Span Of Offering Period</link:label>
    <link:label id="lab_bmrn_SpanOfOfferingPeriod_documentation_en-US" xlink:label="lab_bmrn_SpanOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Span of offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SpanOfOfferingPeriod" xlink:href="bmrn-20221231.xsd#bmrn_SpanOfOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SpanOfOfferingPeriod" xlink:to="lab_bmrn_SpanOfOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c1132cbe-410d-49c7-8e15-e67e0687d682_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance, Noncurrent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_49726846-3fb9-497b-b753-732a6f5e2afb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1aafdc43-13dc-41bb-a72a-cf6539100b59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3c89482d-0926-445b-ab5e-b6e26a318da3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during the period, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_02ed373b-55b9-4d92-98e7-dc5cb45ed96e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL BALANCE SHEET INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0b52dfda-dd76-4722-8510-8d7534810f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Provision for (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_41267219-cd4a-4465-baae-c2c1b009388a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Carrying Amount of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_89ebb232-7e8b-48f0-9f61-91eac850f2a3_negatedTerseLabel_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES act carryback claim</link:label>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_label_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim</link:label>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_documentation_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:to="lab_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1764100e-eb99-46f1-999e-b64a8aec64bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost expected to recognized over weighted average period, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_826dc60a-0e54-4e55-8371-d8ce8fd57f87_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Years, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_9307f08d-296a-4ff2-9c60-b5506822d1de_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_98f13fa7-8d30-4821-b93b-371be52aaffe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ee238f92-c28e-439b-9f6f-7f0b0ce0a616_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_dfd5583d-5473-4c3c-abe0-9d86cf1f7fbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b219eae6-aac8-42ca-b6bb-cecf717335be_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_db541b93-e4e2-4753-92bd-6952b65aa79c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_56391991-ef9c-4a80-beea-8e877a3ae282_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_79919a7c-6f90-44a3-84fe-9984ed88b0b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_MaximumPayrollDeductions_d9f5fa91-5a5b-443a-8488-6f475bfbeffa_terseLabel_en-US" xlink:label="lab_bmrn_MaximumPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payroll deductions</link:label>
    <link:label id="lab_bmrn_MaximumPayrollDeductions_label_en-US" xlink:label="lab_bmrn_MaximumPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Payroll Deductions</link:label>
    <link:label id="lab_bmrn_MaximumPayrollDeductions_documentation_en-US" xlink:label="lab_bmrn_MaximumPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payroll deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MaximumPayrollDeductions" xlink:href="bmrn-20221231.xsd#bmrn_MaximumPayrollDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_MaximumPayrollDeductions" xlink:to="lab_bmrn_MaximumPayrollDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_572f775e-6d4a-4f3a-b916-530dd0123fcf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c986449-b35a-4b54-ab52-dcc9cac3d3bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cd351482-3047-44fd-856e-c60883e53ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from offering debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9d29929c-e411-4c44-b276-4364a6c2d477_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_c4e899ad-4576-431d-a002-96ed43589851_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion rate of shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9b22025b-1f4c-4617-85bd-23b6d16368ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6a182cb0-e3e5-4099-87a8-d92e07d942f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_1c45b9f1-b515-4a41-a3bb-0ccd4930d4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_34db5f4f-8483-4c8d-9a37-3c376b91f7ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves, net of stock-based compensation</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fcf7e3fb-3e1f-466d-8135-f52ca42dc122_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9d58bec4-0684-45a3-904c-98539401fd77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de5770ef-7d6f-4808-99da-c48ee856e008_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fe241ac3-00b9-4098-b44c-241903c984e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3d18d717-6460-4886-aa9e-eb86067f5fed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d17ccd64-70ad-4c55-b266-a569b7ae5e18_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_98d0b1eb-384d-4348-b1e3-2d12297b2dd4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AllowancesForReserveForCashDiscountsMember_c96161b8-5be8-4697-a921-57839966c3dc_terseLabel_en-US" xlink:label="lab_bmrn_AllowancesForReserveForCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for cash discounts</link:label>
    <link:label id="lab_bmrn_AllowancesForReserveForCashDiscountsMember_label_en-US" xlink:label="lab_bmrn_AllowancesForReserveForCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances For Reserve For Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AllowancesForReserveForCashDiscountsMember" xlink:href="bmrn-20221231.xsd#bmrn_AllowancesForReserveForCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AllowancesForReserveForCashDiscountsMember" xlink:to="lab_bmrn_AllowancesForReserveForCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_10db6c9b-04d6-42f8-a2b0-597f2e06d575_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares earned range</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8ff958d8-6026-4569-9ab8-ab477d2534ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ce573b74-27d4-4b14-9fcc-c3f24e38ed5c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f6da1d1c-1b5e-4acd-af3f-0780b056b7e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e911a60-0f51-4634-9851-8b5c40cc20b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_638502ab-a9b1-4065-a36f-631f912e02e7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_3137db3b-f21f-4b00-83be-dd591505ffa2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f065cde-e4b8-4c39-a4a9-f581e8c73df3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_dedbecb5-6ec7-480a-8ab8-63870576b120_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d07b2002-44a0-4513-ba3b-45346df8fab6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationTaxReserves_e9ef892e-2e2b-4fbd-8e00-f3d741f3d75c_terseLabel_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Reserves</link:label>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationTaxReserves_label_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation Tax Reserves</link:label>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationTaxReserves_documentation_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax rate reconciliation tax reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationTaxReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:to="lab_bmrn_IncomeTaxRateReconciliationTaxReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_f6d60850-843b-4947-a077-9b22753918a9_verboseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment related to correction of immaterial error</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_222f27b9-9df4-49ea-be24-379e7eca2864_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e099fc28-c111-4f8c-a503-e28c3eea7abc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities remeasured</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec1f0fb8-8ed9-4098-ab4f-469c459c5b4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_612628bd-9799-4485-9ff5-e6fc8d5dd92f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6026d1ed-00b6-4c7c-bfea-0bbfae1caf9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc2f4187-74e1-4418-adec-1a88f50b9625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d35f1051-0d6c-413e-8976-d6f3227e009f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other short-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fd75c278-a5bd-456e-9c31-9fe1244887c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestOfWorldMember_5dc48ef8-12aa-4f39-93d3-5460fadd6537_terseLabel_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_bmrn_RestOfWorldMember_label_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_bmrn_RestOfWorldMember_documentation_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember" xlink:href="bmrn-20221231.xsd#bmrn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestOfWorldMember" xlink:to="lab_bmrn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1cf4255f-82a9-49b8-99a4-f1c1ef0ed1e2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_ffe47733-b4f0-44fb-af0e-73243b606394_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_85f1f20c-d447-4ea3-bc12-277c57b25788_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_53a0572a-e492-4322-896a-7cd6765b011a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_33f2b09d-a5dc-4bc0-abf8-a3fefbc4357b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income (loss), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_632011f0-a5bf-409b-b17e-ee2595dabb76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_2122c7de-b040-4d86-a444-181e0a55586b_terseLabel_en-US" xlink:label="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of workforce expected to eliminated</link:label>
    <link:label id="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_label_en-US" xlink:label="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</link:label>
    <link:label id="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_documentation_en-US" xlink:label="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:href="bmrn-20221231.xsd#bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:to="lab_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_acbf38cf-d013-406d-990f-ea365f33fc57_negatedLabel_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture basis difference</link:label>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_label_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Related To Joint Venture Basis Difference</link:label>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_documentation_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities related to joint venture basis difference.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:to="lab_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_da3e9a94-e84e-43c6-a9c6-8e10dc79da06_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_8a6bd34e-dcd8-403f-91cd-6c04d608f391_terseLabel_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</link:label>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:href="bmrn-20221231.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:to="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_A2022RestructuringPlanMember_8679c4a6-df98-4ec8-92e0-7b5593445db3_terseLabel_en-US" xlink:label="lab_bmrn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan</link:label>
    <link:label id="lab_bmrn_A2022RestructuringPlanMember_label_en-US" xlink:label="lab_bmrn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan [Member]</link:label>
    <link:label id="lab_bmrn_A2022RestructuringPlanMember_documentation_en-US" xlink:label="lab_bmrn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A2022RestructuringPlanMember" xlink:href="bmrn-20221231.xsd#bmrn_A2022RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_A2022RestructuringPlanMember" xlink:to="lab_bmrn_A2022RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_71fb5c12-39af-4efc-bb05-dd3bbdb2166c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f577a18c-068c-4397-8571-c9259ed3330c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d2aafbc6-c0bc-4240-8d3c-7a9cb29f5912_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_150355c1-474f-4c27-b0bd-448b5683f1fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_15eee7cd-84de-4296-9a2a-36880392a36e_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total ROU assets</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Right Of Use Asset</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_bmrn_OperatingAndFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e95d4212-7035-4bfa-a790-38f5ed9bef1d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b9bd612c-1845-4884-bf29-7198276017e4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_889574d6-2e8c-4fb8-ba2c-cda5f7c3b9e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of qualified compensation to be used for purchase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4098bc96-74e3-4799-9a78-7bd602479d9c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentPaymentMember_77702285-095c-4ea3-bb04-963da619f068_terseLabel_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment</link:label>
    <link:label id="lab_bmrn_ContingentPaymentMember_label_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment [Member]</link:label>
    <link:label id="lab_bmrn_ContingentPaymentMember_documentation_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentPaymentMember" xlink:to="lab_bmrn_ContingentPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9dd31d82-d546-4e6c-9445-8731ee3595ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_50ea81d7-1f50-4769-b8f5-3a3337354629_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fd25a482-f3f3-41be-a239-9d4336c77e10_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_0fc31c41-0d34-4be3-89eb-189ac5c3c3dc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b84cade6-e93b-4cd8-8b06-cb27c8bf5474_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e22d39cc-58ae-4e7b-9fcb-7bcae7d4645f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b363043d-292a-45ef-b510-fe5fa96c43db_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_d1dd95d8-c4db-4adf-a989-347e07decb83_terseLabel_en-US" xlink:label="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition contingent consideration potential cash payments upon achievement of sales milestone</link:label>
    <link:label id="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_label_en-US" xlink:label="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payments Upon Achievement Of Sales Milestone</link:label>
    <link:label id="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_documentation_en-US" xlink:label="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition contingent consideration potential cash payments upon achievement of sales milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:href="bmrn-20221231.xsd#bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:to="lab_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_56320ed4-31d5-4244-84c9-589878bd3cca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible senior subordinated note offering, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_829d52ca-d1f5-4344-88ec-0c02a186fb37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e0312e6d-18e7-45ab-aca6-cff668736982_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0e43d002-1894-409b-91ed-2a4dea841b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_9e632527-7bbd-4b6f-aac0-84604d279ba2_terseLabel_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intra-entity transfer of assets</link:label>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_label_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount</link:label>
    <link:label id="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_documentation_en-US" xlink:label="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:to="lab_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_f1198eca-1a64-4c26-a858-5aeb3260dded_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d81397c5-3e37-4bde-9b8f-8fae38374dd7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_102a8f46-3059-44b1-ab26-7e80a2eaf3c5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_7445e75a-6b9c-42d7-bf51-c1906ffd5a69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayments of financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f0e34810-1938-48a6-b158-2d6f7ccd7138_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bd8f6002-6de7-4a38-9f45-114555a17373_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c21811b3-9cd0-413e-830b-c5128f014383_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c13adeb-6960-4b47-b4c6-dd70962c1fb9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_bd3ab931-f38f-4dce-8056-f3a7ad3e96a6_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_label_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expenses table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable" xlink:to="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_a83c4468-beeb-4c60-ac87-0dfe7d1ca1c4_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense, total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_411686f5-1c25-40d5-9457-d52d4b67659b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_4b89f90e-bce1-44ef-b643-d4d927acbeec_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_53429059-b8b8-493f-a6ad-36c766fc4f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: gain (loss) reclassified from AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_ca57769b-6cd4-4252-ad14-012a18d28aa9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_cf7b68be-b7ed-4778-8926-76e881a83a8c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e0ce386e-a16c-4280-85a5-2f7b1f814f4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_add5190f-3a2b-4802-b1c3-5bccf49d3392_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PositionDomain_fa106203-4aae-48f2-8237-e1d77e3b51f4_terseLabel_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position</link:label>
    <link:label id="lab_us-gaap_PositionDomain_label_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionDomain" xlink:to="lab_us-gaap_PositionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7bd18457-35e5-45fd-a7c0-87cdf15c8af1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_719513cd-eeb7-4707-a8c8-ace59fa994ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_91ad1fa9-bede-4a43-883a-9637b1ee1279_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bf716b29-6fcf-4b6f-8192-dfc980a812f1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_976e4c65-16db-49bc-b298-0af5c7295425_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_e1c7c506-fbd9-4b0d-b2b6-aba1db239f81_negatedTerseLabel_en-US" xlink:label="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in convertible note</link:label>
    <link:label id="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_label_en-US" xlink:label="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable</link:label>
    <link:label id="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_documentation_en-US" xlink:label="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:href="bmrn-20221231.xsd#bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:to="lab_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c6457503-ef68-4bf9-b060-56719be23f49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_66dba098-8bb5-41cb-a1ac-b3532620c73f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1e3b57f0-9a98-46b0-8f7c-39a0b4e2f542_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a652b2ff-e100-4dd3-94a5-08d1c6cd2b29_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_35d556ac-8a08-4dd1-857c-2616ce948514_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_33a0b21c-fc94-4882-b525-dcdd4f9a1e22_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock_694572b0-1036-432c-b55d-32188f9774d9_terseLabel_en-US" xlink:label="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards</link:label>
    <link:label id="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock_label_en-US" xlink:label="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:label id="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating loss and tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:to="lab_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_67ecf5a0-58cf-4336-9d4d-b1335009ccc4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5f1bc44a-4c59-4549-9e40-589464eb8d1a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b4f4154e-8a0c-4596-b0f2-4d81980c1b3d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerTwoMember_f5614abc-c5d6-42d7-ba02-4522520b8729_terseLabel_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_05c3b00b-de05-4487-bef3-9c07652212bc_verboseLabel_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_label_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_documentation_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember" xlink:href="bmrn-20221231.xsd#bmrn_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerTwoMember" xlink:to="lab_bmrn_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_5c95d4e3-f2bf-498b-afd9-f1aefb044722_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_5b22087a-bdd4-4a6d-9d81-b1e549de18d4_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2b423da-9bdf-4971-b2b3-1be6a46c1c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_055f6872-c282-4275-985a-4b53ad5f9fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term convertible debt, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_5fe3a453-5fd6-4cdb-b16b-3689b99e464e_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net of unamortized discount and deferred offering costs</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_20cda840-d47b-42c0-ad95-5b882410e9a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db344c8c-7efb-480c-b8c9-114b8cddb20b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2b222423-81eb-4f66-bfd5-892a49c053f8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_18e4fae0-57d1-4f78-b282-934bb526a0b8_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Five</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_97184a8a-10d8-48de-aa44-4710067129dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_9c58e702-21a6-448d-be59-44674bcd5b96_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options unvested (in dollars per share)</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_653d3f96-cbd0-4371-93d9-3b7e43f14f7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f9f7517f-5097-473b-83d8-2c59a7313a38_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_26626dba-77f7-4363-b0ea-e17111a31e4f_verboseLabel_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other current assets</link:label>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Current Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets current fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_fe55ef7b-a932-45af-af7c-2a0cf8f72a30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_35f17573-4f2c-40d3-8c38-d7b07c44bdd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f8f1b9a6-2d8c-4ca0-9f11-f78dd021f9a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price, per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_62f5e536-ab87-4b3f-a616-78fffe6aca2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductFourMember_d3968c4d-b120-4856-854f-fe29930516bb_terseLabel_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PALYNZIQ</link:label>
    <link:label id="lab_bmrn_ProductFourMember_label_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Four [Member]</link:label>
    <link:label id="lab_bmrn_ProductFourMember_documentation_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 4 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductFourMember" xlink:to="lab_bmrn_ProductFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6323e40-aec0-427a-b32c-27e6387b4bda_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03900ee6-bc6f-43ef-b957-dca067248aa0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5c258b70-c321-4982-8bbb-df9203dcc25e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Source</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_091e2c27-2a62-4c36-9727-1c65ae5bcae0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_0174be4e-cd76-4815-a132-92fb31a1f984_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Years, Options unvested</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested weighted average remaining contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8163139e-913e-4e85-8dbe-5a09b40a596b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a6f60247-d4db-4805-850c-63af47f1078a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_7958df6a-07d8-4222-90bf-dcf0fc41d3df_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment expected to be paid in 2023</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_9692f7ac-febc-4ba0-a192-30a962702fd8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LicensePaymentsMember_40417ab4-0165-47e1-8b42-4b400bfae77b_terseLabel_en-US" xlink:label="lab_bmrn_LicensePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License payments</link:label>
    <link:label id="lab_bmrn_LicensePaymentsMember_label_en-US" xlink:label="lab_bmrn_LicensePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payments [Member]</link:label>
    <link:label id="lab_bmrn_LicensePaymentsMember_documentation_en-US" xlink:label="lab_bmrn_LicensePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LicensePaymentsMember" xlink:href="bmrn-20221231.xsd#bmrn_LicensePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LicensePaymentsMember" xlink:to="lab_bmrn_LicensePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8b46c3d8-b27d-40c6-9e3e-d1c677cd3291_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cb287524-146e-41bf-b941-84f5aa30bc9d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c9637939-376f-442b-8a90-10255b255bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cd03d4ba-bde2-4442-8c8c-a1ca0ebb61fb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_2e6d6931-6144-4bbf-b7d3-67d3202726f7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Interest expense, net of tax, on the Notes</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36dfe1fd-598c-411a-afb3-9229e4833d0b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef142bcf-d9c0-460d-bf1c-b869c34becf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_7887f7e3-55da-497b-a84b-ee3947b82c91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_d1c183a3-c9e8-4a3a-9dee-696dc4781eba_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea048ceb-a337-4765-b370-dc4c0a6ed6ea_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_354f491f-4a04-451b-a534-5f09ac049ff4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e2c99b54-7170-4e93-8ffb-e2874f928038_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_75c55844-b8dc-4d47-909e-e79cd3f696ec_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1bde98b5-a489-4c95-aa28-f742e14a7459_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bbccfbae-0f1a-48e8-bae1-53b8cc711efc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_6eb527da-9f24-4eb7-9b0d-a5b38eea808d_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Three</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_cfbfc7bf-8102-4217-b7e3-c0d8deeda12e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4ccb9879-c2fd-4f87-990a-266e5ba3d5b6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares of common stock, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation_68a9f60b-32a4-44f1-9953-f0645aeee952_terseLabel_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation_label_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation Section162 Limitation</link:label>
    <link:label id="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation_documentation_en-US" xlink:label="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax rate reconciliation section 162 limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationSection162Limitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:to="lab_bmrn_IncomeTaxRateReconciliationSection162Limitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_edc4f031-145f-4f31-872b-1ec7da8239d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AuditInformationAbstract_label_en-US" xlink:label="lab_bmrn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bmrn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bmrn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AuditInformationAbstract" xlink:href="bmrn-20221231.xsd#bmrn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AuditInformationAbstract" xlink:to="lab_bmrn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d4c74f4-6210-40db-82c5-f3a70e15610d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_09e5a9ee-4ad0-4846-bc99-f74dec42e372_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount net of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_689f180e-6b4f-432c-9ee9-da2dbf2ee68e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense on Debt</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5567e666-9999-49b9-87ad-f336981c11da_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_dcfae272-f3b6-49ef-9db2-a0da2d7b9a9b_terseLabel_en-US" xlink:label="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock With Service Based Vesting Conditions</link:label>
    <link:label id="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_label_en-US" xlink:label="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock With Service Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock with service based vesting conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedStockWithServiceBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:to="lab_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationLineItems_66ed62ec-c0d0-4ee9-a277-404c5d3d6d15_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Line Items]</link:label>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationLineItems_label_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Line Items]</link:label>
    <link:label id="lab_bmrn_SupplementalBalanceSheetInformationLineItems_documentation_en-US" xlink:label="lab_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental balance sheet information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:to="lab_bmrn_SupplementalBalanceSheetInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_815ece95-5c71-4f04-82f9-9e2f75dc36dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_51505f06-716a-4915-bfd9-c78cf18d778a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Classification</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_700fc47b-4831-4c3d-b209-0f50957782a7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductSevenMember_d4f6418c-282b-40b3-8861-96c5f63ea33a_terseLabel_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRINEURA</link:label>
    <link:label id="lab_bmrn_ProductSevenMember_label_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Seven [Member]</link:label>
    <link:label id="lab_bmrn_ProductSevenMember_documentation_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 7 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductSevenMember" xlink:to="lab_bmrn_ProductSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_990c7331-4777-404b-ad64-1946746c46fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company common stock held by the NQDC:</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation, Share-Based Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:to="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ff541587-4944-490d-a92a-80bb09cd7ff3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in unrealized holding gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a9874670-0b18-4153-8b42-5d822427d11c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_a820e36e-19a9-491b-8fe0-545554268472_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1c686b12-91a5-4635-9ec4-40906e284885_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_270e5dac-47c9-498b-964c-d07ad9005353_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductThreeMember_6123bddc-a697-466f-a0a3-b8153cced0d9_terseLabel_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NAGLAZYME</link:label>
    <link:label id="lab_bmrn_ProductThreeMember_label_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Three [Member]</link:label>
    <link:label id="lab_bmrn_ProductThreeMember_documentation_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductThreeMember" xlink:to="lab_bmrn_ProductThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherInformationLeaseLiabilityAbstract_893ca31e-5455-4df8-b629-1b54ac187be7_terseLabel_en-US" xlink:label="lab_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Information</link:label>
    <link:label id="lab_bmrn_OtherInformationLeaseLiabilityAbstract_label_en-US" xlink:label="lab_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Information Lease Liability [Abstract]</link:label>
    <link:label id="lab_bmrn_OtherInformationLeaseLiabilityAbstract_documentation_en-US" xlink:label="lab_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Information Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:href="bmrn-20221231.xsd#bmrn_OtherInformationLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:to="lab_bmrn_OtherInformationLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortMember_6cb02c57-e4ac-469b-a10a-ae954c82d45e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell</link:label>
    <link:label id="lab_us-gaap_ShortMember_label_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortMember" xlink:to="lab_us-gaap_ShortMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c9eb3f9e-6108-4a9d-aae6-4cf6b2a9c087_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_02f29f40-e4c0-41e7-bd9c-0c15995833a5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_10b526ef-4bf9-47e6-acb9-6f78d023d0ad_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4bee6811-333a-4192-8573-c1af5c398e5f_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_ebffc625-fba7-495f-a7ec-a3ca5803b48c_terseLabel_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans, net of tax</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_label_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_documentation_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value new issues net excess tax benefit tax deficiency.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:to="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4c3abdd9-6076-4707-a58a-6d33e3c6e9d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1c1018c5-a3c1-43e5-a44c-9f648ed0fa26_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in unrealized holding gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_18b62c61-6bfa-47c7-b387-c2d2a637d3d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_57726fcd-ea54-43e2-bb2a-a1badc024793_terseLabel_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset amortization and contingent consideration</link:label>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_label_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization And Contingent Consideration</link:label>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_documentation_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:href="bmrn-20221231.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:to="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_73db4212-d6b2-443d-a3d3-8fc4bc9a4a12_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Table]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Table]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and geographic information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:to="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_e8cc9d76-66b0-492a-8f0f-a12b5df4f4a3_terseLabel_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates payable</link:label>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates" xlink:href="bmrn-20221231.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AccruedGovernmentAndOtherRebates" xlink:to="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_NumberOfTranchesInOfferingPeriod_9ac4a9c2-e604-40b8-afc7-2a139e8da1c4_terseLabel_en-US" xlink:label="lab_bmrn_NumberOfTranchesInOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches in offering period</link:label>
    <link:label id="lab_bmrn_NumberOfTranchesInOfferingPeriod_label_en-US" xlink:label="lab_bmrn_NumberOfTranchesInOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches In Offering Period</link:label>
    <link:label id="lab_bmrn_NumberOfTranchesInOfferingPeriod_documentation_en-US" xlink:label="lab_bmrn_NumberOfTranchesInOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches In Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NumberOfTranchesInOfferingPeriod" xlink:href="bmrn-20221231.xsd#bmrn_NumberOfTranchesInOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_NumberOfTranchesInOfferingPeriod" xlink:to="lab_bmrn_NumberOfTranchesInOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AccumulatedGainLossFromOtherMember_fb0b414d-83a6-4f94-ae7e-c319846d4493_terseLabel_en-US" xlink:label="lab_bmrn_AccumulatedGainLossFromOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bmrn_AccumulatedGainLossFromOtherMember_label_en-US" xlink:label="lab_bmrn_AccumulatedGainLossFromOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain Loss From Other [Member]</link:label>
    <link:label id="lab_bmrn_AccumulatedGainLossFromOtherMember_documentation_en-US" xlink:label="lab_bmrn_AccumulatedGainLossFromOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated gain (loss) from other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccumulatedGainLossFromOtherMember" xlink:href="bmrn-20221231.xsd#bmrn_AccumulatedGainLossFromOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AccumulatedGainLossFromOtherMember" xlink:to="lab_bmrn_AccumulatedGainLossFromOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongMember_e1479583-4a58-47eb-b57c-dc18676f5593_terseLabel_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase</link:label>
    <link:label id="lab_us-gaap_LongMember_label_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongMember" xlink:to="lab_us-gaap_LongMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_af481675-16f8-4327-9b4b-b1e3762c30d1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a330be32-07ae-4348-927c-360aa2c8fd3c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3de77a55-0787-4797-b29d-b0c83bd01ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_FirdapseMember_a37e7cd0-4a5a-4109-af56-cf92e43b7c8a_terseLabel_en-US" xlink:label="lab_bmrn_FirdapseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firdapse</link:label>
    <link:label id="lab_bmrn_FirdapseMember_label_en-US" xlink:label="lab_bmrn_FirdapseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firdapse [Member]</link:label>
    <link:label id="lab_bmrn_FirdapseMember_documentation_en-US" xlink:label="lab_bmrn_FirdapseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firdapse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FirdapseMember" xlink:href="bmrn-20221231.xsd#bmrn_FirdapseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_FirdapseMember" xlink:to="lab_bmrn_FirdapseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_5eadd397-71b8-4a46-aaa8-5d398386a42e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_a521311c-1dbc-4bb5-a013-ca46cfe61265_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d5e72257-8f67-46ff-8dff-ad044407ef35_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_96a9eabb-c087-4197-89b5-44fbb238811b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_ecb759f8-90db-4e9a-b39e-e2151389d690_terseLabel_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2018 Credit Facility</link:label>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_label_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]</link:label>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_documentation_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving two thousand eighteen credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:href="bmrn-20221231.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:to="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_06b2bbde-2323-4b92-91f9-3ac626d45bfa_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IndependentDirectorMember_32244cce-aba2-451b-9528-ee94ed69edb0_terseLabel_en-US" xlink:label="lab_bmrn_IndependentDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Director</link:label>
    <link:label id="lab_bmrn_IndependentDirectorMember_label_en-US" xlink:label="lab_bmrn_IndependentDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Director [Member]</link:label>
    <link:label id="lab_bmrn_IndependentDirectorMember_documentation_en-US" xlink:label="lab_bmrn_IndependentDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IndependentDirectorMember" xlink:href="bmrn-20221231.xsd#bmrn_IndependentDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IndependentDirectorMember" xlink:to="lab_bmrn_IndependentDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_8ab7b6fd-5df4-41f7-8a23-3f009f8773f9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18144b20-796d-461e-adb9-6544c448e669_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_BiomarinRetirementSavingsPlanMember_d7f691b6-597f-4379-9904-9464747fd19f_terseLabel_en-US" xlink:label="lab_bmrn_BiomarinRetirementSavingsPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Retirement Savings Plan</link:label>
    <link:label id="lab_bmrn_BiomarinRetirementSavingsPlanMember_label_en-US" xlink:label="lab_bmrn_BiomarinRetirementSavingsPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomarin Retirement Savings Plan [Member]</link:label>
    <link:label id="lab_bmrn_BiomarinRetirementSavingsPlanMember_documentation_en-US" xlink:label="lab_bmrn_BiomarinRetirementSavingsPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin retirement savings plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BiomarinRetirementSavingsPlanMember" xlink:href="bmrn-20221231.xsd#bmrn_BiomarinRetirementSavingsPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_BiomarinRetirementSavingsPlanMember" xlink:to="lab_bmrn_BiomarinRetirementSavingsPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_962adb42-a4ba-4b92-ba3a-531a8d207edc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7324deed-f4ce-49a7-ad90-271b935d6012_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3d95a1c2-7126-4f20-9284-8f7856c998a7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_0f25fad7-9c2a-4691-bab1-1cedb3d6b036_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramOneMember_8b8ab384-859c-46b1-a12f-b75ca319b0df_terseLabel_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program One</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramOneMember_label_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program One [Member]</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramOneMember_documentation_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:to="lab_bmrn_EarlyStageDevelopmentProgramOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_53c89e95-d8e4-4319-a8e8-c1041835da50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1918de79-ddb9-4f0f-a2b8-ee896a25fc5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6c06147-28dd-404d-86fb-306e7e3b70b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86ba62ac-29ba-47e3-a67e-0acd40bb5c80_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductSixMember_5200a718-920c-4c4a-887d-0405a78b5d33_terseLabel_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VOXZOGO</link:label>
    <link:label id="lab_bmrn_ProductSixMember_label_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Six [Member]</link:label>
    <link:label id="lab_bmrn_ProductSixMember_documentation_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductSixMember" xlink:to="lab_bmrn_ProductSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_94c99436-460f-4587-b71b-2168bd56c0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Forward Foreign Currency Exchange Contracts Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_ba515e80-0a0b-4457-9eb2-e07fe18e50c5_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Goal Target</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_label_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Strategic Goal Target [Member]</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_documentation_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Strategic Goal Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:to="lab_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_f0da2e52-3ee4-4394-bee6-8f48e588dcf1_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_39bc1bcb-539b-451b-b2f8-63b694917d9c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_da475fd5-e489-4133-bfaa-a1a93087e485_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_d044934b-eb21-418e-8140-f39d1b9d1652_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_422d2262-1ee6-482e-a1bc-c90ceab51454_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_76b74f30-a3d6-4f7d-bd74-450f48808469_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_ee35dcca-6d7f-460a-8ecb-3cf1fd64484d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's contribution to match employees contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_119fe922-9c70-4925-ae71-eefbd3568951_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_6360d354-ea93-44fe-8293-fff42d2f91a9_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceiling achievement level</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_label_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage</link:label>
    <link:label id="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_documentation_en-US" xlink:label="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:to="lab_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2b2fbbf4-a7a1-4406-afb8-b2a7220c3248_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_44bef87d-dba3-47e0-b79f-5395ed918eaa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3eddfb2f-9733-4ac9-87fc-05b0a4d394e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c186f32c-9648-4052-9bae-8d764013b147_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_427ad0cc-19e2-48ca-bf68-9056e6ab0745_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_27462626-21b0-40ec-bce5-1411f5d5286c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c4c53994-d8ae-42ef-80c6-e23e4ec652e9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0c6c66ef-38cb-4109-81ee-624c6808ac07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_08f02347-5912-4dd5-be0c-4cdb5bfc2624_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9c15c23a-bee9-422c-bd51-9007352b2532_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_b15cdf47-590e-4db7-859c-04a448192a02_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange loss (gain)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_44b2aec8-def5-46af-b13c-b77a8a625e29_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_24256903-4434-4579-aacf-7127c245897b_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_abe4dc7e-1921-4b05-8da8-0b8c841dd96d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76710d7b-a85a-4729-bd2d-43a29869ba9d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_06ecbba4-386f-4f5f-b6ca-30e327689f84_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_cdbbe21b-c482-4999-892f-a82523645db8_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8725f42a-d1fc-4287-9b3c-3a36d8cb1026_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3980d0b5-0e21-43ab-bc76-52f7ac03a46d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_cd84979f-bbf0-4e65-a399-c884794e2c2e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod_e50b47fb-d6a3-4ef3-84e3-d29da56ef2b5_terseLabel_en-US" xlink:label="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax statute of limitations period</link:label>
    <link:label id="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod_label_en-US" xlink:label="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Statute Of Limitations Period</link:label>
    <link:label id="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod_documentation_en-US" xlink:label="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax statute of limitation period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxStatuteOfLimitationsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:to="lab_bmrn_IncomeTaxStatuteOfLimitationsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4c1e7ad-4722-4500-ab13-92fed978d6f5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d2e74605-5ed5-444f-acf6-f4479da6a9fb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_200ab739-b3f3-4c12-b364-5fc180b9226f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_6ce285ea-5c61-4289-a749-7c1f139a4514_terseLabel_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange remeasurement of Euro denominated contingent consideration</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_label_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_documentation_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:to="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_2603c21e-fe3b-453a-bf43-dcda44ac2ee8_terseLabel_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems" xlink:to="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f92263b0-48e2-47f3-a76f-948171ddf0d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7458a674-34e9-4152-bd03-a27b75167cc3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dc6fc2b5-f57f-4d7e-824a-d5a45a223e8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RoyaltyRateUpperLimit_4c8e6b47-8a95-4da8-80cc-3657dd96cc7d_terseLabel_en-US" xlink:label="lab_bmrn_RoyaltyRateUpperLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties on net product sales</link:label>
    <link:label id="lab_bmrn_RoyaltyRateUpperLimit_label_en-US" xlink:label="lab_bmrn_RoyaltyRateUpperLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate Upper Limit</link:label>
    <link:label id="lab_bmrn_RoyaltyRateUpperLimit_documentation_en-US" xlink:label="lab_bmrn_RoyaltyRateUpperLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate upper limit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateUpperLimit" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateUpperLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RoyaltyRateUpperLimit" xlink:to="lab_bmrn_RoyaltyRateUpperLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_90630865-862f-41ac-9e93-b6bfd43a9024_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_fd4e39d7-4b61-4733-aa32-1c0356c10959_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_eaf1c6f4-d36b-4c25-bdd5-0707ef35c950_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would affect the effective tax rate if recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e1ff743-d35e-4502-887a-9d3957533969_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of stock option awards, years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_265925d6-8e4f-4445-a728-c9c5dcc6fba0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_d490c6fb-2407-4a09-8268-d2c36b7d33f5_verboseLabel_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other non-current liabilities</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Noncurrent Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities noncurrent fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e95d4420-f8a4-47a1-9aec-62dd444ed073_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_827cffc0-cbdb-416e-b762-48d243a23f52_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bed776d1-82db-422c-8c7b-f362fb94068d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_6e040a8e-82ce-4147-8def-e4dffe367b5b_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f16fde34-654f-479f-8c80-566d76ce33b3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e56fd233-6b6a-41fc-bf74-e28f2a973659_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_f0b834ae-5584-4525-aca9-c944bd06ac35_negatedTerseLabel_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Common stock held by the NQDC</link:label>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_label_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</link:label>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_documentation_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:href="bmrn-20221231.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:to="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fca0c9c7-621a-4c1d-8996-549778b4f702_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e3e617ae-4604-41eb-a76d-82fa91299071_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9cb90448-0865-4d12-8db5-36d7366a6c43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during the period, net &#160;&#160; of tax impact of $3,247, $1,596 and $(227), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c1046825-7e19-4292-89eb-5b00e26e11ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af89f3fc-b7fc-468b-be1b-5f99e2a45d60_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_83f3683a-1bed-4da2-9449-a9a659153f58_terseLabel_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</link:label>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_label_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]</link:label>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_documentation_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Senior Subordinated Convertible Notes Due in May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:href="bmrn-20221231.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:to="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_22e08ff0-0c4d-4a83-a2e6-5becf1c712fb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_21226fab-d0d0-4bb1-9ff6-edc929fc10ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based awards, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_e66f9063-45a4-4457-8836-c4c7984fb41b_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Monetary Long-Lived Assets by Geographic Region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_6fe44ddb-6344-4ca4-acca-809c2c15b81d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_309b429a-5ad7-49ea-9fe1-0b99f2ee6592_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_e6f4ba5c-4778-4f1d-a82e-4e4c507eef3f_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Four</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0e3555d6-3d6e-450b-9f64-c8c215b59f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b6d3bc87-cd43-41d2-af0a-e839e28f8e4f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_599d7070-d43b-4ae5-b7fb-449ab4df9311_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RepurchasedRoyaltyRightsMember_7d02a024-dd90-4574-a773-a9b7517e7241_terseLabel_en-US" xlink:label="lab_bmrn_RepurchasedRoyaltyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased royalty rights</link:label>
    <link:label id="lab_bmrn_RepurchasedRoyaltyRightsMember_label_en-US" xlink:label="lab_bmrn_RepurchasedRoyaltyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased Royalty Rights [Member]</link:label>
    <link:label id="lab_bmrn_RepurchasedRoyaltyRightsMember_documentation_en-US" xlink:label="lab_bmrn_RepurchasedRoyaltyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased royalty rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RepurchasedRoyaltyRightsMember" xlink:href="bmrn-20221231.xsd#bmrn_RepurchasedRoyaltyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RepurchasedRoyaltyRightsMember" xlink:to="lab_bmrn_RepurchasedRoyaltyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f0d53d9b-a68b-43b3-afa4-b98036fea894_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_34dce5f8-573c-4245-8fc2-e98061fa40eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_eb56a23b-f197-44b3-b014-5f11c9aab8df_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_eb8140df-91d0-4a08-b5d4-52f97ec09418_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe2d6b18-1db2-4204-ab95-3a61c6ebdb30_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d45ef0be-922d-4bda-8e7f-652d6b83ad3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2ac3df51-7990-4a99-88b4-4be780a0e28f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AND COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductEightMember_6b1945c2-6d70-435f-b54f-61283260c441_terseLabel_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FIRDAPSE</link:label>
    <link:label id="lab_bmrn_ProductEightMember_label_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Eight [Member]</link:label>
    <link:label id="lab_bmrn_ProductEightMember_documentation_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductEightMember" xlink:to="lab_bmrn_ProductEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2a8df54c-6667-4313-a8d8-c8c9f2cab2d4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_1d6973d6-512b-47ce-a86b-8b07f5f293b9_terseLabel_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities maturity period</link:label>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities Maturity Period</link:label>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:href="bmrn-20221231.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:to="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1898f409-925a-489d-ac56-ffcc6435ee08_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductOneMember_c17e1595-fe91-464f-9399-965d38b99d7c_terseLabel_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALDURAZYME net product revenues marketed by Sanofi</link:label>
    <link:label id="lab_bmrn_ProductOneMember_label_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product One [Member]</link:label>
    <link:label id="lab_bmrn_ProductOneMember_documentation_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductOneMember" xlink:to="lab_bmrn_ProductOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_efbf2cb1-e5d4-4871-8d76-e3b9f97e77a8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_216366ce-abb1-4513-b957-1e4fef9c95aa_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b044841a-0cc6-4516-b9e2-ca49593a88ed_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7b16e014-e0aa-4857-a631-7563d89525f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_f0249a39-1d45-4779-be0e-e629b774bbfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1669fff4-432c-410e-a76f-37d76b41e940_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_faab9963-1cd9-47c5-ba75-66a66f77eba3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4395fcce-ce0e-4c38-af08-8fecd31656c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_07803231-5f68-415a-98f1-27a0f5868884_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_52994c58-b848-44f0-87d3-d161521d8573_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_25e863b4-3f59-4a71-a49e-38f60c9e92be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e061ce38-8622-4888-81a3-3bc5daf30181_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8d4637e9-b2ed-4b4c-8216-3171fb0870ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d6728c12-2516-412b-a033-5cf5ac141a95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AcquiredIntellectualPropertyMember_341107a5-1ccb-4af8-b7bd-b028967376b0_terseLabel_en-US" xlink:label="lab_bmrn_AcquiredIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property</link:label>
    <link:label id="lab_bmrn_AcquiredIntellectualPropertyMember_label_en-US" xlink:label="lab_bmrn_AcquiredIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Intellectual Property [Member]</link:label>
    <link:label id="lab_bmrn_AcquiredIntellectualPropertyMember_documentation_en-US" xlink:label="lab_bmrn_AcquiredIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AcquiredIntellectualPropertyMember" xlink:href="bmrn-20221231.xsd#bmrn_AcquiredIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AcquiredIntellectualPropertyMember" xlink:to="lab_bmrn_AcquiredIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f0ab2ae1-95e9-49f4-a3fa-55bb0585c434_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e308ce17-3cbb-4838-98f9-2d395a5614ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_80d35ba4-2585-4c4d-9693-f874e3ddd0ab_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_eb58515f-2c89-4a46-b426-7c6e4f945092_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aea030a6-da3a-4683-b884-47001103164a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e775905-1ade-4c81-985b-0687d32cc8e1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_WeightedAverageDiscountRateAbstract_db9e7102-5980-49a5-9339-22d72e077f8d_terseLabel_en-US" xlink:label="lab_bmrn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate:</link:label>
    <link:label id="lab_bmrn_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_bmrn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_bmrn_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_bmrn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_WeightedAverageDiscountRateAbstract" xlink:href="bmrn-20221231.xsd#bmrn_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_WeightedAverageDiscountRateAbstract" xlink:to="lab_bmrn_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2bb6c4ea-8798-40ca-81a4-42c4519c7675_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_a1478163-0faf-44ee-b5e0-0632d5430bfa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f33862d5-8615-435f-a831-1c7966be79ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract_04018935-7004-440e-9f24-11ba3543fb0f_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract_label_en-US" xlink:label="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Lease Information [Abstract]</link:label>
    <link:label id="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract_documentation_en-US" xlink:label="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Lease Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalCashFlowLeaseInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:to="lab_bmrn_SupplementalCashFlowLeaseInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b80fe564-38e0-4c68-9538-e48f0a17a844_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3605b183-997c-4250-951e-69288cde8fec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc59a960-a271-440b-aa86-c585f3843c9b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_a7b314cf-b5bb-4a2e-ad25-52fcbeea1706_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ThirdPartyMember_87475312-556c-4db2-a8c2-93ca7629ed55_terseLabel_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party</link:label>
    <link:label id="lab_bmrn_ThirdPartyMember_label_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party [Member]</link:label>
    <link:label id="lab_bmrn_ThirdPartyMember_documentation_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember" xlink:href="bmrn-20221231.xsd#bmrn_ThirdPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ThirdPartyMember" xlink:to="lab_bmrn_ThirdPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_70d32d3d-3a93-485a-a730-a5c132cc9f4d_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract_90c06031-be53-4687-91ca-a9cfbb33e99d_terseLabel_en-US" xlink:label="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years):</link:label>
    <link:label id="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:href="bmrn-20221231.xsd#bmrn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_bmrn_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4d8b889-e7f3-43c6-b7bb-c5eefc1c94ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dd7eae53-182e-42a1-92df-09e534a669ef_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_c5b73111-4223-49af-9477-c8bc61efb53a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d78654b-04c5-4d15-9ab4-32751ed8c885_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3cea4dc6-5603-4d19-ba9e-85b133b0ee13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_a50e003a-d1be-494b-90c5-4d7ff7da4b94_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_MerckSeronoMember_d43a62d6-5230-45a2-8d97-bc2743243aca_terseLabel_en-US" xlink:label="lab_bmrn_MerckSeronoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Serono</link:label>
    <link:label id="lab_bmrn_MerckSeronoMember_label_en-US" xlink:label="lab_bmrn_MerckSeronoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Serono [Member]</link:label>
    <link:label id="lab_bmrn_MerckSeronoMember_documentation_en-US" xlink:label="lab_bmrn_MerckSeronoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Serono.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MerckSeronoMember" xlink:href="bmrn-20221231.xsd#bmrn_MerckSeronoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_MerckSeronoMember" xlink:to="lab_bmrn_MerckSeronoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_44053cdc-01d2-47f0-a81e-b8cd6f721d5b_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_089e73b9-a07c-442c-b67e-b5b74934ca94_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_19423526-b04e-4040-a022-b1eb40c8f7b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ca9e2f5e-d65e-4705-855a-1e340a904f05_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fba453ec-83b3-4fb5-b2e3-f04f42fd19a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_9e1dd6f0-04c3-4332-b29a-47d01c042a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_61a55122-72dc-4057-88f3-cb2bbfd9c49a_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_a64662b6-59cc-438f-a2ac-e4e96a50e1bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ca65927-897f-4776-bb15-938d377ff763_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance/deferred benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_53cea1dd-7d69-47c4-9bb9-37446a3c8faa_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial assets, Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_7c41afe8-82e8-4376-9be2-a2035898797d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentConsiderationMember_1289f889-e898-44d3-93be-125147ca7ae4_terseLabel_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bmrn_ContingentConsiderationMember_label_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_bmrn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember" xlink:href="bmrn-20221231.xsd#bmrn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentConsiderationMember" xlink:to="lab_bmrn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_82279282-0f48-405a-aafa-5bec6fd521e9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_8f95c46c-40ab-487c-a6f7-0b4929a60467_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_30eed393-a393-461f-b61b-c5ccb957596c_terseLabel_en-US" xlink:label="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual shareholder return multiplier</link:label>
    <link:label id="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_label_en-US" xlink:label="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Shareholder Return Multiplier On Absolute Basis, Percentage</link:label>
    <link:label id="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_documentation_en-US" xlink:label="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Shareholder Return Multiplier On Absolute Basis, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:href="bmrn-20221231.xsd#bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:to="lab_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_ed764c00-ea5a-43ca-814b-8223b35ec04a_terseLabel_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Operating Margin Target</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_label_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Core Operating Margin Target [Member]</link:label>
    <link:label id="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_documentation_en-US" xlink:label="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Award, Core Operating Margin Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:to="lab_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_33f6b6c0-b273-4dec-aa62-0ae395b982ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c6466579-391d-4c95-8a76-f201135cbd6b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ec3ad61e-59ab-4df1-afd5-29d0ad21fa39_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cefbb04e-bd51-4d9a-b57b-f3d431807edb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_29d8a978-1c3e-49d4-98d3-d3c949f7be67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Price&#160;in Active Markets For Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_4a9ced01-8670-4232-887c-938e421dc3ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_9cb2920a-390b-4fdc-83a0-6c5359ca9d91_terseLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liabilities Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StrategicInvestmentMember_27bc2079-fa6d-40f3-a999-64aa1b0a5a07_terseLabel_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment</link:label>
    <link:label id="lab_bmrn_StrategicInvestmentMember_label_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment [Member]</link:label>
    <link:label id="lab_bmrn_StrategicInvestmentMember_documentation_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember" xlink:href="bmrn-20221231.xsd#bmrn_StrategicInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StrategicInvestmentMember" xlink:to="lab_bmrn_StrategicInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_3f35d45e-6f6e-47ad-8962-4e29c4af2252_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3534902-7b22-45a4-a3ad-0c3a6d321122_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_6c49e4f7-861b-4868-9c7e-28bc7cd511ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Source Income Subject to US Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_580cb4dd-2f62-4e9e-8165-aa9871cc8d43_terseLabel_en-US" xlink:label="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="bmrn-20221231.xsd#bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_6b334c6d-a671-4865-8fc1-c3b1e553050d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments to Ares Trading S.A. (Merck Serono)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_82b589b2-a2a4-418e-80ba-51831d862f9f_terseLabel_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities maturity period</link:label>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities Maturity Period</link:label>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:href="bmrn-20221231.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:to="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0e5a3db8-0e49-4a2b-ba71-68afbcbab716_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution of maximum percentage over employee's annual compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_bbddd80b-2181-45e4-892d-d23aea816408_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_label_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems" xlink:to="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_5b2f79cd-2621-41fc-9ba7-1de45a4fe24e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_88877e9d-ae4a-418d-ae3c-d18e21ef26e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_5ec21264-8b8b-4cda-aa6a-122416582951_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed by Sanofi</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ace50ee3-5349-4647-ae50-ac2030ce46b7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cd3c39d6-181a-464e-ac43-60150e9f43a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_70ddc7ec-3dde-4e40-9270-540a8ce84bf9_terseLabel_en-US" xlink:label="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_label_en-US" xlink:label="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Loss Other Net Of Tax</link:label>
    <link:label id="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_documentation_en-US" xlink:label="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income loss other net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:href="bmrn-20221231.xsd#bmrn_OtherComprehensiveIncomeLossOtherNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:to="lab_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_bdd351dd-b0ca-4a0a-81f6-6947185e5b11_terseLabel_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_label_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments [Member]</link:label>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_documentation_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestrictedInvestmentsMember" xlink:to="lab_bmrn_RestrictedInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0cb8089f-bc35-45e0-a8d3-7504794ed64c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_09cadabb-0692-4754-8989-e6e10c8cb428_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property Plant and Equipment Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5498acd1-1b7d-4c7c-a7f6-d9dac8d04f8c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_711f58fd-104b-48f8-b839-af4bd59ca03c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_85c2c87d-e496-44de-ae02-c3f14522cac3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_1c7d16c9-3546-40e3-a8dd-055a2f0ab621_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_583b5af1-ed0d-4a9d-b7b6-d9a72696eb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_695720a9-29c9-4ebb-9e5f-aacf2454b752_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_db6ab83a-792a-48df-b8a7-dadf7633bccd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6901e09e-392c-49bf-99d2-9859628b3815_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bfc8763b-a5c9-4406-b5d7-949c48ca834b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Deletions) Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_5a9eecf6-c2f1-47f6-b1cd-cb8727d2e465_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0bb3fdf2-401c-430b-af09-a918b5729957_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_67d301b2-1abe-4943-8bb5-def554fdc1e8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_379ccdc6-d18e-43db-bec0-c807908d69b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e15c7808-3954-4943-b4d8-58da66d5faa0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_5a2bbccd-5c4b-4bf5-9ab7-e391c0697510_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_09abecfe-2578-4f19-8962-3e758b95eae7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Product Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7c1719d5-b747-4eda-aa5c-e03076109980_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_21bac24e-5147-48f3-a9ea-e90b6cffaab5_terseLabel_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty and other revenues</link:label>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_label_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty And Other [Member]</link:label>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_documentation_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RoyaltyAndOtherMember" xlink:to="lab_bmrn_RoyaltyAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a774363f-9274-4fa2-b420-28188006edea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6f6328b7-c664-4bae-92ee-be45c7414215_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_159b8fbf-c533-4b0f-9b58-12e6bd7cc153_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4694a21f-07ac-409c-98f2-fe93644a39bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_8dddb230-809c-45e6-a8bd-57c8db7470fe_negatedTotalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_dbe93c46-c005-42b8-b0ab-b19625f4363e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_b32b8aa1-f2c1-4622-a11d-58dcf153b6e3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_661e8204-ac1a-4f19-91f4-0f787ff34729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6c9e3b65-f905-432f-b00b-5c0460a34013_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_ef790da9-5e70-42b4-8f4b-a8961ab27568_terseLabel_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign and other</link:label>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_label_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government And Other Debt Securities [Member]</link:label>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_documentation_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government and other debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:href="bmrn-20221231.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:to="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerOneMember_cebfaa38-7479-45df-b134-22be154d226d_terseLabel_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_ec678b26-f9a4-4c18-9284-f8125e4baa03_verboseLabel_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_label_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_documentation_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerOneMember" xlink:to="lab_bmrn_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d74b978f-ae4f-411c-86bf-a0f6cb5e4cb5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_2c1e930f-28a2-4f67-ba1a-9ae8723cae72_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19119498-cc46-4c59-9da4-8a4d260b136e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34ce8017-7c7e-4456-9735-6eba52c1a7ac_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b9eacdd8-855e-4da1-9218-4fffbaf4bf42_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e875501e-e319-4ce3-bc8c-ce14783be150_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_21e3c6e1-9d87-44ad-a323-cfc55eaf7fd4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac8a51f2-eac0-4032-a97b-dc41258696a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract_00bfcffc-a557-4313-a1e0-fa2e5a999c9e_terseLabel_en-US" xlink:label="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities</link:label>
    <link:label id="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:href="bmrn-20221231.xsd#bmrn_MaturityOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:to="lab_bmrn_MaturityOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_a0964cd7-a4b7-4e62-bbb0-d74fbdaf7f8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AverageClosingPriceTrailingPeriod_921e3004-5c63-4613-ac5d-599001eeae5d_terseLabel_en-US" xlink:label="lab_bmrn_AverageClosingPriceTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average closing price of common stock, trailing period</link:label>
    <link:label id="lab_bmrn_AverageClosingPriceTrailingPeriod_label_en-US" xlink:label="lab_bmrn_AverageClosingPriceTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Closing Price Trailing Period</link:label>
    <link:label id="lab_bmrn_AverageClosingPriceTrailingPeriod_documentation_en-US" xlink:label="lab_bmrn_AverageClosingPriceTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average closing price trailing period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AverageClosingPriceTrailingPeriod" xlink:href="bmrn-20221231.xsd#bmrn_AverageClosingPriceTrailingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AverageClosingPriceTrailingPeriod" xlink:to="lab_bmrn_AverageClosingPriceTrailingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f67ea8a2-4fc2-43d5-be60-7fa08694c270_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3b29d998-3266-44f4-999c-42a2552c656a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e4001840-416e-4349-b03d-f2a42c941845_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_5d4c6501-2eb5-442b-b4d0-72ccd3b255ae_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_79c1a9f7-f424-48bb-8fca-27a1acd260b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_65738d2d-05ca-4f50-903f-4d4f931e31a6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_baa73838-5ab5-4f69-be40-c5978214f29c_terseLabel_en-US" xlink:label="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:label id="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_documentation_en-US" xlink:label="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="bmrn-20221231.xsd#bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_360d8966-792b-48bf-90c3-d9f3a44debf1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock:</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c3425ed6-5d7e-46e8-ae18-89b9cfb3db37_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_713c7e64-a5ec-4235-bc9a-8f71b6e31528_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_17f8dd12-5296-4090-a7bb-be0d39c41eff_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_005f9c39-da32-44fd-b0a4-4ebe805b96c3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Deletions) Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_1a25a53a-b5e3-40b4-84cc-2aa88cbac7f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing&#160;and&#160;laboratory&#160;equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_de1418ba-b638-4220-b3de-61325f934978_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_aa2ec23b-8f6b-432e-98fb-a060974467ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug &amp; General Business Credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_8339f46b-d3b1-496a-8519-80b4f35bff4c_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ff50c7b9-3db6-4ebd-bfad-7f2924dc6f79_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_6d09afd5-7d6b-4f90-b03b-878d34474be2_verboseLabel_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other non-current assets</link:label>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Noncurrent Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets noncurrent fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2ffa4838-4de3-482f-bac6-f1f860b39b0f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_c2a49671-4a0a-4a9e-9faf-997202f384c5_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Two</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_353623d1-bc58-4f4e-9572-7e84d6fd86c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandImprovementsMember_1effc372-67f8-4474-85b9-c48a03a2cbae_terseLabel_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land improvements</link:label>
    <link:label id="lab_us-gaap_LandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovementsMember" xlink:to="lab_us-gaap_LandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6b6d321c-7fe2-4d11-8339-5b3a708e7655_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_14799bfb-110c-4001-81fe-c874a786b4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_65b1fb21-923d-45ab-a446-c22c6731a848_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e6301415-57f5-49b2-af50-481aeb31c74e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6ed071b7-4763-4eb6-be51-2aa6f73898b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fe4107ae-e50e-4e0e-adcc-72cfc5cd32ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity decrease</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_7efde862-ac70-4003-b23f-46617d536d17_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4c737fec-f850-43eb-8786-a77550ac534c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9afd131a-38cb-4d77-8c94-777e6b075c82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_53394194-59d3-41d7-bb47-46aac3a4e40e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_4204684c-d680-4550-8185-5f26b51c9c62_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_394b0956-0270-4763-9900-cf95c066e18f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_fbc9e367-0348-4ddc-ad16-af8e8b31a0bf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_289a5595-61fc-44dd-b68f-4698062c4cde_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RoyaltyRateLowerLimit_dc06b6b0-44f9-485a-a4ba-bbd619026dcc_terseLabel_en-US" xlink:label="lab_bmrn_RoyaltyRateLowerLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties on net product sales</link:label>
    <link:label id="lab_bmrn_RoyaltyRateLowerLimit_label_en-US" xlink:label="lab_bmrn_RoyaltyRateLowerLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate Lower Limit</link:label>
    <link:label id="lab_bmrn_RoyaltyRateLowerLimit_documentation_en-US" xlink:label="lab_bmrn_RoyaltyRateLowerLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate lower limit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateLowerLimit" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateLowerLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RoyaltyRateLowerLimit" xlink:to="lab_bmrn_RoyaltyRateLowerLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0d1ae4b9-16df-4eda-826b-18dcd67bbba1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6d1d3f36-08a1-4b6b-91b4-949afd6b5ea7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liabilities Measured at Fair Value Using Level 3 Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_TechnologyTransferMember_3e0bda3b-fa27-4e1b-97be-824134b658e6_terseLabel_en-US" xlink:label="lab_bmrn_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology transfer</link:label>
    <link:label id="lab_bmrn_TechnologyTransferMember_label_en-US" xlink:label="lab_bmrn_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer [Member]</link:label>
    <link:label id="lab_bmrn_TechnologyTransferMember_documentation_en-US" xlink:label="lab_bmrn_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TechnologyTransferMember" xlink:href="bmrn-20221231.xsd#bmrn_TechnologyTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_TechnologyTransferMember" xlink:to="lab_bmrn_TechnologyTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_248eabb2-0fea-4962-b9ba-e285445697a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit:</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_c6e2c257-a913-4f95-ba0b-1f7b8b053aac_terseLabel_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Awards with non-Revenue based Performance Conditions</link:label>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_label_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:to="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_c5544063-e4dc-4f42-a6a5-b02467356ecd_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Line Items]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Line Items]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and geographic information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:to="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1422cde5-4b4c-477f-8a25-e503ceb73ef0_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5750c1ee-857d-41af-ae75-b92a014a6eff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock:</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_b8e09ef9-1e67-47cb-999b-0d209a251bdc_terseLabel_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</link:label>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_label_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones</link:label>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_documentation_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:to="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_d1a8e26e-7878-43f6-ac63-268052f65c5d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_02fa298f-b8ea-48d2-b9b4-99af0831a901_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ff489dc4-f4d1-4498-957c-d9527698f5a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9aa036a6-85f3-4044-9955-52c61fc41994_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0159bbf9-1af6-4847-ae78-c922aa0d6ad1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_14ec5e76-0d5e-4e7b-a098-e63acb6910ca_terseLabel_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period between customer control and payment</link:label>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_label_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Period Between Customer Control And Payment</link:label>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_documentation_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Period Between Customer Control And Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:to="lab_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2e674bd7-c5ed-403e-8c37-bfd8d9b3f744_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_12d1d84a-fb2e-4ab0-aa93-27fe9bca78a2_terseLabel_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans (in shares)</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_label_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_documentation_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value new issues net excess tax benefit tax deficiency, shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:to="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ac26191-3a49-426e-941b-80388df22fa0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_187a2653-4c4b-489f-8a5e-9268aa0754d1_terseLabel_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term after customer control</link:label>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_label_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Payment Term After Customer Control</link:label>
    <link:label id="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_documentation_en-US" xlink:label="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Payment Term After Customer Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:to="lab_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0f348217-325b-475c-b48e-315838a104f3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_021762c5-e08a-41fb-9c02-a145a85e1a94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4174c429-afef-416d-a7d3-b29159eb41db_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit carry forward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_df0cf0ea-89f9-4391-bf85-35b39a18c2c2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal R&amp;D and orphan drug credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_8e329f38-ee6c-49e2-bfd6-e16134659ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiability_e19887fb-9b8d-47f9-b06f-e2a09527d377_totalLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiability" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_f0b4de57-7a65-43eb-b661-40476607d6cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's contribution from employment commencement</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_94c36cc9-0bd3-43cc-9f51-fc01fbea1cd2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_eed97100-7c58-459c-9a8c-9d63988e9c17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f164cc8b-4429-4694-a93b-2282131950cf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_07d1a856-7658-4686-b3a0-59fb009d70ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_69dc3d46-acb2-422e-9d9d-241f380ca5a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_9fa8a18a-f348-4948-af95-4a189ae3ffe3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of fixed-rate convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ec4791eb-9775-4724-9aa5-c6eeca62dc05_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_c2e97ca4-ee5f-4317-8682-8dc5385979a8_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities related to fixed assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_label_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Fixed Assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_documentation_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:to="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_d79aed0f-1d2c-4ba0-a391-352f22a3a7d4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_19c0dd80-1e10-49f3-8ac0-71878317665a_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_1793c4b4-fe54-48b2-b9fd-911fa7ac8f72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fafd9b93-3640-42c0-9c6f-723af071a771_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bdd4c39-dc17-4223-a7ce-2eaede8f9a58_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued operating expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e26a449-7e6f-4753-bb82-c4333fdd098c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f66db2ff-4c61-4d67-bfc7-696751e3a0a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6e75bf01-1e9a-4c71-8cef-6c1301b41e85_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7753ad19-9915-4810-bb5b-4eb514594963_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1e62f0f4-577a-44f0-af9d-94b60ca31421_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_c37c599b-90a2-492f-89fc-6cdf0e6acc2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d416ee57-dc92-4afd-85fa-250f4c1496bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38a4e26e-66f0-459b-88bc-92be4789f5c9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d5ef33ff-c13d-4b26-a303-5a9c9889cc6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7cc1af04-20b3-4024-bec6-b2c6f0142267_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_ab6fdcc9-7cc5-43d6-ba26-404d6cfd7441_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5b51eadf-ff1b-4552-a463-fae5f0fa88b1_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_eec1f256-796e-4425-93a2-ecfc7df70d21_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_65fbadd6-128a-409f-8d41-e21eaf8c478a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7b25c650-2fcd-4bdb-96f9-12d698cc6397_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6a5f7c69-96da-41a3-8cd0-6087bc7a1554_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_57a4e7f6-4c4f-4827-b0ef-320a5f538cba_terseLabel_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NQDC Plan assets</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_label_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Deferred Compensation Plan Assets [Member]</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_documentation_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified deferred compensation plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:to="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_58dc2c51-5335-43e4-96ca-1552d8de07cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4690eae2-4eff-4a74-b99f-4d3d6ac1e99f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME (LOSS) FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_d03eaada-5b9d-41cd-b870-499f9a69ba7c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f330d52c-8fb1-4bac-b4ee-8749303dbca5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_b8fcb8ae-d718-4184-9dc6-113372a47958_terseLabel_en-US" xlink:label="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity</link:label>
    <link:label id="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_label_en-US" xlink:label="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Minority Equity Investment in License</link:label>
    <link:label id="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_documentation_en-US" xlink:label="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Minority Equity Investment in License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:href="bmrn-20221231.xsd#bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:to="lab_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cf53c2d4-d292-4d9b-896b-2cbc5e7b5f7d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses, reserves, and prepaids</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_14f546fe-9169-4dcc-8b43-a28945c315bf_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8e6be9de-b338-4401-b3fb-3633656f3741_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_8a49703b-c362-4841-ae02-f82f8c0c5374_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial liabilities, Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_372db4e3-514f-423b-8e5b-84e23211f5e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5f2ba3c6-5791-4054-865d-7328c405eec6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cc8fe41-6d1d-4199-b03c-d851e1ec19e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AAndRKuvanAgreementMember_b1e33277-f67f-436a-9d05-8b7256a9ac4e_terseLabel_en-US" xlink:label="lab_bmrn_AAndRKuvanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A&amp;R Kuvan Agreement</link:label>
    <link:label id="lab_bmrn_AAndRKuvanAgreementMember_label_en-US" xlink:label="lab_bmrn_AAndRKuvanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A And R Kuvan Agreement [Member]</link:label>
    <link:label id="lab_bmrn_AAndRKuvanAgreementMember_documentation_en-US" xlink:label="lab_bmrn_AAndRKuvanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A&amp;R Kuvan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AAndRKuvanAgreementMember" xlink:href="bmrn-20221231.xsd#bmrn_AAndRKuvanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AAndRKuvanAgreementMember" xlink:to="lab_bmrn_AAndRKuvanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6ddfe5d3-8966-4c7a-967c-6a2f59941741_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3aabb69-5d0c-4dc3-aa9e-98aae284f9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8bfeb1b4-3dc1-4ced-a85c-8c0dfa5a758d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_13d85f55-59f0-4bdd-b4ad-949fc541924f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8a552e7c-2652-4332-a5d5-7e4d9d57f61b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3e1178ac-6f59-4c7b-8953-140e2fabd611_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_52c02b32-a028-4956-9e25-1eaf017703a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital:</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_96352ea8-62d7-4a01-b87f-04b0d0e73597_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_700974cc-2de1-492c-a7d0-b29ea8cdcd53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_0fb67660-b376-439e-a803-be381a2376d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3eed0a5-2820-49f3-8d96-6981c70a5568_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa79e9d1-b760-4c60-a9a0-07e9d596b10e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d973eb63-bc4a-40d2-9bf0-791e38620bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8ed69bb9-87b8-4276-8643-97265259d94c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7696b35e-66b6-4bfa-97c4-77ec726895c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_9f429e0e-b4f8-4ed1-9b8a-32c6959043a1_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_32af0de1-ce5c-49e1-931f-d894e45eead6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_32b983b3-066d-417d-8aa1-e31257954fc0_negatedLabel_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Assets</link:label>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Assets</link:label>
    <link:label id="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_bmrn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LeaseRightOfUseAssetsAbstract_16bcb8d0-15c1-452b-b59e-5caaa7b1a90c_terseLabel_en-US" xlink:label="lab_bmrn_LeaseRightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_bmrn_LeaseRightOfUseAssetsAbstract_label_en-US" xlink:label="lab_bmrn_LeaseRightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets [Abstract]</link:label>
    <link:label id="lab_bmrn_LeaseRightOfUseAssetsAbstract_documentation_en-US" xlink:label="lab_bmrn_LeaseRightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LeaseRightOfUseAssetsAbstract" xlink:href="bmrn-20221231.xsd#bmrn_LeaseRightOfUseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract" xlink:to="lab_bmrn_LeaseRightOfUseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2bc69d7-31e6-4783-bc06-87f9452ebcb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per RSU granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_761fed15-627c-4e51-89d6-cdcf64bdd320_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e2ac0770-3c28-48ae-ab28-d17795cdc579_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_272c4789-5671-4d04-99cf-ff48561887ee_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed by Company</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_d6146878-21b4-451b-a2f1-0764f4a3ff19_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_526f6903-dccd-4216-9ef9-e714b6a2e672_negatedLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses reclassified from AOCI to earnings</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_e580fc04-68e5-4c00-a8bd-6ac739cc646b_terseLabel_en-US" xlink:label="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable under the Notes</link:label>
    <link:label id="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_label_en-US" xlink:label="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuable Under The Convertible Notes [Member]</link:label>
    <link:label id="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_documentation_en-US" xlink:label="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuable Under The Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:href="bmrn-20221231.xsd#bmrn_CommonStockIssuableUnderTheConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:to="lab_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c01a46dc-71c9-49f5-8b46-f81e4e24fffb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5105edff-ebbf-4439-8a47-7b2c3a23411d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_77eff8ea-3e29-4c4b-9b2b-4b7ed1d1b761_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss), basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_28b544fd-18fd-4d92-9188-051e4601bb6e_totalLabel_en-US" xlink:label="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset future amortization</link:label>
    <link:label id="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_label_en-US" xlink:label="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Not Commenced, Net</link:label>
    <link:label id="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_documentation_en-US" xlink:label="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Not Commenced, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:href="bmrn-20221231.xsd#bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:to="lab_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_436e189b-0640-48ad-a554-a0f1c9a7d66c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_ec67066e-d10a-413a-9d97-e84da62a103b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_69ab6977-b222-437b-8cd0-fec6b4027e6c_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_bf5df6d1-e3f7-470e-b884-41c94b402a2b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance, Current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83776e15-0721-4b52-8845-58bdd4839b3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6867bd07-effe-481c-b62a-4d84f087d8cf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a6b5aa5a-ac3a-4153-abae-d4773cb14766_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock_395d2f39-cba1-480b-9bb3-410bf719c458_terseLabel_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock_label_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating And Finance Leases Other Information Table [Text Block]</link:label>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating And Finance Leases Other Information Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:to="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_b152afa8-39e7-4f6d-aad6-01af4f8901bf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6ddfc39d-6e44-410c-89a6-34782282fcfa_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ceb413a0-3e7e-4207-baf0-22313954154a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of awards under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_866a0ce5-4924-4286-9cf2-d0cbebe8336b_terseLabel_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Awards with Market Conditions</link:label>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_label_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:to="lab_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ff394a32-7804-4957-9540-8abc1061792a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_2531c498-d247-4a6c-965d-d689f4500880_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_8e76c66c-9844-4759-8ef6-81ec3b52dbe3_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible debt, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_99cb1749-eea2-4816-aae6-4bad87a92f17_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e2e6e39d-8717-42ce-b4cb-878cfbc0f36f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock_eae84933-3141-48e9-83a5-6f502f61545b_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts</link:label>
    <link:label id="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Accrued Rebates And Reserve For Cash Discounts Table [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated accrued rebates and reserve for cash discounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:to="lab_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7eb52309-b7d3-4d55-92b7-4b5f1bef2494_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductTwoMember_04e9447c-40dc-40da-858a-89d6598ee9eb_terseLabel_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIMIZIM</link:label>
    <link:label id="lab_bmrn_ProductTwoMember_label_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Two [Member]</link:label>
    <link:label id="lab_bmrn_ProductTwoMember_documentation_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember" xlink:href="bmrn-20221231.xsd#bmrn_ProductTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductTwoMember" xlink:to="lab_bmrn_ProductTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_240db44e-df33-466f-8239-a0bb7aa8469d_negatedTerseLabel_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized foreign exchange gain on settlement of contingent consideration</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_label_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Gain (Loss) On Foreign Exchange</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_documentation_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Gain (Loss) On Foreign Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:to="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_580919e9-07c9-4f50-b7a1-834c0ad938a8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Current Period Sales</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_78e6feda-54db-4c36-b5bd-86787da11053_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f119404-6ebe-412c-801a-b4af2a07cfed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79808dc7-21f1-40b6-ad30-e3b285454c25_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_bd5ebf9a-76b5-4007-b6b2-89d43c986205_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_label_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share based compensation arrangements by share based payment award equity instruments other than options restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:to="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0ce4c62c-e047-46df-aea4-be1edddc6697_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e3418138-36cc-423c-8feb-e4a0e3631fb6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aa7d7db9-2448-4685-a861-4eddd2f8eec8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bbd702f0-d091-4bac-99ba-a3c2b6605c53_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ff91e3cf-51ee-441d-9546-bf8963cb8ef1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_DebtInstrumentPercentageOfFaceValue_f2d4c1b1-9a9d-4713-90f9-4e86ecd406e8_terseLabel_en-US" xlink:label="lab_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument percentage of face value</link:label>
    <link:label id="lab_bmrn_DebtInstrumentPercentageOfFaceValue_label_en-US" xlink:label="lab_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Percentage Of Face Value</link:label>
    <link:label id="lab_bmrn_DebtInstrumentPercentageOfFaceValue_documentation_en-US" xlink:label="lab_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument percentage of face value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:href="bmrn-20221231.xsd#bmrn_DebtInstrumentPercentageOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:to="lab_bmrn_DebtInstrumentPercentageOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fa65e140-af17-41ee-93c0-457832adc455_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_db3c30a0-ba6e-4d0d-9f87-d0230a91cd5d_terseLabel_en-US" xlink:label="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_bmrn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f743349f-d8ef-4d30-af87-00a2af699cd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_b9c9b598-8147-4e36-a37b-087418baf1c8_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_214aa50e-e1f4-4c0f-bd2e-24113289ea77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_aafc1197-87e4-4bc7-bd2c-f7f32967c5b0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_04ce0ecf-076a-44df-af70-9d33aaede3ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dba85e4f-247d-40d5-9bbc-e7f2c3c814da_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_88ca163e-c4f0-4aeb-a595-b9896890671f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_77ec996e-21ae-48c1-b2cb-64ce98238e15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_832878b3-f8eb-4281-9280-88f1658bb711_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8f0f1196-345a-4ba2-930d-a4a91dc4503c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc5b4700-4a98-475c-9df0-7a606b24de6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_PegvaliaseAgreementMember_73621749-e3e0-4a92-a5a5-2e1e55220701_terseLabel_en-US" xlink:label="lab_bmrn_PegvaliaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pegvaliase Agreement</link:label>
    <link:label id="lab_bmrn_PegvaliaseAgreementMember_label_en-US" xlink:label="lab_bmrn_PegvaliaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pegvaliase Agreement [Member]</link:label>
    <link:label id="lab_bmrn_PegvaliaseAgreementMember_documentation_en-US" xlink:label="lab_bmrn_PegvaliaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pegvaliase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PegvaliaseAgreementMember" xlink:href="bmrn-20221231.xsd#bmrn_PegvaliaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_PegvaliaseAgreementMember" xlink:to="lab_bmrn_PegvaliaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_c5a28a3a-ba97-42fb-bdea-49a837a87e17_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_60b68dab-228e-4837-a443-215535a78502_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_a1ec3f83-c6d7-48cd-b329-30c46f478632_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during the period, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_6b9722d1-77b9-4350-b15a-c34640630285_terseLabel_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable" xlink:to="lab_bmrn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a5028fc9-2bd7-45d4-8859-0533075b7565_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ad2518b4-bd31-4de4-a717-28a614271267_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0518a2d0-4412-4f04-baaa-41f15e3f718c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_41e0598d-08cc-4051-85d2-731cfb43a397_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Balance</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_30dc2893-46cf-4b84-b37e-872b587d972a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c5f95d5b-ed93-49f5-aa95-9bbf3492368e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax benefit from stock options exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_153df2c4-c0df-446f-a28b-588ed6e7597c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83e58d3b-f3a6-4c8e-a9e3-829189fec92f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80986b89-421c-4840-a5af-568354d9a02e_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9ea81990-93f8-4c74-98e1-975070f38982_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_69df1e0d-66c4-4bc9-a81c-0a86222e7240_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_bb8fbd89-8d1c-49cd-981a-9ef848c0dc0a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount on convertible notes</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_75b11c0e-e43e-407e-8990-85b2d7e77926_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_115ec4fe-cfdd-4cd0-88e2-f3461057be11_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_057c7ca8-0850-485a-b1bd-061aa2b988f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_efa35c94-8a2b-40d8-8903-c82f80f01d4f_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7f962da3-8987-46a4-a4c4-a444434ade17_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d7be13e9-c55f-4d73-be64-e7119656314c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6b8f204f-19d7-438d-8950-937a9b49710a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_08996159-fca6-4fc4-a268-75fa66df182a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e2ec2a00-741d-4caa-afc6-1bdb818064c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6f9c8b85-6301-438c-ba46-153f91d12983_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerOneTwoAndThreeMember_e8189ca4-0c3f-4dc5-b5ce-2d4e7df09131_terseLabel_en-US" xlink:label="lab_bmrn_CustomerOneTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A, B, &amp; C</link:label>
    <link:label id="lab_bmrn_CustomerOneTwoAndThreeMember_label_en-US" xlink:label="lab_bmrn_CustomerOneTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One, Two, And Three [Member]</link:label>
    <link:label id="lab_bmrn_CustomerOneTwoAndThreeMember_documentation_en-US" xlink:label="lab_bmrn_CustomerOneTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One, Two, And Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoAndThreeMember" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneTwoAndThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember" xlink:to="lab_bmrn_CustomerOneTwoAndThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e50070c6-7413-4fe0-831c-abcebf12c49a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a15411d4-1453-4f9e-b0b4-2406747b8bfc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_62893303-c728-4b23-9c91-3968f9606fb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_40c9dc33-891e-4c50-ac24-ec90274c1d46_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_7ff1aa98-30f9-4afb-abb4-025efa520840_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd649095-a71d-4ea9-9397-ba3d9e803b60_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_39fe069c-13da-4d7e-a097-43a7f98355dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) Recognized in Earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a5143866-6122-4ff3-850d-aeca35194e55_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_country_NL_ce3fbd0f-be0f-4c10-b04f-ea41abd95c12_terseLabel_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dutch</link:label>
    <link:label id="lab_country_NL_label_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NETHERLANDS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_NL" xlink:to="lab_country_NL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b1d2d644-3910-46c5-9a82-49eb9731af48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff750049-14b3-4b4a-80f6-f32c3001156c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2619b26b-9dc0-45f1-a275-5795d32cc42e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_a250b8e1-6cd0-48f7-b681-6b66782ff11e_verboseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesLineItems_cece1df3-4302-4a05-9ecd-4024a4f81527_terseLabel_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bmrn_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_bmrn_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesLineItems" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems" xlink:to="lab_bmrn_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_6c339f02-48a0-411a-9e3c-6a2a9ad0178d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_3da33315-c545-4640-8e84-34499145b537_terseLabel_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NQDC Plan liability</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_label_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Deferred Compensation Plan Liability [Member]</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_documentation_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified deferred compensation plan liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:to="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_30659d36-c54e-4873-8bfe-d5efbf9c904b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a149d769-d715-4467-b288-cb67f752db20_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_06bf85db-32e0-4984-b2d6-5cae01e00390_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_1ab6be43-7918-4a1f-9c30-ffdfe5201f83_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_bb150e3c-0a6f-44e0-9636-9b9ea9a10166_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AccruedRebatesMember_64aaa553-4483-4e40-a21f-4fd5f1162c02_terseLabel_en-US" xlink:label="lab_bmrn_AccruedRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_bmrn_AccruedRebatesMember_label_en-US" xlink:label="lab_bmrn_AccruedRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates [Member]</link:label>
    <link:label id="lab_bmrn_AccruedRebatesMember_documentation_en-US" xlink:label="lab_bmrn_AccruedRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedRebatesMember" xlink:href="bmrn-20221231.xsd#bmrn_AccruedRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AccruedRebatesMember" xlink:to="lab_bmrn_AccruedRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_f023d306-d6ce-455d-951e-e2c873778ea5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, expected number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7707d302-15aa-4d51-9ca9-4124b45d41f5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_860979b4-f058-43d4-a102-7f9ed8e96088_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a96c01e8-0c2d-4bef-b0d6-72db58d9fa3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b59143ce-a4bf-404a-a563-c7c12f69cf9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_94cefa11-b0b2-4672-914b-9335e33e196e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramTwoMember_0a1dacfb-e596-4907-8b35-55723a2050de_terseLabel_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program Two</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramTwoMember_label_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program Two [Member]</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramTwoMember_documentation_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:to="lab_bmrn_EarlyStageDevelopmentProgramTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71f74ecf-89bc-4db3-a3e0-d4d9eb51af55_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0577cba-3ed0-417c-958d-7d5221c97d4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock_0feaf412-1ab9-40b8-85ee-e0af887e3284_terseLabel_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Information</link:label>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock_label_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating And Finance Leases Other Information Table [Table Text Block]</link:label>
    <link:label id="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating And Finance Leases Other Information Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:to="lab_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_8feea28d-a133-4b20-baf8-853895c60e7b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_aee7b023-59ec-4621-b1b0-c17ced6fd117_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_ad39cbca-e77d-4e68-897c-18a0a149545d_terseLabel_en-US" xlink:label="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Awards with Performance-Based Vesting Conditions</link:label>
    <link:label id="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_label_en-US" xlink:label="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Base Restricted Stock Unit Awards With Revenue Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand nineteen base restricted stock unit awards with revenue based vesting conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:to="lab_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock_1ace1ff2-5384-49b8-81bd-c2d3efc5a7e9_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lessee Lease Assets and Liabilities</link:label>
    <link:label id="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lessee Lease Assets And Liabilities Table [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lessee Lease Assets And Liabilities Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:to="lab_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_3cea1951-a44f-47a5-8a41-2e6edb9cc534_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4b0e0df2-fca1-453d-a6b2-3756517a4b2a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_95120a02-0e20-4a58-8028-ccd2cf2e2424_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d0839aaf-b9f5-43a4-8bd4-4005bcc52ac3_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2f28ce65-e8ac-43a2-ba01-e92b50620bc5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_17326dd1-67b9-40e9-9bf2-d99614d7bc86_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7d20d4b4-c98d-4df8-8280-3802ba402311_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4e8c9736-b97e-44e5-8d37-3a54f3cab358_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_d4148083-8f97-4d11-b47c-a7fe2866627f_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ebecd27a-3f7f-459d-ace3-128269c1895a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_6fb92014-da90-4156-8c8b-15b93b0b0295_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b700d420-3d98-4bf1-9fe5-f7e20c4e28cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_960ba190-3775-410f-b55e-91bb324013ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_94e55217-a29c-44e1-a7c9-a5a8cdd416df_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_25b06209-89c2-47ab-9615-beed7bf77e5b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income/(loss), diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4ec3eec2-a95a-4aed-80d0-682711e189d4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8f513e42-5336-4a99-924e-7cf86df68483_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ecd213b4-b94f-440b-ab26-5f4589b0c764_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d0cb07fb-cfde-48d2-a391-f202e9bf093f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80875e2d-9bba-40a6-9efd-74412c0195de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period, years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_e2afd01e-253a-48d3-b924-97369ff4f222_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Financing Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd803ed1-c599-4318-9668-9e09ecc552f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f54adf31-d1cb-4958-9858-3d7f7425c49d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_98ed39e1-16a5-46ed-ad0d-98497993f338_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d893b3ee-b0f6-4325-80e1-c0dba47ab39d_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d7d192c5-1525-46d7-a1b9-bc49b8889ed4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_929000b0-bfa2-4bf5-9877-946a078e1a36_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a637e77f-1e29-4ce9-9ae5-3b2e418fbf70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Source</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0db6f81e-4410-48a6-b3df-1798f2977b5b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_134658e7-247b-4beb-abc3-fee14da8d6c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_04e75431-7c9e-4832-92d7-6256f9275f84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1da9510b-dbb7-4105-a215-cddd12ab7acb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15997b49-b030-4e3f-81e9-64dd74300604_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense capitalized to inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2239a24b-3c0a-4d80-ad4e-78a104f2e543_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_583a9123-b076-40d8-9957-4f36a3b35237_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_c81a4c4c-cb77-48a8-9fd6-5ef22eaefa25_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense on convertible debt</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c9177070-f491-4f19-98a4-c7ede2d8b242_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_a4561097-3385-4318-b109-2aa4aeacfae7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_6a4681bd-9749-40e0-91a7-87eefa5a3834_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_89377de6-4a06-463a-ba61-0b2793d796bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_913927d6-7183-45a0-9a4c-e5c61d919fef_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LeasesLiabilitiesAbstract_da094ccb-2899-4ed8-9774-60a04dc39284_terseLabel_en-US" xlink:label="lab_bmrn_LeasesLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_bmrn_LeasesLiabilitiesAbstract_label_en-US" xlink:label="lab_bmrn_LeasesLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Liabilities [Abstract]</link:label>
    <link:label id="lab_bmrn_LeasesLiabilitiesAbstract_documentation_en-US" xlink:label="lab_bmrn_LeasesLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LeasesLiabilitiesAbstract" xlink:href="bmrn-20221231.xsd#bmrn_LeasesLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract" xlink:to="lab_bmrn_LeasesLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_cd040e68-867f-40ff-b308-3c64167138b4_terseLabel_en-US" xlink:label="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Licensing Agreement For Tralesinidase Alfa</link:label>
    <link:label id="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_label_en-US" xlink:label="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Licensing Agreement For Tralesinidase Alfa [Member]</link:label>
    <link:label id="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_documentation_en-US" xlink:label="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Licensing Agreement For Tralesinidase Alfa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:href="bmrn-20221231.xsd#bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:to="lab_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_d3afe31e-3244-4d3f-be8d-7d7e801083cb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority equity ownership</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_b093d19e-d19f-4755-9844-c03b94655cb1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ebd06701-4072-4578-83f4-ec876e08271c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3e565c6b-12e1-4680-86e2-63c38d285e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d51b9956-b3d3-4422-86ca-e607f42f1edf_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0adf0593-938b-41a4-8f57-e83930aac553_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_12d6ede5-d17b-4674-8e7d-0902ab9e18fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d17c20d8-40c9-47e0-9c86-7cc7f9ba4d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_52c77a74-c805-4f73-8470-53a5a772a61e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_DeferredTaxAssetsLeaseLiabilities_6be5caa2-15c5-4801-a6ee-ffdd0bf1fc7e_terseLabel_en-US" xlink:label="lab_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_bmrn_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_bmrn_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_bmrn_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_69f9d5fe-1245-4d9f-95c1-2dc48d7664dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0cfd23b5-3d87-43be-9818-59d214daf1d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fa47d2fa-a6f5-45bc-ad7d-97e2898ee7ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cf52e78d-bb4d-44ae-9901-03c0fd57c101_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets remeasured</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ebb42a2f-046e-4319-997d-f8b67f6a9b6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_f447ba86-b4e1-4860-94da-167b4c46b4ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5118ffc6-a3fa-46aa-8f4a-3b28ba0e1361_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_4d0138fd-351d-4432-8abd-b745d3c12a91_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_3af9cd02-0684-4a1b-8ca8-81a4c27a8882_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial equity grant value</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_45be83c7-15cf-442b-b5fe-50e9e32346d0_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_3bacf450-e8c1-417b-97d7-e673de8b1eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65f214f7-d07b-4c86-9c49-608fb4b250b4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_75ece262-dd8c-47c7-aa0b-c606b508b3a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy_14c4812d-6bf9-4da6-b879-455baef1f374_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Marketable Equity Securities</link:label>
    <link:label id="lab_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy_label_en-US" xlink:label="lab_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Owned Not Readily Marketable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy" xlink:to="lab_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_bd9d825c-91ab-4c1d-9373-60e54913034d_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_label_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share based compensation arrangements by share based payment award, equity instruments, other than options, restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:to="lab_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_166b2f04-e7ce-4f01-b10f-2ec5862b89e2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_d014ea46-d3de-4fd1-a8cb-081aa328bf3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Senior Subordinated Convertible Obligations</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerThreeMember_9e39078c-d079-41ec-95cb-36337803c247_terseLabel_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_bmrn_CustomerThreeMember_label_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_bmrn_CustomerThreeMember_documentation_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember" xlink:href="bmrn-20221231.xsd#bmrn_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerThreeMember" xlink:to="lab_bmrn_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_6a2ced24-6dd8-4bdb-a27b-1dc41575b450_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bmrn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8bd79386-164a-4e55-839e-80b5fcadddcb,g:b931fd50-a4a7-444b-8268-6050e6e4ba72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com/role/CoverPage" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b3e00c5c-0883-42da-bf55-5d6a68c0eb5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentType_b3e00c5c-0883-42da-bf55-5d6a68c0eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2ca9842d-fb05-4481-9761-5bbfa58a39ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentAnnualReport_2ca9842d-fb05-4481-9761-5bbfa58a39ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6d86a07-4393-4342-a0d0-7aadd3f21a12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentPeriodEndDate_c6d86a07-4393-4342-a0d0-7aadd3f21a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bfb9dd86-c2cc-4a6a-bdf2-185aeae9e11e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_CurrentFiscalYearEndDate_bfb9dd86-c2cc-4a6a-bdf2-185aeae9e11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_48094090-83e8-4710-b908-466d714d79ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentTransitionReport_48094090-83e8-4710-b908-466d714d79ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_79406ebb-456d-4311-aebf-1b50988186d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityFileNumber_79406ebb-456d-4311-aebf-1b50988186d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6b536c34-ccb2-4200-95df-da91a23956b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityRegistrantName_6b536c34-ccb2-4200-95df-da91a23956b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7cc6f071-44f6-4983-a3e3-d877987a6735" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7cc6f071-44f6-4983-a3e3-d877987a6735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e0ac3bdd-2e25-4f1e-8ec9-00b03426f230" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityTaxIdentificationNumber_e0ac3bdd-2e25-4f1e-8ec9-00b03426f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2d8007cf-aa45-4088-b4b1-a359c61ff4fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityAddressAddressLine1_2d8007cf-aa45-4088-b4b1-a359c61ff4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f10befcc-8978-4778-8938-d4e204c9aa25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityAddressCityOrTown_f10befcc-8978-4778-8938-d4e204c9aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5fb5adc6-4fe5-45cd-841e-e4aa02a3a955" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityAddressStateOrProvince_5fb5adc6-4fe5-45cd-841e-e4aa02a3a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9423ec28-1843-4d66-a196-13afc96b4a0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityAddressPostalZipCode_9423ec28-1843-4d66-a196-13afc96b4a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1fabaeff-994e-42a5-96df-a3956d4a7501" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_CityAreaCode_1fabaeff-994e-42a5-96df-a3956d4a7501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0da03c6c-a9b2-4e2c-9435-d9146e674a81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_LocalPhoneNumber_0da03c6c-a9b2-4e2c-9435-d9146e674a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_013843c1-11f3-42ae-9cc1-671f1452efc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_Security12bTitle_013843c1-11f3-42ae-9cc1-671f1452efc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1654a7a5-4817-4180-900a-6b4c21313206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_TradingSymbol_1654a7a5-4817-4180-900a-6b4c21313206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c42d18aa-569e-4e3f-9072-0b0dac0ae5d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_SecurityExchangeName_c42d18aa-569e-4e3f-9072-0b0dac0ae5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9cd72905-e883-416d-9e54-3524c4849129" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9cd72905-e883-416d-9e54-3524c4849129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_fcd08f14-e4d4-4930-94b0-87b0f7b53525" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityVoluntaryFilers_fcd08f14-e4d4-4930-94b0-87b0f7b53525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4c0b9a6c-5243-4cd3-954e-289e3133e381" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityCurrentReportingStatus_4c0b9a6c-5243-4cd3-954e-289e3133e381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b42e959b-9b63-453b-bc09-69bb45fdb353" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityInteractiveDataCurrent_b42e959b-9b63-453b-bc09-69bb45fdb353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7250843e-1b7e-4e4a-a10d-096cf9eb183e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityFilerCategory_7250843e-1b7e-4e4a-a10d-096cf9eb183e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1a7c497f-6e82-4647-9adc-2a9d67c872f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntitySmallBusiness_1a7c497f-6e82-4647-9adc-2a9d67c872f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_95715f02-0c1a-4b47-9520-0bc668d82c6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityEmergingGrowthCompany_95715f02-0c1a-4b47-9520-0bc668d82c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_20977548-4d78-40a0-9da8-8e5f0442c77d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_20977548-4d78-40a0-9da8-8e5f0442c77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_11d496ac-81be-4fd5-8023-fd400206d19b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityShellCompany_11d496ac-81be-4fd5-8023-fd400206d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f62ab1fa-dd58-410f-8ed1-241a81241b35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityPublicFloat_f62ab1fa-dd58-410f-8ed1-241a81241b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8600345a-193c-44bf-9f47-c3b94298dab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8600345a-193c-44bf-9f47-c3b94298dab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2100d00a-dad6-43a6-be4f-10dcaed6c9f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2100d00a-dad6-43a6-be4f-10dcaed6c9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1d3dc96c-be7a-448b-b8fe-7665df382db6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_AmendmentFlag_1d3dc96c-be7a-448b-b8fe-7665df382db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cd6228f5-e20f-4f50-9f9d-5fa65e8491c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentFiscalYearFocus_cd6228f5-e20f-4f50-9f9d-5fa65e8491c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a45ce766-2f19-4cd7-a837-950747e32678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a45ce766-2f19-4cd7-a837-950747e32678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5a57aff3-2167-4c5b-9cd5-1f68874075dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3c58c3c1-a780-45e4-b8ef-b8af8681802f" xlink:to="loc_dei_EntityCentralIndexKey_5a57aff3-2167-4c5b-9cd5-1f68874075dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/AuditInformation" xlink:type="simple" xlink:href="bmrn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AuditInformationAbstract_e751cb2a-3766-47f8-8cbe-4e112d6b69b3" xlink:href="bmrn-20221231.xsd#bmrn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_76b982f1-1d34-48dd-973c-8b2369241fb3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_AuditInformationAbstract_e751cb2a-3766-47f8-8cbe-4e112d6b69b3" xlink:to="loc_dei_AuditorFirmId_76b982f1-1d34-48dd-973c-8b2369241fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_10319bd2-8a6a-45d5-be08-ae51651a29b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_AuditInformationAbstract_e751cb2a-3766-47f8-8cbe-4e112d6b69b3" xlink:to="loc_dei_AuditorName_10319bd2-8a6a-45d5-be08-ae51651a29b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_95daebf8-80a4-4933-9065-15f04480de53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_AuditInformationAbstract_e751cb2a-3766-47f8-8cbe-4e112d6b69b3" xlink:to="loc_dei_AuditorLocation_95daebf8-80a4-4933-9065-15f04480de53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49f1a46b-db69-4831-840f-8451396460c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_35f424a4-40f3-4d6a-a1b1-3c7219eefeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49f1a46b-db69-4831-840f-8451396460c5" xlink:to="loc_us-gaap_AssetsAbstract_35f424a4-40f3-4d6a-a1b1-3c7219eefeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35f424a4-40f3-4d6a-a1b1-3c7219eefeb9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2218dfef-491d-4ca7-a950-6d238c79f912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2218dfef-491d-4ca7-a950-6d238c79f912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6948000-82d4-4f90-9f1f-bac60dbc313c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6948000-82d4-4f90-9f1f-bac60dbc313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0a8c0d1a-2764-444a-bc8c-dc57d04d1d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0a8c0d1a-2764-444a-bc8c-dc57d04d1d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e6ce78d4-fb8e-4243-a3f8-6bdb78a3daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_InventoryNet_e6ce78d4-fb8e-4243-a3f8-6bdb78a3daaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_364633cc-3b92-462c-ae8a-27889a42e432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_OtherAssetsCurrent_364633cc-3b92-462c-ae8a-27889a42e432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3fc8f5f6-3215-4e44-8a25-5b1345bf931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_839e431c-9e0b-40f2-8fdc-11588c6ef922" xlink:to="loc_us-gaap_AssetsCurrent_3fc8f5f6-3215-4e44-8a25-5b1345bf931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35f424a4-40f3-4d6a-a1b1-3c7219eefeb9" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_86e7ed00-dc83-41a8-b062-070522d8eeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_86e7ed00-dc83-41a8-b062-070522d8eeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de006d07-317b-4685-9d16-09c3cf267313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de006d07-317b-4685-9d16-09c3cf267313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83699d52-6b00-421b-a37b-25eb2fa2e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83699d52-6b00-421b-a37b-25eb2fa2e7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7e61150e-4911-4923-bc64-52ae660ab966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_Goodwill_7e61150e-4911-4923-bc64-52ae660ab966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d5fa0e11-01ff-4b84-9d96-dc760b0cd028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d5fa0e11-01ff-4b84-9d96-dc760b0cd028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6fbc354b-53a3-4714-89f5-fc460c8e40f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_506b75cf-14a1-4cdd-a5d9-60b7929e17fe" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6fbc354b-53a3-4714-89f5-fc460c8e40f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bb88f227-ca8e-423b-8832-f6b830e913de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35f424a4-40f3-4d6a-a1b1-3c7219eefeb9" xlink:to="loc_us-gaap_Assets_bb88f227-ca8e-423b-8832-f6b830e913de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49f1a46b-db69-4831-840f-8451396460c5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b122d078-49dc-4142-9b20-9da2c93d0d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b122d078-49dc-4142-9b20-9da2c93d0d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_171ddab4-1866-4cd9-b2c3-bc9dad0880b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b122d078-49dc-4142-9b20-9da2c93d0d6a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_171ddab4-1866-4cd9-b2c3-bc9dad0880b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b26c5f5c-dc7d-4846-b9d3-23a392db5298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b122d078-49dc-4142-9b20-9da2c93d0d6a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b26c5f5c-dc7d-4846-b9d3-23a392db5298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5c2aef8f-38fe-43a8-b6ee-5302c8d54e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b122d078-49dc-4142-9b20-9da2c93d0d6a" xlink:to="loc_us-gaap_LiabilitiesCurrent_5c2aef8f-38fe-43a8-b6ee-5302c8d54e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_50d7dc76-d2f3-45c2-8802-351e9024de68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_50d7dc76-d2f3-45c2-8802-351e9024de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_c6e80e37-b33d-4601-884b-4422c5832c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_50d7dc76-d2f3-45c2-8802-351e9024de68" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_c6e80e37-b33d-4601-884b-4422c5832c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d4d5f772-ac48-42f1-8f66-50fa8f07688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_50d7dc76-d2f3-45c2-8802-351e9024de68" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d4d5f772-ac48-42f1-8f66-50fa8f07688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c355afcd-3d1b-437c-b21f-a7fd80030853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_50d7dc76-d2f3-45c2-8802-351e9024de68" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c355afcd-3d1b-437c-b21f-a7fd80030853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ead74006-88a1-4f59-96c7-6a519831279f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:to="loc_us-gaap_Liabilities_ead74006-88a1-4f59-96c7-6a519831279f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5f0b9745-ced4-437b-a5b5-d7d6954a0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_CommonStockValue_5f0b9745-ced4-437b-a5b5-d7d6954a0a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5abd7115-b1a4-4fb1-b1f5-e300f0f22833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5abd7115-b1a4-4fb1-b1f5-e300f0f22833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_6b946993-d389-43d1-ba8c-d96f33de9451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_6b946993-d389-43d1-ba8c-d96f33de9451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7b14926-90b5-415f-985f-264087b14d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7b14926-90b5-415f-985f-264087b14d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_798cba0f-6645-4ca5-91bd-01c70443aff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_798cba0f-6645-4ca5-91bd-01c70443aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_062c9598-aba5-4503-b431-0f683f29e1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0fd95e8b-4316-442c-9f13-320960ac2570" xlink:to="loc_us-gaap_StockholdersEquity_062c9598-aba5-4503-b431-0f683f29e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d088ec2-9f05-455f-8303-532cc93affb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd1d631c-ea9d-4f1d-a975-e401e637bb92" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d088ec2-9f05-455f-8303-532cc93affb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c7dbbfb9-9a09-4465-a3ec-90444e387f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3f1d513a-817b-4280-947f-7c8786eeed2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7dbbfb9-9a09-4465-a3ec-90444e387f0f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3f1d513a-817b-4280-947f-7c8786eeed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9f9d13c1-a188-44ca-b909-bad434fdf67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7dbbfb9-9a09-4465-a3ec-90444e387f0f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9f9d13c1-a188-44ca-b909-bad434fdf67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2e7ddb1-fb8d-4413-ae62-67c1dac3df15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7dbbfb9-9a09-4465-a3ec-90444e387f0f" xlink:to="loc_us-gaap_CommonStockSharesIssued_e2e7ddb1-fb8d-4413-ae62-67c1dac3df15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6b1308ea-7563-4b5b-be11-bf876abf5be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7dbbfb9-9a09-4465-a3ec-90444e387f0f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6b1308ea-7563-4b5b-be11-bf876abf5be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cc1f8830-b8f9-4538-a4a3-19128f5548fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc1f8830-b8f9-4538-a4a3-19128f5548fa" xlink:to="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:to="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd515ec9-30cf-4880-89ca-b92d3a4fc14d" xlink:to="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_92de3438-cd18-410b-bba6-19e792f22500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:to="loc_us-gaap_ProductMember_92de3438-cd18-410b-bba6-19e792f22500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_93023b8d-04db-4cc8-a63b-a799dc7b66e5" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82c1ca4c-c40e-4406-93e2-af8029bdd741" xlink:to="loc_bmrn_RoyaltyAndOtherMember_93023b8d-04db-4cc8-a63b-a799dc7b66e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b28d67b9-ed47-40e9-8f01-013dc7fe0908" xlink:to="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb81f786-2847-4f0b-bc20-fb0152b4f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6e545863-ad87-40c0-ac27-db99bad5f150" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb81f786-2847-4f0b-bc20-fb0152b4f6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_77101799-70aa-4b20-9ba1-03c37c75a0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_CostOfRevenue_77101799-70aa-4b20-9ba1-03c37c75a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1b6ad50-197e-47c7-af73-06c449ff3a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1b6ad50-197e-47c7-af73-06c449ff3a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d3520859-0e42-42c1-b57c-8fabf1cd5284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d3520859-0e42-42c1-b57c-8fabf1cd5284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_0f0504d5-a681-43da-84fd-1f83ffe21034" xlink:href="bmrn-20221231.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_0f0504d5-a681-43da-84fd-1f83ffe21034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b8d76461-cb6c-4487-8b98-d3a0b03d094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b8d76461-cb6c-4487-8b98-d3a0b03d094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed2519e0-4171-4327-9276-c01963fefc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b2c5df85-458f-4467-a025-3f775db18878" xlink:to="loc_us-gaap_CostsAndExpenses_ed2519e0-4171-4327-9276-c01963fefc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29639c83-c57c-4eca-8e96-72aac3aa228a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_OperatingIncomeLoss_29639c83-c57c-4eca-8e96-72aac3aa228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4b765e61-085d-4afa-b21a-4828f7f189a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4b765e61-085d-4afa-b21a-4828f7f189a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ba572ef5-6a11-4be5-841b-65d64eafa6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_InterestExpense_ba572ef5-6a11-4be5-841b-65d64eafa6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a498331a-2ce4-4090-972c-623e15c121a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a498331a-2ce4-4090-972c-623e15c121a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_751495f7-2ea4-48e0-9f47-9c6c855d8b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_751495f7-2ea4-48e0-9f47-9c6c855d8b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4044b08a-b734-447b-b4c1-090c9d8e2435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4044b08a-b734-447b-b4c1-090c9d8e2435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3fdc40d0-8ddb-410e-91a6-1a69c3328c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_NetIncomeLoss_3fdc40d0-8ddb-410e-91a6-1a69c3328c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2fb30acd-b873-46c5-9dab-f7921012736b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_EarningsPerShareBasic_2fb30acd-b873-46c5-9dab-f7921012736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d9cfd9d5-1429-47c8-8e28-78466e6c2d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d9cfd9d5-1429-47c8-8e28-78466e6c2d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_295beedf-5f79-4468-8a1a-c34474c63a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_295beedf-5f79-4468-8a1a-c34474c63a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bed8de59-916b-485b-8381-6e2073f2c5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_028064f6-e8bf-4313-908c-46d80234c88d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bed8de59-916b-485b-8381-6e2073f2c5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d73e7812-8b92-4011-88f2-4349dfceaa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b51edc7-8047-46d9-b922-a3e121e43106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d73e7812-8b92-4011-88f2-4349dfceaa0d" xlink:to="loc_us-gaap_NetIncomeLoss_4b51edc7-8047-46d9-b922-a3e121e43106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d73e7812-8b92-4011-88f2-4349dfceaa0d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_d3e31752-53f7-46c9-b482-884aa6aaae27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_d3e31752-53f7-46c9-b482-884aa6aaae27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_07400aa8-796a-4dd9-9261-d4edfe8d41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_d3e31752-53f7-46c9-b482-884aa6aaae27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_07400aa8-796a-4dd9-9261-d4edfe8d41c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0153fcf6-401a-4086-ac45-5af7585bb6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_d3e31752-53f7-46c9-b482-884aa6aaae27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0153fcf6-401a-4086-ac45-5af7585bb6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b5452af5-2435-4291-af45-6eb0a3db7aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_d3e31752-53f7-46c9-b482-884aa6aaae27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b5452af5-2435-4291-af45-6eb0a3db7aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_922801ee-1240-4fdf-acbf-b3927aaefec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_922801ee-1240-4fdf-acbf-b3927aaefec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_deb7a615-3068-4e97-bf35-c96b0d25a989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_922801ee-1240-4fdf-acbf-b3927aaefec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_deb7a615-3068-4e97-bf35-c96b0d25a989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_df4e471f-52ad-4182-b153-2e84a4b99118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_922801ee-1240-4fdf-acbf-b3927aaefec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_df4e471f-52ad-4182-b153-2e84a4b99118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_19b14e73-3ce5-427f-a021-f04dda77e748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_922801ee-1240-4fdf-acbf-b3927aaefec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_19b14e73-3ce5-427f-a021-f04dda77e748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_14f78cc5-5d97-46aa-81f7-9521726a73b8" xlink:href="bmrn-20221231.xsd#bmrn_OtherComprehensiveIncomeLossOtherNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:to="loc_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax_14f78cc5-5d97-46aa-81f7-9521726a73b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b832ea1f-06e2-49d3-bbce-1c521a11166b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b6ddd3e-e386-4c17-84ba-0460521ff32f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b832ea1f-06e2-49d3-bbce-1c521a11166b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e14b2de-459d-4265-998a-91fb1aee0ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d73e7812-8b92-4011-88f2-4349dfceaa0d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e14b2de-459d-4265-998a-91fb1aee0ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a9963d5d-5686-43f3-a46f-88e82f26164b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a9cc9721-ced8-4188-aa54-a9014885fa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a9963d5d-5686-43f3-a46f-88e82f26164b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a9cc9721-ced8-4188-aa54-a9014885fa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_65aedbde-03aa-4107-bb3d-8f7645779029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a9963d5d-5686-43f3-a46f-88e82f26164b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_65aedbde-03aa-4107-bb3d-8f7645779029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_bcdcf9ad-c6ef-45ce-a9d7-4c418b4d9b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a9963d5d-5686-43f3-a46f-88e82f26164b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_bcdcf9ad-c6ef-45ce-a9d7-4c418b4d9b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_0b023484-fe74-4764-9b29-2b938fd9b510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a9963d5d-5686-43f3-a46f-88e82f26164b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_0b023484-fe74-4764-9b29-2b938fd9b510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_82fd39bb-bbe9-47d2-8d8f-354c732f548f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_82fd39bb-bbe9-47d2-8d8f-354c732f548f" xlink:to="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a44181e-2edc-454d-8180-57dd74ec2d5f" xlink:to="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c45fcb4e-630f-4fb3-a9b3-3bd3324e2ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_CommonStockMember_c45fcb4e-630f-4fb3-a9b3-3bd3324e2ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1f628c64-d464-4858-be72-1dc9c40a0770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1f628c64-d464-4858-be72-1dc9c40a0770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_aa7ba89f-6f1a-4fbe-8510-923b4ed99ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_TreasuryStockCommonMember_aa7ba89f-6f1a-4fbe-8510-923b4ed99ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_4d91a327-41b5-45c1-a2fe-90e1dd755b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_4d91a327-41b5-45c1-a2fe-90e1dd755b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c42f17-aaf2-4d2e-bdf8-e746389474fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c42f17-aaf2-4d2e-bdf8-e746389474fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04d829fe-4806-4a2b-8969-14bb255c54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1fa5bb27-b346-4ba5-a46a-0ffae4ad6722" xlink:to="loc_us-gaap_RetainedEarningsMember_04d829fe-4806-4a2b-8969-14bb255c54bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:to="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_4051bce8-ffcb-4afc-8ece-4cecb978f656" xlink:to="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4f31af94-55e9-47ad-99a9-d02a1458795c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4f31af94-55e9-47ad-99a9-d02a1458795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_6e584236-7735-42c6-ab03-4a281d250a88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_c5978ee3-8bbf-4fc2-80ab-d9b9721a6799" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_6e584236-7735-42c6-ab03-4a281d250a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503375fa-db52-477c-b9e2-11194b5ff070" xlink:to="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f31cb91b-0bb0-4ced-8ed8-08d66550ab21" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_234105fa-8d92-4fdb-a608-8a2e1a7567f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_234105fa-8d92-4fdb-a608-8a2e1a7567f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_0f0f6691-8929-48f1-9fee-533f072106e4" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_0f0f6691-8929-48f1-9fee-533f072106e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_74f0cee0-a71a-4185-8e52-de89fa353e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_74f0cee0-a71a-4185-8e52-de89fa353e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4e177c3c-2236-4b77-ab3b-4ce4b997cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4e177c3c-2236-4b77-ab3b-4ce4b997cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a671e965-fd14-4db3-908b-d96c13277c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockholdersEquity_a671e965-fd14-4db3-908b-d96c13277c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_556e0cfe-a74d-4255-88c6-a4d10f86387b" xlink:href="bmrn-20221231.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_556e0cfe-a74d-4255-88c6-a4d10f86387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2431e09a-632c-4745-b8b9-03e33945b3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2431e09a-632c-4745-b8b9-03e33945b3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccfc29e9-9155-46a3-bc28-9cbf7d5a6b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccfc29e9-9155-46a3-bc28-9cbf7d5a6b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_cc3d5511-e23a-43c5-af7d-fefd0beffe88" xlink:href="bmrn-20221231.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_cc3d5511-e23a-43c5-af7d-fefd0beffe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c4625d39-9b9c-434b-9d61-0f8760340d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c4625d39-9b9c-434b-9d61-0f8760340d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d93fc37d-01eb-403b-9b96-3986e926c039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d93fc37d-01eb-403b-9b96-3986e926c039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3fd8f088-5363-4ed1-90b5-436b433703a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_NetIncomeLoss_3fd8f088-5363-4ed1-90b5-436b433703a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a651e10-da49-4e67-a5d4-a38febb9cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_670efce5-1d93-4da5-97cf-d01e912374f1" xlink:to="loc_us-gaap_StockholdersEquity_3a651e10-da49-4e67-a5d4-a38febb9cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6a38910-bfa7-4aa3-a34f-0348b150179d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:to="loc_us-gaap_NetIncomeLoss_e6a38910-bfa7-4aa3-a34f-0348b150179d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7193c721-1071-4f67-870d-23f69479524b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7193c721-1071-4f67-870d-23f69479524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_77e8dfce-0122-47e1-a961-4c2b1b2d3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_77e8dfce-0122-47e1-a961-4c2b1b2d3bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_facac288-204f-4a4e-ac0f-a2acf44fd435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_facac288-204f-4a4e-ac0f-a2acf44fd435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_11be308f-c729-4ae0-9fb9-c5d1cf8419bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_ShareBasedCompensation_11be308f-c729-4ae0-9fb9-c5d1cf8419bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_84cc53d6-f01e-49af-ad39-23a665384a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_84cc53d6-f01e-49af-ad39-23a665384a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_afb3c3a4-b42f-4186-835a-05b81bf5988a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_InventoryWriteDown_afb3c3a4-b42f-4186-835a-05b81bf5988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d10288e1-dd61-4eeb-8ab7-d122c5c04250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d10288e1-dd61-4eeb-8ab7-d122c5c04250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a0b2575c-9679-4d1a-b391-85e390e469c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a0b2575c-9679-4d1a-b391-85e390e469c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a030c09b-4374-41c2-8ef7-c11e0a989e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a030c09b-4374-41c2-8ef7-c11e0a989e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c07b4ffa-4926-43ce-a9e6-ab52175e2414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a25b7da-4096-4a5b-a86e-000218ca9011" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c07b4ffa-4926-43ce-a9e6-ab52175e2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_84d7e974-958e-4685-b32a-899ee490c638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_84d7e974-958e-4685-b32a-899ee490c638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_579f0f87-3f10-4eea-9c76-ff3c6627b610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_579f0f87-3f10-4eea-9c76-ff3c6627b610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_2fc6ad30-f59d-4024-831e-ca0ea8eff3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_2fc6ad30-f59d-4024-831e-ca0ea8eff3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e9b4a40d-7b62-4981-853c-1279555520fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e9b4a40d-7b62-4981-853c-1279555520fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b227b322-1c26-495a-a10a-9b6a0176f049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b227b322-1c26-495a-a10a-9b6a0176f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff31c4c2-c260-45ce-999d-c9451eeefee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d93060a-c29e-4c0e-9c01-51800f0990ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff31c4c2-c260-45ce-999d-c9451eeefee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2699c75a-38aa-4b21-8fd3-3a9ad89a90cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da4296f0-0a5e-40a4-8c0c-5226540143e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2699c75a-38aa-4b21-8fd3-3a9ad89a90cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2fc6fc5b-699d-4d57-a4cc-a08abd1d74c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2fc6fc5b-699d-4d57-a4cc-a08abd1d74c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7b8711d5-b0db-4a51-b718-8ea877d62620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7b8711d5-b0db-4a51-b718-8ea877d62620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a35554c4-3d6b-418f-9d02-7b519ef18c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a35554c4-3d6b-418f-9d02-7b519ef18c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_d330a6e8-bf6e-4e9e-83a3-7e9f634ce8f5" xlink:href="bmrn-20221231.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_d330a6e8-bf6e-4e9e-83a3-7e9f634ce8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04b96201-240f-40d4-8e59-ca9d75dc5305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04b96201-240f-40d4-8e59-ca9d75dc5305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_02838252-ab76-4efd-a194-6b493c5770cc" xlink:href="bmrn-20221231.xsd#bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable_02838252-ab76-4efd-a194-6b493c5770cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_873322bf-9302-4f85-a706-8b7c8287ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_873322bf-9302-4f85-a706-8b7c8287ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_336976d1-8f48-4619-a406-10e1025b66eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf6a1d1-380b-4dc5-a861-5df81ba5f446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_336976d1-8f48-4619-a406-10e1025b66eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_551407f8-9898-45b6-ab36-e96ecebba6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_551407f8-9898-45b6-ab36-e96ecebba6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_da3b9f4f-050e-48b8-acf7-082f9be32b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_da3b9f4f-050e-48b8-acf7-082f9be32b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_16c00a03-23ed-4aca-9669-f51b7481f912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_16c00a03-23ed-4aca-9669-f51b7481f912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_bda35d2e-ea60-46d3-b3b4-f94cda81933a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_bda35d2e-ea60-46d3-b3b4-f94cda81933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_8792ab56-07ab-40e7-9898-ca3873a26fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_8792ab56-07ab-40e7-9898-ca3873a26fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e02c45c4-6e43-45d0-9f0f-6c31ebdee11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e02c45c4-6e43-45d0-9f0f-6c31ebdee11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a8abba2d-3519-4274-b12f-42e07798729d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a8abba2d-3519-4274-b12f-42e07798729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2827a401-3200-4049-aa3e-8fa095352a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2827a401-3200-4049-aa3e-8fa095352a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f10bf54a-c0fc-4d2a-9d80-268b301f226d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29357334-4e41-43fa-9e1a-7470f4f2c4b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f10bf54a-c0fc-4d2a-9d80-268b301f226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_41a9304c-9e54-4e54-8ca1-963788d7f128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_41a9304c-9e54-4e54-8ca1-963788d7f128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eeb42a20-7e69-4b68-a685-d4300ca38589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eeb42a20-7e69-4b68-a685-d4300ca38589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6885093e-748f-4136-a6c8-ec9bc7640de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6885093e-748f-4136-a6c8-ec9bc7640de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69979381-6de4-48cc-9a6f-18030afbc8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6885093e-748f-4136-a6c8-ec9bc7640de9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69979381-6de4-48cc-9a6f-18030afbc8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9b41861-519d-4096-b51f-fc4802d735d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6885093e-748f-4136-a6c8-ec9bc7640de9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9b41861-519d-4096-b51f-fc4802d735d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_72355725-241c-4db4-9455-0f21be30a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_72355725-241c-4db4-9455-0f21be30a4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0f2e8a95-f096-48f4-b776-24656149935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_72355725-241c-4db4-9455-0f21be30a4ab" xlink:to="loc_us-gaap_InterestPaidNet_0f2e8a95-f096-48f4-b776-24656149935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_ee8a827a-7d02-44fc-a7ed-2853624f970c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_72355725-241c-4db4-9455-0f21be30a4ab" xlink:to="loc_us-gaap_IncomeTaxesPaid_ee8a827a-7d02-44fc-a7ed-2853624f970c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_95643f0f-5596-4279-81e7-bf5f491f6e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_000c4e23-8cb6-4ca9-8542-e4dafe5103e4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_95643f0f-5596-4279-81e7-bf5f491f6e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_090459a5-00ad-4aa9-b521-8eb5c40c53af" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_95643f0f-5596-4279-81e7-bf5f491f6e92" xlink:to="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_090459a5-00ad-4aa9-b521-8eb5c40c53af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_0ae01dd2-2f43-4308-b017-95c291c9a3e5" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_95643f0f-5596-4279-81e7-bf5f491f6e92" xlink:to="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_0ae01dd2-2f43-4308-b017-95c291c9a3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af44dcf4-74ea-4bc4-8fca-7b2bdd22fa05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ab05e91-fc38-44ec-ad09-9f6950e4922d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af44dcf4-74ea-4bc4-8fca-7b2bdd22fa05" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ab05e91-fc38-44ec-ad09-9f6950e4922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c5de418b-c552-4409-a398-97608905fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_9ddfffd7-ed67-47c6-8811-243ad968d096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c5de418b-c552-4409-a398-97608905fb16" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_9ddfffd7-ed67-47c6-8811-243ad968d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3dc1fdc-c904-49b7-b0b2-3e7c645e4475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_55744a69-936f-47e2-b444-5b91ebe682b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3dc1fdc-c904-49b7-b0b2-3e7c645e4475" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_55744a69-936f-47e2-b444-5b91ebe682b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0b9b1dd-d58c-4c0f-a0f5-18ba27ae3825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25bea31b-15ff-4b98-bef6-dfdccffe42fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0b9b1dd-d58c-4c0f-a0f5-18ba27ae3825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25bea31b-15ff-4b98-bef6-dfdccffe42fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INVENTORY" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d26859fc-31a5-4921-985c-d5f0743a3296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_4d73a431-bfd2-4bd0-9c6f-af307d0b1207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d26859fc-31a5-4921-985c-d5f0743a3296" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_4d73a431-bfd2-4bd0-9c6f-af307d0b1207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12931728-396f-484a-b1d0-8c26cdd2d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0a621df2-4ec9-43e6-8c13-d732cfbe027d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12931728-396f-484a-b1d0-8c26cdd2d44e" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0a621df2-4ec9-43e6-8c13-d732cfbe027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b02269e9-014a-46e2-a75d-407c1e27f804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_12861fb2-2f6a-461e-84db-6f97c8962f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b02269e9-014a-46e2-a75d-407c1e27f804" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_12861fb2-2f6a-461e-84db-6f97c8962f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_499327fc-5055-4bf9-b608-71560d079ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cbf74106-33ff-4a7c-a3a2-d7ce6b5a7904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_499327fc-5055-4bf9-b608-71560d079ff9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cbf74106-33ff-4a7c-a3a2-d7ce6b5a7904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASES" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3411f3cb-ff1f-4afc-98ce-e796028095fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock_dd432b09-ec52-4d14-886c-8a4a44bd9863" xlink:href="bmrn-20221231.xsd#bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3411f3cb-ff1f-4afc-98ce-e796028095fe" xlink:to="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock_dd432b09-ec52-4d14-886c-8a4a44bd9863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBT" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_11853af0-013c-4d12-a779-573ce7317dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_29a74ba9-5213-41ba-9505-a0c7c0b66568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11853af0-013c-4d12-a779-573ce7317dda" xlink:to="loc_us-gaap_LongTermDebtTextBlock_29a74ba9-5213-41ba-9505-a0c7c0b66568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dc72b695-bd83-40c7-a13e-d121d98ad866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5852e3ef-f141-43b8-b3ff-927819e8696e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dc72b695-bd83-40c7-a13e-d121d98ad866" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5852e3ef-f141-43b8-b3ff-927819e8696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_06ecae15-d8c7-414f-96cb-cd0d4af5db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_a2af7b6e-7e3b-4f03-bec4-cd5a64a08198" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_06ecae15-d8c7-414f-96cb-cd0d4af5db0d" xlink:to="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_a2af7b6e-7e3b-4f03-bec4-cd5a64a08198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c8c5b1-7eb6-4e9e-9af4-99d2b9510778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a72e7e2d-79e7-4878-83ab-85f5a3f1e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c8c5b1-7eb6-4e9e-9af4-99d2b9510778" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a72e7e2d-79e7-4878-83ab-85f5a3f1e31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#OTHEREMPLOYEEBENEFITS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_3611618d-ab82-469d-a89e-36419b903d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_785ed883-3cf6-4c4f-8cd6-2a1427ec9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_3611618d-ab82-469d-a89e-36419b903d60" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_785ed883-3cf6-4c4f-8cd6-2a1427ec9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bbf03317-437b-4044-ac7f-ddaef91b82bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bf072de-31e8-4c1e-8e3a-d333769543af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bbf03317-437b-4044-ac7f-ddaef91b82bf" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bf072de-31e8-4c1e-8e3a-d333769543af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8f7b3609-5a82-4d0a-8547-e828126d8d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_51f90abe-390b-43e0-8aae-c4dc320e717f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f7b3609-5a82-4d0a-8547-e828126d8d9f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_51f90abe-390b-43e0-8aae-c4dc320e717f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LICENSEANDCOLLABORATIONAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59096aba-7fe3-4b59-8f85-4c905a588636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3df9c334-d993-405b-88d3-4f4fcec02fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59096aba-7fe3-4b59-8f85-4c905a588636" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3df9c334-d993-405b-88d3-4f4fcec02fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bmrn-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bd9b518-4a4a-4825-b34c-a9c4c1b76431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fe75b1fb-e981-47be-a7a5-328f69fddbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bd9b518-4a4a-4825-b34c-a9c4c1b76431" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fe75b1fb-e981-47be-a7a5-328f69fddbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81c68040-654d-4bfa-9510-31afed3a4f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81c68040-654d-4bfa-9510-31afed3a4f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d6f62a17-8ec6-4e7a-b920-f56fe1d54c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_UseOfEstimates_d6f62a17-8ec6-4e7a-b920-f56fe1d54c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7b20780-56ad-4d62-b5f9-2179549781f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7b20780-56ad-4d62-b5f9-2179549781f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_3338dfb6-1fc9-40b2-a969-5cc7ef20eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_3338dfb6-1fc9-40b2-a969-5cc7ef20eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy_89dc0450-ae26-470c-9dca-7c8013890af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy_89dc0450-ae26-470c-9dca-7c8013890af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_032f4dca-83f9-41b8-a701-59fcdd224223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_032f4dca-83f9-41b8-a701-59fcdd224223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cf95b438-9763-49ef-913a-4559f1e799ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cf95b438-9763-49ef-913a-4559f1e799ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_25950835-aa0a-4b5c-9072-769732aef7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_25950835-aa0a-4b5c-9072-769732aef7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b4ed15fd-da99-4b27-a894-c56b884a1c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b4ed15fd-da99-4b27-a894-c56b884a1c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_684d9af5-6bea-4aff-8728-3d6884b574bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_684d9af5-6bea-4aff-8728-3d6884b574bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_c0c13a4a-6b91-4a2d-8943-66b1d140507d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_c0c13a4a-6b91-4a2d-8943-66b1d140507d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f11f368f-5d30-4265-9327-3ded19dcd981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f11f368f-5d30-4265-9327-3ded19dcd981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b87c0509-a896-4ec6-86e6-2c9b575bfe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b87c0509-a896-4ec6-86e6-2c9b575bfe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_908ab40c-8946-4e57-820c-4450df41423a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_908ab40c-8946-4e57-820c-4450df41423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_985cee70-0f2d-4961-bfca-a514a8cbfba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_985cee70-0f2d-4961-bfca-a514a8cbfba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_292439e5-b76b-44db-a889-4b79ef781fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_292439e5-b76b-44db-a889-4b79ef781fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_e0ee54ef-9ab4-4fdc-8d0d-302b9f8178ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_e0ee54ef-9ab4-4fdc-8d0d-302b9f8178ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a9976cd3-1ec8-4b7b-b32e-96bcc2d89f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a9976cd3-1ec8-4b7b-b32e-96bcc2d89f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_bf941ea8-8757-487f-9140-48db9b35c066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_bf941ea8-8757-487f-9140-48db9b35c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_14cf8b04-30c3-4100-91c0-2c52f1961aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_14cf8b04-30c3-4100-91c0-2c52f1961aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b46af670-4b78-4a5d-bf95-bd17f37a16b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b46af670-4b78-4a5d-bf95-bd17f37a16b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcdba26d-fb93-4760-863b-6320bb735e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53777b7c-86e9-4e7e-8691-9a870e6df1cd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcdba26d-fb93-4760-863b-6320bb735e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_517a1729-fb07-4a30-b8ce-2cdbfc1512e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_2768801c-375c-4fa8-9695-7342e9f2aa40" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_517a1729-fb07-4a30-b8ce-2cdbfc1512e3" xlink:to="loc_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_2768801c-375c-4fa8-9695-7342e9f2aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b93614dc-a4b6-4246-a670-4651a2506cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_1c5aa378-7147-4b17-b770-9a5a495ba35b" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b93614dc-a4b6-4246-a670-4651a2506cee" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_1c5aa378-7147-4b17-b770-9a5a495ba35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f30a94f-258b-494b-8168-166ed973854e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_75422c4e-81f4-4e5d-9c86-165f1e911f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f30a94f-258b-494b-8168-166ed973854e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_75422c4e-81f4-4e5d-9c86-165f1e911f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_fe1ab042-5412-43ff-9b0f-cbdbbfbc4221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f30a94f-258b-494b-8168-166ed973854e" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_fe1ab042-5412-43ff-9b0f-cbdbbfbc4221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e0b03c6c-60a5-4e1c-8534-59bc787636bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f30a94f-258b-494b-8168-166ed973854e" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e0b03c6c-60a5-4e1c-8534-59bc787636bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c4189b0-a53b-441f-9780-307a1879ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12767a61-f9d2-46b8-8e67-8129e1070665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c4189b0-a53b-441f-9780-307a1879ac7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12767a61-f9d2-46b8-8e67-8129e1070665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INVENTORYTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_12e56bf7-fdbb-4741-8a25-32a1ea983b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1ad167c1-13a1-4424-a823-9bef019164ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_12e56bf7-fdbb-4741-8a25-32a1ea983b9c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1ad167c1-13a1-4424-a823-9bef019164ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1940fcc-b3e1-4e5e-a58d-5b56929b00de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_57648cb4-b7cb-4785-beb0-610922e3e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1940fcc-b3e1-4e5e-a58d-5b56929b00de" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_57648cb4-b7cb-4785-beb0-610922e3e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock_97e0c564-f68e-40cf-9e8f-6317f54bf016" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1940fcc-b3e1-4e5e-a58d-5b56929b00de" xlink:to="loc_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock_97e0c564-f68e-40cf-9e8f-6317f54bf016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cdd7e41b-deb0-483a-b113-633419975591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1818f2b6-59d0-4c3a-94b7-22b6212bfd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cdd7e41b-deb0-483a-b113-633419975591" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1818f2b6-59d0-4c3a-94b7-22b6212bfd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4d73d0d9-f7b3-4e75-9372-b2b9cdaf2af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cdd7e41b-deb0-483a-b113-633419975591" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4d73d0d9-f7b3-4e75-9372-b2b9cdaf2af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dfdf6798-7f8b-470d-abd4-ddcb108dd991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_f66cea9e-88a0-41fa-8121-dd9e56a4e761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dfdf6798-7f8b-470d-abd4-ddcb108dd991" xlink:to="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_f66cea9e-88a0-41fa-8121-dd9e56a4e761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_81951332-5af1-4d88-ab85-cd38bcb6c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dfdf6798-7f8b-470d-abd4-ddcb108dd991" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_81951332-5af1-4d88-ab85-cd38bcb6c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_399d017b-56e7-4669-a6f4-75730d937769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dfdf6798-7f8b-470d-abd4-ddcb108dd991" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_399d017b-56e7-4669-a6f4-75730d937769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LeasesTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock_d6920ae6-d689-475c-8faf-0e195197e9ec" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:to="loc_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock_d6920ae6-d689-475c-8faf-0e195197e9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_bb42ea95-093e-496e-b6dd-c692a3431b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_bb42ea95-093e-496e-b6dd-c692a3431b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e760326b-26f1-4e98-bbba-4bf4ccb8e234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e760326b-26f1-4e98-bbba-4bf4ccb8e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_46abd14f-4d30-485d-a8e2-5373a6161e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_46abd14f-4d30-485d-a8e2-5373a6161e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock_1981c24e-dcc3-4753-913a-be382a5071fc" xlink:href="bmrn-20221231.xsd#bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc56afc9-ffb2-4325-b9e5-478ca5adffd2" xlink:to="loc_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock_1981c24e-dcc3-4753-913a-be382a5071fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_47397b87-0a47-4c06-b3d4-a7ac1350c09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_f734d7fd-b97a-4dc1-95c4-ed248f1ba9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_47397b87-0a47-4c06-b3d4-a7ac1350c09c" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_f734d7fd-b97a-4dc1-95c4-ed248f1ba9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e4e51b51-4bd1-4bb7-911c-72df204128fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_47397b87-0a47-4c06-b3d4-a7ac1350c09c" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e4e51b51-4bd1-4bb7-911c-72df204128fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3522995a-2d09-42b6-823d-c88832313ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_594c6c6b-a967-4354-a272-8cf31f5fca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3522995a-2d09-42b6-823d-c88832313ce0" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_594c6c6b-a967-4354-a272-8cf31f5fca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_c1f87b8b-6dc4-4144-bff8-7b5900e103d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8c2f5aa3-21e6-4c24-8fa8-7591d95f588a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c1f87b8b-6dc4-4144-bff8-7b5900e103d8" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8c2f5aa3-21e6-4c24-8fa8-7591d95f588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ee9176a9-09d3-4552-a123-108ff83427a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c1f87b8b-6dc4-4144-bff8-7b5900e103d8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ee9176a9-09d3-4552-a123-108ff83427a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3018a7c9-7163-44be-80f4-433163fce650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c1f87b8b-6dc4-4144-bff8-7b5900e103d8" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3018a7c9-7163-44be-80f4-433163fce650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_857455dd-b8b8-40a3-9e03-0480fa886bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c1f87b8b-6dc4-4144-bff8-7b5900e103d8" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_857455dd-b8b8-40a3-9e03-0480fa886bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70b75c15-4300-4b35-a08f-c8147133af18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70b75c15-4300-4b35-a08f-c8147133af18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5384a38f-d535-4474-b013-ea5bcedc922b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5384a38f-d535-4474-b013-ea5bcedc922b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_be8bec36-87ca-4b5c-be86-a4ed475031d1" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_be8bec36-87ca-4b5c-be86-a4ed475031d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a44d2512-44e3-4428-8a97-192864ac654c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a44d2512-44e3-4428-8a97-192864ac654c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_49926499-b088-47d8-9a31-4e0e6fa741c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_49926499-b088-47d8-9a31-4e0e6fa741c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_24a48404-e47c-4123-8687-2235d0c5e3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_decca732-a911-4715-9975-cb9762dd407d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_24a48404-e47c-4123-8687-2235d0c5e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_44372fec-5d9a-4e86-bd7f-7a26a1e73ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_44372fec-5d9a-4e86-bd7f-7a26a1e73ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f663d911-bceb-4986-9b39-89a52f4eed28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f663d911-bceb-4986-9b39-89a52f4eed28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_64f22dc8-620b-4bc8-ac48-a67145800047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_64f22dc8-620b-4bc8-ac48-a67145800047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_98a842a6-9f02-4884-a971-08b6d8a5785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_98a842a6-9f02-4884-a971-08b6d8a5785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock_72c8d040-9c82-4ea7-9f89-ffde6c10b4cd" xlink:href="bmrn-20221231.xsd#bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock_72c8d040-9c82-4ea7-9f89-ffde6c10b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e8f262fc-74e9-49a8-9b22-2b96774b74e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f4830de-97b9-4e36-950d-9908924a1989" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e8f262fc-74e9-49a8-9b22-2b96774b74e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b9cb0bdc-8721-45dc-abbc-fe0fa208e750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7cb1763c-98bc-468f-b238-0274016fbd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9cb0bdc-8721-45dc-abbc-fe0fa208e750" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7cb1763c-98bc-468f-b238-0274016fbd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c831d567-b8f1-40ba-8d4a-d96980dd8616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9cb0bdc-8721-45dc-abbc-fe0fa208e750" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c831d567-b8f1-40ba-8d4a-d96980dd8616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fd130006-bdb8-4bd3-accb-b63aab4f23cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fd130006-bdb8-4bd3-accb-b63aab4f23cd" xlink:to="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_490f81e0-a870-45ca-8243-fe7248ebe356" xlink:to="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_66eb022b-0c9f-4fc0-82df-9642b91bcdcf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_e36ec436-fb99-4906-adf1-c86a4592b9f2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_66eb022b-0c9f-4fc0-82df-9642b91bcdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8b0a0d79-fe02-4b00-acde-1ee36b8e30d2" xlink:to="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_b6c65edc-76e6-48a8-b7f9-5d05be43ef64" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23e29cd8-3f71-49a9-9324-a32484ed2aa2" xlink:to="loc_bmrn_ProductOneMember_b6c65edc-76e6-48a8-b7f9-5d05be43ef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f335a823-e742-4641-a677-eceea3d9c388" xlink:to="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_753cc667-0cdc-4161-9879-4b10ae82989a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:to="loc_srt_MinimumMember_753cc667-0cdc-4161-9879-4b10ae82989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d110864d-92bd-4d42-92f8-656482fd2430" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e2805775-29c4-4d7d-88e5-05759d7e3432" xlink:to="loc_srt_MaximumMember_d110864d-92bd-4d42-92f8-656482fd2430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:href="bmrn-20221231.xsd#bmrn_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesTable_39acc41c-8220-4d5f-ab35-e51b30061160" xlink:to="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d8b8bc8-ed9d-4c2c-adf3-b1f2bf755ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NetIncomeLoss_6d8b8bc8-ed9d-4c2c-adf3-b1f2bf755ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109aef9c-44cc-4e0f-8f87-bd271624dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109aef9c-44cc-4e0f-8f87-bd271624dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_85b6f6dd-8132-4040-8fe9-e8df28d32ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_85b6f6dd-8132-4040-8fe9-e8df28d32ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd1d3506-0138-46d9-b4d1-9654a1e0c33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_StockholdersEquity_dd1d3506-0138-46d9-b4d1-9654a1e0c33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7197f570-0820-4ae3-b25a-eac4b575a474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7197f570-0820-4ae3-b25a-eac4b575a474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9e50487b-8fbe-4004-8848-fbbe3dc47013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9e50487b-8fbe-4004-8848-fbbe3dc47013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_533652cd-bdb6-40da-8118-a9f483d1f806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_533652cd-bdb6-40da-8118-a9f483d1f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_eb475bfe-bb18-4391-b979-071cec8a08a2" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl_eb475bfe-bb18-4391-b979-071cec8a08a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_f6cb1a58-193d-45dc-bb1c-e927d405f6a9" xlink:href="bmrn-20221231.xsd#bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment_f6cb1a58-193d-45dc-bb1c-e927d405f6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales_ff4f5738-3269-47de-aaae-2055eeeb371b" xlink:href="bmrn-20221231.xsd#bmrn_PaymentReceivedAsPercentageOfNetProductSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_PaymentReceivedAsPercentageOfNetProductSales_ff4f5738-3269-47de-aaae-2055eeeb371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_b073604c-6c11-4d05-8484-f2d82ba704c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_AdvertisingExpense_b073604c-6c11-4d05-8484-f2d82ba704c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NumberOfTranchesInOfferingPeriod_228b1d19-ecf6-4455-aecc-3a78fdff2e1a" xlink:href="bmrn-20221231.xsd#bmrn_NumberOfTranchesInOfferingPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_NumberOfTranchesInOfferingPeriod_228b1d19-ecf6-4455-aecc-3a78fdff2e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SpanOfOfferingPeriod_eb272a06-88c9-473d-8368-bfad05ed6c05" xlink:href="bmrn-20221231.xsd#bmrn_SpanOfOfferingPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_bmrn_SpanOfOfferingPeriod_eb272a06-88c9-473d-8368-bfad05ed6c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_774c6dfe-80f9-44ed-a353-bdbfcb3e0f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_774c6dfe-80f9-44ed-a353-bdbfcb3e0f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_14e616b3-5571-42d1-ad24-61147a462439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NumberOfReportableSegments_14e616b3-5571-42d1-ad24-61147a462439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_508ded30-54fb-460e-bfd5-41eedc93ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SignificantAccountingPoliciesLineItems_20db70cf-9de1-4dc0-8dc6-a5c400ae7c9e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_508ded30-54fb-460e-bfd5-41eedc93ecef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f837ba08-8a74-4dac-b5d2-9a5ee28728cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f837ba08-8a74-4dac-b5d2-9a5ee28728cd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f98b8ff0-52d1-4cc7-9e75-f8f8c713abc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_257998eb-cd9d-47d6-a9a0-e5b9180dd96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_257998eb-cd9d-47d6-a9a0-e5b9180dd96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb384e63-8b48-422b-bd9c-45c2b0d25ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb384e63-8b48-422b-bd9c-45c2b0d25ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_77e7174b-02e1-44cf-b4a1-c4dcf7fb71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_EquipmentMember_77e7174b-02e1-44cf-b4a1-c4dcf7fb71d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cbec0bef-0e93-4294-adad-8b388000adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_ComputerEquipmentMember_cbec0bef-0e93-4294-adad-8b388000adf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_2f84c522-2ccf-45c0-b4ef-b76960a2d697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_OfficeEquipmentMember_2f84c522-2ccf-45c0-b4ef-b76960a2d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_a9581449-4231-47d4-a4d6-1ede2ef5865b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f20eb43-8a5a-47c2-9cec-a284f2d28986" xlink:to="loc_us-gaap_LandImprovementsMember_a9581449-4231-47d4-a4d6-1ede2ef5865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:to="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdeca991-b703-4596-94b7-f04bb84eb50e" xlink:to="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64300487-dfaf-474c-8620-bfe20700b5a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:to="loc_srt_MinimumMember_64300487-dfaf-474c-8620-bfe20700b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69f66fe2-502e-47a6-974b-2ff4e24e5553" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9cbbeed-006f-4ec6-b2eb-af551a381891" xlink:to="loc_srt_MaximumMember_69f66fe2-502e-47a6-974b-2ff4e24e5553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9c34a5c-6e0a-45b9-9340-4eea5858d013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_8a8736c5-be78-4101-b800-7d52fcc27d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_8a8736c5-be78-4101-b800-7d52fcc27d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_80c56da0-fe1e-4f43-bb4f-d70c1a12f500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_972d3150-8823-4e07-8d26-1917821b0e1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_80c56da0-fe1e-4f43-bb4f-d70c1a12f500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ec403db1-c072-49aa-9d4e-81a41e4db3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ec403db1-c072-49aa-9d4e-81a41e4db3c0" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_35b41a98-4ba9-4af3-bac3-4cd56f93341a" xlink:to="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24e98aa0-2434-446b-819b-9a271fc947a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:to="loc_srt_MaximumMember_24e98aa0-2434-446b-819b-9a271fc947a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0232582a-81cb-4cc9-a0b3-a9c9f525c522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62d58c92-460b-4dc1-8170-1bb718a5d700" xlink:to="loc_srt_MinimumMember_0232582a-81cb-4cc9-a0b3-a9c9f525c522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44a6b268-0360-40d5-8a6b-fbb838921cb0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e360377a-c9c5-40bb-b5ef-c0b7562a0414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e360377a-c9c5-40bb-b5ef-c0b7562a0414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4baf5b01-4588-4ab5-90d0-6b63c28cb13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bd6b67-53e9-467b-a9b7-d75715ed7653" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4baf5b01-4588-4ab5-90d0-6b63c28cb13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d7a93e71-8430-479f-b2f1-a25b4da51dbe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_104bdc4c-77b5-4e31-8355-e4b0c876d2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CashMember_104bdc4c-77b5-4e31-8355-e4b0c876d2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d0b8194-a305-438d-87bf-aaf2debceddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d0b8194-a305-438d-87bf-aaf2debceddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5d6eb5d8-8a72-4c08-8a7f-8887806d8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5d6eb5d8-8a72-4c08-8a7f-8887806d8db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fe3e2e24-9385-4672-b375-fb5b36496106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fe3e2e24-9385-4672-b375-fb5b36496106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_43ffba4a-af55-43f7-923e-ece099c5127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_CommercialPaperMember_43ffba4a-af55-43f7-923e-ece099c5127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2c7da80-13f2-446b-b93b-80df4f1cb4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2c7da80-13f2-446b-b93b-80df4f1cb4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_ed57082a-b098-4717-8410-cd6ee2601b6f" xlink:href="bmrn-20221231.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86824957-ca1e-45ee-9276-3b2938ff99e7" xlink:to="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_ed57082a-b098-4717-8410-cd6ee2601b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_42b78cb2-96d6-44b7-a322-709903d5a0f8" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_bff083c0-f810-479f-92b4-b059c86197f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_Cash_bff083c0-f810-479f-92b4-b059c86197f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02a85835-e98a-42b2-8995-4240f81be3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02a85835-e98a-42b2-8995-4240f81be3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e562fa5a-f15e-45b5-b4d3-49eb7122eac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e562fa5a-f15e-45b5-b4d3-49eb7122eac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fb23a0b-42e3-4d57-86c2-0309673905b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fb23a0b-42e3-4d57-86c2-0309673905b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b345c8ab-d27b-4d64-8f8c-4cb697e7f952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b345c8ab-d27b-4d64-8f8c-4cb697e7f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae7d2431-facd-41b3-b488-6acc17bc0af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae7d2431-facd-41b3-b488-6acc17bc0af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_868cbeba-7fb9-430e-9367-ad8c1301105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_868cbeba-7fb9-430e-9367-ad8c1301105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7c56dd12-4b89-4087-8efb-d06807c7dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7c56dd12-4b89-4087-8efb-d06807c7dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_0fdaa7b7-38d0-41ae-9356-d76fe0c9358d" xlink:href="bmrn-20221231.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_0fdaa7b7-38d0-41ae-9356-d76fe0c9358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_2311a072-04a9-4202-a0e2-9cc28fe7ee78" xlink:href="bmrn-20221231.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_38d87009-9fbb-41b6-a804-246b77f0a22a" xlink:to="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_2311a072-04a9-4202-a0e2-9cc28fe7ee78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6c73e25-d26c-44e9-bbf0-4f8d774d9727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6c73e25-d26c-44e9-bbf0-4f8d774d9727" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af8a02d7-fc46-4642-8f4c-07505fbc1fdf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ee9bfd24-e06e-433d-9e71-8095c91c2044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a117ff2-2d58-480b-9989-1ef1113ffe7a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ee9bfd24-e06e-433d-9e71-8095c91c2044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fe9a90fe-f2b4-4980-af67-e839f0e07a1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember_651025ed-0827-4e52-9e77-867737a7ea9a" xlink:href="bmrn-20221231.xsd#bmrn_StrategicInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_458133c1-f89b-4aa2-9805-cc11fb61a560" xlink:to="loc_bmrn_StrategicInvestmentMember_651025ed-0827-4e52-9e77-867737a7ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_675585ad-0c5a-42b8-bd7b-9b441aed9098" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_90b11305-5a59-45aa-bc57-6b156ea95b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_0389a5e9-36dd-4e6a-a773-4923263fff02" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_90b11305-5a59-45aa-bc57-6b156ea95b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1e5e84b-bf2d-45e3-801b-1b8ffc49328b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_806bb4d6-12cf-46db-9dda-885601fbd95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1e5e84b-bf2d-45e3-801b-1b8ffc49328b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_806bb4d6-12cf-46db-9dda-885601fbd95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437ceeb6-bd93-49bb-b281-6abcbae0cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1e5e84b-bf2d-45e3-801b-1b8ffc49328b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437ceeb6-bd93-49bb-b281-6abcbae0cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2b3dec80-969a-40c4-8146-ce2cc58f081f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1e5e84b-bf2d-45e3-801b-1b8ffc49328b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2b3dec80-969a-40c4-8146-ce2cc58f081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_deb5e533-7fef-4e18-89f3-71cc68c05356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_deb5e533-7fef-4e18-89f3-71cc68c05356" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8f21183-6487-49b7-8daa-f76c9d2854d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AcquiredIntellectualPropertyMember_0df10198-84b1-49be-827f-21b17bcf4d6e" xlink:href="bmrn-20221231.xsd#bmrn_AcquiredIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_AcquiredIntellectualPropertyMember_0df10198-84b1-49be-827f-21b17bcf4d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TechnologyTransferMember_5daa780e-2b2b-4436-9009-faf4917f3aef" xlink:href="bmrn-20221231.xsd#bmrn_TechnologyTransferMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_TechnologyTransferMember_5daa780e-2b2b-4436-9009-faf4917f3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RepurchasedRoyaltyRightsMember_3d1295db-4662-4f3c-adc6-c368b7e50bac" xlink:href="bmrn-20221231.xsd#bmrn_RepurchasedRoyaltyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_RepurchasedRoyaltyRightsMember_3d1295db-4662-4f3c-adc6-c368b7e50bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LicensePaymentsMember_ebd01e0a-51b9-4c2a-b598-60e8e04dbb09" xlink:href="bmrn-20221231.xsd#bmrn_LicensePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_bmrn_LicensePaymentsMember_ebd01e0a-51b9-4c2a-b598-60e8e04dbb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_9e208351-27bd-4130-8e66-9736f6fd68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe2cbb82-ed52-4657-98c0-c7cb523b0f34" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_9e208351-27bd-4130-8e66-9736f6fd68a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9a36d5e-bd66-42b1-a642-37b02c687ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5ffc8d7-88f6-4ff3-b824-23c7d1c5400a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5ffc8d7-88f6-4ff3-b824-23c7d1c5400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1ab6b6d5-3233-49f8-9c12-e2a1b1a539aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b5f0438-144c-4e39-a984-81239e3aa276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1ab6b6d5-3233-49f8-9c12-e2a1b1a539aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_63e6a6ed-9a88-4fc5-8b41-3452bcdd133e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_63e6a6ed-9a88-4fc5-8b41-3452bcdd133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_08bb2206-2bb1-4074-a001-8680ad067f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_08bb2206-2bb1-4074-a001-8680ad067f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9d3d1707-5392-4270-a6d9-87110a3d1372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9d3d1707-5392-4270-a6d9-87110a3d1372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_21e0a2f7-b7a6-4400-a0e8-f3186c24e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_21e0a2f7-b7a6-4400-a0e8-f3186c24e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_61f6fe18-685e-4af9-b10d-dde214fc3a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_61f6fe18-685e-4af9-b10d-dde214fc3a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9b7f2d32-6d81-4d98-b187-055b8d386a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9b7f2d32-6d81-4d98-b187-055b8d386a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_e6445977-e93f-4223-b86e-a5afdca3eaa5" xlink:href="bmrn-20221231.xsd#bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69d66ada-778b-4353-b78d-02ce35b6b8c6" xlink:to="loc_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet_e6445977-e93f-4223-b86e-a5afdca3eaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fdaaed9-bd55-46d9-8301-4804777a7ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3401ec21-a9fd-4d0e-8516-45a0d20a80fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fdaaed9-bd55-46d9-8301-4804777a7ebd" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3401ec21-a9fd-4d0e-8516-45a0d20a80fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9eaff7e4-9702-4617-9eae-0df20dcdfa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9eaff7e4-9702-4617-9eae-0df20dcdfa70" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64ababaf-606b-4323-8388-8128f414c812" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fd617d8a-8948-4df9-9bf8-c4088c3d8b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fd617d8a-8948-4df9-9bf8-c4088c3d8b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_35eb2a48-c501-4c90-953d-51c18836d017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_EquipmentMember_35eb2a48-c501-4c90-953d-51c18836d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a1d9b25e-acbf-44d9-9fa4-0cc491d58c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_ComputerEquipmentMember_a1d9b25e-acbf-44d9-9fa4-0cc491d58c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ce6d6706-3a56-469a-a19f-5561a0380a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LandMember_ce6d6706-3a56-469a-a19f-5561a0380a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_18484871-89c2-4a35-baec-1f354eee26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_18484871-89c2-4a35-baec-1f354eee26e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eee471cf-939f-4579-9791-1d8f8454d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eee471cf-939f-4579-9791-1d8f8454d9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_1a28b03d-9a07-4cda-8a48-3bbf7d53ab20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_LandImprovementsMember_1a28b03d-9a07-4cda-8a48-3bbf7d53ab20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b6d2664e-daf4-4719-9855-3f3d962dbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c94f9c91-7787-4a16-a39b-449750adb1b8" xlink:to="loc_us-gaap_ConstructionInProgressMember_b6d2664e-daf4-4719-9855-3f3d962dbe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6fb663-d399-4a1b-986d-41d411743458" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9c0b1658-3345-4666-9dc8-1010672a86b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9c0b1658-3345-4666-9dc8-1010672a86b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f916376-0176-450f-8343-847c28c704e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f916376-0176-450f-8343-847c28c704e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9959b863-8254-429e-a7f9-fa8d3ae339bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99e12e42-94c6-475c-acd6-8c0a8c940a10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9959b863-8254-429e-a7f9-fa8d3ae339bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#PROPERTYPLANTANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9203b8a-2fa1-408c-950e-8efea4ae6e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_443a409e-34cd-46c3-a61e-932944e39152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9203b8a-2fa1-408c-950e-8efea4ae6e2b" xlink:to="loc_us-gaap_Depreciation_443a409e-34cd-46c3-a61e-932944e39152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INVENTORYScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_aa2faebe-3c3c-4c8c-ac26-af04938fda17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_80083085-a076-4e18-9638-6507a28a3328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2faebe-3c3c-4c8c-ac26-af04938fda17" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_80083085-a076-4e18-9638-6507a28a3328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fbf85be7-ed70-4839-b62c-2c5b9f45bb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2faebe-3c3c-4c8c-ac26-af04938fda17" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fbf85be7-ed70-4839-b62c-2c5b9f45bb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7feaae9b-4aa4-4706-85c4-571dff78044d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2faebe-3c3c-4c8c-ac26-af04938fda17" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7feaae9b-4aa4-4706-85c4-571dff78044d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9207bb67-da03-4873-92ef-10992ad4f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2faebe-3c3c-4c8c-ac26-af04938fda17" xlink:to="loc_us-gaap_InventoryNet_9207bb67-da03-4873-92ef-10992ad4f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_396dbb49-e6f9-40a5-8f9e-7022fee53f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_396dbb49-e6f9-40a5-8f9e-7022fee53f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_98f6b03b-0e50-44e3-950f-f83d5a894acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_98f6b03b-0e50-44e3-950f-f83d5a894acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates_c60d5f86-2805-4bb9-adcd-1177368e5663" xlink:href="bmrn-20221231.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_bmrn_AccruedGovernmentAndOtherRebates_c60d5f86-2805-4bb9-adcd-1177368e5663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_068a7edc-e354-44e0-9abd-7d4b677a645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_068a7edc-e354-44e0-9abd-7d4b677a645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_5de212a4-1091-461b-a850-69f923156438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_5de212a4-1091-461b-a850-69f923156438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_66a180e8-7269-4f65-92c8-2b8cc8bf4081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_66a180e8-7269-4f65-92c8-2b8cc8bf4081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_e2c9f120-a105-4038-955c-4eb5a5cad240" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_e2c9f120-a105-4038-955c-4eb5a5cad240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9bac7f3b-bce5-41ca-9f6b-7d33c4af0598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9bac7f3b-bce5-41ca-9f6b-7d33c4af0598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_4d64fd7e-97a8-46e7-a9e6-7ef5ff25f123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_4d64fd7e-97a8-46e7-a9e6-7ef5ff25f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8bfef335-f090-4943-acd7-2836abb61361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfd3981-634a-440c-b32a-844b5e718614" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8bfef335-f090-4943-acd7-2836abb61361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ce8dbbf-3fc6-49c2-88f0-42f9bef89535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ce8dbbf-3fc6-49c2-88f0-42f9bef89535" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:to="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_8319bc0d-8dc8-43f6-a05b-3c5ff96c8805" xlink:to="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A2022RestructuringPlanMember_4faf3117-e369-4d9f-92ab-0bb9c73945cb" xlink:href="bmrn-20221231.xsd#bmrn_A2022RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b7581231-5ae7-43ea-88f6-1345dd6cb835" xlink:to="loc_bmrn_A2022RestructuringPlanMember_4faf3117-e369-4d9f-92ab-0bb9c73945cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_3df6ddb1-0a34-49c0-952d-7253059eeb68" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_1ba48048-dc41-438a-9f74-2b02a885b189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_1ba48048-dc41-438a-9f74-2b02a885b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_5eaaf566-d59f-4b63-afa9-2fc84cc7a9d0" xlink:href="bmrn-20221231.xsd#bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_5eaaf566-d59f-4b63-afa9-2fc84cc7a9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_40ddcf4a-031e-4919-b3e8-9278c8df9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_RestructuringCharges_40ddcf4a-031e-4919-b3e8-9278c8df9b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_37297e9d-f065-40ab-be8a-74c2ce7fdfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_36af0785-efe6-4b76-865b-a04325debf57" xlink:to="loc_us-gaap_PaymentsForRestructuring_37297e9d-f065-40ab-be8a-74c2ce7fdfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c67e77-8a32-43ec-810a-785e9cd90445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c67e77-8a32-43ec-810a-785e9cd90445" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3afdf40-1dee-420e-9df2-21a59f3673f2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedRebatesMember_31e8d0b0-0fbb-4d30-8890-b2f67f46e7c1" xlink:href="bmrn-20221231.xsd#bmrn_AccruedRebatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:to="loc_bmrn_AccruedRebatesMember_31e8d0b0-0fbb-4d30-8890-b2f67f46e7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AllowancesForReserveForCashDiscountsMember_44f0f44b-787c-42ef-accd-3dd61dfd8ea6" xlink:href="bmrn-20221231.xsd#bmrn_AllowancesForReserveForCashDiscountsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d665351b-925e-4737-84a4-0c9c7534c02b" xlink:to="loc_bmrn_AllowancesForReserveForCashDiscountsMember_44f0f44b-787c-42ef-accd-3dd61dfd8ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalBalanceSheetInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationTable_1bcfaf5a-bcbe-4dc7-971f-c22f8979312e" xlink:to="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalBalanceSheetInformationLineItems_ec062375-ebd5-4c2a-89d0-124c66622218" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a299dfe5-46bf-43be-a750-e7e6e08e23c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a299dfe5-46bf-43be-a750-e7e6e08e23c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f6a272c5-8797-4e8e-9578-a2ef14e54cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_f6a272c5-8797-4e8e-9578-a2ef14e54cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fd279882-9b9e-42d3-8127-10a7bc362f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fd279882-9b9e-42d3-8127-10a7bc362f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_50c99cb3-cbdc-4c74-ac4e-8f2c83a8a417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8fd634ca-1eef-4370-a3c8-e34aa3f37360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_50c99cb3-cbdc-4c74-ac4e-8f2c83a8a417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be3fff27-74ad-443c-807e-167ce7b36d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be3fff27-74ad-443c-807e-167ce7b36d41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28feb6a0-47cf-4a8c-ad09-273fced02358" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4b59f94b-978e-4cf0-8183-411b86a0d717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d0a481a1-7c39-4956-bd53-0095241c5703" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4b59f94b-978e-4cf0-8183-411b86a0d717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_003a6b7f-d7df-4f44-80d2-a6bb84a8b4d2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_41cf8941-9910-4097-9328-7da7607ca7ac" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_41cf8941-9910-4097-9328-7da7607ca7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember_ea0cf8f1-9879-44d7-8349-42dfa8d449f7" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3d9fe9a-87d4-40e7-8f00-e99ef8175cc8" xlink:to="loc_bmrn_RestrictedInvestmentsMember_ea0cf8f1-9879-44d7-8349-42dfa8d449f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f2dcc98-de62-4334-827e-79ad0bccc3b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_335d0afe-b7ed-41a8-9e7a-03c7754b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_335d0afe-b7ed-41a8-9e7a-03c7754b4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5aae0ec9-b325-4396-9000-cba86500fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5aae0ec9-b325-4396-9000-cba86500fbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bd2ca838-11fa-4c69-a0c6-0b1341b0830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b6ee28a-b1b6-4458-91bb-22bff70056f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bd2ca838-11fa-4c69-a0c6-0b1341b0830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1739c53d-7191-4386-8930-f475340ad7e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_b2c2d809-b95b-4d87-8dc9-f57bd2bf19b5" xlink:href="bmrn-20221231.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_b2c2d809-b95b-4d87-8dc9-f57bd2bf19b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember_9916483d-10b7-454f-a393-eee306920901" xlink:href="bmrn-20221231.xsd#bmrn_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00a064a0-958f-4f06-b057-cbff11b156e8" xlink:to="loc_bmrn_ContingentConsiderationMember_9916483d-10b7-454f-a393-eee306920901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35758801-1f1a-497c-a11d-4602ef9d425f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_55f782ea-47d9-4f31-a39d-00b0eff3711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_55f782ea-47d9-4f31-a39d-00b0eff3711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3a0e05b-abe4-41cf-93f3-d9310997ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3a0e05b-abe4-41cf-93f3-d9310997ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_165fe999-d3f3-46f2-ad4a-4d695bff89e5" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_165fe999-d3f3-46f2-ad4a-4d695bff89e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c30b5a7d-b008-4b0b-b855-e2435ed44895" xlink:href="bmrn-20221231.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c30b5a7d-b008-4b0b-b855-e2435ed44895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5f3482b4-8494-409e-9102-7fdf1ebef73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5f3482b4-8494-409e-9102-7fdf1ebef73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_af88b4a0-122d-4632-a4e4-f27474de581f" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_af88b4a0-122d-4632-a4e4-f27474de581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_644c3cdc-4bda-4537-9784-309c2557c336" xlink:href="bmrn-20221231.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_644c3cdc-4bda-4537-9784-309c2557c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8288a5a7-3e11-4d3e-8a96-d614537088cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de9839e5-27b2-4fe0-a82e-93b933006fae" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8288a5a7-3e11-4d3e-8a96-d614537088cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3d8d5aed-100d-4323-9615-04d6cfe8b4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3d8d5aed-100d-4323-9615-04d6cfe8b4b4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ca601c65-20d8-49a0-81dc-ea49dabaec36" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember_0643fe0a-75fa-4932-a15b-d3e1acd0a837" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7a21573c-d5f6-4571-91ad-4a2ec2ab678f" xlink:to="loc_bmrn_ContingentPaymentMember_0643fe0a-75fa-4932-a15b-d3e1acd0a837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8d8ea87-f1d7-4c30-bed7-cc2abb3009ff" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb65c7ad-73f3-485e-9c46-3a4ddb6be4e2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_057e1c25-f3f8-4054-bb5a-ac3c4e269d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_057e1c25-f3f8-4054-bb5a-ac3c4e269d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9aec4766-6f36-42c4-978d-22b995e6375a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9aec4766-6f36-42c4-978d-22b995e6375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c262241e-cc35-4b0c-8fa9-927b3f57e869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c262241e-cc35-4b0c-8fa9-927b3f57e869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_397ad7ba-842e-40e4-a55e-2000d33cc08e" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange_397ad7ba-842e-40e4-a55e-2000d33cc08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_b42bb249-60bc-42ea-8d4b-495429211b77" xlink:href="bmrn-20221231.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_b42bb249-60bc-42ea-8d4b-495429211b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf940cd5-c0a8-4b29-a499-bc518e6aa5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ba97c935-f7c9-48ab-babe-8b6c0f9d5964" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf940cd5-c0a8-4b29-a499-bc518e6aa5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1785eed6-c057-4312-b82c-1795bf6c8121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1785eed6-c057-4312-b82c-1795bf6c8121" xlink:to="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:to="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e854d3cd-45a2-4a3e-8263-b04f87f119b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6adcf57d-6384-47c8-8f66-aee98f563d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6adcf57d-6384-47c8-8f66-aee98f563d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0eda57d9-6a0b-4dab-aab7-e4c9c9f382d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b9eff42-e089-4f33-b48d-a42cb40742f7" xlink:to="loc_us-gaap_NondesignatedMember_0eda57d9-6a0b-4dab-aab7-e4c9c9f382d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a85ad84-8d14-49c2-a8db-7ba5a7e6b360" xlink:to="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_bccccc7e-d3e2-48bb-8a1f-9740214bae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_bccccc7e-d3e2-48bb-8a1f-9740214bae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0b7c8062-a52b-4d05-8d06-563c52fc06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_862b24e9-a584-4901-9e1b-f00f30d2f728" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0b7c8062-a52b-4d05-8d06-563c52fc06b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1698982d-7128-4b26-94d0-d2658d4bce9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1698982d-7128-4b26-94d0-d2658d4bce9e" xlink:to="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d8397af2-e408-4c7c-80e8-220390b606f2" xlink:to="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254f801e-bc3a-4f83-ad68-010b9314cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254f801e-bc3a-4f83-ad68-010b9314cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a1aee908-1f2b-4e61-992d-6604d7817c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1cf3ba8c-d37f-4a01-a196-0729cb80509f" xlink:to="loc_us-gaap_NondesignatedMember_a1aee908-1f2b-4e61-992d-6604d7817c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf51c110-1651-489d-8283-b56690862e69" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d13ca8a8-b02b-4dab-b978-9fcb3a845ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f8d00fa-d63c-4987-8806-8cfbfea2e631" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d13ca8a8-b02b-4dab-b978-9fcb3a845ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionAxis_8bb4b70e-3d36-46bb-a5ac-73e151c44120" xlink:to="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_ba8f9f19-e5fc-47d0-bf4d-0db6d06638d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:to="loc_us-gaap_ShortMember_ba8f9f19-e5fc-47d0-bf4d-0db6d06638d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_0f39a80c-c5ab-4d50-9ccf-d2b48811890d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_3deed215-779a-4344-b703-440aef40df62" xlink:to="loc_us-gaap_LongMember_0f39a80c-c5ab-4d50-9ccf-d2b48811890d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f5575971-4282-401b-a592-e1657a588a38" xlink:to="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8719c462-d8ce-4ea6-97e1-3aae8bcefcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_16b1f595-ae6d-4e51-9e26-433b89a9fb60" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8719c462-d8ce-4ea6-97e1-3aae8bcefcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9ec5fcc3-eb9f-449d-9291-3c7ba2cb9a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9ec5fcc3-eb9f-449d-9291-3c7ba2cb9a2e" xlink:to="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_58ad430c-9217-48c3-9347-96283797af60" xlink:to="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1ae45e07-3bb4-42f0-b31c-d6a8b76a3383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1ae45e07-3bb4-42f0-b31c-d6a8b76a3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_fc55856b-ea5c-4f12-ac32-c83b690fff7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_deeed1ac-57a5-4271-8a64-9b6ae5fc32bc" xlink:to="loc_us-gaap_NondesignatedMember_fc55856b-ea5c-4f12-ac32-c83b690fff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8822d6b-6114-4ed6-aeae-760110a5fde7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7feb0458-5cbe-4e80-894c-e48f8884b21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17f4c861-cbea-4180-82b6-8e00343480d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7feb0458-5cbe-4e80-894c-e48f8884b21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6b85dab3-567f-441f-a9dc-37d67566bbd2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22b7a568-685f-4565-8bcd-c0a2b10f3d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22b7a568-685f-4565-8bcd-c0a2b10f3d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2f069ff8-7c98-4b0b-9cb3-b858d25e3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2f069ff8-7c98-4b0b-9cb3-b858d25e3bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_203680b8-ed98-42fe-87d0-1e63f7a0a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_203680b8-ed98-42fe-87d0-1e63f7a0a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ad51bb1a-ca09-4f7a-b0fe-422380285b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47f1dd0e-2f92-4844-a468-918129a498e6" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ad51bb1a-ca09-4f7a-b0fe-422380285b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5f4a66e3-215b-4801-87a7-31e858e2fc83" xlink:to="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_92c7c71f-3cca-4980-bb10-289d418ca246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_92c7c71f-3cca-4980-bb10-289d418ca246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0962f8c0-187e-4dd8-b8f7-f6d091dfaaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_190f3603-c664-404b-9779-092be01d3044" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0962f8c0-187e-4dd8-b8f7-f6d091dfaaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_358cb182-1ad7-46e0-bdf4-f87d3eaf13ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_358cb182-1ad7-46e0-bdf4-f87d3eaf13ee" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a9826e28-8ad9-4b45-93b7-f26cd70ccad4" xlink:to="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2197e4e4-208e-4858-b514-a9883e22b5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2197e4e4-208e-4858-b514-a9883e22b5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e6a4266-d485-40e9-8c72-7dce18fbd188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9104d96d-ae8c-4b72-b810-5d7befe6f9e9" xlink:to="loc_us-gaap_NondesignatedMember_8e6a4266-d485-40e9-8c72-7dce18fbd188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_84ca5b1e-b05e-48f6-bbe6-b1c672c75874" xlink:to="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a1f4db74-807d-48c8-89a6-fe03c57d218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3518aca1-9305-4129-96e0-a355323a333b" xlink:to="loc_us-gaap_ProductMember_a1f4db74-807d-48c8-89a6-fe03c57d218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70b6e86c-ef8b-456f-89b8-21c69024d0eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_4bd076c2-3b60-44ee-a0ff-da9b4bbcdca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_61747e28-3292-4783-a46f-a6354dd99895" xlink:to="loc_us-gaap_OperatingExpenseMember_4bd076c2-3b60-44ee-a0ff-da9b4bbcdca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3c3d15ae-55df-4162-b949-08ab9d87dbe2" xlink:to="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e6b3b170-4054-4c74-922a-63c9849c025f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_990df17b-0461-4ca1-b1eb-b12b00bf1a07" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e6b3b170-4054-4c74-922a-63c9849c025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a233dbf7-42b4-4b71-a683-8ebd70d86edd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4e11aa24-e647-4248-a7a7-919dbf8eedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4e11aa24-e647-4248-a7a7-919dbf8eedd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2b0b3da8-8489-4772-bad7-fe9a5bc589b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f64b2455-930b-4edc-8763-58053b29018f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2b0b3da8-8489-4772-bad7-fe9a5bc589b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_476262ac-8a09-4227-a4b0-b9adf7845bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1d0f8542-323f-42ba-a484-579ef488a490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_476262ac-8a09-4227-a4b0-b9adf7845bda" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1d0f8542-323f-42ba-a484-579ef488a490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:href="bmrn-20221231.xsd#bmrn_LeaseRightOfUseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1d0f8542-323f-42ba-a484-579ef488a490" xlink:to="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_63d659d1-26b2-4743-bd57-7719824e01f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_63d659d1-26b2-4743-bd57-7719824e01f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_00d8f5bf-cb38-47f7-b803-a77e23c65934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_00d8f5bf-cb38-47f7-b803-a77e23c65934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c25c0355-274c-4621-8081-3e3228d13e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c25c0355-274c-4621-8081-3e3228d13e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ffc93553-9863-4267-85ec-b5a585312d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ffc93553-9863-4267-85ec-b5a585312d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_60a9e82e-e60c-4fad-b7d6-ea3f187af98f" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeaseRightOfUseAssetsAbstract_720686e2-123b-47bb-9a57-9a713ba7a38b" xlink:to="loc_bmrn_OperatingAndFinanceLeaseRightOfUseAsset_60a9e82e-e60c-4fad-b7d6-ea3f187af98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:href="bmrn-20221231.xsd#bmrn_LeasesLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1d0f8542-323f-42ba-a484-579ef488a490" xlink:to="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_833157a7-8eef-4c5d-91ee-7251020d5122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_833157a7-8eef-4c5d-91ee-7251020d5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6362dd2f-9d3a-4aed-862f-a86682164332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6362dd2f-9d3a-4aed-862f-a86682164332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2bf72679-4e85-43b8-83e2-0b771a0ee59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2bf72679-4e85-43b8-83e2-0b771a0ee59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0da5b3d1-b7c7-4148-81db-01ffc7d8d893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0da5b3d1-b7c7-4148-81db-01ffc7d8d893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_aafbef4c-d7b8-4939-b2bd-cb806ae833e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_aafbef4c-d7b8-4939-b2bd-cb806ae833e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83f8d6ea-ceee-433a-9de5-53bd01dfcd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83f8d6ea-ceee-433a-9de5-53bd01dfcd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ec5bcb95-f6d9-49dc-a2eb-f307d78834f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ec5bcb95-f6d9-49dc-a2eb-f307d78834f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f62cebac-37b3-4cad-bc94-5b22eb4ab2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f62cebac-37b3-4cad-bc94-5b22eb4ab2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability_fee03174-7688-4a8c-8bb5-202d16318bdf" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_LeasesLiabilitiesAbstract_11cf7efb-5efc-40d4-96a5-996ead4557b1" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiability_fee03174-7688-4a8c-8bb5-202d16318bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5c0901b5-780e-41e7-aa62-eabf26dc2294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract_929acf57-9ee2-4d27-aa06-5077b670c65c" xlink:href="bmrn-20221231.xsd#bmrn_MaturityOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5c0901b5-780e-41e7-aa62-eabf26dc2294" xlink:to="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract_929acf57-9ee2-4d27-aa06-5077b670c65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract_929acf57-9ee2-4d27-aa06-5077b670c65c" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d372e897-467f-4176-ba0a-d3bbf31857bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d372e897-467f-4176-ba0a-d3bbf31857bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c141084-3018-44c1-8715-df452759aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c141084-3018-44c1-8715-df452759aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a32c5d49-fd64-4c41-9567-1549ccfedd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a32c5d49-fd64-4c41-9567-1549ccfedd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_65705d75-911a-4b52-a175-60ee2157f7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_65705d75-911a-4b52-a175-60ee2157f7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_abecd539-f02c-4d7e-b5e7-a3a12ea435c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_abecd539-f02c-4d7e-b5e7-a3a12ea435c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8baf81a-9d40-4791-befc-50b33f42d408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8baf81a-9d40-4791-befc-50b33f42d408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b5279f9-cea8-4973-95f5-c4545ffc6837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b5279f9-cea8-4973-95f5-c4545ffc6837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e6ec111-2da4-4d81-a5a7-6f62c2827d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e6ec111-2da4-4d81-a5a7-6f62c2827d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0f0797e3-af95-46f9-8ede-1ae97373d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_14006cca-2fce-4cf2-b970-faf3c4b31630" xlink:to="loc_us-gaap_OperatingLeaseLiability_0f0797e3-af95-46f9-8ede-1ae97373d3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract_929acf57-9ee2-4d27-aa06-5077b670c65c" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bc63736d-85c5-41a6-8db6-2f6cead1cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bc63736d-85c5-41a6-8db6-2f6cead1cd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_37addfb1-a76e-48b0-b045-9c2e054f2317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_37addfb1-a76e-48b0-b045-9c2e054f2317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c16a3fda-611b-4336-919e-ac93a0c7848a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c16a3fda-611b-4336-919e-ac93a0c7848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2a00ab3e-1d00-453b-9830-04e36408bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2a00ab3e-1d00-453b-9830-04e36408bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f22f74e5-06bf-4722-9f1d-21508f0fc9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f22f74e5-06bf-4722-9f1d-21508f0fc9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_24647d2d-cfee-4177-95e1-288246f5fd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_24647d2d-cfee-4177-95e1-288246f5fd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2020c12f-d860-48cd-afe2-fd6e1100018d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2020c12f-d860-48cd-afe2-fd6e1100018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_46325fc5-9435-466a-a639-0dc78d22a272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_46325fc5-9435-466a-a639-0dc78d22a272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_11b4180b-a741-4ef3-97ec-9269b5e90d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_739ea057-af4b-44d0-947f-8e38b910d112" xlink:to="loc_us-gaap_FinanceLeaseLiability_11b4180b-a741-4ef3-97ec-9269b5e90d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_MaturityOfLeaseLiabilitiesAbstract_929acf57-9ee2-4d27-aa06-5077b670c65c" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6b431d74-bcfb-4b62-bb76-36faa11dee8d" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6b431d74-bcfb-4b62-bb76-36faa11dee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_c0dabf13-d4aa-4c70-b318-6d10fe8b0647" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_c0dabf13-d4aa-4c70-b318-6d10fe8b0647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_ff07186f-4e8f-44a6-8ffc-e4a1a82f2421" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_ff07186f-4e8f-44a6-8ffc-e4a1a82f2421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_65f7a084-5862-4c7f-a600-6a3be86840bc" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_65f7a084-5862-4c7f-a600-6a3be86840bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_246fef94-61f2-45f2-87d4-6bf28e8eae1a" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive_246fef94-61f2-45f2-87d4-6bf28e8eae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_6d483763-d504-4471-a2c3-7e50631ecc9b" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_6d483763-d504-4471-a2c3-7e50631ecc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_7293de68-3ccd-4e9a-abfb-67b4d24f1465" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue_7293de68-3ccd-4e9a-abfb-67b4d24f1465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_ba2e9621-ff63-440f-8aa0-f1160f5a1c19" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_ba2e9621-ff63-440f-8aa0-f1160f5a1c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiability_f39c2ad7-b815-44ac-9824-c23a1c679eb1" xlink:href="bmrn-20221231.xsd#bmrn_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_953497df-c9a0-4bf8-92fc-f2fc38873736" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiability_f39c2ad7-b815-44ac-9824-c23a1c679eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c04ebcd9-75c2-4980-91bb-7abb9203f83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c04ebcd9-75c2-4980-91bb-7abb9203f83f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9e0f89bd-82ac-4162-a574-7341187f1d4e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_9e9ef336-3488-455f-ad88-aee190e814ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2316880b-cec3-4c00-9b3e-e9216576e217" xlink:to="loc_us-gaap_OperatingExpenseMember_9e9ef336-3488-455f-ad88-aee190e814ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_040288d8-55d0-4e7e-b6c8-0a126cf78af7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_30576e70-b5a2-4e42-999c-add7a0684421" xlink:to="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bf0ae6c1-feed-4fde-9758-a0055026ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_OperatingLeaseCost_bf0ae6c1-feed-4fde-9758-a0055026ee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5600978e-2338-4c70-a3d2-471f6bafa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5600978e-2338-4c70-a3d2-471f6bafa31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ac7c2a9f-b96a-43f0-a61c-011e098a98bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ac7c2a9f-b96a-43f0-a61c-011e098a98bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fe558d44-421c-40bd-b357-a7787c5b89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5701f65a-8135-4c17-b21e-2793b3185858" xlink:to="loc_us-gaap_LeaseCost_fe558d44-421c-40bd-b357-a7787c5b89d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5689cfe4-a3a7-4f2e-80c9-20676eec24fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherInformationLeaseLiabilityAbstract_a4360172-109e-4390-8ec6-9bf2932e3bc5" xlink:href="bmrn-20221231.xsd#bmrn_OtherInformationLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5689cfe4-a3a7-4f2e-80c9-20676eec24fd" xlink:to="loc_bmrn_OtherInformationLeaseLiabilityAbstract_a4360172-109e-4390-8ec6-9bf2932e3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract_d9da2d59-3e15-41fd-9703-5ce17f3320ee" xlink:href="bmrn-20221231.xsd#bmrn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OtherInformationLeaseLiabilityAbstract_a4360172-109e-4390-8ec6-9bf2932e3bc5" xlink:to="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract_d9da2d59-3e15-41fd-9703-5ce17f3320ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eea86a40-0a6b-443f-9bc4-7433e99c3180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract_d9da2d59-3e15-41fd-9703-5ce17f3320ee" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eea86a40-0a6b-443f-9bc4-7433e99c3180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f7927942-abd9-46e1-972e-91f011f816f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_WeightedAverageRemainingLeaseTermAbstract_d9da2d59-3e15-41fd-9703-5ce17f3320ee" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f7927942-abd9-46e1-972e-91f011f816f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_WeightedAverageDiscountRateAbstract_f80557a5-b76b-40fe-87d4-10d224d00e32" xlink:href="bmrn-20221231.xsd#bmrn_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_OtherInformationLeaseLiabilityAbstract_a4360172-109e-4390-8ec6-9bf2932e3bc5" xlink:to="loc_bmrn_WeightedAverageDiscountRateAbstract_f80557a5-b76b-40fe-87d4-10d224d00e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6abd1b39-47d2-4f23-a753-355275f7ddb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_WeightedAverageDiscountRateAbstract_f80557a5-b76b-40fe-87d4-10d224d00e32" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6abd1b39-47d2-4f23-a753-355275f7ddb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f6ad7a62-c35e-4a2a-a591-d831e7f7304d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_WeightedAverageDiscountRateAbstract_f80557a5-b76b-40fe-87d4-10d224d00e32" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f6ad7a62-c35e-4a2a-a591-d831e7f7304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LEASESScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_01fc8e2f-918e-445e-984c-ff521f7d4d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract_6af1a253-a14c-442f-ac38-b12caa0bc6eb" xlink:href="bmrn-20221231.xsd#bmrn_SupplementalCashFlowLeaseInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_01fc8e2f-918e-445e-984c-ff521f7d4d89" xlink:to="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract_6af1a253-a14c-442f-ac38-b12caa0bc6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_0e85edfc-94fa-4d79-9f0d-c136885f8b54" xlink:href="bmrn-20221231.xsd#bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract_6af1a253-a14c-442f-ac38-b12caa0bc6eb" xlink:to="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_0e85edfc-94fa-4d79-9f0d-c136885f8b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_eb2804bd-eb98-492e-81e2-79132a5bcca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_0e85edfc-94fa-4d79-9f0d-c136885f8b54" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_eb2804bd-eb98-492e-81e2-79132a5bcca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5f1791fc-9e16-46c3-9399-d51895795695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_eb2804bd-eb98-492e-81e2-79132a5bcca0" xlink:to="loc_us-gaap_OperatingLeasePayments_5f1791fc-9e16-46c3-9399-d51895795695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8b79ffcc-02b3-4f44-961c-3ee73c3f0697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_eb2804bd-eb98-492e-81e2-79132a5bcca0" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8b79ffcc-02b3-4f44-961c-3ee73c3f0697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_814cd55d-ad56-431e-bdc4-99b3385aed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_0e85edfc-94fa-4d79-9f0d-c136885f8b54" xlink:to="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_814cd55d-ad56-431e-bdc4-99b3385aed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_93664e78-cf09-410a-b141-3bbf9e147714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_814cd55d-ad56-431e-bdc4-99b3385aed6b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_93664e78-cf09-410a-b141-3bbf9e147714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_1ed9b994-24a1-4d63-95fc-dc33166e11eb" xlink:href="bmrn-20221231.xsd#bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_SupplementalCashFlowLeaseInformationAbstract_6af1a253-a14c-442f-ac38-b12caa0bc6eb" xlink:to="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_1ed9b994-24a1-4d63-95fc-dc33166e11eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0e249ff-b4c1-4954-b98d-6a915def6004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_1ed9b994-24a1-4d63-95fc-dc33166e11eb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0e249ff-b4c1-4954-b98d-6a915def6004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_05aa1f64-49a6-4925-a1c2-0cb15ec1b323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_1ed9b994-24a1-4d63-95fc-dc33166e11eb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_05aa1f64-49a6-4925-a1c2-0cb15ec1b323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_277029da-8911-42bd-92d5-ea5db583ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_277029da-8911-42bd-92d5-ea5db583ac1e" xlink:to="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:to="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_817e21df-0754-46d0-9e8a-361ce85b0371" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_3657e71f-f733-402b-a79a-e4471386bcb4" xlink:href="bmrn-20221231.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_3657e71f-f733-402b-a79a-e4471386bcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_ffea594c-b555-422c-9c38-62c9d72f4093" xlink:href="bmrn-20221231.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_ffea594c-b555-422c-9c38-62c9d72f4093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_122808b7-fe8d-446b-9906-8ca1f29a60e4" xlink:href="bmrn-20221231.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f2410de-e830-43e5-947a-fa273baef708" xlink:to="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_122808b7-fe8d-446b-9906-8ca1f29a60e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a84006eb-9c83-439d-ab9e-d0dc5e9d5a70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_7195c22e-612c-40fb-9f45-918db9f3a729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorSubordinatedNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f692171f-8fca-4224-a5ca-493b1001c3ed" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_7195c22e-612c-40fb-9f45-918db9f3a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57e2d5f8-ef77-4b6b-a7b8-cad900da1b7a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_05e7e26f-4345-4b3c-b59b-8c2e46718400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_05e7e26f-4345-4b3c-b59b-8c2e46718400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1f63974c-caf2-4917-a9de-677320bd1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1f63974c-caf2-4917-a9de-677320bd1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa3a248f-33ab-4151-a764-8ebfeb6c6b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa3a248f-33ab-4151-a764-8ebfeb6c6b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_eb60891a-2277-4471-9b75-8b3cbaa4bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_eb60891a-2277-4471-9b75-8b3cbaa4bfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_189160f3-a009-40e1-be81-af2d3df41c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_189160f3-a009-40e1-be81-af2d3df41c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0016d17e-1d18-4214-8027-3b48f5cf4ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0016d17e-1d18-4214-8027-3b48f5cf4ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c0cfb120-61bd-4aba-83d7-611491e1b6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c0cfb120-61bd-4aba-83d7-611491e1b6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_3cd46cba-ccd0-4c4e-b1bf-73fec3900559" xlink:href="bmrn-20221231.xsd#bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount_3cd46cba-ccd0-4c4e-b1bf-73fec3900559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DebtInstrumentPercentageOfFaceValue_aa84575c-5035-40eb-a5e7-780bf856fb25" xlink:href="bmrn-20221231.xsd#bmrn_DebtInstrumentPercentageOfFaceValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_bmrn_DebtInstrumentPercentageOfFaceValue_aa84575c-5035-40eb-a5e7-780bf856fb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b34ff168-e52c-4a75-aafc-3b644ac71fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b34ff168-e52c-4a75-aafc-3b644ac71fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d4072ba8-d093-42c6-a2ee-fa1d309a34e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d4072ba8-d093-42c6-a2ee-fa1d309a34e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2948939f-a72f-4fcc-83ea-16afc7727617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_03a6ac0c-c9a4-42c3-b4e2-0a46e1173d5d" xlink:to="loc_us-gaap_LineOfCredit_2948939f-a72f-4fcc-83ea-16afc7727617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e578d0f9-1e50-424b-8e27-ab717a2fe797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e578d0f9-1e50-424b-8e27-ab717a2fe797" xlink:to="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:to="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_949dca8b-0a28-44d9-b4db-8aa71a287c7d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_84bdebca-1831-470e-b11d-54991f1030fe" xlink:href="bmrn-20221231.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_84bdebca-1831-470e-b11d-54991f1030fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_29e2f82f-6d36-459a-a83c-1ee51189260a" xlink:href="bmrn-20221231.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7c955d8-43aa-437e-9889-33f2b0367e50" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_29e2f82f-6d36-459a-a83c-1ee51189260a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d6c4cad8-a845-491e-81a9-13f04d580622" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc10ab4e-688f-4c5c-880c-77ff74211f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc10ab4e-688f-4c5c-880c-77ff74211f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec02f68c-fcce-42c3-8a16-1311accaf7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec02f68c-fcce-42c3-8a16-1311accaf7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eb08383-5622-48e1-999b-47aee7873fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eb08383-5622-48e1-999b-47aee7873fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_155d5282-7282-4107-a395-9a85659aaa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_155d5282-7282-4107-a395-9a85659aaa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_3bac7a6a-b4a8-49b9-bcf3-17f5746dadbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebt_3bac7a6a-b4a8-49b9-bcf3-17f5746dadbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e571575-4f29-460f-b163-98730a08bb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6f8cd884-b1db-450b-bdcb-63642e29f7d5" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e571575-4f29-460f-b163-98730a08bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#DEBTScheduleofInterestExpenseonDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8b5058d0-35b8-4900-84f8-00fd047ab130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8b5058d0-35b8-4900-84f8-00fd047ab130" xlink:to="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d5f8fa94-9114-4210-b4b6-43ff9528610f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_211b2289-85d3-4065-8edf-c886c6908a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3be1b115-a770-40ce-b28f-522ea18fae6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_211b2289-85d3-4065-8edf-c886c6908a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_40ac1a2f-e980-4bdc-bea4-72444b220a24" xlink:to="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f6bf4a7d-41a0-48e0-bf7e-82e5aad7dfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f6bf4a7d-41a0-48e0-bf7e-82e5aad7dfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7468c2c3-a0a1-4bbd-920d-ce0a54faeff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7468c2c3-a0a1-4bbd-920d-ce0a54faeff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c9954a01-b5d6-40b7-a042-1849a88ec874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c9954a01-b5d6-40b7-a042-1849a88ec874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_478dea76-81bd-42e6-8800-620109200518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_179a5305-6a3b-4503-8acb-5467c46110d8" xlink:to="loc_us-gaap_InterestExpense_478dea76-81bd-42e6-8800-620109200518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_82bfa4f1-9263-4148-966f-0f019632f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82bfa4f1-9263-4148-966f-0f019632f365" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710b49a-98a1-416f-93d3-c186216fd489" xlink:to="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_59f9de1d-93e2-4ce9-a140-5aa76bcb837a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_0babb432-399b-4c7b-ae3b-864d3a0c5696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_0babb432-399b-4c7b-ae3b-864d3a0c5696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2f0f9363-96fa-4719-9932-b9b99a390e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2f0f9363-96fa-4719-9932-b9b99a390e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccumulatedGainLossFromOtherMember_557a8e61-61bc-4ece-8b41-03ae6abf00cf" xlink:href="bmrn-20221231.xsd#bmrn_AccumulatedGainLossFromOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a18f9eac-29ef-4e91-acb5-bbd86567e59c" xlink:to="loc_bmrn_AccumulatedGainLossFromOtherMember_557a8e61-61bc-4ece-8b41-03ae6abf00cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bbeb0fbe-9fc6-4f1d-a645-b79e5f050b29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8495c129-8de5-4756-b60e-83cbfea1daa3" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45b15422-8ba8-4350-bbea-f53928ee057e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_StockholdersEquity_45b15422-8ba8-4350-bbea-f53928ee057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_7de45780-3185-4dee-b8e2-c74871109975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_7de45780-3185-4dee-b8e2-c74871109975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d3414581-9fd5-414d-917f-fe5680fd2261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d3414581-9fd5-414d-917f-fe5680fd2261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_9aa11ca9-fa2a-4407-b5c8-24b0a9dca885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_9aa11ca9-fa2a-4407-b5c8-24b0a9dca885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abe88927-e28e-44e6-83ff-36e5f25add2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abe88927-e28e-44e6-83ff-36e5f25add2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6fac9ba-edba-4378-b25a-2b351d82ecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fcebb90d-c741-4230-a59c-630ea88e84b9" xlink:to="loc_us-gaap_StockholdersEquity_a6fac9ba-edba-4378-b25a-2b351d82ecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_ca4e6531-dd7a-460a-8861-0d2c1b59295a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_ca4e6531-dd7a-460a-8861-0d2c1b59295a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:to="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3da1ead4-213b-44da-a22e-bb6c87d5c2c2" xlink:to="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:to="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember_078b1537-5c3a-44eb-a261-f5856738ee45" xlink:href="bmrn-20221231.xsd#bmrn_ProductTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductTwoMember_078b1537-5c3a-44eb-a261-f5856738ee45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember_9ee8d979-cc61-4b7b-97e3-df639cbb3d4c" xlink:href="bmrn-20221231.xsd#bmrn_ProductThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductThreeMember_9ee8d979-cc61-4b7b-97e3-df639cbb3d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember_dd4f9c15-0b03-421d-b9bf-5df96aee8969" xlink:href="bmrn-20221231.xsd#bmrn_ProductFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductFourMember_dd4f9c15-0b03-421d-b9bf-5df96aee8969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFiveMember_4e4f2ec5-aa9a-479c-aa80-652f6104049a" xlink:href="bmrn-20221231.xsd#bmrn_ProductFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductFiveMember_4e4f2ec5-aa9a-479c-aa80-652f6104049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember_0f52d0a9-7300-4e5a-b88b-8faee4b44e0b" xlink:href="bmrn-20221231.xsd#bmrn_ProductSixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductSixMember_0f52d0a9-7300-4e5a-b88b-8faee4b44e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember_7a25aec1-505d-40cd-9c40-9341c5f8ac35" xlink:href="bmrn-20221231.xsd#bmrn_ProductSevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductSevenMember_7a25aec1-505d-40cd-9c40-9341c5f8ac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember_2325d4ab-4d20-4b3b-a5b9-95633a260021" xlink:href="bmrn-20221231.xsd#bmrn_ProductEightMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductEightMember_2325d4ab-4d20-4b3b-a5b9-95633a260021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_74ab0838-52a0-4d74-9c65-102f35417533" xlink:href="bmrn-20221231.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_74ab0838-52a0-4d74-9c65-102f35417533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_a56d573e-b582-4c44-bdba-efee3e887805" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_810dccf3-0c62-4094-ae70-ce4db49b0b94" xlink:to="loc_bmrn_ProductOneMember_a56d573e-b582-4c44-bdba-efee3e887805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_11b50faf-3c97-4f8f-bcab-c8e726daa4fd" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfdb039c-4788-4d0a-85fc-ffb61cc46cdd" xlink:to="loc_bmrn_RoyaltyAndOtherMember_11b50faf-3c97-4f8f-bcab-c8e726daa4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_72e79ec7-f543-4ba4-b948-4d3180fcf2f2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_8e77079d-bdbf-429f-9fc2-71133dac87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_8e77079d-bdbf-429f-9fc2-71133dac87ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_fbc94d76-af72-4257-88bf-f784d87ae516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b9ba33fa-0449-4863-9942-8e61bc3c2478" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_fbc94d76-af72-4257-88bf-f784d87ae516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_11ab6b6d-ddd3-4c86-85dc-3383b203e826" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_990e89a3-28a3-4de9-9abe-c30b02c6a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_db0c0446-23c3-4c41-a500-71f1f85b5db3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_990e89a3-28a3-4de9-9abe-c30b02c6a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2abb37e0-ef4c-4a40-80a4-3f29789ac31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2abb37e0-ef4c-4a40-80a4-3f29789ac31c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_62f36e2d-5ff0-4339-9406-1add3306a0cf" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_39aec0b9-72c6-4dd8-8b51-3a7f7c2bf3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_39aec0b9-72c6-4dd8-8b51-3a7f7c2bf3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_3892fa39-8de1-44ea-97b5-9c3556727d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_fda38914-0058-4f47-ad9a-f9f17db27199" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_3892fa39-8de1-44ea-97b5-9c3556727d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_14bf9cb9-b343-4f82-bfa1-94f13254f814" xlink:to="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_895920c8-3e10-407c-96e3-c60080e27f91" xlink:to="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_570cf04e-2277-446d-bf5e-8afeb87eef25" xlink:href="bmrn-20221231.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_570cf04e-2277-446d-bf5e-8afeb87eef25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_64ac0382-1ba3-4aff-9b19-ad86d0025599" xlink:href="bmrn-20221231.xsd#bmrn_ProductOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_af02507c-731d-4e80-8487-f3e0ad59caf1" xlink:to="loc_bmrn_ProductOneMember_64ac0382-1ba3-4aff-9b19-ad86d0025599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8f72d904-fccd-46a3-9d46-6bdf28ae62a6" xlink:to="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5303c340-8ef4-4031-9910-eab8f6721abb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_country_US_5303c340-8ef4-4031-9910-eab8f6721abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2133cc4f-923a-4f17-9b73-c1e574ceb538" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_srt_EuropeMember_2133cc4f-923a-4f17-9b73-c1e574ceb538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_ced2b891-7070-408b-985e-e37202e1058c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_srt_LatinAmericaMember_ced2b891-7070-408b-985e-e37202e1058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_4db99373-bddd-4a69-b485-fec939c99eaa" xlink:href="bmrn-20221231.xsd#bmrn_RestOfWorldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cf1739e3-8655-449e-8afe-27d85dec9f25" xlink:to="loc_bmrn_RestOfWorldMember_4db99373-bddd-4a69-b485-fec939c99eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3241d01b-2d27-452f-be12-12d8091a0bd1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53f99a28-0e67-4aa1-9a57-4786625914f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_84ba2b42-75a3-45ae-a187-2d692caa6da2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53f99a28-0e67-4aa1-9a57-4786625914f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_f9011605-8a83-4945-9175-a12f307b2486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_f9011605-8a83-4945-9175-a12f307b2486" xlink:to="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44361f8a-a35e-4c03-82fb-de650c31c64a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a9abf78-d7ec-4270-bf1d-2f3e4778ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bd3f89b0-7faa-4b69-a198-b03716099c2a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a9abf78-d7ec-4270-bf1d-2f3e4778ee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c8dba69e-0f0c-46b8-ac2a-dd9e3b8b0d2a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_354e2254-453a-444a-95df-4ce0b858688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba71b04-5689-4bac-8c41-c18f0814dfd8" xlink:to="loc_us-gaap_SalesRevenueNetMember_354e2254-453a-444a-95df-4ce0b858688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_819bb07b-f509-489d-9fcb-f4c01baacd96" xlink:to="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneTwoAndThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_25753fed-e980-4939-862a-ba2ce05f4919" xlink:to="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_f0bde07d-fdaa-44bf-9d9d-83416efe24b9" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerOneMember_f0bde07d-fdaa-44bf-9d9d-83416efe24b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_2ad24fbc-0eba-4b36-b9ce-d0714ba65c8a" xlink:href="bmrn-20221231.xsd#bmrn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerTwoMember_2ad24fbc-0eba-4b36-b9ce-d0714ba65c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember_44838ad8-ea07-4c57-8848-b803aec2334f" xlink:href="bmrn-20221231.xsd#bmrn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoAndThreeMember_9d332c7d-76d3-41e9-b4ac-66d9b5b6246b" xlink:to="loc_bmrn_CustomerThreeMember_44838ad8-ea07-4c57-8848-b803aec2334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_792cd138-d8f4-4f8d-a45a-365fe3eb297c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f549328-d20e-4a4a-9e5f-3a765804d866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58a8b096-0c44-44cb-a3b4-875e80fd867f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f549328-d20e-4a4a-9e5f-3a765804d866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_e386b42c-649b-4c4d-aaa7-90cd7c86f013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_e386b42c-649b-4c4d-aaa7-90cd7c86f013" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_13629be9-cc4f-4131-9cd8-0a709bc2f46d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_be062292-cf85-46c9-a192-f9a576248218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_56e0a8f2-4a86-47ad-8510-acd7753e4d20" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_be062292-cf85-46c9-a192-f9a576248218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a716428d-4ea0-4af9-b02f-11a266a59fbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e46d48fb-4001-4c31-a602-ab533abf9dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_eb6823e2-6ee1-4554-a509-431c6862ceca" xlink:to="loc_us-gaap_AccountsReceivableMember_e46d48fb-4001-4c31-a602-ab533abf9dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_55a749f6-87db-4f4a-a5a4-7c5d5b7e9948" xlink:to="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_0f184854-2752-49b8-8d2e-5ef05ef41a7e" xlink:href="bmrn-20221231.xsd#bmrn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomerOneMember_0f184854-2752-49b8-8d2e-5ef05ef41a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_68c6c424-7ba4-418b-83b4-73def509b76b" xlink:href="bmrn-20221231.xsd#bmrn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomerTwoMember_68c6c424-7ba4-418b-83b4-73def509b76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember_28e460bd-2d18-41f9-84ab-99f354bc2e16" xlink:href="bmrn-20221231.xsd#bmrn_CustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e5e37cbd-985a-40d2-b1de-de7f58f0c936" xlink:to="loc_bmrn_CustomersMember_28e460bd-2d18-41f9-84ab-99f354bc2e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:href="bmrn-20221231.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_aa3621ef-0a16-418d-ab72-54901d53734e" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26601492-decd-4938-9adc-ef0b9883f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26601492-decd-4938-9adc-ef0b9883f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d370d997-bd34-4b2b-9734-e9f647da4f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_4d51ae57-992b-48e7-841e-61e10cde12e5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d370d997-bd34-4b2b-9734-e9f647da4f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_c012ab7e-472e-4a07-82a2-86fdc4b659f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c012ab7e-472e-4a07-82a2-86fdc4b659f3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:to="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_45f63661-0525-4445-9ed9-42f746851f97" xlink:to="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b2eb6be0-ae17-461a-ab59-13d5979bd39f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_country_US_b2eb6be0-ae17-461a-ab59-13d5979bd39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_b22323e5-d14e-4a61-a154-c60c454212bd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_country_IE_b22323e5-d14e-4a61-a154-c60c454212bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_39cca9ea-0fda-422f-a0fa-f7b20cb03ff1" xlink:href="bmrn-20221231.xsd#bmrn_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d014db3c-2dcc-4073-82c6-67e34bc628fd" xlink:to="loc_bmrn_RestOfWorldMember_39cca9ea-0fda-422f-a0fa-f7b20cb03ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b8d5747b-61ed-48f3-ad2a-c2d5a2d6e466" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_5629404e-7ca7-4129-b0e6-e5327a5739d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6aa66882-43bb-46a9-b541-805caa79874f" xlink:to="loc_us-gaap_NoncurrentAssets_5629404e-7ca7-4129-b0e6-e5327a5739d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2bea7fb-79b1-4937-a29c-ea66e9c83130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2bea7fb-79b1-4937-a29c-ea66e9c83130" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_aa481307-23cd-4c4e-bc21-ca4be165de42" xlink:to="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_1c152e65-1510-4fea-a568-d820d8b93caf" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2cfd2856-1283-45a0-a6b5-75ed60f7f7d1" xlink:to="loc_bmrn_TwoThousandSeventeenEquityIncentivePlanMember_1c152e65-1510-4fea-a568-d820d8b93caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e8200e42-1e77-4c5d-a25a-428c3c5bd272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_1be5d834-dae8-4ea2-b2f6-c8aeaccc88fe" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedStockWithServiceBasedVestingConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_1be5d834-dae8-4ea2-b2f6-c8aeaccc88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_82709c4e-bcc7-4817-9eaa-ab857a6d5614" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember_82709c4e-bcc7-4817-9eaa-ab857a6d5614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4ce445f4-b57f-41ba-83e6-c7f405e14d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4ce445f4-b57f-41ba-83e6-c7f405e14d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d140fe87-5861-4ce2-b258-067919dfada1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_us-gaap_RestrictedStockMember_d140fe87-5861-4ce2-b258-067919dfada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_df0745e8-8d5d-4edf-905f-63db0c61802f" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_df0745e8-8d5d-4edf-905f-63db0c61802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_d2493bac-b0e0-47d4-8818-8417605b586e" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb33577-d0c3-4964-ac54-fc22945ab860" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_d2493bac-b0e0-47d4-8818-8417605b586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0ebfe39d-eb49-4075-98dc-521459c693bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IndependentDirectorMember_750f9d5b-9767-430d-8ceb-bd733d244a86" xlink:href="bmrn-20221231.xsd#bmrn_IndependentDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b46030ff-eb06-4063-9afc-ec24bbc84593" xlink:to="loc_bmrn_IndependentDirectorMember_750f9d5b-9767-430d-8ceb-bd733d244a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd819998-3956-45f6-bb14-721bc0722b14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51637d60-f0d7-46d2-a8d6-89dd2750fb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281471ae-ca84-4773-96cd-3a48e4db8206" xlink:to="loc_us-gaap_EmployeeStockMember_51637d60-f0d7-46d2-a8d6-89dd2750fb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c60f1aa-eabc-42d8-a251-870747b7be93" xlink:to="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c23e483-8b4f-4c6f-aab8-6da1e0e5fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d8e2991-570f-4662-9177-506444542948" xlink:to="loc_us-gaap_CommonStockMember_0c23e483-8b4f-4c6f-aab8-6da1e0e5fcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ff48049-b772-4302-8c6a-cf16daea032e" xlink:to="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3db159e0-975f-4824-81a1-7a1bfb43718f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:to="loc_srt_MinimumMember_3db159e0-975f-4824-81a1-7a1bfb43718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_102f22d7-0f53-4c21-8b6a-6562d66c882a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5ab6dc51-df87-4030-bd93-e4962a1290e5" xlink:to="loc_srt_MaximumMember_102f22d7-0f53-4c21-8b6a-6562d66c882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2c3a62a5-8b6b-4ffa-81ee-cc27f86fb066" xlink:to="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_837277ef-69ea-4292-a466-8001510aa36b" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember_837277ef-69ea-4292-a466-8001510aa36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_db120dda-879c-4eb0-8691-042857502feb" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember_db120dda-879c-4eb0-8691-042857502feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_4e4d44ba-6042-409b-a989-39f722aab6e4" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_91141290-84bc-41dc-a8ec-350f72c4492f" xlink:to="loc_bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember_4e4d44ba-6042-409b-a989-39f722aab6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60704996-8417-4184-a3a7-35613277dcd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e158c375-110a-4a34-aaa2-5cd538e68d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e158c375-110a-4a34-aaa2-5cd538e68d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01869e6e-2876-4985-b7b9-9c2ac7bb2b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01869e6e-2876-4985-b7b9-9c2ac7bb2b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_d6b0a9bc-348a-4d38-884e-e5e3801b9fd5" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement_d6b0a9bc-348a-4d38-884e-e5e3801b9fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d5f6a63a-c061-478c-8e1a-db9435a8e8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d5f6a63a-c061-478c-8e1a-db9435a8e8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d44acd29-dca6-4980-98ce-d65bea6e07f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d44acd29-dca6-4980-98ce-d65bea6e07f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63385a54-518d-47a9-a1b0-788c63cca8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63385a54-518d-47a9-a1b0-788c63cca8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SpanOfOfferingPeriod_e7909496-b115-49a5-b944-898d9e0fb5b3" xlink:href="bmrn-20221231.xsd#bmrn_SpanOfOfferingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_SpanOfOfferingPeriod_e7909496-b115-49a5-b944-898d9e0fb5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4f5d4dd6-25fa-407a-bb35-a00664758605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4f5d4dd6-25fa-407a-bb35-a00664758605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MaximumPayrollDeductions_6841495c-a73b-47a5-9aa1-04e1fc2682e2" xlink:href="bmrn-20221231.xsd#bmrn_MaximumPayrollDeductions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_MaximumPayrollDeductions_6841495c-a73b-47a5-9aa1-04e1fc2682e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7fadd38d-647f-4303-a08b-441366657e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7fadd38d-647f-4303-a08b-441366657e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_e65cb837-06cb-4cda-9f8d-279adad6c279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_e65cb837-06cb-4cda-9f8d-279adad6c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AverageClosingPriceTrailingPeriod_61def96f-1bc0-458b-8425-b0f4e88b567a" xlink:href="bmrn-20221231.xsd#bmrn_AverageClosingPriceTrailingPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_AverageClosingPriceTrailingPeriod_61def96f-1bc0-458b-8425-b0f4e88b567a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4906c018-c202-4c8f-8628-935b2550c91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4906c018-c202-4c8f-8628-935b2550c91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0f3fcfa-b0b2-41ef-a73f-effaaf7b3307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0f3fcfa-b0b2-41ef-a73f-effaaf7b3307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_0c47716f-3666-4b41-b6e6-7868f7b94253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_0c47716f-3666-4b41-b6e6-7868f7b94253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21bdc13e-1837-4ec8-9153-8890a1ce7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21bdc13e-1837-4ec8-9153-8890a1ce7f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ca18aa5-bd66-48f8-aeb1-7e76df923bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ca18aa5-bd66-48f8-aeb1-7e76df923bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fb6ba99d-51db-4c9f-a5bd-726d0afb485d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fb6ba99d-51db-4c9f-a5bd-726d0afb485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_af959582-2b62-44a7-be46-7fddccf03fcb" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage_af959582-2b62-44a7-be46-7fddccf03fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_0939f929-c2f7-4551-981c-2c294dfd8432" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage_0939f929-c2f7-4551-981c-2c294dfd8432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_f31da968-3f23-4964-9732-e090086e88f7" xlink:href="bmrn-20221231.xsd#bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage_f31da968-3f23-4964-9732-e090086e88f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7db4021f-7d6d-4a1f-9bbe-011f9fb78a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7db4021f-7d6d-4a1f-9bbe-011f9fb78a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5baf4c37-f34c-4214-bff0-1ad1fb6768bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5baf4c37-f34c-4214-bff0-1ad1fb6768bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_280de73a-1d0d-4cd7-a2bc-6ee47108920e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d879145-91cb-462f-b666-2253aac23e0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_280de73a-1d0d-4cd7-a2bc-6ee47108920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58024604-b773-4f1a-b518-b962b7c10594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58024604-b773-4f1a-b518-b962b7c10594" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ad4c06c-35c8-4c19-9745-48c6de56cfad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7007800c-657d-4ecb-bca2-63bd4429136f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_CostOfSalesMember_7007800c-657d-4ecb-bca2-63bd4429136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be25ee3-4682-40ea-b0c9-a10ba87a835f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be25ee3-4682-40ea-b0c9-a10ba87a835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_74b78b64-3f3c-45cf-90ab-17b4726ea834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b0a6e8b-be6d-4115-968f-e1cf9b968704" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_74b78b64-3f3c-45cf-90ab-17b4726ea834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f241508b-0994-4b67-a16b-5170414f273a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_df883d21-786c-4be8-8da1-2e3923614273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5d7aa1b-626d-407f-8983-c04a92e52401" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_df883d21-786c-4be8-8da1-2e3923614273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f6f5794-958a-40af-846d-139e2e49cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f6f5794-958a-40af-846d-139e2e49cd9d" xlink:to="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:to="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_071467f2-ea1e-43f5-b67e-8834cd160c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_2152df84-de33-4616-a535-0b0733ffcee6" xlink:href="bmrn-20221231.xsd#bmrn_RestrictedStockWithServiceBasedVestingConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_RestrictedStockWithServiceBasedVestingConditionsMember_2152df84-de33-4616-a535-0b0733ffcee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_d5607166-a60f-4829-8f96-18dab00cb7df" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember_d5607166-a60f-4829-8f96-18dab00cb7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_df0d4e73-fdc6-4653-be29-f082ebbb05f1" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7de9be-3c2f-4032-9a78-f6b41ebf5e5d" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_df0d4e73-fdc6-4653-be29-f082ebbb05f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:href="bmrn-20221231.xsd#bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_0ed7f4ca-60a6-4e91-af85-6fa866c4b0a2" xlink:to="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f7fc553-f369-4007-94fd-72e42df5e0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f7fc553-f369-4007-94fd-72e42df5e0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06ddc64a-d9ef-49f8-bfff-e94fdf86a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06ddc64a-d9ef-49f8-bfff-e94fdf86a59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1fb06e6-fa5f-464b-8e37-160535e88ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1fb06e6-fa5f-464b-8e37-160535e88ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15634d89-ea0b-4c53-ae39-68df9e8ea0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15634d89-ea0b-4c53-ae39-68df9e8ea0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee573772-5fe3-41c4-bb0b-37d4c7647df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33a0da7b-1c64-45dd-b473-380b6f4c04f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee573772-5fe3-41c4-bb0b-37d4c7647df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_79fa39b6-bc59-4439-b4e7-e6e736dfbf7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c121abc-b468-4551-9e5d-f88727e5e735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c121abc-b468-4551-9e5d-f88727e5e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d26ecbe-80f1-4664-8f8b-9ced8d9eb685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d26ecbe-80f1-4664-8f8b-9ced8d9eb685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94ebd2d4-09f6-4336-bf56-eeb2007d0499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94ebd2d4-09f6-4336-bf56-eeb2007d0499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc2df80a-42f1-4eab-83fb-2bfca4a2250e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc2df80a-42f1-4eab-83fb-2bfca4a2250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cdce99f9-4247-4c72-a298-0b57f8baf3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_85e23df6-6556-456a-b15a-fc06d3df6605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cdce99f9-4247-4c72-a298-0b57f8baf3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28389df0-ed8b-453d-8c8f-7f6c0eb7d923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28389df0-ed8b-453d-8c8f-7f6c0eb7d923" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:to="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b5e82113-2eca-4dae-a7fa-266bafb73826" xlink:to="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ded0678e-da14-4467-883d-d10be7f99252" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:to="loc_srt_MinimumMember_ded0678e-da14-4467-883d-d10be7f99252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70e612c2-b85e-4647-aba3-5773839d3d4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc3fa1c8-1606-4094-9a00-fd002ff80b46" xlink:to="loc_srt_MaximumMember_70e612c2-b85e-4647-aba3-5773839d3d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:to="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d60832e-18f6-49aa-8244-e48b681a5a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_a92775b8-23f7-415a-b9c8-8511ef56d085" xlink:href="bmrn-20221231.xsd#bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d12ca2a-fdc8-48c9-8441-8e1487cd2b9e" xlink:to="loc_bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember_a92775b8-23f7-415a-b9c8-8511ef56d085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd35608b-d56f-4df6-a259-771baf452d37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eeb86b04-7a7a-4335-85be-a9f313e7be79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eeb86b04-7a7a-4335-85be-a9f313e7be79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1e7a8f25-3596-4bd0-b41a-ec2a0aaeccda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1e7a8f25-3596-4bd0-b41a-ec2a0aaeccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2b0ba4d7-0d37-4d98-9810-dc870edc4b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2b0ba4d7-0d37-4d98-9810-dc870edc4b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6f1e245-5fab-4696-9e4e-b98e200a64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6f1e245-5fab-4696-9e4e-b98e200a64d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_530942cb-1741-4ecd-b57b-26e8eb10dd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_530942cb-1741-4ecd-b57b-26e8eb10dd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ecbc6bc9-1b4e-4bb0-9880-f2cf2ac008ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ecbc6bc9-1b4e-4bb0-9880-f2cf2ac008ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_795eb568-09d7-4c09-8f63-83706bd256f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_795eb568-09d7-4c09-8f63-83706bd256f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_304613de-8bae-4122-b13d-bbe36e280a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fb9170a-8d8f-4ad6-93da-1c002597cbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_304613de-8bae-4122-b13d-bbe36e280a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3114e3d8-9c0e-4d16-8280-c327a85a53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3114e3d8-9c0e-4d16-8280-c327a85a53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e1be35cb-f407-4d77-931a-e1c7cfeb00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e1be35cb-f407-4d77-931a-e1c7cfeb00a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8b38c85a-7b64-4ac4-ab88-41f8d95654e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8b38c85a-7b64-4ac4-ab88-41f8d95654e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9ac10ebe-9e7c-49c2-b0f7-bd5c82b75270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9ac10ebe-9e7c-49c2-b0f7-bd5c82b75270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d75f4c74-2ddd-4440-9e72-d6ece3b00b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fe98f696-0c4e-4cbe-8a14-98b8753a62de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d75f4c74-2ddd-4440-9e72-d6ece3b00b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c893ef80-509f-410c-bae2-477e3450147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c893ef80-509f-410c-bae2-477e3450147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b9d6d152-eb93-4b69-8e5d-85e805849bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b9d6d152-eb93-4b69-8e5d-85e805849bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4219928-b126-4bc4-b480-ca924f09628c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4219928-b126-4bc4-b480-ca924f09628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bcdd05e2-d448-4259-8044-2c2a97131861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bcdd05e2-d448-4259-8044-2c2a97131861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9234d0e0-d39b-4472-88a9-66e9f47c9b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9234d0e0-d39b-4472-88a9-66e9f47c9b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_558ea616-82a6-4bb0-ba3a-1960460aef63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_558ea616-82a6-4bb0-ba3a-1960460aef63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10670223-a02d-4dda-8e82-a661ea64f013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caeec223-a632-451b-8b6d-17cccddfdc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10670223-a02d-4dda-8e82-a661ea64f013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_fafb0fd5-5fb4-4367-87e5-24c77b993c13" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_fafb0fd5-5fb4-4367-87e5-24c77b993c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_551eb1c6-49fb-4c4b-a365-34e6b8af1456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_551eb1c6-49fb-4c4b-a365-34e6b8af1456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_babc6298-b548-4f74-88cc-4bb3f66c115e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_babc6298-b548-4f74-88cc-4bb3f66c115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_22eba1d0-6cb2-456b-91ad-115938a29e96" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_22eba1d0-6cb2-456b-91ad-115938a29e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_83cd0573-8b15-4ae8-97f1-37d42cfc348d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_83cd0573-8b15-4ae8-97f1-37d42cfc348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84ba391e-a117-40e6-9bd1-74344c99a2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84ba391e-a117-40e6-9bd1-74344c99a2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_1182e5b1-2da5-48d9-a10b-7258bfe0ed15" xlink:href="bmrn-20221231.xsd#bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_1182e5b1-2da5-48d9-a10b-7258bfe0ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_52290326-c7e7-48c7-aa10-1aad158e8553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f94dad38-7f2a-4fba-8739-c28b82fc0ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_52290326-c7e7-48c7-aa10-1aad158e8553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d2132345-0310-4024-a5b9-065bdefd60a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef59c4f7-8188-4a82-8c64-534018408677" xlink:to="loc_us-gaap_SharePrice_d2132345-0310-4024-a5b9-065bdefd60a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024fe0b0-7bb2-4b81-b8a1-5e60350bfcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024fe0b0-7bb2-4b81-b8a1-5e60350bfcec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:to="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_707df0e8-87f5-4eba-b1b7-4c5843258fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6314148d-6e3c-4b5d-a080-78eadd9cfbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c78b05b-7067-41df-a8d2-0abb896967e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6314148d-6e3c-4b5d-a080-78eadd9cfbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:to="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1a421d12-856c-4723-98a9-88c7fa68715d" xlink:to="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_064b6352-bc57-4883-867f-9803a47fdc65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:to="loc_srt_MinimumMember_064b6352-bc57-4883-867f-9803a47fdc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7f205a3-4303-4520-8a5c-ec3de41dc348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df7669d-d55e-4626-8132-24425b9cd41b" xlink:to="loc_srt_MaximumMember_c7f205a3-4303-4520-8a5c-ec3de41dc348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62811fb8-a9cf-4ad3-bdd7-a6d778604af9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5edea640-64d3-40b0-85f6-75c0dfb7dbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5edea640-64d3-40b0-85f6-75c0dfb7dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a6f7dbc4-f672-42a2-8596-11cb569dd446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a6f7dbc4-f672-42a2-8596-11cb569dd446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30cb1a20-1d21-465e-b8b7-b5d89884b1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30cb1a20-1d21-465e-b8b7-b5d89884b1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f8494ed0-8219-4154-9ae5-12a6975a8ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f8494ed0-8219-4154-9ae5-12a6975a8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_85105867-60c5-46cf-8070-4463ad292c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_85105867-60c5-46cf-8070-4463ad292c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0903d37b-ca83-4e14-bb78-625f5ef81b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f6a32bd-b66f-49ae-b37a-f7f97d8ac078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0903d37b-ca83-4e14-bb78-625f5ef81b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51db078f-80ec-40b4-9f17-e93200e8d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51db078f-80ec-40b4-9f17-e93200e8d999" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b889bd5-5370-4ac0-8e3d-c6c46c798953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_03d42f05-dea1-43dc-a4d3-31ea84b7d711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d0f5a50-7f40-4743-ab1b-39f537ee1ddb" xlink:to="loc_us-gaap_EmployeeStockMember_03d42f05-dea1-43dc-a4d3-31ea84b7d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:to="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ac74853-2f4e-411c-a71a-ae55ee95fa3d" xlink:to="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6289e20c-02df-4f6a-8051-d85afd3d7ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:to="loc_srt_MinimumMember_6289e20c-02df-4f6a-8051-d85afd3d7ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95d1068a-c3ea-459b-b391-bd5c43c2402e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2c8b929-775a-4fa6-9f36-ae0c41584d0c" xlink:to="loc_srt_MaximumMember_95d1068a-c3ea-459b-b391-bd5c43c2402e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3256e4b-8cb9-4ed7-84b7-999d8ebed96d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37a328dd-4416-4d4a-adde-e9922303ca39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37a328dd-4416-4d4a-adde-e9922303ca39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc4ad749-fcac-4a89-b998-363db08930e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc4ad749-fcac-4a89-b998-363db08930e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36f8495a-bb95-4956-a5a2-9544de14a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36f8495a-bb95-4956-a5a2-9544de14a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_04f4a0d9-ec56-49e0-81f4-b699c9ef211e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_04f4a0d9-ec56-49e0-81f4-b699c9ef211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_771a30f0-60ae-4694-8f4a-46d6efae1ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_771a30f0-60ae-4694-8f4a-46d6efae1ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_35931aa5-7907-4a6f-bda9-dbb411218112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_459289f1-5670-4a2d-bb0c-e9e8fe938fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_35931aa5-7907-4a6f-bda9-dbb411218112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_02cacb21-7d54-4b36-a8ec-fcfe933ba3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_02cacb21-7d54-4b36-a8ec-fcfe933ba3f9" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:to="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ecce9e67-a11e-4dad-b89d-0d8633f4887d" xlink:to="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BiomarinRetirementSavingsPlanMember_e23e4d6d-b52e-41b7-8e10-b50421c3803c" xlink:href="bmrn-20221231.xsd#bmrn_BiomarinRetirementSavingsPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ddd2b1d-c8a1-4afb-85ad-c5fe86200241" xlink:to="loc_bmrn_BiomarinRetirementSavingsPlanMember_e23e4d6d-b52e-41b7-8e10-b50421c3803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_a95e9878-3b06-4363-871b-099645961308" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6422745f-19f6-46ff-869d-e0f455a46eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6422745f-19f6-46ff-869d-e0f455a46eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d3526ec-f7ae-4696-91f1-07cc9fc804c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d3526ec-f7ae-4696-91f1-07cc9fc804c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_72ebd411-4674-4a21-a036-f97b1404eece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_9440ced6-bb3e-4556-bec8-221bc725e1ca" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_72ebd411-4674-4a21-a036-f97b1404eece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_320b4da9-7e46-4cc8-abfd-d7760641e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_95e35a68-aa59-4e88-96cc-e019ed5e7e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_320b4da9-7e46-4cc8-abfd-d7760641e1de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_95e35a68-aa59-4e88-96cc-e019ed5e7e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b7a9a1fd-4bd7-47c0-bf90-95879eaefc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_320b4da9-7e46-4cc8-abfd-d7760641e1de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b7a9a1fd-4bd7-47c0-bf90-95879eaefc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff5e3531-3771-4de0-a374-a512bf687cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_320b4da9-7e46-4cc8-abfd-d7760641e1de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff5e3531-3771-4de0-a374-a512bf687cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7aa3e0a2-b6f8-47e9-90a1-738b4806f753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7aa3e0a2-b6f8-47e9-90a1-738b4806f753" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3ee4a4aa-6c28-4320-a8bf-4cf1a9501846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3ee4a4aa-6c28-4320-a8bf-4cf1a9501846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3b7732c6-76d2-4cfa-ab6b-7df6aada2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3b7732c6-76d2-4cfa-ab6b-7df6aada2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_31922699-5aec-4533-8863-abb87bfb0e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_31922699-5aec-4533-8863-abb87bfb0e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5c7094f-72f5-4ba3-9088-8302669af764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8830fd8e-a4fa-45bd-b043-add0a29969d1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5c7094f-72f5-4ba3-9088-8302669af764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7aa3e0a2-b6f8-47e9-90a1-738b4806f753" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d2e8c5fd-60ca-48c9-8501-b6e9a233f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d2e8c5fd-60ca-48c9-8501-b6e9a233f60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7d5d7640-39eb-43cd-967c-ff5d795ec8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7d5d7640-39eb-43cd-967c-ff5d795ec8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9488664f-48d8-45c4-9ed6-1988f987de95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9488664f-48d8-45c4-9ed6-1988f987de95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1d56401a-86d5-44b0-bec4-72acd20e4868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2bc55b9c-8e25-4d9e-9759-242f92ab9a8f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1d56401a-86d5-44b0-bec4-72acd20e4868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e14731e3-3f88-4341-9e29-fe41d1ecc709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7aa3e0a2-b6f8-47e9-90a1-738b4806f753" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e14731e3-3f88-4341-9e29-fe41d1ecc709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c2cadef2-3133-40ac-a936-544b69123452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c2cadef2-3133-40ac-a936-544b69123452" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_73a39367-1111-4a35-9fb3-a46114cd3cc2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2d3c196d-f1a6-4363-84ea-a7ef25aaff84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38da6c79-446e-4658-8adf-6c4ecedc8dcd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2d3c196d-f1a6-4363-84ea-a7ef25aaff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_157a6774-f483-4394-b0e6-c5002c41d18c" xlink:to="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_5506e022-16e2-4efd-aedd-79a2bfdcee38" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f6805da3-7b6e-4920-ab66-033d80ef6d73" xlink:to="loc_country_IE_5506e022-16e2-4efd-aedd-79a2bfdcee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fbc2f0d2-0354-4dd1-bcd4-242d2750415a" xlink:to="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4fc68661-5c78-469f-b2e8-da9ad055208e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:to="loc_srt_MinimumMember_4fc68661-5c78-469f-b2e8-da9ad055208e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_862539ad-b4cc-4c72-8a4d-ad9ba44cdb4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f16d455-88a1-4a52-a6fe-e115af2e4e16" xlink:to="loc_srt_MaximumMember_862539ad-b4cc-4c72-8a4d-ad9ba44cdb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_17dad171-990a-4368-9ef7-790828a1c83b" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_15302752-0670-43eb-af27-aecd3a906dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_15302752-0670-43eb-af27-aecd3a906dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d89ba96d-3e19-4a66-b5f4-b9b246040584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d89ba96d-3e19-4a66-b5f4-b9b246040584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77e49351-94ff-4ada-ba03-1fe1b286e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77e49351-94ff-4ada-ba03-1fe1b286e79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod_ceb2d030-8201-41cb-9bf2-6eeb682401f7" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxStatuteOfLimitationsPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_bmrn_IncomeTaxStatuteOfLimitationsPeriod_ceb2d030-8201-41cb-9bf2-6eeb682401f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_b8edd203-7975-4203-bda3-0eea59362319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_89356253-0bde-473d-a036-648868a79d64" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_b8edd203-7975-4203-bda3-0eea59362319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21f4e73f-a2af-4169-b6b5-b920ad24e242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21f4e73f-a2af-4169-b6b5-b920ad24e242" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:to="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd0bb2e3-a1af-4bc3-ab76-2d27827f95b7" xlink:to="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_7a9dbc73-1f25-42d7-af2b-287d47adb93f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_edd3ca15-1798-4739-ae1d-809278802216" xlink:to="loc_country_NL_7a9dbc73-1f25-42d7-af2b-287d47adb93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dfb8b025-b358-4b13-8021-8adba7bd4524" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fedf2f27-63b2-4037-9dcb-42643af56a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fedf2f27-63b2-4037-9dcb-42643af56a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8551b19f-ec8f-47eb-a353-c08e8ece19ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8551b19f-ec8f-47eb-a353-c08e8ece19ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7f45334b-19cc-480e-9be0-2ca5930a60d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7f45334b-19cc-480e-9be0-2ca5930a60d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_222a694d-b80e-4785-9e2b-8c370ea17578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_222a694d-b80e-4785-9e2b-8c370ea17578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_48c9c9bd-cd0c-4d15-8712-c3696b4a8686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_48c9c9bd-cd0c-4d15-8712-c3696b4a8686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_41162703-8c57-40c1-9f92-d08f459ddf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_41162703-8c57-40c1-9f92-d08f459ddf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_953e5f95-34d2-4923-9e93-72781580ae49" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationSection162Limitation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_IncomeTaxRateReconciliationSection162Limitation_953e5f95-34d2-4923-9e93-72781580ae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_d33d33ff-7a9b-458a-b688-3a0db097f49f" xlink:href="bmrn-20221231.xsd#bmrn_IncomeTaxRateReconciliationTaxReserves"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_IncomeTaxRateReconciliationTaxReserves_d33d33ff-7a9b-458a-b688-3a0db097f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_98e46bb2-5bfe-4848-ade8-0200996ac42f" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount_98e46bb2-5bfe-4848-ade8-0200996ac42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_415886fa-7b8c-458a-a873-c3ffb0799bb0" xlink:href="bmrn-20221231.xsd#bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim_415886fa-7b8c-458a-a873-c3ffb0799bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ae03ca7-2474-4fdd-af64-704105e071b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ae03ca7-2474-4fdd-af64-704105e071b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91deb923-7901-4a88-8ceb-9af26772281a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91deb923-7901-4a88-8ceb-9af26772281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78ca88fa-bd8c-42e1-b371-aa519073eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78ca88fa-bd8c-42e1-b371-aa519073eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f9ea15d9-81f4-4a52-bbd8-10cb061c11de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d8915b4c-a32f-4bde-b577-7d8f10b25d8a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f9ea15d9-81f4-4a52-bbd8-10cb061c11de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e1a4f0b5-6e09-4199-be6b-f328f6048633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1a4f0b5-6e09-4199-be6b-f328f6048633" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2141d71e-5069-4264-ba09-422924d33883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2141d71e-5069-4264-ba09-422924d33883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_306bbc06-4cb6-4b58-93cb-725afab4f708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_306bbc06-4cb6-4b58-93cb-725afab4f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_81309f05-c348-4dfc-b795-92df6320d663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_81309f05-c348-4dfc-b795-92df6320d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f306051a-ed72-4b10-bfda-1f5801425685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f306051a-ed72-4b10-bfda-1f5801425685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_069bf5c2-530e-4668-a4c7-47542e8fc89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_069bf5c2-530e-4668-a4c7-47542e8fc89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ec98ba3a-2946-459c-8e6e-883232055551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ec98ba3a-2946-459c-8e6e-883232055551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxAssetsLeaseLiabilities_96bb55b8-9350-48b7-8a06-a9b9a9a43fac" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_bmrn_DeferredTaxAssetsLeaseLiabilities_96bb55b8-9350-48b7-8a06-a9b9a9a43fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_97b731e4-14d0-4e0e-8fdc-38bfa3ae7772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_97b731e4-14d0-4e0e-8fdc-38bfa3ae7772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_37111a2a-9760-46f6-8c65-021530da36f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_37111a2a-9760-46f6-8c65-021530da36f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fda59010-1af3-480c-8b45-eb19a7bc74b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fda59010-1af3-480c-8b45-eb19a7bc74b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1e563ad7-384c-4208-8bcc-e37820df3419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c1f1ddcd-bb04-4b5e-9f9c-5090954d28b9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1e563ad7-384c-4208-8bcc-e37820df3419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1a4f0b5-6e09-4199-be6b-f328f6048633" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_53de0b34-6539-4e78-8f0a-ed734435fa8f" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:to="loc_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference_53de0b34-6539-4e78-8f0a-ed734435fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a372d248-71a3-4565-acd3-7ca16aeb5f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a372d248-71a3-4565-acd3-7ca16aeb5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_d93eb301-07e3-445b-b201-7ba9612ddddf" xlink:href="bmrn-20221231.xsd#bmrn_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:to="loc_bmrn_DeferredTaxLiabilitiesRightOfUseAssets_d93eb301-07e3-445b-b201-7ba9612ddddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_84481c26-bec1-4ebf-bb81-bd2ac99e2be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_84481c26-bec1-4ebf-bb81-bd2ac99e2be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0ccebb18-9c3e-4c6d-8a32-c30ca170a592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_af1712f7-c9fe-40a1-a985-3a841217b461" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0ccebb18-9c3e-4c6d-8a32-c30ca170a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3dac81bd-730e-4135-8e40-968a9049f8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1a4f0b5-6e09-4199-be6b-f328f6048633" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3dac81bd-730e-4135-8e40-968a9049f8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ffbd92a-1e4f-4458-a456-f3909bedcd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ffbd92a-1e4f-4458-a456-f3909bedcd55" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:to="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c9c748d3-1497-4edd-a14b-6f83bc465961" xlink:to="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_fe390f26-8ad1-47b2-bdc8-52fa8c87cbb8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_837c4457-f19d-4f67-961d-fc86cd89ed8f" xlink:to="loc_country_NL_fe390f26-8ad1-47b2-bdc8-52fa8c87cbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2355a6d3-1d66-41ea-8594-caf25ab260f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a87f8f11-862d-4405-a448-a51be0281f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_DomesticCountryMember_a87f8f11-862d-4405-a448-a51be0281f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3fc8fa92-12c1-4e1d-9997-5211a3780bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3fc8fa92-12c1-4e1d-9997-5211a3780bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9c8caea2-f7c5-41c4-ab76-daaefbc278c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c404d-a475-49f4-b439-06cdf400938c" xlink:to="loc_us-gaap_ForeignCountryMember_9c8caea2-f7c5-41c4-ab76-daaefbc278c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_20e82abb-25ec-4aa7-94b2-4117a9055228" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_290ed945-2748-4f90-ba8e-12ce2e6874d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_290ed945-2748-4f90-ba8e-12ce2e6874d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8a614b3c-fe61-4237-93c8-66390e2ae765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8a614b3c-fe61-4237-93c8-66390e2ae765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_4168b330-a93b-489b-84ec-0daad71ac3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_193fa78c-eabe-43a7-9cd0-93ae93f24c77" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_4168b330-a93b-489b-84ec-0daad71ac3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bae440fc-cf98-4fd6-9a8a-62d0c5144887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bae440fc-cf98-4fd6-9a8a-62d0c5144887" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a706e259-15ce-4b16-8356-f0fc7f6669da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a706e259-15ce-4b16-8356-f0fc7f6669da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_89312a03-96d3-4147-93e4-fa50e9ca4dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_89312a03-96d3-4147-93e4-fa50e9ca4dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_602ab29f-1b45-496d-becb-a8d66fae998c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_602ab29f-1b45-496d-becb-a8d66fae998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_001576ae-44f8-48cc-9209-0a9f19adfe72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_001576ae-44f8-48cc-9209-0a9f19adfe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_a0c33ede-e463-4779-8e86-f0e8419486d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_a0c33ede-e463-4779-8e86-f0e8419486d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8a99e8c1-9b76-4a78-9e45-679b4c2e6b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8274ec39-d165-4eec-856d-1e78fc35e51f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8a99e8c1-9b76-4a78-9e45-679b4c2e6b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_85588e64-f50e-4ffc-9e5a-b74de9b8ad41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85588e64-f50e-4ffc-9e5a-b74de9b8ad41" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bb91265-7fa6-475b-8c8b-390bb3d23a79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_6979d0a8-78df-4663-8916-4464bf764ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:to="loc_us-gaap_StockCompensationPlanMember_6979d0a8-78df-4663-8916-4464bf764ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_c4682738-67ed-4a03-9113-85214ee0345b" xlink:href="bmrn-20221231.xsd#bmrn_CommonStockIssuableUnderTheConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1e1e8778-0119-48bb-96d3-14eb86bae3c9" xlink:to="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_c4682738-67ed-4a03-9113-85214ee0345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b51774a6-4d1d-4e52-bcef-9330eda9d862" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d7a03e1-cb4c-414a-9795-0a39fd472142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d7a03e1-cb4c-414a-9795-0a39fd472142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_e6e521d3-51c5-46ad-b499-cddd12d66fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_e6e521d3-51c5-46ad-b499-cddd12d66fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1bb29458-8497-46d2-b38d-688a96517e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6c831fbf-cef8-4d94-9304-d1bb2319b008" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1bb29458-8497-46d2-b38d-688a96517e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0658377e-a86d-4bd5-94f5-64da6fb78dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62405506-3e05-479f-a877-8ef1704999a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0658377e-a86d-4bd5-94f5-64da6fb78dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7083be14-f799-4c02-8de7-055e0b340eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_856a4485-35be-48ef-8d1b-64e16ea0788c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7083be14-f799-4c02-8de7-055e0b340eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_124256d4-ed15-4ff6-a114-c427a35e462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_124256d4-ed15-4ff6-a114-c427a35e462a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7275ab80-1afc-4d11-b939-4cde74edee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_EarningsPerShareBasic_7275ab80-1afc-4d11-b939-4cde74edee7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9c345f39-4634-4b78-86d0-b990b0fdaa46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a35db58c-e26b-47e6-bdf7-55239dae79bc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9c345f39-4634-4b78-86d0-b990b0fdaa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a83e9aba-5854-4e23-99e0-207b840fef0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a83e9aba-5854-4e23-99e0-207b840fef0c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45826837-1160-4a46-932b-542037ae1869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_58084918-52b5-4e17-8cf0-1b778026c6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:to="loc_us-gaap_StockCompensationPlanMember_58084918-52b5-4e17-8cf0-1b778026c6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_2d76bd9c-784b-4c3e-96fc-bfee11f4a23a" xlink:href="bmrn-20221231.xsd#bmrn_CommonStockIssuableUnderTheConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fdd6f6a-c1a2-4230-9b20-53b1940aacd7" xlink:to="loc_bmrn_CommonStockIssuableUnderTheConvertibleNotesMember_2d76bd9c-784b-4c3e-96fc-bfee11f4a23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_553338f0-b941-487d-947f-b6cb94470ffb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8eed26-ef6f-4940-8a75-0a48def7cb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32aa17e8-6172-49fa-96eb-11fc1ff66457" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8eed26-ef6f-4940-8a75-0a48def7cb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#LICENSEANDCOLLABORATIONAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77268241-a0d0-4aeb-a422-a0bee62c89e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77268241-a0d0-4aeb-a422-a0bee62c89e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c73b518b-6ee9-4846-841a-b1fa5223d922" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_2d8b97ca-0b91-4ba8-9eed-5665088ed952" xlink:href="bmrn-20221231.xsd#bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember_2d8b97ca-0b91-4ba8-9eed-5665088ed952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AAndRKuvanAgreementMember_9b435393-56b9-44f3-b596-49fd7d95488c" xlink:href="bmrn-20221231.xsd#bmrn_AAndRKuvanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_AAndRKuvanAgreementMember_9b435393-56b9-44f3-b596-49fd7d95488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_PegvaliaseAgreementMember_92f25207-32e2-4a86-83b0-f889663f646b" xlink:href="bmrn-20221231.xsd#bmrn_PegvaliaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7be8918-5159-4738-b40d-0bcc4035f236" xlink:to="loc_bmrn_PegvaliaseAgreementMember_92f25207-32e2-4a86-83b0-f889663f646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1dc81f73-bf8c-4016-b04d-8fa78eb2abac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_MerckSeronoMember_02d07600-dec1-4af4-a461-9c3c24b3db1c" xlink:href="bmrn-20221231.xsd#bmrn_MerckSeronoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d1df15-6197-487f-9a8b-359b5d96ae96" xlink:to="loc_bmrn_MerckSeronoMember_02d07600-dec1-4af4-a461-9c3c24b3db1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c094e547-3bbf-4033-8821-60ad88138ba7" xlink:to="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e74ba42-ffd9-45b2-af58-4078765b1dea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_722b4532-b552-4009-b51b-78510cb2e75a" xlink:to="loc_srt_MaximumMember_2e74ba42-ffd9-45b2-af58-4078765b1dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3bcb759-2a04-4507-beb4-7f77d02710ea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FirdapseMember_9b7e4fd2-c86d-4d39-8ec4-eb0bd516589b" xlink:href="bmrn-20221231.xsd#bmrn_FirdapseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cc4f3ac9-d3b8-4489-8885-59735019a540" xlink:to="loc_bmrn_FirdapseMember_9b7e4fd2-c86d-4d39-8ec4-eb0bd516589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6954982e-c3fd-49b5-99aa-7e553e6ea1f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4ca924e4-9a8e-4209-a9af-7e08dc409925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ae6ad0dc-3155-482e-b4b6-d7044751ab2a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4ca924e4-9a8e-4209-a9af-7e08dc409925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4b449edd-ca00-439a-a171-e3ac18e93ada" xlink:to="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ad83ba8c-2f4e-4c73-bf1f-88631fb6f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_33f7879f-bdc4-41b6-b702-9cdb3f47f8b9" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ad83ba8c-2f4e-4c73-bf1f-88631fb6f7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_05c9181f-3bbf-44df-9cfd-15cf657e9f5f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edc5a134-b94b-4cb8-b431-2d55f779c216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edc5a134-b94b-4cb8-b431-2d55f779c216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_64d3dca8-00f4-4adf-a0c2-88737fd42035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_64d3dca8-00f4-4adf-a0c2-88737fd42035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_cb9e6708-1c7e-4fc4-9774-e223b06f3322" xlink:href="bmrn-20221231.xsd#bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense_cb9e6708-1c7e-4fc4-9774-e223b06f3322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_856c3c5b-206d-4fb1-8f78-4e9f2dc548a0" xlink:href="bmrn-20221231.xsd#bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone_856c3c5b-206d-4fb1-8f78-4e9f2dc548a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b9b9b643-c892-4ff5-8f14-4244ff6f8262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b9b9b643-c892-4ff5-8f14-4244ff6f8262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_22eb7553-7820-4fae-a3ab-61ad5fc5ae0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_22eb7553-7820-4fae-a3ab-61ad5fc5ae0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateLowerLimit_c7e48706-2e36-476a-a28d-9b01671235cc" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateLowerLimit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_RoyaltyRateLowerLimit_c7e48706-2e36-476a-a28d-9b01671235cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyRateUpperLimit_88edc1e4-4b1b-4460-9218-db0f32cfbaaf" xlink:href="bmrn-20221231.xsd#bmrn_RoyaltyRateUpperLimit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25e9efc1-e984-4769-bd47-525fef66fd17" xlink:to="loc_bmrn_RoyaltyRateUpperLimit_88edc1e4-4b1b-4460-9218-db0f32cfbaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="bmrn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_23269dff-605b-4aaa-ae3a-a5afd7f08bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_23269dff-605b-4aaa-ae3a-a5afd7f08bb4" xlink:to="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c6bf1dd9-089c-4333-bee8-1a1ddb669b26" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramOneMember_1858d52f-51da-4349-abfa-88ca2f506b6a" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramOneMember_1858d52f-51da-4349-abfa-88ca2f506b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramTwoMember_3aebdb51-0068-4845-bde0-301b7ae79578" xlink:href="bmrn-20221231.xsd#bmrn_EarlyStageDevelopmentProgramTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3bdf5454-c70e-47e4-8f5a-d9fe162442f1" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramTwoMember_3aebdb51-0068-4845-bde0-301b7ae79578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6cd3e994-d37b-4dc9-a93d-b3cb62619015" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember_f893d00c-396a-4157-8976-8963c56301bf" xlink:href="bmrn-20221231.xsd#bmrn_ThirdPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff5c8e38-6d22-430f-8735-4814f7455e63" xlink:to="loc_bmrn_ThirdPartyMember_f893d00c-396a-4157-8976-8963c56301bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:href="bmrn-20221231.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_5b2ca4ae-8034-466e-a7f6-c661f4775d08" xlink:to="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_89b327e2-7773-4e7e-88a0-e84295ab71f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_89b327e2-7773-4e7e-88a0-e84295ab71f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_51c373f0-171e-4ede-8b25-f140eae1fe90" xlink:href="bmrn-20221231.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_51c373f0-171e-4ede-8b25-f140eae1fe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_41635e2e-67e9-48d9-ba06-577341e1340f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_PurchaseObligation_41635e2e-67e9-48d9-ba06-577341e1340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0592279f-9880-4f59-8f2d-1e696a37b604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_345ae58a-c731-40d4-a2cd-470d2ccbc069" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0592279f-9880-4f59-8f2d-1e696a37b604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>bmrn-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bmrn-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &L LP# 2(  A$! Q$!_\0
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M^%&NL_9UUS5(+,S8Z[/-==V/:E<#K**H1:]ID^BC6(M1M)-),/VD7ZSJ8/*
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M<=0*\/\ !.H>*?BI9^$?V*-;2\^U^%O%$X\3:F8SY<WAZS83VZY/:4O&BG
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M*,;BL2(@)/)VJHR3@"M>BBK;<G=D)**L@HHHI#"BBB@ HHHH **** "BBB@
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MUW3KJVT/3%M%$UJ8;-+UX89I8[<R$QRMLN?W4C F1)5<J^7\-?V=M7N?AO\
M#?PKXR\(QW6B:+XNUB]N=)U?^SY8DTZ5+_[+YD-MBW89GA'E1H%4GA JC'IG
MC3X^:GX;\:?V=8>%[74O#]K'H\^HZI/JK6\\4>HW;VT9AMQ XE*%-S!I(_E/
MRECQ5F3XY:BOQ+;11X8A/A9-=7PT^M_VG_I0OVM!<@BT\K:8,,J>9YV_>?\
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M;^&3?$@2:/86VE3MJ5M:GPYJ$<TCSW!E>19+??O@)GLUEE/V?&T[4W8'P?\
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M/O"DT=AK/A75_&ATVYN[G1O%?PYU:+0KJQ%RR3?9_L5W?;)8$E5R8YY98\+
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MMK^-B>96NO3\+_D>CT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2*2,^8-JF;)*\[X@_:(^)G@.\^(^MZKJZ:C:W%CXDN_"5C8:AIM]96JZ?*J
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M%%% !1110 4444 %%%% !1110 4444 %%%% "&EI#2T %%%% !1110 4444
M%%%% !1110 4444 %<O>?\E-TC_L#WO_ *.M:ZBN7O/^2FZ1_P!@>]_]'6M
M'44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=O 9C+:Z5>I+YD$D8SY]L/E+* PX/*DBAJW]=R4[JZ.VHHHI#"BBB@ HHHH
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MQYU;P587UN@YO-,BDG! _B*K(2/Q KZ$HKZ2%:52C[#&MUO[S]V?_@<%%O\
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MO5M[9E,:+*P96+2"5Y 6'R8& =)1LW'_ !?^2J_XK;\;#C%RY5WM^-_\G?\
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M7_X3)_\ CE3_ &/C_P#GRP]I'N?6M%?&[?\ !3[P4K$#X5_%E@#U'AV'!_\
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M-O3^U(GU#\_M#29KU[PYX)\.^#XO*T'0=,T2/&W9IMG';C'IA%%>8?V=\9O
MO_'K?Z7X^T].!'=J+:ZV_7(&?<LU;7@WXW'7O$EGX<USPMJ_AC6[K>(DNHMT
M$A1&=MLG&>%/;'O7FXG#XRO%U%6]M%:MJ5W;NXRM+\#>CG6']I&CB:<J,Y-)
M*4=&WI92C>#UV]ZYZ?1117SQ](%%%% !1110 4444 %%%% !1110 AI:0TM
M!1110 4444 %%%% !1110 5SOCSX=^&/BCX=ET'Q=H&G^(]'D=9&LM2MUFCW
MJ<JP##AAV(YYKHJ* ,MO"VBO'I$;:18-'H[*^FJ;9"+)A&8P81C]V1&S("N/
ME8CH:I67P[\*:;K>L:S:>&-'M=7UE/+U/4(;")+B^7&-LT@7=(,=F)KH:*8[
MVV,;PGX+\/> ='72?#&A:9X<TI7:1;'2;..U@#,<LP2-0N2>IQS5"\_Y*;I'
M_8'O?_1UK745R]Y_R4W2/^P/>_\ HZUHNWN(ZBLW5/#.CZYD:CI5C?@\'[5;
M))G_ +Z!K2HIQE*#O%V9$Z<*BY9JZ\SS[5/V?_AYK&[S_"MC'G_GUW6__HLK
M7*WW[)/@N96%C<ZQI.>0+6\!7\0ZM_.O:Z*]!9EC%'D=63CV;NON=T>+4R+*
MZDN=X:"EW44G]ZL_Q/GBZ_92OK53_97C61,=$O\ 3HYR?JV?Z5D7'[/_ ([T
MW+Q1^%]<'_35[F!SU[(54?G7T]17F5:.!Q/^]8*C4_Q4:=_O44_Q.F&"JX?_
M '7%UZ7^&M4M]SDX_@?(NI?"O7(?^0U\*9-03D>=I>K1/Z<A'60_G7%:C\&_
MA(EP9=?^%&L:5,3S-?>&K2X3'.?G**3SDY ]:^[Z*RAEV21^' J'_7N=2G^4
MFOP-_:Y[#^'F4Y?]?(4Y_P#ML7^)\#0_!']GC6 JPW/A[3I0,>5<^%5@/XNH
M _4]ZO6?[$_P=UR1WTZ?P7J4DN1MCO9H&Y&.%BE!4_0"OMK5/#FDZV"-1TNS
MOP>#]JMTD_\ 0@:Y#5/@'\/=8R9_"EC'G_GU#6__ *+*UM_9N5_\NZ^*I>E>
MI)?<Y1(>/X@C_$CAJWK24']Z4SY;N/\ @F_X.\F,P>#-)DY5Q+:^(M6#,/0%
M[C'OG'^%9MQ_P3L\-Q3%U\&:PJ8P4L/%TR+QW_>.Q_7\J^E6_9<\*6Q+:1J.
MO: _4'3]0*X/_ @:3_A3/C72SNT;XK:PH4Y5-4MUN^_<LW]*/[)3_@YS6C_C
ML_SC4,O[7Q<?]XR:E+_!)?JZ1\N:7_P3)TV\NEE+:Y8V_7R=2\1R2''UA4'^
M5=UIO[)_P;^$^?[<\0Z?%,GWH))6NIQCT\UY'_):]H;X"ZQXB8MXO^(>N:PC
M<M:V)6S@/L4&0?R%=+X;^ _@/POL:S\-V<LJ\^=> W#9]?WA.#],5I4RO"U(
M\N8YA7Q"_E4Y1A]RY(_^2,VCG6<STP."I8==Y6E+[ES_ /IQ'S'K/A/P3XH5
M['P;<?$;64'R@:'%:VT"_P#;1K8NGY5Q:?\ !/77/&VH"YO[OQ!IUDQW>3X@
M\537;XSV$(7'TP/PK]"X84MXUCB18XU&%5!@ >@%/KOP%; 9-_R*<'"D_P":
MR<OFTHIOU3.3$8?-LR_Y&685)+^6'N1_]NE]TD?*?@O_ ()[^#_#MF$O-6O)
MI<<26B*'4_[\WFL:L:Y_P3S\#>(3_I7C'QW&O]RTU:&W7\1' N?QKZDHKMGG
M^9S=W7:]++\C&CD&64)>T5%2E_-*\Y??)M_B?'#?\$L/A.S$GQ)X])/4G75_
M^-4G_#J_X3?]#'X\_P#!XO\ \:K[(HK+^VLQ_P"?\OO/;]E#L?&__#J_X3?]
M#'X\_P#!XO\ \:H_X=7_  F_Z&/QY_X/%_\ C5?9%%']M9C_ ,_Y?>/V<.Q\
M;_\ #J_X3?\ 0Q^//_!XO_QJC_AU?\)O^AC\>?\ @\7_ .-5]D44?VUF/_/^
M7WA[.'8^/;/_ ();?"*VFWR:UXWNEQCRYM=(7Z_+&#^M.;_@E7\!KB\^TW=A
MX@OI"07^T:S*V_ Q@D8/3WK[ HI?VUF._MY?>'LX=CY+_P"'6G[.W_0IW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 AI:0TM !1110 4444 %%%% !1110 4444 %%%%
M !7+WG_)3=(_[ ][_P"CK6NHKE[S_DIND?\ 8'O?_1UK0!U%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "&EI#2T %%%% !1110 4444 %%%% !1110 4444 %<O>?\E-TC_L#WO_
M *.M:ZBN7O/^2FZ1_P!@>]_]'6M '44444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:6D-+0 4444
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M )Z7W_@KNO\ XW1_PLC0O^>E]_X*[K_XW7444 <O_P +(T+_ )Z7W_@KNO\
MXW1_PLC0O^>E]_X*[K_XW7444 <7:_%+3)=2O898;Z*VBV>1/_9UR?-R,MQY
M?&#Q5S_A9&A?\]+[_P %=U_\;KJ** .7_P"%D:%_STOO_!7=?_&Z/^%D:%_S
MTOO_  5W7_QNNHHH Y?_ (61H7_/2^_\%=U_\;H_X61H7_/2^_\ !7=?_&ZZ
MBB@#E_\ A9&A?\]+[_P5W7_QNC_A9&A?\]+[_P %=U_\;KJ** .7_P"%D:%_
MSTOO_!7=?_&Z/^%D:%_STOO_  5W7_QNNHHH Y?_ (61H7_/2^_\%=U_\;H_
MX61H7_/2^_\ !7=?_&ZZBB@#D-0^)VD6]A<RVRWUQ<1Q,T</]FW0WL 2%SY?
M&3Q3[7XF:-+;1/+]OAE9 7C_ +,NCM)'(SY?:NLHH Y?_A9&A?\ /2^_\%=U
M_P#&Z/\ A9&A?\]+[_P5W7_QNNHHH Y?_A9&A?\ /2^_\%=U_P#&Z/\ A9&A
M?\]+[_P5W7_QNNHHH Y?_A9&A?\ /2^_\%=U_P#&Z/\ A9&A?\]+[_P5W7_Q
MNNHHH Y?_A9&A?\ /2^_\%=U_P#&Z/\ A9&A?\]+[_P5W7_QNNHHH Y?_A9&
MA?\ /2^_\%=U_P#&Z/\ A9&A?\]+[_P5W7_QNNHHH Y?_A9&A?\ /2^_\%=U
M_P#&ZIV?Q2TR:^OXIX;Z&"&15@F_LZY/G*44DX\OC#$K^%=I10!R_P#PLC0O
M^>E]_P""NZ_^-T?\+(T+_GI??^"NZ_\ C==110!R_P#PLC0O^>E]_P""NZ_^
M-T?\+(T+_GI??^"NZ_\ C==110!R_P#PLC0O^>E]_P""NZ_^-T?\+(T+_GI?
M?^"NZ_\ C==110!R_P#PLC0O^>E]_P""NZ_^-T?\+(T+_GI??^"NZ_\ C==1
M10!R_P#PLC0O^>E]_P""NZ_^-T?\+(T+_GI??^"NZ_\ C==110!R_P#PLC0O
M^>E]_P""NZ_^-TV/Q_::AJ^E6.FV]W<FZG9)Y)+.>%8(Q#(^\LZ ?>1%QG^.
MNJHH **** "BBB@ HHHH **** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@
M HHHH **** /"?VMOA_J7C3PGX9NM-EURZFTOQ+H]S_9&E,QAN%&I6Q>6=$7
M=(L48=L$[%Y<@E5*^4>)8=/N_P!KZ36+'P!XGT'_ (1N:74KOQ6/#.JWEWXF
MN?L;QBQMKL1/%#8HN"4,BK)*%")R7;[-HI*Z5D^K?WJ/Y<M_^&*YKJS]/EK^
M=[??;74^'O%_PONM*O/A4L'@C7;SXFV=UI.JWNMV^F3S03>9>O<7]O;WX=HM
M-Q)+,\WF(OG1$1 MD%.\UCP;XJ\#_%[XVZUHB>(M=OM<\)Z=#I=]?1O<0K?2
M7-]&D,.U0BQ0^9"S(H&U27?)9F/U+15MIIQMHW)V_P 2LU^'WZ@I-:];1U_P
MNZ_KL?#]O\/].A_:8TK1O"O@GQ!X.'A2(1IXUO/#^J7$VO7(L&MHK2*^\IH8
M-/C4*SAI$1Y -B#+.T_[-GPCU>?3?$&EII7BGX?V5QX,TFPU^XAMY--N;_Q!
M&]PU]-'(\8,SNK(KW<0^?<-LF0"/MFBH=Y1:D]7_ )-?=KMM=1[:D7RZ+96M
M\FG]]UOOK+NK?#O@']G.Q\=0_LVZ3XG^&L%O_8/AJ'6-<UK4-%6.\^T6B11V
M>G27#)YB8DE>5HBPW"'!!4L#]Q445K*?,V^[;^;?^5E\C.VM_)+Y+^F_F%%%
M%9E!1110!3UG3Y-6TF\LHKZYTR2XA:);RS*": L"-Z%U9=PZC*D9[5\-ZYX5
M/@+]FJW\/ZK\+_$/Q%U8^-=;32[+6=+U+5+2 27MR$U+4H8DD>XB$4GF*6CD
M9V92F#\Z_>%%2U=-=_\ -/\ 2WS+4K)+L[_@U^I\?V/P]L%\!1Q>)M \6>/O
M"7AOPOI.@6PN-$O$O+YY)EFNIY+%FBGF@7R[+?;@,VV*2/:YRM85O\)/%&H?
MLO\ @6UEM?$\%UH7C*UN+71;6"2TBN[0ZY'(EQ)8[/-@@C@+-';2'$" ;@3&
MK+]NT5LIM2YO-2^?-S?G?[WO[ML_LV?]>[R_EOZ>M_C7]HRQ\^#Q7K^K?"S5
M/B%JFJZ_#H^@Z?<:+?WVFV=O;6QB^W7]K;QN98$FGO)$S&Y?=&8P"!(O&ZM\
M)=;L-2\(VMGI?BCQ9JMKI'A.U\'^*+S1+N&2P:WOW;5&E,D8;3RT&W<LQ0NF
MR/#E:^_**BG^[:?9Q?\ X"K?CJWZM;6M<G>ZZ6:_&_Z6M^K9\._M ?"+Q)'X
MW^+-Q9Z?XG\66.MV'AJ:6YN[>6_MPD>JW#W$"VT2K]HMXH=N^SA&^16.3ND+
MGW;]CW0M1\-_ ^RL-0TJYT?R]2U%[6VN+-[ &W>[E>)XK-P'LX2K I;OEHUV
MJ2>M>V441?+'E_KI^5M/5WOI8G+G=_3\%;^OE:VMRBBBD2%%%% !7S[XO\!W
MNG_M7:#XPD?Q+JVCR>$]9@NO*\V2UL,/9%(8%B4;))-LK#DRN5X)"*%^@J*5
MM;KS_%-?J4G;3T_!W/@?X-^#V\2:;XQCT/P#KWPYL/%ESIF@?\(E<^&]2LS#
MI<=PYN;^_NIXECGO9H/.#2*\A7=$K.[-FO0? /@7S?VG/$%WX7\+^)_!6FWV
MCZI8ZUJ4NF26<RWK74;1W;7DYFBU$N QM_+)%NFY64;]B_6]%6I6:?:_XJUO
M3=^OHB7=W3ZV_!Z?HO1>;O\ (WPQ^'^K:+\-_#W@_4-)\1'2;;QOKNLZC-=Q
M74EW+96MY=3VSF7'F-++,;21"#ND 8KGK7DG@_P+)XB\&^-=6T;X=>(?!.@W
M>HZ%#>?#U_#&I03W6C6NH!KFXO'FA"ZA>3Q&0R)$9F,8",TC,37Z*45,6XM/
MT^]66O>Z237:_<J3YF_._P!S;=EVLW=/?1=-#XFN/A%X@U3]GW0#:V/BC3;+
M3OB!'J&B^%((9+=8]+;78W@,]KL\Q4AM\LL3X6->60%%VZOP'^'>L^'OVGKV
M]T_3M8M=*BCUK^V]1U;PY)IMS>22W<;6JW%]YKQ:H<"5H9(@/)B 5@K,5K[$
MHJHOE:\K^NL5'7OM?S?EH3/]Y=OO?\6_NUT"BBBI **** "N=^(7AE_&'@W5
M='34]3TC[5"5:YT>?R;K;U*))@E-P&TLN& )VE3@CHJ*B<>>+CW*C+E:DC\]
M_'WA'S/V<_@?X*U3X:^(;WQ1/X9CT^;Q!=>&M4U2W\(Q>7'YUQ]EMXI"-0R@
M6([%=3DLZ+D/Z;\4/!-AXD\/>+-6\5>$=?\ $<5]J,.DZ+-=>';O5UM8K2R=
M(;R]TV-DEN4-Q+=LIV,-TD3D*%#CZ[HK2H_:<_-]IOY7=]/-:V?FV$9.+BX]
M/\K?CI\E;O?Y*T_X9^*I8?V6M:U2#Q5_:6B2V]IJ>D7=V;N&Q5=+NT>YN3&@
M!E9_*4R2$[2VU=I9MWGOQX\+KX@T*QAU3X<:]J7BKQMJ6IWK^))O#>IZI:^%
M+*218XK@6EO%)MU 6UO;)%\BNK!BSHN5;[WHJJDG4FYOJV_OM=?>D3'W4DNB
M27RYK/\ \F_(^);CP)J]G^T$NJ2>'?$U[K4?B9;[_A*ETZZWR>&%T/RFMOM:
MH,,;G/\ HH;S#*2X09R/*_"OP_L=>\16OB6Z^%/B7P]\-_[4CAU;X;GP;JCR
M2V<-I?);7]^)+<C4+N2XEB9S$96C B9W8JS5^EU%0]5;^MK?I?\ Q.35KZ7S
M:67:WYO\W]RBM4G?S;]FW1_$'A_X!^ =-\5+<1^(;71[>*\CNWWS(X0?*YR<
ML!@'GJ*])HHJYRYY.7<S6BL%%%%0,**** /GWQ?X#O=/_:NT'QA(_B75M'D\
M*:S!=>5YLEK88>R*0P+$HV22;96')E<KP2$4+X3\&_![>)-/\8QZ'X!U[X<V
M'BRYTS0/^$2N?#>I69ATN.X<W-_?W4\2QSWDT'G!I%>0KNB5G=FS7WQ13A[O
M+Y?_ "3?ZV^_J[CDW)-=_P#)6_)/Y);:'R1X!\"^9^TYK]WX7\+^)O!6FWVD
M:I8ZUJ4NF26<RWK74;1W;7LYFBU$N Q@\LD6Z;E91OV*WX8_#_5M%^&_A[P=
MJ&D^(CI-MXWUW6=1GNXKF2[ELK6[N9[9S+CS&EEF-JZ$'=( Q7/6OKFBEKRJ
M*Z*W_DW,ON>R[:#;YF[]7=_^ N/XI[]]3\Z_!_@63Q%X-\:ZMHWPZ\0^"="N
M]1T.&\^'K^&-2@GNM&M=0#7-Q>//"%U"\GB,AD2(S,8P$9I&8FH_''@X3?##
M0?"MQ\+_ !'(^K:KK:Z'K%WX7U34+7P9HDMZ[PS)8P1.T5YY800(41XOXFC4
M%6_1BBGY?UK;_+Y7E_-H^9_/_*]M-NOSM&^VOS[\(?AWJ'@_]I3QUJDEWXEU
MK3-4\,:08]8\0;V#2K/>;H(R454V(8R8P 1OW-EG+'Z"HHIRES?UYMF=M6_3
M\$E^@4445(PHHHH \:_; \"7_P 0_P!G7QSI>FW&MB]&DW4L-AH3E9M0D$+[
M+=@BEW1F*Y1""^ IRI*GQ/XW:%9>)/C5\/\ 1E\"^(K+4[>+2[O4/B)_PCNJ
M:B-/C@E5X['3GABDCMI96)$TN8T6,G>7; 3[1HHC[LDUT:?W7_S_  L]+CD^
M:/+Y-??;_+\;[I'PW\=/A_)XG^&=[J%[X&\1WWC[Q'>:IJNCWUOH=S?#3Y#+
M%':P^6C_ .@7CVT-LJ7DL96%ED8L,E6]7U[PIK.@_M+>%O'TUKXEU6!?!VK"
M[LP7N[73Y%-BR6T*QH%\R0K*<\O(5."0JA?HVBA7C%1B]KI>5XN/Y/\ !>=V
MVF[M?U=/\UIZ^EO@GQ-X C7QQ\,?#=]X&U^S\4*EAK/B#XC1^'M4U)+*X-T;
MJ2RTUX8I([:26>67SI<QHL1PYD( 5VC>";W0/&'B/4-=\!>+K^>.R\5?\)I/
MHVG7<5QXABGOD;2X8+B+8;IO(RJ"-V,*$JS(,BOO2BA[.VGQ?^3:?@K:=;7>
MM[N,FK7U^'\+_G?Y=-$D?EY<^#]/U3PC]@;X2:_I>M^++V:98H/ &OMH7P\M
M7BB5GM;46@$VH$0J1/#&H\UG.]$&'_3;18A!H]C&LUQ<*D$:B:[#"9\*/F<,
M =QZG(!SFKM%5S:<O]:?UZ][LSU;3;_I_P!>BMI8****D84444 %%%% !111
M0 AI:0TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)Y7^33?Y+\49J2<>9=VON:3_ #/HNBO!?$/BCQ9\1?VA/$7P[T7Q=>^ M/\
M#F@6>J_:M,LK2XN+^>ZEF4!_M44JB",0<JBJ[,Y_>*!@Z_C#XL^*O!NO>&/
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M%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !1110 AI:0TM !1110 4444 %%%% !1110
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M+7J&D_L]^!-'\(^*_#<>E75UIOBM777)-1U6\O;N_#1"$B2ZFE><XC 4?/\
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MMR:EX>CE.M:$OAF^6*XFA23359F6W54<! "[?,@#<XS@"F77[/G@"\DUAYM
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1 4444 %%%% "&EI#2T ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322527040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioMarin Pharmaceutical Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 Lindaro Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Rafael<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-6700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,528,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Specified portions of the registrant's definitive proxy statement for the registrant's 2023 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2022, are incorporated by reference under Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322452192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321936544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 724,531<span></span>
</td>
<td colspan="2" class="nump">$ 587,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">567,006<span></span>
</td>
<td colspan="2" class="nump">426,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">461,316<span></span>
</td>
<td colspan="2" class="nump">373,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">894,083<span></span>
</td>
<td colspan="2" class="nump">776,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">104,521<span></span>
</td>
<td colspan="2" class="nump">110,442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,751,457<span></span>
</td>
<td colspan="2" class="nump">2,274,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">333,835<span></span>
</td>
<td colspan="2" class="nump">507,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,073,366<span></span>
</td>
<td colspan="2" class="nump">1,035,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">338,569<span></span>
</td>
<td colspan="2" class="nump">388,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">196,199<span></span>
</td>
<td colspan="2" class="nump">196,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,505,412<span></span>
</td>
<td colspan="2" class="nump">1,450,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">176,236<span></span>
</td>
<td colspan="2" class="nump">152,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,375,074<span></span>
</td>
<td colspan="2" class="nump">6,004,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">572,959<span></span>
</td>
<td colspan="2" class="nump">498,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">15,925<span></span>
</td>
<td colspan="2" class="nump">48,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">588,884<span></span>
</td>
<td colspan="2" class="nump">546,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long-term convertible debt, net</a></td>
<td class="nump">1,083,019<span></span>
</td>
<td colspan="2" class="nump">1,079,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">15,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">100,015<span></span>
</td>
<td colspan="2" class="nump">98,362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,771,918<span></span>
</td>
<td colspan="2" class="nump">1,739,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively</a></td>
<td class="nump">186<span></span>
</td>
<td colspan="2" class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">5,404,895<span></span>
</td>
<td colspan="2" class="nump">5,191,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIssuedEmployeeStockTrust', window );">Company common stock held by the Nonqualified Deferred Compensation Plan</a></td>
<td class="num">(8,859)<span></span>
</td>
<td colspan="2" class="num">(9,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(3,867)<span></span>
</td>
<td colspan="2" class="nump">14,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(789,199)<span></span>
</td>
<td colspan="2" class="num">(930,760)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,603,156<span></span>
</td>
<td colspan="2" class="nump">4,265,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 6,375,074<span></span>
</td>
<td colspan="2" class="nump">$ 6,004,772<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockIssuedEmployeeStockTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123585891&amp;loc=d3e19833-108362<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockIssuedEmployeeStockTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321673712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">186,250,719<span></span>
</td>
<td class="nump">183,912,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">186,250,719<span></span>
</td>
<td class="nump">183,912,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321954752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,096,039<span></span>
</td>
<td class="nump">$ 1,846,275<span></span>
</td>
<td class="nump">$ 1,860,455<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">483,669<span></span>
</td>
<td class="nump">470,515<span></span>
</td>
<td class="nump">524,272<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">649,606<span></span>
</td>
<td class="nump">628,793<span></span>
</td>
<td class="nump">628,116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">854,009<span></span>
</td>
<td class="nump">759,375<span></span>
</td>
<td class="nump">737,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_IntangibleAssetAmortizationAndContingentConsideration', window );">Intangible asset amortization and contingent consideration</a></td>
<td class="nump">67,193<span></span>
</td>
<td class="nump">69,933<span></span>
</td>
<td class="nump">66,658<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="num">(108,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,820)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,946,477<span></span>
</td>
<td class="nump">1,928,616<span></span>
</td>
<td class="nump">1,903,895<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME (LOSS) FROM OPERATIONS</a></td>
<td class="nump">149,562<span></span>
</td>
<td class="num">(82,341)<span></span>
</td>
<td class="num">(43,440)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">18,034<span></span>
</td>
<td class="nump">10,482<span></span>
</td>
<td class="nump">16,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15,970)<span></span>
</td>
<td class="num">(15,337)<span></span>
</td>
<td class="num">(29,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="num">(2,050)<span></span>
</td>
<td class="nump">11,846<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">149,576<span></span>
</td>
<td class="num">(75,350)<span></span>
</td>
<td class="num">(48,997)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">8,015<span></span>
</td>
<td class="num">(11,270)<span></span>
</td>
<td class="num">(903,026)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="nump">$ 854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)</a></td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">185,266<span></span>
</td>
<td class="nump">182,852<span></span>
</td>
<td class="nump">180,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">188,963<span></span>
</td>
<td class="nump">182,852<span></span>
</td>
<td class="nump">191,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,042,025<span></span>
</td>
<td class="nump">$ 1,783,498<span></span>
</td>
<td class="nump">$ 1,805,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember', window );">Royalty and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 54,014<span></span>
</td>
<td class="nump">$ 62,777<span></span>
</td>
<td class="nump">$ 54,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_IntangibleAssetAmortizationAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_IntangibleAssetAmortizationAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322414432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[3]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="nump">$ 854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during the period, net &#160;&#160; of tax impact of $3,247, $1,596 and $(227), respectively</a></td>
<td class="num">(10,720)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassifications to net income (loss), net of tax impact of &#160;&#160;$0, $0 and $(127), respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change in unrealized holding gain (loss), net of tax</a></td>
<td class="num">(10,720)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented</a></td>
<td class="nump">29,045<span></span>
</td>
<td class="nump">34,379<span></span>
</td>
<td class="num">(23,462)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented</a></td>
<td class="nump">36,624<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
<td class="nump">13,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net change in unrealized holding gain (loss), net of tax</a></td>
<td class="num">(7,579)<span></span>
</td>
<td class="nump">35,833<span></span>
</td>
<td class="num">(36,642)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX</a></td>
<td class="num">(18,299)<span></span>
</td>
<td class="nump">30,571<span></span>
</td>
<td class="num">(36,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="nump">$ 123,262<span></span>
</td>
<td class="num">$ (33,509)<span></span>
</td>
<td class="nump">$ 817,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherComprehensiveIncomeLossOtherNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income loss other net of tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherComprehensiveIncomeLossOtherNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321673472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gain (loss) arising during the period, tax</a></td>
<td class="nump">$ 3,247,000<span></span>
</td>
<td class="nump">$ 1,596,000<span></span>
</td>
<td class="num">$ (227,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification, tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(127,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gain (loss) arising during the period, tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassifications to net income (loss), tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318325728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Previously Reported</div></th>
<th class="th" colspan="2"><div>Adjustment related to correction of immaterial error</div></th>
<th class="th"><div>Common stock:</div></th>
<th class="th"><div>Additional paid-in capital:</div></th>
<th class="th"><div>Treasury stock:</div></th>
<th class="th"><div>Company common stock held by the NQDC:</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss):</div></th>
<th class="th">
<div>Accumulated other comprehensive income (loss): </div>
<div>Previously Reported</div>
</th>
<th class="th" colspan="2"><div>Accumulated deficit:</div></th>
<th class="th">
<div>Accumulated deficit: </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Accumulated deficit: </div>
<div>Adjustment related to correction of immaterial error</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">179,838,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(518,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,122,381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,122,381<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 4,832,707<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9,961)<span></span>
</td>
<td class="nump">$ 20,164<span></span>
</td>
<td class="nump">$ 20,164<span></span>
</td>
<td class="num">$ (1,720,709)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,720,709)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency', window );">Issuances under equity incentive plans, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="nump">27,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan', window );">Change in Common stock held by the NQDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(36,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 4,100,931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,106,002<span></span>
</td>
<td class="num">(5,071)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">4,993,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,839)<span></span>
</td>
<td class="num">(16,139)<span></span>
</td>
<td class="num">(16,139)<span></span>
</td>
<td class="num">(866,680)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(861,609)<span></span>
</td>
<td class="num">(5,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">183,912,514<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">183,913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency', window );">Issuances under equity incentive plans, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan', window );">Change in Common stock held by the NQDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 30,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(64,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 4,265,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 4,270,740<span></span>
</td>
<td class="num">$ (5,071)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">5,191,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,689)<span></span>
</td>
<td class="nump">14,432<span></span>
</td>
<td class="nump">$ 14,432<span></span>
</td>
<td class="num">(930,760)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (925,689)<span></span>
</td>
<td class="num">$ (5,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">186,250,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">186,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency', window );">Issuances under equity incentive plans, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">14,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan', window );">Change in Common stock held by the NQDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (18,299)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">141,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 4,603,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 5,404,895<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,859)<span></span>
</td>
<td class="num">$ (3,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (789,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The years ended December 31, 2021 and 2020 have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.<br/></span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues net excess tax benefit tax deficiency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues net excess tax benefit tax deficiency, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321482624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">101,969<span></span>
</td>
<td class="nump">108,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">105,172<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense</a></td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">4,146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investments</a></td>
<td class="nump">3,043<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">196,308<span></span>
</td>
<td class="nump">197,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">189,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="num">(108,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(52,820)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserves, net of stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(52,087)<span></span>
</td>
<td class="num">(15,608)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(889,993)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss (gain)</a></td>
<td class="num">(14,287)<span></span>
</td>
<td class="num">(1,810)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,011<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">8,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(2,043)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(997)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(82,033)<span></span>
</td>
<td class="nump">65,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(59,035)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(68,264)<span></span>
</td>
<td class="num">(35,060)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(61,151)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">7,822<span></span>
</td>
<td class="nump">29,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(19,859)<span></span>
</td>
<td class="num">(6,593)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(29,007)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other short-term liabilities</a></td>
<td class="nump">59,018<span></span>
</td>
<td class="nump">15,689<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(87,025)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">6,933<span></span>
</td>
<td class="num">(3,336)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,029)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">175,902<span></span>
</td>
<td class="nump">304,536<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">85,365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(120,959)<span></span>
</td>
<td class="num">(95,578)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(114,312)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="nump">619,995<span></span>
</td>
<td class="nump">691,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">555,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(611,809)<span></span>
</td>
<td class="num">(937,143)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(529,663)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ProceedsFromSaleOfNonfinancialAssets', window );">Proceeds from sale of nonfinancial assets</a></td>
<td class="nump">103,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(10,581)<span></span>
</td>
<td class="num">(23,647)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(23,207)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable', window );">Investment in convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,709)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(723)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,029)<span></span>
</td>
<td class="num">(366,313)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(53,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercises of awards under equity incentive plans</a></td>
<td class="nump">69,333<span></span>
</td>
<td class="nump">49,194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">71,913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(54,283)<span></span>
</td>
<td class="num">(45,805)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(44,638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(50,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible senior subordinated note offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">585,752<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(374,991)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration</a></td>
<td class="num">(31,095)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal repayments of financing leases</a></td>
<td class="num">(2,605)<span></span>
</td>
<td class="num">(3,039)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,918)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(18,650)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181,118<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">32<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">137,255<span></span>
</td>
<td class="num">(61,882)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">211,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">587,276<span></span>
</td>
<td class="nump">649,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">437,446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">724,531<span></span>
</td>
<td class="nump">587,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">649,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">10,281<span></span>
</td>
<td class="nump">10,395<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">54,372<span></span>
</td>
<td class="nump">18,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets', window );">Decrease in accounts payable and accrued liabilities related to fixed assets</a></td>
<td class="num">(1,482)<span></span>
</td>
<td class="num">(4,749)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,184)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets', window );">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">$ 9,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (292)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ProceedsFromSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Nonfinancial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ProceedsFromSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327637104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Founded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. ROCTAVIAN (formerly known as valoctocogene roxaparvovec) was granted conditional marketing approval in the European Union (EU) on August 24, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Correction of Immaterial Error </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company became aware of an unrecorded amount due to a third party following the January 2020 sale of the worldwide rights of FIRDAPSE, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. The Company evaluated the materiality of the previously described error from a qualitative and quantitative perspective. Based on such evaluation, the Company concluded that the error was not material to any individual current or prior period, nor did it have an effect on the Company&#8217;s trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 108, C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">onsidering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Although the effect of the error was not material to the current or previously issued financial statements, the Company has corrected the accompanying Consolidated Balance Sheets, Statement of Operations, Statement of Comprehensive Income and Statements of Stockholders Equity. As a result, the correction decreased 2020 Net Income and increased the 2020 Accumulated Deficit balance by $5.1&#160;million. Consequently, this had the following impact on certain December 31, 2021 balances: an increase to Accounts Payable and Accrued Liabilities of $6.7&#160;million, a decrease to Total Stockholders&#8217; Equity of $5.1&#160;million, an increase to Deferred Tax Assets of $1.1&#160;million, an increase to Other Assets of $0.4&#160;million and a decrease to Other Long-term Liabilities of $0.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company&#8217;s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument&#8217;s underlying contractual maturity date and its availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company&#8217;s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment&#8217;s amortized cost and fair value at such date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Inventory </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;D).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;D and Selling, General and Administrative (SG&amp;A), as appropriate, in the Consolidated </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Statements of Operations. Property and equipment purchased for specific R&amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;D in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing&#160;and&#160;laboratory&#160;equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&amp;D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company&#8217;s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company&#8217;s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment by comparing the fair value of the Company&#8217;s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-lived Asset Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify a manufacturing facility for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capitalized Software</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt">identification of the promised goods or services in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt">measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt">allocation of the transaction price to the performance obligations based on estimated selling prices; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Company&#8217;s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company&#8217;s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company&#8217;s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company&#8217;s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company&#8217;s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Reserves</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. Such variable consideration includes rebates, chargebacks, sales returns and other incentives. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Government and Commercial Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company&#8217;s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers&#8217; limited return rights and the Company&#8217;s historical experience with returns. Because of the pricing of the Company&#8217;s commercial products, the limited number of patients and the customers&#8217; limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Other incentives include fees paid to the Company&#8217;s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient&#8217;s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:&#160;For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D costs are generally expensed as incurred. These expenses include contract R&amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs and R&amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Advertising Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The costs of advertising are presented in SG&amp;A in the Consolidated Statements of Operations and are expensed as incurred. Advertising expenses were $25.2&#160;million, $30.2&#160;million and $29.3&#160;million in 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Earnings (Loss) Per Common Share</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;D or SG&amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company&#8217;s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of each stock option award and purchase rights under the Company&#8217;s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13">twenty-four</span>-month period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company&#8217;s stock price and may use assumptions regarding a number of complex and subjective variables.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company&#8217;s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction losses resulting from remeasurement recognized in SG&amp;A in the Consolidated Statements of Operations totaled $11.4&#160;million, $11.7&#160;million and $9.9&#160;million in 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;A in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Income approach, which is based on the present value of a future stream of net cash flows</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Notes</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"> 2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_193" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further information on the nature of these financial instruments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during 2022 that the Company believes are of significance or potential significance to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800418608368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,926)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,006&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,641,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,926)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,625,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,835&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9">one</span></span> and five years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#8217;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#8217;s strategic investments was $23.9 million and $16.5 million, respectively. These investments were recorded in Other Assets on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800418610592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(352,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the carrying value and estimated remaining life of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Remaining Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intellectual property</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology transfer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchased royalty rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain technology transfer intangible assets have not yet been placed into service. The average remaining life presented is only for those placed into service. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the estimated future amortization expense associated with the Company&#8217;s finite-lived intangible assets that have been placed into service, was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022 the Company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the first quarter of 2022 on the Company's Consolidated Statement of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800418610592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">774,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(802,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,073,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense, net of amounts capitalized into inventory, was $38.6 million, $46.1 million and $43.0 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322743600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,356&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,083&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,669&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327676128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">SUPPLEMENTAL BALANCE SHEET INFORMATION</a></td>
<td class="text">SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,573</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The balance as of December 31, 2021 has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-bottom:12pt;margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Plan Costs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 6, 2022, the Company announced a plan to simplify its organizational design, which included a planned reduction in headcount of approximately 120 employees (representing approximately 4% of the Company&#8217;s global workforce), </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">most of whom were from the Company's U.S. operations. The reduction in headcount was substantially completed as of December 31, 2022. In 2022, the Company recorded costs of $23.0 million related to one-time termination severance and employee termination benefits within SG&amp;A expense, of which</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $11.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has been paid as of December 31, 2022. The Company does not expect to incur any significant incremental costs in future periods. The unpaid balance at December 31, 2022 is recorde</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d to Accounts Payable and Accrued Liabilities on the Consolidated Balance Sheet and is expected to be paid within the next 12 months. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Revenue Rebates and Reserves for Cash Discounts</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December&#160;31, 2022, 2021 and 2020, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision for Current Period Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800405218720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December&#160;31, 2022 and 2021. Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December&#160;31, 2022 and 2021. Refer to Notes </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:54.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The restricted investments as of December&#160;31, 2022 and 2021 secure the Company&#8217;s irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payments to Ares Trading S.A. (Merck Serono)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized foreign exchange gain on settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327610976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</a></td>
<td class="text">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's forward contracts designated as hedging instruments have maturities up to 1 year, 9 months. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to 3 months. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:67.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Refer to Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional information related to the Company&#8217;s fair value measurements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="15" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company expects to reclassify unrealized losses of $7.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_175" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318308624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s ROU assets and lease liabilities for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,418&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company&#8217;s leases for the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company&#8217;s lease liabilities:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, no </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">leases were expected to commence that would create significant rights and obligations for the Company.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Finance Leases Other Information Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800405431184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#8217;s convertible debt:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,083,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The fair value of the Company&#8217;s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional discussion of fair value measurements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s fixed-rate convertible debt consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2027 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company&#8217;s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company&#8217;s common stock. A holder may convert fewer than all of such holder&#8217;s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8&#160;million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company&#8217;s existing and future senior debt, (ii) equal in right of payment with the Company&#8217;s existing and future senior subordinated debt, (iii) senior in right of payment to the Company&#8217;s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">preferred equity, if any, of the Company&#8217;s subsidiaries. Upon the occurrence of a &#8220;fundamental change,&#8221; as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder&#8217;s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The offer and sale of the 2027 Notes and the shares of the Company&#8217;s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2024 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company&#8217;s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company&#8217;s common stock. A holder may convert fewer than all of such holder&#8217;s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million. In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9&#160;million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company&#8217;s existing and future senior debt, (ii) equal in right of payment to any of the Company&#8217;s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company&#8217;s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company&#8217;s subsidiaries. Upon the occurrence of a &#8220;fundamental change,&#8221; as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder&#8217;s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_190" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on earnings (loss) per common share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million, which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of December&#160;31, 2022, there were no amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800405288592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,858)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,967)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,093)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,867)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323499712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock', window );">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</a></td>
<td class="text">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents Total Revenues and disaggregates Net Product Revenues by product.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FIRDAPSE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,777&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#8217;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#8217;s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for 22% and 15% of the Company&#8217;s December&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021 when two customers accounted for 28% and 16% of the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accounts receivable balance, respectively. As of December&#160;31, 2022 and 2021, the accounts receivable balance for Sanofi included $68.8 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#8217; financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the year ended December&#160;31, 2022, 2021, and 2020, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients. While the extent and duration of such effects remain uncertain and difficult to predict, the Company does not expect significant impacts to its operating results and financial condition as a result of the COVID-19 pandemic in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could affect the Company&#8217;s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company&#8217;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-lived assets by geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,114,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and segment reporting disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323611664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</a></td>
<td class="text">EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Shares Available Under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of approximately 41.5 million unissued shares was authorized for future issuance under the Company&#8217;s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan (2017 EIP) and the ESPP. Under the 2017 EIP, shares issued and outstanding under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company&#8217;s stock-based compensation plans are administered by the Company&#8217;s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2017 EIP provides for awards of RSUs and stock options as well as other forms of equity compensation. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. RSU Awards with Performance-based Vesting Conditions (PRSUs) generally vest over a three-year period on a cliff basis three years after the grant date. Stock option awards granted to employees generally vest over a four-year period on a cliff basis 12 months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally 10 years from the grant date. As of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022, approximately 27.7 million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ESPP was initially approved in June&#160;2006, replacing the Company&#8217;s previous plan, and was most recently amended in June 2019. Under BioMarin&#8217;s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Internal Revenue Code. During the year ended December&#160;31, 2022, the Company issued 0.3&#160;million shares under the ESPP. As of December&#160;31, 2022, approximately 7.0&#160;million shares were authorized and 2.8 million shares reserved for future issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Board of Director Grants</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the date of the Company&#8217;s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000, with the number of RSUs to be granted calculated based on the thirty-day trailing average closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market. The annual RSU grant for a director who has served for less than a year is prorated to the nearest quarter of the calendar year. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company&#8217;s next annual meeting of stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense included on the Company&#8217;s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $21.3&#160;million, $20.0&#160;million and $20.1&#160;million was capitalized into inventory for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Service-Based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with service-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,437,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,609,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, was $79.43, $78.46 and $77.13, respectively. The total intrinsic value of restricted stock that vested and released in the years ended December&#160;31, 2022, 2021 and 2020, was $130.1&#160;million, $117.2&#160;million and $109.9&#160;million respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $251.2 million was expected to be recognized over a weighted average period of 2.5 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Performance-based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with vesting conditions based on performance targets under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the PRSUs for the years ended December&#160;31, 2022, 2021 and 2020, was $78.27, $78.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$84.17, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-vested PRSUs included grants with vesting contingent upon the achievement of a three-year Non-GAAP income target, upon the achievement of a three-year Core Operating margin target, vesting contingent upon achievement of a three-year strategic goal target and vesting contingent upon achievement of certain regulatory milestones. The awarded PRSUs generally vest over a three-year service period on a cliff basis. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the quarter granted. The number of shares that may be earned range between 50% and 200% of the base PRSUs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense related to non-vested PRSUs of $12.8&#160;million was expected to be recognized over a weighted average period of 1.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Market-based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company&#8217;s TSR is above the 50th percentile but negative on an absolute basis. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The grant date fair values and assumptions used to determine the grant date fair value of TSR-RSUs granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$124.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$112.12 &#8211; $217.65</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5 &#8211; 157.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7 &#8211; 161.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3 &#8211; 159.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 &#8211; 2.8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 &#8211; 0.4%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense of $17.1&#160;million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.8 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes activity under the Company&#8217;s stock option plans for the year ended December&#160;31, 2022. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:50.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,449,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(943,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,943,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255,818&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,687,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $103.49, the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on December&#160;30, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average fair value per stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, were $32.45, $31.61 and $27.47, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020, were $32.1&#160;million, $40.7&#160;million and $71.9&#160;million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1 &#8211; 40.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4 &#8211; 41.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 &#8211; 42.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 &#8211; 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 &#8211; 6.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 &#8211; 5.9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 &#8211; 4.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 &#8211; 1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 &#8211; 1.7%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options of $31.5&#160;million was expected to be recognized over a weighted average period of 2.5 years.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net tax expense from stock options exercised during the year ended December&#160;31, 2022 was $0.2&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 &#8211; 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7 &#8211; 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 &#8211; 69.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04 &#8211; 4.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04 &#8211; 2.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 &#8211; 2.8%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $14.0&#160;million was expected to be recognized over a weighted average period of 1.3 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323611664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">OTHER EMPLOYEE BENEFITS</a></td>
<td class="text">OTHER EMPLOYEE BENEFITS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">401(k) Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan) for eligible U.S. employees. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee&#8217;s eligible contributions, up to a maximum of the lesser of 6% of the employee&#8217;s annual compensation or the annual statutory contribution limit. The Company&#8217;s matching contribution vests immediately and was approximately $30.8 million, $31.6 million and $26.4 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains the Nonqualified Deferred Compensation (NQDC) plan under which eligible directors and key employee may defer compensation. The NQDC prohibits the diversification of deferrals of Company stock. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity with no changes in the fair value of Company stock held in the NQDC recognized in earnings. Other contributions held in the NQDC are classified as trading securities, recorded at fair value with the corresponding deferred compensation obligation classified as a liability and subsequent changes in the fair value of these non-BioMarin investments are recognized in earnings in the period they occur. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span> to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323331520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Source</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(299,403)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(169,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Source</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,997)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(838,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(889,993)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903,026)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights from a wholly owned foreign subsidiary (tax resident in the Bahamas) to its wholly owned Irish subsidiary. The rights were sold to the Company&#8217;s Irish subsidiary where its ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The intra-entity transfer did not result in a taxable gain in 2020 in any jurisdiction including the U.S. as the transaction was disregarded for U.S. tax purposes. The Company filed an election to treat the Irish subsidiary as a disregarded entity for U.S. income tax purposes in 2011. The transaction resulted in a step-up in the tax basis in the transferred intellectual property rights and the Company&#8217;s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1&#160;million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The fair value of the transferred intellectual property rights was determined utilizing the income approach which relied on projections of product-specific revenues and the inclusion or exclusion of a terminal value for each product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The tax deductions related to the amortization of these transferred intellectual property rights will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a reconciliation of the statutory federal income tax benefit to the Company&#8217;s effective tax rate:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan Drug &amp; General Business Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Source Income Subject to US Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax rate differential </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,051)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfer of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(852,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CARES act carryback claim</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance/deferred benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903,026)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and is offset by the PRV income taxed at a higher tax rate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company&#8217;s Dutch subsidiary of $9.3&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s net deferred tax assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryforwards </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, reserves, and prepaids</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,571,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,514,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joint venture basis difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,221)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,450,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in net deferred tax assets is primarily related to capitalization of research and development expenses offset by a decrease in intangible assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, the Company renegotiated a license agreement that resulted in lower royalty projections for its Dutch subsidiary. The revised royalty projections required establishment of a valuation allowance on net operating loss deferred tax assets that were no longer expected to be realizable. The valuation allowance also increased in 2021 due to the Company&#8217;s expectation that state R&amp;D credits will not be utilized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2030-2033 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal R&amp;D and orphan drug credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2024-2042 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2023-2042 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Indefinite </span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not included in the table above are $152.7 million of state research credit carryovers that will carry forward indefinitely.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&#160;31, 2022 and 2021, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Deletions) Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31, 2022 were potential benefits of $223.3 million that, if recognized, would affect the effective tax rate. The Company&#8217;s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December&#160;31, 2022. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NjY_b6dc29f0-a3a7-485e-8db1-2fd76231c141">three</span> to five years. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.</span></div>U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.&#160;This excess totaled approximately $17.3 million as of December&#160;31, 2022, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318308624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER COMMON SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER COMMON SHARE<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#8217;s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income/(loss), diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted earnings (loss) per common share as they were anti-dilutive (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for information on the Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318308624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">LICENSE AND COLLABORATION AGREEMENTS</a></td>
<td class="text">LICENSE AND COLLABORATION AGREEMENTSIn October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0&#160;million, a minority 15% equity ownership interest in the licensee, and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sales milestones are met by the licensee. Subsequently, the third party licensee raised additional funding and issued the Company incremental shares to maintain its 15% minority interest. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee&#8217;s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December&#160;31, 2022. As a result, the Company's loss exposure is limited to the value of the equity investment of $12.6&#160;million which is included in Other Assets on the Company&#8217;s Consolidated Balance Sheets as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2017, the Company executed a license agreement with Sarepta Therapeutics (Sarepta) that provides Sarepta with global exclusive rights to the Company&#8217;s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under the license agreement, Sarepta pays the Company royalties and may pay the Company certain milestone payments for exons 51, 45, 53 and possibly other exon-skipping products. In the fourth quarter of 2021, the Company and Sarepta amended the license agreement to, among other things, make the license co-exclusive at a future date and reduce future royalty rates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan. Previously, the Company had exclusive rights to KUVAN in the U.S. and Canada and PALYNZIQ in the U.S. and Japan. Pursuant to the amended and restated KUVAN Agreement, if future sales milestones were met, the Company was obligated to pay Merck Serono up to a maximum of &#8364;60.0 million, all of which were met as of December&#160;31, 2022, &#8364;15.0 million of which was unpaid as of December&#160;31, 2022. Pursuant to the Pegvaliase Agreement, the Company also paid Merck Serono &#8364;125.0&#160;million in cash when the PALYNZIQ development milestones were achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market FIRDAPSE, the Company's former commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to FIRDAPSE, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of FIRDAPSE in North America. In January 2020, the Company completed the sale of worldwide rights to FIRDAPSE to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further information about the FIRDAPSE sale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the KUVAN New Drug Application. The Company receives royalties on net sales of the product in Japan.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is engaged in R&amp;D collaborations with various other entities. These provide for sponsorship of R&amp;D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321586944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#8217;s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various purported shareholder class action and derivative lawsuits filed against the Company and certain officers and directors. For example, there are shareholder class actions alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act) for making materially false or misleading statements regarding information for two of its clinical products. The estimated long-term loss contingency recorded on the Company's Consolidated Balance Sheets was $13.0&#160;million as of December&#160;31, 2022. The same amount was recorded for expected insurance recoveries. Legal proceedings may occur that may result in a change in the estimated loss accrued by the Company. While it is not feasible to predict the outcome of such proceedings and exposures with certainty, management believes this should not have a material adverse effect on the Company&#8217;s Consolidated Balance Sheets, Statement of Operations or Statement of Cash Flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $762.5 million, which included $381.5 million and $210.0 million for two early stage development programs licensed from third parties. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;D activities. These amounts are included as R&amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services, production services and facility construction services. As of December&#160;31, 2022, such commitments were estimated at approximately $225.5 million, of which $188.7 million is expected to be paid in 2023. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318148816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company&#8217;s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsThe Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument&#8217;s underlying contractual maturity date and its availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company&#8217;s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment&#8217;s amortized cost and fair value at such date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy', window );">Non-Marketable Equity Securities</a></td>
<td class="text">Non-Marketable Equity SecuritiesThe Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Inventory </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;D).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant And Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;D and Selling, General and Administrative (SG&amp;A), as appropriate, in the Consolidated </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Statements of Operations. Property and equipment purchased for specific R&amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;D in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing&#160;and&#160;laboratory&#160;equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&amp;D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company&#8217;s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company&#8217;s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment by comparing the fair value of the Company&#8217;s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. </span></div>Long-lived Asset ImpairmentThe Company&#8217;s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify a manufacturing facility for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Capitalized Software</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capitalized Software</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt">identification of the promised goods or services in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt">measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt">allocation of the transaction price to the performance obligations based on estimated selling prices; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Company&#8217;s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company&#8217;s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company&#8217;s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company&#8217;s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company&#8217;s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Reserves</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. Such variable consideration includes rebates, chargebacks, sales returns and other incentives. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Government and Commercial Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company&#8217;s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers&#8217; limited return rights and the Company&#8217;s historical experience with returns. Because of the pricing of the Company&#8217;s commercial products, the limited number of patients and the customers&#8217; limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Other incentives include fees paid to the Company&#8217;s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient&#8217;s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:&#160;For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where </span></div>attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D costs are generally expensed as incurred. These expenses include contract R&amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs and R&amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">Advertising ExpensesThe costs of advertising are presented in SG&amp;A in the Consolidated Statements of Operations and are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Earnings (Loss) Per Common Share</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;D or SG&amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company&#8217;s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of each stock option award and purchase rights under the Company&#8217;s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13">twenty-four</span>-month period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company&#8217;s stock price and may use assumptions regarding a number of complex and subjective variables.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company&#8217;s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign CurrencyFor the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;A in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Income approach, which is based on the present value of a future stream of net cash flows</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Notes</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"> 2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_193" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for further information on the nature of these financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during 2022 that the Company believes are of significance or potential significance to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for not readily marketable securities, valuation methods and significant assumptions used to determine fair value, restrictions on the investment and reasons investments are not readily marketable, including securities that are not registered, investments in nonpublic entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 820<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=35710923&amp;loc=d3e45360-110995<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317496400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock', window );">Schedule of Property, Plant and Equipment Estimated Useful Lives</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing&#160;and&#160;laboratory&#160;equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323482640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock', window );">Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,926)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,006&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,641,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,926)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,625,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,835&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9">one</span></span> and five years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323701008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(352,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the carrying value and estimated remaining life of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Remaining Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intellectual property</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology transfer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchased royalty rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>(1)Certain technology transfer intangible assets have not yet been placed into service. The average remaining life presented is only for those placed into service.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the estimated future amortization expense associated with the Company&#8217;s finite-lived intangible assets that have been placed into service, was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323401616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">774,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(802,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,073,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323295376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,356&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,083&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,669&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327871648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,573</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The balance as of December 31, 2021 has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock', window );">Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December&#160;31, 2022, 2021 and 2020, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision for Current Period Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated accrued rebates and reserve for cash discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800418608496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December&#160;31, 2022 and 2021. Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December&#160;31, 2022 and 2021. Refer to Notes </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:54.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The restricted investments as of December&#160;31, 2022 and 2021 secure the Company&#8217;s irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Liabilities Measured at Fair Value Using Level 3 Inputs</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payments to Ares Trading S.A. (Merck Serono)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized foreign exchange gain on settlement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323365328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Forward Foreign Currency Exchange Contracts Outstanding</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Fair Value Carrying Amount of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:67.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Refer to Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional information related to the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Effect of Derivative Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="15" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327906880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock', window );">Schedule of Lessee Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s ROU assets and lease liabilities for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,418&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Finance Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company&#8217;s leases for the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock', window );">Schedule of Other Information</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company&#8217;s lease liabilities:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Finance Leases Other Information Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Lessee Lease Assets And Liabilities Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800418608496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Senior Subordinated Convertible Obligations</a></td>
<td class="text">The Notes are senior subordinated convertible obligations, and <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#8217;s convertible debt:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,083,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The fair value of the Company&#8217;s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for additional discussion of fair value measurements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense on Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s fixed-rate convertible debt consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800323435440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,858)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,967)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,093)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,867)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800325315120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents Total Revenues and disaggregates Net Product Revenues by product.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FIRDAPSE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,777&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location</a></td>
<td class="text">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME net product revenues marketed by Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,783,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Non-Monetary Long-Lived Assets by Geographic Region</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-lived assets by geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,114,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800414895088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense included on the Company&#8217;s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with service-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,437,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,609,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with vesting conditions based on performance targets under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of TSR-RSU Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The grant date fair values and assumptions used to determine the grant date fair value of TSR-RSUs granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$124.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$112.12 &#8211; $217.65</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5 &#8211; 157.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7 &#8211; 161.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3 &#8211; 159.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 &#8211; 2.8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 &#8211; 0.4%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes activity under the Company&#8217;s stock option plans for the year ended December&#160;31, 2022. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:50.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,449,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(943,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,943,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255,818&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,687,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $103.49, the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on December&#160;30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1 &#8211; 40.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4 &#8211; 41.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 &#8211; 42.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 &#8211; 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 &#8211; 6.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 &#8211; 5.9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 &#8211; 4.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 &#8211; 1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 &#8211; 1.7%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 &#8211; 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7 &#8211; 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 &#8211; 69.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 &#8211; 2.0 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04 &#8211; 4.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04 &#8211; 2.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 &#8211; 2.8%</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327622656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Source</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(299,403)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(169,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Source</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,997)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for (Benefit From) Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(838,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(889,993)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903,026)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a reconciliation of the statutory federal income tax benefit to the Company&#8217;s effective tax rate:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan Drug &amp; General Business Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Source Income Subject to US Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax rate differential </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,051)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfer of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(852,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CARES act carryback claim</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance/deferred benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(903,026)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and is offset by the PRV income taxed at a higher tax rate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company&#8217;s Dutch subsidiary of $9.3&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s net deferred tax assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryforwards </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, reserves, and prepaids</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,571,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,514,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joint venture basis difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,221)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,450,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock', window );">Schedule of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2030-2033 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal R&amp;D and orphan drug credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2024-2042 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;2023-2042 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Indefinite </span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&#160;31, 2022 and 2021, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Deletions) Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of operating loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800405342400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income/(loss), diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings (loss) per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted earnings (loss) per common share as they were anti-dilutive (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318039760">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>tranche</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">789,199<span></span>
</td>
<td class="nump">930,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity decrease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,603,156)<span></span>
</td>
<td class="num">(4,265,669)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(4,100,931)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,122,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,505,412<span></span>
</td>
<td class="nump">1,450,161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">176,236<span></span>
</td>
<td class="nump">152,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Decrease in other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (100,015)<span></span>
</td>
<td class="num">(98,362)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl', window );">Payment term after customer control</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment', window );">Period between customer control and payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_NumberOfTranchesInOfferingPeriod', window );">Number of tranches in offering period | tranche</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SpanOfOfferingPeriod', window );">Span of offering period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember', window );">ALDURAZYME net product revenues marketed by Sanofi | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_PaymentReceivedAsPercentageOfNetProductSales', window );">Payment received as percentage of net product sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember', window );">ALDURAZYME net product revenues marketed by Sanofi | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_PaymentReceivedAsPercentageOfNetProductSales', window );">Payment received as percentage of net product sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity decrease</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Decrease in other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The years ended December 31, 2021 and 2020 have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.<br/></span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Payment Term After Customer Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Period Between Customer Control And Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_NumberOfTranchesInOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches In Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_NumberOfTranchesInOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_PaymentReceivedAsPercentageOfNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment received from sale of a product as percentage of worldwide net product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_PaymentReceivedAsPercentageOfNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SpanOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Span of offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SpanOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321384624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, plant and equipment, estimated useful life</a></td>
<td class="text">Shorter of life of asset or lease term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing&#160;and&#160;laboratory&#160;equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing&#160;and&#160;laboratory&#160;equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Land improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Land improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life, (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319175712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,641,139<span></span>
</td>
<td class="nump">$ 1,523,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15,926)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">1,625,372<span></span>
</td>
<td class="nump">1,521,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">724,531<span></span>
</td>
<td class="nump">587,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">567,006<span></span>
</td>
<td class="nump">426,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">333,835<span></span>
</td>
<td class="nump">507,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">463,248<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">463,248<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">463,248<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,177,891<span></span>
</td>
<td class="nump">1,222,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15,926)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">1,162,124<span></span>
</td>
<td class="nump">1,220,491<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">261,283<span></span>
</td>
<td class="nump">286,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">567,006<span></span>
</td>
<td class="nump">426,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">333,835<span></span>
</td>
<td class="nump">507,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">248,933<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">248,933<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">248,933<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">504,984<span></span>
</td>
<td class="nump">584,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11,541)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">493,477<span></span>
</td>
<td class="nump">582,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">299,153<span></span>
</td>
<td class="nump">200,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">192,443<span></span>
</td>
<td class="nump">381,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">312,720<span></span>
</td>
<td class="nump">224,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,771)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">308,994<span></span>
</td>
<td class="nump">224,631<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">229,846<span></span>
</td>
<td class="nump">146,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">79,148<span></span>
</td>
<td class="nump">78,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">48,103<span></span>
</td>
<td class="nump">68,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">48,092<span></span>
</td>
<td class="nump">68,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">10,469<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">37,623<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">63,151<span></span>
</td>
<td class="nump">56,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(592)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">62,628<span></span>
</td>
<td class="nump">56,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">9,451<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">$ 62,244<span></span>
</td>
<td class="nump">47,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Foreign and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShortTermMarketableSecuritiesMaturityPeriod', window );">Short-term marketable securities maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod', window );">Long-term marketable securities maturity period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod', window );">Long-term marketable securities maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LongTermMarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShortTermMarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShortTermMarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322527696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Strategic Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Strategic investments fair value</a></td>
<td class="nump">$ 23.9<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327630960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 690,871<span></span>
</td>
<td class="nump">$ 677,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(352,302)<span></span>
</td>
<td class="num">(288,698)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">$ 338,569<span></span>
</td>
<td class="nump">$ 388,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317316864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 338,569<span></span>
</td>
<td class="nump">$ 388,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_AcquiredIntellectualPropertyMember', window );">Acquired intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 240,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Average Remaining Life</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_TechnologyTransferMember', window );">Technology transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 86,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Average Remaining Life</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_RepurchasedRoyaltyRightsMember', window );">Repurchased royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 6,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Average Remaining Life</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_LicensePaymentsMember', window );">License payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 5,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Average Remaining Life</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Balance</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Average Remaining Life</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_AcquiredIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_AcquiredIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_TechnologyTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_TechnologyTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_RepurchasedRoyaltyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_RepurchasedRoyaltyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_LicensePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmrn_LicensePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800414878576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 63,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">57,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">38,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">38,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">38,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">25,746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet', window );">Finite-lived intangible asset future amortization</a></td>
<td class="nump">$ 261,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Not Commenced, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318238752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52,820<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321535184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,875,511<span></span>
</td>
<td class="nump">$ 1,756,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(802,145)<span></span>
</td>
<td class="num">(720,574)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">1,073,366<span></span>
</td>
<td class="nump">1,035,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">819,100<span></span>
</td>
<td class="nump">774,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing&#160;and&#160;laboratory&#160;equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">475,663<span></span>
</td>
<td class="nump">444,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">214,829<span></span>
</td>
<td class="nump">201,382<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">90,786<span></span>
</td>
<td class="nump">90,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">59,532<span></span>
</td>
<td class="nump">55,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">45,762<span></span>
</td>
<td class="nump">42,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">26,455<span></span>
</td>
<td class="nump">10,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 143,384<span></span>
</td>
<td class="nump">$ 136,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322457968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 38.6<span></span>
</td>
<td class="nump">$ 46.1<span></span>
</td>
<td class="nump">$ 43.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321342528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 131,071<span></span>
</td>
<td class="nump">$ 80,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">410,656<span></span>
</td>
<td class="nump">415,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">352,356<span></span>
</td>
<td class="nump">281,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 894,083<span></span>
</td>
<td class="nump">$ 776,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321939296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued operating expenses</a></td>
<td class="nump">$ 231,238<span></span>
</td>
<td class="nump">$ 199,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">207,573<span></span>
</td>
<td class="nump">204,446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AccruedGovernmentAndOtherRebates', window );">Accrued rebates payable</a></td>
<td class="nump">72,654<span></span>
</td>
<td class="nump">47,987<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">16,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties payable</a></td>
<td class="nump">13,306<span></span>
</td>
<td class="nump">15,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Foreign currency exchange forward contracts</a></td>
<td class="nump">12,601<span></span>
</td>
<td class="nump">6,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">10,375<span></span>
</td>
<td class="nump">10,464<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other</a></td>
<td class="nump">8,288<span></span>
</td>
<td class="nump">6,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 572,959<span></span>
</td>
<td class="nump">$ 498,265<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800414882160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details) - 2022 Restructuring Plan<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2022 </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SupplementalBalanceSheetInformationLineItems', window );"><strong>Supplemental Balance Sheet Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Restructuring and related cost, expected number of positions eliminated | employee</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce', window );">Percentage of workforce expected to eliminated</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SupplementalBalanceSheetInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SupplementalBalanceSheetInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bmrn_A2022RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bmrn_A2022RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317146992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AccruedRebatesMember', window );">Accrued rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Period</a></td>
<td class="nump">$ 47,987<span></span>
</td>
<td class="nump">$ 65,526<span></span>
</td>
<td class="nump">$ 57,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision for Current Period Sales</a></td>
<td class="nump">140,260<span></span>
</td>
<td class="nump">116,691<span></span>
</td>
<td class="nump">113,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments</a></td>
<td class="num">(115,593)<span></span>
</td>
<td class="num">(134,230)<span></span>
</td>
<td class="num">(104,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Period</a></td>
<td class="nump">72,654<span></span>
</td>
<td class="nump">47,987<span></span>
</td>
<td class="nump">65,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AllowancesForReserveForCashDiscountsMember', window );">Reserve for cash discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Period</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision for Current Period Sales</a></td>
<td class="nump">20,351<span></span>
</td>
<td class="nump">16,003<span></span>
</td>
<td class="nump">17,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments</a></td>
<td class="num">(18,725)<span></span>
</td>
<td class="num">(15,706)<span></span>
</td>
<td class="num">(17,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Period</a></td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">$ 2,013<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AccruedRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AccruedRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AllowancesForReserveForCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bmrn_AllowancesForReserveForCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317542976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Price&#160;in Active Markets For Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Financial assets remeasured</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liabilities remeasured</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">22,296,000<span></span>
</td>
<td class="nump">26,869,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">24,950,000<span></span>
</td>
<td class="nump">28,912,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">18,579,000<span></span>
</td>
<td class="nump">50,275,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">39,096,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">38,446,000<span></span>
</td>
<td class="nump">89,371,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,654,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">15,925,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">22,296,000<span></span>
</td>
<td class="nump">26,869,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">24,950,000<span></span>
</td>
<td class="nump">28,912,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,654,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">22,521,000<span></span>
</td>
<td class="nump">25,972,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2) | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,654,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2) | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">15,925,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">15,925,000<span></span>
</td>
<td class="nump">63,399,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3) | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3) | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">15,925,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">2,654,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">2,654,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">19,867,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">2,429,000<span></span>
</td>
<td class="nump">2,940,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">2,429,000<span></span>
</td>
<td class="nump">2,940,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets current fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets noncurrent fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherAssetsNoncurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities current fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherLiabilitiesCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities noncurrent fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_NonqualifiedDeferredCompensationPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_NonqualifiedDeferredCompensationPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_RestrictedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_RestrictedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327466688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details) - Contingent Payment<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, beginning balance</a></td>
<td class="nump">$ 63,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Milestone payments to Ares Trading S.A. (Merck Serono)</a></td>
<td class="num">(47,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange', window );">Realized foreign exchange gain on settlement of contingent consideration</a></td>
<td class="num">(2,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement', window );">Foreign exchange remeasurement of Euro denominated contingent consideration</a></td>
<td class="num">(1,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, ending balance</a></td>
<td class="nump">$ 15,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Gain (Loss) On Foreign Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327768224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Unrealized losses reclassified from AOCI to earnings</a></td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity of derivatives</a></td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity of derivatives</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317486800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details) - Foreign exchange contracts - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 808,635<span></span>
</td>
<td class="nump">$ 740,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">177,393<span></span>
</td>
<td class="nump">183,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments: | Sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">218,903<span></span>
</td>
<td class="nump">113,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments: | Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 6,785<span></span>
</td>
<td class="nump">$ 31,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_ShortMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_ShortMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_LongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_LongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800325105360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">$ 22,995<span></span>
</td>
<td class="nump">$ 22,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">13,675<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">21,523<span></span>
</td>
<td class="nump">22,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">13,204<span></span>
</td>
<td class="nump">6,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Level 2 | Other&#160;current&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">19,464<span></span>
</td>
<td class="nump">17,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Level 2 | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Level 2 | Accounts&#160;payable&#160;and accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">12,130<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Level 2 | Other&#160;long-term&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments: | Level 2 | Other&#160;current&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments: | Level 2 | Accounts&#160;payable&#160;and accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321561328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Operating expenses | Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</a></td>
<td class="num">$ (11,917)<span></span>
</td>
<td class="num">$ (1,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments: | Net product revenues | Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</a></td>
<td class="nump">48,541<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gains (Losses) Recognized in Earnings</a></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322491408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of ROU Assets and Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LeaseRightOfUseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating</a></td>
<td class="nump">$ 34,935<span></span>
</td>
<td class="nump">$ 38,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing</a></td>
<td class="nump">$ 6,021<span></span>
</td>
<td class="nump">$ 8,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total ROU assets</a></td>
<td class="nump">$ 40,956<span></span>
</td>
<td class="nump">$ 46,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_LeasesLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating, Current</a></td>
<td class="nump">$ 8,088<span></span>
</td>
<td class="nump">$ 8,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance, Current</a></td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating, Noncurrent</a></td>
<td class="nump">$ 26,329<span></span>
</td>
<td class="nump">$ 31,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance, Noncurrent</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 1,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 36,888<span></span>
</td>
<td class="nump">$ 44,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LeaseRightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LeaseRightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LeasesLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LeasesLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800325302480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 9,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">7,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">4,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">4,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">39,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(5,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">34,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">12,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">7,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">4,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">42,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(5,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 36,888<span></span>
</td>
<td class="nump">$ 44,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liabilities Payments Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Payments Due Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317358400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Schedule of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 16,690<span></span>
</td>
<td class="nump">$ 17,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating</a></td>
<td class="nump">13,669<span></span>
</td>
<td class="nump">13,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317521120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Other Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term (in years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Financing leases</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Financing leases</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317886640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="nump">$ 10,760<span></span>
</td>
<td class="nump">$ 10,664<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing leases</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Cash used in financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing leases</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
<td colspan="2" class="nump">$ 6,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>ROU assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">5,252<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Financing leases</a></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right Of Use Assets Obtained In Exchange For Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319235664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member', window );">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member', window );">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes) | Senior Subordinated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate of shares</a></td>
<td class="nump">0.0072743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 137.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of notes</a></td>
<td class="nump">$ 585,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, unamortized discount</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount', window );">Repurchase of note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember', window );">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.599%<span></span>
</td>
<td class="nump">0.599%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember', window );">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) | Senior Subordinated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.599%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0080212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount', window );">Repurchase of note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_DebtInstrumentPercentageOfFaceValue', window );">Debt instrument percentage of face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from offering debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember', window );">The 2018 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_DebtInstrumentPercentageOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument percentage of face value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_DebtInstrumentPercentageOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Senior subordinated notes repurchased percentage of principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317966640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Senior Subordinated Convertible Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">1,083,019<span></span>
</td>
<td class="nump">$ 1,079,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt, net</a></td>
<td class="nump">1,083,019<span></span>
</td>
<td class="nump">1,079,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 1,173,600<span></span>
</td>
<td class="nump">$ 1,146,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member', window );">1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount net of deferred offering costs</a></td>
<td class="num">(8,941)<span></span>
</td>
<td class="num">(10,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">591,059<span></span>
</td>
<td class="nump">589,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 647,370<span></span>
</td>
<td class="nump">$ 625,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember', window );">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage, per annum</a></td>
<td class="nump">0.599%<span></span>
</td>
<td class="nump">0.599%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount net of deferred offering costs</a></td>
<td class="num">(3,040)<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">491,960<span></span>
</td>
<td class="nump">490,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 526,230<span></span>
</td>
<td class="nump">$ 521,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319104848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Interest Expense on Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfInterestExpensesLineItems', window );"><strong>Schedule Of Interest Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense on convertible debt</a></td>
<td class="nump">$ 15,970<span></span>
</td>
<td class="nump">$ 15,337<span></span>
</td>
<td class="nump">$ 29,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ScheduleOfInterestExpensesLineItems', window );"><strong>Schedule Of Interest Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest expense</a></td>
<td class="nump">10,465<span></span>
</td>
<td class="nump">10,465<span></span>
</td>
<td class="nump">12,350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of discount on convertible notes</a></td>
<td class="nump">3,349<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">14,682<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense on convertible debt</a></td>
<td class="nump">$ 14,407<span></span>
</td>
<td class="nump">$ 14,397<span></span>
</td>
<td class="nump">$ 28,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfInterestExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfInterestExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322548144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 4,265,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,100,931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,122,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">15,078<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27,521<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="nump">36,624<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,454)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(18,299)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">4,603,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,265,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,100,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income (loss):</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">14,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,139)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(3,867)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,139)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20,028)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">29,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34,379<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(23,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="nump">36,624<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,454)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(7,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">8,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20,028)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(1,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(13,967)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,858)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(10,720)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,262)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(12,093)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bmrn_AccumulatedGainLossFromOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bmrn_AccumulatedGainLossFromOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bmrn_AccumulatedGainLossFromOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321974528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,096,039<span></span>
</td>
<td class="nump">$ 1,846,275<span></span>
</td>
<td class="nump">$ 1,860,455<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,042,025<span></span>
</td>
<td class="nump">1,783,498<span></span>
</td>
<td class="nump">1,805,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductTwoMember', window );">VIMIZIM | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">663,739<span></span>
</td>
<td class="nump">623,145<span></span>
</td>
<td class="nump">544,257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductThreeMember', window );">NAGLAZYME | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">443,794<span></span>
</td>
<td class="nump">380,449<span></span>
</td>
<td class="nump">391,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductFourMember', window );">PALYNZIQ | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">255,032<span></span>
</td>
<td class="nump">237,474<span></span>
</td>
<td class="nump">170,983<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductFiveMember', window );">KUVAN | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">227,577<span></span>
</td>
<td class="nump">285,776<span></span>
</td>
<td class="nump">457,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductSixMember', window );">VOXZOGO | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">169,128<span></span>
</td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductSevenMember', window );">BRINEURA | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">154,333<span></span>
</td>
<td class="nump">128,034<span></span>
</td>
<td class="nump">110,192<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductEightMember', window );">FIRDAPSE | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember', window );">Total net product revenues marketed by the Company | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,913,603<span></span>
</td>
<td class="nump">1,660,733<span></span>
</td>
<td class="nump">1,675,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember', window );">ALDURAZYME net product revenues marketed by Sanofi | Marketed by Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">128,422<span></span>
</td>
<td class="nump">122,765<span></span>
</td>
<td class="nump">130,107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember', window );">Royalty and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 54,014<span></span>
</td>
<td class="nump">$ 62,777<span></span>
</td>
<td class="nump">$ 54,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321392592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,096,039<span></span>
</td>
<td class="nump">$ 1,846,275<span></span>
</td>
<td class="nump">$ 1,860,455<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,042,025<span></span>
</td>
<td class="nump">1,783,498<span></span>
</td>
<td class="nump">1,805,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Total net product revenues marketed by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,913,603<span></span>
</td>
<td class="nump">1,660,733<span></span>
</td>
<td class="nump">1,675,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Total net product revenues marketed by the Company | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">684,284<span></span>
</td>
<td class="nump">657,700<span></span>
</td>
<td class="nump">756,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Total net product revenues marketed by the Company | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">650,952<span></span>
</td>
<td class="nump">558,952<span></span>
</td>
<td class="nump">498,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Total net product revenues marketed by the Company | Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">266,801<span></span>
</td>
<td class="nump">191,151<span></span>
</td>
<td class="nump">205,862<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Total net product revenues marketed by the Company | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">311,566<span></span>
</td>
<td class="nump">252,930<span></span>
</td>
<td class="nump">214,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember', window );">Marketed by Sanofi | ALDURAZYME net product revenues marketed by Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 128,422<span></span>
</td>
<td class="nump">$ 122,765<span></span>
</td>
<td class="nump">$ 130,107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmrn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmrn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800325089824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) - Customer Concentration Risk - Net Product Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A, B, &amp; C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneTwoAndThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneTwoAndThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319104912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 461,316<span></span>
</td>
<td class="nump">$ 373,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=bmrn_CustomersMember', window );">Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 68,800<span></span>
</td>
<td class="nump">$ 67,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable Balance | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable Balance | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndGeographicInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327700432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">$ 1,114,322<span></span>
</td>
<td class="nump">$ 1,081,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">786,509<span></span>
</td>
<td class="nump">763,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">309,180<span></span>
</td>
<td class="nump">304,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bmrn_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">$ 18,633<span></span>
</td>
<td class="nump">$ 13,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmrn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmrn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800316681296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based awards, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SpanOfOfferingPeriod', window );">Span of offering period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense capitalized to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,300,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.45<span></span>
</td>
<td class="nump">$ 31.61<span></span>
</td>
<td class="nump">$ 27.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,100,000<span></span>
</td>
<td class="nump">$ 40,700,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Net tax benefit from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based awards, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Options to purchase shares of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_SpanOfOfferingPeriod', window );">Span of offering period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of qualified compensation to be used for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_MaximumPayrollDeductions', window );">Maximum payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under the employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to recognized over weighted average period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember', window );">Restricted Stock With Service Based Vesting Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per RSU granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.43<span></span>
</td>
<td class="nump">$ 78.46<span></span>
</td>
<td class="nump">$ 77.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">The total intrinsic value of restricted stock vested and released</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,100,000<span></span>
</td>
<td class="nump">$ 117,200,000<span></span>
</td>
<td class="nump">$ 109,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to recognized over weighted average period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to recognized over weighted average period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Independent Director | Common stock:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Initial equity grant value</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AverageClosingPriceTrailingPeriod', window );">Average closing price of common stock, trailing period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per RSU granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.27<span></span>
</td>
<td class="nump">$ 78.09<span></span>
</td>
<td class="nump">$ 84.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to recognized over weighted average period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Non-GAAP Income Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Core Operating Margin Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Strategic Goal Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage', window );">Shares earned range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage', window );">Shares earned range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per RSU granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.67<span></span>
</td>
<td class="nump">$ 117.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to recognized over weighted average period, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage', window );">Ceiling achievement level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with Market Conditions | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per RSU granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage', window );">Shares earned range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage', window );">Annual shareholder return multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with Market Conditions | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per RSU granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage', window );">Shares earned range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Restricted Stock With Service Based Vesting Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Restricted Stock Unit Awards with Performance-Based Vesting Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement', window );">Initial time period vesting requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement', window );">Initial time period vesting requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of stock option awards, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Shareholder Return Multiplier On Absolute Basis, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AverageClosingPriceTrailingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average closing price trailing period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AverageClosingPriceTrailingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_MaximumPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payroll deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_MaximumPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award initial time period vesting requirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SpanOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Span of offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SpanOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bmrn_IndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bmrn_IndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmrn_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321534880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 196,308<span></span>
</td>
<td class="nump">$ 197,263<span></span>
</td>
<td class="nump">$ 189,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">17,709<span></span>
</td>
<td class="nump">22,357<span></span>
</td>
<td class="nump">26,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">61,702<span></span>
</td>
<td class="nump">67,196<span></span>
</td>
<td class="nump">61,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 116,897<span></span>
</td>
<td class="nump">$ 107,710<span></span>
</td>
<td class="nump">$ 101,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318168592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember', window );">Restricted Stock With Service Based Vesting Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units beginning balance (in shares)</a></td>
<td class="nump">4,437,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,266,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,609,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(574,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units ending balance (in shares)</a></td>
<td class="nump">4,519,746<span></span>
</td>
<td class="nump">4,437,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units beginning balance (in dollars per share)</a></td>
<td class="nump">$ 80.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">79.43<span></span>
</td>
<td class="nump">$ 78.46<span></span>
</td>
<td class="nump">$ 77.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">81.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">79.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units ending balance (in dollars per share)</a></td>
<td class="nump">$ 79.55<span></span>
</td>
<td class="nump">$ 80.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with non-Revenue based Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units beginning balance (in shares)</a></td>
<td class="nump">437,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">147,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(102,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(34,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units ending balance (in shares)</a></td>
<td class="nump">447,662<span></span>
</td>
<td class="nump">437,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units beginning balance (in dollars per share)</a></td>
<td class="nump">$ 78.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">78.27<span></span>
</td>
<td class="nump">$ 78.09<span></span>
</td>
<td class="nump">$ 84.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">82.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">65.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.75<span></span>
</td>
<td class="nump">$ 78.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember', window );">Restricted Stock Unit Awards with Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units beginning balance (in shares)</a></td>
<td class="nump">350,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">147,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(89,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(12,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units ending balance (in shares)</a></td>
<td class="nump">396,120<span></span>
</td>
<td class="nump">350,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units beginning balance (in dollars per share)</a></td>
<td class="nump">$ 123.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">124.67<span></span>
</td>
<td class="nump">$ 117.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">143.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">120.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units ending balance (in dollars per share)</a></td>
<td class="nump">$ 119.61<span></span>
</td>
<td class="nump">$ 123.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_RestrictedStockWithServiceBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321322080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details) - Restricted Stock Unit Awards with Market Conditions - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 124.67<span></span>
</td>
<td class="nump">$ 117.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">24.50%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
<td class="nump">21.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">157.60%<span></span>
</td>
<td class="nump">161.70%<span></span>
</td>
<td class="nump">159.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319036816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning balance (in shares)</a></td>
<td class="nump">6,449,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">695,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(943,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired and forfeited (in shares)</a></td>
<td class="num">(258,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding ending balance (in shares)</a></td>
<td class="nump">5,943,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options unvested (in shares)</a></td>
<td class="nump">1,255,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,687,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in dollars per share)</a></td>
<td class="nump">$ 78.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">78.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">55.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired and forfeited (in dollars per share)</a></td>
<td class="nump">79.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in dollars per share)</a></td>
<td class="nump">82.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice', window );">Options unvested (in dollars per share)</a></td>
<td class="nump">78.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 83.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Years, Options outstanding</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Years, Options unvested</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Years, exercisable</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="nump">$ 132,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options unvested</a></td>
<td class="nump">31,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 101,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800315953536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details) - Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">38.10%<span></span>
</td>
<td class="nump">39.40%<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">40.50%<span></span>
</td>
<td class="nump">41.60%<span></span>
</td>
<td class="nump">42.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321534880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details) - Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">28.60%<span></span>
</td>
<td class="nump">23.70%<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">69.20%<span></span>
</td>
<td class="nump">69.20%<span></span>
</td>
<td class="nump">69.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321609904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS - Additional Information (Details) - BioMarin Retirement Savings Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company's contribution to match employees contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employer contribution of maximum percentage over employee's annual compensation</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution from employment commencement</a></td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmrn_BiomarinRetirementSavingsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmrn_BiomarinRetirementSavingsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800322674720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Source</a></td>
<td class="num">$ (299,403)<span></span>
</td>
<td class="num">$ (259,258)<span></span>
</td>
<td class="num">$ (169,614)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S. Source</a></td>
<td class="nump">448,979<span></span>
</td>
<td class="nump">183,908<span></span>
</td>
<td class="nump">120,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">$ 149,576<span></span>
</td>
<td class="num">$ (75,350)<span></span>
</td>
<td class="num">$ (48,997)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800319107408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Provision for (benefit from) income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 12,798<span></span>
</td>
<td class="num">$ (2,038)<span></span>
</td>
<td class="num">$ (15,073)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">5,058<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">42,246<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense, total</a></td>
<td class="nump">60,102<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
<td class="num">(13,033)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Provision for (benefit from) deferred income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(79,270)<span></span>
</td>
<td class="num">(29,895)<span></span>
</td>
<td class="num">(46,124)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(5,143)<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
<td class="num">(5,321)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">32,326<span></span>
</td>
<td class="nump">15,517<span></span>
</td>
<td class="num">(838,548)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit), total</a></td>
<td class="num">(52,087)<span></span>
</td>
<td class="num">(15,608)<span></span>
</td>
<td class="num">(889,993)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">$ 8,015<span></span>
</td>
<td class="num">$ (11,270)<span></span>
</td>
<td class="num">$ (903,026)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317391488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 1,505,412<span></span>
</td>
<td colspan="2" class="nump">$ 1,450,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect the effective tax rate if recognized</a></td>
<td class="nump">223,300<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings of foreign subsidiaries</a></td>
<td class="nump">$ 17,300<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_IncomeTaxStatuteOfLimitationsPeriod', window );">Income tax statute of limitations period</a></td>
<td class="text">3 years<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_IncomeTaxStatuteOfLimitationsPeriod', window );">Income tax statute of limitations period</a></td>
<td class="text">5 years<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 835,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carry forward</a></td>
<td class="nump">$ 152,700<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_IncomeTaxStatuteOfLimitationsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax statute of limitation period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_IncomeTaxStatuteOfLimitationsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800316528368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">$ 31,412<span></span>
</td>
<td class="num">$ (15,824)<span></span>
</td>
<td class="num">$ (10,289)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="num">(1,017)<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Orphan Drug &amp; General Business Credit</a></td>
<td class="num">(35,674)<span></span>
</td>
<td class="num">(29,363)<span></span>
</td>
<td class="num">(44,114)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">6,433<span></span>
</td>
<td class="nump">7,859<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Foreign Source Income Subject to US Tax</a></td>
<td class="num">(5,644)<span></span>
</td>
<td class="nump">16,878<span></span>
</td>
<td class="nump">6,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(4,051)<span></span>
</td>
<td class="num">(16,971)<span></span>
</td>
<td class="num">(16,238)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_IncomeTaxRateReconciliationSection162Limitation', window );">Section 162(m) limitation</a></td>
<td class="nump">6,577<span></span>
</td>
<td class="nump">6,304<span></span>
</td>
<td class="nump">9,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_IncomeTaxRateReconciliationTaxReserves', window );">Tax Reserves</a></td>
<td class="nump">18,043<span></span>
</td>
<td class="nump">15,530<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount', window );">Intra-entity transfer of assets</a></td>
<td class="num">(18,752)<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
<td class="num">(852,338)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim', window );">CARES act carryback claim</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,201)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance/deferred benefit</a></td>
<td class="nump">7,851<span></span>
</td>
<td class="nump">6,821<span></span>
</td>
<td class="nump">6,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2,837<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">8,015<span></span>
</td>
<td class="num">(11,270)<span></span>
</td>
<td class="num">$ (903,026)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 116,299<span></span>
</td>
<td class="nump">109,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">Dutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_IncomeTaxRateReconciliationSection162Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax rate reconciliation section 162 limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_IncomeTaxRateReconciliationSection162Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_IncomeTaxRateReconciliationTaxReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax rate reconciliation tax reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_IncomeTaxRateReconciliationTaxReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318086224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Company Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Net deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 20,657<span></span>
</td>
<td class="nump">$ 25,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">555,319<span></span>
</td>
<td class="nump">564,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses, reserves, and prepaids</a></td>
<td class="nump">88,697<span></span>
</td>
<td class="nump">72,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">836,402<span></span>
</td>
<td class="nump">875,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">103,212<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">49,472<span></span>
</td>
<td class="nump">50,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">7,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">22,726<span></span>
</td>
<td class="nump">25,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(116,299)<span></span>
</td>
<td class="num">(109,176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,571,539<span></span>
</td>
<td class="nump">1,514,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Net deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference', window );">Joint venture basis difference</a></td>
<td class="num">(745)<span></span>
</td>
<td class="num">(1,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_DeferredTaxLiabilitiesRightOfUseAssets', window );">ROU Assets</a></td>
<td class="num">(5,347)<span></span>
</td>
<td class="num">(6,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(58,897)<span></span>
</td>
<td class="num">(54,498)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(66,127)<span></span>
</td>
<td class="num">(64,221)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 1,505,412<span></span>
</td>
<td class="nump">$ 1,450,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities related to joint venture basis difference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800317378736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal R&amp;D and orphan drug credit carryforwards</a></td>
<td class="nump">585,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">186,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal R&amp;D and orphan drug credit carryforwards</a></td>
<td class="nump">152,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">Dutch | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">$ 38,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321338624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 205,095<span></span>
</td>
<td class="nump">$ 182,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">26,762<span></span>
</td>
<td class="nump">23,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">(Deletions) Additions for tax positions of prior years</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">(Deletions) Additions for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 232,856<span></span>
</td>
<td class="nump">$ 205,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800316591792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss), basic</a></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="nump">$ 854,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: Interest expense, net of tax, on the Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income/(loss), diluted</a></td>
<td class="nump">$ 141,561<span></span>
</td>
<td class="num">$ (64,080)<span></span>
</td>
<td class="nump">$ 862,342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">185,266<span></span>
</td>
<td class="nump">182,852<span></span>
</td>
<td class="nump">180,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">188,963<span></span>
</td>
<td class="nump">182,852<span></span>
</td>
<td class="nump">191,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per common share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per common share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Issuances under equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember', window );">Common stock issuable under the Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800321574352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)</a></td>
<td class="nump">16,483<span></span>
</td>
<td class="nump">20,785<span></span>
</td>
<td class="nump">7,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Issuances under equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)</a></td>
<td class="nump">8,148<span></span>
</td>
<td class="nump">12,450<span></span>
</td>
<td class="nump">7,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember', window );">Common stock issuable under the Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)</a></td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderTheConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800318985264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION AGREEMENTS (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,096,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,846,275<span></span>
</td>
<td colspan="2" class="nump">$ 1,860,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmrn_FirdapseMember', window );">Firdapse | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_RoyaltyRateLowerLimit', window );">Royalties on net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_RoyaltyRateUpperLimit', window );">Royalties on net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember', window );">Exclusive Licensing Agreement For Tralesinidase Alfa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense', window );">Investment in equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember', window );">Exclusive Licensing Agreement For Tralesinidase Alfa | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Minority equity ownership</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bmrn_AAndRKuvanAgreementMember', window );">A&amp;R Kuvan Agreement | Merck Serono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bmrn_AAndRKuvanAgreementMember', window );">A&amp;R Kuvan Agreement | Merck Serono | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone', window );">Business acquisition contingent consideration potential cash payments upon achievement of sales milestone | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bmrn_PegvaliaseAgreementMember', window );">Pegvaliase Agreement | Merck Serono</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition, cash paid | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration potential cash payments upon achievement of sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Minority Equity Investment in License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_RoyaltyRateLowerLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty rate lower limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_RoyaltyRateLowerLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_RoyaltyRateUpperLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty rate upper limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_RoyaltyRateUpperLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmrn_FirdapseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmrn_FirdapseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bmrn_AAndRKuvanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bmrn_AAndRKuvanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bmrn_MerckSeronoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bmrn_MerckSeronoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bmrn_PegvaliaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bmrn_PegvaliaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139800327332432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimated long-term loss contingency</a></td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones', window );">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</a></td>
<td class="nump">762.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment</a></td>
<td class="nump">225.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitment expected to be paid in 2023</a></td>
<td class="nump">188.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramOneMember', window );">Early Stage Development Program One | Third Party</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones', window );">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</a></td>
<td class="nump">381.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramTwoMember', window );">Early Stage Development Program Two | Third Party</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones', window );">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</a></td>
<td class="nump">$ 210.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>bmrn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bmrn="http://www.bmrn.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20221231.xsd" xlink:type="simple"/>
    <context id="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide07883475384c4c80f688861264b837_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ice67fd0aa4d94423bd076cc3f7bfe365_I20230216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="ib246871d78d94c228e7dec2d91f453a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6babf135cae34564ae9f1313c802cf9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58108302281b46cebd5051fdc34011c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8381a40443874d71bf070c391e0c7639_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i730600aac0774220b24184631d3ca45a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6cf6d8813654851864101d16af22c9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6719d1697cfe461fbe7e1476076d5020_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib09dd10764f7419a9a4650c424edaaf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10b42c69baf241b0b203d3fa4c47e397_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9ebf8a2e2374a5abb965688a2d10d21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6098bafbae9d4819be0567307e54bb0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i662d4660c31e4fe99f786fb1fb315bcb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia44e8bd9c9b746cfbddaca2a0eb336ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic12190384e734edabd0ce99df1427a69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie70ebaa31f544fe581553f2fab670db8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i037d2ed2bca94a4db141fccb8f4098cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i094472930d474e9db0bb25616669cfaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i778dfb0b1c9b4191b55f82d31f87abfb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib45678d32ad246c5bc437806356fe440_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff477083f4d346f6ac8e1fca2a77ac95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a3fd3335b8041b9b3010fb2ffa6e213_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4626a538858248e5b6ffc8ab8d43cffc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb05616fee644133b5237b50cb6c2646_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d0c42bea91a4dc2a7a17b7338db6938_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4d7235bf19146b596b6df0be03b57f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1d3e943b1074224a9e5025c4dcc0935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4d353eb18df493b84f05bd498c9b00b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f810b0c8fb345f4bfb8bcbade131882_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4459fe0e1d3a4f18891f7db2ecc5a055_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i436459593c174d1e9727d5e56761f15e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0d3c22869c8421394b488a8626e5406_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i808e908af0344804823d766893b68cc5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i104acad50b8a4571a58be492b9d7df86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib54cd08c98774db68e3cb795308fff9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d01a3eb633442b8a24963b9a15b0f21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7875a67714c6452c84f63885164473d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id485da7dafae40ddabd0f37725dd651a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia23b0b2b780d494282ba40678c605752_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if02848a53e7a45cba266b90b81b13c5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba09bd3b78014fbfa684be4eb9247536_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1fb34c9bea594b0eabc679077dde1e28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02be9ecdb8dc4d27a02fe43f8746d284_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i297dbbe3b39e4ab6a4b37e0a86515b1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4230919f8e50464c89c33c99ae0bba5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba0c13891df446e79adeb971585c3cb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7c5b90e497444cab72b951983c3c835_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ab00f1aa61d4a799d6596e92e9ea772_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84b7329ecd8e4081bb41b08925e77b86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfee12a83d534677a3997b39f21b3db2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f07c323c9ed43ab9344a7d19cd1632a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadd55ebfa48d4b8e91fb580564bc2ebf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52310aa2a3a247b697aa20cecbad91fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f6c3ef715354e01be0ce46fef7ade7d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6eedfe89ea9847a1b1177eebb3b74933_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8b1e6d47d184565b72aec37b1bad113_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d169bd2b3f74f53a7bf1f5cccef2259_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bea8c595cc8498f897680fba3204460_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3293e8e2731d413a88a25a0d3bb69545_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i623384117ca2486288e722c61f359369_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71e5affca8dd4c6290c3e523c042ca61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id44211095b6f4687bae28103060052c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4068777477954ecd9a0dcd931dbcab88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4983aee6ed6f40a097f55f2b514fc899_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i301449ebc7e54567b1a8e9d3529a7296_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3429f515a1f74193939e9ed2c23c5c04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60b853a38b944bfea4923c8120facacb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14c8137f742a475fbc0a9c6d4094825e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41682380abc342c0a800728472affb1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i160b43862b4443b8b71abb1941361269_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7401b5a80acd48d992723aa4414c7abe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i561448975fb740788726f49b7214216d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie97ca426a1d5427cadae21dbf77cd8be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff7dfd70a907429b878635ece7bc1fd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a7f65a195224b5d827cb975542f273c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4df4ef5fd4294091833bfc00f71675ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a56284d386d47d5b5eb46c28db68c52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i529f551790304de7a1f979501912d7bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94ae8ab120e1442b9b2b47f85170d9db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i465f964e015842ad9df73023d86585b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c6c18d583ad4920abd1d0bcfedc9627_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6943ad4dcf614dd68d73dc3e5298e4f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:AcquiredIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c33f2a42d5842a59975b6b1c2729669_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:AcquiredIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f59e0944d0043aa8bbc9c5903fda1f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:TechnologyTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47f772ec89c942a7a3e166b25c359f88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:TechnologyTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7317f10ceb0c4e0cb47f102d6347f258_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:RepurchasedRoyaltyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff2619b7b15f451e8c6ceb0626894102_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:RepurchasedRoyaltyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18b044b28769473fa1bf7da098b3d52e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:LicensePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i596215e6117a4f52b5c0d7d97a1ef282_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmrn:LicensePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie41fa8108fc04c34b1787046ebcdad40_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i674d0d14122b41c48b74ae0001c8fd9d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1c89fa21a6740b4ae70eb14c57b4658_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdd0df068ef64e57beb016ebea921ad8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib04df3be9f9247e0a45ecf03bf54bdcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifba77569d60840a79ea41ac5cfaf6073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a01c0ded34748d0bce2340302388477_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib586210770d7493e9072422b6c53e69d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9296d886772647e196d034a5c7da7e16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic38d7d015d9641a2afccceaff3825715_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb0f8b8eab5543b8a5874a2155f9b22e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41a6bb5565934ac188f62eb1cf6acf5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a99600f7613497d89438354f0bada80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i521cb957123a469e9a9db648b7ecd32d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53ba21556ac84294bfa877f64bdd66f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3380a5d1065a44fe975fa8e9b0e091ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0b02b6e13e842f682a38f22a659d47f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f45be8b0d354e1e8b7391f4a5dd0d20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i079459cd9ea04678bb91caba28143414_D20221006-20221006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <context id="i9644565e09324c2bbebec177f02b7bc7_I20221006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bmrn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia23981085b84481d8fc2be75b9fbd5db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if37f7a71be894ef6bba5307f5c4f92c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46791bdce16445e6898c45c3fd47dc0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb2e8fd98e264368a035b1b756757df5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i474ce592912e4ee484fa06718d15d2fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i499a122963a44c19831951e9e567eaa7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ed072224703463aac2c7d7482c6ffb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4446cd995b344e0ba108320ca62f991_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91f9d3b26b0d4fe587d64e56b034ed55_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bmrn:AllowancesForReserveForCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i846fa6c590bb43c9b2c023bbeee9119a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id956bf9fc1b44873ab5ad29095686daa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63ce1991d8464caba76b61ad0d0a2227_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d3183b154e44b52ba30e133758be6a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c0827b42d3347d0afe4307d1f64a381_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1697a254339d443f8484e8d6d3c078e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ef36079c8034aeb9d95e92fa8da0e7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32b8aa0219e04f549a524810fe170d31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i843b636f6cdd45d9ad126a7384b4f37e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18e735b9eb6e4c1083bb535a258b00f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab9bbb374233424ba61bcc6ed8300a30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2160a34a98f34909b7b6148fe186d3a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f15a50eebbd49b0a6ac560862776c4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ffc1b1354b24fe9ba6f0f76f2c77735_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b6b493cf9db47da80212141f81c1d71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2f30189483c422fa011c8cb6d4922bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04dda45e829740f79226f6631d6049eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb9c061692ee4459bfff0add9bcd50a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1808bc04910249a8a0f00222d3bf7e02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff430fafcf154f4e812f7d333d1d8d7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb05d919991b4e81a5d5ffacd7d4969b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd451bf195104b4fa89b348031fa3c06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief4aad42990645598a710e3fdc875927_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59fa5863ad174cd78a94e49878481b58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf63f31c217048c0b0893f82f7a57cc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i361e100279e84b2abd489b481fc38b7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bc636c5add94dcdb064bdd55b0154bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idce35887d4b441e7903b44b39adba651_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia1739c85dcaf415cacb59ea7ea04ca80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bbdcfdf6d7f44e98151b2323cc59a91_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4cc530299f847d189a72330922c67cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07b156ee48534e11b0e4ec467c89f063_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6630e8205694223b373923bba0b4d10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5347e22ccf064748b88e50f6bd0c2161_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03ad5d6c2ce54eb183ff3585f491d96e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8acf9e28afb48f9a9b97f6033ce470a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i049d9f5eac174d9e9fb8daaf63a40764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfd631e0c0be404fbdac1dbda30f94fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5453050b0674bbfaf495fdbe38838bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78357676b9ad4a62990f8ad0e3be1b8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i701ea9c137b743d5b8fbcf9a4516ee31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e05c8915f6d4424a51797377fec49d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia81ef93ba75f4c7f9a65f2262abc826c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2949967682844b40b3939cf685911572_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i120af3133b724435b609f48a754ddc28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id034c5704d704b1899e0fe63a9b16d85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0459695791c54a5c9470c16c53c5e1b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea5945041fd04f8fa60d89c188909d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idda7870ff3904fafa6c5f6898f8ea22b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc8c32dfdf364e6ebfeca0e2dbe52145_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7810729b64f4f81ab7e6d7951dd41db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2249a32749024298ac14d49e5abc5209_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i535f35b9a823419bbd09b248cdd5f011_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9fcf787fd284d24881b86f72e6d9c06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i929eedfedb93483daed0c9feb18c8083_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0aabd222ee0c445889bc6c55761ef645_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if99c4348a7ed4696a2143a068c963e32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5daf35554b6a433a843510d389717d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib36660209faa4d7ab26ebb76638229b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86ac5b26310a44ef85642267c702776c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="icc7acb734e7a46518521815a0e658880_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i97af8e39d55a45988666e9a615166ab0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e3514162b114cccb5bd4903da892d79_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ica62b7ca7a3f4aee8d2b64beac63adb6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76aebdd53eb84ceab8638e5fb1ff8e9b_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i3efb3be452cd4b8cb7fea7f3c05ba63e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e306c702cbb420eac9580746df9ae30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i618baef4a9c943558fad300e0bb46e9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6872ed12f9164d05957167fd36693e24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ec53576eff54be9aebf7078e363312e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d0e209b4cba44c8841984717c05fdfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e6451fcf8cc42d5bbe8a6ac07fa5fa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aa7db8b29e9457f93217ca8c42e681e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d843487721d43b7a6cf7175f69e01fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd5dbb579b5f418cb0577509240e9084_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8ff2134016c43a48d2be70284677ab2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70c36fee11624160a9a8777da81c0128_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd084d19fafe4eb08800335bbaa0fdb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied7e67f5a5634503ad5879c8009f97f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3d2704044e74eec86232f6b5bbfa0a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmrn:AccumulatedGainLossFromOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83d540593f644f2cb082a24558b3f758_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i107111d003394f429df9bc3b7e72083a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i766158ee331f4b6dad23cc139f408d52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice70b2f98d8f46ee95e52f2e5d8735cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbbfc39daa5e4e86b8925b3c91e0a20f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifcc10f3a93ae418882d57641c30e6fa2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91a42714856349788ac98ef18c9c4eec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia58bdf6d90d34e0e9c7db18bf1df4dc1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i509d47fe3d174696acd23ae2feb9495e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6660ddacf84f446083b9e0ca5bce39fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ef27eef923e434e862de91ae5beafca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e7292c071f44cd4ba482c581dbba9e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f2ca389fb2d47f3991717f9e5b9757c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b179a96cee8425daa243c6ec126fa90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieded801c64bf44adb38c0af09661c7f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6399581bf17e49c697410cb0a73c682c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0245c8a131434573a4579c1ffa6fe178_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68a7a34d6b8446b19864867ebc10546d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ff71e7217274546b0d948f39fc97420_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i503208303f7343d68d5b53c7fb08f251_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7039784a43724956bd81fdb85ade56d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if32233365d594b308746b274d89d9e5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae042974731b47fa8462f91e2b1ce268_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6b2cd85806b4c09a10ee05befb288eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec738639a3694be7b566566f59fefda1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7afae57055d2464bbca1472128e2dd4b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifde566a1a304443a9740252495984863_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b889898bba94b54af9a9335b9b82b62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia344194268dd43fd989b6b04a378902f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i826dd83d81b24084b26e5b5cc42493b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie581ba1d1b064e6986a21f9ea9fdc7a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib31425f01f73430a9a3aec5dfc86da0d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id209fbaf4cd14f198010a1f4ff75159e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52ed09d29aa1432fa6575525ede1e854_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0770f55d5c104f969b9acc886090f5fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iacafee45f91e46ebb714c46c2ff89823_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59f95dec71974a66bbde2f90b523281c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9e42fce28b14ebbb8a5a4411c1433ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94e7695ed7954a5fb9f808089e78a85d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5749604fcebc42ada76e2e1b582da09c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40ade8d0054c45b997b2f2e5fb9e1490_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4553d6d08ef849c8a72048bc17b8ed75_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idca4f3f8044a4465aad5cc36317e02b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i692965d349e34f3ea4acc8a50f53276d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63e7463435974d1d98101460b30a9c62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoAndThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i843ac21f80f24e97b5709f27f83dc60c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6558cc5ad3094460971e3ff939e6623a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe58d8557902475b9ecb613007413f59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2aadf30296f940eeb46c2095e3ef8568_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b5fa7ec2b1541f2a9aecd40ae5ca28b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fea8ab604b143e89c4c4066ac2d10d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05278f7e11d545918819b0e5fd3de8f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ede14dcb48b4252953a1349a4dcdcd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc3eff93ecba4e9ab0b751bba0479273_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0d4996c3e9141c19bf5436bd1dfe088_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6853f1a77d1449f9e25fc0db6cfd462_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic617813345644c10af3fae918e7bce97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4183315e314d4360bb0502134885d9dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia93e432edc5048a0ac3ab95326ff5424_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i174e38c567da498382c9b71cd2020fac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bmrn:IndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="i1445253420474375b7efe62ace67131e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i934a6fe3c5d2413c87067ea339f198cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a9c60963aff483fa114c7b304603a7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e06e2017d4b477e9b69593553036531_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12938f6823a94b1c837db430e15262c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c5dda00a8514dd59ad5007c3cd8c578_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b264f9c740640838312c3dbd938c92e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6dfc5eb6e4d04a6390d4d537c078c61f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab5359457de041eaba77b73a3803bcfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77524339bb424d85b4d57ae104a84f24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:RestrictedStockWithServiceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cf62fa1ecfd497ea4311496211dd174_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1572514829d644a68de7022821a70b1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id16e0033fc1948dc9e1fa09a786eaa23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f2a458d9fee49c6a103d0f775c380d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77a7c1018d1f4444a8560a5468103fba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardNonGAAPIncomeTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26584ec2b88147ebad7a6bf69b3d15d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardCoreOperatingMarginTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27f49f0589db4d3fa2f9f5fb5d1f4355_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bmrn:ShareBasedPaymentAwardStrategicGoalTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied0260b6f7eb4a6fb48d30eb32daec80_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee4d086842524837b758a134e20de2d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i595951030a5d4e73a012f1be549c5e5a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2b318a52937403fb847cf89e01b77ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ca3a5fc58404fb58b979773eea67088_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i933002237df241fbaa8a2f1845212112_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2538be3f0665431588d86ae58a47b620_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f9a014bff6d4b1096c43e4334589a74_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47b49962d5a640488eada80fa0f8ae01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b7db90010f7454bb02b375d36208b18_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i974da25672b24547a1fb86cd010d66a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifae9719aaf7c4895bd6972ec9d5a1cdd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia46fdf7486a84e9f90ef98b86432eb8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee705d880c0c46c7808d9be2b86c9f85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia481385bca9741cb9627136de2e3b7a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1119551690714a89bd7e32c788eedfae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia88d13cac03446da910f4bdda092a94d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba90d1418dc34fbcbca22b21986af64b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58aaac40a42b4a7fb111583b886ae23f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f1866f0f98b4968a4a0b7d8ec1061c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i94d5c058dd7843b99ec211cfd4eaef44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id45d9cb0ae984b8a895192c71ec4dc6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if33b1905895a4c0d9c697f26aee83f66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64eb5ac7ff2c441b8532f7bcb1ddab8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmrn:BiomarinRetirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0acf8a65e32646eda1218b113bbf892f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i501529bab97849e78084830bdba9baf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7af5d8557d8a40ae8beee5eedec3c302_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaba0e7db091b498bbec2338419da0c3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i942bc095adee430bad3ee06049a4834a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7eeb745948249f9b5df95030b886512_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55d2632b90814ba38f50774fec161236_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableUnderTheConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3436f033fc741c0ad3de97901f0af87_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i5762589687004ef6b263f4cd981bf8cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c68988441f541e28fb1eef7917f2f8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:AAndRKuvanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i894b46e6d24741dca61467eef21c957a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:AAndRKuvanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69e41e511f7c45fab191013826ff05c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:MerckSeronoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bmrn:PegvaliaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bmrn:FirdapseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i35e08db3d4814a13a6b9f06ccc018757_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5349719ab5245ecb53681104dd48921_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>bmrn:tranche</measure>
    </unit>
    <unit id="segment">
        <measure>bmrn:segment</measure>
    </unit>
    <unit id="employee">
        <measure>bmrn:employee</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF8yLTEtMS0xLTc3NjM4_99b3a40a-0df8-4c79-b174-9088523ba171">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF8zLTEtMS0xLTgyOTQ2_f5bc20e5-6a2b-4c4d-8d26-42ce70fee556">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF80LTEtMS0xLTc3NjM4_11bb98dd-f125-46d7-bda8-ed964a68b179">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl80L2ZyYWc6NTFlMTYyMzc3YTFmNDc3Y2E1Y2ZmMjYzMWUyMTAyN2EvdGFibGU6YjQ0NmM5ZDQ0ODU5NGVjNDhiYjI0NTdjZDNlNGQ0YzQvdGFibGVyYW5nZTpiNDQ2YzlkNDQ4NTk0ZWM0OGJiMjQ1N2NkM2U0ZDRjNF81LTEtMS0xLTc3NjM4_9975fbf1-2caf-4463-af47-0049ac13ecea">0001048477</dei:EntityCentralIndexKey>
    <bmrn:SpanOfOfferingPeriod
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13">P24M</bmrn:SpanOfOfferingPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i529f551790304de7a1f979501912d7bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945">P1Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i94ae8ab120e1442b9b2b47f85170d9db_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9">P1Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="icc7acb734e7a46518521815a0e658880_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8yMTQyL2ZyYWc6ODIxNGVmOGVjMTJlNDk2Nzk3YTA2NjBlNTA3ZDhjMjEvdGV4dHJlZ2lvbjo4MjE0ZWY4ZWMxMmU0OTY3OTdhMDY2MGU1MDdkOGMyMV8zODQ4MjkwNjk3Njk1_57296b6e-53a2-4c5c-9419-0969537f7b00"
      unitRef="number">0.0072743</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8yMTQyL2ZyYWc6ODIxNGVmOGVjMTJlNDk2Nzk3YTA2NjBlNTA3ZDhjMjEvdGV4dHJlZ2lvbjo4MjE0ZWY4ZWMxMmU0OTY3OTdhMDY2MGU1MDdkOGMyMV8xNjQ5MjY3NDQyMjI0_99103c13-7f7c-4daf-b139-d45fd58f77da"
      unitRef="number">0.0080212</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <bmrn:IncomeTaxStatuteOfLimitationsPeriod
      contextRef="i529f551790304de7a1f979501912d7bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NjY_b6dc29f0-a3a7-485e-8db1-2fd76231c141">P3Y</bmrn:IncomeTaxStatuteOfLimitationsPeriod>
    <dei:DocumentType
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF85Nw_276847f5-5792-4f3b-b379-75cc1b84358b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6MTM2MGU0MTQwNDM0NDk4NWIyMGQ5OWNkZDJmMGMzZjIvdGFibGVyYW5nZToxMzYwZTQxNDA0MzQ0OTg1YjIwZDk5Y2RkMmYwYzNmMl8wLTAtMS0xLTc3NjM4_16776248-afe5-412c-930e-0883c5d917a3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTcyMTU_e0781f0c-f332-40de-985f-48281bead921">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTcyMTU_c76f428a-e7cf-4b63-8851-99628025ebb0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YmYzMDVhNjlkOGFiNDkyYWJlODc2ODFmZTNiNjA4YWMvdGFibGVyYW5nZTpiZjMwNWE2OWQ4YWI0OTJhYmU4NzY4MWZlM2I2MDhhY18wLTAtMS0xLTc3NjM4_d6f711e8-083f-469d-a2ac-adc446fcb10d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yNzI_0bf0fe16-8884-424a-9d26-6c0c99cdac7e">000-26727</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yODg_51898ec6-27c6-45a6-9eb8-0581e8184ce8">BioMarin Pharmaceutical Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8wLTAtMS0xLTc3NjM4_1be002b3-2809-4e0a-aabb-d66199a40bc7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8wLTMtMS0xLTc3NjM4_2ee5570d-7daa-4cc5-9c39-5c026f699d43">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTAtMS0xLTc3NjM4_238d48ae-a981-4d3f-9078-61243a84b074">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTEtMS0xLTc3NjM4_7e97e571-6fc8-4170-b4bd-4e23b3a78ffe">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTItMS0xLTc3NjM4_5012ffbb-94f7-43da-8fe2-97f80304fcdf">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6NzZlZWU1YWM5NTkyNGE0ZTg3MjI0MTQ4MTMxYWFiMjQvdGFibGVyYW5nZTo3NmVlZTVhYzk1OTI0YTRlODcyMjQxNDgxMzFhYWIyNF8zLTMtMS0xLTc3NjM4_f2783805-ff4b-4af8-959a-7edcf0e5add1">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zNDk_b5148955-1ad6-40b9-991b-56c717f62f4b">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zNTM_8363cf33-0d34-4fb8-9b57-94a7940956c1">506-6700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTAtMS0xLTc3NjM4_f618c5a5-1ed2-48db-b92c-cdfd39bae452">Common Stock, par value $.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTItMS0xLTc3NjM4_bacd4558-6f84-4e01-81e5-5523a1985e7b">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6OGEyZTBiNzg3NTNmNDc0NDlmMzNjYWU3MDEzZDU3YjIvdGFibGVyYW5nZTo4YTJlMGI3ODc1M2Y0NzQ0OWYzM2NhZTcwMTNkNTdiMl8xLTQtMS0xLTc3NjM4_ad858214-fbcc-4cf8-9434-a855fae4fda3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF82NjU_a3c66453-177d-4698-aa74-599ee783566a">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF84MTg_af09ee6a-3250-4f96-bf71-c90849bf931a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8xMTcy_bcc9651f-0d18-4fe5-996c-a75e66e77098">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8xNTAw_befd0847-e8c7-4195-9eef-682ace4a9b98">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8wLTAtMS0xLTc3NjM4_ca47bd2b-8c33-4522-aaf1-026841c92aa1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8xLTUtMS0xLTc3NjM4_4bb89103-8208-4bfc-a776-a9a25546c80b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGFibGU6YWY0Yzk5MTBlM2U2NGZkN2E4YzUyMTFlZTVkMGUxNDQvdGFibGVyYW5nZTphZjRjOTkxMGUzZTY0ZmQ3YThjNTIxMWVlNWQwZTE0NF8yLTUtMS0xLTc3NjM4_f3665aab-8848-412f-9506-c1d401aa5b19">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zMzAx_2793640a-621a-49d0-9b85-8a5e9f986de8">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF81NDk3NTU4MTQyMjY3_aac0a125-7e5f-464a-8a6e-addc906a0c8c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ide07883475384c4c80f688861264b837_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yNzMx_19babcc5-2373-4316-a3c3-85ebad6225b2"
      unitRef="usd">9000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ice67fd0aa4d94423bd076cc3f7bfe365_I20230216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8yODY1_ebfb458f-f3d3-4f57-a59f-9b4b8c96451b"
      unitRef="shares">186528784</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xL2ZyYWc6ZGVhYTc0OTZhYzEyNDNkYjg2ZmU4MTBjNTQyZjQwYmQvdGV4dHJlZ2lvbjpkZWFhNzQ5NmFjMTI0M2RiODZmZTgxMGM1NDJmNDBiZF8zMzAy_e0ee86a4-01fa-488c-9405-0c9e0339c20f">Specified portions of the registrant's definitive proxy statement for the registrant's 2023 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2022, are incorporated by reference under Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMDMvZnJhZzpmYTBjODZlYTkwYmQ0OGIwYjc4NjQ3MTFlZmFiZDFlYi90YWJsZTpkZWYzZGMxOWZjNjk0Zjk1YTdlMDMxNzhlMWRlNTQ4OC90YWJsZXJhbmdlOmRlZjNkYzE5ZmM2OTRmOTVhN2UwMzE3OGUxZGU1NDg4XzQtMC0xLTEtODM2ODcvdGV4dHJlZ2lvbjpkMzc0MjkzNTA3NzY0ZDg5YWNlNDFlMmQ3MDIwY2ZjOF8xMTU0NDg3MjA5MTc2Nw_3edb11b0-593c-41f9-ad36-341cd1057a7f">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjEvZnJhZzpmYjJjMjg2ZjhkYmM0NmQ4ODRkZGRmZmI1ZTkyYTllOS90ZXh0cmVnaW9uOmZiMmMyODZmOGRiYzQ2ZDg4NGRkZGZmYjVlOTJhOWU5XzEwMjkw_88ba79ac-9b2e-4435-9d8c-a3d92d175101">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjEvZnJhZzpmYjJjMjg2ZjhkYmM0NmQ4ODRkZGRmZmI1ZTkyYTllOS90ZXh0cmVnaW9uOmZiMmMyODZmOGRiYzQ2ZDg4NGRkZGZmYjVlOTJhOWU5XzEwMjkx_feffa6d2-5301-4391-bd3d-6655fed18528">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMS0xLTEtNzc3OTc_50374629-7d8b-4092-b7a6-7f56add573b3"
      unitRef="usd">724531000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d"
      unitRef="usd">587276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMS0xLTEtNzc3OTc_ddc3fd21-9233-4c05-b9ef-9889d8f22efb"
      unitRef="usd">567006000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMS0xLTEtNzc3OTc_4025b165-f693-4c0a-a6a5-a1f8a480d891"
      unitRef="usd">461316000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792"
      unitRef="usd">373399000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMS0xLTEtNzc3OTc_c7ece4dc-f922-46b5-a131-f2af92d394bc"
      unitRef="usd">894083000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4"
      unitRef="usd">776669000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMS0xLTEtNzc3OTc_b6988fc5-62a3-4f2b-8bc1-d6492f166abe"
      unitRef="usd">104521000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7"
      unitRef="usd">110442000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMS0xLTEtNzc4NDk_a90077cf-2fc7-4c9d-b8ef-97d31b00fbda"
      unitRef="usd">2751457000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f"
      unitRef="usd">2274385000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTEtMS0xLTc3ODQ5_55168085-6de2-4c5e-bd25-eb488bb71bb0"
      unitRef="usd">333835000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTEtMS0xLTc3ODQ5_9ffb949b-c0c0-4bd1-8cfe-857ce9a4a9cc"
      unitRef="usd">1073366000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c"
      unitRef="usd">1035461000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTEtMS0xLTc3ODQ5_e312e60c-625e-413b-9a34-64987c9185bd"
      unitRef="usd">338569000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563"
      unitRef="usd">388652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTEtMS0xLTc3ODQ5_eb83e6a7-2f99-41be-99e5-e79a077cbf17"
      unitRef="usd">196199000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd"
      unitRef="usd">196199000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTEtMS0xLTc3ODQ5_d60f7829-7fa5-4b27-9fc9-802c479dd042"
      unitRef="usd">1505412000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c"
      unitRef="usd">1450161000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTEtMS0xLTc3ODQ5_295b3ad8-f4eb-4828-929a-35df815481c2"
      unitRef="usd">176236000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d"
      unitRef="usd">152121000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTEtMS0xLTc3ODQ5_e31c416c-d505-4b8b-8b29-1e56583fd28c"
      unitRef="usd">6375074000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889"
      unitRef="usd">6004772000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTEtMS0xLTc3ODQ5_df65dbd7-b6b7-4a31-97d9-2b378455edf4"
      unitRef="usd">572959000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee"
      unitRef="usd">498265000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTEtMS0xLTc3ODQ5_56535373-e5ee-49a6-bfe2-2d608757d6bf"
      unitRef="usd">15925000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f"
      unitRef="usd">48232000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTEtMS0xLTc3ODQ5_bb72c213-1632-480c-b2af-f6811a7587d9"
      unitRef="usd">588884000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571"
      unitRef="usd">546497000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTEtMS0xLTc3ODQ5_f939d0c8-d2d5-44df-8c03-8d0a36fd153e"
      unitRef="usd">1083019000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0"
      unitRef="usd">1079077000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTEtMS0xLTc3ODQ5_2d5352ff-0c09-4e1b-a5d4-3fe18ed78f9f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848"
      unitRef="usd">15167000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTEtMS0xLTc3ODQ5_b339e999-fb3d-46ba-b04c-83c8217c610e"
      unitRef="usd">100015000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee"
      unitRef="usd">98362000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTEtMS0xLTc3ODQ5_896aef71-3a20-4c48-ad8b-49b10f3e39da"
      unitRef="usd">1771918000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da"
      unitRef="usd">1739103000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk4Mg_66900386-1fa5-40cb-b877-e6099b28e0c0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk4Mg_a8b20e8c-6b96-4830-8743-b88bacd3c371"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5MA_0c6a31e8-8fd3-444f-bf91-974ee21fb33b"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5MA_ef4148a1-6004-4654-8a6b-2a7f7e022b0e"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5NQ_245740a9-be8a-47af-a538-13e28fb5872f"
      unitRef="shares">186250719</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyNzk5NQ_28422acb-db26-440a-b799-c8746f3ef14e"
      unitRef="shares">186250719</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyODAwMg_d77ed93f-0d83-4136-8f34-78a0a9301fd9"
      unitRef="shares">183912514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTAtMS0xLTc3NjM4L3RleHRyZWdpb246Y2NkYjlkZDRmODhjNDJmMmJmODBjNjJlMmIzNDg2YWFfMTA5OTUxMTYyODAwMg_e028824f-f3d0-4961-9c7a-29f279931fa8"
      unitRef="shares">183912514</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTEtMS0xLTc3ODQ5_343b1f3d-21e4-4d71-923a-efbe385f61c1"
      unitRef="usd">186000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb"
      unitRef="usd">184000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTEtMS0xLTc3ODQ5_5b32d9ba-a4de-46bf-94cd-d375360b286a"
      unitRef="usd">5404895000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565"
      unitRef="usd">5191502000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockIssuedEmployeeStockTrust
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTEtMS0xLTc3ODQ5_a2251964-78f2-4fc1-91ef-a7397dd49586"
      unitRef="usd">8859000</us-gaap:CommonStockIssuedEmployeeStockTrust>
    <us-gaap:CommonStockIssuedEmployeeStockTrust
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2"
      unitRef="usd">9689000</us-gaap:CommonStockIssuedEmployeeStockTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTEtMS0xLTc3ODQ5_a99205bc-f8cd-41c6-809f-453bc40af43c"
      unitRef="usd">-3867000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824"
      unitRef="usd">14432000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTEtMS0xLTc3ODQ5_f0109836-0b96-4942-8e76-89e3d595927c"
      unitRef="usd">-789199000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db"
      unitRef="usd">-930760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTEtMS0xLTc3ODQ5_83e56efc-8f91-46b0-ad94-fc4aa0099875"
      unitRef="usd">4603156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d"
      unitRef="usd">4265669000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTEtMS0xLTc3ODQ5_74582a0b-d6b3-487b-895f-8935c4c92ba9"
      unitRef="usd">6375074000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224"
      unitRef="usd">6004772000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItMS0xLTEtNzc4ODg_3707e77b-520b-4c87-99f4-a8f54d528bab"
      unitRef="usd">2042025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItMy0xLTEtNzc4ODg_5c4431a0-eaf6-4669-9251-8db91d826ae2"
      unitRef="usd">1783498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941"
      unitRef="usd">1805861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtMS0xLTEtNzc4ODg_534dbf48-e1d2-4c32-92e5-5e66c1080fb9"
      unitRef="usd">54014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtMy0xLTEtNzc4ODg_df991375-653d-464c-acbc-98a39f8e53f8"
      unitRef="usd">62777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd"
      unitRef="usd">54594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtMS0xLTEtNzc4ODg_71c78a97-07f7-403c-b3bf-a0996e1b9271"
      unitRef="usd">2096039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtMy0xLTEtNzc4ODg_653675b8-3901-46b2-9fb5-86d46185abbe"
      unitRef="usd">1846275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a"
      unitRef="usd">1860455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtMS0xLTEtNzc4ODg_f02dd3e6-6438-4ab2-bc6e-96ab54cf5f8c"
      unitRef="usd">483669000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtMy0xLTEtNzc4ODg_6126fcfd-51b4-48c8-87e5-159fddef79be"
      unitRef="usd">470515000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78"
      unitRef="usd">524272000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctMS0xLTEtNzc4ODg_b7befc02-d917-48d0-8911-37ab77d321c4"
      unitRef="usd">649606000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctMy0xLTEtNzc4ODg_72d60f1e-58c4-4162-bc5e-6133924fdc6b"
      unitRef="usd">628793000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a"
      unitRef="usd">628116000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtMS0xLTEtNzc4ODg_d1a24c13-7fd4-4de2-a130-d2dfd3e6ea3b"
      unitRef="usd">854009000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtMy0xLTEtNzc4ODg_1f80de7a-0045-4bcf-be90-2d0e4064a62f"
      unitRef="usd">759375000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408"
      unitRef="usd">737669000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bmrn:IntangibleAssetAmortizationAndContingentConsideration
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktMS0xLTEtNzc4ODg_c96c56aa-cf5c-423c-a6e6-f0f75890c450"
      unitRef="usd">67193000</bmrn:IntangibleAssetAmortizationAndContingentConsideration>
    <bmrn:IntangibleAssetAmortizationAndContingentConsideration
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktMy0xLTEtNzc4ODg_9fc3d78a-5d2d-43f5-a9f0-1e9bccfbac72"
      unitRef="usd">69933000</bmrn:IntangibleAssetAmortizationAndContingentConsideration>
    <bmrn:IntangibleAssetAmortizationAndContingentConsideration
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df"
      unitRef="usd">66658000</bmrn:IntangibleAssetAmortizationAndContingentConsideration>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTEtMS0xLTc3ODg4_9de99928-fb9f-46d5-9482-7bc8de10ec8a"
      unitRef="usd">108000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTMtMS0xLTc3ODg4_fcb915ba-9808-4855-8205-d1be901664a7"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de"
      unitRef="usd">52820000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:CostsAndExpenses
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTEtMS0xLTc3ODg4_31d1dada-473c-4b0e-97f9-d7864e87bfd8"
      unitRef="usd">1946477000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTMtMS0xLTc3ODg4_8c25245f-d971-4d6e-bed2-fe6e7115238b"
      unitRef="usd">1928616000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02"
      unitRef="usd">1903895000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTEtMS0xLTc3ODg4_9537b582-9846-4995-81d4-4170a382a00f"
      unitRef="usd">149562000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTMtMS0xLTc3ODg4_1260145f-b706-442b-863e-2cfdd2fdb1ac"
      unitRef="usd">-82341000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7"
      unitRef="usd">-43440000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTEtMS0xLTc3ODg4_1f310a23-fd3d-4b5e-ba58-b9fdde6c2fef"
      unitRef="usd">18034000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTMtMS0xLTc3ODg4_8486fe8a-b5fd-4e3a-9348-097fd85e1299"
      unitRef="usd">10482000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67"
      unitRef="usd">16610000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTEtMS0xLTc3ODg4_be8f7be3-933e-4b12-96fd-59a038bebedb"
      unitRef="usd">15970000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTMtMS0xLTc3ODg4_9044248f-aa5d-425f-ba46-98788ba70339"
      unitRef="usd">15337000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c"
      unitRef="usd">29309000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTEtMS0xLTc3ODg4_3780955c-b848-4587-a07f-0b2559a9bac0"
      unitRef="usd">-2050000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTMtMS0xLTc3ODg4_fb7604de-e686-48e3-974a-8fc1edbddadf"
      unitRef="usd">11846000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de"
      unitRef="usd">7142000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTEtMS0xLTc3ODg4_9635c08b-9666-4ece-9ab3-db57927ca89d"
      unitRef="usd">149576000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTMtMS0xLTc3ODg4_a9231661-f46f-4755-9b93-964748c4db87"
      unitRef="usd">-75350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251"
      unitRef="usd">-48997000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTEtMS0xLTc3ODg4_8e13ad60-34c7-4941-82e0-962718b2997c"
      unitRef="usd">8015000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTMtMS0xLTc3ODg4_a82d66c7-a485-46ad-9745-c5bab963da77"
      unitRef="usd">-11270000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7"
      unitRef="usd">-903026000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTEtMS0xLTc3ODg4_1a2738a7-b941-4b01-acb7-5d4a6daf1c90"
      unitRef="usd">141561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTMtMS0xLTc3ODg4_cf8fe135-b45c-438b-93c1-1666935a0e27"
      unitRef="usd">-64080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8"
      unitRef="usd">854029000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTEtMS0xLTc3ODg4_2022af65-b355-41a7-a119-1612c8109092"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTMtMS0xLTc3ODg4_df4a8e30-c193-457d-8397-1651395f1153"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb"
      unitRef="usdPerShare">4.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTEtMS0xLTc3ODg4_4096be7e-5d38-4cc7-8139-d43f3b28eac3"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTMtMS0xLTc3ODg4_55eeba34-96a3-4236-a4b2-83bb3360cfe4"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c"
      unitRef="usdPerShare">4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTEtMS0xLTc3ODg4_de549fdc-42fc-448e-8fa9-5e76a6c5b30f"
      unitRef="shares">185266000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTMtMS0xLTc3ODg4_617068be-fd3a-496a-bfa2-80c43f6e6bc4"
      unitRef="shares">182852000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8"
      unitRef="shares">180804000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTEtMS0xLTc3ODg4_73ffc4ac-ca09-43c6-8daa-ba3c03bb7386"
      unitRef="shares">188963000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTMtMS0xLTc3ODg4_126619be-8942-45a2-bfba-cb77ba5f3d4c"
      unitRef="shares">182852000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b"
      unitRef="shares">191678000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtMi0xLTEtNzkyNDE_7a9de89a-90ae-40f9-b132-8d12978e8f45"
      unitRef="usd">141561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNC0xLTEtNzkyNDE_29871c29-014b-4bf6-b5fc-185d1e2529ba"
      unitRef="usd">-64080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398"
      unitRef="usd">854029000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1Njg2_8b6e46b3-5005-4225-91ac-f781b32cb349"
      unitRef="usd">3247000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1Njk1_b079e72f-4e14-4f98-94aa-bd310ec1c2b2"
      unitRef="usd">1596000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjoxMmM1YmIzNTcxZjk0NGY1YmVlN2FhZjMxM2FjYjYwYl8yMTk5MDIzMjU1NzA2_1485d52f-39ec-46f0-9a47-33159da4c86c"
      unitRef="usd">-227000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtMi0xLTEtNzkyNDE_51c7e0e4-050b-4369-a9b0-02934bc333d9"
      unitRef="usd">-10720000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNC0xLTEtNzkyNDE_5b727b3c-3104-4749-92cc-6f8a376ec402"
      unitRef="usd">-5262000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9"
      unitRef="usd">749000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1NjYx_dc36df92-2476-4f97-84a4-6b93fa022625"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1Njcw_3dec9f4d-bb11-4abb-a5c4-eca5d0f74d56"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphYjhhOGI1YjVkZGY0ZjA2ODY4MjI2YzRlYThjZDE3N18yMTk5MDIzMjU1Njc1_cb17eb7e-a5cf-4b6f-a5d8-96d97b1c842e"
      unitRef="usd">127000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtMi0xLTEtNzkyNDE_8b1a779d-e8cd-4b7e-a3cc-920fe270ecf2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNC0xLTEtNzkyNDE_33b6b852-c550-43e5-8f8f-37dc1617b0e4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427"
      unitRef="usd">425000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtMi0xLTEtNzkyNDE_692283a1-15cc-4f58-9954-1a894ccd89a4"
      unitRef="usd">-10720000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNC0xLTEtNzkyNDE_b58cc42f-6e0f-41a8-b44a-739e92210195"
      unitRef="usd">-5262000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad"
      unitRef="usd">324000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_445f57b8-0b76-4e9c-8e0d-0f1bc25d36fe"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_4f5a1fa0-e9dd-4b1a-9a03-5ecf85e2523b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjphOGRhOGU3ZjBmNTI0N2M0Yjg1YzE3M2Q2Y2ZjZDZjMl8yMTk5MDIzMjU1NjY3_a4c98ba8-cdc9-4d65-b7a1-97b0b7dc343e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtMi0xLTEtNzkyNDE_cddf0bed-c669-4407-80d4-2eadb3ade80f"
      unitRef="usd">29045000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNC0xLTEtNzkyNDE_60958c4c-c2d1-4cf1-b404-e794aa06371e"
      unitRef="usd">34379000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd"
      unitRef="usd">-23462000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_489d7cad-1b15-4807-879d-a0da393add8f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_7ad5e0a9-ec3f-47b0-a5ca-067d8ec62ee2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMC0xLTEtNzc2MzgvdGV4dHJlZ2lvbjo5NzQzNTQ0ODU0ODM0MmU3YTdlNjEzYjE0ODUwNjQ5YV8yMTk5MDIzMjU1NjU1_9c8253db-aa03-4f10-87bf-a4bcb2298a73"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktMi0xLTEtNzkyNDE_7db4d784-81f7-4dd7-9a78-a647820e5eab"
      unitRef="usd">36624000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNC0xLTEtNzkyNDE_de4e75e9-7a5e-4904-8efb-8debe7f486e7"
      unitRef="usd">-1454000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363"
      unitRef="usd">13180000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTItMS0xLTc5MjQx_fd5d018c-4092-4de2-9323-9595f8722758"
      unitRef="usd">-7579000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTQtMS0xLTc5MjQx_00085046-f7c2-4b09-b4ac-086a991771fe"
      unitRef="usd">35833000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61"
      unitRef="usd">-36642000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <bmrn:OtherComprehensiveIncomeLossOtherNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTItMS0xLTc5MjQ5_8ebc107c-8762-4625-911e-31932e7743cc"
      unitRef="usd">0</bmrn:OtherComprehensiveIncomeLossOtherNetOfTax>
    <bmrn:OtherComprehensiveIncomeLossOtherNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTQtMS0xLTc5MjQ5_5a22f0f4-8073-45a8-94d9-2d65fc3e44b9"
      unitRef="usd">0</bmrn:OtherComprehensiveIncomeLossOtherNetOfTax>
    <bmrn:OtherComprehensiveIncomeLossOtherNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942"
      unitRef="usd">15000</bmrn:OtherComprehensiveIncomeLossOtherNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTItMS0xLTc5MjQ5_2d937cb7-7a2c-4d54-93df-cdb2eb2a0abf"
      unitRef="usd">-18299000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTQtMS0xLTc5MjQ5_3ab16787-5784-4fa5-9eb5-a76686f41309"
      unitRef="usd">30571000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a"
      unitRef="usd">-36303000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTItMS0xLTc5MjQ5_0190d1f5-e7f9-44d1-9633-10d41ab4068d"
      unitRef="usd">123262000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTQtMS0xLTc5MjQ5_4d73f081-cbbc-41f0-9271-193cebc4abc5"
      unitRef="usd">-33509000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177"
      unitRef="usd">817726000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItMS0xLTEtNzc5Mzc_704b7ded-acf3-4d1f-9490-6a83fcd08a0d"
      unitRef="shares">183913000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItMy0xLTEtNzc5Mzc_a4a4a3ed-f076-4a14-aa60-03714d3e907d"
      unitRef="shares">181741000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib09dd10764f7419a9a4650c424edaaf4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzItNS0xLTEtNzk0MDk_2e95c066-bc56-4208-bdda-823b803aaa7c"
      unitRef="shares">179838000</us-gaap:CommonStockSharesOutstanding>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares
      contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtMS0xLTEtNzc5NzM_335ebde4-f67a-4ab9-9617-54c27035eaf3"
      unitRef="shares">2338000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares
      contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtMy0xLTEtNzc5NzM_53c7ff7b-be2f-4d3e-8092-5f0ab492a59f"
      unitRef="shares">2172000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares
      contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMtNS0xLTEtNzk0MDk_d762a4b0-4a3d-4ed4-bd47-e1580e6a4e56"
      unitRef="shares">2421000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtMS0xLTEtNzkzMTQ_ee673289-3ebc-409c-8e46-b49262c4d9fb"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtMy0xLTEtNzc5NDA_83ca7caa-15ad-43eb-9751-b5fde6e9e95d"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQtNS0xLTEtNzk0MDk_f64ea1af-ab80-41c2-ac51-93d02e00b074"
      unitRef="shares">518000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i10b42c69baf241b0b203d3fa4c47e397_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtMS0xLTEtNzc5NDQ_0b263f01-106f-4d74-890e-6fe9bd5260fb"
      unitRef="shares">186251000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtMy0xLTEtNzc5NDQ_1fdfccc7-0712-407c-b4cc-37a95e82e2c1"
      unitRef="shares">183913000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzYtNS0xLTEtNzk0MDk_aafc4542-1a19-4aee-9a21-4d7f2a9276a9"
      unitRef="shares">181741000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic9ebf8a2e2374a5abb965688a2d10d21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtMS0xLTEtNzc5NDk_2c043f7c-f298-41da-8cbd-d9f253ecdc35"
      unitRef="usd">4270740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6098bafbae9d4819be0567307e54bb0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtMy0xLTEtNzc5NDk_dbce3999-dc1a-4b38-a1be-f483151f5dc4"
      unitRef="usd">4106002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i662d4660c31e4fe99f786fb1fb315bcb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzgtNS0xLTEtNzk0MDk_312bb075-9e56-4baf-9619-003c3d15440f"
      unitRef="usd">3122381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c"
      unitRef="usd">-5071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065"
      unitRef="usd">-5071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia44e8bd9c9b746cfbddaca2a0eb336ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTEtMS0xLTc3OTU0_c417c0fa-7a87-480a-aa07-4c53c55b2d04"
      unitRef="usd">4265669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic12190384e734edabd0ce99df1427a69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTMtMS0xLTc3OTU0_96754669-c138-4427-8fb3-ba283d34f462"
      unitRef="usd">4100931000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie70ebaa31f544fe581553f2fab670db8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEwLTUtMS0xLTgyOTcy_a2b3b693-0a31-45c2-845d-276684ede287"
      unitRef="usd">3122381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTEtMS0xLTc3OTc3_3aafa8db-bf6a-4a19-9a7b-b05c8085d450"
      unitRef="usd">184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTMtMS0xLTc3OTc3_640560e9-30c4-4ada-96e0-447659cd2657"
      unitRef="usd">182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib09dd10764f7419a9a4650c424edaaf4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEyLTUtMS0xLTc5NDA5_da951ede-3bb2-441d-9f86-f2e6357f0bfc"
      unitRef="usd">180000</us-gaap:StockholdersEquity>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i98d1a016ca3a4c69a349db7f7c1103ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTEtMS0xLTc3OTc3_52f13e60-59e3-488c-8bee-20964b55dcb5"
      unitRef="usd">2000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i7a1a8981eafe44238f412c8f86d52328_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTMtMS0xLTc3OTc3_ed49788c-aada-47b4-9b70-70441a526c5d"
      unitRef="usd">2000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i978beaa306864ac9bc1af193bc48b6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzEzLTUtMS0xLTc5NDA5_f8b0da66-2d3d-4c27-8993-5f518b8b0623"
      unitRef="usd">2000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <us-gaap:StockholdersEquity
      contextRef="i10b42c69baf241b0b203d3fa4c47e397_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTEtMS0xLTc3OTgx_44286ebe-63cf-4d13-8ea0-241952933bdc"
      unitRef="usd">186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6cf6d8813654851864101d16af22c9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTMtMS0xLTc3OTgx_1fc85ec3-3feb-41c1-9aa5-4ae8529b5e33"
      unitRef="usd">184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6719d1697cfe461fbe7e1476076d5020_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE1LTUtMS0xLTc5NDA5_396d3c03-605d-4ea4-80a9-a81378e1f840"
      unitRef="usd">182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i037d2ed2bca94a4db141fccb8f4098cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTEtMS0xLTc3OTg1_412828e4-af9f-49b8-a288-4676f4fe38b4"
      unitRef="usd">5191502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i094472930d474e9db0bb25616669cfaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTMtMS0xLTc3OTg1_a0741258-731e-4053-8d7e-80cd9c597727"
      unitRef="usd">4993407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i778dfb0b1c9b4191b55f82d31f87abfb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE3LTUtMS0xLTc5NDA5_033909fb-d5b9-4991-8fed-87f39e1c739c"
      unitRef="usd">4832707000</us-gaap:StockholdersEquity>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTEtMS0xLTc3OTg5_1f7cf5c9-2898-42f4-818b-dd73bca9e216"
      unitRef="usd">14328000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTMtMS0xLTc3OTg5_c28712fb-cfc4-4cfe-b239-13b67bcda7b0"
      unitRef="usd">3389000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE4LTUtMS0xLTc5NDA5_337ad288-e0ff-490d-afd6-a110f50b75ff"
      unitRef="usd">27275000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTEtMS0xLTc3OTkz_27e89f60-8913-4fd9-80f3-1472ffd5b56e"
      unitRef="usd">199895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTMtMS0xLTc3OTkz_be6f77be-1eab-48af-9f26-051736b014a0"
      unitRef="usd">194856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzE5LTUtMS0xLTc5NDA5_570f3d02-4234-4fa2-8718-7cf93a67dab6"
      unitRef="usd">183547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTEtMS0xLTc5NDA5_b0015f9b-6d8c-432b-a582-68535e192283"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTMtMS0xLTc5NDA5_ffe9d073-31d9-4fad-907f-7443ce08e66a"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIwLTUtMS0xLTc5NDA5_2a3559f6-643e-4937-a290-9d451cfb5218"
      unitRef="usd">50000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i64e098ce7f6e43ceb6d36ee3f304bd07_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTEtMS0xLTc3OTk5_a66599ea-ec5a-4cce-ae76-a5205bcfe95a"
      unitRef="usd">830000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i75b8ef1fb8ab4d39a7d20eb606a8ad5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTMtMS0xLTc3OTk5_ed8154c9-87db-4d3c-8a78-ccf502c01944"
      unitRef="usd">150000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i803dfcba67b04d938248e0f634c5fb3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzIyLTUtMS0xLTc5NDA5_8743f32a-64ff-4584-b549-dbfffc36a281"
      unitRef="usd">122000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <us-gaap:StockholdersEquity
      contextRef="ib45678d32ad246c5bc437806356fe440_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTEtMS0xLTc4MDAz_f6f93b89-27a8-4127-847b-ab17a64df02d"
      unitRef="usd">5404895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i037d2ed2bca94a4db141fccb8f4098cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTMtMS0xLTc4MDAz_83c8fc29-b968-47dc-80be-a6ff5bd65028"
      unitRef="usd">5191502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i094472930d474e9db0bb25616669cfaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI0LTUtMS0xLTc5NDA5_2f0f7e14-0e77-4eed-8f2d-1c8606c1eb8a"
      unitRef="usd">4993407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTEtMS0xLTc5NDA5_978150d1-5a61-40ab-84ed-e36f00091f30"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff477083f4d346f6ac8e1fca2a77ac95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTMtMS0xLTc5NDA5_97968232-95a5-4058-a2e7-529b94da23c2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a3fd3335b8041b9b3010fb2ffa6e213_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI2LTUtMS0xLTc5NDA5_4281c9cb-414a-45c1-99b7-6be3eb5b2b68"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTEtMS0xLTc5NDA5_cf7dca7d-c349-4525-8602-e501da3bb00a"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTMtMS0xLTc5NDA5_c3b47d3b-4248-468c-a892-c203a791faa2"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI3LTUtMS0xLTc5NDA5_5358d692-f8ff-412f-acf5-31e69a1923a0"
      unitRef="usd">50000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="id14be4e9ea654f79a6326b1573ff96f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTEtMS0xLTc5NDA5_a1c93f90-c9b2-43fd-a2cd-dbaeae3bd30f"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i43fd2acf7e3b409ca1770a1e8f6b35e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTMtMS0xLTc5NDA5_70b89ad7-b188-407f-a3b9-6af78e27a43d"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i578e199c163941bdb9f243c6fac6a43d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI4LTUtMS0xLTc5NDA5_5c55159d-17bf-4635-b3d1-3c538a52095a"
      unitRef="usd">-50000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockholdersEquity
      contextRef="i4626a538858248e5b6ffc8ab8d43cffc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTEtMS0xLTc5NDA5_3042e569-b811-4ae6-a5e6-655b0c9bfa64"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb9d3c043e92435c8e5e38b6d34c23c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTMtMS0xLTc5NDA5_c2642529-6e60-49b0-affc-34205f7ba76b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff477083f4d346f6ac8e1fca2a77ac95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzI5LTUtMS0xLTc5NDA5_d4044c09-925f-490c-9459-9b2d9747cc55"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTEtMS0xLTc4MDEz_943586ba-5405-4b8d-a067-37c065f65935"
      unitRef="usd">-9689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb05616fee644133b5237b50cb6c2646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTMtMS0xLTc4MDEz_eb17fddd-9478-49af-a1e5-35bc7a12a446"
      unitRef="usd">-9839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d0c42bea91a4dc2a7a17b7338db6938_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMxLTUtMS0xLTc5NDA5_8079440b-2a5f-4851-a9aa-05b0a1625e75"
      unitRef="usd">-9961000</us-gaap:StockholdersEquity>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="ie4d7235bf19146b596b6df0be03b57f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTEtMS0xLTc4MDEz_ab44c8a2-ce32-4bca-8668-1538979d92ec"
      unitRef="usd">-830000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="ie1d3e943b1074224a9e5025c4dcc0935_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTMtMS0xLTc4MDEz_dfb281c9-88ac-4b42-91bb-a5c989fa0dab"
      unitRef="usd">-150000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="ic4d353eb18df493b84f05bd498c9b00b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzMyLTUtMS0xLTc5NDA5_326d1293-4569-496b-88ee-f32e456306c4"
      unitRef="usd">-122000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <us-gaap:StockholdersEquity
      contextRef="i2f810b0c8fb345f4bfb8bcbade131882_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTEtMS0xLTc4MDE3_fc56ee9b-890b-41f8-adce-fedceca821fd"
      unitRef="usd">-8859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5da9cf2fd4b4736b1e4afbeea1103aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTMtMS0xLTc4MDE3_29d74c19-321a-498a-ba6b-15e9891fc0bf"
      unitRef="usd">-9689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb05616fee644133b5237b50cb6c2646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM0LTUtMS0xLTc5NDA5_37cf9b36-d6b4-4c0f-925d-69dd254b4eba"
      unitRef="usd">-9839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4459fe0e1d3a4f18891f7db2ecc5a055_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTEtMS0xLTc4MDI2_5fc52b32-2ce2-4605-95a1-bc348ebca612"
      unitRef="usd">14432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i436459593c174d1e9727d5e56761f15e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTMtMS0xLTc4MDI2_85685170-679d-4eb5-baa8-bed89cadcf3c"
      unitRef="usd">-16139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0d3c22869c8421394b488a8626e5406_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM2LTUtMS0xLTc5NDA5_40586205-45c8-49a5-89d7-cfd11039adb9"
      unitRef="usd">20164000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i808e908af0344804823d766893b68cc5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTEtMS0xLTc4MDMw_e2faaf52-8d21-4adc-a7fa-4cba3a808d95"
      unitRef="usd">-18299000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i104acad50b8a4571a58be492b9d7df86_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTMtMS0xLTc4MDMw_aad35db4-4fab-4ec5-8d46-ed6aa8672069"
      unitRef="usd">30571000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib54cd08c98774db68e3cb795308fff9f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM4LTUtMS0xLTc5NDA5_14e0f96a-03f4-4c52-84db-aff0f66e737b"
      unitRef="usd">-36303000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i2d01a3eb633442b8a24963b9a15b0f21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTEtMS0xLTc4MDMw_c584c672-f2ce-46a6-a38f-e9bf865593e8"
      unitRef="usd">-3867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7875a67714c6452c84f63885164473d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTMtMS0xLTc4MDMw_ada6355a-ef4a-42ac-b9f3-9cd005aa3ff9"
      unitRef="usd">14432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id485da7dafae40ddabd0f37725dd651a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzM5LTUtMS0xLTc5NDA5_d4018978-482d-436d-b75e-01323696791c"
      unitRef="usd">-16139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia23b0b2b780d494282ba40678c605752_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTEtMS0xLTc4MDM0_6f4bd12d-9ec5-4728-aedb-f12d8b3fc020"
      unitRef="usd">-925689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if02848a53e7a45cba266b90b81b13c5a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTMtMS0xLTc4MDM0_2bdb21c9-e548-441e-8bb5-7959bc2b47b9"
      unitRef="usd">-861609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba09bd3b78014fbfa684be4eb9247536_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQxLTUtMS0xLTc5NDA5_afa8509a-74eb-431c-83be-2f80a0bcf568"
      unitRef="usd">-1720709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fb34c9bea594b0eabc679077dde1e28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTg3Mzgw_1ff60593-9663-42af-bc09-e04b3029c0a4"
      unitRef="usd">-5071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02be9ecdb8dc4d27a02fe43f8746d284_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTg3Mzgw_a4abb31b-9e16-4ed5-ab3a-359d486f990e"
      unitRef="usd">-5071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i297dbbe3b39e4ab6a4b37e0a86515b1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTg3Mzgw_8c601828-61e3-4d2c-88a4-dd8b9ae8b398"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4230919f8e50464c89c33c99ae0bba5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTEtMS0xLTg3Mzgw_5d8e3bc7-c1e1-4d0d-a8d3-2af9dc030e9c"
      unitRef="usd">-930760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba0c13891df446e79adeb971585c3cb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTMtMS0xLTg3Mzgw_b9a9ae8d-ba6c-4568-8e88-2d50f3843393"
      unitRef="usd">-866680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7c5b90e497444cab72b951983c3c835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTUtMS0xLTg3Mzgw_c28ee63e-bb3e-47e6-bf2b-0f0e394ce12f"
      unitRef="usd">-1720709000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9ab00f1aa61d4a799d6596e92e9ea772_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062"
      unitRef="usd">141561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i84b7329ecd8e4081bb41b08925e77b86_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b"
      unitRef="usd">-64080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfee12a83d534677a3997b39f21b3db2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96"
      unitRef="usd">854029000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i0f07c323c9ed43ab9344a7d19cd1632a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTEtMS0xLTc4MDQ0_65318ea5-427c-4653-9b44-d58e06846735"
      unitRef="usd">-789199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4230919f8e50464c89c33c99ae0bba5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTMtMS0xLTc4MDQ0_260a5e36-1323-4016-af29-3a660dc2945b"
      unitRef="usd">-930760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba0c13891df446e79adeb971585c3cb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ0LTUtMS0xLTc5NDA5_7d829830-bcbd-4950-808c-07e761cf9d40"
      unitRef="usd">-866680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTEtMS0xLTc4MDQ0_b81bc193-58d8-4b60-a045-e8a5c2b7b958"
      unitRef="usd">4603156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTMtMS0xLTc4MDQ0_81d4aaa7-efb9-45b8-a24d-f552a3d2eb75"
      unitRef="usd">4265669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic12190384e734edabd0ce99df1427a69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQ1LTUtMS0xLTc5NDA5_3710c1a7-d309-4ebb-a816-c54da7a35b0a"
      unitRef="usd">4100931000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItMS0xLTEtNzgwNjc_a9f3800b-0002-4b60-a1ad-994df6fe3f70"
      unitRef="usd">141561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItMy0xLTEtNzgwNjc_7250722d-989b-47a6-8988-46a90ff53a94"
      unitRef="usd">-64080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa"
      unitRef="usd">854029000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtMS0xLTEtNzgwNjc_2a87fbee-fe37-48df-906d-8bed21379491"
      unitRef="usd">101969000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtMy0xLTEtNzgwNjc_f84b1a59-1037-4090-b8f3-224867437f4e"
      unitRef="usd">108039000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9"
      unitRef="usd">105172000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtMS0xLTEtNzgwNjc_8c33bef5-fcdc-4257-a26f-59fd40366b6d"
      unitRef="usd">4117000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtMy0xLTEtNzgwNjc_4395c075-2597-4d5e-b562-2b8eecb7e5a1"
      unitRef="usd">4146000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8"
      unitRef="usd">16511000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtMS0xLTEtNzgwNjc_1edfe25e-23f9-4afb-8bec-1348a1012da1"
      unitRef="usd">-3043000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtMy0xLTEtNzgwNjc_81ac69cf-9868-4b87-a28a-f3423c57d928"
      unitRef="usd">-5155000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca"
      unitRef="usd">-567000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctMS0xLTEtNzgwNjc_67a8f1e8-1228-45eb-ab88-a14631d311d5"
      unitRef="usd">196308000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctMy0xLTEtNzgwNjc_8d0056ea-832c-42d1-8cb2-b182214b1a69"
      unitRef="usd">197263000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae"
      unitRef="usd">189711000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtMS0xLTEtNzgwNjc_796c5ab1-6c96-4a3d-b600-6a36fdff657e"
      unitRef="usd">108000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtMy0xLTEtNzgwNjc_03543073-9f00-4be8-944a-485004f04b37"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d"
      unitRef="usd">52820000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:InventoryWriteDown
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktMS0xLTEtNzgwNjc_2cd456dd-17e7-4a94-8df4-e6fabe509688"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktMy0xLTEtNzgwNjc_c7569333-8f43-4faf-bc53-c11bed922648"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051"
      unitRef="usd">75609000</us-gaap:InventoryWriteDown>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTEtMS0xLTc4MDY3_7b373c6d-9e84-4812-afea-d02594643c7d"
      unitRef="usd">-52087000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTMtMS0xLTc4MDY3_1f859630-8c89-45a9-ab4a-7ead0cae1288"
      unitRef="usd">-15608000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e"
      unitRef="usd">-889993000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTEtMS0xLTc4MDY3_58ccd9ac-70b9-41c2-9004-517c4cf5a644"
      unitRef="usd">14287000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTMtMS0xLTc4MDY3_cb7e9239-efdc-4190-9474-38cd7417a745"
      unitRef="usd">1810000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5"
      unitRef="usd">-8011000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTEtMS0xLTc4MDY3_404e12f5-9c01-4afb-bbf3-287b4808fc29"
      unitRef="usd">1704000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTMtMS0xLTc4MDY3_21cb5172-6db9-464e-8e2e-2e6c53e0f952"
      unitRef="usd">8026000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTEtMS0xLTc4MDY3_44b4cca4-abdd-4052-a8e5-d78f198f3bad"
      unitRef="usd">2043000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTMtMS0xLTc4MDY3_76194aa8-7d61-463c-a01e-6c92a264dcb7"
      unitRef="usd">2629000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd"
      unitRef="usd">997000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTEtMS0xLTc4MDY3_61d78bc4-81a7-4c1a-af00-7c33016890af"
      unitRef="usd">82033000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTMtMS0xLTc4MDY3_7e7e341e-28f6-4479-a6bd-c945d5c3f99b"
      unitRef="usd">-65574000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e"
      unitRef="usd">59035000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTEtMS0xLTc4MDY3_2f6a56ee-e6f6-414f-9504-4dcb4f3c5a99"
      unitRef="usd">68264000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTMtMS0xLTc4MDY3_ab7eb697-5b64-489f-9344-c6b86e4c97a8"
      unitRef="usd">35060000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605"
      unitRef="usd">61151000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTEtMS0xLTc4MDY3_09ffecb3-84e8-4a30-8d3e-e9002aaa847d"
      unitRef="usd">-7822000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTMtMS0xLTc4MDY3_125d4cf3-7986-4669-bf7d-7d24ec3f885c"
      unitRef="usd">-29760000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f"
      unitRef="usd">-18312000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTEtMS0xLTc4MDY3_369b5cda-9bb3-43fb-b7d8-df874b439d4d"
      unitRef="usd">19859000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTMtMS0xLTc4MDY3_ef653303-0223-4cfd-b978-cf0848285e66"
      unitRef="usd">6593000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94"
      unitRef="usd">29007000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTEtMS0xLTc4MDY3_53082fab-d7ba-4ad3-9b22-4cd21c49d175"
      unitRef="usd">59018000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTMtMS0xLTc4MDY3_b3c697b9-ae84-49cb-b9d1-1d1decb9ddbe"
      unitRef="usd">15689000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57"
      unitRef="usd">-87025000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTEtMS0xLTc4MDY3_addf8fc2-347a-41f7-b9ea-1ab579036347"
      unitRef="usd">6933000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTMtMS0xLTc4MDY3_48a4180a-e520-40e0-993e-c2f59bc54906"
      unitRef="usd">-3336000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62"
      unitRef="usd">-7029000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTEtMS0xLTc4MDY3_f8408e0c-6100-48ae-bc56-b3acdf583049"
      unitRef="usd">175902000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTMtMS0xLTc4MDY3_bc4288e3-81d7-4e54-98a4-b32dde778d6c"
      unitRef="usd">304536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7"
      unitRef="usd">85365000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTEtMS0xLTc4MDcz_7d295b32-c395-4d68-8d40-39d81e402d02"
      unitRef="usd">120959000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTMtMS0xLTc4MDcz_a107d964-b25e-424e-9d48-544979c0d38e"
      unitRef="usd">95578000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274"
      unitRef="usd">114312000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTEtMS0xLTc4MDcz_32bffd50-f04f-4be7-829c-640e61d063e5"
      unitRef="usd">619995000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTMtMS0xLTc4MDcz_8648e345-4d1e-4857-859c-26f7f919db63"
      unitRef="usd">691049000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608"
      unitRef="usd">555834000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTEtMS0xLTc4MDcz_2696ba18-d076-4b79-bd04-40c2254bb937"
      unitRef="usd">611809000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTMtMS0xLTc4MDcz_06f74c2d-2997-45a4-b880-4c61dcb46f06"
      unitRef="usd">937143000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea"
      unitRef="usd">529663000</us-gaap:PaymentsToAcquireInvestments>
    <bmrn:ProceedsFromSaleOfNonfinancialAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTEtMS0xLTc4MDcz_5aab6e1c-482e-424d-bb22-2d7b4a2fd18d"
      unitRef="usd">103325000</bmrn:ProceedsFromSaleOfNonfinancialAssets>
    <bmrn:ProceedsFromSaleOfNonfinancialAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTMtMS0xLTc4MDcz_d821f955-48c3-4ae3-af02-2504d8ae3f2a"
      unitRef="usd">0</bmrn:ProceedsFromSaleOfNonfinancialAssets>
    <bmrn:ProceedsFromSaleOfNonfinancialAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66"
      unitRef="usd">67159000</bmrn:ProceedsFromSaleOfNonfinancialAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTEtMS0xLTc4MDcz_632d0db3-a134-4a3f-91f4-c8ac1c5ff1f7"
      unitRef="usd">10581000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTMtMS0xLTc4MDcz_98044676-00f2-4347-b1df-6f3bf44de5b8"
      unitRef="usd">23647000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f"
      unitRef="usd">23207000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTEtMS0xLTc5NTY3_7c55e330-15a2-4d1f-9b61-9c6711617c12"
      unitRef="usd">0</bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable>
    <bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTMtMS0xLTc5NTY3_5eda4fe5-5918-445d-915a-0db4b642287b"
      unitRef="usd">0</bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable>
    <bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06"
      unitRef="usd">8709000</bmrn:PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTEtMS0xLTc4MDgw_470253c0-9136-471e-a301-8a2cfbab2f7c"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTMtMS0xLTc4MDgw_8483a985-7e7e-4e30-ac7a-f336607114c9"
      unitRef="usd">994000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4"
      unitRef="usd">723000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTEtMS0xLTc4MDgw_d0245b0b-51d6-48ac-bcb5-6d12169fe457"
      unitRef="usd">-20029000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTMtMS0xLTc4MDgw_e8714e9f-d36f-4ba0-b726-159d7a805e00"
      unitRef="usd">-366313000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e"
      unitRef="usd">-53621000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTEtMS0xLTc4MDg0_c81a2081-1950-477c-accc-a92dca14c497"
      unitRef="usd">69333000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTMtMS0xLTc4MDg0_584324d6-d88b-46ba-aa22-66a7a79b57e1"
      unitRef="usd">49194000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d"
      unitRef="usd">71913000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTEtMS0xLTc4MDg0_b53bae34-6b0f-443e-a1a2-08ee3fdd91fc"
      unitRef="usd">54283000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTMtMS0xLTc4MDg0_036b2fc4-8701-4d8e-9681-d2ec7bb7edfd"
      unitRef="usd">45805000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657"
      unitRef="usd">44638000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTEtMS0xLTc5NTg4_4106be7c-7c83-4507-93ec-65f965fc85d6"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTMtMS0xLTc5NTg4_18f4d5b7-c0bf-40a9-8cf9-f13fe856a62a"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f"
      unitRef="usd">50000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTEtMS0xLTc5NTg4_9e011a17-daa8-4afe-ab2e-ff9b5a614c67"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTMtMS0xLTc5NTg4_42f9f089-ad78-4001-a334-32c766a8004d"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4"
      unitRef="usd">585752000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTEtMS0xLTc5NTg4_2f491944-019a-43b5-829a-c7937b2f8573"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTMtMS0xLTc5NTg4_4933a0ba-aecb-4d2d-9438-456e22c893e9"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52"
      unitRef="usd">374991000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTEtMS0xLTk4Mjg1_ab8f910d-2621-4c49-a821-c392c5affd8e"
      unitRef="usd">31095000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTMtMS0xLTk4Mjg1_900c306e-647d-4fa6-b953-5518664559e2"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTEtMS0xLTc4MDk2_f55d3784-59b7-40ef-ad8b-e6dbeb2faa8e"
      unitRef="usd">2605000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTMtMS0xLTc4MDk2_3d1a3dd3-82d7-4a6d-ac36-42a0f67f6f61"
      unitRef="usd">3039000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4"
      unitRef="usd">6918000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTEtMS0xLTc4MTA1_28a705c2-4d0d-493f-aaf2-d644e5125d45"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTMtMS0xLTc4MTA1_ffd42b38-0baa-4ed3-93bf-347af53dfec5"
      unitRef="usd">-398000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTEtMS0xLTc4MTA5_9584cdff-13e9-4fb8-8123-5a57d5eddcf4"
      unitRef="usd">-18650000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTMtMS0xLTc4MTA5_e1522c4e-7537-4109-b3ed-a10f7bcb8375"
      unitRef="usd">-48000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d"
      unitRef="usd">181118000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTEtMS0xLTc4MTA5_421b8d07-56ca-4578-8621-764bbd2b1ce4"
      unitRef="usd">32000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTMtMS0xLTc4MTA5_5767a4d9-41f3-4bff-82a5-bb822a776a13"
      unitRef="usd">-57000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053"
      unitRef="usd">-1150000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTEtMS0xLTc4MTEz_155df6a3-dd48-420b-9681-4d14e40dbd7d"
      unitRef="usd">137255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTMtMS0xLTc4MTEz_daa74b43-8133-459b-94ea-94d1f52d3b9f"
      unitRef="usd">-61882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc"
      unitRef="usd">211712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTEtMS0xLTc4MTE3_52f6c83e-f7c2-49f3-9725-23c5a20a4586"
      unitRef="usd">587276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic12190384e734edabd0ce99df1427a69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTMtMS0xLTc4MTE3_b2f96b26-6e87-4d9e-a31f-256aaf278b6d"
      unitRef="usd">649158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie70ebaa31f544fe581553f2fab670db8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802"
      unitRef="usd">437446000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTEtMS0xLTc4MTE3_da30b457-081b-46d4-a2b6-940526c07eac"
      unitRef="usd">724531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTMtMS0xLTc4MTE3_3fca0474-f2c9-44b8-9cbc-9d89649adae3"
      unitRef="usd">587276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic12190384e734edabd0ce99df1427a69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3"
      unitRef="usd">649158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTEtMS0xLTc4MTI1_856e6c32-90bc-4523-af8c-f227128f0505"
      unitRef="usd">10281000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTMtMS0xLTc4MTI1_04b85eaa-b9af-48ee-9dad-b788fae3af2d"
      unitRef="usd">10395000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6"
      unitRef="usd">12178000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTEtMS0xLTc4MTIx_e81eada0-67cc-4ff1-82e4-608eb47d2059"
      unitRef="usd">54372000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTMtMS0xLTc4MTIx_fb532296-9125-4bb9-9991-005929f74eed"
      unitRef="usd">18153000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d"
      unitRef="usd">8977000</us-gaap:IncomeTaxesPaid>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTEtMS0xLTc4MTMy_59c54177-e89a-4a16-8173-0e599656ea57"
      unitRef="usd">-1482000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTMtMS0xLTc4MTMy_27b30699-d306-4bc3-b3a1-213d75f9e38f"
      unitRef="usd">-4749000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83"
      unitRef="usd">-5184000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTEtMS0xLTc4MTMy_6a353117-411f-4180-8563-69e10fdb71a9"
      unitRef="usd">742000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTMtMS0xLTc4MTMy_abc0a1c7-f48f-4c26-aab9-3829f10fa517"
      unitRef="usd">9428000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f"
      unitRef="usd">-292000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA0_286ce116-4034-4f3c-ba88-3a6ac30021be">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Founded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. ROCTAVIAN (formerly known as valoctocogene roxaparvovec) was granted conditional marketing approval in the European Union (EU) on August 24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company&#x2019;s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Correction of Immaterial Error &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Company became aware of an unrecorded amount due to a third party following the January 2020 sale of the worldwide rights of FIRDAPSE, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. The Company evaluated the materiality of the previously described error from a qualitative and quantitative perspective. Based on such evaluation, the Company concluded that the error was not material to any individual current or prior period, nor did it have an effect on the Company&#x2019;s trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 108, C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;onsidering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Although the effect of the error was not material to the current or previously issued financial statements, the Company has corrected the accompanying Consolidated Balance Sheets, Statement of Operations, Statement of Comprehensive Income and Statements of Stockholders Equity. As a result, the correction decreased 2020 Net Income and increased the 2020 Accumulated Deficit balance by $5.1&#160;million. Consequently, this had the following impact on certain December 31, 2021 balances: an increase to Accounts Payable and Accrued Liabilities of $6.7&#160;million, a decrease to Total Stockholders&#x2019; Equity of $5.1&#160;million, an increase to Deferred Tax Assets of $1.1&#160;million, an increase to Other Assets of $0.4&#160;million and a decrease to Other Long-term Liabilities of $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company&#x2019;s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Marketable and Non-Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument&#x2019;s underlying contractual maturity date and its availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company&#x2019;s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment&#x2019;s amortized cost and fair value at such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory Produced Prior to Regulatory Approval&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;amp;D).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;amp;D and Selling, General and Administrative (SG&amp;amp;A), as appropriate, in the Consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Statements of Operations. Property and equipment purchased for specific R&amp;amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;amp;D in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of life of asset or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20 to 50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing&#160;and&#160;laboratory&#160;equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&amp;amp;D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company&#x2019;s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company&#x2019;s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill is assessed for impairment by comparing the fair value of the Company&#x2019;s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-lived Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify a manufacturing facility for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;amp;A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Capitalized Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt"&gt;identification of the promised goods or services in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt"&gt;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt"&gt;measurement of the transaction price, including the constraint on variable consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt"&gt;allocation of the transaction price to the performance obligations based on estimated selling prices; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(v)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company&#x2019;s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company&#x2019;s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company&#x2019;s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company&#x2019;s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company&#x2019;s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company&#x2019;s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. Such variable consideration includes rebates, chargebacks, sales returns and other incentives. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company&#x2019;s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Commercial Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company&#x2019;s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers&#x2019; limited return rights and the Company&#x2019;s historical experience with returns. Because of the pricing of the Company&#x2019;s commercial products, the limited number of patients and the customers&#x2019; limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Incentives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: Other incentives include fees paid to the Company&#x2019;s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient&#x2019;s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&#160;For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are generally expensed as incurred. These expenses include contract R&amp;amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;amp;D activities, facilities and regulatory costs and R&amp;amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Advertising Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The costs of advertising are presented in SG&amp;amp;A in the Consolidated Statements of Operations and are expensed as incurred. Advertising expenses were $25.2&#160;million, $30.2&#160;million and $29.3&#160;million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;amp;D or SG&amp;amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company&#x2019;s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Purchase Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award and purchase rights under the Company&#x2019;s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13"&gt;twenty-four&lt;/span&gt;-month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company&#x2019;s stock price and may use assumptions regarding a number of complex and subjective variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company&#x2019;s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction losses resulting from remeasurement recognized in SG&amp;amp;A in the Consolidated Statements of Operations totaled $11.4&#160;million, $11.7&#160;million and $9.9&#160;million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#x2019;s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;amp;A in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Notes&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_193" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;17&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for further information on the nature of these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company&#x2019;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during 2022 that the Company believes are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA4_28e11c15-3ad8-4e5d-99d8-e9328ccb8ac7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company&#x2019;s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iadd55ebfa48d4b8e91fb580564bc2ebf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNDUz_acbdeaea-fdc3-4bca-bad3-25b70d08c27a"
      unitRef="usd">-5100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifd25a8e7e67c4faf965abb8067c4c3d3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNDUz_cacf18ce-4fbd-4ba4-8048-7e3b8f01055b"
      unitRef="usd">-5100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3ODA_4c0a2e89-de40-41da-b3af-3751a953343f"
      unitRef="usd">6700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwNDQ1MzYwNTIwNzI1_98f39301-6122-412c-ac54-c11d5664580f"
      unitRef="usd">-5100000</us-gaap:StockholdersEquity>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3OTA_c4795e1f-0205-40c0-9e65-afad76672d18"
      unitRef="usd">1100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM3OTg_6fbcfdcc-964c-416c-9d41-487172e02f3c"
      unitRef="usd">400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if91d4e1f7c95415d8691c79bc47ddb8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM4MDY_92efc5b5-24fb-46be-ac88-708a72bd01c6"
      unitRef="usd">-100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:UseOfEstimates
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTIw_c20ad5d8-357e-44b2-80bd-a5676da181d3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company&#x2019;s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEy_3a7beb78-d062-4aee-8c99-99a86bcecbd8">Cash and Cash EquivalentsThe Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTIz_b12d5600-6a00-4012-995e-42d447fb03e5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument&#x2019;s underlying contractual maturity date and its availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company&#x2019;s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment&#x2019;s amortized cost and fair value at such date.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:SecuritiesOwnedNotReadilyMarketablePolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEw_7e587eda-be69-455d-9d0a-cd0513c9981e">Non-Marketable Equity SecuritiesThe Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.</us-gaap:SecuritiesOwnedNotReadilyMarketablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEz_5d6d98a2-4933-416c-a602-50e7ce29d2ae">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory Produced Prior to Regulatory Approval&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;amp;D).&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE2_04293c2e-8033-4711-b66f-c828b62f39fb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;amp;D and Selling, General and Administrative (SG&amp;amp;A), as appropriate, in the Consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Statements of Operations. Property and equipment purchased for specific R&amp;amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;amp;D in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of life of asset or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20 to 50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing&#160;and&#160;laboratory&#160;equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE3_9861096f-67f1-433e-af9d-9f1023a442d4">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of life of asset or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20 to 50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing&#160;and&#160;laboratory&#160;equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzAtMS0xLTEtNzc2Mzg_b58d615d-8961-4800-9f69-ab3c39ead3a4">Shorter of life of asset or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i52310aa2a3a247b697aa20cecbad91fd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzEtMS0xLTEtNzk2NzQvdGV4dHJlZ2lvbjowNTc2NWUxN2JkN2I0YTFiOWEzYjA4ZWNkZjYwM2M4YV8yMTk5MDIzMjU1NTcy_0d219c1b-d77a-4672-9766-13c39375855c">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1f6c3ef715354e01be0ce46fef7ade7d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzEtMS0xLTEtNzk2NzQvdGV4dHJlZ2lvbjowNTc2NWUxN2JkN2I0YTFiOWEzYjA4ZWNkZjYwM2M4YV8yMTk5MDIzMjU1NTgz_b6485c54-ef4b-4781-9f47-a8fc606f49e1">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6eedfe89ea9847a1b1177eebb3b74933_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzItMS0xLTEtNzk2OTQvdGV4dHJlZ2lvbjo4N2RhN2NkZWY4NWE0YzJjOGJmODU5ZWQzZjI4ZTU3MF8xMDk5NTExNjI3ODA1_65d305c8-7e4a-4b57-8d68-266ca16d1d74">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia8b1e6d47d184565b72aec37b1bad113_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzItMS0xLTEtNzk2OTQvdGV4dHJlZ2lvbjo4N2RhN2NkZWY4NWE0YzJjOGJmODU5ZWQzZjI4ZTU3MF8yMTk5MDIzMjU1NTc3_94dc0a7c-a93f-4f04-824d-cf62b6a0dc34">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0d169bd2b3f74f53a7bf1f5cccef2259_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzMtMS0xLTEtNzk3MDAvdGV4dHJlZ2lvbjplZDA5MGQ4ZWU1NGQ0OTAyYjhiNzk1Y2RlODhkNzhkZV8xMDk5NTExNjI3ODAz_8ca1ae17-24e3-49d8-918f-516c1c0e5e71">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6bea8c595cc8498f897680fba3204460_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzMtMS0xLTEtNzk3MDAvdGV4dHJlZ2lvbjplZDA5MGQ4ZWU1NGQ0OTAyYjhiNzk1Y2RlODhkNzhkZV8yMTk5MDIzMjU1NTc1_56034320-0419-4872-b07d-29cfe2aacaf4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3293e8e2731d413a88a25a0d3bb69545_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzQtMS0xLTEtNzk3MDcvdGV4dHJlZ2lvbjo1ZDFiMmMxYzg5MzQ0ZTE2YjJiM2I2M2M5YWNkZGZiMV8xMDk5NTExNjI3Nzg2_570f1011-f395-43ae-a75a-ab6c547c9c3e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i623384117ca2486288e722c61f359369_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzUtMS0xLTEtNzk3MTQvdGV4dHJlZ2lvbjozMGUxMzExMzI4MjI0MmQ1ODQ0NGI2ZTcyZTU1NmMwNl8yMTk5MDIzMjU1NTcy_af3c58e7-10ad-4b5b-837c-926c608c1ca3">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i71e5affca8dd4c6290c3e523c042ca61_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90YWJsZTo2YzkxYjhjMjJjMmI0N2IxOWFlZDA0ZDhlNDMwYzdkOC90YWJsZXJhbmdlOjZjOTFiOGMyMmMyYjQ3YjE5YWVkMDRkOGU0MzBjN2Q4XzUtMS0xLTEtNzk3MTQvdGV4dHJlZ2lvbjozMGUxMzExMzI4MjI0MmQ1ODQ0NGI2ZTcyZTU1NmMwNl8xMDk5NTExNjI3ODA3_dd48bbbd-3528-4e2b-8242-3359184ea8ea">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE0_de99fd27-a9eb-4a28-a899-e44fb93cb8f7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&amp;amp;D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company&#x2019;s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company&#x2019;s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE4_95511990-5194-4855-8a5d-08b2b046a7b2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA1_9de343b0-2f92-4536-86e2-a83a52ec7d96">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill is assessed for impairment by comparing the fair value of the Company&#x2019;s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. &lt;/span&gt;&lt;/div&gt;Long-lived Asset ImpairmentThe Company&#x2019;s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify a manufacturing facility for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;amp;A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzE2NDkyNjc1MTA2ODA_9e78373a-f459-4542-be4c-16ee7908aa03">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Capitalized Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE5_9a59d895-3a97-4bae-b8f6-d67071b2c3ce">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt"&gt;identification of the promised goods or services in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt"&gt;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt"&gt;measurement of the transaction price, including the constraint on variable consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt"&gt;allocation of the transaction price to the performance obligations based on estimated selling prices; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(v)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company&#x2019;s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company&#x2019;s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company&#x2019;s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company&#x2019;s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company&#x2019;s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company&#x2019;s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. Such variable consideration includes rebates, chargebacks, sales returns and other incentives. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company&#x2019;s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Commercial Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company&#x2019;s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers&#x2019; limited return rights and the Company&#x2019;s historical experience with returns. Because of the pricing of the Company&#x2019;s commercial products, the limited number of patients and the customers&#x2019; limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Incentives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: Other incentives include fees paid to the Company&#x2019;s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient&#x2019;s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&#160;For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where &lt;/span&gt;&lt;/div&gt;attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bmrn:ContractWithCustomerLiabilityPaymentTermAfterCustomerControl
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzMxODg1ODM3Mjc1MDIw_4d7e0edd-76ca-43ab-8828-b205ba67be61">P1Y</bmrn:ContractWithCustomerLiabilityPaymentTermAfterCustomerControl>
    <bmrn:ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzMxODg1ODM3Mjc1MDM3_7394e31b-a823-4c9a-9fa6-f956cc39016b">P1Y</bmrn:ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment>
    <bmrn:PaymentReceivedAsPercentageOfNetProductSales
      contextRef="id44211095b6f4687bae28103060052c4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgxODA2NjM_a4cf237f-7302-4e9a-bfa4-478d24e6d05b"
      unitRef="number">0.395</bmrn:PaymentReceivedAsPercentageOfNetProductSales>
    <bmrn:PaymentReceivedAsPercentageOfNetProductSales
      contextRef="i4068777477954ecd9a0dcd931dbcab88_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgxODA2NzA_409762ad-7d4b-4873-979d-77a14faff54d"
      unitRef="number">0.50</bmrn:PaymentReceivedAsPercentageOfNetProductSales>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI1_8fcb2939-6707-4851-b113-267851aad0df">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are generally expensed as incurred. These expenses include contract R&amp;amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;amp;D activities, facilities and regulatory costs and R&amp;amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzU0OTc1NTgyMDQ3Nzc_a1abb3be-c572-46ea-9fbf-e855d37411b9">Advertising ExpensesThe costs of advertising are presented in SG&amp;amp;A in the Consolidated Statements of Operations and are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyMzI_518919bc-4382-4997-b554-d4ab2569074f"
      unitRef="usd">25200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyNTM_f2016ac7-77a9-47ef-8454-c926f7ae3a38"
      unitRef="usd">30200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTMyNzM_65b9257f-3477-43b7-814e-4ea8738d97e5"
      unitRef="usd">29300000</us-gaap:AdvertisingExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA2_96d58678-cd7e-4cfa-83b3-e6a94c164374">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI2_bf50f0dd-c8e7-4bf0-8b2f-71404388330d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;amp;D or SG&amp;amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company&#x2019;s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Purchase Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award and purchase rights under the Company&#x2019;s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTYx_53dd50d0-ae99-4bdb-bea6-3159ce522a13"&gt;twenty-four&lt;/span&gt;-month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company&#x2019;s stock price and may use assumptions regarding a number of complex and subjective variables.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bmrn:NumberOfTranchesInOfferingPeriod
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzI3MTQ0_962ad8ff-d6e1-415e-9715-373b8d6de6aa"
      unitRef="tranche">4</bmrn:NumberOfTranchesInOfferingPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTE1_00a05946-6472-460b-8600-7a4b15a1da40">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company&#x2019;s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTI3_284fb459-5a71-4788-841d-05429a4e5f98">Foreign CurrencyFor the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc0ODk_d4bdf9f6-69a7-40f4-9a80-9961606f11c6"
      unitRef="usd">-11400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc1MDk_e8bfec8b-5b67-42a3-aa63-03e78494479b"
      unitRef="usd">-11700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzEwOTk1MTE2OTc1Mjg_9aa18948-237a-447b-ac35-edac143efbe3"
      unitRef="usd">-9900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTA3_6634a213-a25d-46dd-8cfc-00e496f85895">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#x2019;s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;amp;A in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTAy_69974d1b-4cb1-4060-a70e-a099254cfe3b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Notes&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_193" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;17&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for further information on the nature of these financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTAz_5b887a7c-69aa-4101-9ae0-fe7b80270fcf">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company&#x2019;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzExNTQ0ODcyMTM3NTM5_a823dd32-fbac-4325-bfc5-7b620f018333"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzIxOTkwMjMzMDM4NTM_19399624-7682-48cd-9a8b-94cecf20d8a9"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzExNTQ0ODcyMTM3NTQz_44b500bf-dc7c-4e59-99e4-479bb9eab1f7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDUvZnJhZzo0YzFmY2QwNGEzN2Y0ZmQ4YjQyMmZmYjU4NWYzMmJhOC90ZXh0cmVnaW9uOjRjMWZjZDA0YTM3ZjRmZDhiNDIyZmZiNTg1ZjMyYmE4XzM2OTEx_f12a708a-9a3a-4ca6-a896-6c9f1400926c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during 2022 that the Company believes are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzE1MDA_d4524f72-b1e5-4b97-9559-558b9d434c03">FINANCIAL INSTRUMENTS&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;504,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,641,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,625,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,222,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The Company&#x2019;s long-term marketable securities mature between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9"&gt;one&lt;/span&gt;&lt;/span&gt; and five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#x2019;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#x2019;s strategic investments was $23.9 million and $16.5 million, respectively. These investments were recorded in Other Assets on the Company&#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzE1MDE_3a70a4ba-3101-4839-a981-32a4a7516124">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;504,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,641,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,625,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,222,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The Company&#x2019;s long-term marketable securities mature between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_551c5c22-ac05-44de-bdcb-f2aecf8fb945"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM0Nw_715f1038-2a74-403c-8d41-f2f59c5794a9"&gt;one&lt;/span&gt;&lt;/span&gt; and five years.&lt;/span&gt;&lt;/div&gt;</bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock>
    <us-gaap:Cash
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMS0xLTEtNzgyMzk_c1cff2ec-ce62-4cef-9eb8-6633b8a00007"
      unitRef="usd">463248000</us-gaap:Cash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMy0xLTEtNzgyMzk_5728c60c-11cc-4d0d-8885-18d1703808ee"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtNS0xLTEtNzgyMzk_5adbd487-e9a8-4942-84ff-63b2c8835e16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtNy0xLTEtNzgyMzk_dc661c83-9e4d-4aee-9616-c03dd1b5eed9"
      unitRef="usd">463248000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtOS0xLTEtNzgyMzk_e68587f5-6720-46dd-82af-4fcb644b8456"
      unitRef="usd">463248000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMTEtMS0xLTc4MjM5_5025a846-c663-49e5-ab7d-b0f175e59cf4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4983aee6ed6f40a097f55f2b514fc899_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzMtMTMtMS0xLTc4MjM5_d463bb5e-0020-4388-a780-916a4204d280"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMS0xLTEtNzgyMzk_cd16884a-ef2d-432e-99ed-cc694eee38f6"
      unitRef="usd">248933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMy0xLTEtNzgyMzk_daba6354-5010-423c-9ebc-f47feaa41498"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtNS0xLTEtNzgyMzk_9b2d48ee-98e3-4804-8c7e-019d36421b45"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtNy0xLTEtNzgyMzk_279a8daf-1563-4617-a1d4-c928338712b4"
      unitRef="usd">248933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtOS0xLTEtNzgyMzk_2c2d0cbe-c71d-4f8b-9f6a-b324916b7d6a"
      unitRef="usd">248933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMTEtMS0xLTc4MjM5_c9a758d1-3edd-4eee-8da0-cbeb2583bcd8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i301449ebc7e54567b1a8e9d3529a7296_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzYtMTMtMS0xLTc4MjM5_84c33241-976d-41ad-875d-78f7ae4dbb11"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMS0xLTEtNzgyMzk_7faa8f6b-4cb3-496b-b644-b35a16dec0df"
      unitRef="usd">504984000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMy0xLTEtNzgyMzk_3322aa67-ed88-43cb-a6c0-2e3b1ac7a19e"
      unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctNS0xLTEtNzgyMzk_83fe0783-437e-4c2d-8589-ce3f6a8c9944"
      unitRef="usd">11541000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctNy0xLTEtNzgyMzk_be08a9af-c582-4d33-a96d-ba0dded53c81"
      unitRef="usd">493477000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctOS0xLTEtNzgyMzk_d61996fd-8f4d-454d-b697-9bcfb6a1eb14"
      unitRef="usd">1881000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMTEtMS0xLTc4MjM5_126e40fb-94ab-4831-b0c2-df44dcbb7b3b"
      unitRef="usd">299153000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3429f515a1f74193939e9ed2c23c5c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzctMTMtMS0xLTc4MjM5_987e0f76-7842-44f4-aaf0-e050b9af028a"
      unitRef="usd">192443000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMS0xLTEtNzgyMzk_402b7a7e-4a2e-4bf6-8317-9fdb1db14020"
      unitRef="usd">312720000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMy0xLTEtNzgyMzk_45bbb7ce-1473-4d76-b994-867eed8aa35a"
      unitRef="usd">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtNS0xLTEtNzgyMzk_35bc6468-9419-457c-bc5b-326229b7b23c"
      unitRef="usd">3771000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtNy0xLTEtNzgyMzk_e5f4ee18-5a1a-4d80-ba8c-d5faced0cb9a"
      unitRef="usd">308994000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtOS0xLTEtNzgyMzk_54db5706-3e64-4f8f-b981-6a411ad8c1a3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMTEtMS0xLTc4MjM5_b9f6c353-69fc-4d12-b6a4-9a545e1db39f"
      unitRef="usd">229846000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i60b853a38b944bfea4923c8120facacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzgtMTMtMS0xLTc4MjM5_9264d5e7-d55a-4aa4-8eb6-f91aa27a9d27"
      unitRef="usd">79148000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMS0xLTEtNzgyMzk_e501054b-606a-4a3f-bf94-9b4c2b1119b3"
      unitRef="usd">48103000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMy0xLTEtNzgyMzk_0b43db0b-2cde-4bed-85e8-bde2a3adb429"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktNS0xLTEtNzgyMzk_b85e2608-0b6c-4a8f-b838-c8e317d406d4"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktNy0xLTEtNzgyMzk_9e52f236-90d8-4162-a592-a0eea102ad77"
      unitRef="usd">48092000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktOS0xLTEtNzgyMzk_c4e834f2-576e-4fcc-bbb2-f95948411529"
      unitRef="usd">10469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMTEtMS0xLTc4MjM5_32db3bef-d9a2-4497-9a5d-e246c83decbb"
      unitRef="usd">37623000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i14c8137f742a475fbc0a9c6d4094825e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzktMTMtMS0xLTc4MjM5_c4ec990b-0df6-48a8-b928-b7a4898c9058"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTEtMS0xLTc4MjM5_c870f924-d0a2-4635-913a-0fdf132d9656"
      unitRef="usd">63151000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTMtMS0xLTc4MjM5_856cac44-f9e0-45b5-b140-ff6e01a56028"
      unitRef="usd">69000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTUtMS0xLTc4MjM5_c3ead0ee-8578-4a43-bdb9-ded0067078f9"
      unitRef="usd">592000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTctMS0xLTc4MjM5_741daf1c-c523-46f5-a375-c04ec21d41ac"
      unitRef="usd">62628000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTktMS0xLTc4MjM5_be9c39ce-c90f-4c4f-9b5a-c8d221332394"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTExLTEtMS03ODIzOQ_1a76dbbb-19ef-4565-b16d-7fe04fd447f1"
      unitRef="usd">384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i41682380abc342c0a800728472affb1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEwLTEzLTEtMS03ODIzOQ_d2496c9c-b325-45c1-b29e-5277bed4386c"
      unitRef="usd">62244000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTEtMS0xLTc4MjM5_69366646-fe90-4b13-8687-42ef333807d8"
      unitRef="usd">1177891000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTMtMS0xLTc4MjM5_9156fcf4-7eaf-41dd-8009-a3a4aba1da03"
      unitRef="usd">159000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTUtMS0xLTc4MjM5_64341c0b-d5e5-4de7-bedc-d6e231d33d88"
      unitRef="usd">15926000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTctMS0xLTc4MjM5_f4f6bf24-b499-4ffe-8ec6-05bd058d88c9"
      unitRef="usd">1162124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTktMS0xLTc4MjM5_d1082d9f-94f4-4dbc-b761-6b9be26aad01"
      unitRef="usd">261283000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTExLTEtMS03ODIzOQ_5117b9fa-31e2-4e52-9500-8210e48dd032"
      unitRef="usd">567006000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i160b43862b4443b8b71abb1941361269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEyLTEzLTEtMS03ODIzOQ_0d5e2343-2ef0-4799-b254-ccada03a3b80"
      unitRef="usd">333835000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTEtMS0xLTc4MjM5_0c4d42d7-6e1d-4ef5-861f-80eda1040cd9"
      unitRef="usd">1641139000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTMtMS0xLTc4MjM5_7f9bb847-54b4-4cc6-b23a-381727889fb0"
      unitRef="usd">159000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTUtMS0xLTc4MjM5_8801df6a-a2ee-4463-95d5-91bd8760084d"
      unitRef="usd">15926000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTctMS0xLTc4MjM5_c90a3e29-fb08-4f00-80d0-bb5e810acf8d"
      unitRef="usd">1625372000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTktMS0xLTc4MjM5_52104b13-fc5d-499b-b046-ae3b6dfff082"
      unitRef="usd">724531000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTExLTEtMS03ODIzOQ_8cb330de-7801-492f-aa84-7d033e95265b"
      unitRef="usd">567006000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTphNzgxNTU3OGIwMzA0YjJhOTdhNzViOTZjMDgwYzgxOC90YWJsZXJhbmdlOmE3ODE1NTc4YjAzMDRiMmE5N2E3NWI5NmMwODBjODE4XzEzLTEzLTEtMS03ODIzOQ_c4000a2f-ee21-44d8-a7f4-050834ba7d22"
      unitRef="usd">333835000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:Cash
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMS0xLTEtNzgyMjU_e2bf2379-3cc8-422a-a876-3a5e09b893e2"
      unitRef="usd">301177000</us-gaap:Cash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMy0xLTEtNzgyMjU_7f13f05a-35d8-4939-82a2-2dd354eb18c1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtNS0xLTEtNzgyMjU_19d3a5d4-6b52-4e94-ac02-a950fa7e48f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtNy0xLTEtNzgyMjU_aa1597cf-6d02-438e-8b3e-e6a4468eaaf3"
      unitRef="usd">301177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtOS0xLTEtNzgyMjU_1ffe7034-7c11-4fd8-bf06-8c51521819d3"
      unitRef="usd">301177000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMTEtMS0xLTc4MjI1_a7368777-217c-4a2f-bfa0-e61539924895"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7401b5a80acd48d992723aa4414c7abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzMtMTMtMS0xLTc4MjI1_c301eaf8-d8e7-4763-89e3-446b75ccab8f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMS0xLTEtNzgyMjU_0492c504-e780-476f-843d-ae00ad772e30"
      unitRef="usd">285099000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMy0xLTEtNzgyMjU_7f4f8692-1e38-425c-94f8-8a2685840c79"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtNS0xLTEtNzgyMjU_025c4648-2de2-4f9d-a7aa-991b79702e8c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtNy0xLTEtNzgyMjU_35e75732-7470-4deb-9d5a-81e35e42c8ce"
      unitRef="usd">285099000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtOS0xLTEtNzgyMjU_969ffd6a-f7f9-497e-a6bd-cbf90fa2192c"
      unitRef="usd">285099000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMTEtMS0xLTc4MjI1_6576fb5b-5701-4d25-af94-c657bc5c04f6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i561448975fb740788726f49b7214216d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzYtMTMtMS0xLTc4MjI1_66b2fa99-ca35-4ada-b600-2d6d891ae887"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMS0xLTEtNzgyMjU_8ec7b737-76f4-470a-b6da-3f4022000bd2"
      unitRef="usd">584000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMy0xLTEtNzgyMjU_0740cbb6-8617-443e-941e-14db220893af"
      unitRef="usd">386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctNS0xLTEtNzgyMjU_055d1f85-4d84-4b22-a949-a34dc7328d4b"
      unitRef="usd">2086000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctNy0xLTEtNzgyMjU_6f82671c-bdc1-4020-afac-e7a1c25cdec9"
      unitRef="usd">582300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctOS0xLTEtNzgyMjU_b8bef2c0-0d37-4046-afe0-b22359f5a196"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMTEtMS0xLTc4MjI1_481a392f-6012-4f6b-b0be-89394be23018"
      unitRef="usd">200304000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie97ca426a1d5427cadae21dbf77cd8be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzctMTMtMS0xLTc4MjI1_4ccec112-0814-4b1b-abc4-9e4e2bd608d3"
      unitRef="usd">381996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMS0xLTEtNzgyMjU_561e61ad-6aeb-4fa9-a5e5-e03bf594f1e2"
      unitRef="usd">224774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMy0xLTEtNzgyMjU_0802825f-d92e-4714-bd27-5785de1bf98a"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtNS0xLTEtNzgyMjU_b0fbe87b-18ad-44fb-ad1a-811477039b90"
      unitRef="usd">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtNy0xLTEtNzgyMjU_b0e102f8-1d2b-45df-bfbf-0476fe9a4364"
      unitRef="usd">224631000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtOS0xLTEtNzgyMjU_72d7d67c-7550-4e4d-92f1-9d9ba35ac580"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMTEtMS0xLTc4MjI1_e2c436ba-91a1-46ae-92eb-5b28f49462b0"
      unitRef="usd">146421000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iff7dfd70a907429b878635ece7bc1fd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzgtMTMtMS0xLTc4MjI1_8b807c1e-a136-4ca8-9d88-db563bd7afb8"
      unitRef="usd">78210000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMS0xLTEtNzgyMjU_0f117f6b-c83a-432d-9ff3-4613e0a85df7"
      unitRef="usd">68384000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMy0xLTEtNzgyMjU_71d9ec41-cb95-49d1-8c7d-171fcab417cc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktNS0xLTEtNzgyMjU_895a415f-f7ca-4602-9964-fb2dee6e23ee"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktNy0xLTEtNzgyMjU_dee48deb-d7cf-47b4-8e2e-aa54f57ba82c"
      unitRef="usd">68384000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktOS0xLTEtNzgyMjU_a62167ed-1b6b-4fc2-a7a0-4d9e0e462500"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMTEtMS0xLTc4MjI1_f741dd6c-2262-4092-8b7c-43d7b06e4df2"
      unitRef="usd">67384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia8eec0bbea254a19849bf1ad7fee9dcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzktMTMtMS0xLTc4MjI1_3878964c-b8d6-4722-b8ac-858ef65be121"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTEtMS0xLTc4MjI1_67697c26-5938-4bd4-8035-aa3c28e2d3a4"
      unitRef="usd">56936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTMtMS0xLTc4MjI1_c8260d6a-e19f-42b4-b1eb-5cb1068d7067"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTUtMS0xLTc4MjI1_679127c8-35b6-4d69-bab1-e5de04631a8e"
      unitRef="usd">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTctMS0xLTc4MjI1_504251ff-e7d5-4855-af1f-5f46f1d23dcf"
      unitRef="usd">56851000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTktMS0xLTc4MjI1_5d606491-a5ca-45e1-a2be-e0a9453ec372"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTExLTEtMS03ODIyNQ_70434e00-ada2-4b5f-a153-1e2b4f6135d1"
      unitRef="usd">9451000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0a7f65a195224b5d827cb975542f273c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEwLTEzLTEtMS03ODIyNQ_c5833148-a895-49ea-be7d-fca13e3b62e5"
      unitRef="usd">47400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTEtMS0xLTc4MjI1_874fe1aa-2a2d-4aea-8324-8969996a891c"
      unitRef="usd">3097000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTMtMS0xLTc4MjI1_db593d61-edee-4fc6-9099-96687c42cbd4"
      unitRef="usd">141000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTUtMS0xLTc4MjI1_d9182335-fed5-42a5-bf73-20dd2136d6b5"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTctMS0xLTc4MjI1_7975babe-ba3b-4ebd-93bb-ae597e38ae5e"
      unitRef="usd">3226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTktMS0xLTc4MjI1_09b0958c-fbc1-4245-98e5-a68a16e14e78"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTExLTEtMS03ODIyNQ_ac4ccc85-f0cd-439b-9ed5-d103461fdb42"
      unitRef="usd">3039000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4df4ef5fd4294091833bfc00f71675ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzExLTEzLTEtMS03ODIyNQ_7dd8ba60-6cf9-4b21-8050-8fd6089a12b2"
      unitRef="usd">187000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTEtMS0xLTc4MjI1_f15b61e0-8b51-45b1-9242-afb6b196bfd3"
      unitRef="usd">1222290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTMtMS0xLTc4MjI1_b058392e-e448-4be6-8a0e-f91b0e8a92a5"
      unitRef="usd">719000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTUtMS0xLTc4MjI1_f98c49d2-0a32-40a4-859c-03b0e911b83d"
      unitRef="usd">2518000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTctMS0xLTc4MjI1_31ef0561-8d23-441a-a5c1-02e5e74d1a64"
      unitRef="usd">1220491000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTktMS0xLTc4MjI1_4b4d6864-85ea-46c7-8ed1-75245aec8e34"
      unitRef="usd">286099000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTExLTEtMS03ODIyNQ_272b8af3-a17d-4972-8c01-f54ce2ad372e"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1a56284d386d47d5b5eb46c28db68c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzEyLTEzLTEtMS03ODIyNQ_d462a307-6e01-4ba0-a240-5c9780c893c4"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTEtMS0xLTc4MjM0_d31c855a-8693-4284-b368-9bdec1d7c277"
      unitRef="usd">1523467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTMtMS0xLTc4MjM0_ef76e889-756f-4114-9c88-abd5af9a9eea"
      unitRef="usd">719000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTUtMS0xLTc4MjM0_dd05e864-4c98-4639-87be-3781d5318288"
      unitRef="usd">2518000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTctMS0xLTc4MjM0_b8babb2a-3c07-45bb-a825-de83976d8aa5"
      unitRef="usd">1521668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTktMS0xLTc4MjM0_2eff9a73-a4a2-4dbf-a405-3714971e9f91"
      unitRef="usd">587276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTExLTEtMS03ODIzNA_6b002ce3-4c1f-4a6d-9e60-0d3fa2078715"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90YWJsZTo4YzI1MWVkNmMyMGE0ODE3ODU2NjVmMzBhMjc5Y2MwOS90YWJsZXJhbmdlOjhjMjUxZWQ2YzIwYTQ4MTc4NTY2NWYzMGEyNzljYzA5XzE0LTEzLTEtMS03ODIzNA_7b448c40-aee5-4a93-a54d-bb7ebe5cd30e"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <bmrn:ShortTermMarketableSecuritiesMaturityPeriod
      contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzI3NA_2bc8d19a-bc02-4c0e-89b7-6598b66504b2">P1Y</bmrn:ShortTermMarketableSecuritiesMaturityPeriod>
    <bmrn:ShortTermMarketableSecuritiesMaturityPeriod
      contextRef="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzI3NA_d51c0764-9d3d-4382-aecd-379dff38fb6f">P1Y</bmrn:ShortTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i088ceb31b59048beb1fd6f6d3a9970a9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM1NA_5c680365-ea9d-48d3-bb1e-8cc5df185cca">P5Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzM1NA_fc5a033e-2452-4048-bd3c-301773429213">P5Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i465f964e015842ad9df73023d86585b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzEwOTk1MTE2MjkzMzk_7f8be9ff-f596-4168-8621-0289213b10fa"
      unitRef="usd">23900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8c6c18d583ad4920abd1d0bcfedc9627_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNDgvZnJhZzpiZjZkNTcyYmI5NDE0Y2Q4OGMyZTlhYmNhNzk4N2MwZS90ZXh0cmVnaW9uOmJmNmQ1NzJiYjk0MTRjZDg4YzJlOWFiY2E3OTg3YzBlXzEwOTk1MTE2MjkzNTU_71b9ded6-ef74-4697-a47e-a21a20e13c6a"
      unitRef="usd">16500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzc_3677754e-8f28-4f94-873b-ca6ae1142ea1">INTANGIBLE ASSETS&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible Assets, Net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(352,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying value and estimated remaining life of the Company&#x2019;s finite-lived intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology transfer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repurchased royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain technology transfer intangible assets have not yet been placed into service. The average remaining life presented is only for those placed into service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the estimated future amortization expense associated with the Company&#x2019;s finite-lived intangible assets that have been placed into service, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022 the Company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the first quarter of 2022 on the Company's Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzM_cbf66aae-f35d-416c-bb63-d2d203ecf83f">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible Assets, Net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(352,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzItMS0xLTEtNzgyNzA_aeacafc9-a41a-48fc-9511-e0e5796d5c5e"
      unitRef="usd">690871000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzItMy0xLTEtNzgyNzA_0b4fd5e0-0113-402d-9641-c2f603401d03"
      unitRef="usd">677350000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzUtMS0xLTEtNzgyNzQ_7c2a6369-e57c-47c7-9db8-0f14caf97b4f"
      unitRef="usd">352302000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzUtMy0xLTEtNzgyNzQ_21446ee9-0ef5-4102-b3f2-b2f01592a3b4"
      unitRef="usd">288698000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzYtMS0xLTEtNzgyNzg_ae1349e6-a611-4fb4-a30a-74e499e34cea"
      unitRef="usd">338569000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozNjZmOTcxOGRiYTE0Njg0OGRiMjZhYjBhNDEzNTUzMy90YWJsZXJhbmdlOjM2NmY5NzE4ZGJhMTQ2ODQ4ZGIyNmFiMGE0MTM1NTMzXzYtMy0xLTEtNzgyNzg_37ae75e7-a5f2-465a-a032-87ca34190591"
      unitRef="usd">388652000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzQ_e7923c0f-0ca5-449a-8315-a270ed697eaf">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying value and estimated remaining life of the Company&#x2019;s finite-lived intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology transfer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repurchased royalty rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Certain technology transfer intangible assets have not yet been placed into service. The average remaining life presented is only for those placed into service.</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6943ad4dcf614dd68d73dc3e5298e4f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzEtMS0xLTEtNzg4ODE_44e2bd54-6a54-49fb-80cb-84545fe51bcf"
      unitRef="usd">240321000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i0c33f2a42d5842a59975b6b1c2729669_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzEtMy0xLTEtNzg4ODE_721d49b1-cbae-447f-a058-2c7f0957e2a1">P5Y1M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4f59e0944d0043aa8bbc9c5903fda1f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzItMS0xLTEtNzg4ODE_635812c4-6d83-492a-9d30-6451ec762b08"
      unitRef="usd">86578000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i47f772ec89c942a7a3e166b25c359f88_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzItMy0xLTEtNzg4ODEvdGV4dHJlZ2lvbjowMzY4ZmIyMDUzNDA0NTExYjkwM2NiOTI0NWI2Yzk3Ml8xMDk5NTExNjI3ODQw_eeecc721-7ebc-4fed-bf12-3e95989cdaf6">P5Y4M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7317f10ceb0c4e0cb47f102d6347f258_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzMtMS0xLTEtNzg4ODE_a3122a1b-6a0f-43c6-b9fd-0cbbc5079902"
      unitRef="usd">6188000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="iff2619b7b15f451e8c6ceb0626894102_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzMtMy0xLTEtNzg4ODE_72e9ad52-51be-4366-b72d-9b5dbcfbcc1c">P0Y10M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i18b044b28769473fa1bf7da098b3d52e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzQtMS0xLTEtNzg4ODE_2ee19bc2-0456-4fb5-a9d1-23e63184ed28"
      unitRef="usd">5436000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i596215e6117a4f52b5c0d7d97a1ef282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzQtMy0xLTEtNzg4ODE_e0c1f583-36bf-4f26-938e-0b267606da48">P7Y8M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie41fa8108fc04c34b1787046ebcdad40_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzUtMS0xLTEtNzg4ODE_17b775a8-384d-4374-9d85-8be30b7fe12a"
      unitRef="usd">46000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i674d0d14122b41c48b74ae0001c8fd9d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzUtMy0xLTEtNzg4ODE_697ce589-dd91-426b-b0ac-86d2f0bd8234">P0Y3M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTo0ZWVjNjY5MzNhODg0MzIzOWZhZjljNzNmMGJlMjFhMC90YWJsZXJhbmdlOjRlZWM2NjkzM2E4ODQzMjM5ZmFmOWM3M2YwYmUyMWEwXzYtMS0xLTEtNzg4ODE_82024598-8b19-45c5-9360-98b3672845bd"
      unitRef="usd">338569000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzIxNzU_faa9f821-fe46-4adb-8218-93f23eee7544">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the estimated future amortization expense associated with the Company&#x2019;s finite-lived intangible assets that have been placed into service, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzEtMi0xLTEtNzk5ODI_7a01ff8d-58df-47d4-89e0-0e9c66b15e7a"
      unitRef="usd">63688000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzItMi0xLTEtNzk5ODI_7da308ab-0a95-4be7-9650-bbacf8096b6d"
      unitRef="usd">57413000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzMtMi0xLTEtNzk5ODI_72830fe2-9661-4cfb-816c-f0b381e501b4"
      unitRef="usd">38136000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzQtMi0xLTEtNzk5ODI_1f32f76e-890b-4000-917a-670a7ee74ea8"
      unitRef="usd">38136000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzUtMi0xLTEtNzk5ODI_ccd41a1e-ec8d-47ac-835b-57704b302dfd"
      unitRef="usd">38136000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzYtMi0xLTEtNzk5ODI_88f32d68-ca86-43e9-a9b2-74c694f9fc91"
      unitRef="usd">25746000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <bmrn:FiniteLivedIntangibleAssetsAmortizationNotCommencedNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90YWJsZTozYmY5Y2RkNGUwNzU0ZDJhOWI4ODFkMDE2MDZkZjJlMC90YWJsZXJhbmdlOjNiZjljZGQ0ZTA3NTRkMmE5Yjg4MWQwMTYwNmRmMmUwXzctMi0xLTEtNzk5ODI_b4d7d818-99b7-4636-8143-598fdd3e62b8"
      unitRef="usd">261255000</bmrn:FiniteLivedIntangibleAssetsAmortizationNotCommencedNet>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTEvZnJhZzpkOTU3ZDMwZDcyNzE0ZjAyOWNlZmI3YzNmYTg3ZjM4Mi90ZXh0cmVnaW9uOmQ5NTdkMzBkNzI3MTRmMDI5Y2VmYjdjM2ZhODdmMzgyXzEwOTk1MTE2MzA4MDc_83fa78e7-5a78-4ce1-99f2-bf12f3608b31"
      unitRef="usd">108000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzI4Nw_0bf51c69-8961-44a3-8e86-7ee47e8d4113">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment, Net, consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;774,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(802,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,035,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation expense, net of amounts capitalized into inventory, was $38.6 million, $46.1 million and $43.0 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzI4OA_7ae33e01-590e-4ae6-bc6c-c020958f93e0">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment, Net, consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;774,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(802,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,035,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1c89fa21a6740b4ae70eb14c57b4658_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzItMS0xLTEtODAwNTY_d224f1c0-413a-43d7-bbb1-8d500629b105"
      unitRef="usd">819100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icdd0df068ef64e57beb016ebea921ad8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzItMy0xLTEtODAwNTY_a98cff15-d6b4-4b86-9c9a-0e5e08966d90"
      unitRef="usd">774923000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib04df3be9f9247e0a45ecf03bf54bdcf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzMtMS0xLTEtODAwNTY_c27027a0-90bd-4b63-8488-88a36be10000"
      unitRef="usd">475663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifba77569d60840a79ea41ac5cfaf6073_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzMtMy0xLTEtODAwNTY_9f0496fb-b673-4179-81de-d7b439fbb87d"
      unitRef="usd">444182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a01c0ded34748d0bce2340302388477_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzQtMS0xLTEtODAwNTY_f28d2506-f963-4f96-9c74-1ea106692642"
      unitRef="usd">214829000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib586210770d7493e9072422b6c53e69d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzQtMy0xLTEtODAwNTY_ea6a9f21-eb8d-4e3b-9c7b-e54b45fe45bc"
      unitRef="usd">201382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9296d886772647e196d034a5c7da7e16_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzUtMS0xLTEtODAwNTY_93935c0c-93f1-4a0e-a647-4059b1312e62"
      unitRef="usd">90786000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic38d7d015d9641a2afccceaff3825715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzUtMy0xLTEtODAwNTY_c7036177-a14c-4729-b72b-736e03adcf31"
      unitRef="usd">90418000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb0f8b8eab5543b8a5874a2155f9b22e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzYtMS0xLTEtODAwNTY_63957c67-11d1-42e1-a169-3bef17a6f3a1"
      unitRef="usd">59532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i41a6bb5565934ac188f62eb1cf6acf5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzYtMy0xLTEtODAwNTY_1766502c-2bb0-4410-b09b-857bf5d3cca5"
      unitRef="usd">55279000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a99600f7613497d89438354f0bada80_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzctMS0xLTEtODAwNTY_c5801199-502e-4e24-974d-06c2be7d38db"
      unitRef="usd">45762000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i521cb957123a469e9a9db648b7ecd32d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzctMy0xLTEtODAwNTY_7c246ea4-2c57-4d26-8cb7-dd88eefda4c9"
      unitRef="usd">42976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53ba21556ac84294bfa877f64bdd66f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzgtMS0xLTEtODAwNTY_93d989b8-f53b-4018-bb9d-db842d05234e"
      unitRef="usd">26455000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3380a5d1065a44fe975fa8e9b0e091ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzgtMy0xLTEtODAwNTY_350be046-6860-4162-8ef6-2e462ab48b21"
      unitRef="usd">10132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0b02b6e13e842f682a38f22a659d47f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzktMS0xLTEtODAwNTY_171436e4-8073-4b21-bb0d-e36735368b11"
      unitRef="usd">143384000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1f45be8b0d354e1e8b7391f4a5dd0d20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzktMy0xLTEtODAwNTY_e97dc3ee-cbd1-49a5-a568-d6d139843bb6"
      unitRef="usd">136743000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEwLTEtMS0xLTgwMDU2_603187d2-222f-46cf-8693-0a3c430bf936"
      unitRef="usd">1875511000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEwLTMtMS0xLTgwMDU2_f003d21e-0ae6-43b5-9b4c-b2277a8f08d8"
      unitRef="usd">1756035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzExLTEtMS0xLTgwMDU2_dbf8790b-b62b-4baf-becb-350ebde2c720"
      unitRef="usd">802145000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzExLTMtMS0xLTgwMDU2_d8cff892-7da7-4adb-844a-948f60d00acf"
      unitRef="usd">720574000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEyLTEtMS0xLTgwMDU2_d0110fa2-35d7-450f-9d8b-019819763e4a"
      unitRef="usd">1073366000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90YWJsZTphNDM2NWJhNzM1YWM0ZjRmOGYwODM4MjVjNzQ5YTZjNS90YWJsZXJhbmdlOmE0MzY1YmE3MzVhYzRmNGY4ZjA4MzgyNWM3NDlhNmM1XzEyLTMtMS0xLTgwMDU2_b59c7147-56d3-4c6b-9298-217aad61368c"
      unitRef="usd">1035461000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzU0OTc1NTgxNDI3MA_abbd7783-fd5c-49b6-81de-8dfee6128e37"
      unitRef="usd">38600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzU0OTc1NTgxNDI3Nw_0160d0c0-caf7-4c02-8027-25d845b02c9d"
      unitRef="usd">46100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTQvZnJhZzo5MGYzMzA4MmQ4OGI0MDcwODNkNTg1OTcyZGE3YzIxMS90ZXh0cmVnaW9uOjkwZjMzMDgyZDg4YjQwNzA4M2Q1ODU5NzJkYTdjMjExXzIxOTkwMjMyNTU5NTE_4246df6a-dc8f-468c-a552-f501c0bf7506"
      unitRef="usd">43000000</us-gaap:Depreciation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90ZXh0cmVnaW9uOjQwMzEyODZkNGJjMjRjNjNhMmY4NTY5NWVjMjBmZDg3XzExOTQ_7f7dd52c-1e5d-4335-8541-ca8ba0be1b34">INVENTORY&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90ZXh0cmVnaW9uOjQwMzEyODZkNGJjMjRjNjNhMmY4NTY5NWVjMjBmZDg3XzExOTU_1bb01089-fed4-469b-9a62-e6e2fb15f008">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzItMS0xLTEtNzgyODk_bf2baa8c-e26b-4815-b58b-a060ab8aaeb0"
      unitRef="usd">131071000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzItMy0xLTEtNzgyODk_8fef3005-5450-4f52-becd-ab93930b8d9b"
      unitRef="usd">80269000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzMtMS0xLTEtNzgyODk_f36314b2-8708-4518-ad69-735e349fb902"
      unitRef="usd">410656000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzMtMy0xLTEtNzgyODk_4e6baf52-6e66-49e0-8e29-39b2f64f019c"
      unitRef="usd">415261000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzQtMS0xLTEtNzgyODk_16889cf0-485b-4815-97cd-d05c75f430ee"
      unitRef="usd">352356000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzQtMy0xLTEtNzgyODk_db683369-01c8-40ba-9af6-8dec600a5282"
      unitRef="usd">281139000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzUtMS0xLTEtNzgyODk_c5ec9630-92fc-4107-9ca6-5a088ce9a866"
      unitRef="usd">894083000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNTcvZnJhZzo0MDMxMjg2ZDRiYzI0YzYzYTJmODU2OTVlYzIwZmQ4Ny90YWJsZTo5OTI4ZTQ5MDNjNzg0MDE2OGQyZDgyYjczMWZiOTc1NC90YWJsZXJhbmdlOjk5MjhlNDkwM2M3ODQwMTY4ZDJkODJiNzMxZmI5NzU0XzUtMy0xLTEtNzgyODk_283b77d4-1728-4c85-84cb-22e764edb995"
      unitRef="usd">776669000</us-gaap:InventoryNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI4MQ_02e1cb5e-12e4-412c-a25a-00c463db645e">SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts Payable and Accrued Liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The balance as of December 31, 2021 has been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reorganization Plan Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On October 6, 2022, the Company announced a plan to simplify its organizational design, which included a planned reduction in headcount of approximately 120 employees (representing approximately 4% of the Company&#x2019;s global workforce), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;most of whom were from the Company's U.S. operations. The reduction in headcount was substantially completed as of December 31, 2022. In 2022, the Company recorded costs of $23.0 million related to one-time termination severance and employee termination benefits within SG&amp;amp;A expense, of which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; $11.9 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; has been paid as of December 31, 2022. The Company does not expect to incur any significant incremental costs in future periods. The unpaid balance at December 31, 2022 is recorde&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;d to Accounts Payable and Accrued Liabilities on the Consolidated Balance Sheet and is expected to be paid within the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Revenue Rebates and Reserves for Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December&#160;31, 2022, 2021 and 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Provision for Current Period Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;End of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI4Mg_ee7257e1-69fa-4423-81d8-84946758f89e">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts Payable and Accrued Liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The balance as of December 31, 2021 has been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzItMS0xLTEtNzgzMTA_608db194-31df-4720-a476-4dd8a5005be0"
      unitRef="usd">231238000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzItMy0xLTEtNzgzMTA_3b161f54-79b7-4133-8801-32554f05a70f"
      unitRef="usd">199678000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzMtMS0xLTEtNzgyOTU_72e33ae5-1164-4610-b768-51f8c848a3fd"
      unitRef="usd">207573000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzMtMy0xLTEtNzgyOTU_93f4722b-5f8d-44a8-81f3-b26cb025857b"
      unitRef="usd">204446000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bmrn:AccruedGovernmentAndOtherRebates
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzQtMS0xLTEtNzgyOTk_389f4f7d-3dc6-49d1-b0ce-5afccba1c420"
      unitRef="usd">72654000</bmrn:AccruedGovernmentAndOtherRebates>
    <bmrn:AccruedGovernmentAndOtherRebates
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzQtMy0xLTEtNzgyOTk_74554278-86ae-4e76-89f9-b8879e9887e7"
      unitRef="usd">47987000</bmrn:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzUtMS0xLTEtNzgzMDY_e6d51b29-03a7-4853-84c3-d29387e06c0b"
      unitRef="usd">16213000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzUtMy0xLTEtNzgzMDY_1a39bd8d-ca0d-45ca-a035-b1d66d1f5171"
      unitRef="usd">1213000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzYtMS0xLTEtNzgzMTc_7ca0063f-d3d3-4258-a0a0-7b59fcb45eb8"
      unitRef="usd">13306000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzYtMy0xLTEtNzgzMTc_1bb06c13-cfed-4546-bf72-ba167ec495dd"
      unitRef="usd">15215000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzctMS0xLTEtNzgzMjE_54adf032-5979-4079-af99-f42ee4e4d1ce"
      unitRef="usd">12601000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzctMy0xLTEtNzgzMjE_383a203e-f49e-48c5-9c52-7607041de473"
      unitRef="usd">6263000</us-gaap:DerivativeLiabilitiesCurrent>
    <bmrn:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzgtMS0xLTEtNzgzMjU_d0e478c9-8175-43e6-a343-2a556d5e2425"
      unitRef="usd">10375000</bmrn:OperatingAndFinanceLeaseLiabilityCurrent>
    <bmrn:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzgtMy0xLTEtNzgzMjU_eea7dc7f-f449-4c8b-9d3c-e669e85b9f26"
      unitRef="usd">10464000</bmrn:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEwLTEtMS0xLTc4MzI5_1241f209-2188-4501-b13e-08dd407dd9ed"
      unitRef="usd">711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEwLTMtMS0xLTc4MzI5_2dffbd8c-c38b-427b-bf29-3b893ac968a4"
      unitRef="usd">6956000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzExLTEtMS0xLTc4MzMz_abc6ac0f-1725-40ad-a597-44381b4267d9"
      unitRef="usd">8288000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzExLTMtMS0xLTc4MzMz_cb28f66e-8f00-4458-a868-5318b5685515"
      unitRef="usd">6043000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEyLTEtMS0xLTc4MzM3_9eb64dfc-5721-4b59-b435-0195f79f4cb5"
      unitRef="usd">572959000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo2YjI1MjRkYjQ4NTk0NjVhYjhkODY1YzI2MzhkMjk0OC90YWJsZXJhbmdlOjZiMjUyNGRiNDg1OTQ2NWFiOGQ4NjVjMjYzOGQyOTQ4XzEyLTMtMS0xLTc4MzM3_dd91c8f0-cf51-4ac9-afdb-f951e9d65404"
      unitRef="usd">498265000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="i079459cd9ea04678bb91caba28143414_D20221006-20221006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzM4NDgyOTA3MDE4NjU_3e2fbbcc-ef33-4182-bd0d-818680d722b7"
      unitRef="employee">120</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <bmrn:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce
      contextRef="i9644565e09324c2bbebec177f02b7bc7_I20221006"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzM4NDgyOTA3MDE4NzA_bd1b15cb-713c-4a1f-9520-fc419a2ec46a"
      unitRef="number">0.04</bmrn:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce>
    <us-gaap:RestructuringCharges
      contextRef="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzEwNDQ1MzYwNDY2OTgw_6cb79a8d-b044-44ba-8752-a5d891521531"
      unitRef="usd">23000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i97be2b1e769a4a06b7385e7b724b219b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzEwOTk1MTE2MzI2NzM_5f66bc0f-d1aa-4c75-aaad-246491a319dd"
      unitRef="usd">11900000</us-gaap:PaymentsForRestructuring>
    <bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90ZXh0cmVnaW9uOjhkZjJhYWEzNWI5NzRiMDBiYzY2YzYxMzFlZWYwZDQ2XzI3OQ_e7183f35-b187-46a1-ad1a-6941e8905117">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December&#160;31, 2022, 2021 and 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Provision for Current Period Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;End of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for cash discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia23981085b84481d8fc2be75b9fbd5db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItMS0xLTEtODAyODM_d055a7a3-1851-461b-84d8-18edba4ed332"
      unitRef="usd">47987000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItMy0xLTEtODAyODM_d2b235f5-3756-4f77-9fc3-5173adcb595c"
      unitRef="usd">140260000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if262d08d46b048c990d422f6b4daa9d2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItNS0xLTEtODAyODM_c2f238c2-de46-46ea-a414-e38cdd35bd8b"
      unitRef="usd">115593000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if37f7a71be894ef6bba5307f5c4f92c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzItNy0xLTEtODAyODM_2bd0e94c-b552-402d-9455-7381001357a1"
      unitRef="usd">72654000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i46791bdce16445e6898c45c3fd47dc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtMS0xLTEtODAyODM_d4faece4-873e-4f68-ac12-aff21d4cfeaf"
      unitRef="usd">2013000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtMy0xLTEtODAyODM_a135ad49-cd96-4733-8f1d-ceb5eec18d62"
      unitRef="usd">20351000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i73469a2a2a2f4ffcac868b4d95d28e7b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtNS0xLTEtODAyODM_7d9d87b2-3583-4049-9bd0-c8a6f484ac5c"
      unitRef="usd">18725000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idb2e8fd98e264368a035b1b756757df5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzMtNy0xLTEtODAyODM_19371d7e-9ba9-41a0-9cf1-95cde3d85b91"
      unitRef="usd">3639000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i474ce592912e4ee484fa06718d15d2fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtMS0xLTEtODAyNzU_de0ba51f-8c63-4447-8653-245f425f5690"
      unitRef="usd">65526000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i499a122963a44c19831951e9e567eaa7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtMy0xLTEtODAyNzU_3d377648-426f-4d3f-b1ed-295e9f9007f5"
      unitRef="usd">116691000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i499a122963a44c19831951e9e567eaa7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtNS0xLTEtODAyNzU_043f62c0-5887-46c1-8b23-4d2a7a85d827"
      unitRef="usd">134230000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia23981085b84481d8fc2be75b9fbd5db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzYtNy0xLTEtODAyNzU_9cfaae13-ea8f-491e-b8f4-bbc8debfa242"
      unitRef="usd">47987000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2ed072224703463aac2c7d7482c6ffb3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctMS0xLTEtODAyNzU_23000340-fab7-4655-8151-663b22b316bf"
      unitRef="usd">1716000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctMy0xLTEtODAyNzU_065ed687-0b6e-4de3-9198-b08c8635f1f4"
      unitRef="usd">16003000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9eb9531f623e49e78ce96ee3cac0227d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctNS0xLTEtODAyNzU_9c4ea245-a999-4561-8522-f2059a59fe74"
      unitRef="usd">15706000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i46791bdce16445e6898c45c3fd47dc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzctNy0xLTEtODAyNzU_b20b3c01-c2e2-4dde-baa6-72306e64f384"
      unitRef="usd">2013000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if4446cd995b344e0ba108320ca62f991_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTEtMS0xLTgwMjU5_03b134c3-e886-42a8-a787-0cd435638778"
      unitRef="usd">57163000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTMtMS0xLTgwMjU5_6015357b-4fab-4fd9-9406-60ffe1825591"
      unitRef="usd">113165000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i24f6ac4cf03f43f08c29c7d9a2d58970_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTUtMS0xLTgwMjY3_54375337-cb8b-4fcc-bc92-7961622f4f89"
      unitRef="usd">104802000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i474ce592912e4ee484fa06718d15d2fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzEwLTctMS0xLTgwMjY3_c688f990-d255-4278-872f-81de0c3b2f81"
      unitRef="usd">65526000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i91f9d3b26b0d4fe587d64e56b034ed55_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTEtMS0xLTgwMjU5_a120920f-6cec-46e3-a031-ec6b88c85b95"
      unitRef="usd">1889000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTMtMS0xLTgwMjU5_a756cb06-9bc2-48db-8ee4-0b6ae6a8d7bc"
      unitRef="usd">17191000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ida6d65e4b79a4053b8be421cf27c5426_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTUtMS0xLTgwMjY3_062a7614-dee3-4e92-9f83-8bd18dd2710c"
      unitRef="usd">17364000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2ed072224703463aac2c7d7482c6ffb3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjAvZnJhZzo4ZGYyYWFhMzViOTc0YjAwYmM2NmM2MTMxZWVmMGQ0Ni90YWJsZTo5MWE4NTM1OTI1Nzc0ZDE3YWU1NjRkM2FkOTM5YWU5Zi90YWJsZXJhbmdlOjkxYTg1MzU5MjU3NzRkMTdhZTU2NGQzYWQ5MzlhZTlmXzExLTctMS0xLTgwMjY3_d066c277-264a-48b2-af01-2a14b7bcb12f"
      unitRef="usd">1716000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExNzc_99f2696c-436c-4de1-a9f7-269e13f7fc54">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December&#160;31, 2022 and 2021. Other than the Company&#x2019;s fixed-rate convertible debt disclosed in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December&#160;31, 2022 and 2021. Refer to Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The restricted investments as of December&#160;31, 2022 and 2021 secure the Company&#x2019;s irrevocable standby letters of credit obtained in connection with certain commercial agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payments to Ares Trading S.A. (Merck Serono)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realized foreign exchange gain on settlement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange remeasurement of Euro denominated contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExNzk_1d5eec3b-b6d7-49c4-b5fe-6d0620a0bcf1">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December&#160;31, 2022 and 2021. Other than the Company&#x2019;s fixed-rate convertible debt disclosed in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December&#160;31, 2022 and 2021. Refer to Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_148" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_166" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The restricted investments as of December&#160;31, 2022 and 2021 secure the Company&#x2019;s irrevocable standby letters of credit obtained in connection with certain commercial agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i846fa6c590bb43c9b2c023bbeee9119a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_24b5a826-de49-44aa-a266-6794e4fc4d84"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id956bf9fc1b44873ab5ad29095686daa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_4351849a-6a3a-401a-bcbc-ca7ea7c8e287"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i846fa6c590bb43c9b2c023bbeee9119a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_643a5c4c-8a52-43fe-8f91-10d0f7336ba1"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id956bf9fc1b44873ab5ad29095686daa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzU5MQ_d3043ea1-229b-4a43-b92c-6be52bdc4ea7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i63ce1991d8464caba76b61ad0d0a2227_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtMi0xLTEtNzgzNTI_44ade62b-44d7-448c-b3e9-134cdf02fbd5"
      unitRef="usd">2654000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i1d3183b154e44b52ba30e133758be6a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtNC0xLTEtNzgzNTI_d30fe09b-8e11-4ca1-beb3-410c2006e89a"
      unitRef="usd">0</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i5c0827b42d3347d0afe4307d1f64a381_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzQtNi0xLTEtNzgzNTI_c560961f-df2f-4878-82ca-0589f3d4a680"
      unitRef="usd">2654000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i63ce1991d8464caba76b61ad0d0a2227_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtMi0xLTEtNzgzNTI_c69fc197-cae9-4144-9f3e-a6a34e73004d"
      unitRef="usd">19867000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i1d3183b154e44b52ba30e133758be6a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtNC0xLTEtNzgzNTI_2f21d71c-f76a-4dc2-8cdf-85ef3b368c2f"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i5c0827b42d3347d0afe4307d1f64a381_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzYtNi0xLTEtNzgzNTI_24d3514d-676d-4edb-a922-063db10dae09"
      unitRef="usd">19867000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i1697a254339d443f8484e8d6d3c078e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctMi0xLTEtNzgzNTI_e68fc1a3-61ed-46c5-9b08-a7a5e971b324"
      unitRef="usd">2429000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i2ef36079c8034aeb9d95e92fa8da0e7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctNC0xLTEtNzgzNTI_04fa9fa5-fca8-444a-8bb1-e94b2f8b202c"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i32b8aa0219e04f549a524810fe170d31_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzctNi0xLTEtNzgzNTI_2fd19954-2bed-49cd-8d4e-9e604cdc9f27"
      unitRef="usd">2429000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtMi0xLTEtNzgzNTI_e50535de-baa2-4f1c-ae3f-c155b88c293f"
      unitRef="usd">22296000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtNC0xLTEtNzgzNTI_6f3420b9-6542-4975-be3d-c2cc7928f707"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzgtNi0xLTEtNzgzNTI_0602344c-97d2-4b45-b01f-5c1038b0db75"
      unitRef="usd">22296000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktMi0xLTEtNzgzNTI_7d1b5fb1-d92e-4a1a-b589-375a1fbc3e01"
      unitRef="usd">24950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktNC0xLTEtNzgzNTI_29c78530-ff7a-463b-8948-ab01d701d1b8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzktNi0xLTEtNzgzNTI_1903f4f8-73a3-497f-9626-a3c384992cab"
      unitRef="usd">24950000</us-gaap:AssetsFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i18e735b9eb6e4c1083bb535a258b00f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTItMS0xLTc4MzUy_02232120-f764-445b-bebf-cfe5f49e2f5a"
      unitRef="usd">2654000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="iab9bbb374233424ba61bcc6ed8300a30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTQtMS0xLTc4MzUy_34db202c-ea3f-4bbf-af57-e4e5af3242b0"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i2160a34a98f34909b7b6148fe186d3a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEyLTYtMS0xLTc4MzUy_c95b8c2f-0393-4a48-b048-4ff24f82f8d6"
      unitRef="usd">2654000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i3f15a50eebbd49b0a6ac560862776c4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTItMS0xLTc4MzUy_83459f31-c29c-4662-bd3f-f75f75f79c69"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i1ffc1b1354b24fe9ba6f0f76f2c77735_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTQtMS0xLTc4MzUy_d3281c87-e359-442e-800e-e43176b3f8a3"
      unitRef="usd">15925000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i9b6b493cf9db47da80212141f81c1d71_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzEzLTYtMS0xLTc4MzUy_698bb1ed-c005-45e3-bb7e-3b3bf778ed65"
      unitRef="usd">15925000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTItMS0xLTc4MzUy_ac14dcdb-8cf2-43d2-8597-9e98a8fee25b"
      unitRef="usd">2654000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTQtMS0xLTc4MzUy_534ca1e6-2e2d-472a-a28a-b60199cb36ba"
      unitRef="usd">15925000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE0LTYtMS0xLTc4MzUy_ac1cfb29-6e1a-4782-b992-ea5adf6285ba"
      unitRef="usd">18579000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i18e735b9eb6e4c1083bb535a258b00f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTItMS0xLTc4MzUy_5a060e37-a292-41a9-9c08-d020a9b159d3"
      unitRef="usd">19867000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="iab9bbb374233424ba61bcc6ed8300a30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTQtMS0xLTc4MzUy_ee3f8603-baf6-4f2b-a599-7c340c1db24b"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i2160a34a98f34909b7b6148fe186d3a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE2LTYtMS0xLTc4MzUy_27b4e8d2-26d6-4e13-b3bd-82a3510a84d9"
      unitRef="usd">19867000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTItMS0xLTc4MzUy_15e1f17c-10dc-42e8-8a1d-2cca5d7487d2"
      unitRef="usd">19867000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTQtMS0xLTc4MzUy_c3d914ca-5ebf-42d5-8dc1-39e9c22d0f21"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE4LTYtMS0xLTc4MzUy_2c1bf2cf-a0ce-426f-9b7f-735cd4b3be29"
      unitRef="usd">19867000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a5b34aea52e42c7a2ec2b0dad3bee6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTItMS0xLTc4MzUy_d1168e39-d6fa-4437-b234-67e897c0d870"
      unitRef="usd">22521000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic6dd5edbcc39481389ccf3c19f4c20be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTQtMS0xLTc4MzUy_ce28573c-aad7-499e-b29e-c85cda2a9bce"
      unitRef="usd">15925000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i843b636f6cdd45d9ad126a7384b4f37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTo0ZWMwYjNjNzc3MjY0OWJkYTlmZjg2ZWU0YTRmMjA4Yy90YWJsZXJhbmdlOjRlYzBiM2M3NzcyNjQ5YmRhOWZmODZlZTRhNGYyMDhjXzE5LTYtMS0xLTc4MzUy_d41e4ea3-ab8d-41d9-949a-1a2047c867ca"
      unitRef="usd">38446000</us-gaap:LiabilitiesFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="ie2f30189483c422fa011c8cb6d4922bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtMy0xLTEtNzgzOTk_f52bc71d-c913-4e45-924c-462e23291148"
      unitRef="usd">2043000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i04dda45e829740f79226f6631d6049eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtNS0xLTEtNzgzOTk_c1f64e28-f448-48e4-a78a-8ea89862f8ff"
      unitRef="usd">0</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="idb9c061692ee4459bfff0add9bcd50a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzQtNy0xLTEtNzgzOTk_6f2a2314-dfa2-4a00-b656-89819a1bb419"
      unitRef="usd">2043000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ie2f30189483c422fa011c8cb6d4922bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtMy0xLTEtNzgzODI_82d3db21-9697-44ee-9fa4-7e67b498b0c3"
      unitRef="usd">23929000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i04dda45e829740f79226f6631d6049eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtNS0xLTEtNzgzODI_adc59dc1-ade6-4e9c-966c-5a35593f1f23"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="idb9c061692ee4459bfff0add9bcd50a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzgtNy0xLTEtNzgzODI_4d0e59ad-cc70-41eb-b9ae-62a70b53143c"
      unitRef="usd">23929000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i1808bc04910249a8a0f00222d3bf7e02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktMy0xLTEtNzgzODc_ade5a9bc-5c66-4869-baa3-79309ca2b5b8"
      unitRef="usd">2940000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="iff430fafcf154f4e812f7d333d1d8d7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktNS0xLTEtNzgzODc_df5037c1-cabc-41a5-b095-ff5ed26c4e4b"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="icb05d919991b4e81a5d5ffacd7d4969b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzktNy0xLTEtNzgzODc_8d7c24f6-1111-49a8-9cc7-6d9b3e6749f7"
      unitRef="usd">2940000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTMtMS0xLTc4Mzkx_465876e3-d052-4309-a805-e9e413f065b9"
      unitRef="usd">26869000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTUtMS0xLTc4Mzkx_83be11c2-d2d7-40d5-9c1b-9b8e19bf1212"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzEwLTctMS0xLTc4Mzkx_6f938a50-60c0-40fc-a931-b667d924ccc7"
      unitRef="usd">26869000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTMtMS0xLTc4Mzk1_e2078e16-e8e4-4bf4-a688-cc156cf7defd"
      unitRef="usd">28912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTUtMS0xLTc4Mzk1_02728962-2557-4f64-8d93-d6a18f584652"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzExLTctMS0xLTc4Mzk1_4f4ce096-8af8-4838-b836-5a7c596ccedd"
      unitRef="usd">28912000</us-gaap:AssetsFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ief4aad42990645598a710e3fdc875927_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTMtMS0xLTc4NDAz_8b486137-8fdd-486d-85d6-09739a294cae"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i59fa5863ad174cd78a94e49878481b58_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTUtMS0xLTc4NDAz_368dd167-359b-488b-935c-8888ac74a64f"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="idf63f31c217048c0b0893f82f7a57cc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE0LTctMS0xLTc4NDAz_8c16ea5f-9a06-4989-8c7e-3d241d02a07c"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTMtMS0xLTc4NDIx_82e182d6-6694-4bd4-b91d-685140b1cd00"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i361e100279e84b2abd489b481fc38b7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTUtMS0xLTc4NDIx_1c5484a9-b5ef-4bcb-a143-4c2f18fdf186"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i4bc636c5add94dcdb064bdd55b0154bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE1LTctMS0xLTc4NDIx_f4bf67cd-6a3e-48e5-967b-ac74177730ba"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTMtMS0xLTc4NDI1_50145aae-6df3-4e85-a8a7-41f7cead78af"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTUtMS0xLTc4NDI1_88ef38fd-3468-43bf-8b2b-58e1c77f0198"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE2LTctMS0xLTc4NDI1_2de5eec7-9b86-48c7-8a8b-094d1c9b4444"
      unitRef="usd">50275000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="ief4aad42990645598a710e3fdc875927_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTMtMS0xLTc4NDA3_172c2260-c6c4-481b-a2ca-7b84e93bbe47"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i59fa5863ad174cd78a94e49878481b58_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTUtMS0xLTc4NDA3_94523555-829d-40bf-b5e1-44bc9ab88392"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="idf63f31c217048c0b0893f82f7a57cc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE4LTctMS0xLTc4NDA3_51ab78d2-b9f7-4694-8506-c594fddd3479"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i1f7ebb5cb3f743c7850979e39f87f4d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTMtMS0xLTc4NDA3_75e2e5f8-6fff-463c-b589-648ea1235fcb"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i361e100279e84b2abd489b481fc38b7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTUtMS0xLTc4NDA3_9527676e-4fa8-466a-b180-3c9a7bbe25fd"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i4bc636c5add94dcdb064bdd55b0154bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzE5LTctMS0xLTc4NDA3_67fadc20-dc24-44fb-8da8-c1bc5569e21e"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTMtMS0xLTc4NDEx_0766f969-65ab-4df0-ae0b-244454161d5c"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTUtMS0xLTc4NDEx_f2001252-076e-4904-9e60-1a6d8e676e0b"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIwLTctMS0xLTc4NDEx_b52b90ce-de3e-4ceb-961b-975e77a87d66"
      unitRef="usd">39096000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i854c0f2d747c4115b8ded4dc5b6ed619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTMtMS0xLTc4NDEx_6fa02887-383a-41d5-8d55-671497fc1129"
      unitRef="usd">25972000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a44f63916f346f4bfe2a7ed94fb2103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTUtMS0xLTc4NDEx_b6a8bb64-2536-4deb-a49d-fe66e448f730"
      unitRef="usd">63399000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icd451bf195104b4fa89b348031fa3c06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZTpjMThhM2U1MmYzNjc0NmVjOTcyMGI3ZDQzNzdlNzAyZS90YWJsZXJhbmdlOmMxOGEzZTUyZjM2NzQ2ZWM5NzIwYjdkNDM3N2U3MDJlXzIxLTctMS0xLTc4NDEx_e8a97115-b631-4c66-9457-f8cd22e40b15"
      unitRef="usd">89371000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90ZXh0cmVnaW9uOmVlMWNhNDhlY2MwZjRjZDViZjQwM2VhYTlmZTU0MGM5XzExODE_180965c2-918c-4654-9c69-307825d54449">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payments to Ares Trading S.A. (Merck Serono)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realized foreign exchange gain on settlement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange remeasurement of Euro denominated contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzAtMS0xLTEtNzg0NDU_c2668843-dee5-4704-872b-e4b02875ed0b"
      unitRef="usd">63399000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzEtMS0xLTEtNzg0NzA_1ebbe1b4-3e57-4312-95a9-b125440bf7a0"
      unitRef="usd">47738000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzMtMS0xLTEtNzg0NDk_d81b2b2a-a64c-429f-a3d5-c65bc0bcc125"
      unitRef="usd">4399000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bmrn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange
      contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzQtMS0xLTEtNzg0NzQ_652a0144-ab10-475b-987b-5f3807b84089"
      unitRef="usd">2333000</bmrn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange>
    <bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement
      contextRef="idce35887d4b441e7903b44b39adba651_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzUtMS0xLTEtNzg0NTM_6ec6436f-4f84-4e16-bdbe-a42309ef8bb0"
      unitRef="usd">-1802000</bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia1739c85dcaf415cacb59ea7ea04ca80_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjMvZnJhZzplZTFjYTQ4ZWNjMGY0Y2Q1YmY0MDNlYWE5ZmU1NDBjOS90YWJsZToyNTc2N2M1MjJlYmQ0ZTc1Yjc4MGVmNjliNDhkNjkyMC90YWJsZXJhbmdlOjI1NzY3YzUyMmViZDRlNzViNzgwZWY2OWI0OGQ2OTIwXzYtMS0xLTEtNzg0Nzg_320dc3be-1801-4b7f-9928-7d3da69c353e"
      unitRef="usd">15925000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzExOTE_6e327736-53a2-48ba-8a7c-dad1e9ca8fe3">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's forward contracts designated as hedging instruments have maturities up to 1 year, 9 months. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to 3 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate notional amounts for the Company&#x2019;s derivatives outstanding as of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value carrying amounts of the Company&#x2019;s derivatives, as classified within the fair value hierarchy, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Refer to Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for additional information related to the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company expects to reclassify unrealized losses of $7.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_175" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i1bbdcfdf6d7f44e98151b2323cc59a91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzE3NTkyMTg2MDQ1NzM2_cc0cf263-5e7f-45a1-a22b-c3497c5a876c">P1Y9M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ia4cc530299f847d189a72330922c67cd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzE3NTkyMTg2MDQ1NzQw_8422ba71-dd2e-4fe4-a7a9-75d9636b5186">P3M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzExOTI_6152da71-0084-493e-8f3b-cceb532b930a">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate notional amounts for the Company&#x2019;s derivatives outstanding as of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i07b156ee48534e11b0e4ec467c89f063_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzItMS0xLTEtNzg0ODY_46b3ae97-0acc-4865-a490-0e18dd0314f9"
      unitRef="usd">808635000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id6630e8205694223b373923bba0b4d10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzItMy0xLTEtNzg0ODY_4e08a4ca-f5b7-4887-bba5-96ba27370c52"
      unitRef="usd">740667000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5347e22ccf064748b88e50f6bd0c2161_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzMtMS0xLTEtNzg0ODY_0c50a37c-2b26-445a-aa18-9e2a10feb700"
      unitRef="usd">177393000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i03ad5d6c2ce54eb183ff3585f491d96e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzMtMy0xLTEtNzg0ODY_e2d31e4d-3bfc-4a79-9a68-2cccbc32cafd"
      unitRef="usd">183256000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if8acf9e28afb48f9a9b97f6033ce470a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzYtMS0xLTEtNzg0ODY_25703082-8c77-468f-bb91-b7ebe56a222a"
      unitRef="usd">218903000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i049d9f5eac174d9e9fb8daaf63a40764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzYtMy0xLTEtNzg0ODY_96ff48e9-a367-4a84-a1f9-ae7c8467f5a2"
      unitRef="usd">113257000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idfd631e0c0be404fbdac1dbda30f94fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzctMS0xLTEtNzg0ODY_7db1ada9-0a57-49bf-b63a-ef55c25fe124"
      unitRef="usd">6785000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id5453050b0674bbfaf495fdbe38838bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTo3OTk2NzcwOGQ2NDU0MWE3YTdjZGQ1MWVkN2Q0YmExNS90YWJsZXJhbmdlOjc5OTY3NzA4ZDY0NTQxYTdhN2NkZDUxZWQ3ZDRiYTE1XzctMy0xLTEtNzg0ODY_d5d296e2-ea98-49b4-8685-da3ba8330850"
      unitRef="usd">31068000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzU0OTc1NTgxNDYxNDc_cd2e1aed-da78-48a5-8795-7155d9907b71">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value carrying amounts of the Company&#x2019;s derivatives, as classified within the fair value hierarchy, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Refer to Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for additional information related to the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i78357676b9ad4a62990f8ad0e3be1b8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzMtMS0xLTEtMTA0MTAx_c9b2c1ce-5422-444a-9953-b537947e6ab2"
      unitRef="usd">19464000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i701ea9c137b743d5b8fbcf9a4516ee31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzMtMy0xLTEtMTA0MTAx_4179b2d8-2370-4b88-9cb4-edd7a3de2f5b"
      unitRef="usd">17357000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i0e05c8915f6d4424a51797377fec49d4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzQtMS0xLTEtMTA0MTAx_1d2236e5-3a9c-40df-8620-633ec1c0c452"
      unitRef="usd">2059000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia81ef93ba75f4c7f9a65f2262abc826c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzQtMy0xLTEtMTA0MTAx_cdaea01d-cec1-4b20-ba16-928df0560775"
      unitRef="usd">4991000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzUtMS0xLTEtMTA0MTAx_7a47e927-cdba-4cc9-bc9f-463569e61b42"
      unitRef="usd">21523000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2949967682844b40b3939cf685911572_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzUtMy0xLTEtMTA0MTAx_9fbe327c-8417-4304-954d-29e40793d48c"
      unitRef="usd">22348000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i120af3133b724435b609f48a754ddc28_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzgtMS0xLTEtMTA0MTAx_3c5c6f4a-f001-405f-822c-3093c8e06818"
      unitRef="usd">12130000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id034c5704d704b1899e0fe63a9b16d85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzgtMy0xLTEtMTA0MTAx_c7ffc0f1-193a-44e0-902b-21d834242fe4"
      unitRef="usd">5487000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0459695791c54a5c9470c16c53c5e1b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzktMS0xLTEtMTA0MTAx_8eb0cc53-d7a7-42d7-826b-48a38ccfd9b4"
      unitRef="usd">1074000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iea5945041fd04f8fa60d89c188909d74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzktMy0xLTEtMTA0MTAx_91a3da32-0f75-4987-89e7-416cd52b16cc"
      unitRef="usd">1378000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibcd7b8185a0f402d85ad0a4747a0e036_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzEwLTEtMS0xLTEwNDEwMQ_17f5dddc-54af-47e5-8f19-eee8bdeebeae"
      unitRef="usd">13204000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2949967682844b40b3939cf685911572_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzEwLTMtMS0xLTEwNDEwMQ_78b67f90-7cca-4d52-a771-11caa78b89a4"
      unitRef="usd">6865000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idda7870ff3904fafa6c5f6898f8ea22b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE0LTEtMS0xLTEwNDEwMQ_a8ee207d-2085-4d37-8ef9-304472e568fa"
      unitRef="usd">1472000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idc8c32dfdf364e6ebfeca0e2dbe52145_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE0LTMtMS0xLTEwNDEwMQ_bf352c6c-8b34-4d83-8bab-e0fd1e40d75a"
      unitRef="usd">427000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie7810729b64f4f81ab7e6d7951dd41db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE5LTEtMS0xLTEwNDEwMQ_6ff2beb2-25b0-4768-bb11-91b30ab90e2e"
      unitRef="usd">471000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2249a32749024298ac14d49e5abc5209_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzE5LTMtMS0xLTEwNDEwMQ_cd4aaeda-a1cb-4a70-b371-122a8dd195a7"
      unitRef="usd">776000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzIzLTEtMS0xLTEwNDEwMQ_94344e9a-444b-4844-aba5-eb180be316b3"
      unitRef="usd">22995000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzIzLTMtMS0xLTEwNDEwMQ_56570220-fb5d-4b14-b85c-5979ff30a90b"
      unitRef="usd">22775000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzI0LTEtMS0xLTEwNDEwMQ_868c114e-8661-4b64-a180-e7058e1df241"
      unitRef="usd">13675000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZToxMGY4NmIyZTdhNWY0MjZjOWI2ODBkOWVlNjY1NmNiYy90YWJsZXJhbmdlOjEwZjg2YjJlN2E1ZjQyNmM5YjY4MGQ5ZWU2NjU2Y2JjXzI0LTMtMS0xLTEwNDEwMQ_ffb0e3d5-fd44-48e0-80f2-f5aafcb5174f"
      unitRef="usd">7641000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzU0OTc1NTgxNDYxNDg_c9b78bbe-eb54-434f-b96d-bbebce4014d9">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i535f35b9a823419bbd09b248cdd5f011_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzQtMy0xLTEtMTA0MTAx_36e5acab-73f0-4b7d-bd13-a2a97f070117"
      unitRef="usd">48541000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if9fcf787fd284d24881b86f72e6d9c06_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzQtNy0xLTEtMTA0MTAx_ad760256-8e60-45cb-8ed8-bbbe578f178a"
      unitRef="usd">196000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzUtMy0xLTEtMTA0MTAx_a59c3e6b-cbb2-4a20-9034-e83390e90762"
      unitRef="usd">-11917000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i929eedfedb93483daed0c9feb18c8083_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzUtNy0xLTEtMTA0MTAx_a7c015ba-4860-4e79-be1a-e7de9f8e457d"
      unitRef="usd">-1650000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia4cc530299f847d189a72330922c67cd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzgtMy0xLTEtMTA0MTAx_91a30c21-0df6-4390-9257-e1a4943ba727"
      unitRef="usd">872000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i0aabd222ee0c445889bc6c55761ef645_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90YWJsZTowYTRiYzBiM2M0NWU0YTlmOTBmM2Y4OTE0ZmMzY2JlYy90YWJsZXJhbmdlOjBhNGJjMGIzYzQ1ZTRhOWY5MGYzZjg5MTRmYzNjYmVjXzgtNy0xLTEtMTA0MTAx_75c28c16-b919-4adb-b33d-8cd9d63d0e37"
      unitRef="usd">1548000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjYvZnJhZzo1Mjk0ZDY0NmRkMWI0MTgzOTFkZGY0MTEzYzkxNTBlMi90ZXh0cmVnaW9uOjUyOTRkNjQ2ZGQxYjQxODM5MWRkZjQxMTNjOTE1MGUyXzEwOTk1MTE2MzMzNDc_4f002b46-e63f-43ed-8991-fac18c8c9764"
      unitRef="usd">-7200000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1NA_79090c65-bdb3-4cb8-afba-c43313e5bc6e">LEASES&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s ROU assets and lease liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease costs associated with payments under the Company&#x2019;s leases for the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Includes short-term leases and variable lease costs, both of which were not material in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company&#x2019;s lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;leases were expected to commence that would create significant rights and obligations for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock>
    <bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1NQ_11ae744a-22d4-4b8b-ab74-2e197a1ee165">&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s ROU assets and lease liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_8bf7c681-9ff8-408e-a7a9-d394053367ad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtMi0xLTEtNzc2Mzg_d9d1ab9f-e13b-4b40-be11-c065e7f32e36"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_3b8dabff-68ab-41b7-91d0-63c7b8ed483f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtMi0xLTEtNzc2Mzg_5433f135-a3c0-4b2b-9248-b19d2cb0d5b0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_15cb6eed-4197-4976-ba57-9fe385d20057"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtMi0xLTEtNzc2Mzg_b5c22652-2ba1-4114-a6b6-f2b601af4ea4"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_cc463285-cd4d-4979-a827-80285a5b7a86"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktMi0xLTEtNzc2Mzg_d8c4fed4-f1b1-4708-80a1-c763d9166264"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_be78929e-13d6-483b-b57a-3a8ec202301a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTItMS0xLTc3NjM4_e81756ca-5f75-4eb0-89e4-473a2958abd9"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_141ef275-cc5b-459c-a4aa-922b8f971d46"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTItMS0xLTc3NjM4_934c008a-56b4-46d6-a591-0059ed3a495c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtNC0xLTEtODA2MjQ_54d42f55-cfe3-4242-a251-d84450aa713e"
      unitRef="usd">34935000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzMtNi0xLTEtODA2MjQ_6b983b2d-096e-45c1-a09c-ba1bc96faab3"
      unitRef="usd">38198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtNC0xLTEtODA2MjQ_a8684dae-4e83-4d58-b751-1820480763db"
      unitRef="usd">6021000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzQtNi0xLTEtODA2MjQ_36b993f5-72fa-40f9-b945-af5586de5e6e"
      unitRef="usd">8220000</us-gaap:FinanceLeaseRightOfUseAsset>
    <bmrn:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzUtNC0xLTEtODA2MjQ_00773891-c13e-49f1-85c8-9190d8598804"
      unitRef="usd">40956000</bmrn:OperatingAndFinanceLeaseRightOfUseAsset>
    <bmrn:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzUtNi0xLTEtODA2MjQ_c2c54bb0-5910-4f1f-9c7f-e879ef18cb7d"
      unitRef="usd">46418000</bmrn:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtNC0xLTEtODA2MjQ_17e79932-cb7b-41db-93d2-144b7cf68e47"
      unitRef="usd">8088000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzgtNi0xLTEtODA2MjQ_affbea0d-5a91-4e80-a60f-8e3f631b673f"
      unitRef="usd">8198000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktNC0xLTEtODA2MjQ_a0c7f529-9a2d-409b-94ff-a4c3fdcc3cff"
      unitRef="usd">2287000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzktNi0xLTEtODA2MjQ_28207ce1-40a4-4c74-a1ba-5f491c9d141f"
      unitRef="usd">2266000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTQtMS0xLTgwNjI0_6ba59258-1b56-4e5d-abf4-68dda549ae99"
      unitRef="usd">26329000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzExLTYtMS0xLTgwNjI0_866dd75a-f5f7-49d2-ac10-6baccaf791d2"
      unitRef="usd">31882000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTQtMS0xLTgwNjI0_6e872df4-e5a4-47fa-a132-e45d330b1767"
      unitRef="usd">184000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEyLTYtMS0xLTgwNjI0_7e885337-efd1-4e27-8c6c-bafdcb4c7f77"
      unitRef="usd">1960000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <bmrn:OperatingAndFinanceLeaseLiability
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEzLTQtMS0xLTgwNjI0_653e843e-b1fb-4d69-9069-f666aaad3eaa"
      unitRef="usd">36888000</bmrn:OperatingAndFinanceLeaseLiability>
    <bmrn:OperatingAndFinanceLeaseLiability
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZToxODA1N2NlNjEyZDE0NTcxODBlNzk1OGVlNmQwNzM0Ny90YWJsZXJhbmdlOjE4MDU3Y2U2MTJkMTQ1NzE4MGU3OTU4ZWU2ZDA3MzQ3XzEzLTYtMS0xLTgwNjI0_2e5e2aef-6222-4c59-84e6-2cb8b6720949"
      unitRef="usd">44306000</bmrn:OperatingAndFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1OQ_7e6c9af7-41eb-45d1-8b71-4792b8454c00">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc1OQ_b59f4dc9-0a9c-4b93-b914-2727dd611a69">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 by fiscal year were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtMi0xLTEtODA2NDE_6a0dc89d-7805-431e-a9e4-365a31cd3c9e"
      unitRef="usd">9691000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtNC0xLTEtODA2NDE_8968daff-6ab2-4bc1-9fb4-90d4265b4f61"
      unitRef="usd">2341000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzEtNi0xLTEtODA2NDE_fd7bbb30-5015-4747-8b00-f36be10ef121"
      unitRef="usd">12032000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItMi0xLTEtODA2NDE_5e522b10-bb17-48f7-932e-70ba75126ff2"
      unitRef="usd">7586000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItNC0xLTEtODA2NDE_3035a4ca-8bd0-4acb-a979-a8971bf663f8"
      unitRef="usd">123000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzItNi0xLTEtODA2NDE_65a4f641-18f7-4a31-86ad-775ab635cd21"
      unitRef="usd">7709000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtMi0xLTEtODA2NDE_32ca9667-a6a4-463e-b79d-50df0cff261d"
      unitRef="usd">5960000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtNC0xLTEtODA2NDE_19c5bf37-be24-4b16-a3ed-af88279b671d"
      unitRef="usd">53000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzMtNi0xLTEtODA2NDE_5655b9d7-eb70-42de-b6db-bc4dce29eede"
      unitRef="usd">6013000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtMi0xLTEtODA2NDE_503a92c0-bbbe-4e8c-a760-8f0acc60b041"
      unitRef="usd">4978000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtNC0xLTEtODA2NDE_0d54ca24-5b94-49fc-9f45-7f3850c7d54a"
      unitRef="usd">6000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzQtNi0xLTEtODA2NDE_e6ca3e7e-b434-4a8d-b163-5ea55362be53"
      unitRef="usd">4984000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtMi0xLTEtODA2NDE_659591a2-deb1-4661-b142-b2d2158cf32b"
      unitRef="usd">4341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtNC0xLTEtODA2NDE_5b17ebb6-f51d-4ebc-8eee-fa09fa535948"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzUtNi0xLTEtODA2NDE_945abc84-bc92-440e-9d08-06357d287ef2"
      unitRef="usd">4341000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtMi0xLTEtODA2NDE_1428e068-c1d0-40ab-a75f-77975af4fdf8"
      unitRef="usd">7211000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtNC0xLTEtODA2NDE_eca6187b-7ea2-4ff7-9859-c7b255d8dc15"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzYtNi0xLTEtODA2NDE_b32b282e-8eaa-473b-b7c7-272ef1dcf683"
      unitRef="usd">7211000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctMi0xLTEtODA2NDE_e1ad6051-31ad-46da-961b-77611828bc2e"
      unitRef="usd">39767000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctNC0xLTEtODA2NDE_36ed00f3-3c9a-4376-b9be-0c74c5e8ce01"
      unitRef="usd">2523000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzctNi0xLTEtODA2NDE_4c9eade2-fdee-496e-97af-b3c35a8be452"
      unitRef="usd">42290000</bmrn:OperatingAndFinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtMi0xLTEtODA2NDE_5fb68e56-4a31-4c06-acdc-d0b4f0e81cb6"
      unitRef="usd">5350000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtNC0xLTEtODA2NDE_aaf5517e-b6b8-452b-90cd-d98289f8dfe0"
      unitRef="usd">52000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <bmrn:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzgtNi0xLTEtODA2NDE_1ecc9146-d0a4-43da-9702-1147b034fa3a"
      unitRef="usd">5402000</bmrn:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktMi0xLTEtODA2NDE_fac8a46c-b742-4dbc-af58-e3a154cbe144"
      unitRef="usd">34417000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktNC0xLTEtODA2NDE_d8812ec8-6a75-4433-8941-ec850f9ffe0d"
      unitRef="usd">2471000</us-gaap:FinanceLeaseLiability>
    <bmrn:OperatingAndFinanceLeaseLiability
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTplNDhhMDRiZTlkNzg0MWU0OGRmOGNiNDlkYjYzMWZmOC90YWJsZXJhbmdlOmU0OGEwNGJlOWQ3ODQxZTQ4ZGY4Y2I0OWRiNjMxZmY4XzktNi0xLTEtODA2NDE_5a8d4ecf-538b-4890-9931-bfdda9768858"
      unitRef="usd">36888000</bmrn:OperatingAndFinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc2MA_9587ec0e-2bde-472a-bf94-e0acf5da89cb">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease costs associated with payments under the Company&#x2019;s leases for the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Includes short-term leases and variable lease costs, both of which were not material in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzItNC0xLTEtODA2OTk_456860c5-e381-4345-afac-088e9b3bd40b"
      unitRef="usd">13669000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzItNi0xLTEtODA2OTk_b26a7d26-25ed-4cf9-b46a-dbc0fc5a67d2"
      unitRef="usd">13962000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzQtNC0xLTEtODA2OTk_9ee98503-b1c6-4f5b-9aac-8283a0e58713"
      unitRef="usd">2858000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzQtNi0xLTEtODA2OTk_f3bb7f60-c826-420c-a82b-ebdbf80ce188"
      unitRef="usd">3339000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="iff472b40fc0d45fe8a7c6832f3cd8a77_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzUtNC0xLTEtODA2OTk_ce3c6240-2c7d-4ad1-a18a-70837c83aa96"
      unitRef="usd">163000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6652e5e8832d434a8faf448e80c020b5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzUtNi0xLTEtODA2OTk_45d6cff8-154e-438d-ab1a-7f716e74d2bc"
      unitRef="usd">283000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzYtNC0xLTEtODA2OTk_ef2a8e15-3b4d-4864-bd8f-105512a3831e"
      unitRef="usd">16690000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo2ZjdhMGIwYzc4MTQ0ZWRkODJlYzE5OGVkMTM1ZWVjZS90YWJsZXJhbmdlOjZmN2EwYjBjNzgxNDRlZGQ4MmVjMTk4ZWQxMzVlZWNlXzYtNi0xLTEtODA2OTk_42870677-04a4-4427-aa2d-29e55cc3a79e"
      unitRef="usd">17584000</us-gaap:LeaseCost>
    <bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90ZXh0cmVnaW9uOmM3ZTRlYzJkMjcxMDRlODVhYTUyZGRhODNmZjdjYjRkXzc2Mg_a9ed4532-0d1e-46ed-8641-3567e713e3bf">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company&#x2019;s lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzMtMi0xLTEtODA3NTM_17839275-bb4d-419c-829c-9098f5415ad0">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzMtNC0xLTEtODA3NTM_0102566e-32cc-4a96-a0da-c02790bc1fcf">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzQtMi0xLTEtODA3NTM_d00f8545-8334-46a0-8875-6fe8c0672958">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzQtNC0xLTEtODA3NTM_1ba8c9c4-6cb9-4eb7-8d6d-a48f6b153893">P1Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzctMi0xLTEtODA3NTM_f009d76e-c02d-46a7-8fa3-bda25c87da6c"
      unitRef="number">0.051</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzctNC0xLTEtODA3NTM_0a6b7cee-a403-4c13-be44-33af512f8952"
      unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzgtMi0xLTEtODA3NTM_bbac41ff-7e22-4200-a68b-27212799aad5"
      unitRef="number">0.054</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo3M2ZlYTNmNTkyNmQ0ZmM1YWFhNDM2ZTYxMTI0NWRlZS90YWJsZXJhbmdlOjczZmVhM2Y1OTI2ZDRmYzVhYWE0MzZlNjExMjQ1ZGVlXzgtNC0xLTEtODA3NTM_323ea9c3-8ae1-4dba-86eb-70c837e3347a"
      unitRef="number">0.051</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzQtMi0xLTEtODA3OTM_19d4cc95-f146-4975-8aa6-78369fe441ef"
      unitRef="usd">10760000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzQtNC0xLTEtODA3OTM_d8ce56ed-08f3-4245-bdb7-3ceab5af8cf2"
      unitRef="usd">10664000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzUtMi0xLTEtODA3OTM_84dee11a-f763-4d55-b40f-9724976035e8"
      unitRef="usd">165000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzUtNC0xLTEtODA3OTM_55d9f39c-ee23-4f58-9c8a-cfd25be5f7cb"
      unitRef="usd">283000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzctMi0xLTEtODA3OTM_ebd98f48-9a70-4560-ab23-9c50943b217e"
      unitRef="usd">2605000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzctNC0xLTEtODA3OTM_5736e09b-6a51-4cbb-a228-0000c041a689"
      unitRef="usd">3039000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzktMi0xLTEtODA3OTM_148e50d6-cf5e-48f6-b66a-a17dfa51d908"
      unitRef="usd">5252000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzktNC0xLTEtODA3OTM_594d8b6d-3449-49c3-8e48-16000b1e3e79"
      unitRef="usd">760000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzEwLTItMS0xLTgwNzkz_b4dfcd79-214b-4700-972b-14dc80178ab8"
      unitRef="usd">878000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNjkvZnJhZzpjN2U0ZWMyZDI3MTA0ZTg1YWE1MmRkYTgzZmY3Y2I0ZC90YWJsZTo1YWI3ZjIwOTYxNmQ0ZGFmOWQwMmY2ZTE5M2U1OTc5Yy90YWJsZXJhbmdlOjVhYjdmMjA5NjE2ZDRkYWY5ZDAyZjZlMTkzZTU5NzljXzEwLTQtMS0xLTgwNzkz_7143565c-637a-4065-8970-eac4f4504ffe"
      unitRef="usd">462000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LongTermDebtTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDY_c4c43b34-b918-4ebf-a04d-796e96f8f4ad">DEBT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#x2019;s convertible debt:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;591,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total convertible debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,083,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of fixed-rate convertible debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;647,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total fair value of fixed-rate convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The fair value of the Company&#x2019;s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for additional discussion of fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense on the Company&#x2019;s fixed-rate convertible debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of discount on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;2027 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company&#x2019;s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company&#x2019;s common stock. A holder may convert fewer than all of such holder&#x2019;s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8&#160;million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company&#x2019;s existing and future senior debt, (ii) equal in right of payment with the Company&#x2019;s existing and future senior subordinated debt, (iii) senior in right of payment to the Company&#x2019;s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company&#x2019;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;preferred equity, if any, of the Company&#x2019;s subsidiaries. Upon the occurrence of a &#x201c;fundamental change,&#x201d; as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder&#x2019;s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The offer and sale of the 2027 Notes and the shares of the Company&#x2019;s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company&#x2019;s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company&#x2019;s common stock. A holder may convert fewer than all of such holder&#x2019;s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million. In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9&#160;million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company&#x2019;s existing and future senior debt, (ii) equal in right of payment to any of the Company&#x2019;s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company&#x2019;s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company&#x2019;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company&#x2019;s subsidiaries. Upon the occurrence of a &#x201c;fundamental change,&#x201d; as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder&#x2019;s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_190" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;16&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on earnings (loss) per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million, which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of December&#160;31, 2022, there were no amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzU0OTc1NTgyMTIwOQ_9e059330-6c76-4f04-8919-7ba777d4f2df"
      unitRef="usd">1100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDM_3d3ea7e8-b13f-4dff-9d41-eceeb06c2591">The Notes are senior subordinated convertible obligations, and &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#x2019;s convertible debt:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;591,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total convertible debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,083,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 37pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of fixed-rate convertible debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;647,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total fair value of fixed-rate convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The fair value of the Company&#x2019;s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for additional discussion of fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjphYTIzZTE1NTUxZjA0ZDg2ODY0MzNhODkwMDgzMDE2NF8xNjQ5MjY3NDQxNzY1_7f8c9fe1-855b-4d9c-9340-50c9e9633995"
      unitRef="number">0.01250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5daf35554b6a433a843510d389717d6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjphYTIzZTE1NTUxZjA0ZDg2ODY0MzNhODkwMDgzMDE2NF8xNjQ5MjY3NDQxNzY1_8a3c2193-03f5-4095-8dd7-c40e87c94d5d"
      unitRef="number">0.01250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMS0xLTEtNzg1NDM_94c6aa71-db10-4dcb-aca3-0dafe4aff759"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5daf35554b6a433a843510d389717d6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzItMy0xLTEtNzg1NDM_8cc47798-f790-41f7-9096-2ed589392286"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzMtMS0xLTEtNzg1NDM_f8f9ab73-2301-4642-ab4a-ec48a98bf093"
      unitRef="usd">8941000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i5daf35554b6a433a843510d389717d6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzMtMy0xLTEtNzg1NDM_2845d8f4-b52e-4443-be33-89d4471b685a"
      unitRef="usd">10971000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzQtMS0xLTEtNzg1NDM_62a8effa-a364-4032-9c4e-82641cd96dcb"
      unitRef="usd">591059000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i5daf35554b6a433a843510d389717d6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzQtMy0xLTEtNzg1NDM_ec6d44e7-6b57-474f-8809-96ea32694236"
      unitRef="usd">589029000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjozNWFkODEwYTg4NzA0ODRjOWFiZmNjZGU4YjhmODY4ZF8xNjQ5MjY3NDQxNzcw_c72942a5-1702-4c33-a4e3-dd507088c7fa"
      unitRef="number">0.00599</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ac5b26310a44ef85642267c702776c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMC0xLTEtNzg1NDEvdGV4dHJlZ2lvbjozNWFkODEwYTg4NzA0ODRjOWFiZmNjZGU4YjhmODY4ZF8xNjQ5MjY3NDQxNzcw_cedf81b9-5247-4373-9488-efabbd6c9e13"
      unitRef="number">0.00599</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMS0xLTEtNzg1NDM_b1d4176b-dd4d-44be-a622-bee94b27c1d2"
      unitRef="usd">495000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i86ac5b26310a44ef85642267c702776c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzYtMy0xLTEtNzg1NDM_84999a08-de68-4ae6-b875-b0ce897882e7"
      unitRef="usd">495000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzctMS0xLTEtNzg1NDM_06b8dbcb-e904-44b9-9d72-5e2586ca7d36"
      unitRef="usd">3040000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i86ac5b26310a44ef85642267c702776c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzctMy0xLTEtNzg1NDM_515657f8-a697-4be3-9f9f-a8dcae445adb"
      unitRef="usd">4952000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzgtMS0xLTEtNzg1NDM_a8ff704d-99c9-4e22-b873-e3385844535f"
      unitRef="usd">491960000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i86ac5b26310a44ef85642267c702776c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzgtMy0xLTEtNzg1NDM_d79871f1-ff3d-4c08-a0b5-d15aaadff520"
      unitRef="usd">490048000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEwLTEtMS0xLTc4NTQz_b3d59e83-55d0-4a90-adfb-1f5dd5835110"
      unitRef="usd">1083019000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEwLTMtMS0xLTc4NTQz_7447a477-e863-438e-ba53-4740bdd25853"
      unitRef="usd">1079077000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="if99c4348a7ed4696a2143a068c963e32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEzLTEtMS0xLTc4NTQz_2d1edd81-bd96-419b-9517-6686f8ca1607"
      unitRef="usd">647370000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i5daf35554b6a433a843510d389717d6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzEzLTMtMS0xLTc4NTQz_d67193d4-c92a-41a4-89ce-7a8b21f8a2f8"
      unitRef="usd">625122000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ib36660209faa4d7ab26ebb76638229b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE0LTEtMS0xLTc4NTQz_77fd4300-6b15-427d-966f-6a19f4ebc9df"
      unitRef="usd">526230000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i86ac5b26310a44ef85642267c702776c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE0LTMtMS0xLTc4NTQz_d98dded9-8ed9-4b8f-ae53-35719bb1f741"
      unitRef="usd">521082000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE1LTEtMS0xLTc4NTQz_46d5eba2-f07b-4f99-b509-3dcda66846fe"
      unitRef="usd">1173600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZToxOTc5NjFhMjJkODc0YjZlOTM2NjcyN2VkZWY2OGMwNy90YWJsZXJhbmdlOjE5Nzk2MWEyMmQ4NzRiNmU5MzY2NzI3ZWRlZjY4YzA3XzE1LTMtMS0xLTc4NTQz_4c951053-bb6d-4cf0-b838-b0000bbbfd82"
      unitRef="usd">1146204000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcyMDQ_5adecdba-6881-4de6-90ab-090e48eab528">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense on the Company&#x2019;s fixed-rate convertible debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of discount on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItMS0xLTEtNzg1NTY_e0f858a3-14a2-46f4-9fbc-8ff05d8eefe2"
      unitRef="usd">10465000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItMy0xLTEtNzg1NTY_3e910b31-e5ed-48f9-8706-0b1b1269735a"
      unitRef="usd">10465000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzItNS0xLTEtODEzNzI_f4fa4acc-27f9-4c1a-8aba-2a6cb7e2bac6"
      unitRef="usd">12350000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtMS0xLTEtNzg1NTY_80a05c36-8a5b-48e8-b940-a43f8eeecf6d"
      unitRef="usd">3349000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtMy0xLTEtNzg1NTY_725e5aed-68c7-4a80-aa4c-039868de6aa0"
      unitRef="usd">3339000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzMtNS0xLTEtODEzNzI_dc04d0e9-9080-4b2b-b8fa-06fe73ed404d"
      unitRef="usd">14682000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtMS0xLTEtNzg1NTY_15a36d7a-d9d7-4bf2-ae29-c019d48a26c9"
      unitRef="usd">593000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtMy0xLTEtNzg1NTY_b6723e88-6c3e-4f24-8c82-0f262a2051af"
      unitRef="usd">593000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzQtNS0xLTEtODEzNzI_fc601cf3-7ac1-465f-aa16-af92d9966296"
      unitRef="usd">1829000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpense
      contextRef="if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtMS0xLTEtNzg1NTY_3d6cc2f3-cbaa-43dd-af34-bad96224a3ba"
      unitRef="usd">14407000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia077dce57e04428aaceee8635cd93fdd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtMy0xLTEtNzg1NTY_41714b57-68f1-415d-b659-8a28cbde8718"
      unitRef="usd">14397000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6dcc1cc9b3384ccebe217ff9b5efef34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90YWJsZTowOWRlZjRlMjYyOGY0Y2U2YTY1MjhkYmI5NzM3YTc1Ny90YWJsZXJhbmdlOjA5ZGVmNGUyNjI4ZjRjZTZhNjUyOGRiYjk3MzdhNzU3XzUtNS0xLTEtODEzNzI_93d39da6-c179-44e5-ad03-eea203957316"
      unitRef="usd">28861000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNTk_3b3d620f-6fd4-4cb4-9387-13c46f3d3055"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNjk_ac276b66-f29c-4741-b93b-a7504b698618"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzE0MTk_6b8f1e97-76b5-44ab-8d2b-7398432fc6b4"
      unitRef="usdPerShare">137.47</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="icc7acb734e7a46518521815a0e658880_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzE5NjA_9a4d1145-1db7-41a4-af72-416f455a2447"
      unitRef="usd">585800000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwNzg_d7653fbd-b1ba-4e79-8f29-fe603f7461d0"
      unitRef="usd">13500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount
      contextRef="i97af8e39d55a45988666e9a615166ab0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzMyMjk_3df3184a-f75f-4880-ab2f-3cd98a24ca3a"
      unitRef="number">1</bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzM3MDE_766410d3-a8bd-4653-a1e0-010b2480cb0c"
      unitRef="usd">495000000</us-gaap:DebtInstrumentFaceAmount>
    <bmrn:DebtInstrumentPercentageOfFaceValue
      contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzM4NDc_09544a3a-ec19-4a1e-9ac4-ae8661b27592"
      unitRef="number">0.98</bmrn:DebtInstrumentPercentageOfFaceValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzEwOTk1MTE2MzUwOTM_753aa417-45d4-4b76-aa26-ace9848f21d2"
      unitRef="number">0.00599</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQyODI_638d2e08-a38a-4b29-a42c-761d4ce0ca86"
      unitRef="usdPerShare">124.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ie2fdc2e63a8246c6b4b8a6d78d13fce6_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQ4MTk_c1a7c584-a995-43e4-9d0e-6e86bc9787ce"
      unitRef="usd">481700000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7e3514162b114cccb5bd4903da892d79_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzQ5Mjc_9d278928-704f-49f4-99a5-98c1f776210a"
      unitRef="usd">9900000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount
      contextRef="ica62b7ca7a3f4aee8d2b64beac63adb6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzYwOTk_0d227f83-afb3-4cc7-8452-e779f22d7c2f"
      unitRef="number">1</bmrn:SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i76aebdd53eb84ceab8638e5fb1ff8e9b_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzY0OTQ_a8260f94-e996-4bbc-8e47-aa94273edc1c"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i3efb3be452cd4b8cb7fea7f3c05ba63e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzIvZnJhZzpjNTg2YmZjOWRlNWE0ZGVkYWNhNTY0YjJjZGRjM2M5ZS90ZXh0cmVnaW9uOmM1ODZiZmM5ZGU1YTRkZWRhY2E1NjRiMmNkZGMzYzllXzcwNDQ_dc597146-602a-48fb-8e30-6a4bf1680b7a"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90ZXh0cmVnaW9uOmFiZDQwOWI2MjgyYTQwNWU4NTk0YWVmMDYxNDJmMGRkXzI3Mw_48199ab9-00e8-447e-b041-346b58217e55">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90ZXh0cmVnaW9uOmFiZDQwOWI2MjgyYTQwNWU4NTk0YWVmMDYxNDJmMGRkXzI3NA_0e37f1b6-41d6-4cc5-bcce-603dee130fd3">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i7e306c702cbb420eac9580746df9ae30_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtMS0xLTEtODEzNzU_8a7c76f8-0521-4b98-b8d9-39e00d882ee1"
      unitRef="usd">16614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i618baef4a9c943558fad300e0bb46e9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtMy0xLTEtODEzNzU_e8647f69-eb7b-412f-95e8-fc77c8fd11dd"
      unitRef="usd">3565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6872ed12f9164d05957167fd36693e24_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtNS0xLTEtODEzNzU_13151765-568f-4aa8-b914-1d1d3eecb74e"
      unitRef="usd">-15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ec53576eff54be9aebf7078e363312e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEtNy0xLTEtODEzNzU_143f7aef-7c82-4908-b60a-455b5a586cb3"
      unitRef="usd">20164000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItMS0xLTEtODEzNzU_d856469b-1f68-49ba-8cf7-96c9d2e9435c"
      unitRef="usd">-23462000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItMy0xLTEtODEzNzU_5b4966c2-504b-4ba1-a650-d499f959e7e7"
      unitRef="usd">976000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItNS0xLTEtODEzNzU_40846f52-f53f-43df-9f31-0d4fd06fb226"
      unitRef="usd">15000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzItNy0xLTEtODEzNzU_8dc97e9a-4bea-4ddd-8120-84f8b84108e3"
      unitRef="usd">-22471000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtMS0xLTEtODEzNzU_7f8f1859-45d1-44ad-82e2-11c2c477e562"
      unitRef="usd">13180000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtMy0xLTEtODEzNzU_9e16e203-7319-4ad6-9b30-fdd581e4c75b"
      unitRef="usd">552000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtNS0xLTEtODEzNzU_f087c6dc-8a8f-484d-8b0b-12ff1319ccbf"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzMtNy0xLTEtODEzNzU_de736716-e8b4-4aa5-b807-a9e65f716209"
      unitRef="usd">13732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtMS0xLTEtODEzNzU_7989a01f-13eb-46d9-85bb-e0cb26b43435"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtMy0xLTEtODEzNzU_d642bad5-55d7-4663-8ec5-4c180063ac41"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtNS0xLTEtODEzNzU_a17780ff-43ba-433b-89c7-7db2af5fce3b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzQtNy0xLTEtODEzNzU_38aff9dc-4f2c-4bff-9c2d-176e3ad0fefe"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0cbef4dbde134fed9aee31eb6a11f846_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtMS0xLTEtODEzNzU_656f37db-afc6-4556-9880-e8e4754d5959"
      unitRef="usd">-36642000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1b387152de104a6fb93cb485db96d18d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtMy0xLTEtODEzNzU_9077a8ec-fb90-47e1-a34f-edb1141ed2f2"
      unitRef="usd">324000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0462067e91ab4a40b4d15b96c79133ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtNS0xLTEtODEzNzU_bc68eab7-db64-4d36-b754-f97879908afb"
      unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzUtNy0xLTEtODEzNzU_e6ec1286-ca60-4044-9ec6-84041c7c52fd"
      unitRef="usd">-36303000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i4d0e209b4cba44c8841984717c05fdfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtMS0xLTEtNzg1Njg_0f303696-3047-4c85-aa84-f27b547ca3d2"
      unitRef="usd">-20028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e6451fcf8cc42d5bbe8a6ac07fa5fa8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtMy0xLTEtNzg1Njg_ab5bb3c3-aa74-474d-9313-1b76109505a7"
      unitRef="usd">3889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8aa7db8b29e9457f93217ca8c42e681e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtNS0xLTEtNzg1Njg_52251862-0b13-4358-860a-81f717b3c85c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id485da7dafae40ddabd0f37725dd651a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzYtNy0xLTEtNzg1Njg_a6003c3c-b2be-48a5-9ca3-080b8a9bd1bf"
      unitRef="usd">-16139000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctMS0xLTEtNzg1Njg_6aef68b1-708b-415a-8b36-e29c2a26f405"
      unitRef="usd">34379000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctMy0xLTEtNzg1Njg_369db5b1-af88-44fc-b531-e2d74259e745"
      unitRef="usd">-6858000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctNS0xLTEtNzg1Njg_e0527b53-28bd-47d3-a4f8-da45fcac3720"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzctNy0xLTEtNzg1Njg_33790656-82b4-47c1-a1d2-c6c5c235f3e0"
      unitRef="usd">27521000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtMS0xLTEtNzg1Njg_65dbc19b-7d76-4935-ad4c-1abf49cb8683"
      unitRef="usd">-1454000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtMy0xLTEtNzg1Njg_58f7aeb5-70fa-4fe3-853d-f778e7704891"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtNS0xLTEtNzg1Njg_94fbb4f6-bf4f-49b2-bbae-daa504371594"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzgtNy0xLTEtNzg1Njg_1ea7c100-77c7-48ce-83f6-b0de5afbe8da"
      unitRef="usd">-1454000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktMS0xLTEtNzg1Njg_018f3965-23c5-44c2-8035-28b77f4c8354"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktMy0xLTEtNzg1Njg_9360679d-e2eb-4599-92a3-e3aa651629fc"
      unitRef="usd">-1596000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktNS0xLTEtNzg1Njg_4fd3dc75-1be5-43f5-94ff-dfa5d6f0f50d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzktNy0xLTEtNzg1Njg_65ceef1e-3318-440a-8b13-73af38b13875"
      unitRef="usd">-1596000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8564ed0d837241d2b083a1127ff9ffe6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTEtMS0xLTc4NTY4_8cd637cd-e472-4a23-9793-aee145282b64"
      unitRef="usd">35833000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3bbfda3579ee4e79a6aa1e261636e7b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTMtMS0xLTc4NTY4_aa6983e4-86f5-47a0-916f-2a4b4de527e3"
      unitRef="usd">-5262000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5bac0997f0d9454983d1fc6b1afd02ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTUtMS0xLTc4NTY4_6e33a06d-77f1-4156-9dd2-2301956be3f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEwLTctMS0xLTc4NTY4_c4686175-b8f5-4ecb-857c-f92bc5e19008"
      unitRef="usd">30571000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i2d843487721d43b7a6cf7175f69e01fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTEtMS0xLTc4NTY4_c11cadbe-d185-409a-b13e-58aefbc163ac"
      unitRef="usd">15805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd5dbb579b5f418cb0577509240e9084_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTMtMS0xLTc4NTY4_6d0ae9ca-533a-4d5c-a8db-659dae8128da"
      unitRef="usd">-1373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8ff2134016c43a48d2be70284677ab2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTUtMS0xLTc4NTY4_c59f9e02-bf97-4ea5-a53b-5eac7b576c3d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7875a67714c6452c84f63885164473d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzExLTctMS0xLTc4NTY4_8295a61b-4ac2-45ed-a93f-5032bfdb32b0"
      unitRef="usd">14432000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTEtMS0xLTc4NTc0_d9baf702-afe9-48a3-80c5-ed93ce383631"
      unitRef="usd">29045000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTMtMS0xLTc4NTc0_fe18b44c-8733-4220-aa3f-6978348b0fcf"
      unitRef="usd">-13967000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTUtMS0xLTc4NTc0_015bd02d-dcea-4c94-bdbf-d2979f305a59"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEyLTctMS0xLTc4NTc0_91839bd4-0da5-4583-bece-df0369c3b201"
      unitRef="usd">15078000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTEtMS0xLTc4NTc0_8e7cfd26-2f6d-4135-a1bf-fb2166d16ac5"
      unitRef="usd">36624000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTMtMS0xLTc4NTc0_d00b555a-addd-4f9f-9820-6c74db797247"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTUtMS0xLTc4NTc0_98677808-be35-4e34-ba3b-baf0f31cd475"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzEzLTctMS0xLTc4NTc0_bc76c5c2-9cce-4f79-86da-e64fb9e29eb5"
      unitRef="usd">36624000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTEtMS0xLTc4NTc0_40d326c0-03a4-4e71-92a4-0482c26a343c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTMtMS0xLTc4NTc0_fa9f95e3-717e-4e25-9245-939745ad2c75"
      unitRef="usd">-3247000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTUtMS0xLTc4NTc0_4b3846ea-91c6-46cc-bb17-7a14e228c377"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE0LTctMS0xLTc4NTc0_b5284cf4-1629-41f3-a68f-e848f090c56a"
      unitRef="usd">-3247000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i70c36fee11624160a9a8777da81c0128_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTEtMS0xLTc4NTc0_77b8a673-152a-476d-9481-edfdf3c81607"
      unitRef="usd">-7579000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib62888ee57f04d85bf4225065051e0c9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTMtMS0xLTc4NTc0_bfaf29f2-83e1-47a8-b3e0-5250060f57d5"
      unitRef="usd">-10720000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i88c8c0270e6d4a3b84b98a350e4693cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTUtMS0xLTc4NTc0_8c52187e-faf8-4792-a80e-38c6de0fab33"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE1LTctMS0xLTc4NTc0_175cd4bb-ef6e-4d2f-88d2-f85fc593ab50"
      unitRef="usd">-18299000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="icd084d19fafe4eb08800335bbaa0fdb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTEtMS0xLTc4NTc0_6062c8a1-cd3f-43a1-a2ea-af756f2b67f7"
      unitRef="usd">8226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied7e67f5a5634503ad5879c8009f97f2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTMtMS0xLTc4NTc0_5ca857e8-1d8f-4788-9ac0-565a98ddbb42"
      unitRef="usd">-12093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3d2704044e74eec86232f6b5bbfa0a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTUtMS0xLTc4NTc0_4582e111-d985-4ad3-9c89-277fc8df785d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d01a3eb633442b8a24963b9a15b0f21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzUvZnJhZzphYmQ0MDliNjI4MmE0MDVlODU5NGFlZjA2MTQyZjBkZC90YWJsZTozY2ZlNTE2N2MxNjI0NTBiOTVhN2M4NjQ4ZjQwZGI0YS90YWJsZXJhbmdlOjNjZmU1MTY3YzE2MjQ1MGI5NWE3Yzg2NDhmNDBkYjRhXzE2LTctMS0xLTc4NTc0_89600720-78fa-477a-a4f3-b12d9e7be08e"
      unitRef="usd">-3867000</us-gaap:StockholdersEquity>
    <bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1Nzk_2bbb0546-4f3e-476a-bdde-2f1afa689fc7">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents Total Revenues and disaggregates Net Product Revenues by product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues by product:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;VIMIZIM&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;623,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;544,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NAGLAZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PALYNZIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;KUVAN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;VOXZOGO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;BRINEURA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;FIRDAPSE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,913,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,675,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ALDURAZYME net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,042,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,783,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,805,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,096,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#x2019;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#x2019;s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;756,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,913,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,675,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ALDURAZYME net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,042,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,783,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,805,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table illustrates the percentage of the Company&#x2019;s total Net Product Revenues attributed to the Company&#x2019;s largest customers for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On a consolidated basis, two customers accounted for 22% and 15% of the Company&#x2019;s December&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021 when two customers accounted for 28% and 16% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;accounts receivable balance, respectively. As of December&#160;31, 2022 and 2021, the accounts receivable balance for Sanofi included $68.8 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#x2019; financial condition and requires prepayments in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the year ended December&#160;31, 2022, 2021, and 2020, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients. While the extent and duration of such effects remain uncertain and difficult to predict, the Company does not expect significant impacts to its operating results and financial condition as a result of the COVID-19 pandemic in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could affect the Company&#x2019;s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company&#x2019;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-lived assets by geography:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,114,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,081,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODE_7dbd14dd-50ea-4001-bde1-6bb7653a09cd">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents Total Revenues and disaggregates Net Product Revenues by product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues by product:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;VIMIZIM&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;623,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;544,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NAGLAZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PALYNZIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;KUVAN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;VOXZOGO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;BRINEURA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;FIRDAPSE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,913,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,675,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ALDURAZYME net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,042,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,783,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,805,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,096,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83d540593f644f2cb082a24558b3f758_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtMS0xLTEtNzg1Nzk_13fe4095-4bab-44e9-935d-b989ce87d1d3"
      unitRef="usd">663739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i107111d003394f429df9bc3b7e72083a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtMy0xLTEtNzg1Nzk_0108bdd1-57a7-4e7c-b711-2165ae6d213b"
      unitRef="usd">623145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i766158ee331f4b6dad23cc139f408d52_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzMtNS0xLTEtODEzNzg_bd18c21c-3c51-4d17-adf2-b8c479fc5fc9"
      unitRef="usd">544257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice70b2f98d8f46ee95e52f2e5d8735cd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtMS0xLTEtNzg1Nzk_5a7eb51a-d33d-4d92-9886-6c136dd93663"
      unitRef="usd">443794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbbfc39daa5e4e86b8925b3c91e0a20f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtMy0xLTEtNzg1Nzk_20785189-a31c-4385-a03f-01ae4bd798bb"
      unitRef="usd">380449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc10f3a93ae418882d57641c30e6fa2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzQtNS0xLTEtODEzNzg_2fd43839-aaa1-4915-9e45-182db32923a6"
      unitRef="usd">391298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91a42714856349788ac98ef18c9c4eec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtMS0xLTEtNzg1Nzk_b7a223c1-1fb5-40ca-ac12-188ecfffdf51"
      unitRef="usd">255032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia58bdf6d90d34e0e9c7db18bf1df4dc1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtMy0xLTEtNzg1Nzk_3c4fcce8-3bfd-4e71-80d5-545e9129e75d"
      unitRef="usd">237474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i509d47fe3d174696acd23ae2feb9495e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzUtNS0xLTEtODEzNzg_767538e1-5a19-48ab-99c7-f74c10c6761d"
      unitRef="usd">170983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6660ddacf84f446083b9e0ca5bce39fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtMS0xLTEtNzg1Nzk_d8353f25-2cac-4adf-a51f-88e76ae74d62"
      unitRef="usd">227577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ef27eef923e434e862de91ae5beafca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtMy0xLTEtNzg1Nzk_58495325-c25a-4c44-b241-8014194b31d5"
      unitRef="usd">285776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e7292c071f44cd4ba482c581dbba9e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzYtNS0xLTEtODEzNzg_a2527c02-110f-48d0-8f3a-5c2d361932c8"
      unitRef="usd">457736000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f2ca389fb2d47f3991717f9e5b9757c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctMS0xLTEtNzg1Nzk_12cde75a-dff4-4ecf-b9d8-e55539d520e1"
      unitRef="usd">169128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b179a96cee8425daa243c6ec126fa90_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctMy0xLTEtNzg1Nzk_c38fe649-e26a-4e10-8386-0ac622ae95cf"
      unitRef="usd">5855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieded801c64bf44adb38c0af09661c7f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzctNS0xLTEtODEzNzg_a4aa5e68-702d-4583-bb28-230788f13054"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6399581bf17e49c697410cb0a73c682c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtMS0xLTEtNzg1Nzk_8543b5f6-12b8-4131-80a6-a93e2652a542"
      unitRef="usd">154333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0245c8a131434573a4579c1ffa6fe178_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtMy0xLTEtNzg1Nzk_5663ec8f-2776-494a-aec1-795c8bb374e9"
      unitRef="usd">128034000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a7a34d6b8446b19864867ebc10546d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzgtNS0xLTEtODEzNzg_6f8945f9-00ad-4513-b250-bebe5cf86cfd"
      unitRef="usd">110192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ff71e7217274546b0d948f39fc97420_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktMS0xLTEtNzg1Nzk_f0c360e2-f7cd-4a35-bd22-15321306c744"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i503208303f7343d68d5b53c7fb08f251_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktMy0xLTEtNzg1Nzk_42f4d8c4-f2b7-49f1-867a-c14ea0b9e7d4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7039784a43724956bd81fdb85ade56d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzktNS0xLTEtODEzODA_fb4bdc22-a5ab-4a50-a14d-c4f3985d3ab6"
      unitRef="usd">1288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTEtMS0xLTc3NjM4_6f66abfa-062c-4727-950c-163644a2debd"
      unitRef="usd">1913603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTMtMS0xLTc3NjM4_f42ce139-ac21-44b0-b89c-934e07d4c709"
      unitRef="usd">1660733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEwLTUtMS0xLTc3NjM4_61211306-5807-4db2-aa25-f8dce53433d8"
      unitRef="usd">1675754000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTEtMS0xLTc4NTc5_e4c9ee71-753c-4107-9d6b-1c918c32a67f"
      unitRef="usd">128422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if32233365d594b308746b274d89d9e5f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTMtMS0xLTc4NTc5_ceebd3b9-6434-4864-b145-b4af07121248"
      unitRef="usd">122765000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzExLTUtMS0xLTgxMzc4_3022dd1e-0bbe-48b9-b629-899ce16d6ef3"
      unitRef="usd">130107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTEtMS0xLTc4NTc5_8087b13a-82ac-436d-87fa-4ce4b106f7eb"
      unitRef="usd">2042025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTMtMS0xLTc4NTc5_4697472d-e093-4080-aded-5371fae6e582"
      unitRef="usd">1783498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEyLTUtMS0xLTgxMzc4_09f3add0-b1dd-4939-877c-507de6345025"
      unitRef="usd">1805861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d6535a6a14748dfb373e6f3165110cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTEtMS0xLTc3NjM4_cc57e559-840c-4ce1-bc0b-a9c5b7ee1e8e"
      unitRef="usd">54014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61457d6e7ce7447382cab490c66e3877_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTMtMS0xLTc3NjM4_b5552547-a0a7-479c-9edf-869da6e55498"
      unitRef="usd">62777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b563b8dccea4af991c2b129876b40d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzEzLTUtMS0xLTc3NjM4_fc951521-6717-4bed-80af-cbfb60e12b05"
      unitRef="usd">54594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTEtMS0xLTc3NjM4_baf86be7-64f5-4a84-85a8-4d99b8fd8191"
      unitRef="usd">2096039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTMtMS0xLTc3NjM4_81912af7-eefa-4dd8-ad67-38f68aa59ed9"
      unitRef="usd">1846275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo4OThjZmFiMTdlZGQ0Nzg2YTUyZDhiMmQ2ODU3YWFjOC90YWJsZXJhbmdlOjg5OGNmYWIxN2VkZDQ3ODZhNTJkOGIyZDY4NTdhYWM4XzE0LTUtMS0xLTc3NjM4_140f687f-0658-47a6-9816-55d0839f1d0b"
      unitRef="usd">1860455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODI_18b82673-e6ee-4d4b-8c3c-f130c2df654c">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;756,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,913,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,675,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ALDURAZYME net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,042,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,783,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,805,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae042974731b47fa8462f91e2b1ce268_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtMS0xLTEtNzg2MDk_81dc2cca-0e3c-4015-b965-c19762dce15c"
      unitRef="usd">684284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6b2cd85806b4c09a10ee05befb288eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtMy0xLTEtNzg2MDk_ab3ec98c-2c86-4ba5-9a87-9add1be173d8"
      unitRef="usd">657700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec738639a3694be7b566566f59fefda1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzMtNS0xLTEtODEzODI_1d3b4521-92a7-4a73-8429-4e77e33c972e"
      unitRef="usd">756863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7afae57055d2464bbca1472128e2dd4b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtMS0xLTEtNzg2MDk_0461751b-036f-45f4-b7d6-23068c144833"
      unitRef="usd">650952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifde566a1a304443a9740252495984863_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtMy0xLTEtNzg2MDk_d21334a7-0dac-4e05-8033-40903ef8dd04"
      unitRef="usd">558952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b889898bba94b54af9a9335b9b82b62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzQtNS0xLTEtODEzODI_b6f8b3fa-4abc-468e-8ecc-ae0d461566ed"
      unitRef="usd">498725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia344194268dd43fd989b6b04a378902f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtMS0xLTEtNzg2MDk_769d81ea-acc9-4f65-a08d-794603ec5e37"
      unitRef="usd">266801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i826dd83d81b24084b26e5b5cc42493b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtMy0xLTEtNzg2MDk_5cb3f5e4-e373-48af-9789-d5d5840bbbe8"
      unitRef="usd">191151000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie581ba1d1b064e6986a21f9ea9fdc7a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzUtNS0xLTEtODEzODI_7fe20336-8fc6-4dcb-a1ba-9767f835231f"
      unitRef="usd">205862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib31425f01f73430a9a3aec5dfc86da0d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtMS0xLTEtNzg2MDk_cfb93059-d3c1-4575-984a-7a3287158e84"
      unitRef="usd">311566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id209fbaf4cd14f198010a1f4ff75159e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtMy0xLTEtNzg2MDk_0ed467aa-30a1-4697-9a54-5a0eb6133f97"
      unitRef="usd">252930000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52ed09d29aa1432fa6575525ede1e854_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzYtNS0xLTEtODEzODI_09f9d8a0-8e79-41ab-ac95-9c36aa92385f"
      unitRef="usd">214304000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f5aab165faf45f5bc871d23828f2d36_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctMS0xLTEtNzg2MDk_f9128ae4-cbe0-4b54-b2ab-ca24b638aca4"
      unitRef="usd">1913603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9c6d46f9374f14a4f901b76a9c37c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctMy0xLTEtNzg2MDk_ea20dffd-a707-4782-b760-07e31f22a5d4"
      unitRef="usd">1660733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113bbb13e0574dd1a87851236a08248f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzctNS0xLTEtODEzODI_2f566046-fdaf-4c76-ad8f-1b662c306ac1"
      unitRef="usd">1675754000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d551af16606495ab705b3be0a5083f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtMS0xLTEtNzg2MDk_f69c0821-6d3f-4acd-b3e7-ede906fb9860"
      unitRef="usd">128422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if32233365d594b308746b274d89d9e5f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtMy0xLTEtNzg2MDk_a15224a0-e590-4b8f-8d4e-2726317fc84f"
      unitRef="usd">122765000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c90c2e1c7f64b99b37b3517601005da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzgtNS0xLTEtODEzODI_150e732e-d056-48ee-a2de-78f6041624be"
      unitRef="usd">130107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3feb4b16a55e4b8eae5ebe640ded1fbf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktMS0xLTEtODMwMzU_74b55167-001b-4e58-b52b-a7892e57a248"
      unitRef="usd">2042025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58108302281b46cebd5051fdc34011c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktMy0xLTEtODMwMzU_4b34d552-f9bc-443a-acf6-89fcf32a4c7d"
      unitRef="usd">1783498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8381a40443874d71bf070c391e0c7639_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowNmZjMDJmZjIxMTA0MWQ5YWVmODQyNWY4ZWM5ZjdiMy90YWJsZXJhbmdlOjA2ZmMwMmZmMjExMDQxZDlhZWY4NDI1ZjhlYzlmN2IzXzktNS0xLTEtODMwMzU_691dab07-2e00-4ff7-8711-9c306887ef4c"
      unitRef="usd">1805861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODM_f77eda1a-ad01-4c92-a3ec-d0343c814cc5">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table illustrates the percentage of the Company&#x2019;s total Net Product Revenues attributed to the Company&#x2019;s largest customers for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0770f55d5c104f969b9acc886090f5fb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItMS0xLTEtNzg2MTc_c18894e7-5566-45d6-a036-1972ec3ca625"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iacafee45f91e46ebb714c46c2ff89823_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItMy0xLTEtNzg2MTc_d3193bdd-f089-41cf-a01c-02a015f307a5"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59f95dec71974a66bbde2f90b523281c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzItNS0xLTEtODEzODU_0f5dc176-2bda-4f9c-a141-d77216d15713"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9e42fce28b14ebbb8a5a4411c1433ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtMS0xLTEtNzg2MTc_9306b490-4c72-4ec3-8a43-0fd04faa9dc4"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i94e7695ed7954a5fb9f808089e78a85d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtMy0xLTEtNzg2MTc_67810924-4e03-41dd-be16-6b62a317dce5"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5749604fcebc42ada76e2e1b582da09c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzMtNS0xLTEtODEzODU_629a4f90-b4b7-4d85-903b-bc982ed2f512"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i40ade8d0054c45b997b2f2e5fb9e1490_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtMS0xLTEtNzg2MTc_92e88698-579f-499c-b96a-f0a2602dd388"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4553d6d08ef849c8a72048bc17b8ed75_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtMy0xLTEtNzg2MTc_076ad239-3722-4677-b24a-e35148239703"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idca4f3f8044a4465aad5cc36317e02b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzQtNS0xLTEtODEzODU_fb5ef194-20fc-48de-95d6-197cf2fa3da5"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtMS0xLTEtNzg2MjE_d088d574-7db0-40e8-a82c-47bab01815c1"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i692965d349e34f3ea4acc8a50f53276d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtMy0xLTEtNzg2MjE_cfe72d93-d562-4e7b-a6d4-caf7bcd90357"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i63e7463435974d1d98101460b30a9c62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTowYWQ2YWNlZWJhMGQ0MmZlYTI1MTI3Y2FlMTkyZTQ5OS90YWJsZXJhbmdlOjBhZDZhY2VlYmEwZDQyZmVhMjUxMjdjYWUxOTJlNDk5XzUtNS0xLTEtODEzODU_29597aa6-2eb4-454e-861a-9b3059e756e9"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i843ac21f80f24e97b5709f27f83dc60c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzEzNzQ_d0dafad0-9a92-4569-9c3a-8061221467c5"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6558cc5ad3094460971e3ff939e6623a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzEzODA_0e55accc-946c-4243-9630-5daa61584cc2"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe58d8557902475b9ecb613007413f59_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0MzY_698ab8ca-09a2-4d1a-adae-76423918468b"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2aadf30296f940eeb46c2095e3ef8568_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0NDQ_0e640ce9-e71f-4ba6-bfe0-3ce1c20617d7"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7b5fa7ec2b1541f2a9aecd40ae5ca28b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE0OTk_4c0eb78e-7412-4d50-8ac4-15b94091bdb2"
      unitRef="usd">68800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4fea8ab604b143e89c4c4066ac2d10d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzEwOTk1MTE2MzE1MDc_2fc8e1c6-f3d3-4be5-8206-6f8f56387ae6"
      unitRef="usd">67900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90ZXh0cmVnaW9uOjQ4NGIwMmVlMDQ2OTQ1Mjc5ZGQzNThiYTk4ODVkMzAwXzM1ODQ_b2e2c24b-5d07-4dcb-acf7-016fcd696c3d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-lived assets by geography:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,114,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,081,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i05278f7e11d545918819b0e5fd3de8f3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzMtMS0xLTEtODA4Nzg_a63d3b3a-182f-45c9-909e-18de8895c955"
      unitRef="usd">786509000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i6ede14dcb48b4252953a1349a4dcdcd0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzMtMy0xLTEtODA4Nzg_c1ee43b5-c0bd-4eec-900b-1b5b2dd7fe0b"
      unitRef="usd">763847000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icc3eff93ecba4e9ab0b751bba0479273_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzQtMS0xLTEtODA4Nzg_56bc2bef-ce17-49d1-b212-1a5f9a0ffac7"
      unitRef="usd">309180000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib0d4996c3e9141c19bf5436bd1dfe088_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzQtMy0xLTEtODA4Nzg_8bac3867-c99b-4ae1-87a0-d7853e1acac6"
      unitRef="usd">304748000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib6853f1a77d1449f9e25fc0db6cfd462_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzUtMS0xLTEtODA4Nzg_d633a65f-5310-402c-906d-7a91a5cb538e"
      unitRef="usd">18633000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic617813345644c10af3fae918e7bce97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzUtMy0xLTEtODA4Nzg_714bc0a5-9d8a-4f47-b76a-f2b93207d01f"
      unitRef="usd">13284000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzYtMS0xLTEtODA4Nzg_1a766187-8871-49ed-9cab-6792d68fc40b"
      unitRef="usd">1114322000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xNzgvZnJhZzo0ODRiMDJlZTA0Njk0NTI3OWRkMzU4YmE5ODg1ZDMwMC90YWJsZTo2NzU3YTcxZjlkYjQ0Y2ZiYWU2ZWMxYmUwYWI2MDBkNy90YWJsZXJhbmdlOjY3NTdhNzFmOWRiNDRjZmJhZTZlYzFiZTBhYjYwMGQ3XzYtMy0xLTEtODA4Nzg_fa0836d1-1f6f-4234-a2d2-8dce5005cb24"
      unitRef="usd">1081879000</us-gaap:NoncurrentAssets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzU0OTc1NTgxNTMyNzQ_ff8d59ed-b9af-4dc4-b268-3439933faee3">EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shares Available Under Equity Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, an aggregate of approximately 41.5 million unissued shares was authorized for future issuance under the Company&#x2019;s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan (2017 EIP) and the ESPP. Under the 2017 EIP, shares issued and outstanding under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company&#x2019;s stock-based compensation plans are administered by the Company&#x2019;s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The 2017 EIP provides for awards of RSUs and stock options as well as other forms of equity compensation. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. RSU Awards with Performance-based Vesting Conditions (PRSUs) generally vest over a three-year period on a cliff basis three years after the grant date. Stock option awards granted to employees generally vest over a four-year period on a cliff basis 12 months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally 10 years from the grant date. As of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, approximately 27.7 million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The ESPP was initially approved in June&#160;2006, replacing the Company&#x2019;s previous plan, and was most recently amended in June 2019. Under BioMarin&#x2019;s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section&#160;423 of the Internal Revenue Code. During the year ended December&#160;31, 2022, the Company issued 0.3&#160;million shares under the ESPP. As of December&#160;31, 2022, approximately 7.0&#160;million shares were authorized and 2.8 million shares reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Board of Director Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On the date of the Company&#x2019;s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000, with the number of RSUs to be granted calculated based on the thirty-day trailing average closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market. The annual RSU grant for a director who has served for less than a year is prorated to the nearest quarter of the calendar year. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company&#x2019;s next annual meeting of stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included on the Company&#x2019;s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation of $21.3&#160;million, $20.0&#160;million and $20.1&#160;million was capitalized into inventory for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Unit Awards with Service-Based Vesting Conditions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with service-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,437,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,266,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,609,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(574,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,519,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, was $79.43, $78.46 and $77.13, respectively. The total intrinsic value of restricted stock that vested and released in the years ended December&#160;31, 2022, 2021 and 2020, was $130.1&#160;million, $117.2&#160;million and $109.9&#160;million respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $251.2 million was expected to be recognized over a weighted average period of 2.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Unit Awards with Performance-based Vesting Conditions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with vesting conditions based on performance targets under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of the PRSUs for the years ended December&#160;31, 2022, 2021 and 2020, was $78.27, $78.09&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$84.17, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-vested PRSUs included grants with vesting contingent upon the achievement of a three-year Non-GAAP income target, upon the achievement of a three-year Core Operating margin target, vesting contingent upon achievement of a three-year strategic goal target and vesting contingent upon achievement of certain regulatory milestones. The awarded PRSUs generally vest over a three-year service period on a cliff basis. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the quarter granted. The number of shares that may be earned range between 50% and 200% of the base PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation expense related to non-vested PRSUs of $12.8&#160;million was expected to be recognized over a weighted average period of 1.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Unit Awards with Market-based Vesting Conditions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company&#x2019;s TSR is above the 50th percentile but negative on an absolute basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(89,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The grant date fair values and assumptions used to determine the grant date fair value of TSR-RSUs granted during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$124.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$112.12 &#x2013; $217.65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5 &#x2013; 157.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7 &#x2013; 161.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3 &#x2013; 159.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5 &#x2013; 2.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2 &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation expense of $17.1&#160;million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Purchase Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity under the Company&#x2019;s stock option plans for the year ended December&#160;31, 2022. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,449,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;695,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(943,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(258,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,943,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,687,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#x2019;s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $103.49, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on December&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value per stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, were $32.45, $31.61 and $27.47, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020, were $32.1&#160;million, $40.7&#160;million and $71.9&#160;million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.1 &#x2013; 40.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.4 &#x2013; 41.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5 &#x2013; 42.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 &#x2013; 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 &#x2013; 6.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6 &#x2013; 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 &#x2013; 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7 &#x2013; 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3 &#x2013; 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options of $31.5&#160;million was expected to be recognized over a weighted average period of 2.5 years.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The net tax expense from stock options exercised during the year ended December&#160;31, 2022 was $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Purchase Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.6 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.6 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.04 &#x2013; 4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.04 &#x2013; 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1 &#x2013; 2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $14.0&#160;million was expected to be recognized over a weighted average period of 1.3 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NDkw_525151e2-4bce-4181-bd56-6340e61f8b2c"
      unitRef="shares">41500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4183315e314d4360bb0502134885d9dc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk3MTA_a5673e6a-1eb9-4506-b01a-1ad4ecc4704c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk3MTc_c6b1acec-512f-466e-956c-904989a66dfe">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement
      contextRef="i388771fccfc84611acf99ca5e9c53a41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzMDQ_473fce67-0e6f-442e-8f6a-12ac480890d2">P3Y</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzU0OTc1NTgxNjI1MjY_dccf587d-2d95-47a7-9f05-dc34ac1b60a2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement
      contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NDM5NjE3_697b29f6-106f-41f6-b08c-67189fee0343">P12M</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i80e05e6a4d564c8d887a6ee18fe55ca3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NDM5NzI4_6677fc99-b6dc-46d7-bfd1-ab1011129568">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia93e432edc5048a0ac3ab95326ff5424_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NTA1_e6a54363-57b3-4123-b292-0524596b3fe6"
      unitRef="shares">27700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzNjA_7aed1458-7c8d-4386-ba27-e386b90e1845"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <bmrn:SpanOfOfferingPeriod
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzNzM_c9703287-db5b-4890-8ba9-0444d88e3a95">P2Y</bmrn:SpanOfOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzODA_52b8afd5-6a22-471a-80e6-b060bc09c74c"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <bmrn:MaximumPayrollDeductions
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2MzkzOTE_a077db13-0d18-47e5-a93c-c8cb64b10eff"
      unitRef="usd">25000</bmrn:MaximumPayrollDeductions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE1ODQ4_fd650b14-e453-47e7-91cf-07351db8b280"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDUw_9c11836c-7a8d-4c2d-8d4f-9961ca411d83"
      unitRef="shares">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDU3NDk3_76f3448f-7331-4e0f-aaa1-7bd3d9cf522b"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMyOTE_9732d238-76f4-4f02-9011-6866003832e8"
      unitRef="usd">400000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <bmrn:AverageClosingPriceTrailingPeriod
      contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDIw_1224987d-cd1d-40dd-a501-20141e43494c">P30D</bmrn:AverageClosingPriceTrailingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iae6e88a7e42a4b75a5e8ca286d351341_D20190919-20190919"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDE5_d646c500-ccab-47ff-9205-a2076f9ed70d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDIx_08513b76-c4ff-4ddd-aa5a-e9758030392c">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included on the Company&#x2019;s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1445253420474375b7efe62ace67131e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItMS0xLTEtNzg2NjE_ccfad749-404b-4451-8597-bc7d10965c4d"
      unitRef="usd">17709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i934a6fe3c5d2413c87067ea339f198cc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItMy0xLTEtNzg2NjE_a16a583d-72c1-40ef-b94e-bebe6d95c5bc"
      unitRef="usd">22357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a9c60963aff483fa114c7b304603a7d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzItNS0xLTEtODEzODg_c540f210-c4e9-4ea1-9b68-717d8fa0a90a"
      unitRef="usd">26246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e06e2017d4b477e9b69593553036531_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtMS0xLTEtNzg2NjE_32e01376-1ead-4af8-bdee-f0b2b2397a4e"
      unitRef="usd">61702000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12938f6823a94b1c837db430e15262c0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtMy0xLTEtNzg2NjE_bb361d5a-9aca-4531-83d0-b08e4318904e"
      unitRef="usd">67196000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c5dda00a8514dd59ad5007c3cd8c578_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzMtNS0xLTEtODEzODg_a68706cd-38a7-42e5-a752-1829c6e147f0"
      unitRef="usd">61942000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b264f9c740640838312c3dbd938c92e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtMS0xLTEtNzg2NjE_59d79352-02eb-4d25-bc48-92ff552bfdb1"
      unitRef="usd">116897000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6dfc5eb6e4d04a6390d4d537c078c61f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtMy0xLTEtNzg2NjE_e2e4e7e4-9b2b-47af-ad1d-8b2d686c0b5b"
      unitRef="usd">107710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab5359457de041eaba77b73a3803bcfe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzQtNS0xLTEtODEzODg_a1b17c31-5181-4a86-bdcc-1f5e413b929c"
      unitRef="usd">101523000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtMS0xLTEtNzg2NjE_46eddf62-3fec-43f1-b680-3daf90231e98"
      unitRef="usd">196308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtMy0xLTEtNzg2NjE_37183703-1fc1-45cf-83a0-51f77d77b242"
      unitRef="usd">197263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTplMDMwZmNiY2MwMzM0MzgyOTlhMDBlYzVmMmE1YzI2NS90YWJsZXJhbmdlOmUwMzBmY2JjYzAzMzQzODI5OWEwMGVjNWYyYTVjMjY1XzUtNS0xLTEtODEzODg_37ee6b51-41e8-4c60-a92d-fcab1775bbdb"
      unitRef="usd">189711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDk1_ea2b582b-2e69-464f-8f53-b6846c7200f4"
      unitRef="usd">21300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTA2_1dc8c9ef-441a-48ff-9007-3b7eafaea2a9"
      unitRef="usd">20000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTE4_81f04b85-c9bc-4ae7-9a84-39f27590bedb"
      unitRef="usd">20100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI0_202eee35-c8e1-47a0-afe8-2c096eecee28">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with service-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,437,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,266,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,609,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(574,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,519,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with vesting conditions based on performance targets under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(89,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzEtMS0xLTEtODIyNjI_26f632e2-07e7-40b2-99a7-be3877ae9920"
      unitRef="shares">4437512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzEtMy0xLTEtODIyNjI_6887ca93-920e-4c85-bd3d-a1a83084b21f"
      unitRef="usdPerShare">80.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzItMS0xLTEtODIyNjI_57116bb4-dbc8-4b74-b8d3-00fb2522d82a"
      unitRef="shares">2266150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzItMy0xLTEtODIyNjI_777058bd-8ae5-425c-80ed-8af83e3b5a0e"
      unitRef="usdPerShare">79.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzMtMS0xLTEtODIyNjI_c8213142-ecfa-451a-941d-0b9c67fd920f"
      unitRef="shares">1609186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzMtMy0xLTEtODIyNjI_a17a1f10-9f11-4be0-8c3d-128e1f440893"
      unitRef="usdPerShare">81.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzQtMS0xLTEtODIyNjI_90d76632-9042-4408-8165-9626e3392fa7"
      unitRef="shares">574730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzQtMy0xLTEtODIyNjI_f9d17de3-e8ba-4677-b610-c5a0ff87f2ca"
      unitRef="usdPerShare">79.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzUtMS0xLTEtODIyNjI_b8cae14e-5903-48c5-85b5-37853274b481"
      unitRef="shares">4519746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpkODdjYzNlMzhhMWY0YWM2ODQzNGZmY2Q1YzEzZDYzYS90YWJsZXJhbmdlOmQ4N2NjM2UzOGExZjRhYzY4NDM0ZmZjZDVjMTNkNjNhXzUtMy0xLTEtODIyNjI_50c1d903-b670-4d98-805a-5765b1b0de4d"
      unitRef="usdPerShare">79.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2MzU_2ea87c9f-00f1-4eeb-8d59-e226fe47dd71"
      unitRef="usdPerShare">79.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2NDQ_5a911fde-c5e5-4b80-b801-fb0ae176ad77"
      unitRef="usdPerShare">78.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk2NTM_c8751c49-2e31-48cb-b0fd-51d5a54cf48d"
      unitRef="usdPerShare">77.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTQ2_67df4760-c264-47e8-b299-47fe048401ce"
      unitRef="usd">130100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="idcd8b61460e0418aa1b256366aa65a3a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk5MDE_1594d50a-b8eb-44c9-898f-460815a6e502"
      unitRef="usd">117200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i1ca7787336604bfc86c501d1727ff0f7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MDk5MTc_2706b002-13c3-4c25-a5c4-3f415b7efa48"
      unitRef="usd">109900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i77524339bb424d85b4d57ae104a84f24_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NTg5_a5ca1f0e-50bb-4164-a21b-e9c01652bf02"
      unitRef="usd">251200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2Mzk3ODQ_153830ad-d3a0-4626-97b9-ddd2a4c6ea06">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3cf62fa1ecfd497ea4311496211dd174_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzEtMS0xLTEtODIyOTQ_48885ff3-4d0f-4ded-aaa7-efa7f52b2685"
      unitRef="shares">437049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3cf62fa1ecfd497ea4311496211dd174_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzEtMy0xLTEtODIyOTQ_75ea2f61-54fd-4171-8ae5-01ac435b5e6b"
      unitRef="usdPerShare">78.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzItMS0xLTEtODIyOTQ_89181765-6670-4bf9-8771-5a23fa88b9ec"
      unitRef="shares">147840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzItMy0xLTEtODIyOTQ_8859c914-70bb-4519-8af6-67877cb34e72"
      unitRef="usdPerShare">78.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzMtMS0xLTEtODIyOTQ_d57f716e-f63b-40ac-a9bd-c474688fbf6e"
      unitRef="shares">102489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzMtMy0xLTEtODIyOTQ_69d68e89-f44d-42fc-832f-42b5ee00489b"
      unitRef="usdPerShare">82.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzQtMS0xLTEtODIyOTQ_bd1dfc78-5e5b-4155-a593-343e34fcb163"
      unitRef="shares">34738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzQtMy0xLTEtODIyOTQ_e08be090-9540-46b2-8c58-1aa2466a2bad"
      unitRef="usdPerShare">65.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1572514829d644a68de7022821a70b1d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzUtMS0xLTEtODIyOTQ_de036510-0807-4d0a-85fe-772c58b00981"
      unitRef="shares">447662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1572514829d644a68de7022821a70b1d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo2ZTU5NDEwMWRhOWI0ZDRkYjIzZDM3NDYwNjExMzZiNi90YWJsZXJhbmdlOjZlNTk0MTAxZGE5YjRkNGRiMjNkMzc0NjA2MTEzNmI2XzUtMy0xLTEtODIyOTQ_1f85e6d9-24ab-4e5a-b62b-a7c85889a686"
      unitRef="usdPerShare">78.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMDU_8859c914-70bb-4519-8af6-67877cb34e72"
      unitRef="usdPerShare">78.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id16e0033fc1948dc9e1fa09a786eaa23_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMTQ_6857ae3b-08b1-4ad3-9325-106b9d8b6815"
      unitRef="usdPerShare">78.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0f2a458d9fee49c6a103d0f775c380d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyMjM_7f64b7c5-259c-4335-8bbf-4b30c9e6a804"
      unitRef="usdPerShare">84.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i77a7c1018d1f4444a8560a5468103fba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMxODg1ODM3MjI4MTM1_96232c56-06ab-4312-a5d7-c19e98a3da64">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i26584ec2b88147ebad7a6bf69b3d15d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzMxODg1ODM3MjI4MTM2_9d17748e-ddf1-456f-8f0e-43d32f2b140c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i27f49f0589db4d3fa2f9f5fb5d1f4355_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE2NDkyNjc0NTYwNjk_b9b5c56d-b3b3-4bca-a258-0062246c244d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI2_45469910-0618-4278-b4b6-e18742ac6363">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage
      contextRef="ied0260b6f7eb4a6fb48d30eb32daec80_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzc1Njc_caec9f38-a95d-4999-ba6f-07db0ca19cee"
      unitRef="number">0.50</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage
      contextRef="iee4d086842524837b758a134e20de2d5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzc1NzQ_6e9bf3d0-2e27-4e15-8cea-aac85a91aa4a"
      unitRef="number">2</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1572514829d644a68de7022821a70b1d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2ODcz_4b1f4f02-80d7-4f9d-9012-6eab22d82af8"
      unitRef="usd">12800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3ae942d2f6e24c628c79ff2782fdf9f2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDYwNjY5_7c53ae17-ceb6-4c29-a15b-5ddf6a1ad248">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDMz_f336eca7-8333-4a47-83b2-15062835e9a3">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage
      contextRef="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg2NjU_d81f6b29-fe6d-4cb2-b857-9e765723572a"
      unitRef="number">0</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage
      contextRef="i595951030a5d4e73a012f1be549c5e5a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg2ODA_92929492-0e09-4608-a7fb-2c8532b8a868"
      unitRef="number">2</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg3NDA_a65044fb-2028-4109-b5be-50c7f5c1694d"
      unitRef="number">1</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage>
    <bmrn:AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage
      contextRef="i3cf1fdcf5cbe47f7a2d0ff917d1cb0fd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzg4MDg_ddf34464-96e1-472a-ac3e-e559f9308861"
      unitRef="number">0.50</bmrn:AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie2b318a52937403fb847cf89e01b77ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzEtMS0xLTEtODI0NjQ_9e420e19-74f4-4fb9-a994-ad6765d76dc9"
      unitRef="shares">350860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie2b318a52937403fb847cf89e01b77ea_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzEtMy0xLTEtODI0NjQ_276a6c01-281d-4e64-acb9-35ca098ec77a"
      unitRef="usdPerShare">123.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzItMS0xLTEtODI0NjQ_7a5c5786-38aa-4f08-9ce0-afb789ae8434"
      unitRef="shares">147770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzItMy0xLTEtODI0NjQ_3bbc7cfa-6750-4c78-8763-d4d8c64d2bee"
      unitRef="usdPerShare">124.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzMtMS0xLTEtODI0NjQ_5182a651-bfa7-4d58-8f52-ea19fa95a691"
      unitRef="shares">89640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzMtMy0xLTEtODI0NjQ_89364ff4-d9c3-4861-89ec-a4d617d941a1"
      unitRef="usdPerShare">143.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzQtMS0xLTEtODI0NjQ_a9e38e8c-1a78-4cf4-8a23-50477f74f8ff"
      unitRef="shares">12870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzQtMy0xLTEtODI0NjQ_1f91f952-1a3b-4fdf-b43a-288891380e77"
      unitRef="usdPerShare">120.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzUtMS0xLTEtODI0NjQ_f377e2c2-8d2a-4529-8bc1-c05c8caac296"
      unitRef="shares">396120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNjIyNjBlOGYyNzc0MTk4OGQwMmUzOGE2YWY4ZGU1OS90YWJsZXJhbmdlOmM2MjI2MGU4ZjI3NzQxOTg4ZDAyZTM4YTZhZjhkZTU5XzUtMy0xLTEtODI0NjQ_1171fd3a-5548-418d-b706-6efdd3a0dc1c"
      unitRef="usdPerShare">119.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bmrn:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDI4_c13f578b-8ba8-4013-b2be-a111d7fdddef">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The grant date fair values and assumptions used to determine the grant date fair value of TSR-RSUs granted during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$124.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$112.12 &#x2013; $217.65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5 &#x2013; 157.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7 &#x2013; 161.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3 &#x2013; 159.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5 &#x2013; 2.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2 &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItMS0xLTEtODI1OTI_869b41be-0ab7-42d1-b77a-aec3445ca30d"
      unitRef="usdPerShare">124.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItMy0xLTEtODI1NTE_aa4c673b-1c06-4a46-8981-6f8f3f1cd762"
      unitRef="usdPerShare">117.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItNS0xLTEtODI0ODAvdGV4dHJlZ2lvbjpkNTk0NzdlZTdlYWU0Y2MyOTcyYzcxNjRkYzQzMDAxMF8xMDk5NTExNjI3ODM2_3acdb66a-a472-49b8-989d-6bec82942958"
      unitRef="usdPerShare">112.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzItNS0xLTEtODI0ODAvdGV4dHJlZ2lvbjpkNTk0NzdlZTdlYWU0Y2MyOTcyYzcxNjRkYzQzMDAxMF8xMDk5NTExNjI3ODI2_a00d623f-0607-4778-929b-89785d4c8b01"
      unitRef="usdPerShare">217.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMS0xLTEtODI1OTkvdGV4dHJlZ2lvbjplMjVkNDdmMTFkMjM0ZGFjYjlkOWU2ZjdiNjRiNDg5ZF8xMDk5NTExNjI3OTIw_f5bf0907-44d4-4b97-962f-f8ed8495a8e0"
      unitRef="number">0.245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMS0xLTEtODI1OTkvdGV4dHJlZ2lvbjplMjVkNDdmMTFkMjM0ZGFjYjlkOWU2ZjdiNjRiNDg5ZF8xMDk5NTExNjI3OTMw_c9c1d281-7df0-4cd9-adbb-3ce8158b2a1d"
      unitRef="number">1.576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMy0xLTEtODI1NTgvdGV4dHJlZ2lvbjpkNjNlOTViOTliYzE0NWM3YmJkZjNkNjNjYmRkZjY3ZV8xMDk5NTExNjI3ODAw_d7337124-d1cb-44f6-ae1f-a9e875ef5f95"
      unitRef="number">0.247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtMy0xLTEtODI1NTgvdGV4dHJlZ2lvbjpkNjNlOTViOTliYzE0NWM3YmJkZjNkNjNjYmRkZjY3ZV8xMDk5NTExNjI3ODA5_26debe5b-5366-4826-adb9-d0a0d2131926"
      unitRef="number">1.617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtNS0xLTEtODI0ODcvdGV4dHJlZ2lvbjphNDg3ZTY5MGJiNTI0OTlmYTgxNjJkNWNkYjNjYzhiZV8xMDk5NTExNjI3ODAw_eca22dba-f291-496b-87f1-ba2acbed1ceb"
      unitRef="number">0.213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzMtNS0xLTEtODI0ODcvdGV4dHJlZ2lvbjphNDg3ZTY5MGJiNTI0OTlmYTgxNjJkNWNkYjNjYzhiZV8xMDk5NTExNjI3ODA5_674fb47e-f818-4dd8-9eb8-0f6c1e64e085"
      unitRef="number">1.599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtMS0xLTEtODI2MTI_e755d1e0-1913-428c-97f1-5a63bc3882fc"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtMy0xLTEtODI1NzA_616c2e0f-50f6-45b4-a8a7-ba94c049e817"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzQtNS0xLTEtODI1MDA_d98d7f12-5c7e-4a42-aaf3-fca5ad6db59a"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtMS0xLTEtODI2MjA_777d603b-23d9-4238-9cbd-860c2c887120">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtMy0xLTEtODI1NzYvdGV4dHJlZ2lvbjozZjU0Y2Q2ZjY4ZTE0NjExOTA2ZjU1ZTBmMTVmNDBjZl8xMDk5NTExNjI3Nzk5_a89c847f-8fc2-4fb9-b10c-beefdfce50d7">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic0600bdbb4374691acd726c6afbf5b23_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtNS0xLTEtODI1MDcvdGV4dHJlZ2lvbjo4MDg2M2Q1ODU2NmQ0YjVhODBiNDkyOWE4Yzk5MTMwNF8xMDk5NTExNjI3Nzg4_fdb93834-6c4b-4e5a-b832-3520444f73ae">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i644ec2fa96924455860f28d3fde4787f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzUtNS0xLTEtODI1MDcvdGV4dHJlZ2lvbjo4MDg2M2Q1ODU2NmQ0YjVhODBiNDkyOWE4Yzk5MTMwNF8xMDk5NTExNjI3ODA1_68a9064b-811e-4bb4-8fad-0f2d71fbaafc">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtMS0xLTEtODI2MjgvdGV4dHJlZ2lvbjplYWUxZWE5ZWY4Njk0MzdkYTNlNzA3MmJlZDM5OGE5NV8xMDk5NTExNjI3Nzky_74840420-3d43-4108-8829-23fa332629f9"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i933002237df241fbaa8a2f1845212112_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtMy0xLTEtODI1ODQ_2a2c2987-c4f7-40c2-8ea1-2725d1740c9d"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtNS0xLTEtODI1MjAvdGV4dHJlZ2lvbjo5YmJlODU3MDQ5NGI0N2U0OGZjZWZjYjQwNTRlZDczYl8xMDk5NTExNjI3Nzg1_505296a0-d6e4-40de-a7a6-b7f3e1996f2a"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i2538be3f0665431588d86ae58a47b620_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpmNDIwNjZlYzUxNjM0YmQwODg2MjZmNDgxNmUwNTE1OC90YWJsZXJhbmdlOmY0MjA2NmVjNTE2MzRiZDA4ODYyNmY0ODE2ZTA1MTU4XzYtNS0xLTEtODI1MjAvdGV4dHJlZ2lvbjo5YmJlODU3MDQ5NGI0N2U0OGZjZWZjYjQwNTRlZDczYl8xMDk5NTExNjI3Nzk2_89ae44e2-7432-4ff5-b409-d3447780ab30"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i3ca3a5fc58404fb58b979773eea67088_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2OTE1_219bb420-704d-4d23-8abd-637eee93b1b7"
      unitRef="usd">17100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6fdaf4f8f69f454b810125453581568e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwOTk1MTE2NDAyNDI_6c882108-ac7f-46fb-8e35-161287d2858c">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM0_ae09ba06-bdad-466a-b18b-9b4b6c56a75c">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity under the Company&#x2019;s stock option plans for the year ended December&#160;31, 2022. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,449,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;695,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(943,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(258,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,943,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,687,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#x2019;s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $103.49, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on December&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtMS0xLTEtODI3MDQ_5fc89d4b-2b6e-447d-a892-7e2088651ae7"
      unitRef="shares">6449692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtMy0xLTEtODI3MTI_0026bf53-4f4d-4d44-a9b3-0ce7b8121d69"
      unitRef="usdPerShare">78.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzEtNy0xLTEtODI3MzY_2a541680-e016-4d9f-8fa6-19e1f691ef75"
      unitRef="usd">80857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzItMS0xLTEtODI3MDQ_13ae0636-4e8e-4912-b3c6-9aedd268949b"
      unitRef="shares">695180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzItMy0xLTEtODI3MTI_ab676fd3-b553-4c60-9434-b68b5f8917e4"
      unitRef="usdPerShare">78.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzMtMS0xLTEtODI3MDQ_e275a445-2c14-4d5a-88fa-40ae1b0322dc"
      unitRef="shares">943038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzMtMy0xLTEtODI3MTI_a0c6df37-efa2-49d2-afe1-ae000b13aeae"
      unitRef="usdPerShare">55.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzQtMS0xLTEtODI3MDQ_c5988b81-7178-4d3b-a478-1d3de77772d4"
      unitRef="shares">258299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzQtMy0xLTEtODI3MTI_559e49a9-d27c-468c-85dc-8d0166dc6e9d"
      unitRef="usdPerShare">79.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtMS0xLTEtODI3MDQ_844427e7-98f8-4f43-a830-605d59849da4"
      unitRef="shares">5943535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtMy0xLTEtODI3MTI_434c4f0a-0e6d-42cc-9e60-1b1b6804029e"
      unitRef="usdPerShare">82.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtNS0xLTEtODI3MjA_22588f32-050a-41e1-bd60-4a822b98b4f9">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzUtNy0xLTEtODI3Mjg_2ebbe414-f38a-4f0b-ab6f-fd73531696fd"
      unitRef="usd">132395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtMS0xLTEtODI3MDQ_3ca09746-6468-49bf-b1d1-ef8313f95859"
      unitRef="shares">1255818</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtMy0xLTEtODI3MTI_54b6f81f-5b66-4d71-b78d-f20a35b5e7aa"
      unitRef="usdPerShare">78.64</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtNS0xLTEtODI3MjA_b2a5aa82-ce36-4678-a647-d226676255e2">P8Y7M6D</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzYtNy0xLTEtODI3Mjg_be017f18-4665-44dd-b581-a3769859bd67"
      unitRef="usd">31309000</bmrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctMS0xLTEtODI3MDQ_8328825e-3b98-4dde-ad84-2d0e43bd3e3b"
      unitRef="shares">4687717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctMy0xLTEtODI3MTI_65e2f397-58e5-4c82-9dc8-ca7d722d29f1"
      unitRef="usdPerShare">83.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctNS0xLTEtODI3MjA_4d8d6194-7591-4599-b5fd-021aa5df1f4c">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTowNjAzZmQzMDBkNmY0ZTBhOGQwZWRhMWMxZDA1ODA3NC90YWJsZXJhbmdlOjA2MDNmZDMwMGQ2ZjRlMGE4ZDBlZGExYzFkMDU4MDc0XzctNy0xLTEtODI3Mjg_ffc52bc3-f260-4f98-8485-bda3f45fc246"
      unitRef="usd">101085000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="i9f9a014bff6d4b1096c43e4334589a74_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEwMDU4_7b82ac29-c8f5-4e24-b592-64c52331e6f9"
      unitRef="usdPerShare">103.49</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDEw_7488cce1-fc24-4097-acd4-479f519854cd"
      unitRef="usdPerShare">32.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDIx_de864c81-5cf3-47f5-af88-55e4d6472631"
      unitRef="usdPerShare">31.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzEzMDY0_229384b6-4bb0-4cc5-898a-58f3bb01372c"
      unitRef="usdPerShare">27.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDI1_5da8bf60-841b-4106-bc14-6baf00e2c494"
      unitRef="usd">32100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAwOTg_ea2b402a-4d18-4638-85d1-bcd0d0f0e24c"
      unitRef="usd">40700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAwODI_06313d30-95b0-40cc-a058-1abc834e0591"
      unitRef="usd">71900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM1_00dfdae1-2fc1-414d-9873-ae610eef8ec0">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.1 &#x2013; 40.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.4 &#x2013; 41.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5 &#x2013; 42.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 &#x2013; 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 &#x2013; 6.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6 &#x2013; 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 &#x2013; 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7 &#x2013; 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3 &#x2013; 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMS0xLTEtOTQ4NTAvdGV4dHJlZ2lvbjo0NzkwN2NhYzU1YTE0MDY3YWJmZDBiNWUwNzVmYzk3NV8xNTk0MjkxODYwMjc5OA_9ca4581c-21cc-4f7d-87ef-1925d61e42e9"
      unitRef="number">0.381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMS0xLTEtOTQ4NTAvdGV4dHJlZ2lvbjo0NzkwN2NhYzU1YTE0MDY3YWJmZDBiNWUwNzVmYzk3NV8xNTk0MjkxODYwMjc5MQ_875a49f0-5113-4e95-bc3c-88b07b3fbc3c"
      unitRef="number">0.405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMy0xLTEtOTA1MzkvdGV4dHJlZ2lvbjowMTEzZDg0OTE0YTQ0OTdkOTYyNzM2Y2Y5ZjYwOTE4ZV8xMDk5NTExNjI3Nzk2_e59d6881-30ad-4a2e-927d-d9c3c742b80e"
      unitRef="number">0.394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItMy0xLTEtOTA1MzkvdGV4dHJlZ2lvbjowMTEzZDg0OTE0YTQ0OTdkOTYyNzM2Y2Y5ZjYwOTE4ZV8xMDk5NTExNjI3ODA1_44d22daa-6870-4079-acbf-55639f7b8eb0"
      unitRef="number">0.416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItNS0xLTEtOTA0OTcvdGV4dHJlZ2lvbjphYWVlNTE3Zjc5MDc0MmQ5YWNjOTVmYzdhYzAxOGQ2ZV8xMDk5NTExNjI3Nzk2_bf166038-4d1b-4682-9d01-0a9f55ef5345"
      unitRef="number">0.365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzItNS0xLTEtOTA0OTcvdGV4dHJlZ2lvbjphYWVlNTE3Zjc5MDc0MmQ5YWNjOTVmYzdhYzAxOGQ2ZV8xMDk5NTExNjI3ODA3_3587c88c-2092-41cb-bc2f-44fd46ed8765"
      unitRef="number">0.422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtMS0xLTEtODQwNzY_3b55140b-b725-48d2-9759-fd89ce88e3b0"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtMy0xLTEtODQwNzY_7882fec9-27c6-4058-b4d1-c1454c0b02b9"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzMtNS0xLTEtODQwNzY_d866bdce-7d7c-4eb3-8821-683a74ae44d8"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i47b49962d5a640488eada80fa0f8ae01_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMS0xLTEtOTQ4MTgvdGV4dHJlZ2lvbjo2N2QyNWI3MzY4ZTY0MDNlYmYyNTM1NDYyODZmZWMwMF8xNTk0MjkxODYwMjc5Mg_ab9c8ec6-75cb-406d-ba03-b78be69be31f">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7b7db90010f7454bb02b375d36208b18_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMS0xLTEtOTQ4MTgvdGV4dHJlZ2lvbjo2N2QyNWI3MzY4ZTY0MDNlYmYyNTM1NDYyODZmZWMwMF8xNTk0MjkxODYwMjc4Ng_b3bc3bde-3693-44b2-aef9-fdf0f156d1a4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i974da25672b24547a1fb86cd010d66a4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMy0xLTEtOTA1NTcvdGV4dHJlZ2lvbjoxYmE2OTBkNWViOTM0NWZlOGJiNzkwNjBmZGI0ZDNmMl8xMDk5NTExNjI3Nzk4_d9f451da-410c-45f5-a97e-5e2cee943434">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifae9719aaf7c4895bd6972ec9d5a1cdd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtMy0xLTEtOTA1NTcvdGV4dHJlZ2lvbjoxYmE2OTBkNWViOTM0NWZlOGJiNzkwNjBmZGI0ZDNmMl8xMDk5NTExNjI3ODEx_3eb99b79-807f-4095-9995-5c2ba8062377">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia46fdf7486a84e9f90ef98b86432eb8a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtNS0xLTEtOTA1MTUvdGV4dHJlZ2lvbjplZDE3NzMzNTAyYWY0YzhiOWZjN2ZjZTE3ZjA1ZDZlY18xMDk5NTExNjI3Nzk4_eb420a79-97f8-4172-a7b2-0cf8d3b5aea3">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iee705d880c0c46c7808d9be2b86c9f85_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzQtNS0xLTEtOTA1MTUvdGV4dHJlZ2lvbjplZDE3NzMzNTAyYWY0YzhiOWZjN2ZjZTE3ZjA1ZDZlY18xMDk5NTExNjI3ODEx_eb841b8a-e2ca-44aa-a366-fe7f5ca56e81">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMS0xLTEtOTQ4NDQvdGV4dHJlZ2lvbjozNGFiNTk2YmExZTc0NWQ4ODZhMzM4M2NjYTZjMTE5Nl8xNTk0MjkxODYwMjc5MA_1dd28d01-a58e-42f6-86d6-8b391b363898"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMS0xLTEtOTQ4NDQvdGV4dHJlZ2lvbjozNGFiNTk2YmExZTc0NWQ4ODZhMzM4M2NjYTZjMTE5Nl8xNTk0MjkxODYwMjc4NA_6a7c0b93-6865-402e-a77c-7884839f27c2"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMy0xLTEtOTA1NjkvdGV4dHJlZ2lvbjo2NTllNDg1NDI0OWY0MGM5YTE4MmZmMDY2NDhhNWNmZV8xMDk5NTExNjI3Nzkz_8ff09834-1ef3-419a-ba3c-14ee52eadc0a"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i28838537864a4aaf81c70bfd0bdc3332_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtMy0xLTEtOTA1NjkvdGV4dHJlZ2lvbjo2NTllNDg1NDI0OWY0MGM5YTE4MmZmMDY2NDhhNWNmZV8xMDk5NTExNjI3ODAx_74a550d5-a020-4378-8b3b-f2eb88d48902"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtNS0xLTEtOTA1MjcvdGV4dHJlZ2lvbjpkZjViYTZjMDk5NWQ0ZmRjYjMwYzJlYTVmZmJlZTY2ZF8xMDk5NTExNjI3Nzkz_65393904-6f44-4418-8d59-8f9d02a3a2e4"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1916af9e1dda47ad9c26228e51bd2c7e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTpjNTZlYzEzZmEwNTY0YjNlYmEzYjc5ODUyMjZlMjJlOC90YWJsZXJhbmdlOmM1NmVjMTNmYTA1NjRiM2ViYTNiNzk4NTIyNmUyMmU4XzUtNS0xLTEtOTA1MjcvdGV4dHJlZ2lvbjpkZjViYTZjMDk5NWQ0ZmRjYjMwYzJlYTVmZmJlZTY2ZF8xMDk5NTExNjI3ODAx_162c5580-8ef8-4570-9c81-6c8003b10d62"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia481385bca9741cb9627136de2e3b7a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDMz_56683b75-8083-4ff5-8a7d-08dd58a7f98d"
      unitRef="usd">31500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2NDQ0_f0a92ce1-9fe7-4102-b6f6-450feda1bdc9">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzM4NDgyOTA3MTAxMTQ_082f3383-3dbe-4951-9a8c-d4df37739c3b"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzExNDM2_86c07155-a4af-4241-89be-4000791875fb">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.6 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.6 &#x2013; 69.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 &#x2013; 2.0 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.04 &#x2013; 4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.04 &#x2013; 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1 &#x2013; 2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMS0xLTEtMTA0NzIyL3RleHRyZWdpb246YzczYjdkYzJlNDYwNGFhODljNzJlYmExMjM0YzM2ZmRfMTA5OTUxMTYyNzc5Ng_3fe95ea5-5406-414a-946f-7e1933f7a79c"
      unitRef="number">0.286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMS0xLTEtMTA0NzIyL3RleHRyZWdpb246YzczYjdkYzJlNDYwNGFhODljNzJlYmExMjM0YzM2ZmRfMTA5OTUxMTYyNzgwNQ_66f2dbae-bc25-4af3-b2a6-6ac13b43b2bf"
      unitRef="number">0.692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMy0xLTEtOTA2OTMvdGV4dHJlZ2lvbjo4NDRjYjc1MTRkNTA0N2YxYWRjM2RiNTNkMDJlNmFjNV8xMDk5NTExNjI3Nzk2_81825b5a-5c2d-466e-a293-474781e15eeb"
      unitRef="number">0.237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItMy0xLTEtOTA2OTMvdGV4dHJlZ2lvbjo4NDRjYjc1MTRkNTA0N2YxYWRjM2RiNTNkMDJlNmFjNV8xMDk5NTExNjI3ODA1_3cf67de0-b86c-400a-9810-da77452d96ce"
      unitRef="number">0.692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItNS0xLTEtOTA2NDkvdGV4dHJlZ2lvbjphNTZjZGE5ZWUwMzc0NmM0OWEzZjRmOThiOTNiYzUzNV8xMDk5NTExNjI3Nzk2_a64b84eb-99b6-43b9-add8-c5e480c4ad37"
      unitRef="number">0.306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzItNS0xLTEtOTA2NDkvdGV4dHJlZ2lvbjphNTZjZGE5ZWUwMzc0NmM0OWEzZjRmOThiOTNiYzUzNV8xMDk5NTExNjI3ODA1_83505e9a-9c99-4e92-a179-6d8257cfff3e"
      unitRef="number">0.692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtMS0xLTEtODQwNzQ_1ea16e3b-2be2-43bb-b53e-04ba919cb09c"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtMy0xLTEtODQwNzQ_ff8ff33f-11bb-489c-b6c6-c41e855401ec"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzMtNS0xLTEtODQwNzQ_596591ac-1ee0-43ec-af42-1428889cb37c"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia88d13cac03446da910f4bdda092a94d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMS0xLTEtMTA0NzQwL3RleHRyZWdpb246NWU5NjM4ZDEwZTFhNDllZTg1MzlkZGM0ZmNkNzUwZGFfMTA5OTUxMTYyNzc5OA_d72cd69a-7d7a-47e7-ab62-5b0d9eb61c85">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iba90d1418dc34fbcbca22b21986af64b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMS0xLTEtMTA0NzQwL3RleHRyZWdpb246NWU5NjM4ZDEwZTFhNDllZTg1MzlkZGM0ZmNkNzUwZGFfMTA5OTUxMTYyNzgxMQ_3e89b504-e0e8-4c15-a49a-798f6b066485">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i58aaac40a42b4a7fb111583b886ae23f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMy0xLTEtOTA3MTEvdGV4dHJlZ2lvbjozY2YyN2EyYmJkYTc0NmJjOTllNGJkOGM3ZGJlZTAyYV8xMDk5NTExNjI3Nzk4_fa88bc7a-0f2d-4d27-bc1a-14d79c632dc8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4f1866f0f98b4968a4a0b7d8ec1061c9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtMy0xLTEtOTA3MTEvdGV4dHJlZ2lvbjozY2YyN2EyYmJkYTc0NmJjOTllNGJkOGM3ZGJlZTAyYV8xMDk5NTExNjI3ODEx_48c13b05-cad3-42a3-9b70-ecb2aa7f41b1">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i94d5c058dd7843b99ec211cfd4eaef44_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtNS0xLTEtOTA2NjkvdGV4dHJlZ2lvbjo1YjI1M2I3ZWI2NDI0NjJkOWE5MjI1NmU5YWExOGQ2Y18xMDk5NTExNjI3Nzk4_f9cb0464-ca01-4882-9b40-adb8b3c63f78">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id45d9cb0ae984b8a895192c71ec4dc6a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzQtNS0xLTEtOTA2NjkvdGV4dHJlZ2lvbjo1YjI1M2I3ZWI2NDI0NjJkOWE5MjI1NmU5YWExOGQ2Y18xMDk5NTExNjI3ODEx_7a1498d0-f8d8-43b5-ab7c-750e22ca8d40">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMS0xLTEtMTA0NzUyL3RleHRyZWdpb246ODE0ZDBiMmFkNjVlNDFhZmI4ZDkyNTBkZGY4ZjJiMTVfMTA5OTUxMTYyNzc5Ng_3f6e3377-aff4-4098-af22-495b0664a52d"
      unitRef="number">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMS0xLTEtMTA0NzUyL3RleHRyZWdpb246ODE0ZDBiMmFkNjVlNDFhZmI4ZDkyNTBkZGY4ZjJiMTVfMTA5OTUxMTYyNzgwNQ_813ebe65-534e-4f77-aade-ef796fa011e3"
      unitRef="number">0.0475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMy0xLTEtOTA3MjMvdGV4dHJlZ2lvbjpkN2YwOGRjODBlNjc0MjkxYjNkY2FkZTM4NzliM2Y1Ml8xMDk5NTExNjI3Nzk3_c90ea1c7-08ea-406d-b605-462ba6ec6056"
      unitRef="number">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i76ce5ef4f0874d3e82db1b733d2ce037_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtMy0xLTEtOTA3MjMvdGV4dHJlZ2lvbjpkN2YwOGRjODBlNjc0MjkxYjNkY2FkZTM4NzliM2Y1Ml8xMDk5NTExNjI3ODA1_3490f49a-4e61-47c2-b06e-0d534ec24617"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtNS0xLTEtOTA2ODEvdGV4dHJlZ2lvbjoxOTQ5MmJiNWQ4ZjM0YzNjOTY5MzhkMDJjOWYyODBkM18xMDk5NTExNjI3Nzkz_eb976dfd-c489-4442-b6d4-4b2c1301fc3c"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1119551690714a89bd7e32c788eedfae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90YWJsZTo0ZDM5MDM3NzljZjY0YTI2OTMzMDUxMDY0MWViYTQ0ZS90YWJsZXJhbmdlOjRkMzkwMzc3OWNmNjRhMjY5MzMwNTEwNjQxZWJhNDRlXzUtNS0xLTEtOTA2ODEvdGV4dHJlZ2lvbjoxOTQ5MmJiNWQ4ZjM0YzNjOTY5MzhkMDJjOWYyODBkM18xMDk5NTExNjI3ODAx_7ff998df-ec17-434f-9f9a-e211908877d5"
      unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic8017b4ee43c4ecab167dfd09c805a3a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE1OTQyOTE4NjE2OTUx_711c64d5-bb4c-4760-a2d5-52cfb68011bf"
      unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i174e38c567da498382c9b71cd2020fac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODEvZnJhZzo5OTIwNDBkMzE1Njg0ZWU4YWFkNzcxZjMyMjk5MjU1Yy90ZXh0cmVnaW9uOjk5MjA0MGQzMTU2ODRlZThhYWQ3NzFmMzIyOTkyNTVjXzE3NTkyMTg2MDYwOTAy_a33f0e38-6b0b-43c8-bfe9-aaeaf5a9ba5d">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzE2NTc_3011ed68-8e20-4a4b-9e93-a6e76bc49a88">OTHER EMPLOYEE BENEFITS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan) for eligible U.S. employees. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee&#x2019;s eligible contributions, up to a maximum of the lesser of 6% of the employee&#x2019;s annual compensation or the annual statutory contribution limit. The Company&#x2019;s matching contribution vests immediately and was approximately $30.8 million, $31.6 million and $26.4 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company maintains the Nonqualified Deferred Compensation (NQDC) plan under which eligible directors and key employee may defer compensation. The NQDC prohibits the diversification of deferrals of Company stock. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity with no changes in the fair value of Company stock held in the NQDC recognized in earnings. Other contributions held in the NQDC are classified as trading securities, recorded at fair value with the corresponding deferred compensation obligation classified as a liability and subsequent changes in the fair value of these non-BioMarin investments are recognized in earnings in the period they occur. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt; to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities.</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MTQ_17615ee3-7a04-4dc1-a10f-15bcd6ac29b0"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk0Mzc_895fbacb-a46d-4493-b224-ee1fb02e7af1"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MzM_a94ac67c-b28e-46ca-be69-d000c337288a"
      unitRef="usd">30800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if33b1905895a4c0d9c697f26aee83f66_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MjY_051e5961-207f-4ec1-b20d-dc65463e4a95"
      unitRef="usd">31600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i64eb5ac7ff2c441b8532f7bcb1ddab8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODQvZnJhZzpiYWNjM2ZlMjBjYjE0YjI3OTQ2MzA2OWFkZTE3ZGIyOC90ZXh0cmVnaW9uOmJhY2MzZmUyMGNiMTRiMjc5NDYzMDY5YWRlMTdkYjI4XzEwOTk1MTE2Mjk2MTk_35c368af-e39b-48d3-b6c5-fcfeb5067f7e"
      unitRef="usd">26400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDY_5ad1a690-1c26-465b-afce-a6340f4a6f15">INCOME TAXES&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Source&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(299,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(259,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(169,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(838,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(889,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(903,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights from a wholly owned foreign subsidiary (tax resident in the Bahamas) to its wholly owned Irish subsidiary. The rights were sold to the Company&#x2019;s Irish subsidiary where its ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The intra-entity transfer did not result in a taxable gain in 2020 in any jurisdiction including the U.S. as the transaction was disregarded for U.S. tax purposes. The Company filed an election to treat the Irish subsidiary as a disregarded entity for U.S. income tax purposes in 2011. The transaction resulted in a step-up in the tax basis in the transferred intellectual property rights and the Company&#x2019;s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1&#160;million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The fair value of the transferred intellectual property rights was determined utilizing the income approach which relied on projections of product-specific revenues and the inclusion or exclusion of a terminal value for each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The tax deductions related to the amortization of these transferred intellectual property rights will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the statutory federal income tax benefit to the Company&#x2019;s effective tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan Drug &amp;amp; General Business Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Source Income Subject to US Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intra-entity transfer of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(852,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CARES act carryback claim&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance/deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(903,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and is offset by the PRV income taxed at a higher tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company&#x2019;s Dutch subsidiary of $9.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s net deferred tax assets were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;555,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses, reserves, and prepaids&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,571,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,514,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Joint venture basis difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,450,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2021 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The increase in net deferred tax assets is primarily related to capitalization of research and development expenses offset by a decrease in intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, the Company renegotiated a license agreement that resulted in lower royalty projections for its Dutch subsidiary. The revised royalty projections required establishment of a valuation allowance on net operating loss deferred tax assets that were no longer expected to be realizable. The valuation allowance also increased in 2021 due to the Company&#x2019;s expectation that state R&amp;amp;D credits will not be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2030-2033 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal R&amp;amp;D and orphan drug credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2024-2042 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2023-2042 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dutch net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Not included in the table above are $152.7 million of state research credit carryovers that will carry forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&#160;31, 2022 and 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Deletions) Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits as of December&#160;31, 2022 were potential benefits of $223.3 million that, if recognized, would affect the effective tax rate. The Company&#x2019;s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December&#160;31, 2022. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NjY_b6dc29f0-a3a7-485e-8db1-2fd76231c141"&gt;three&lt;/span&gt; to five years. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.&lt;/span&gt;&lt;/div&gt;U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.&#160;This excess totaled approximately $17.3 million as of December&#160;31, 2022, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDA_31425f7a-cbf2-47ca-9ac2-1035859af407">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Source&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(299,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(259,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(169,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItMS0xLTEtODEwMDA_ad4f4cee-98a9-4617-8b39-0020d4768d8e"
      unitRef="usd">-299403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItMy0xLTEtODEwMDA_d5789a7b-c8aa-4fb1-b411-51ca22902592"
      unitRef="usd">-259258000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzItNS0xLTEtODEwMDA_43996f61-7129-4a6d-b6e4-76e2be8ec2cb"
      unitRef="usd">-169614000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtMS0xLTEtODEwMDA_1491387a-0282-46c4-ab64-1f10879f974f"
      unitRef="usd">448979000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtMy0xLTEtODEwMDA_daa1b128-2873-468d-b797-9023f8ad1934"
      unitRef="usd">183908000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzMtNS0xLTEtODEwMDA_b217b917-62ec-4d63-8781-1757b76af427"
      unitRef="usd">120617000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtMS0xLTEtODEwMDA_6d212634-dcce-4014-b361-b0fa36565c99"
      unitRef="usd">149576000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtMy0xLTEtODEwMDA_3897047e-ee9e-4cbe-a814-9c18e12634fb"
      unitRef="usd">-75350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTozMTUwMzhiN2NhNGM0MzI5OTQ5ZjQwMzE0ZTBmZTZiNi90YWJsZXJhbmdlOjMxNTAzOGI3Y2E0YzQzMjk5NDlmNDAzMTRlMGZlNmI2XzQtNS0xLTEtODEwMDA_257b5847-2f2b-44c1-a772-b6e2bf555f3b"
      unitRef="usd">-48997000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MTA_023e42cd-088b-4374-a478-4141c27178d4">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(838,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(889,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(903,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtMS0xLTEtODEwMTE_bc3582d4-702d-4aac-a24c-6e7afd3dadca"
      unitRef="usd">12798000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtMy0xLTEtODEwMTE_41a1ddd4-c40d-46de-94a0-e64f55cdec01"
      unitRef="usd">-2038000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzMtNS0xLTEtODEwMTE_8b5b2c76-f32f-4497-bfcb-868bc03b679c"
      unitRef="usd">-15073000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtMS0xLTEtODEwMTE_c500f4b8-b591-4593-8b37-43ddb67075b1"
      unitRef="usd">5058000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtMy0xLTEtODEwMTE_9ef80f53-8961-4d4a-830b-e264ef9dec39"
      unitRef="usd">1339000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzQtNS0xLTEtODEwMTE_b27f1ca8-d944-45bc-847b-b7a325e6c2f0"
      unitRef="usd">998000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtMS0xLTEtODEwMTE_1d57b5a9-2c56-45f5-98e6-63ed04c3d822"
      unitRef="usd">42246000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtMy0xLTEtODEwMTE_82d52ed6-9378-450b-b8dc-cf48375ff77e"
      unitRef="usd">5037000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzUtNS0xLTEtODEwMTE_c6c6c9e3-a855-4d90-941b-5d2772a2c7ef"
      unitRef="usd">1042000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtMS0xLTEtODEwMTE_8408c95f-2468-46ee-b447-ad42384c6fcc"
      unitRef="usd">60102000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtMy0xLTEtODEwMTE_8c0fa173-adba-4c2e-a711-975b77667dbd"
      unitRef="usd">4338000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzYtNS0xLTEtODEwMTE_aa625030-516f-49aa-a21d-5b708c41719f"
      unitRef="usd">-13033000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtMS0xLTEtODEwMTE_51c5e3f0-86c7-42bb-86f3-e984df40d0e8"
      unitRef="usd">-79270000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtMy0xLTEtODEwMTE_4bcbe171-9615-46d3-bdce-0bffc8d350ee"
      unitRef="usd">-29895000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzgtNS0xLTEtODEwMTE_aa91d5a3-8380-44fb-8846-a1c0c8c4a71c"
      unitRef="usd">-46124000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktMS0xLTEtODEwMTE_4f853032-fc20-49dc-b11c-bc1636057c40"
      unitRef="usd">-5143000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktMy0xLTEtODEwMTE_c18b6966-6acb-4aa8-bf83-a923bb48404c"
      unitRef="usd">-1230000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzktNS0xLTEtODEwMTE_49151722-c6c7-4cbf-8df6-0545281d99d7"
      unitRef="usd">-5321000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTEtMS0xLTgxMDEx_eff5c1bc-25da-42b9-8a17-a390a38b4f18"
      unitRef="usd">32326000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTMtMS0xLTgxMDEx_6282486d-779e-497f-b6d6-6919b405e673"
      unitRef="usd">15517000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEwLTUtMS0xLTgxMDEx_a7b89f80-59a0-444f-9875-47907fa965f1"
      unitRef="usd">-838548000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTEtMS0xLTgxMDEx_34ba5e42-e266-4500-8540-b514e1e979b3"
      unitRef="usd">-52087000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTMtMS0xLTgxMDEx_a4cf6242-4a12-4760-aef7-527171c2a181"
      unitRef="usd">-15608000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzExLTUtMS0xLTgxMDEx_92a85515-3ed4-486c-a77f-fa58dd0d9df9"
      unitRef="usd">-889993000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTEtMS0xLTgxMDEx_d5675946-ec68-4a36-9951-548e1b2a99a8"
      unitRef="usd">8015000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTMtMS0xLTgxMDEx_2e38b7ea-190a-4b89-aabb-34b373f9dd65"
      unitRef="usd">-11270000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTo3NzY0MjMyMjMzZDY0YTdhODhlYWNhOTBmNWExYWM3Yy90YWJsZXJhbmdlOjc3NjQyMzIyMzNkNjRhN2E4OGVhY2E5MGY1YTFhYzdjXzEyLTUtMS0xLTgxMDEx_a2f9848c-e9cd-4efe-aac3-b5dcc46c6eaa"
      unitRef="usd">-903026000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0acf8a65e32646eda1218b113bbf892f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEyNzQ_f0179dac-564c-454e-b558-16f295347d2a"
      unitRef="usd">835100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MTE_40ab1e03-d946-478b-8c4c-90d45984577d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the statutory federal income tax benefit to the Company&#x2019;s effective tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan Drug &amp;amp; General Business Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Source Income Subject to US Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intra-entity transfer of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(852,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CARES act carryback claim&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance/deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(903,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and is offset by the PRV income taxed at a higher tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company&#x2019;s Dutch subsidiary of $9.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItMS0xLTEtODEwMzA_1a2b7db4-c9ee-4832-9f49-df67db2a4982"
      unitRef="usd">31412000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItMy0xLTEtODEwMzA_8834530f-3d10-4a12-b8d1-dda569f8c43e"
      unitRef="usd">-15824000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzItNS0xLTEtODEwMzA_ee4b5499-54ea-49e8-96a6-eba584baa2ed"
      unitRef="usd">-10289000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtMS0xLTEtODEwMzA_4111b07b-a5bc-45cb-bcf1-33d05d0dd2ff"
      unitRef="usd">-1017000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtMy0xLTEtODEwMzA_b40aa29a-9d11-47b5-b1e2-50c97319aeae"
      unitRef="usd">509000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzMtNS0xLTEtODEwMzA_da34a35a-0468-47b3-8329-39b3a5e05f38"
      unitRef="usd">-3467000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtMS0xLTEtODEwMzA_0ea1d62a-2e7c-49fd-9682-eda98f21234a"
      unitRef="usd">35674000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtMy0xLTEtODEwMzA_8c09000c-973b-418f-94b9-3f07de3e361d"
      unitRef="usd">29363000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzQtNS0xLTEtODEwMzA_e1fc58b5-dee4-493e-809a-a9a81ffe4c73"
      unitRef="usd">44114000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtMS0xLTEtODEwNDE_22b06f6a-7687-4ae9-ad7b-5933c7f1f436"
      unitRef="usd">6433000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtMy0xLTEtODEwNDE_4d86de12-6e27-433c-91d9-bf077426394b"
      unitRef="usd">7859000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzUtNS0xLTEtODEwNDE_e523ddd7-6481-4581-b007-8e6815552d35"
      unitRef="usd">-1101000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctMS0xLTEtODEwNDE_5d517ebd-744a-4fdc-862d-58654eaf0164"
      unitRef="usd">-5644000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctMy0xLTEtODEwNDE_40360778-640a-450f-b750-83a044f5f741"
      unitRef="usd">16878000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzctNS0xLTEtODEwNDE_3cf3317b-70f9-4e57-a995-0ce6fa5c473c"
      unitRef="usd">6266000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtMS0xLTEtODEwNTU_8e222ac5-848f-4dfd-9aa8-d25ce8ccfffd"
      unitRef="usd">-4051000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtMy0xLTEtODEwNTU_9914a459-eb06-4b24-887a-13c8bd81856e"
      unitRef="usd">-16971000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzgtNS0xLTEtODEwNTU_a5e0c160-d371-415b-b507-0b6ca4c66402"
      unitRef="usd">-16238000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <bmrn:IncomeTaxRateReconciliationSection162Limitation
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktMS0xLTEtODEwNTU_f1c829c8-448d-468d-bfd1-d0cc1725d712"
      unitRef="usd">6577000</bmrn:IncomeTaxRateReconciliationSection162Limitation>
    <bmrn:IncomeTaxRateReconciliationSection162Limitation
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktMy0xLTEtODEwNTU_d6487a2f-9876-4518-a02f-c4ab67a48814"
      unitRef="usd">6304000</bmrn:IncomeTaxRateReconciliationSection162Limitation>
    <bmrn:IncomeTaxRateReconciliationSection162Limitation
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzktNS0xLTEtODEwNTU_ae4c7122-dd1b-492d-b740-fea25eb1697b"
      unitRef="usd">9571000</bmrn:IncomeTaxRateReconciliationSection162Limitation>
    <bmrn:IncomeTaxRateReconciliationTaxReserves
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTEtMS0xLTgxMDU1_a1f74eef-8d76-4944-85d6-1d0a8079ca5a"
      unitRef="usd">18043000</bmrn:IncomeTaxRateReconciliationTaxReserves>
    <bmrn:IncomeTaxRateReconciliationTaxReserves
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTMtMS0xLTgxMDU1_2ba96631-bef4-4ac0-9978-4f329fca8bac"
      unitRef="usd">15530000</bmrn:IncomeTaxRateReconciliationTaxReserves>
    <bmrn:IncomeTaxRateReconciliationTaxReserves
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEwLTUtMS0xLTgxMDU1_f170f7b6-97da-4352-be7d-7b7688bc76f7"
      unitRef="usd">2166000</bmrn:IncomeTaxRateReconciliationTaxReserves>
    <bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTEtMS0xLTgxMDgw_6c11beb8-4d9f-4415-8789-e47826d14dcf"
      unitRef="usd">-18752000</bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount>
    <bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTMtMS0xLTgxMDgw_f738b030-629a-42ec-bfc8-b6dc5a68485d"
      unitRef="usd">-3920000</bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount>
    <bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzExLTUtMS0xLTgxMDgw_07f9125f-e747-4492-a087-64d03c1e6eb9"
      unitRef="usd">-852338000</bmrn:EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount>
    <bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTEtMS0xLTgxMDkx_dc5253d7-0cf7-4d86-9262-cefe10bb946e"
      unitRef="usd">0</bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim>
    <bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTMtMS0xLTgxMDkx_478e28c6-c732-4302-821f-988de0cd54a7"
      unitRef="usd">0</bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim>
    <bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEyLTUtMS0xLTgxMDkx_3b6bd164-9b7e-447e-b501-c171a305eb08"
      unitRef="usd">2201000</bmrn:EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTEtMS0xLTgxMTAy_a5229e53-e221-4db9-9050-d3785e621265"
      unitRef="usd">7851000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTMtMS0xLTgxMTAy_76de24f5-fbd2-440f-92e1-2e5c9449abfc"
      unitRef="usd">6821000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzEzLTUtMS0xLTgxMTAy_49a17676-ae32-4a39-b87f-49bf4306adc6"
      unitRef="usd">6876000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTEtMS0xLTgxMTEz_ff71b079-4dba-4773-9bbd-31cb7b5271fe"
      unitRef="usd">2837000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTMtMS0xLTgxMTEz_33156384-ea94-4cb4-96b0-c64cd9c87f48"
      unitRef="usd">907000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE0LTUtMS0xLTgxMTEz_e267c236-e5c1-4d5d-8da5-ddedbf31168b"
      unitRef="usd">1843000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTEtMS0xLTgxMTI0_2f106b23-0a9c-41ae-80d0-629874be43bf"
      unitRef="usd">8015000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTMtMS0xLTgxMTI0_db3a5085-85a1-4434-80fa-7397aab358dc"
      unitRef="usd">-11270000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpjMTQ2NmU4YzJiMzY0OWU5YjFiMDcyM2ViMTg2ZDc5Zi90YWJsZXJhbmdlOmMxNDY2ZThjMmIzNjQ5ZTliMWIwNzIzZWIxODZkNzlmXzE1LTUtMS0xLTgxMTI0_85b094e1-acc2-4bbb-afb1-6eab9d300afc"
      unitRef="usd">-903026000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i501529bab97849e78084830bdba9baf9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2Mzk0MjY_ea37a49d-edc7-4c74-90fc-72db2cddd4ad"
      unitRef="usd">9300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDE_2b5dbfd4-aba4-44f3-beb9-46d408d4f195">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s net deferred tax assets were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;555,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses, reserves, and prepaids&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,571,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,514,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Joint venture basis difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,450,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2021 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzMtMS0xLTEtODExNDc_fb64ce8a-5807-4e26-8d3a-85aabb81101f"
      unitRef="usd">20657000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzMtMy0xLTEtODExNDc_ccdf65bb-b637-479a-8841-bbbd1f9448ac"
      unitRef="usd">25936000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzQtMS0xLTEtODExNDc_95babdd3-a5be-440f-8866-fd0c2ff824fc"
      unitRef="usd">555319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzQtMy0xLTEtODExNDc_9ad65c44-c57a-4c0c-9430-e904de633862"
      unitRef="usd">564109000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzUtMS0xLTEtODExNDc_2e41d0b5-1cea-4517-8223-2b28c23c443b"
      unitRef="usd">88697000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzUtMy0xLTEtODExNDc_4eb13355-e555-46ea-a77d-1e90d3b2fd94"
      unitRef="usd">72759000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzYtMS0xLTEtODExNDc_0cbbf5ae-7616-4330-b8b4-7948f7d3397e"
      unitRef="usd">836402000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzYtMy0xLTEtODExNDc_71785437-ffa4-4f42-a523-3e8034fccb62"
      unitRef="usd">875311000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMS0xLTEtMTA3NDc0_371900bc-7a37-46a1-bb0e-373159564dce"
      unitRef="usd">103212000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMy0xLTEtMTA3NDY2_ad7f3692-910b-493c-be25-ccec3371b242"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMS0xLTEtODExNDc_45d8a60c-863a-497c-8123-bdad60a8d2ad"
      unitRef="usd">49472000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzctMy0xLTEtODExNDc_10127c7a-d1a9-4672-86f3-c0a1cfb09703"
      unitRef="usd">50910000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bmrn:DeferredTaxAssetsLeaseLiabilities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzgtMS0xLTEtODExNDc_1392141d-8c50-4992-96a9-14d9a68d67e5"
      unitRef="usd">5757000</bmrn:DeferredTaxAssetsLeaseLiabilities>
    <bmrn:DeferredTaxAssetsLeaseLiabilities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzgtMy0xLTEtODExNDc_764d4f77-ff85-4679-ad84-9d5a788e755c"
      unitRef="usd">7422000</bmrn:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzktMS0xLTEtODExNDc_e73bfb74-9160-49ed-8947-83df1db046d9"
      unitRef="usd">22726000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzktMy0xLTEtODExNDc_33eb6bde-d808-4b4f-9562-80449f7136d1"
      unitRef="usd">25169000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEwLTEtMS0xLTgxMTQ3_23b3db66-5f87-4207-9dd0-7187c7c2a20e"
      unitRef="usd">5596000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEwLTMtMS0xLTgxMTQ3_1356cdcc-eefe-4e1c-9e5b-8dc75404cbf2"
      unitRef="usd">1942000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzExLTEtMS0xLTgxMTQ3_881680c3-2794-4ce4-9d28-08ea1d923df2"
      unitRef="usd">116299000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzExLTMtMS0xLTgxMTQ3_b20728f9-bea8-4fe2-ae6a-da73917ff1b0"
      unitRef="usd">109176000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEyLTEtMS0xLTgxMTQ3_72f74ce9-085a-4528-98e7-bfd75e35f3ff"
      unitRef="usd">1571539000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzEyLTMtMS0xLTgxMTQ3_53359af9-2f7a-4bab-9e04-7832b488fee9"
      unitRef="usd">1514382000</us-gaap:DeferredTaxAssetsNet>
    <bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE0LTEtMS0xLTgxMTYx_de466e59-cf0a-472e-bed4-b7f55e26dd7b"
      unitRef="usd">745000</bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference>
    <bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE0LTMtMS0xLTgxMTYx_02c38373-8810-4e1c-98d7-59e25171580b"
      unitRef="usd">1665000</bmrn:DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE1LTEtMS0xLTgxMTYx_1e09ffce-86eb-4d32-a57c-967f8af93889"
      unitRef="usd">1138000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE1LTMtMS0xLTgxMTYx_4a00abef-0900-4741-ab7b-20b7a2d31737"
      unitRef="usd">1250000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <bmrn:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE3LTEtMS0xLTgxMTcy_9f6e050a-17cb-40cc-94d6-b575f03d7b90"
      unitRef="usd">5347000</bmrn:DeferredTaxLiabilitiesRightOfUseAssets>
    <bmrn:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE3LTMtMS0xLTgxMTcy_30aef316-f0b5-4b68-90d6-e4af8a2f6222"
      unitRef="usd">6808000</bmrn:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE4LTEtMS0xLTgxMTcy_7c41fbb2-954c-4240-ba4a-56bb6d31b8d4"
      unitRef="usd">58897000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE4LTMtMS0xLTgxMTcy_9d3f691c-e73b-495b-b79e-f49dafd4d819"
      unitRef="usd">54498000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE5LTEtMS0xLTgxMTcy_08b6ca98-dd60-49ad-85fe-8f15843bf277"
      unitRef="usd">66127000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzE5LTMtMS0xLTgxMTcy_548152a4-4471-4e6d-a284-9c580286db55"
      unitRef="usd">64221000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzIwLTEtMS0xLTgxMTcy_7c35ba77-75ea-462d-be5c-ccfa0d38afc2"
      unitRef="usd">1505412000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTpmMTc4OTk0NDM3YzY0NmRjOTE5OTU5MjgxMjNlNjA1My90YWJsZXJhbmdlOmYxNzg5OTQ0MzdjNjQ2ZGM5MTk5NTkyODEyM2U2MDUzXzIwLTMtMS0xLTgxMTcy_efd75052-5c1c-4b64-86c4-64196d172c40"
      unitRef="usd">1450161000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDI_9aaff22c-c593-42e2-87a3-23dbcf6c513d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2030-2033 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal R&amp;amp;D and orphan drug credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2024-2042 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;2023-2042 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dutch net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i7af5d8557d8a40ae8beee5eedec3c302_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzEtMi0xLTEtODEyMDM_8335b993-59cc-4b9a-be9f-d6d490baba6a"
      unitRef="usd">3628000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i7af5d8557d8a40ae8beee5eedec3c302_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzItMi0xLTEtODEyMDM_0b40d98c-7fd5-411a-abc1-e49163448c16"
      unitRef="usd">585322000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="iaba0e7db091b498bbec2338419da0c3c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzMtMi0xLTEtODEyMDM_9ac89d23-1c72-411f-9567-f2d5452323d9"
      unitRef="usd">186594000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i942bc095adee430bad3ee06049a4834a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphMTJiOWE0ZTFhOTM0N2U3ODJmYTVjYzA2OGYyNmNkZi90YWJsZXJhbmdlOmExMmI5YTRlMWE5MzQ3ZTc4MmZhNWNjMDY4ZjI2Y2RmXzQtMi0xLTEtODEyMDM_ab351c23-f096-4a44-ba50-aa757929b2a7"
      unitRef="usd">38912000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iaba0e7db091b498bbec2338419da0c3c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1ODE_58c21ab5-b175-4263-98f9-ba4cd0aa6828"
      unitRef="usd">152700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzY2MDQ_c0199f59-de5c-4742-bd5a-71991f8ad618">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&#160;31, 2022 and 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Deletions) Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzItMS0xLTEtODEyMzU_bc108fc7-33e1-41f5-afa6-56712092bd3d"
      unitRef="usd">205095000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic12190384e734edabd0ce99df1427a69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzItMy0xLTEtODEyMzU_6f414cba-41a4-4147-b5b5-4e355921de3d"
      unitRef="usd">182564000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzMtMS0xLTEtODEyMzU_d641c169-ca9c-4376-828c-67fa22f5d461"
      unitRef="usd">26762000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzMtMy0xLTEtODEyMzU_e6566e77-7716-4e18-b6c0-62192390e9a6"
      unitRef="usd">23499000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzQtMS0xLTEtODEyMzU_5e06b6e8-9231-4651-9e25-ec4349e12f2e"
      unitRef="usd">1017000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzQtMy0xLTEtODEyMzU_46dc71c2-19d6-4c1e-8ecc-4f7dd1ef4b43"
      unitRef="usd">786000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzUtMS0xLTEtODEyMzU_23f1b5eb-8e62-4b9e-95df-8fe81f1ac1da"
      unitRef="usd">18000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzUtMy0xLTEtODEyMzU_5be1b69a-bca4-438b-aa2b-df451ae260c3"
      unitRef="usd">182000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzYtMS0xLTEtODEyMzU_2505e96e-1ce3-46d2-a8ff-03e97bc66a5e"
      unitRef="usd">232856000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6babf135cae34564ae9f1313c802cf9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90YWJsZTphZWNlMzY1MjA1Yjg0OTExOGM4NDJkZWI3MjU1MWJmMS90YWJsZXJhbmdlOmFlY2UzNjUyMDViODQ5MTE4Yzg0MmRlYjcyNTUxYmYxXzYtMy0xLTEtODEyMzU_619de8e7-ce2f-4cbb-b390-5abbc5e5549d"
      unitRef="usd">205095000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NzY_47369083-4089-4c01-8c21-f49d19e3ebbf"
      unitRef="usd">223300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <bmrn:IncomeTaxStatuteOfLimitationsPeriod
      contextRef="i50493d32a16347769cc9afd7ce181d7b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzEwOTk1MTE2MzU1NzE_4778a348-a2a4-448a-bcfb-3cbe32738db9">P5Y</bmrn:IncomeTaxStatuteOfLimitationsPeriod>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xODcvZnJhZzo1YTYxZTI5ZWJmMDY0Y2UxYmI3ZjYyOGEzOGJiZDE5Yy90ZXh0cmVnaW9uOjVhNjFlMjllYmYwNjRjZTFiYjdmNjI4YTM4YmJkMTljXzIxOTkwMjMyNjcxODM_54333664-56cf-4ad0-825d-8e8d0305eb38"
      unitRef="usd">17300000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzM_c50b81c0-bf2b-48bb-93e8-d4b73bfa1283">EARNINGS (LOSS) PER COMMON SHARE&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#x2019;s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss), basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;854,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest expense, net of tax, on the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income/(loss), diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances under equity incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted earnings (loss) per common share as they were anti-dilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances under equity incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_172" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for information on the Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzQ_1c073087-6f45-4dfc-92f5-b3cf250385bf">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss), basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;854,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest expense, net of tax, on the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income/(loss), diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances under equity incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"&gt;Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtMS0xLTEtNzg2NjY_791857fe-2d33-452b-9f7c-01cda0dc52e6"
      unitRef="usd">141561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtMy0xLTEtNzg2NjY_6ff5a5ea-a18f-418b-b3ef-feb4f2d762e2"
      unitRef="usd">-64080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzMtNS0xLTEtODE0MDc_8654fbd5-d8c1-4404-8192-c74d30f4534a"
      unitRef="usd">854029000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtMS0xLTEtNzg2NjY_f937bcea-8407-4fdb-8265-07fe604d54d8"
      unitRef="usd">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtMy0xLTEtNzg2NjY_ef156ca5-77a2-4d8d-8251-15521933c0bd"
      unitRef="usd">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzQtNS0xLTEtODE0MDc_474b112a-cf26-4c3b-b2d5-4aea5078ba53"
      unitRef="usd">8313000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtMS0xLTEtNzg2NjY_0ebbee98-ecda-4e2f-8126-bc45b89a4a17"
      unitRef="usd">141561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtMy0xLTEtNzg2NjY_542abff6-3913-4f82-9560-ae465a585caa"
      unitRef="usd">-64080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzUtNS0xLTEtODE0MDc_f7a11a23-faa0-40d9-95b8-352f6871f5d5"
      unitRef="usd">862342000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctMS0xLTEtNzg2NzA_ab56a505-bbe8-4fd2-b606-15a847ecc625"
      unitRef="shares">185266000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctMy0xLTEtNzg2NzA_7d33bf5e-3d97-4c54-8b8c-72521de5ed0d"
      unitRef="shares">182852000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzctNS0xLTEtODE0MDc_fce1efe0-96cf-4c62-81f8-ca518bd56409"
      unitRef="shares">180804000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktMS0xLTEtODE0MDc_90e19a73-8c62-4699-909f-ff06edafc195"
      unitRef="shares">3697000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ic7eeb745948249f9b5df95030b886512_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktMy0xLTEtODE0MDc_0005b75c-98f0-465f-a014-499805329c47"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i55d2632b90814ba38f50774fec161236_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzktNS0xLTEtODE0MDc_5114ee5b-f616-4808-885a-a51721aee4e8"
      unitRef="shares">4030000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTEtMS0xLTgxNDA3_ceb4cd81-ad0b-47f8-b5dc-80f8e0ed94e7"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTMtMS0xLTgxNDA3_8c95cd07-d3db-4535-83a5-c4d55c170e74"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzEwLTUtMS0xLTgxNDA3_6567d1fe-d3f8-4a3f-bf0c-416750dfe41e"
      unitRef="shares">6844000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTEtMS0xLTc4Njk1_1d8bc4fe-1a4c-4ad7-9c7d-0199e983104c"
      unitRef="shares">188963000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTMtMS0xLTc4Njk1_f550de96-02e0-498d-a9fb-f0c9ccd2733b"
      unitRef="shares">182852000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE2LTUtMS0xLTgxNDA3_33ada0ea-0269-4570-bcdd-f53e7f72d025"
      unitRef="shares">191678000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTEtMS0xLTc4Njk1_2280cea6-8e78-4084-8ffd-39632ca4bdc2"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTMtMS0xLTc4Njk1_e86ddd43-12d1-48b8-8bc1-b81cfd25f873"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE3LTUtMS0xLTgxNDA3_d2648b6d-d016-47b8-b4be-5ca29403d482"
      unitRef="usdPerShare">4.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTEtMS0xLTc4Njk1_15a27b92-a607-4338-912b-49b347492301"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTMtMS0xLTc4Njk1_19e20015-7cf1-4709-b44c-c5a8305fda32"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTo1NGY4ZWM5ZmU5NjY0MWM2OWQzODhjYWI2ZjM2NGQ3MC90YWJsZXJhbmdlOjU0ZjhlYzlmZTk2NjQxYzY5ZDM4OGNhYjZmMzY0ZDcwXzE4LTUtMS0xLTgxNDA3_5550976f-c86e-49d8-825e-e51ae4da4e4f"
      unitRef="usdPerShare">4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90ZXh0cmVnaW9uOjYzOTA0YjNkMWE2NzRkYTFhNzU5NGQxYjJiN2JmNGI0XzEzNzU_f4f57840-db4e-4ae1-8829-49966b609f15">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted earnings (loss) per common share as they were anti-dilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances under equity incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic08771dadb0e4346a2da464fc29a2040_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItMS0xLTEtODE0MDQ_0b1c4101-d720-4ace-80a2-f27614232bc9"
      unitRef="shares">8148000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic7eeb745948249f9b5df95030b886512_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItMy0xLTEtODE0MDQ_7e2d55ab-0c09-4883-a658-993259a2b93b"
      unitRef="shares">12450000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i55d2632b90814ba38f50774fec161236_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzItNS0xLTEtODE0MDQ_be4e05df-cacd-4d7c-8758-cdbe25964f58"
      unitRef="shares">7836000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45d32fa6a8fa400883dcf9bc8733950b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtMS0xLTEtODE0MDQ_4b6203dd-3047-47be-acfa-ccd4a8d0f8e4"
      unitRef="shares">8335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7397c5ca381f44f6a28ac452f85027c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtMy0xLTEtODE0MDQ_695a25e3-ad8d-4434-8780-9bf9aa9f4e1d"
      unitRef="shares">8335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i86a3ad7f64094ff5a8132805184ab8bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzMtNS0xLTEtODE0MDQ_41fca5e8-cfc9-40d1-999a-8a84df57c99e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktMS0xLTEtODE0MDQ_732eae5c-7438-4927-9db6-580237920bfa"
      unitRef="shares">16483000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i730600aac0774220b24184631d3ca45a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktMy0xLTEtODE0MDQ_c564c678-f655-459b-9e35-970fcacd024a"
      unitRef="shares">20785000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c06f5479fa8421cbf835cd3416a2fac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTAvZnJhZzo2MzkwNGIzZDFhNjc0ZGExYTc1OTRkMWIyYjdiZjRiNC90YWJsZTozNmJkMTgwZDM3NjI0MDIyOTVhZDU2MzkwNzgyZTYyNC90YWJsZXJhbmdlOjM2YmQxODBkMzc2MjQwMjI5NWFkNTYzOTA3ODJlNjI0XzktNS0xLTEtODE0MDQ_14671491-97c4-44be-bf15-4992e9ef333a"
      unitRef="shares">7836000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzQzMzE_0c58c2a9-0541-4aa0-87c8-1bd5f7514deb">LICENSE AND COLLABORATION AGREEMENTSIn October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0&#160;million, a minority 15% equity ownership interest in the licensee, and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;sales milestones are met by the licensee. Subsequently, the third party licensee raised additional funding and issued the Company incremental shares to maintain its 15% minority interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee&#x2019;s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December&#160;31, 2022. As a result, the Company's loss exposure is limited to the value of the equity investment of $12.6&#160;million which is included in Other Assets on the Company&#x2019;s Consolidated Balance Sheets as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In July 2017, the Company executed a license agreement with Sarepta Therapeutics (Sarepta) that provides Sarepta with global exclusive rights to the Company&#x2019;s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under the license agreement, Sarepta pays the Company royalties and may pay the Company certain milestone payments for exons 51, 45, 53 and possibly other exon-skipping products. In the fourth quarter of 2021, the Company and Sarepta amended the license agreement to, among other things, make the license co-exclusive at a future date and reduce future royalty rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan. Previously, the Company had exclusive rights to KUVAN in the U.S. and Canada and PALYNZIQ in the U.S. and Japan. Pursuant to the amended and restated KUVAN Agreement, if future sales milestones were met, the Company was obligated to pay Merck Serono up to a maximum of &#x20ac;60.0 million, all of which were met as of December&#160;31, 2022, &#x20ac;15.0 million of which was unpaid as of December&#160;31, 2022. Pursuant to the Pegvaliase Agreement, the Company also paid Merck Serono &#x20ac;125.0&#160;million in cash when the PALYNZIQ development milestones were achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market FIRDAPSE, the Company's former commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to FIRDAPSE, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of FIRDAPSE in North America. In January 2020, the Company completed the sale of worldwide rights to FIRDAPSE to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib1aad3959e884c01b6a07e04db98b99b_145" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to these Consolidated Financial Statements for further information about the FIRDAPSE sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the KUVAN New Drug Application. The Company receives royalties on net sales of the product in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is engaged in R&amp;amp;D collaborations with various other entities. These provide for sponsorship of R&amp;amp;D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3436f033fc741c0ad3de97901f0af87_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzM1Mw_65cdf701-a08b-4a07-ad33-23e928e80a0e"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzM2OA_4edb1a35-b087-4e53-aa0c-4e04bce240d8"
      unitRef="number">0.15</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ide09f74cad344ee0afd4d0d8a7309e38_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzE2NDkyNjc0NTAwNTI_99c8eb95-f241-4aaf-a8fa-34982b500ef9"
      unitRef="number">0.15</us-gaap:VariableInterestEntityOwnershipPercentage>
    <bmrn:CollaborativeArrangementMinorityEquityInvestmentInLicense
      contextRef="i5762589687004ef6b263f4cd981bf8cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzIzMTI_cd71ee6f-900b-4b6a-8d77-7793d84e156f"
      unitRef="usd">12600000</bmrn:CollaborativeArrangementMinorityEquityInvestmentInLicense>
    <bmrn:BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone
      contextRef="i7c68988441f541e28fb1eef7917f2f8f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzI2NDI_37f742b2-eb15-4cc2-90db-a1429d682aa2"
      unitRef="eur">60000000</bmrn:BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i894b46e6d24741dca61467eef21c957a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzEwOTk1MTE2MzQ4MDg_9d4aeb56-94fe-43f3-b15c-8e113caba7d1"
      unitRef="eur">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i69e41e511f7c45fab191013826ff05c7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzI4Nzk_239d5df3-b589-4fc4-a9f2-4e3ae033b8bd"
      unitRef="eur">125000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <bmrn:RoyaltyRateLowerLimit
      contextRef="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzMzMjA_698441f5-6fb7-4e7c-8f24-393419ca9302"
      unitRef="number">0.07</bmrn:RoyaltyRateLowerLimit>
    <bmrn:RoyaltyRateUpperLimit
      contextRef="i77a677ec0b154c0b9ee244bb19c37ea5_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTMvZnJhZzo2ZjZiOGVjYWRmZTA0NDZjOWVkY2U1NmJkOWNiODliMS90ZXh0cmVnaW9uOjZmNmI4ZWNhZGZlMDQ0NmM5ZWRjZTU2YmQ5Y2I4OWIxXzMzMjY_d8ac46e1-0f60-4b63-aed1-dd6e63d42c45"
      unitRef="number">0.10</bmrn:RoyaltyRateUpperLimit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzE3NDA_7695b355-9f6c-463d-911d-b8e944f91ba9">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#x2019;s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is involved in various purported shareholder class action and derivative lawsuits filed against the Company and certain officers and directors. For example, there are shareholder class actions alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act) for making materially false or misleading statements regarding information for two of its clinical products. The estimated long-term loss contingency recorded on the Company's Consolidated Balance Sheets was $13.0&#160;million as of December&#160;31, 2022. The same amount was recorded for expected insurance recoveries. Legal proceedings may occur that may result in a change in the estimated loss accrued by the Company. While it is not feasible to predict the outcome of such proceedings and exposures with certainty, management believes this should not have a material adverse effect on the Company&#x2019;s Consolidated Balance Sheets, Statement of Operations or Statement of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $762.5 million, which included $381.5 million and $210.0 million for two early stage development programs licensed from third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;amp;D activities. These amounts are included as R&amp;amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;amp;D services, production services and facility construction services. As of December&#160;31, 2022, such commitments were estimated at approximately $225.5 million, of which $188.7 million is expected to be paid in 2023. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzM4NDgyOTA3MDg5OTE_dbe47af6-030d-43c1-af48-2b835bfb53b8"
      unitRef="usd">13000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1NTM_26531034-c321-4b88-8ce5-8e5c9979f87f"
      unitRef="usd">762500000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="i35e08db3d4814a13a6b9f06ccc018757_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1NzE_73788096-a8ca-4a51-89bf-d7ce0658664e"
      unitRef="usd">381500000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="if5349719ab5245ecb53681104dd48921_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk1ODk_fa720ee6-60b7-4b5d-83d3-2ff227ed2d9b"
      unitRef="usd">210000000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <us-gaap:PurchaseObligation
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzEwOTk1MTE2Mjk2MjY_c43ccb62-cb0a-4c0c-ac5a-29ccdd01321f"
      unitRef="usd">225500000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="ib246871d78d94c228e7dec2d91f453a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xOTYvZnJhZzowMDk4ZjgzZDUyYjc0NWZjYTMwM2JkZjc3NDkzYWZkMi90ZXh0cmVnaW9uOjAwOThmODNkNTJiNzQ1ZmNhMzAzYmRmNzc0OTNhZmQyXzExNTQ0ODcyMTA1MDQz_4791e535-51bc-47c4-971f-5de382ac880a"
      unitRef="usd">188700000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note </xhtml:span><xhtml:span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><xhtml:a
      href="#ib1aad3959e884c01b6a07e04db98b99b_145"
      style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</xhtml:a></xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzE0LTYtMS0xLTc5MjQ5_f7d53189-bd59-4753-ab5d-3df52c59a177"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzktNi0xLTEtNzkyNDE_bad4c79e-2303-43f0-9edd-b5e178b4f363"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzUtNi0xLTEtNzkyNDE_95074f82-cf29-4abf-8334-ce07fb83c427"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzQtNi0xLTEtNzkyNDE_2d4c3631-db6f-4615-b4d3-6e02fb1f86b9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzYtNi0xLTEtNzkyNDE_2124f941-03d5-422a-ab9c-e4b62a3ebbad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEtNi0xLTEtNzkyNDE_26a3cf89-ddd8-4859-8870-3465b82e3398"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEyLTYtMS0xLTc5MjQ5_68445a3a-7838-494a-8212-e5f078434942"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEzLTYtMS0xLTc5MjQ5_544e3780-8759-4b21-9ce1-b11b4f4f934a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzEwLTYtMS0xLTc5MjQx_82c7126d-9e58-446a-86b7-606e9ca8ad61"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90YWJsZTpmYWZmYzljM2FkODU0OWI1YjI3YWNmZjY3YTJlNmZhZC90YWJsZXJhbmdlOmZhZmZjOWMzYWQ4NTQ5YjViMjdhY2ZmNjdhMmU2ZmFkXzgtNi0xLTEtNzkyNDE_1fb49196-05cb-48ca-a15f-d31edcfe22dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzMvZnJhZzowMDA0MTVlNGE5NWE0MDUyOGM1NzFlMzVlMzZhMWFhZC90ZXh0cmVnaW9uOjAwMDQxNWU0YTk1YTQwNTI4YzU3MWUzNWUzNmExYWFkXzM4NDgyOTA2OTc3ODQ_134ff087-40af-4261-8fc1-4771ab479eb5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </xhtml:span><xhtml:span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><xhtml:a
      href="#ib1aad3959e884c01b6a07e04db98b99b_145"
      style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</xhtml:a></xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMzLTMtMS0xLTc3ODQ5_00e49040-b49a-4c19-96b3-decaa8203e1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI4LTMtMS0xLTc3ODQ5_90ad85f0-a35c-4e77-943c-8d3ed200a0cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMtMy0xLTEtNzc4NDE_5168a44c-67b8-421a-a481-16dce6a0622d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzQtMy0xLTEtNzc4NDE_87b4a1c5-bfad-41bc-881c-e5524734b0a7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzgtMy0xLTEtNzc4NDk_a75904f2-d7e7-4243-9648-8eb47ebeb22f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI1LTMtMS0xLTc3ODQ5_10b0f1dc-6a84-43fd-a1cd-0faeeb46bcee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEzLTMtMS0xLTc3ODQ5_d18b10b7-17e4-4084-8af9-2e92a5caa5dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE2LTMtMS0xLTc3ODQ5_b2c0eba2-1a30-4cee-b040-cc42c6569889"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIxLTMtMS0xLTc3ODQ5_46aab1a3-0bc9-44f5-a75f-2a1f8c409571"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI0LTMtMS0xLTc3ODQ5_82015462-8923-4f90-8a04-6b0de6888848"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI2LTMtMS0xLTc3ODQ5_35035489-ccbb-482f-90f0-8d8f273120da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE0LTMtMS0xLTc3ODQ5_ffe5d998-ee3a-40a4-808f-542d5db4f79c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE5LTMtMS0xLTc3ODQ5_7629c93b-c678-4bb4-a024-a0719e8ffbee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzM0LTMtMS0xLTc3ODQ5_c16f9b72-ec62-42c8-945d-8385c9409224"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzYtMy0xLTEtNzc4NDE_548a608a-f105-456c-b07d-35d159712ed4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEwLTMtMS0xLTc3ODQ5_efa09086-f575-4c90-8486-bbf4e486dc4e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIzLTMtMS0xLTc3ODQ5_130f5b29-d110-4109-9834-6183e32bb7f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzEyLTMtMS0xLTc3ODQ5_4d39742d-b056-4053-92a1-c237e2181563"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMwLTMtMS0xLTc3ODQ5_6bed8c17-e930-43d8-8dc6-ca7d913f03e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzI5LTMtMS0xLTc3ODQ5_d54d9afb-3589-4714-b507-1ccf0bd04565"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMyLTMtMS0xLTc3ODQ5_480995b2-4a07-4aa7-a2c2-96517bd697db"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzctMy0xLTEtNzc4NDE_918c7fcb-b801-4ba9-8229-d1108ea1c2b7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzE1LTMtMS0xLTc3ODQ5_8bc5eff6-4254-4d95-b3bc-433148c0df8d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzIwLTMtMS0xLTc3ODQ5_adb40980-d8b9-47b4-b947-fdc2bd6c883f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzExLTMtMS0xLTc3ODQ5_ff024599-3022-4684-9977-b6fa3d3b6f6c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzUtMy0xLTEtNzc4NDE_8600f106-3f16-4ef3-af83-f67d5c78a792"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90YWJsZTo5MzYxOTkwM2FhODM0ZWU1OTQ4ZjE3YmYzMWY4MjIyNC90YWJsZXJhbmdlOjkzNjE5OTAzYWE4MzRlZTU5NDhmMTdiZjMxZjgyMjI0XzMxLTMtMS0xLTc3ODQ5_9fa1681a-511d-4f80-9f1d-36499b77a824"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMjcvZnJhZzozZTE5YmUxNzIwZDU0N2VhYmZmMzEwY2EwOTUyMmJlOS90ZXh0cmVnaW9uOjNlMTliZTE3MjBkNTQ3ZWFiZmYzMTBjYTA5NTIyYmU5XzMyOTg1MzQ4ODM5NDc_4a6b3c6c-d09b-4064-88b3-d0b972fea062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note </xhtml:span><xhtml:span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><xhtml:a
      href="#ib1aad3959e884c01b6a07e04db98b99b_145"
      style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</xhtml:a></xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzItNS0xLTEtODEyNjM_d5e2f205-acce-4cec-98d9-9e7cdb79d941"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIxLTUtMS0xLTgxMjYz_558f2f40-e7b9-437c-9c08-358241a2531c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzQtNS0xLTEtODEyNjM_161cb549-399d-4871-92c8-3476a8e98a4a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzYtNS0xLTEtODEyNjM_d36297a1-3bde-4b0d-8bc0-570bc09e1e78"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzctNS0xLTEtODEyNjM_1f382d8d-b7c6-4a29-9c18-9b2b489f745a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE1LTUtMS0xLTgxMjYz_ebe6c8cc-eb9a-461f-8380-445b6ef7008c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzktNS0xLTEtODEyNjM_2a1ff334-c8dd-4c1a-b1d7-2c96746a66df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEyLTUtMS0xLTgxMjYz_0e48995c-85fc-479c-aae4-e9837124b3e7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE4LTUtMS0xLTgxMjYz_3c472486-61e8-4e13-a962-e287dead90b7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE3LTUtMS0xLTgxMjYz_a906ac66-42e6-4431-8744-177a6c63e251"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzMtNS0xLTEtODEyNjM_e908eb34-e6c5-439a-80e0-e24b660e23bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzExLTUtMS0xLTgxMjYz_f59827df-6f02-4519-af50-105f99374c02"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIyLTUtMS0xLTgxMjYz_436fe794-6bf6-491f-a23e-3b670be3fbe8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIzLTUtMS0xLTgxMjYz_9b83690a-7f16-4c56-9d19-8fa6e849748b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzEwLTUtMS0xLTgxMjYz_0941de1b-fa41-49a2-83d0-29622b8818de"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE5LTUtMS0xLTgxMjYz_af78bcf5-0569-47d4-a852-74ac423001e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE0LTUtMS0xLTgxMjYz_668d9866-c7d6-4b6f-bf72-ab3a5f54be67"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzgtNS0xLTEtODEyNjM_0cce384f-1bfe-4dc7-adc2-b948ff864408"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzIwLTUtMS0xLTgxMjYz_35f061f7-d776-47a0-b001-be60ddded9bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90YWJsZTo0OTdkNDVmNzY2Njg0YTAxODE2MjA0NGQ1ZGE2OTJkZi90YWJsZXJhbmdlOjQ5N2Q0NWY3NjY2ODRhMDE4MTYyMDQ0ZDVkYTY5MmRmXzE2LTUtMS0xLTgxMjYz_67570829-918d-4c61-9a95-bd9a5cb9d4de"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzAvZnJhZzpiNGZhYmI3M2JkNTI0ODU4YTU3YjM4ZWFjYmFkZGVjNy90ZXh0cmVnaW9uOmI0ZmFiYjczYmQ1MjQ4NThhNTdiMzhlYWNiYWRkZWM3XzM4NDgyOTA2OTc3MzQ_f6d52f06-213b-442f-9517-b90109aa3171"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note </xhtml:span><xhtml:span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><xhtml:a
      href="#ib1aad3959e884c01b6a07e04db98b99b_145"
      style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</xhtml:a></xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzktNS0xLTEtNzk1NDg_f7d6932d-2196-4190-94ec-be70c14b1051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI3LTUtMS0xLTc5NTQ4_3a952dee-d738-4f5b-827b-6ba8659ded1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIzLTUtMS0xLTc5NTQ4_86599888-2b54-4bc9-aa88-5f1222c0c274"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzExLTUtMS0xLTc5NTQ4_3701e91c-240f-4b48-a431-301019275bc5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM1LTUtMS0xLTc5NTQ4_d871772e-6e50-4b1c-83d0-7cf689aed7a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI2LTUtMS0xLTc5NTQ4_49d81586-bb02-4be0-baeb-ee0dedc66f66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI5LTUtMS0xLTc5NTQ4_7978c8f7-a5ff-443c-a368-388dd6d55dd4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzctNS0xLTEtNzk1NDg_8a2f77a7-35f3-486e-a530-dd7689c7a5ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ1LTUtMS0xLTc5NTQ4_283de7e1-5a3a-4cf8-a3c7-8b9c3a7ee3d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE5LTUtMS0xLTc5NTQ4_f2a2e061-dd0e-4571-9286-af700de7fc57"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ4LTUtMS0xLTc5NTQ4_263ff9fc-ff63-4845-a11b-cae03920ee9d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQtNS0xLTEtNzk1NDg_fc2a155b-cccf-431f-a729-3f4735e607e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzgtNS0xLTEtNzk1NDg_d637c440-ec55-43b2-b70e-52ca720f6e6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ3LTUtMS0xLTc5NTQ4_864b96e6-f589-4e1c-9d30-9bd9e9fb91c6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQyLTUtMS0xLTc5NTQ4_d0d4f5ec-1f61-4cd2-9a16-2af5c320e5fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzItNS0xLTEtNzk1NDg_6e67f502-e0e5-40e0-9cac-2a97647ee8fa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTk4Mjg1_0201c92e-85f7-4252-8a7a-45d314271cf0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUtNS0xLTEtNzk1NDg_8865ff20-043f-434c-b6c0-5cc9e73063a8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM2LTUtMS0xLTc5NTQ4_d12791b8-eebf-4541-9419-19dc34eacb52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM0LTUtMS0xLTc5NTQ4_37f3b0a3-5a19-4765-8b1a-b1213f11f01f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE2LTUtMS0xLTc5NTQ4_7415ee04-a51d-40cd-a36a-f8ad5a396605"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI4LTUtMS0xLTc5NTQ4_6f0a8357-55ea-4093-b3f0-abe34cd42c06"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMyLTUtMS0xLTc5NTQ4_b0229e8c-6a14-4d01-94e2-74fae873469d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE3LTUtMS0xLTc5NTQ4_fe5b68bb-fd8a-4c17-ba32-e1f60e6f3e3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE4LTUtMS0xLTc5NTQ4_848bdad8-484c-4109-a4de-36bf942b1f94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEzLTUtMS0xLTc5NTQ4_680b51f1-cffe-4894-ab12-eb8e97b0efbd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUwLTUtMS0xLTc5NTQ4_29b75b46-ec96-4724-9a96-456bb327fc83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzYtNS0xLTEtNzk1NDg_366894c1-6428-4fd0-9e0b-cc2a59ddeeca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMzLTUtMS0xLTc5NTQ4_cf0feef7-0e27-46dc-b43f-05b38958c657"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEyLTUtMS0xLTc5NTQ4_e57c4499-532e-4e0e-a32e-7277e628fcf9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQxLTUtMS0xLTc5NTQ4_82bb5aaa-8813-4083-b30b-e0111a617053"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzMwLTUtMS0xLTc5NTQ4_f82640e7-833a-4cb8-99bb-a4ecce84716e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzE1LTUtMS0xLTc5NTQ4_218b0195-7fc6-4198-be71-f217466bb32e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM5LTUtMS0xLTc5NTQ4_ac3567b5-800c-459c-8bec-a7e902681e5a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIxLTUtMS0xLTc5NTQ4_7cfc7682-7254-4a92-b5c3-e87e238928c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzIwLTUtMS0xLTc5NTQ4_0c768678-b7f6-4732-9938-a09a456bac62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI0LTUtMS0xLTc5NTQ4_73e76c7e-726c-4c7e-a205-00df02306608"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzEwLTUtMS0xLTc5NTQ4_ddf2503d-5433-4231-a710-6d602467947e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzM4LTUtMS0xLTc5NTQ4_856e10cc-e886-43e3-a739-7d699bdc5bf4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQwLTUtMS0xLTc5NTQ4_879a52b9-2786-48ba-9084-c1baa6c5402d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzI1LTUtMS0xLTc5NTQ4_ed158322-eab3-4050-b641-0392759c30ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzQ0LTUtMS0xLTc5NTQ4_5482daaa-b1c0-4b2d-9806-8acdbb874802"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90YWJsZToyNTcxNDNjZjVlMzI0MjU1OWRiMGZhOWI5MGI1ZDA1YS90YWJsZXJhbmdlOjI1NzE0M2NmNWUzMjQyNTU5ZGIwZmE5YjkwYjVkMDVhXzUxLTUtMS0xLTc5NTQ4_f0f62db9-293b-4ac8-bb6f-a863bb29d41f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzkvZnJhZzowYmZiYzM5OTlhMTU0MGE0OTUwY2QzYjY5NDMwOWQ2Ni90ZXh0cmVnaW9uOjBiZmJjMzk5OWExNTQwYTQ5NTBjZDNiNjk0MzA5ZDY2XzU0OTc1NTgxNDAwMTI_2177d216-4d4e-48cb-9fe7-d58929d741bf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The years ended December 31, 2021 and 2020 have been corrected for an immaterial error identified in the third quarter of 2022. See Note </xhtml:span><xhtml:span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><xhtml:a
      href="#ib1aad3959e884c01b6a07e04db98b99b_145"
      style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">1</xhtml:a></xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements for details.<xhtml:br/></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMy0xLTEtNzc5NTQ_13d287a8-c996-4c96-9e8d-fc8bcbfe3065"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktNS0xLTEtNzk0MzI_26ae4168-aac0-4a06-a04a-2ed78105cd48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTEtMS0xLTc4MDQw_162232d8-d4d6-4a1d-9a6d-e845bbe5f062"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTUtMS0xLTc5NDA5_52115a35-7cd6-49c1-b673-45d429a00d96"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzktMS0xLTEtNzc5NTQ_fdc4a599-4d72-4b74-a93d-080b982f786c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90YWJsZTo1NzkzNGJkY2RhNzU0YWIxYjFjMWI5NDEzZTYxNzgzZS90YWJsZXJhbmdlOjU3OTM0YmRjZGE3NTRhYjFiMWMxYjk0MTNlNjE3ODNlXzQzLTMtMS0xLTc4MDQw_2ffdf676-b664-4168-a73b-dd609efad67b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmIxYWFkMzk1OWU4ODRjMDFiNmEwN2UwNGRiOThiOTliL3NlYzpiMWFhZDM5NTllODg0YzAxYjZhMDdlMDRkYjk4Yjk5Yl8xMzYvZnJhZzpmNTgzYzNmMTgzYjI0ZGI1Yjk2MGY3YmM4ZmRmOTE3Zi90ZXh0cmVnaW9uOmY1ODNjM2YxODNiMjRkYjViOTYwZjdiYzhmZGY5MTdmXzcxNDY4MjU1ODE5MDE_c369d1f7-b216-4c80-8817-04e064257ecf"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ>MLB*JV5QW%2UL>YUSI8FN;N;X.09@ /;_@7#UW3,5M+MCX#U!+ P04
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M:+HMBVI"#R"4!D#C$R'T4\-,4#^I_#]02P,$%     @ -HM;5H[@PR<:#@
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M@'9L 7U70.<*:/NJ9.P*&%R!\;X,XUV!\;%5,G<%3+Z L:? 9%=@PF^#M:>
MM2M@\1G,/07L70&;*Z#;^QI.?6XYE2MB3/85>6ELOK7-O46>FYOP[:V1?46>
M&YSP+;ZW/<ASDQ.^S8V]69X;G?"M/MG7B.2YV<FVW4=/(MDJ;)K6Z<5Y63PH
M91//>,V+K4RWY9FPLKSI4:[KDGV;L7+UQ65\=1V'WO3]S6RJ7-^P/]'LZN9:
MB3^P=_%EX,;A=/;Q^A_*[)=?O9O_**?*K]=3Y<<?WB@_*%FNW"R+397FB^I\
M5+/:-,S1?)?YYZ?,VI[,-T6=K@3%IO)B24F_9BSIZE'Y2.^+LJ8+ 60FA[Q?
M_(_M7-8QUJQ77*6,H=2%,B_*<M?1%;=*QKK8FI99NE)H61:E((LCSW)9K->,
MQ5IQ_N5,4-P]5,E%UE2&5> ^S1:G;'?/T_N,[341S#NPM]EP4VW*Q_VU\0]N
MS'V:/[*=U&Z4LJ2KA?+Y4:F75+GZ97HIX@8'MG(^WZPW3VU0,$[99&"#X[(9
MM;Y2=I"Q]U3Y<554U1L1/T3RE>,.K^CXG&QTR^99+:IY/)QR9/V2;R#_>4V,
M6-_ST@%I+QV0MJV+L:<N/].[+,^S_(Y-#%9I/F=-P0[T:IF6M'JCI+4RI?.W
MBDY^4C25V*)N1LIO9F1GU7TZI^].6*M7M/Q*3R[^_C=BJO\4=3Y(V P)<YY@
MYA;6S!._7I");>F6JJKGHZ^ONQ5D6@\)\Y&P  D+D; ("8N1L 0$ZRA=?U&Z
MOJ7K>Y3NY?-F$&("9Y+>OGK33"&NFY%D6:P6M*S8-..W358_*I\^%JN5PLX9
M'M)R\5^1ZG6DZI&P&1+F(&$N$N8A83X2%B!A(1(6(6$Q$I: 8)V.P7CI& SI
M%,"KJDTS\E?*)F>]@$*?^@ V,V.3D6:.=L\F!M7K>8&H0Y#F&-HA(&$S),PQ
M>M, S=!(?Q* 3.HA83X2%B!A(1(6(6$Q$I: 8!VMCU^T/I9JG9VT;,KYLID&
ML/.)SLGD 7U+N4/UC83-D#!GW-/WZ9@()OG(I!X2YB-A 1(6(F$1$A8C80D(
MUM&W^:)O4ZKO6;XX[EQ>4T4BE\*'BAP)FR%ACMD_E[?(Q! ,X\BT'A+F(V$!
M$A8B81$2%B-A"0C6D?GD1>:3@5?MCKE2]\0<OSKL=:)IND6Z!_WTR+A9/XZ3
MSP?Y5GPBHDL+3A_+!F!.E_T8P]*UB3KIQGD'J^CW(TYMV^0V->A'L9UL&MVH
M\*BH2)"13#1UHMK=P/C8P$2VE9WCRWHYOJSO>*W(0HXJ2-@,"7.0,!<)\Y P
M'PD+D+ 0"8N0L!@)2T"P3L=@OW0,-N!:T4]*3NOF!+-.?Q=U"-(<0SL$)&R&
MA#EV_UH1-XP)(B;:9,P-8LA*^4A8@(2%2%B$A,5(6 *"=>1+U-9OHDH%O!W"
M3QL3V&+[2SS-J[3Y>5EH()&BANH42IM!:0Z4YNYHW?-+?6SPDU-H5A]*"Z"T
M$$J+H+082DM0M*Z\7]G)R#=>WQ4*7 H;+' D;0:E.5":NZ-UKQ*KO:M'WI%Q
M/K1V 9060FD1E!9#:0F*UI5N:\0B<B?6Y3+-[QI#G'(I\_@)=0SU8$%I,RC-
M@=)<TC=UG1)-XU4,]6 )<O92!M"4(90606DQE):@:%T)MPXK(O5IL-&WSDJZ
M]7 V)[\=SZ]0MU 7%90V@](<*,V%TKP=[;4BA8,TU"0%I8506@2EQ5!:@J)U
M%=Y:I8C<*Q4?LK +9=XW#9WJIJ[JW2/L\D#N3YKHZOI47FJP[*%N*2C-A=(\
M*,V'TH(CCY@0FC6"TF(H+4'1NKIO;5-$[INZHO41.N^;AZRQH6HVKW-Y+J;S
MGS[I[)\AUCO4/"6H\^F8\(.? TWJ0FD>E.9#:0&4%D)IT9&'Z]6APU7X*WX,
MK6N"HG7EW[JJR"!;U3%6JAVQ8U%@NK)UWFU!^FXD%FBJ*G=2.!,$GH[5"<?[
M<&!3]I@N!-4E%O]SE:BJMJT;/=N%(+ WG19LC6WI-G\F+ @C)N'CPB/C(E&<
M99HF[S")Q8'LB.+-%P>;I7O,M18?,OF.'@PBM>(,/M5$TF90F@.EN5":!Z7Y
M4%H I8506@2EQ5!:@J)UNXG6J46D?@_0ZAUYDL'= ]2D!:4Y.UK'<]&XZGK6
M7VA:#TKSH;0 2@NAM A*BZ&T!$7K*K^U8A&Y%^O;U_+(P8/5#G5@06D.Z3NL
M>CI')O2@-!]*"Z"T$$J+H+082DM0M.X-.EK+EB:W;!V_IH>(Q*X)W4@VT<:$
M<Z9/Y149JF0HS=FW&;K@!AS(Q!Z4YD-I 9060FD1E!9#:0F*UE5TZ]+2R'<\
MM=>@+BXH;0:E.5":"Z5Y4)H/I0506@BE15!:#*4E*%JWFV@=89K<$899;"%/
M,KA[P-ZA"WN++JUW#9N_@JWUW5>Z;G&7=#UHM7PH+8#20B@M@M)B*"U!T;I:
M;JUAFMP:-F3=A1PU6+%06QB4YD!IKM8W<A';L,8F+V_HO;.@M !*"Z&T"$J+
MH;0$1>O*N_6%:7)OUK!U%W+88(%##6!0F@.EN5K?%L4ON3@<XD/K%$!I(906
M06DQE):@:%W!MH8N3>Y:^1.K+>3DP>J%VKF@- =*<S6!U8R,>P*&NKD$.7LI
M VC*$$J+H+082DM0M*Z$6U.6)G<R#5UM(<<-UBWT]E90F@.EN5":IQVVAD$3
M!E!:"*5%4%H,I24H6E?=K?U-D]\<ZIM66FB"6U>I8]XB.96G'JQ=J'T-2G.A
M- ]*\Z&T8$<SY4T?0I-&4%H,I24H6E>_K2]-D_O2CEHQH?7-6*>FH?)FW*D\
MUV#!0@UE4)H+I7E0F@^E!5!:"*5%1QZ75P<TL&=I!+2N"8K6U7GK0M/D+C3Y
MT@BQ(\7NC=*&9HY-DU\H=2#UI[%P@900/U$G!M=Z,T&@:$'%H5J(%U0(X,0R
M^)^C^O:T,;'9&2I_#P)!8&_6W \YM4W^MZU $$8,0]?X<5)0_7Y8)$RJJQ.3
M7TXAVM>V-N[5+SG8*-V'G[0N*EW]CIX+'7IK+"AM!J4Y4)H+I7E0F@^E!5!:
M"*5%4%H,I24H6K>;:*U9NOP&6ICE%/(D@[L'J"4+2G/T_BVN-%WT5#1H6@]*
M\Z&T $H+H;0(2HNAM 1%ZRJ_=5OI<K?5MR^GD(,'JQWJL(+2'+UOG^KI'/KX
M0RC-A]("*"V$TB(H+8;2$A2MJ_-7CT&4.[&.7TZA"<4N,!E9IM:<HG"G,E-Y
M108K&?M@PSV;(7@&"C2Q!Z7Y4%H I8506@2EQ5!:@J)U%=V:KW3C>Y[:0\U9
M4-H,2G.@-!=*\Z T'TH+H+002HN@M!A*2U"T;C?16KYTN>4+LYQ"GF1P]P!U
M?T%ISHXF6TZA"^Q5AJY9W-5K:+U\*"V TD(H+8+28B@M0=&Z8F[-7[K<_#5D
M/84<-5BR4.,7E.9 ::XN>$ZB;5LV_WP::%8?2@N@M!!*BZ"T&$I+4+2NO%OW
MERYW?PU;3R&'#18XU!T&I3E0FJOW/5.\'?MPB ^M4P"EA5!:!*7%4%J"HG4%
MV]J]=+G5Y4^LIY"3!ZL7:A6#TAPHS=4%)B5+[PD8:@$3Y.RE#* I0R@M@M)B
M*"U!T;H2;IU<^J'[B0U;3R''#=8M]"YB4)H#I;E0FJ<?=H9!$P906@BE15!:
M#*4E*%I'W4;K?S/D=Q'[IO44.V;W$=269O._=,ES#Q4OE.9 :2Z4YD%I/I06
M&/T;KHG:/H1FC:"T&$I+4+2N@EMKFB&WIAVUHL+H^[&(0<;\ ^VG\ER#%0OU
ME$%I+I3F06D^E!9 :2&4%AUY7%X=T,">%170NB8H6E?GK1'-D!O1Y"LJA*84
MHW_G*\-4=<+?^F8J3SU8]E!SF6 CB,5M@"L(&ANJT;\H+0CDY\6"D%/+&O,K
M)D1ANF5.^'$0:N 2)9U8-N&'WQB:-D'1NH=^X\WJ?M)Z.PSIC\*-X)6;)54>
M:5I6"LT7=-'(@:X_L]GL\R(C)<T7VP>Q*,N436L_4YJSF6Y9TGG-PF^+D@4H
MV7J=UK3,TI5"RY)]EBV:WWUO,Q:2Y=LK5/4R*Q?*;YNT9('-27"CM[?*-:7*
M55%3A2AUT0165+DL\JI898NTR? ARYE4&_)US3YH3J&K;=H%K=-L5;WM55E5
MFM'<>QK-EVGU5ZSS)2W9JUQ0]UW75/UE=_?^JJ?K8M.$_[_5G/SE=[JH QA5
M2TKK:5JG%^=K6M[12[I:5:S>K V:SNW5ITI);YM;TY]=DI-1[_,9.?L@^CPB
M9U>BS]\;^EG"^AW1-P;[QFB^&;55NCB_3^]HE)9W65XI*WK+JJ>^G;#NM\SN
MEB]OZN+^W0F;'7PNZKI8;U\N:;J@91/ OK\MV"[<O6D2/!3EE^TNN/@#4$L#
M!!0    ( #:+6U8LR>G?PPL  " X   8    >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&ULS9MO;]LX$H>_"I%;'%J@;D12U)]<&\!UE%T#K9.+T^Z+Q;Y0;#K6
MK2RYDIPT^^EO*"F638[H9,\'[)O6D7^D.4-R^'!(?7C,BS_*I905^;%*L_+C
MR;*JUF>GI^5L*5=Q^3Y?RPR^6>3%*J[@S^+^M%P7,I[7A5;I*7,<[W05)]G)
M^8?ZV75Q_B'?5&F2R>N"E)O5*BZ>/LDT?_QX0D^>']PD]\M*/3@]_[".[^54
M5E_7UP7\=;JM99ZL9%8F>48*N?AX,J1GET*H K7B6R(?RYW/1)ERE^=_J#_&
M\X\GCFJ13.6L4E7$\-^#',DT535!.[ZWE9YL?U,5W/W\7/ME;3P8<Q>7<I2G
MOR;S:OGQ)#@A<[F(-VEUDS_^(EN#Z@;.\K2L_R6/K=8Y(;--6>6KMC"T8)5D
MS?_QC]81.P6HUU. M0687L#M*<#; EPOP'L*N&T!]Z6_(-H"XJ6_X+4%O-KW
MC;-J3U_$57S^H<@?2:'44)OZ4'=771H<G&1J9$VK KY-H%QU/KJ:3*\^CR^&
MM]$%F=["?U^BR>V47%V2T7#Z"[G\?/7KE S(U^D%>?/36_(323)RN\PW99S-
MRP^G%;1!U70Z:W_O4_-[K.?W*"-?\JQ:EB3*YG*^7\$I-'YK 7NVX!.SUG@A
M9^\)I^\(<QA#&C1Z>7&*%(]>7MQ!BE_:B_]&?[>X@&\[D=>U\+Y.['KJ\N;J
M"[FZCFZ&M^/)SV0XNAU_&]^.H^D9UE=-M2Y>K0IJ9^4ZGLF/)Q"U2ED\R)/S
M?_Z#>LZ_,#\?L[+H2)7MN=/=NM.UU7X^@8">9+-\)<F;-"_+MYCKFBI$784*
MWP_GU*7"@R'TL.L44S;P7"=P]F61*0N$Z[!P7W9I;_=O[/=WOW';@!);#PCK
M@!K._P.A!Q:0JB15#BO(+,]F22I)IKM&?:T>SN)R2=9%_I# K"9W3P36OB*N
MDNR^63R2*I$E.@;%,<?@,2N+CE397@]XVQ[PK'UY(:'261(WRV\V)_$J+ZKD
MS_H!YL:F.F]W/#HT]+01-,)D@<,U683)!/795K9GE+\URK=/K#P;U ,ER2H)
M/JN(_ &(5$K,(-]H@DNIKYF#B5Q/,\8444]0BML2;&T)K+8,=_J#Y L8^W*5
M;%8$_DJR!]G.'LRPP&@.=URN&6:*!!5",PP1>3YN5K@U*[2:-:WRV1\#Q6IS
M M-<]4[OD M-OX8>=P+-%$SF,T^S.$)D0>CW=1-U.L!QK!;]#'BM>J6,(7Y!
M1V5YMDBR&.)9G)*X+&55OE,A#&49QVC40,T71XO?(T2HAWBL+L$"YO08N$-P
MU&K@&(9;5N7%$VG#4&./LK5\16^VOV(Q8718$B$27WA.V&,DZXQD!^+A0A8%
MF-&N/E7\0^+XR3 W.X$>.3 =K-_ZZ(TP71"$8<A[3.J@C5HAYOQK!EO!-/D3
MC((=(FR!,@B'LV6<W4NBUE;RYAZ&+@H?;<W[C7>9:22F"ZC1::8L<'IG7H=1
M] !'/8?[QJA2;1VJI22+."G(0YQNZOD(:*$P 8:P^E@"/Q3]8]0U@X3ON+K5
MIBIPF+XJ("I7.'VSL2,G:L6"\RNPL$#;+LR^8&;@1V6>3H(1)@O#GN!/.^J@
MGGTGT?74#L#50;*FD#2)[Y*T'^:HE6I>2W-'K2TZ5FW[KNW8A]KA9SB;Y1L%
MU,!U,GF([U+9O^Z8R#* E8(;@\74>4+XKCY8D.I$Z'#1,UPZ!J)V"-HN/:@1
M)IX,O(!YQG1%=%PXGA&EL/HH%7UQJD,>:F>>>LJ2V0;6%PA"S6A'#3(1Q0\8
MT\TQ52ST36LPWN&TA[!9ASO,CCN-,?U&, QIPD#H&P5,YXE0IS9,QD+'Z8E$
MK*,:9J>:[719QT]JKM3A)Z^-*Y> W@/80:QVXQ%JK$DC,.ZI3JB(#% @T&,N
M(AL$OL-ZIA'KX(;9X:;ILS3/[E]FE8DD7FC$!D0UX)SKRR F\W<S#_LV=73#
M['0S>6E2 +70!!+J0\_I<PW1P5Y*F$8B@ .JOH[K"(>YKTJ\C2??HNE+$F_,
M2DZO72>/6EMTK-KV?=H!%+,#U/6F %XL 4+J7;4:,M73.[).8Q6<(0C([YMD
MK7;7J&,1+J+,"<WXA@$4K)TZ_Z,54K<_4G>LQ>PIGB]QM2GJ*5";I?:GM<T'
MT@?,S,UX%/8C0C<0T874<8VH9NJ$$ %W>^SK@(?9@6>O(P\9A1 *K.V!8W0;
M(@RY3W6.CC"A8*'G]>S;6 <]S X]UT4^DW)>DD61KVQI!=10$V(H<!TS>L_4
MZ02!2#R?BK[(W>$0L^/0<[\UW5;!AB"IU]]^FTR4&5!'!'HN'-,Q[KF^;ABJ
M8WU,P3LVXG8V&F\'H=K@P&[S 6)+;5R65V@2DA_,ZXP.2R)$HL"AIZ=XQTC<
MSDB]>TU^.)>#2& #J>\<,)7/>J80[X"'VX%G"P>;LD[IM.'A,!APA%:88QR4
MC# =A[E/]3"!"8$,6,^F@N\<R;WN3.YR/!E.1B\YDSONH=QQ3^7^'\=RO,,M
M;D\H[4=>^4,6LZ1=7^+'N( O-MD<2%H10O6D4H4PU9,'6<,#/I[,))!":9VE
M$9D;4G.VF#*?AK1ONG1(Q.U(=*N2G; 12N:DD&E<P9QIC]W*95Q( H&Y2F4=
MU\ 5K?6-1U"C$:01+@L,JQ&=*P)'/X9 =:['@QZ[.T+B=D*ZD>N=M6B6KU8J
MCZ]RVJA9)L@80>^@)$(D ^$X?8E!WN$0/X!#>X-W=_$I99;DZK;/75[,@2%4
M_ZH%"8Q>R *"8F^>B)N08YA\4!(A$A$(7_00+N](B=M)"?HO?FI.D9M$[];D
MN;S##3J(/:/#D@B1#+COAF%?5._8B!]@HWU[7IRXY@C2<.H8T([H#.-LDOW[
M#AT8N78PNH91-DO60*[%7I>U1 O+<BH5R:,7(; ,D*<'B1$FX^;!,R:#;4M/
M*'$[5'+_(BJYAU$)D0QXJ&\4K17MM[KC)/>%G+2;1'G30M/;G>ZQ4Y.+G74%
MGC ,172N8:<IH@&EO5W4$9-KSQA%$.UFS0KV? P&$TIN3X\@]BM?H 8B>2 ]
M5X1H!D+?>F B2D5?1^[<*#IP%!;=DO%D=!,-IQ%Y<Q$UG]["L^::W7!RT7R(
M_OUU_&WX6=W!0PU%#L"XS_2; 2-$!_OI(&"ZO::.4>KW)3?<#EE<^PVBD1JU
M*JU1#U^%) ^P48:P@C*O>]1+0$>M+3I6;?N.[!C(M3/0)WF?9)F:XRH=!CB0
MSU$/(EF<P&>^IP\,)"L$*"NT67YQH%7&O<765V;M+BR\.S=R]KW0P9-KAZ=(
M)?^M]IL,XS-7<.,^'L8ZII\B1*?Y:=^2CHG<P#HQIE^OKS_7EVR'G[LKMN1B
M/!U]OII^O>G9%;I6TGKU##EF;=&Q:MOW:,=DKIW)ZE!3;XX60-'/5\M0)R)G
M;@XS\E2HC.NL%F$R1OV>$2(Z&!-V&-/ML=]W$28P"9AS^NJ'R&#5%GHZ!)$%
MH=^3>!,=?0GZ/PYZ<GEU0R97DT'][<XY"BR,+TZ=""L#OOHNZ3%KBXY5VWX/
M="0I#MV?FA4*X56R+<:.5N%AL9%[-SQVDPV+Y =\Z,\!"PPQ79TW1IC,]8TS
M"4PF:-!S)"$ZQ!1VQ!QGK1?>S%M_O/VK#GE19KQMSNZ];M\U?&**0I?IV(VH
M!BSLX32AP'3_R<[5;WNR"99V,H)]NKHV":-&KNYDL7W#@=S%*6PYP!7+^$&2
M.RE5'KTH -R;:VS@.I*L5N"E0AV$R*)0,6RN\G"+I,GUJBM@U3(IYN3[)BY
MJ%9V]?+&>S*5DDQ4YH,J%X,0NFH$>^L\3>:UXR^W1RS3"AXT&U7ULW,)#4[+
M]Y:FQZNFD_^N+3=;K+9_XR;^+^/R;]AF+#2=[KR,M)+%??W:6$GJ&=:\@;!]
MNGTU;5B_D*4]_T3/+BGR?,3.+C#]4+AGE\)%OQ'/;[^==DUJWIW[$A< V"5)
MY0*:Y[SW8784S>MHS1]5OJY?G[K+JRI?U1^7,I[+0@G@^T4.+FS_4#^P?2GP
M_+]02P,$%     @ -HM;5M_[(7H3*@  %X8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&ULO3UK<]M&DG\%I<WN2E44;<GQ)G$<5\FRDM6='UK)SM;N
MU7T @2$Y,0@P&$ R\^NOG_, 0,E.[NY#8I$<S/3T]+M[&L_OFO:C6QO399\V
M5>U^.%AWW?;9HT>N6)M-[N;-UM3PR[)I-WD'']O5([=M35[20YOJT>GCQW][
MM,EM??#B.7UWU;YXWO1=96MSU6:NWVSR=O?25,W=#P<G!_K%M5VM._SBT8OG
MVWQE;DSW87O5PJ='?I;2;DSM;%-GK5G^<'!V\NSEUSB>!OQLS9V+_LYP)XNF
M^8@?+LL?#AXC0*8R18<SY/#/K3DW5843 1B_RIP'?DE\,/Y;9_^1]@Y[6>3.
MG#?5/VW9K7\X^/8@*\TR[ZONNKG[NY']/,7YBJ9R]/_LCL<^_?H@*WK7-1MY
M&"#8V)K_S3\)'J('OGV\YX%3>>"4X.:%",I7>9>_>-XV=UF+HV$V_(.V2D\#
M<+;&0[GI6OC5PG/=BY<?;B[?7MS<9.]^OKC^^?+BG]G9VU?9S>5/;R]_O#P_
M>_L^.SL_?_?A[?O+MS]E5^]>7YY?7MP\?]3!TCC!HT*6><G+G.Y9YN0T>]/4
MW=IE%W5IRG2"1P"S!_Q4 7]Y>N^,KTPQSYZ<S++3QZ>G]\SWQ"/B"<WW9,]\
M9T71]'5GZU5VU52VL,9E_W6V<%T+A//?4SOF^;Z>G@^9Z9G;YH7YX0"XQ9GV
MUAR\^,N?3O[V^/M[H/W:0_OU?;/_[QW;O<M,;^)WK9V]S;N^-5FSS-YM39LC
M2[KL1T YD$-FZ^SDN^^^F64O;?,F;^'CU3H'GBM,W]DBK[++&D[[L%N;[+S9
M;/-ZES6M'WR469?EV:IJ%C!T89O.%.NZJ9K5+BMD.*P"$W6P5M=D<*:U0X&&
MIUV!5'!9MVZ;?K7.5J8VL&166E<TMZ;=S;/WT:JEN04YMH7EZA+GWIBVL'EE
M?\,I\G9E:(4U;'!K:=:\R_*R!-SA!Y.U3=-E1=X[PH0N5C1U:0DCR6I_=3!^
M 3(@0]SG;;&F904&D(PXU39?V H>AM76^:W!H2"0&*<;^,MN*P-_U\UMCO(O
M CJ"$W"1;>%WF-*! .K669O#847(:-K2M"/PX ?@&!*L6;[=MDT., *"R[9?
M!10"8"Z#'\N^ +AR^ &^!0QL[=8@Q2$J EBSK( O\=1GM%T@O&/]!O8+F"KA
M' >XS3-G5[5=PB# 2E]O0)UMZ,BKK#:FG#%R[D#Z'R/)M2!8FQ)I!:E$%VIN
M;0D;J;-FNVW:KJ]MM\/M+$RVM/#(<=<<@^KZ"),#PIKETK2X<@]2 I9%E"X
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M[Y_($J1. G;8'PNTCW' BD-M^'WG&&NRY-C-9%N&11"+&>L$2H>B%-B0\$0
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M_U!1H48D!XZ#')):T=NC_^=V ,K-.Z-E2R-?AG4UU5[QA<R0%7U8>R?W:OZ
M+A>'*D[*3.OS"6/M=ZOSGU+E%UW4NV8MD#V;M!T]B[' X:$J'3F $JL@K+3-
M-Y%R>T/=WVPY&^K<J"8K&LYWK4K,<)F@GW)N ".*(([7Q>T%1G9M;)5,E^O)
M[GSE(:D9$7CQX439@UB0>*&UL9]$8@V%7E)QR6?,G$JDL*#;*Q3SIT#WPG<N
M29F/T",_#ZI*M]R&+Z&F4>\3TC7A.F,H#M-CQJE">XWX,I^$FY0.YI+"NA;[
M8)IJ_-5T7R(M)R.&%58!Q0KSRPYX;',"5(940W)A+"H(HB85? QQ*'QTBWX
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M,8Q&D6,Y8*J:@'.EE>6,<MK;-*(H6[N^I>?B</[=NF%'BU*)?A;?\M''8Q'
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M]4&9.H-=!3YW]>'N_OK^]N[Z-W)W/WWX_.7C^_N'Z<7$ =H33*H=S$T'PU^
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MM;[YKI6E5NZW.YJ=J)T"W6^4LD?!.1BF\>(?4$L#!!0    ( #:+6U8V/"!
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M6]W=0:W*"V;9?*K5!K2+)C9GM*FV:!+'I2O*O=7DY82S\^O;Q\O;AQ_+7]/
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M3;EPVXXV>]'Y!Y&X$4NI%!4G.$Y]U' KT=^DOQ%[V_P$</L_9[P2/BI-NSJ
MPB7L .0?H/@>PXL_C;.S_03#>$Q#M.X0JY\B#*-LG-#X;.?<\_N^P8@-0DPX
M/#%RLL@#C()AG)%\$N3)^!2IZ!BI'/KCG$AAB.;C!C-),<C#\S?.)TE%P3#R
M")AI8>(!LF 8YN<=X1.DPF.DLF$0Y8DGE6"5>4Q<$T9A?/[&^7^0&HUH3$:
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M6H#G"P-,:FY(P?;;4I?_ 5!+ P04    "  VBUM6>Y_W]2<$  !H"@  &0
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MB3E?E>96KL_$)I_0XJ6RU,TOK%O?('(@76DCJTTP,JB*NAWYXT:')P&)]T8
MVP2PAG>[4</RE!L^["NY!F6]$<U^-*DVT4BNJ.VA3(W"U0+CS' T'M]?WE^,
M[B:G<'UW-KF%\?7ES>WD;'(U/?\Z@?,KM"?0N;B>3KM]U^"6-M!--_ G+3Q[
M YXRN)2UR35,ZDQDSP%<Y+HCS+:$3]A!Q%.1'H%/"3"/L0-X_DX O\'SW\";
M?%\5Y@?\.9IIH[!&_GHMR18B>!W"WIMCO>2I&#AX,;10#\(9?OQ (^_S 8+!
MCF!P"/V_G]#_" ]WN8"Y+/$J%_4"#)^58G.?B[^%AC3G]0+'H@:#GCQ-5]6J
MY$9D>'5*7J>XAHT$!$]S2&6UE+6H#<@YC*['YP3CTG*56>ATI91=6@I5R PD
MPJDF0HG<MH0'89UE):!32JV[P.L,FT1:<JV+>9%R>^<U8!O:H]N=+:T64T-S
M6#62.X+[&CM:B3ED\#MV,HWY(JI 7.P<8ZYS^((YPYG(;'H'O4</O"BM,)]P
MOT]3C@J=BIF!J<"<"E-@_'63S9TTO&RH;<4!;M W%=4,E]L:ISWX#6A$(AK@
MAT_"*,2Q0\,N#LPC- HV<(?$F0GD@A;S21"Q+O3B"&B(-B-!3+MP(;0^A@7F
MLHW82XE)SI6L6J+4)S3Q( P9?/R0,,H^VZG89W#''T',Y]AL=RL=ZGG=%]85
M_L_\Z[/M^"A @+Q]%C2\T?8]O_LS\9AGM4*5/)9T&_F2Q.JYI62%C CU>]WW
M:^@'Q(][T(E($B;[[%A,0D;?+V2'DB ,]O%[E=KY5^2D).Q%+ZQ?DM,/2>+[
MT D)L\6P1?0]$L;TIYI26Y"(X+6%B&KXW6>:TH $6!#O5I3UB!?@H6(A]:)X
MSP<W\>+D_9+:(L'Z>*GH9OH507W"@OB%]6OUB8<?8Q%AB9.8/:OYA+!>[^>%
MRE W=&51HRDC7N^%J!VL713GM?\3]\F_?R74HGGC8"^6J]JT#X'=[.X9-6I?
M#WOW]@UVR=7"]K-2S#'4.XI#!U3[KFD-(Y?-6V(F#;Y,FL\<GX)"60=<GTMI
MMH;=8/>X'/X#4$L#!!0    ( #:+6U: I[J^PPD  .@7   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;-5867,;N1'^*RBMO'F9E>;D#&U)5;0D>UFQ
MCE#'QD[E 1R").+A@ M@1#._/E]C#I(2I=U*Y24/HN8 ^OBZ^^O&G*R4_F[F
M0ECV8U&4YO1@;NWR_?&QR>=BP<V16HH2;Z9*+[C%K9X=FZ46?.(V+8KCT/=[
MQPLNRX.S$_?L5I^=J,H6LA2WFIEJL>!Z_5$4:G5Z$!RT#T9R-K?TX/CL9,EG
MXD[8A^6MQMUQ)V4B%Z(T4I5,B^GIP2!X_S&F]6[!HQ0KLW7-R).Q4M_I9C@Y
M/?#)(%&(W)($CG]/XEP4!0F"&;\W,@\ZE;1Q^[J5_LGY#E_&W(AS5?PF)W9^
M>I =L(F8\JJP([7Z533^)"0O5X5QOVQ5KTVP.*^,58MF,RQ8R++^SW\T.&QM
MR/Q7-H3-AM#972MR5EYPR\].M%HQ3:LAC2Z<JVXWC),E!>7.:KR5V&?/1I>/
ME]</EQX['UU>#._9^<WU^>7U_6AP/[RYOF.#ZPOV^?+F\VAP^^OPG VO/]V,
MKMR[DV,+]23D.&]4?:Q5A:^H"D)VI4H[-^RRG(C)KH!CV-T9'[;&?PS?E'@A
M\B,6!1X+_3!\0U[4@1$Y>=%K8$CSW3!>3MA#F0MMD=-6"L/^,1@;JY% _]SG
M=2TSWB^3BNJ]6?)<G!Z@:HS03^+@[.>?@I[_X0V+X\[B^"WI_]OPO:EJOR/_
MM7YV/Q=LJ@J0@BQGS/)Q(9B36UK#[I7E!1N))U%6HH[(1!H^FVDQXQ9/KD%7
MMUI-JMQNEHW7D.">';&O@NLFT1C21"S&0G>I0C\!_?A.4+,)'/-"T'OV.+P:
M?AM>L4/6ZT5>&O7I*HR\($YPE<2Q%R8INQY\_C+X]O7JDL4Q5O5C%F6^%\=]
M%O4#+^QG[';PY>OUM^'?6)@DGA_!ABCUXC1F0>I[_2QB?WUX'%RS,$R])$U9
MF"5>FO98G*10VF./-W__=O/YA@6]OA>$&4N\+$G8SS]E81!^8!]'P^O+A]&
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M3P4!F(.W=RJH&Q-F;.?Q0/7$G7,B)%WKG#M<)!]A<,<1],;!DQ>UL<M*ZH)
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MN=ZI2AE9DWQQL"QR5F40)EZ161 NH=_;7O:*1:O;$JMQ.X/V@B0I1(%-[[S
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M$K2':3DPA 6V:8:@X[2VK!9:ECQW3']+!24RB[P@IB)-)"V%B>7D;ZF'5/'
M\IP[%G=]H:\!NE::5J5KE??^N+-F2WF+WM[&T@Y*X&X2JU7OFO%3'=@4S,"&
M&$=\ZPRLE*S^I_;"M 7:M@88.?*JI\#!#_::;Z1+Z@5Q"D'HQ50?$R^-DF]D
M"S61:-S][ACS41K*H&B<3Y2)^IDK+DB\.(W(5V^2CCO+]T7B?V^5<-&.SNX,
M]IK?\+'A8+0WR5$W7KMYU=XM5/_M4-?O]B/Q63L)WHNW\_054VLJ/RAQ1:J6
M=0-0[8S:OAA9N[EP*0U-F6Y9T%B/R@K0]Y4D-[L7:Z#_HS#]&U!+ P04
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MZ'TXZ43PJB_>Y.'=Y,QX;[+P<2DXD* #^'UND+'E%U)0OZP^_P]02P,$%
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MU'&8?BP*74O4D].O<]T%GTE?B@(RF?)/IE[]=+*8O__H!9H &P9UH9IFBE)
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M0IX!-K.L-H5Q#O0>8CMYMLQMFVUC5@L#9%^'D/@KC\1?'43!B]RM"=#TGTM
M.N <N)\I;/Z#4_T<'5L'*B'* 5""@ U6%IY"[GEG!(P(NKRT\!NPDSLX7;NH
M#&)^ 9/.0.GIUL Y[ I.I@+ =<K&B>1;8[(-ZPP /.#_3I$>A RP>"?\#9D5
MKM&$-1Z"Y=<>EE\?! !P^H^FRW'!0<!,P?$/3)/%0"P-2 F0 <2[83O;;=L
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M1=,R*PY ^Q('G7XI@RZ8"%K0M-KRGKQ7,- URXX^?($/?RW/OD<)A9!K:TO
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M5C/DI7P562;:HFMIB$=;7^ X/,N1%8'MCE@D"Q$ XU#U:U"/B^FT9/D@R2Z
MAY?DV#R!IY'E6':8JB3@4&YE.3KO$8-#;@&C;.WZEL;%[OS[=<.&%H42_2R^
MXYCWQ^("'UR*D^^B]U+F"B>9A:7!2ZGFDU-()-9XZ/W><*&XL=1I<'FH!(N
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MLQ^0T8(69F7K6GI710M+@IU1]XT)@V3H_?'O\A$IMJ\&=R]PY-1'R)+^>3)
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M' ADS?\ZV!S@++1!/#O<ME"LN9\Q@W_*&GC"\$$5L!B04HC+CBCM9DV#N&K
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M-J]_PUZDNWW1*3\UQ?Q5:?+AFJ#,8.09$VQ:3& K1FPN+=P-"^;L( VVB)5
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M2[KZHK(+Z/]<4K]I/JR#]C(]^!=02P,$%     @ -HM;5C6Z&H"W!0  P1
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M:.QKJM<$&TDNS03\OA1";P.SP*XU'?X+4$L#!!0    ( #:+6U9Y,9M%'08
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M<X6Y;(8KO \SH3?@^H)SM9EH!>T-N_\/4$L#!!0    ( #:+6U:_%;5N% @
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M],'[]@AL?81+ME?CM4ALXE*+,(>Q/?K<-B2NUN<^HV\TX[4XN814IV3(5X!
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M+PCCISC'B1?$4#<.O#"B$^!;"/^L\48A/J<,9B8@[SB/<B^)<]H''^39CO-
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M2T9,M_]JM!^L6KI_$J;*6K5PR[G@R&G:@.]G"A6^^T *^K^6#O\-4$L#!!0
M   ( #:+6U9:^]M#Q 0  (,+   9    >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;*U6;6_;-A#^*P=U*!Q M?5F14D3 TF:M@&:%\3=BF'8!UHZ640ETB&I
M./GW.U*RG&")EPW[(I$4[[GG.=Z=>+26ZJ>N$ T\-+70QUYES.IP,M%YA0W3
M8[E"05]*J1IF:*J6$[U2R IGU-23* C22<.X\&9';NU&S8YD:VHN\$:!;IN&
MJ<=3K.7ZV N]S<(M7U;&+DQF1RNVQ#F:7U<WBF:3 :7@#0K-I0"%Y;%W$AZ>
M3NU^M^$WCFO]9 Q6R4+*GW9R41Q[@26$->;&(C!ZW>,9UK4%(AIW/:8WN+2&
M3\<;],]..VE9,(UGLO[!"U,=>YD'!9:LK<VM7'_%7H\CF,M:NR>L^[V!!WFK
MC6QZ8V+0<-&]V4,?A[<81+U!Y'AWCAS+3\RPV9&2:U!V-Z'9@9/JK(D<%_90
MYD;15TYV9G9^<GMU<?5E#J-OU_/Y'MR<W\+9]>7E]17,OY[<GL/H.UO4J/>.
M)H;<6:-)WD.?=M#1*]!A!)=2F$K#N2BP> XP(9X#V6A#]C3:B?@)\S'$H0]1
M$$4[\.)!?.SPXM?$,R6X6&JX007SBBF$/TX6VBC*E3]?$MS!)2_#V?HYU"N6
MX[%'!:)1W:,W>_\N3(./.\@F ]ED%_IL3O58M#6"+.%,-JO6,)?7-#UEFN?
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MB5^89?Y!&F\5'H1^NI]ML_Z5--N>?S#>3VWP@W$\M:%/QOO1&\RW!T@ T^<
MTR[_SE 9^A?^+4\#8(UL!=5-14IA@2@(7"DZ$@*D6J*" 4Y_1DH[SFI I6B-
M%S;X):<MO$LY4W%5P%W+%&VTAVEK8 QS[,(,(1AI-VJD8Q%:UKQ@UL-G2BB1
M6^0Y52K2?[4K8?J%$=]:CW>TJ.G0HJ9O:U'79==MJ&@?\KJU=?M9R>:?^Y8M
MFF\4_&U'?JEA[63Q<AN^H M 47#GN0O0-L&IX;==/"C9.[:;8+M$9@MY3X>_
M75C8NPPX<&NUHKC3*5%H-TE;#GGC2L)4S,":V@DUD]Y!:</Q__1.IBW08^>
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MK_?IW '53+$F,+*L!\%2&AHK]7)-@Q^5!=!Y)J5Y#NQLZ3XE\3]02P,$%
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M9[)F[$EW%O'$ZFE#0"&2.@)6KRU< J4ZD++QLXEIM4@MW&V_1+\VN:M<UEC
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M^[U/!W)PVQS<0]%#M21NEZ=:Y1F5OIS;T'?](!C;VP[8H(4-CL$&7;!:Y>_
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MZ/)E4$ZLVA:=;*4L]<5BF-%C"K53H/6UHO!5$V>@?I[%OP%02P,$%     @
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MAF%L!QLU8*-W@54PP3QK.+?AC(X )'X<A0<PCZW"I-U*["CC!F7\+I1<(*E
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M=#4W+GAM;,5876^C.!3]*Q8[6LU(;<%\)MTD4A(RFDIM)VK:V8?5/KC@)&@
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MO&:;SZ04U-9\(4M%\0N;LM:Q(,R%9%D)5B/($KJ]XOO2B#T :CT!<$N ^UR
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MTKL!=0D'APH'A_3N065P)?$Z'CJ4^'&4@TZLY:AP7:BIZWJ3PC6:F?I"SY:
M)K1R6PM_B%K:I*_5Q.E"*_,N3!RJ-4MO6^'=H]U5QX.'ZC\.\CSW0/WFWCL'
M]<+G&V92OAR$9"&SK"M/IK/T'4IZ(N@Z>0TQHT+0*#E<$3PG3 7(^PM*Q>N)
M>K.1O\GJ_P=02P,$%     @ -HM;5B0D\!>5 P  :@T  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C,N>&ULO5=;;QH[$/XKHSW542.UV0O7I(!$@"9(#8V
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M))DU]ME$BZ7MC1^%ID[;#B-Z#*$T K0_%T)O)^: XGG5^0%02P,$%     @
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MWSO3O^N1#X+KM2(SGD!R3&"CF%J1]Z)HXEUDC"#N$-]]2SS'\UH&-+T>[K;
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MYUR6Y4[YHL6FR.<70F-U4#RNL40$:0+P^U*@A=6+Z: N.L?_ 5!+ P04
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M5&B1?I++Y_[$J>A-!(Z/PNG7Z?S+M(/\<!K,GI'_./>G\^=P_#Q[G#^A\3Q
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MXY[/MA2A_/YM1]:-VQN8VU.!6J,\IQX5M$>Y550MI6Z54O=*;[5-_R+VK<M
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MNNF)'2K=WW'L*YQLU*G_A7!A7%5< XZ!R@#1OR2$'RIR@.JF:?0O4$L#!!0
M   ( #:+6U;Y29RJ,@0  % 0   9    >&PO=V]R:W-H965T<R]S:&5E=#<V
M+GAM;+U8;6_B.!#^*Z/<ZK0K]<@;KSU HD"[2%=:0;OW8;4?3#(4JTG,V@;V
MI/OQ-TX@)=T074]</T!B>^;QS#-C,T-W)^2S6B%J^!%'B>I9*ZW7E[:M@A7&
M3-7$&A-:60H9,TU#^62KM406IDIQ9'N.T[1CQA.KWTWG[F6_*S8ZX@G>2U";
M.&;RKRN,Q*YGN=9A8L:?5MI,V/WNFCWA'/7C^E[2R,Y10AYCHKA(0.*R9PW<
MRY';, JIQ!>..W7T#L:5A1#/9C )>Y9C+,(( VT@&#VV.,0H,DADQ_<]J)7O
M:12/WP_HUZGSY,R"*1R*Z$\>ZE7/:EL0XI)M(CT3N\^X=R@U,!"12K]AMY=U
M+ @V2HMXKTP6Q#S)GNS'GH@C!;=Y0L';*WBO%>HG%/R]@O]:P3^A4-\KU%-F
M,E=2'D9,LWY7BAU((TUHYB4E,]4F]WEBXC[7DE8YZ>G^;/QE/'T<7\!P-AY-
M'F!X-QV.IP^SP</D;CJ'P70$-^.[F]G@_O-D")/I]=WL-EV#WV 0AMP$CT4P
M2;(4-*'\.$+->*0^D<CC? 0?/WR"#\ 3>%B)C6))J+JV)M.- 7:P-_,J,],[
M8:;KP:U(]$K!. DQ+ +8Y'/NN'=P_,JK1!QA4 /?O0#/\;P2@X;_7MVM,,?/
MX^"G>/X)O*%( DRTS"B<<?4,@R2$&Q1/DJU7/"A0_/4/4H>)QEA]*R,SVZM>
MOI>Y2B[5F@78L^BN4"BW:/5__<5M.K^7$7$FL (M]9R6>A5Z?Q $8I-H15=,
M@'S+%A%>0(*ZS.D,J9$BF>MNVZ\W7=]M=NWML3L_B_DMW^]TBF*C:KN^NM\J
MO&ODWC4J48;I^499YDVEYEM#>":P@I/-W,GF.V9V\YRTG FL0$LKIZ5UMLQN
M_92RS7;;<5XE=HE4JW,D53"SG9O9KDY1B73)0TD0_X;<A5GN ERQB)$HK1Z2
M&^X2+'.J<M^W1O),8 6*.CE%G7=,\,XY:3D36($6UWDI+9SJW"D0(XF8"UBC
M-'-44I86 1F@>>1)[-3,[W,ATT^(M<M3W3VJA=S_.]D?=J+4L<J-WQK6<Z$5
M:?)>:/+>,>'WFYV+FC.A%:EYJ>+<RFKHOZ2\7Y;+;N-URI>+-4^DO*FOBC,O
M-8E;7910:0-#E%3")T!5+L8+2NM#I4L]5IKR"E9LB[! 3" 0DG[#-(9 00>6
M *<64J/DU!>@E#3'0_*?+SF)$*A>(7VX#.'[ADD2!+%,J_ :S!%A*C2""UH8
M087F-"H1\9"9':YY0ML;Y+FF"6I Z42:;<.LYZB51=$^:H_HC#ZE;::"]#QG
MQ5H^F[>R@[2!>S5_95K<DOFA=SDJDQ^X=5*HEZXT#MVR_6)2UFO?,OG$$P41
M+LD\I]:B>,FL?<T&6JS3AFXA-%TZZ>N*6GZ41H#6EX(HW _,!OF?"/U_ %!+
M P04    "  VBUM6#&5@XUD#  !0#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970W-RYX;6RU5UUOVDH0_2LCMZI:J8D_ 9.")6IHBI20R)#VH>K#!@:PNO;2
MW072?W]W%\?%N0YJ).<%=KUS#G-FCLVXMV?\EU@C2GC(:"[ZUEK*S85MB_D:
M,R+.V09S=;)D/"-2;?G*%AN.9&% &;4]QVG;&4ES*^J9:[<\ZK&MI&F.MQS$
M-LL(__,9*=OW+==ZO)"DJ[74%^RHMR$KG**\V]QRM;-+ED6:82Y2E@/'9=\:
MN!>QZVF B?B6XEX<K4%+N6?LE]Z,%WW+T1DAQ;G4%$1][3!&2C63RN-W06J5
MOZF!Q^M']B]&O!)S3P3&C'Y/%W+=MT(+%K@D6RH3MO^*A:"6YILS*LPG[(M8
MQX+Y5DB6%6"509;FAV_R4!3B". &SP"\ N#]*\ O +X1>LC,R!H22:(>9WO@
M.EJQZ86IC4$K-6FNVSB57)VF"B>C9/1M-+D;?80X&0W',XAO)O%H,DL&L_'-
M9 J#R1 N1S>7R>#VZSB&\>3+37)MSN ,ILI3BRU%8$N8L/SLFN4HE1?@BN6K
MLRO5G@4,A$ IX/X/7");<;)9IW-(<*5;^'ZHPE,J/BBNN^D0WK_] &\AS6&V
M9EM!\H7HV5)IU)G:\T+/YX,>[QD]0YR?@^]^!,_QO!IX_.]PMPJW567+\GIE
M>3W#YS]77MQAOD58<I;!Z$$BSPF%V/05.?RX4O$PEIB)GW5:#^1!/;F^PR_$
MALRQ;ZE;6"#?H16]>^.VG4]URALBJ]3!+^O@GV*/9DPJW53[@AI?$..+.LT'
MHI8AT@^A7>2Z;N#K;NZ.Y=3$.:$;=KIE7"73H,PT.)GI79Y*E=]4$HFU^9V$
MO[0G#9%5E+9*I:W7]&:KR3HT1%:I0[NL0[LI;QZ(VD>>ZX3MEM-]8LV:L+8?
M!IUZ9W;*/#LG\QQSI.JA6)?72>!+>]$0645C6&H,7].389-U:(BL4H=N68=N
M4Y[L_L]LOM-U0^>))^O"@DX0UGO2=?[.#\[)3!,44@\ :EJCM=X\C7]I4YIB
MJZH]FI;<U_1GP=Y4+1IBJ];B[VCCGIP87N+1@JGR9QVV??^)1^O"?"\,GGC4
M/AIW];O&->&K-!= <:EPSGE'$?##^'[82+8Q$_ ]DZI/9KE6KSS(=8 Z7S(F
M'S=ZJ"Y?HJ+_ %!+ P04    "  VBUM69 #8,B<.  #SC@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W."YX;6S-76MOVS@6_2N$=["8 5K;>MARNDF Q.+.
M!CMILTT[@\5B/Z@V'0N5)8\D)\UB?OQ2#YNF3%];[4D]Q6#B..0A=8]XR7MX
M19T_)>GG;"Y$SKXLHCB[Z,SS?/FFU\LF<[$(LFZR%+'\RRQ)%T$N?TT?>MDR
M%<&TK+2(>G:_/^PM@C#N7)Z7W]VEE^?)*H_"6-RE+%LM%D'Z?"VBY.FB8W76
M7[P/'^9Y\47O\GP9/(A[D7]<WJ7RM]X&91HN1)R%2<Q2,;OH7%EO^,@K*I0E
M?@W%4[;UF167\BE)/A>_W$PO.OVB1R(2D[R ".2/1S$6450@R7[\7H-V-FT6
M%;<_K]'_7EZ\O)A/02;&2?1;.,WG%YU1ATW%+%A%^?ODZ1^BOJ!!@3=)HJS\
M/WNJR_8[;++*\F115Y8]6(1Q]3/X4AMBJX+E[JE@UQ7L1@5[7P6GKN <VX);
M5W"/K3"H*Y27WJNNO32<'^3!Y7F:/+&T*"W1B@^E]<O:TEYA7-PH]WDJ_QK*
M>ODE_]?'FP__9N-WMW?\[?W5AYMW;]G=+U=O[]G56Y_=?W@W_N?KZZM[[NM%
M7K.KZ30LJ XB=A-7-VQ!_(^^R(,PRGZ213[>^^S''WYB/[ >R^9!*C(6QNQC
M'.;9JZTO;L,HDE6S\UXN+ZCH5F]2=WY<==[>TWG+9K=)G,\SQN.IF.H /6F)
MC3GLM3FN;1+Q7BR[S#I[Q>R^=6;J$%W=%Y,N<ZRBNFT;JOO'5[<,U?GQU?N$
M,9S-O>&4>,X^8Q04O2Z&X92-DX7T35E%\E6:!O&#D/XB9Y^>V7:YN^"Y_/KJ
M*4BG[#^_2$AVDXM%]E_#]5Q7[;OF]@L?^29;!A-QT9%.,!/IH^A<_O4OUK#_
M-Q,U2# ?"<9!8!J)[H9$ET*O2&05.4%!BAQ[P2J?)VGX/_G5CW( 5D/Q)Q-!
M)'9;@BHPJT(K9K#'2]?J#LY[C]N61S;)06":Y0<;RP]HRR^#F"4S^=],I&'\
MP);R1S)]5?B\9Q&D)H=W34*V-3C=/]MEB])[FNY_9#\X"$QC8;AA84BSD">3
MS[5SFFP[,?&E^"S8)%B&>1"5HR%/)#F/TG\EZ;.)';*IMNQ48(.MT6!;3K_X
MUQ@1AH+]OJ$@-Q6T](*:#;V-#3W2AK^5RRTQ?1T\BE0N']DL"%/V&$0K4=S4
M+%F6%GV0LT)>^Y1I$D7R%B__7/H7HWLAFVUKSPILM'7UCMUUF^[%4,KJ#JV&
M)7=+V5[7]<QF'&W,."+-^"&1]YF\P7+I#;)P4ANP\!"E_3)Y2XIT$F;-E4QE
M*Q*[K:U&.W>*8UNF>V^WH-OW3/?>;D'/.B/NO;.-T<Y(H[V5P5(>?&&?1"QF
M8<YF:;)@63&HCS,;B=[6;&=[1F+#:,@V.0A,,[[55^%!GS0_7RRCY%D(5OI1
M=K=*)W/I2]E=%,0F<]-P;>T-1?.A:!R%IA.S%;=9)UZ<UQU 48E$\Z%H'(6F
M4VDK*NT77*+3X*UIJM"&VWZ\X=V@#7(4FFY[%>):9/!5V3YC-?24S9*4S5;Y
M2A(29MDJB"?B( '0*+9&TZ(DNSMJ<@"-3U%H.@<J0K7H$/5=/8_+U?=R/;_4
M\I!<',E%NPQ3JBG_5;&>G$@7)A>A1BJ@\6J-5CCZ#17][JBYHH0VRE%H.A<J
M9K5>(&BE,5N;_4#8NK<?/K0?'(6F,Z'B5HL.7&^#+^%BM=BZXPM>?E_)4'46
M-H-9.70^";;*:@^V'D9&LJ!!;(W6&"-6<X@@V^0H-)T8%0Q;=#2\(29X3F64
MRZ9BNBIW/<QC QKCUFA:!#+8#4"@C7(4FFYO%35;=-A<3]'%="QO[U4\%2G+
MYX*)=6A218.;J6,I0Y.#<S8TFJ[1M#F[WW6:I"#;Y"@TG105E5MT6/XQ3L4D
M>8C+%:KFBB9)ELOU5!3DE:"VBA]%EF^6MD8VH$&ZM1NE6ZY)+_.A[7(4FKYQ
MI2)UFX[4#S!2R)V3FI*M@LFC'$U/M;['UOK>,9,^W9VVI!VX.*OL!W-JQ9I9
M(S8-GHV+ &B_. I-)U5%^389>EZ^ET,G#4O>*@'FMS"?LWO93B@#D^LR9/Q5
MEBE6:N,DKK9DS71!HWDHF@]%XR@TG3(5S=OVB849&QKQ0]%\*!I'H>E4*G'
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M0.SQAE!!!(K&46@ZE4H0&1PX]?!('PA5-0:&LR#LI@>$:A4H--W*2JL8T*K
M80]X&Z2?17X@;89NI34+T%P+*!I'H>E\*75C<.J'1@90)0.*YD/1. I-IU(I
M&0,ZV>-ETF;H1EO3=[:3Z&+9;G?8S)LQE;.\[J#A.SFJ=_HYNDIQ&'Y3-D>[
M_!JZK;:6KM&T_!K/^(@NM%V.0M,942K$D%8AOG=^#=V=UJ31%U?GUYP=<>0'
MM%\<A::3JI2((9W:T3:_AH9K30K=.4+?@_:#H]!T$I2&,*0UA+&HTM.#R3R4
M 6RY HCDA\C( %1)&!J4A.8)#M 6.0I-M[72$8;?JB/LK*)IT91NKS4?4,$
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M970W.2YX;6S%6&%OJS84_2L6>YK>DUX+-@DD71(I"7E:M=<V*^FF:=H'!YR
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M"98B [U]0$"\!DL>NS_ PRZYDE-Y)7W^"M[/"<=^P#Z(LY^6<_#^W0?P#@P
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M (MKU'+?(\_Q/$-"D\OAK@$>7 YW:M2TBO%K:;Y6!=]\C1E<J9D?H@F-Y7+
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MI@+D]R6EXO"B.BCN=8;_ U!+ P04    "  VBUM6#&T@AN,#  #O$0  &0
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MX'4D'NGV3\@%M11?0".NO]$VCW4L%*RYH'$.EAG$),E^\6MNQ ' ;9\ >#G
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M9G-HP)S.8;))$>02'I3<\OP\T'&$BS$*7'(#2R6S2[@1L<P0GM@K:AC33B5
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M$#)-59UY=:/EIFP]EU)#(UM>KCF#G<\ X/E*0@CK&S-!\WUD\B]02P,$%
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M8Z1@[PV[0ZA;II8<R_ <%N@9X=D0DX':G>OL;HQ<EP<7<VF,+,K+%; ,E!V
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M__?3+1J@B5@L1<UJK9"8-G>T?D9?83I=L"F3DI7HCCZA<Z48F+R_8)KR2GT
MS_O;"_3^W0?T#O$:W<W%2M&Z5$-? Z3YE%_L@#YN@4@'T 4K3E&(3Q )"'&X
M3W[<';]V]Z$T;7U(6Q_2Q L[XIG4RY?4-:1.F]3/7(EM(T7N2&8]GJDE+=C(
M@P6GF%PS;_S[;S@)_G"E^8N"O4HZ;),.^Z(W24.CD%3S>H8JH10JJ)3/T#4V
M5+I'=1LQ;B*:WK$>DR")TZ&_/LS*817G8=):O<*-6MRH%]?,R +&A^NW,;>1
MD@. .(Y#G!]Q.LR2" >Y&S1N0>->T/.BD"N81^P)NK!BZ@3MQ@ZN8+4@&,HE
MY6[PV"+*LB0_KJ]ME9(T[L!.6NRD%_NRUK2>\8>*[6:_BR^Q^<(D"L@1H,,L
MA?IC-V':$J:]A!.ZY)I6_#\HKBDIE<6\J6C)UJ!42] =W5;=19]:6#@("3ZF
MM\T"-WC6@F>]X+=:%(\#HT,E*J#; B U\N9BS*R/1WF4'B/:5G&0XP[,O,7,
M>S'_9D"(*DX?>,4U=]<PM[^<6@W -DHC0MQT.-B+6/#&#%W#" OY[-2;P/HF
M(2E)CLA<9C%..M8./A!8W,MVI>=,.KFPHQ?E%I9MA?.HJV)[6<.] C+^1JL5
MW6ZD*MC*T;I@3D9B?7V <4+RXX;I-(2)EW;T=KS7(MPO1G<"5K9+@YV\H5VM
M.,5Q:/&Z#'$49EV5W8L1CGYNQ_#&LL&]XO:SVX9?%>UU\GN!P_T*]Y?@T&G-
M8EQ)9O;77*&23Z$:K&N&V9(U2*/X>+@<5CA)XH[!VBL;[I>V\^+[BIN!XJW&
MN0?)UBU8!V%VC.DR(W%']\5[></]^G9S=;_;<SOA;%D:Q&%TW'I=9DD69!UP
M>PG#_1IV+<U>43^?H&5%8?2-[C(H:Z.Z3EY;HP9QEEF;&:==%.5=Q'LUP_UR
MYF@I;RU26[<&28*)A>RR X'KV-^0O<*1?H7K.(<XCR&!M<G&<1!'UF[&91C%
M 4Z.:?V#\Z4YW'^A<L9KA2HV!<_@-(40<GM>WMYHL6R.G ]"PP&VN9PS6C)I
M#.#]5 C]<F-.L>U_+<;_ U!+ P04    "  VBUM6B_SL'0P#   B"@  &0
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M;!#<,,<6#I0UP/V-E.9I8@]HF\+D'U!+ P04    "  VBUM6<LU,L7X%  !
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MR/T3N>.Q.(+A2YL#(81;"8J)R/5:F'%L3]QOK/Q0Y6#"'$R8BPGS,&$^)BQ
M@M6$.M@)=?!.PNH 4[.8, <3YF+"/$R8CPD+D& US0YWFATVA]7LB<=:BIS
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M^:BT (M6UYE)V]1+JO5VUKS>_HW^169":2Y3XHA0)/="5>],\B3;F!%TQ6'
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M1AS!'( '# D"_1S<>AYYZ^>4U_PK?O074$L#!!0    ( #:+6U:7BKL<P
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M>7A89+,OBK$Z-BN#*ET_/?;]],CZE_\ 4$L#!!0    ( #:+6U84-@ <O@(
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MV^.ORZ^+DW?\BG-[7S$\_0502P,$%     @ -HM;5D;]('I, @  GC8  !,
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  VBUM6F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M #:+6U9F".X\V@<  *0O   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  VBUM6/Q%,%38"  "U!0  &
M            @($>$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ -HM;5L4Y^HGA!P  "B   !@              ("!BA(  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #:+6U:XZ\VHJ0(  &P'
M   8              " @:$:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  VBUM6QF%HWF\'  !Z(   &               @(& '0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -HM;5L4(VIZ
M!0  <A4  !@              ("!)24  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( #:+6U;,5/O_% ,  %X)   8              "
M@=LJ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  VBUM6
MCN##)QH.  "EJ   &               @($E+@  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ -HM;5BS)Z=_#"P  (#@  !@
M     ("!=3P  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M #:+6U;?^R%Z$RH  !>&   9              " @6Y(  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ -HM;5IQ4BRP#!P  ^!   !D
M             ("!N'(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  VBUM6^BAY3N $  !S"@  &0              @('R>0  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #:+6U;9E6OTHP,
M )D'   9              " @0E_  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ -HM;5C8\($!_ @  7P4  !D              ("!
MXX(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  VBUM6
MBT% ^4D&  !M#@  &0              @(&9A0  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( #:+6U:$78U4T04  .40   9
M      " @1F,  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ -HM;5D=V^"F[!0  T@X  !D              ("!(9(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  VBUM6^M3.V)@%   \#@
M&0              @($3F   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( #:+6U80(I>WY H  #DE   9              " @>*=  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ -HM;5GN?]_4G
M!   : H  !D              ("!_:@  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  VBUM6@*>ZOL,)  #H%P  &0
M@(%;K0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #:+
M6U:@WX-\SQ   &0U   9              " @56W  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ -HM;5JF=*56C!   O0H  !D
M         ("!6\@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  VBUM6QLYVO 8/  !_*0  &0              @($US0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #:+6U9;X(^- P4  #0,
M   9              " @7+<  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ -HM;5MSTZSYU"0  N!8  !D              ("!K.$
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  VBUM6;F8I
MK9 '   L$0  &0              @(%8ZP  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( #:+6U9G@2O0M"P  'J7   9
M  " @1_S  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M-HM;5L^F\';X @  -@8  !D              ("!"B ! 'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  VBUM6>K,H^#H%  "@#   &0
M            @($Y(P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( #:+6U8W9+9R*P0   D*   9              " @:HH 0!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ -HM;5GXQLV-: P
M\08  !D              ("!#"T! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  VBUM60H !HHX"  !J!0  &0              @(&=
M, $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #:+6U;X
MHZM'V 0  %@+   9              " @6(S 0!X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ -HM;5C6Z&H"W!0  P1   !D
M     ("!<3@! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #:+6U9Y,9M%'08  &T/   9              "
M@5I3 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ -HM;
M5K\5M6X4"   >Q@  !D              ("!KED! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  VBUM6!W,LNGL)  !F&@  &0
M        @('Y80$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( #:+6U9:^]M#Q 0  (,+   9              " @:MK 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ -HM;5MD$5I*6"   N38
M !D              ("!IG ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  VBUM6I)Z1E%4$  !R&0  &0              @(%S>0$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( #:+6U9;7EJX
MX H  *5)   9              " @?]] 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ -HM;5AI7"SF( @  5@8  !D
M ("!%HD! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  V
MBUM6VMG?4:8"  "/!@  &0              @('5BP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( #:+6U:E]-UF=@0  &08   9
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M970U,RYX;6Q02P$"% ,4    "  VBUM6"3+3750#  #,"   &0
M    @(&&H@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M #:+6U;G1L\T>P0  '(-   9              " @1&F 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ -HM;5AY?@9\F P  P @  !D
M             ("!PZH! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    "  VBUM6^L*>WB\$  #-$   &0              @($@K@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( #:+6U;W^D]8 P@
M .E&   9              " @8:R 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ -HM;5JH1WK9F P  E@@  !D              ("!
MP+H! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  VBUM6
M(%.G3_("  #T"   &0              @(%=O@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( #:+6U8>NV(-:0,  )4.   9
M      " @8;! 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ -HM;5CQI?XJ4!   U1H  !D              ("!)L4! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  VBUM6)"3P%Y4#  !J#0
M&0              @('QR0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( #:+6U:P>_70Y ,  (\1   9              " @;W- 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ -HM;5N/B:\]:
M!   D!H  !D              ("!V-$! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    "  VBUM6S!4 H-P"   ]"0  &0
M@(%IU@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( #:+
M6U90/FSGF (  '((   9              " @7S9 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ -HM;5NX?8E<:!   <P\  !D
M         ("!2]P! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
M    "  VBUM6F?Y+X'X'  #^0@  &0              @(&<X $ >&PO=V]R
M:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( #:+6U85U:#Y*P4  )H5
M   9              " @5'H 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL
M4$L! A0#%     @ -HM;5O0R%14+!   @ X  !D              ("!L^T!
M 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  VBUM6F-?;
M*HX'  !I*0  &0              @('U\0$ >&PO=V]R:W-H965T<R]S:&5E
M=#<R+GAM;%!+ 0(4 Q0    ( #:+6U9*?_FA$P<  /LN   9
M  " @;KY 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
M-HM;5L]_!/SV!0  YB$  !D              ("!! $" 'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    "  VBUM6C[XQTK(#  !U$@  &0
M            @($Q!P( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( #:+6U;Y29RJ,@0  % 0   9              " @1H+ @!X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ -HM;5@QE8.-9 P
M4 T  !D              ("!@P\" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX
M;6Q02P$"% ,4    "  VBUM69 #8,B<.  #SC@  &0              @($3
M$P( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( #:+6U:X
M3\E.X@,  /<1   9              " @7$A @!X;"]W;W)K<VAE971S+W-H
M965T-SDN>&UL4$L! A0#%     @ -HM;5I/C-1;S!@  +#(  !D
M     ("!BB4" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M"  VBUM6A\-O\[($  !_&   &0              @(&T+ ( >&PO=V]R:W-H
M965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( #:+6U:^;N7UYP4    B   9
M              " @9TQ @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L!
M A0#%     @ -HM;5@?O=L[O P  XQ$  !D              ("!NS<" 'AL
M+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  VBUM6#&T@AN,#
M  #O$0  &0              @('A.P( >&PO=V]R:W-H965T<R]S:&5E=#@T
M+GAM;%!+ 0(4 Q0    ( #:+6U9^73]36 ,  ,L)   9              "
M@?L_ @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ -HM;
M5IW6["BP P  0PH  !D              ("!BD," 'AL+W=O<FMS:&5E=',O
M<VAE970X-BYX;6Q02P$"% ,4    "  VBUM62-+K8*@$   K$0  &0
M        @(%Q1P( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0
M   ( #:+6U8$;_=;404  &D;   9              " @5!, @!X;"]W;W)K
M<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ -HM;5@ F7J#G!0  ]Q8
M !D              ("!V%$" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q0
M2P$"% ,4    "  VBUM6=;44G9,$  #!$   &0              @('V5P(
M>&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( #:+6U:+_.P=
M# ,  "(*   9              " @<!< @!X;"]W;W)K<VAE971S+W-H965T
M.3$N>&UL4$L! A0#%     @ -HM;5AHFL-=G P  ( H  !D
M ("! V " 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4    "  V
MBUM6<LU,L7X%  ! &   &0              @(&A8P( >&PO=V]R:W-H965T
M<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( #:+6U;^V?UPMP,  )0/   9
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M @!X;"]S='EL97,N>&UL4$L! A0#%     @ -HM;5I>*NQS     $P(   L
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64$L%!@    !H &@ CQP  "** @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>397</ContextCount>
  <ElementCount>500</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>121</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - OTHER EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS</Role>
      <ShortName>LICENSE AND COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/INTANGIBLEASSETS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/INVENTORY</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/DEBT</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/INCOMETAXES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - INVENTORY - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails</Role>
      <ShortName>INVENTORY - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Schedule of ROU Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - LEASES - Schedule of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails</Role>
      <ShortName>LEASES - Schedule of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - LEASES - Schedule of Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails</Role>
      <ShortName>LEASES - Schedule of Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>LEASES - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - DEBT - Schedule of Senior Subordinated Convertible Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails</Role>
      <ShortName>DEBT - Schedule of Senior Subordinated Convertible Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - DEBT - Schedule of Interest Expense on Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails</Role>
      <ShortName>DEBT - Schedule of Interest Expense on Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Components of Company Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails</Role>
      <ShortName>LICENSE AND COLLABORATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="bmrn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>96</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: bmrn:IncomeTaxStatuteOfLimitationsPeriod, bmrn:LongTermMarketableSecuritiesMaturityPeriod, bmrn:SpanOfOfferingPeriod, us-gaap:DebtInstrumentConvertibleConversionRatio1 -  bmrn-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings has a value of -5644000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings fact are: Context: if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231, Unit: usd, Rule Element Id: 2833. bmrn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="bmrn-20221231.htm">bmrn-20221231.htm</File>
    <File>bmrn-20221231.xsd</File>
    <File>bmrn-20221231_cal.xml</File>
    <File>bmrn-20221231_def.xml</File>
    <File>bmrn-20221231_lab.xml</File>
    <File>bmrn-20221231_pre.xml</File>
    <File>bmrn-20221231xexx231.htm</File>
    <File>bmrn-20221231xexx311.htm</File>
    <File>bmrn-20221231xexx312.htm</File>
    <File>bmrn-20221231xexx321.htm</File>
    <File>bmrn-2022xexx211.htm</File>
    <File>exhibit10_35.htm</File>
    <File>exhibit10_36.htm</File>
    <File>exhibit10_37.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bmrn-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1327">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bmrn-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 38,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1327,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 397,
   "dts": {
    "calculationLink": {
     "local": [
      "bmrn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmrn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bmrn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmrn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 824,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 14,
    "http://www.bmrn.com/20221231": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 22
   },
   "keyCustom": 69,
   "keyStandard": 431,
   "memberCustom": 53,
   "memberStandard": 68,
   "nsprefix": "bmrn",
   "nsuri": "http://www.bmrn.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bmrn.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - INVENTORY",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.bmrn.com/role/INVENTORY",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION",
     "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.bmrn.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.bmrn.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.bmrn.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - OTHER EMPLOYEE BENEFITS",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS",
     "shortName": "OTHER EMPLOYEE BENEFITS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.bmrn.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE",
     "shortName": "EARNINGS (LOSS) PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS",
     "shortName": "LICENSE AND COLLABORATION AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETSTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - INVENTORY (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.bmrn.com/role/INVENTORYTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables",
     "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.bmrn.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.bmrn.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.bmrn.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables",
     "shortName": "EARNINGS (LOSS) PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "bmrn:ContractWithCustomerLiabilityPaymentTermAfterCustomerControl",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6e5794221fb845cb984a6fa0fadee3ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i465f964e015842ad9df73023d86585b8_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i465f964e015842ad9df73023d86585b8_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6943ad4dcf614dd68d73dc3e5298e4f7_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i15ef335077bf4d05985d7bb62daece5a_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - INVENTORY - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails",
     "shortName": "INVENTORY - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i079459cd9ea04678bb91caba28143414_D20221006-20221006",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails",
     "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION -Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i079459cd9ea04678bb91caba28143414_D20221006-20221006",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ia23981085b84481d8fc2be75b9fbd5db_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails",
     "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if4446cd995b344e0ba108320ca62f991_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "span",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "id956bf9fc1b44873ab5ad29095686daa_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "span",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "id956bf9fc1b44873ab5ad29095686daa_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i52a8c6de8e56463ea5c2aa40267ceb5c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i07b156ee48534e11b0e4ec467c89f063_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i07b156ee48534e11b0e4ec467c89f063_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i4dd179c35f4c4ed4a6d43b5692d9df3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails",
     "shortName": "LEASES - Schedule of ROU Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "LEASES - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - LEASES - Schedule of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails",
     "shortName": "LEASES - Schedule of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - LEASES - Schedule of Other Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails",
     "shortName": "LEASES - Schedule of Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails",
     "shortName": "LEASES - Schedule of Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - DEBT - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
     "shortName": "DEBT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i8c5c2c7efc1c4baf96b5f8d0f4fb47b3_I20200531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - DEBT - Schedule of Senior Subordinated Convertible Obligations (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails",
     "shortName": "DEBT - Schedule of Senior Subordinated Convertible Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - DEBT - Schedule of Interest Expense on Debt (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails",
     "shortName": "DEBT - Schedule of Interest Expense on Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if5f5fd8d831c4d5aba3c5f22f1194475_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6babf135cae34564ae9f1313c802cf9c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i83d540593f644f2cb082a24558b3f758_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "iae042974731b47fa8462f91e2b1ce268_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "id742fff2407f462e9b1a4affc1a0fdd6_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i7b5fa7ec2b1541f2a9aecd40ae5ca28b_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Non-Monetary Long-Lived Assets by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib09dd10764f7419a9a4650c424edaaf4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib09dd10764f7419a9a4650c424edaaf4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ic903dc53bec74ccfa03bf69bf3f03b5e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i66bd0a3324f54e36b1cfa7011ff3c61b_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6fdaf4f8f69f454b810125453581568e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of TSR-RSUs Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6fdaf4f8f69f454b810125453581568e_D20220101-20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6babf135cae34564ae9f1313c802cf9c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6babf135cae34564ae9f1313c802cf9c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i08dbc2fa9a96443cb2310c3bbfbeb4ad_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i174e38c567da498382c9b71cd2020fac_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
     "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Employee Stock Purchase Plan Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i174e38c567da498382c9b71cd2020fac_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails",
     "shortName": "OTHER EMPLOYEE BENEFITS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ie1e5f26fb18a48b48da751bdfa0bc2f7_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails",
     "shortName": "INCOME TAXES - Components of Company Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i7af5d8557d8a40ae8beee5eedec3c302_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails",
     "shortName": "INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i7af5d8557d8a40ae8beee5eedec3c302_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i6babf135cae34564ae9f1313c802cf9c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ic12190384e734edabd0ce99df1427a69_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "if2a3f8009206494baa271b5e43a86c5b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails",
     "shortName": "LICENSE AND COLLABORATION AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "i77a677ec0b154c0b9ee244bb19c37ea5_I20190331",
      "decimals": "2",
      "lang": "en-US",
      "name": "bmrn:RoyaltyRateLowerLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20221231.htm",
      "contextRef": "ib246871d78d94c228e7dec2d91f453a0_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 121,
   "tag": {
    "bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.25% Senior Subordinated Convertible Notes Due in May 2027",
        "label": "1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]",
        "terseLabel": "1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)"
       }
      }
     },
     "localname": "A125SeniorSubordinatedConvertibleNotesDueInMay2027Member",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_A2022RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Restructuring Plan",
        "label": "2022 Restructuring Plan [Member]",
        "terseLabel": "2022 Restructuring Plan"
       }
      }
     },
     "localname": "A2022RestructuringPlanMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AAndRKuvanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A&amp;R Kuvan agreement.",
        "label": "A And R Kuvan Agreement [Member]",
        "terseLabel": "A&amp;R Kuvan Agreement"
       }
      }
     },
     "localname": "AAndRKuvanAgreementMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued rebates payable"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_AccruedRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued rebates.",
        "label": "Accrued Rebates [Member]",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebatesMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AccumulatedGainLossFromOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated gain (loss) from other.",
        "label": "Accumulated Gain Loss From Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccumulatedGainLossFromOtherMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AcquiredIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired intellectual property.",
        "label": "Acquired Intellectual Property [Member]",
        "terseLabel": "Acquired intellectual property"
       }
      }
     },
     "localname": "AcquiredIntellectualPropertyMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan",
        "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan",
        "negatedTerseLabel": "Change in Common stock held by the NQDC"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_AllowancesForReserveForCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowances For Reserve For Cash Discounts [Member]",
        "terseLabel": "Reserve for cash discounts"
       }
      }
     },
     "localname": "AllowancesForReserveForCashDiscountsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage",
        "label": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage",
        "terseLabel": "Annual shareholder return multiplier"
       }
      }
     },
     "localname": "AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bmrn_AverageClosingPriceTrailingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average closing price trailing period.",
        "label": "Average Closing Price Trailing Period",
        "terseLabel": "Average closing price of common stock, trailing period"
       }
      }
     },
     "localname": "AverageClosingPriceTrailingPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_BiomarinRetirementSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioMarin retirement savings plan.",
        "label": "Biomarin Retirement Savings Plan [Member]",
        "terseLabel": "BioMarin Retirement Savings Plan"
       }
      }
     },
     "localname": "BiomarinRetirementSavingsPlanMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration potential cash payments upon achievement of sales milestone.",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payments Upon Achievement Of Sales Milestone",
        "terseLabel": "Business acquisition contingent consideration potential cash payments upon achievement of sales milestone"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Minority Equity Investment in License",
        "label": "Collaborative Arrangement, Minority Equity Investment in License",
        "terseLabel": "Investment in equity"
       }
      }
     },
     "localname": "CollaborativeArrangementMinorityEquityInvestmentInLicense",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_CommonStockIssuableUnderTheConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable Under The Convertible Notes",
        "label": "Common Stock Issuable Under The Convertible Notes [Member]",
        "terseLabel": "Common stock issuable under the Notes"
       }
      }
     },
     "localname": "CommonStockIssuableUnderTheConvertibleNotesMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ConcentrationRiskAndGeographicInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and geographic information.",
        "label": "Concentration Risk And Geographic Information [Line Items]",
        "terseLabel": "Concentration Risk And Geographic Information [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskAndGeographicInformationLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ConcentrationRiskAndGeographicInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and geographic information.",
        "label": "Concentration Risk And Geographic Information [Table]",
        "terseLabel": "Concentration Risk And Geographic Information [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskAndGeographicInformationTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and segment reporting disclosure.",
        "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ContingentPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Payment",
        "label": "Contingent Payment [Member]",
        "terseLabel": "Contingent Payment"
       }
      }
     },
     "localname": "ContingentPaymentMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.",
        "label": "Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones",
        "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones"
       }
      }
     },
     "localname": "ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ContractWithCustomerLiabilityPaymentTermAfterCustomerControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Payment Term After Customer Control",
        "label": "Contract With Customer, Liability, Payment Term After Customer Control",
        "terseLabel": "Payment term after customer control"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPaymentTermAfterCustomerControl",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Period Between Customer Control And Payment",
        "label": "Contract With Customer, Liability, Period Between Customer Control And Payment",
        "terseLabel": "Period between customer control and payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPeriodBetweenCustomerControlAndPayment",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1",
        "label": "Customer One [Member]",
        "terseLabel": "Customer A",
        "verboseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerOneTwoAndThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One, Two, And Three",
        "label": "Customer One, Two, And Three [Member]",
        "terseLabel": "Customer A, B, &amp; C"
       }
      }
     },
     "localname": "CustomerOneTwoAndThreeMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 3",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 2",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer B",
        "verboseLabel": "Customer Two"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers.",
        "label": "Customers [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomersMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_DebtInstrumentPercentageOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument percentage of face value.",
        "label": "Debt Instrument Percentage Of Face Value",
        "terseLabel": "Debt instrument percentage of face value"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfFaceValue",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities related to joint venture basis difference.",
        "label": "Deferred Tax Liabilities Related To Joint Venture Basis Difference",
        "negatedLabel": "Joint venture basis difference"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-Of-Use Assets",
        "label": "Deferred Tax Liabilities, Right-Of-Use Assets",
        "negatedLabel": "ROU Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_EarlyStageDevelopmentProgramOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Stage Development Program One",
        "label": "Early Stage Development Program One [Member]",
        "terseLabel": "Early Stage Development Program One"
       }
      }
     },
     "localname": "EarlyStageDevelopmentProgramOneMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_EarlyStageDevelopmentProgramTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Stage Development Program Two",
        "label": "Early Stage Development Program Two [Member]",
        "terseLabel": "Early Stage Development Program Two"
       }
      }
     },
     "localname": "EarlyStageDevelopmentProgramTwoMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim",
        "label": "Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim",
        "negatedTerseLabel": "CARES act carryback claim"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount",
        "terseLabel": "Intra-entity transfer of assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive Licensing Agreement For Tralesinidase Alfa",
        "label": "Exclusive Licensing Agreement For Tralesinidase Alfa [Member]",
        "terseLabel": "Exclusive Licensing Agreement For Tralesinidase Alfa"
       }
      }
     },
     "localname": "ExclusiveLicensingAgreementForTralesinidaseAlfaMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Gain (Loss) On Foreign Exchange",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Gain (Loss) On Foreign Exchange",
        "negatedTerseLabel": "Realized foreign exchange gain on settlement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsGainLossOnForeignExchange",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement",
        "terseLabel": "Foreign exchange remeasurement of Euro denominated contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Not Commenced, Net",
        "label": "Finite-Lived Intangible Assets, Amortization Not Commenced, Net",
        "totalLabel": "Finite-lived intangible asset future amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_FirdapseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firdapse",
        "label": "Firdapse [Member]",
        "terseLabel": "Firdapse"
       }
      }
     },
     "localname": "FirdapseMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign government and other debt securities.",
        "label": "Foreign Government And Other Debt Securities [Member]",
        "terseLabel": "Foreign and other"
       }
      }
     },
     "localname": "ForeignGovernmentAndOtherDebtSecuritiesMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_IncomeTaxRateReconciliationSection162Limitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax rate reconciliation section 162 limitation.",
        "label": "Income Tax Rate Reconciliation Section162 Limitation",
        "terseLabel": "Section 162(m) limitation"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationSection162Limitation",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_IncomeTaxRateReconciliationTaxReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax rate reconciliation tax reserves.",
        "label": "Income Tax Rate Reconciliation Tax Reserves",
        "terseLabel": "Tax Reserves"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationTaxReserves",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_IncomeTaxStatuteOfLimitationsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax statute of limitation period.",
        "label": "Income Tax Statute Of Limitations Period",
        "terseLabel": "Income tax statute of limitations period"
       }
      }
     },
     "localname": "IncomeTaxStatuteOfLimitationsPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_IndependentDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Independent director.",
        "label": "Independent Director [Member]",
        "terseLabel": "Independent Director"
       }
      }
     },
     "localname": "IndependentDirectorMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_IntangibleAssetAmortizationAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.",
        "label": "Intangible Asset Amortization And Contingent Consideration",
        "terseLabel": "Intangible asset amortization and contingent consideration"
       }
      }
     },
     "localname": "IntangibleAssetAmortizationAndContingentConsideration",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_LeaseRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Right Of Use Assets",
        "label": "Lease Right Of Use Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_LeasesLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases Liabilities",
        "label": "Leases Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LeasesLiabilitiesAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating And Finance Leases Other Information Table",
        "label": "Lessee Operating And Finance Leases Other Information Table [Table Text Block]",
        "terseLabel": "Schedule of Other Information"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating And Finance Leases Other Information Table",
        "label": "Lessee Operating And Finance Leases Other Information Table [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_LicensePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Payments",
        "label": "License Payments [Member]",
        "terseLabel": "License payments"
       }
      }
     },
     "localname": "LicensePaymentsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_LongTermMarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities maturity period.",
        "label": "Long Term Marketable Securities Maturity Period",
        "terseLabel": "Long-term marketable securities maturity period"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMaturityPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_MaturityOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Of Lease Liabilities",
        "label": "Maturity Of Lease Liabilities [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "MaturityOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_MaximumPayrollDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payroll deductions.",
        "label": "Maximum Payroll Deductions",
        "terseLabel": "Maximum payroll deductions"
       }
      }
     },
     "localname": "MaximumPayrollDeductions",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_MerckSeronoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Serono.",
        "label": "Merck Serono [Member]",
        "terseLabel": "Merck Serono"
       }
      }
     },
     "localname": "MerckSeronoMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified deferred compensation plan assets.",
        "label": "Nonqualified Deferred Compensation Plan Assets [Member]",
        "terseLabel": "NQDC Plan assets"
       }
      }
     },
     "localname": "NonqualifiedDeferredCompensationPlanAssetsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified deferred compensation plan liability.",
        "label": "Nonqualified Deferred Compensation Plan Liability [Member]",
        "terseLabel": "NQDC Plan liability"
       }
      }
     },
     "localname": "NonqualifiedDeferredCompensationPlanLiabilityMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_NumberOfTranchesInOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Tranches In Offering Period",
        "label": "Number Of Tranches In Offering Period",
        "terseLabel": "Number of tranches in offering period"
       }
      }
     },
     "localname": "NumberOfTranchesInOfferingPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liabilities Payments Due",
        "label": "Operating And Finance Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability",
        "label": "Operating And Finance Lease Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails",
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability, Current",
        "label": "Operating And Finance Lease Liability, Current",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due",
        "label": "Operating And Finance Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due After Year Five",
        "label": "Operating And Finance Lease Liability Payments Due After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due Next Twelve Months",
        "label": "Operating And Finance Lease Liability Payments Due Next Twelve Months",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due Year Five",
        "label": "Operating And Finance Lease Liability Payments Due Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due Year Four",
        "label": "Operating And Finance Lease Liability Payments Due Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due Year Three",
        "label": "Operating And Finance Lease Liability Payments Due Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Payments Due Year Two",
        "label": "Operating And Finance Lease Liability Payments Due Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_2": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability Undiscounted Excess Amount",
        "label": "Operating And Finance Lease Liability Undiscounted Excess Amount",
        "negatedTotalLabel": "Less: Interest"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OperatingAndFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Right Of Use Asset",
        "label": "Operating And Finance Lease Right Of Use Asset",
        "totalLabel": "Total ROU assets"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherAssetsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets current fair value disclosure.",
        "label": "Other Assets Current Fair Value Disclosure",
        "verboseLabel": "Fair value of other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherAssetsNoncurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets noncurrent fair value disclosure.",
        "label": "Other Assets Noncurrent Fair Value Disclosure",
        "verboseLabel": "Fair value of other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherComprehensiveIncomeLossOtherNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income loss other net of tax",
        "label": "Other Comprehensive Income Loss Other Net Of Tax",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherNetOfTax",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherInformationLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Information Lease Liability",
        "label": "Other Information Lease Liability [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "OtherInformationLeaseLiabilityAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities current fair value disclosure.",
        "label": "Other Liabilities Current Fair Value Disclosure",
        "verboseLabel": "Fair value of other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities noncurrent fair value disclosure.",
        "label": "Other Liabilities Noncurrent Fair Value Disclosure",
        "verboseLabel": "Fair value of other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_PaymentReceivedAsPercentageOfNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received from sale of a product as percentage of worldwide net product sales.",
        "label": "Payment Received As Percentage Of Net Product Sales",
        "terseLabel": "Payment received as percentage of net product sales"
       }
      }
     },
     "localname": "PaymentReceivedAsPercentageOfNetProductSales",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable",
        "label": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable",
        "negatedTerseLabel": "Investment in convertible note"
       }
      }
     },
     "localname": "PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_PegvaliaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pegvaliase agreement.",
        "label": "Pegvaliase Agreement [Member]",
        "terseLabel": "Pegvaliase Agreement"
       }
      }
     },
     "localname": "PegvaliaseAgreementMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProceedsFromSaleOfNonfinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Nonfinancial Assets",
        "label": "Proceeds From Sale Of Nonfinancial Assets",
        "terseLabel": "Proceeds from sale of nonfinancial assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNonfinancialAssets",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ProductEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Eight",
        "label": "Product Eight [Member]",
        "terseLabel": "FIRDAPSE"
       }
      }
     },
     "localname": "ProductEightMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 5 [Member]",
        "label": "Product Five [Member]",
        "terseLabel": "KUVAN"
       }
      }
     },
     "localname": "ProductFiveMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 4 [Member]",
        "label": "Product Four [Member]",
        "terseLabel": "PALYNZIQ"
       }
      }
     },
     "localname": "ProductFourMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 1 [Member]",
        "label": "Product One [Member]",
        "terseLabel": "ALDURAZYME net product revenues marketed by Sanofi"
       }
      }
     },
     "localname": "ProductOneMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 7 [Member]",
        "label": "Product Seven [Member]",
        "terseLabel": "BRINEURA"
       }
      }
     },
     "localname": "ProductSevenMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product six.",
        "label": "Product Six [Member]",
        "terseLabel": "VOXZOGO"
       }
      }
     },
     "localname": "ProductSixMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 3 [Member]",
        "label": "Product Three [Member]",
        "terseLabel": "NAGLAZYME"
       }
      }
     },
     "localname": "ProductThreeMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 2 [Member]",
        "label": "Product Two [Member]",
        "terseLabel": "VIMIZIM"
       }
      }
     },
     "localname": "ProductTwoMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductsExcludingProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products excluding product one.",
        "label": "Products Excluding Product One [Member]",
        "verboseLabel": "Total net product revenues marketed by the Company"
       }
      }
     },
     "localname": "ProductsExcludingProductOneMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RepurchasedRoyaltyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchased royalty rights.",
        "label": "Repurchased Royalty Rights [Member]",
        "terseLabel": "Repurchased royalty rights"
       }
      }
     },
     "localname": "RepurchasedRoyaltyRightsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of world.",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestrictedInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted investments.",
        "label": "Restricted Investments [Member]",
        "terseLabel": "Restricted Investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestrictedStockWithServiceBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock with service based vesting conditions.",
        "label": "Restricted Stock With Service Based Vesting Conditions [Member]",
        "terseLabel": "Restricted Stock With Service Based Vesting Conditions"
       }
      }
     },
     "localname": "RestrictedStockWithServiceBasedVestingConditionsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce",
        "label": "Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce",
        "terseLabel": "Percentage of workforce expected to eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right Of Use Assets Obtained In Exchange For Lease Obligations",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "ROU assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_RoyaltyAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and other.",
        "label": "Royalty And Other [Member]",
        "terseLabel": "Royalty and other revenues"
       }
      }
     },
     "localname": "RoyaltyAndOtherMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RoyaltyRateLowerLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty rate lower limit.",
        "label": "Royalty Rate Lower Limit",
        "terseLabel": "Royalties on net product sales"
       }
      }
     },
     "localname": "RoyaltyRateLowerLimit",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_RoyaltyRateUpperLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty rate upper limit.",
        "label": "Royalty Rate Upper Limit",
        "terseLabel": "Royalties on net product sales"
       }
      }
     },
     "localname": "RoyaltyRateUpperLimit",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated accrued rebates and reserve for cash discounts.",
        "label": "Schedule Of Estimated Accrued Rebates And Reserve For Cash Discounts Table [Table Text Block]",
        "terseLabel": "Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts"
       }
      }
     },
     "localname": "ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ScheduleOfInterestExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of interest expenses.",
        "label": "Schedule Of Interest Expenses [Line Items]",
        "terseLabel": "Schedule Of Interest Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInterestExpensesLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfInterestExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of interest expenses table.",
        "label": "Schedule Of Interest Expenses [Table]",
        "terseLabel": "Schedule Of Interest Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfInterestExpensesTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Lessee Lease Assets And Liabilities Table",
        "label": "Schedule Of Lessee Lease Assets And Liabilities Table [Table Text Block]",
        "terseLabel": "Schedule of Lessee Lease Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Table [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment Estimated Useful Lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation arrangements by share based payment award equity instruments other than options restricted stock units.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Line Items]",
        "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation arrangements by share based payment award, equity instruments, other than options, restricted stock units.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of TSR-RSU Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior subordinated notes repurchased percentage of principal amount.",
        "label": "Senior Subordinated Notes Repurchased Percentage Of Principal Amount",
        "terseLabel": "Repurchase of note principal amount"
       }
      }
     },
     "localname": "SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior unsecured revolving two thousand eighteen credit facility.",
        "label": "Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]",
        "terseLabel": "The 2018 Credit Facility"
       }
      }
     },
     "localname": "SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage",
        "terseLabel": "Shares earned range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award initial time period vesting requirement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Initial Time Period Vesting Requirement",
        "terseLabel": "Initial time period vesting requirements"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price",
        "terseLabel": "Options unvested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Years, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage",
        "terseLabel": "Ceiling achievement level"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bmrn_ShareBasedPaymentAwardCoreOperatingMarginTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Award, Core Operating Margin Target",
        "label": "Share-Based Payment Award, Core Operating Margin Target [Member]",
        "terseLabel": "Core Operating Margin Target"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardCoreOperatingMarginTargetMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ShareBasedPaymentAwardNonGAAPIncomeTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Award, Non-GAAP Income Target",
        "label": "Share-Based Payment Award, Non-GAAP Income Target [Member]",
        "terseLabel": "Non-GAAP Income Target"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardNonGAAPIncomeTargetMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ShareBasedPaymentAwardStrategicGoalTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Award, Strategic Goal Target",
        "label": "Share-Based Payment Award, Strategic Goal Target [Member]",
        "terseLabel": "Strategic Goal Target"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardStrategicGoalTargetMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities maturity period.",
        "label": "Short Term Marketable Securities Maturity Period",
        "terseLabel": "Short-term marketable securities maturity period"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMaturityPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_SpanOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Span of offering period.",
        "label": "Span Of Offering Period",
        "terseLabel": "Span of offering period, in years",
        "verboseLabel": "Span of offering period"
       }
      }
     },
     "localname": "SpanOfOfferingPeriod",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency.",
        "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency",
        "terseLabel": "Issuances under equity incentive plans, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares.",
        "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares",
        "terseLabel": "Issuances under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "bmrn_StrategicInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment.",
        "label": "Strategic Investment [Member]",
        "terseLabel": "Strategic Investment"
       }
      }
     },
     "localname": "StrategicInvestmentMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of operating loss and tax credit carryforwards.",
        "label": "Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.",
        "label": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Fixed Assets",
        "terseLabel": "Decrease in accounts payable and accrued liabilities related to fixed assets"
       }
      }
     },
     "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets",
        "label": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets",
        "terseLabel": "Increase (decrease) in accounts payable and accrued liabilities related to intangible assets"
       }
      }
     },
     "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_SupplementalBalanceSheetInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental balance sheet information",
        "label": "Supplemental Balance Sheet Information [Line Items]",
        "terseLabel": "Supplemental Balance Sheet Information [Line Items]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationLineItems",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails",
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_SupplementalBalanceSheetInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental balance sheet information.",
        "label": "Supplemental Balance Sheet Information [Table]",
        "terseLabel": "Supplemental Balance Sheet Information [Table]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationTable",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails",
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_SupplementalCashFlowLeaseInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Lease Information",
        "label": "Supplemental Cash Flow Lease Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowLeaseInformationAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_TechnologyTransferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology Transfer",
        "label": "Technology Transfer [Member]",
        "terseLabel": "Technology transfer"
       }
      }
     },
     "localname": "TechnologyTransferMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ThirdPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party.",
        "label": "Third Party [Member]",
        "terseLabel": "Third Party"
       }
      }
     },
     "localname": "ThirdPartyMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen base restricted stock unit awards with revenue based vesting conditions.",
        "label": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Revenue Based Vesting Conditions [Member]",
        "terseLabel": "Restricted Stock Unit Awards with Performance-Based Vesting Conditions"
       }
      }
     },
     "localname": "TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions",
        "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions [Member]",
        "terseLabel": "Restricted Stock Unit Awards with Market Conditions"
       }
      }
     },
     "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions",
        "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions [Member]",
        "terseLabel": "Restricted Stock Unit Awards with non-Revenue based Performance Conditions"
       }
      }
     },
     "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term (in years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.",
        "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]",
        "terseLabel": "0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)"
       }
      }
     },
     "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember",
     "nsuri": "http://www.bmrn.com/20221231",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Dutch"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r274",
      "r532",
      "r533",
      "r535",
      "r536",
      "r588",
      "r665",
      "r765",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r274",
      "r532",
      "r533",
      "r535",
      "r536",
      "r588",
      "r665",
      "r765",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r347",
      "r692",
      "r772",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r442",
      "r619",
      "r636",
      "r666",
      "r667",
      "r689",
      "r702",
      "r712",
      "r770",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r442",
      "r619",
      "r636",
      "r666",
      "r667",
      "r689",
      "r702",
      "r712",
      "r770",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r347",
      "r692",
      "r772",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r344",
      "r621",
      "r690",
      "r710",
      "r762",
      "r763",
      "r772",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r344",
      "r621",
      "r690",
      "r710",
      "r762",
      "r763",
      "r772",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r434",
      "r442",
      "r472",
      "r473",
      "r474",
      "r595",
      "r619",
      "r636",
      "r666",
      "r667",
      "r689",
      "r702",
      "r712",
      "r760",
      "r770",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r434",
      "r442",
      "r472",
      "r473",
      "r474",
      "r595",
      "r619",
      "r636",
      "r666",
      "r667",
      "r689",
      "r702",
      "r712",
      "r760",
      "r770",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r219",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r315",
      "r357",
      "r358",
      "r513",
      "r540",
      "r541",
      "r542",
      "r543",
      "r568",
      "r586",
      "r587",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r219",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r315",
      "r357",
      "r358",
      "r513",
      "r540",
      "r541",
      "r542",
      "r543",
      "r568",
      "r586",
      "r587",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Error Correction, Adjustment",
        "verboseLabel": "Adjustment related to correction of immaterial error"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r219",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r295",
      "r315",
      "r513",
      "r540",
      "r541",
      "r542",
      "r568",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r756",
      "r757",
      "r813",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r345",
      "r346",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r691",
      "r711",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r650",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r691",
      "r711",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r750",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r199",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts\u00a0payable\u00a0and accrued\u00a0liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued operating expenses"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable Balance"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r196",
      "r208"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r17",
      "r670"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r96",
      "r228"
     ],
     "calculation": {
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r246",
      "r256",
      "r257",
      "r534",
      "r675",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r246",
      "r256",
      "r257",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r28",
      "r29",
      "r233",
      "r631",
      "r642",
      "r646"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r255",
      "r256",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r29",
      "r152",
      "r587",
      "r637",
      "r638",
      "r725",
      "r726",
      "r727",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss):"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r738",
      "r739",
      "r740",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital:"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r129",
      "r130",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r40",
      "r56",
      "r187",
      "r414"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of discount on convertible notes"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r35",
      "r414",
      "r566",
      "r734"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r414",
      "r566",
      "r687",
      "r688",
      "r734"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r697",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r194",
      "r207",
      "r232",
      "r269",
      "r329",
      "r338",
      "r342",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r532",
      "r535",
      "r552",
      "r709",
      "r766",
      "r767",
      "r825"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease Classification"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r222",
      "r237",
      "r269",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r532",
      "r535",
      "r552",
      "r709",
      "r766",
      "r767",
      "r825"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Fair value of financial assets, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r351",
      "r364"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r77",
      "r350",
      "r364",
      "r625"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r76",
      "r364"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term Marketable Securities",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r76",
      "r226",
      "r364"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term Marketable Securities",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r159",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r525",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r525",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r528",
      "r733"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Non-cash changes in the fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r146",
      "r147",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Long-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r648",
      "r649",
      "r709",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r58",
      "r225",
      "r668"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r52",
      "r58",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r186"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Financing Activities, Lessee [Abstract]",
        "terseLabel": "Cash used in financing activities:"
       }
      }
     },
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "negatedLabel": "Unrealized losses reclassified from AOCI to earnings"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash used in operating activities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "LICENSE AND COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r383",
      "r384",
      "r652",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockIssuedEmployeeStockTrust": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.",
        "label": "Common Stock Issued, Employee Stock Trust",
        "negatedLabel": "Company common stock held by the Nonqualified Deferred Compensation Plan"
       }
      }
     },
     "localname": "CommonStockIssuedEmployeeStockTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r738",
      "r739",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock:"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r709"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "terseLabel": "OTHER EMPLOYEE BENEFITS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]",
        "terseLabel": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r251",
      "r253",
      "r260",
      "r627",
      "r633"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r42",
      "r259",
      "r626",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r183",
      "r184",
      "r347",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r183",
      "r184",
      "r347",
      "r647",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r183",
      "r184",
      "r347",
      "r651",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r67",
      "r68",
      "r183",
      "r184",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r69",
      "r183",
      "r185",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r183",
      "r184",
      "r347",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r420",
      "r421",
      "r432"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r696",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r696",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r3",
      "r197",
      "r209"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Total convertible debt, net"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Total fair value of fixed-rate convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r103",
      "r399",
      "r400",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Long-term convertible debt, net",
        "totalLabel": "Convertible notes, net of unamortized discount and deferred offering costs"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Senior Subordinated Convertible Obligations"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r697",
      "r699",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r37",
      "r269",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r552",
      "r766"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r737",
      "r805",
      "r807"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r737",
      "r805"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r509",
      "r517",
      "r737"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense, total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r737",
      "r805",
      "r807"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r66",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r195",
      "r197",
      "r206",
      "r274",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r567",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r197",
      "r206",
      "r416"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Carrying value of equity component",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r104",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price, per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r20",
      "r107",
      "r108",
      "r110",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate of shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r188",
      "r190",
      "r399",
      "r567",
      "r685",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage, per annum"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r274",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r567",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r107",
      "r109",
      "r110",
      "r111",
      "r187",
      "r188",
      "r190",
      "r204",
      "r274",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r567",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r187",
      "r190",
      "r771"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt Instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r189",
      "r405",
      "r417",
      "r685",
      "r686"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized discount net of deferred offering costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofSeniorSubordinatedConvertibleObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.",
        "label": "Deferred Compensation, Share-Based Payments [Member]",
        "terseLabel": "Company common stock held by the NQDC:"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedPaymentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r737",
      "r806",
      "r807"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r737",
      "r806"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r143",
      "r510",
      "r516",
      "r517",
      "r737"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Deferred income tax expense (benefit), total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Provision for (benefit from) deferred income taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r737",
      "r806",
      "r807"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Net deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r803"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r803"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r139",
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r139",
      "r140",
      "r804"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal R&amp;D and orphan drug credit carryforwards",
        "verboseLabel": "Research credit carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses, reserves, and prepaids"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r132",
      "r803"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r140",
      "r804"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company's contribution from employment commencement"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company's contribution to match employees contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Employer contribution of maximum percentage over employee's annual compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r56",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r56",
      "r327"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r24",
      "r161",
      "r191",
      "r238",
      "r674"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r24",
      "r161",
      "r191",
      "r238",
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r811"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gains (Losses) Recognized in Earnings"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r160",
      "r162",
      "r165",
      "r167",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r174",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r157",
      "r160",
      "r165",
      "r167",
      "r171",
      "r172",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Foreign currency exchange forward contracts"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Maturity of derivatives"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r165",
      "r168",
      "r170",
      "r172",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r157",
      "r158",
      "r169",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedging instruments:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r431",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r446",
      "r478",
      "r479",
      "r481",
      "r487",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r261",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r297",
      "r300",
      "r309",
      "r310",
      "r311",
      "r315",
      "r542",
      "r543",
      "r628",
      "r634",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings (loss) per common share, basic (in dollars per share)",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r261",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r300",
      "r309",
      "r310",
      "r311",
      "r315",
      "r542",
      "r543",
      "r628",
      "r634",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings (loss) per common share, diluted (in dollars per share)",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r817"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation expense capitalized to inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost expected to recognized over weighted average period, in years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Net tax benefit from stock options exercised"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Manufacturing\u00a0and\u00a0laboratory\u00a0equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r218",
      "r255",
      "r256",
      "r257",
      "r281",
      "r282",
      "r283",
      "r285",
      "r292",
      "r295",
      "r318",
      "r356",
      "r419",
      "r483",
      "r484",
      "r485",
      "r512",
      "r513",
      "r541",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r587",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Strategic investments fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r544",
      "r545",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r175",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r175",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r407",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r545",
      "r592",
      "r593",
      "r594",
      "r685",
      "r686",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r547",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r407",
      "r435",
      "r440",
      "r545",
      "r592",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Price\u00a0in Active Markets For Identical Assets (Level 1)",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r407",
      "r435",
      "r440",
      "r545",
      "r593",
      "r685",
      "r686",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Significant\u00a0Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r407",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r545",
      "r594",
      "r685",
      "r686",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r176",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r176",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Liabilities Measured at Fair Value Using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "terseLabel": "Financial assets remeasured"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Milestone payments to Ares Trading S.A. (Merck Serono)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Contingent consideration, ending balance",
        "periodStartLabel": "Contingent consideration, beginning balance",
        "terseLabel": "Liabilities remeasured"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r407",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r592",
      "r593",
      "r594",
      "r685",
      "r686",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r572",
      "r578",
      "r708"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r574",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Financing leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Financing"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r570",
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance, Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance, Noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r573",
      "r580"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal repayments of financing leases",
        "terseLabel": "Financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Financing"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r572",
      "r578",
      "r708"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r583",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Financing leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r582",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Financing leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r415",
      "r418",
      "r539",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r682",
      "r752",
      "r753",
      "r754",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r230",
      "r375"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r88",
      "r623"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r88",
      "r622"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Balance",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails",
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Average Remaining Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign currency transaction losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r57",
      "r815",
      "r816"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange loss (gain)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r674",
      "r697",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r734"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain on sale of nonfinancial assets, net",
        "terseLabel": "Gain on sale of nonfinancial assets, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r734"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Gain on sale of nonfinancial assets, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r229",
      "r372",
      "r624",
      "r683",
      "r709",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r157",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r270",
      "r518"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. Source"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r192",
      "r200",
      "r215",
      "r329",
      "r337",
      "r341",
      "r343",
      "r629",
      "r681"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r270",
      "r518"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Non-U.S. Source"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofProvisionforBenefitfromIncomeTaxesBasedonIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r271",
      "r498",
      "r504",
      "r508",
      "r514",
      "r519",
      "r521",
      "r522",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r272",
      "r294",
      "r295",
      "r328",
      "r496",
      "r515",
      "r520",
      "r635"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetails",
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r254",
      "r492",
      "r493",
      "r504",
      "r505",
      "r507",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance/deferred benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Foreign Source Income Subject to US Tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State and local taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Orphan Drug &amp; General Business Credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r53",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other short-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r733"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r733"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r305",
      "r306",
      "r311"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r189",
      "r202",
      "r258",
      "r326",
      "r565"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total interest expense on convertible debt"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r41",
      "r413",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Coupon interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense on Debt"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r299",
      "r302",
      "r311"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Add: Interest expense, net of tax, on the Notes"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r264",
      "r266",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INVENTORY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r81",
      "r671"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r235",
      "r669",
      "r709"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r224",
      "r234",
      "r317",
      "r368",
      "r370",
      "r371",
      "r620",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r81",
      "r673"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r81",
      "r672"
     ],
     "calculation": {
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory reserves, net of stock-based compensation"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r39",
      "r325"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land improvements"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r584",
      "r708"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r269",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r533",
      "r535",
      "r536",
      "r552",
      "r680",
      "r766",
      "r825",
      "r826"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r198",
      "r211",
      "r709",
      "r736",
      "r755",
      "r814"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r223",
      "r269",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r533",
      "r535",
      "r536",
      "r552",
      "r709",
      "r766",
      "r825",
      "r826"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of financial liabilities, Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r3",
      "r197",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Outstanding amount"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Non-Monetary Long-Lived Assets by Geographic Region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates an ownership position in, or purchase of, a security.",
        "label": "Long [Member]",
        "terseLabel": "Purchase"
       }
      }
     },
     "localname": "LongMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails",
      "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r385",
      "r386",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimated long-term loss contingency"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r57",
      "r201",
      "r214",
      "r221",
      "r249",
      "r252",
      "r257",
      "r269",
      "r284",
      "r286",
      "r287",
      "r289",
      "r290",
      "r294",
      "r295",
      "r307",
      "r329",
      "r337",
      "r341",
      "r343",
      "r355",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r543",
      "r552",
      "r681",
      "r766"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "NET INCOME (LOSS)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r286",
      "r287",
      "r289",
      "r290",
      "r297",
      "r298",
      "r308",
      "r311",
      "r329",
      "r337",
      "r341",
      "r343",
      "r681"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss), basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r308",
      "r311"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income/(loss), diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Total long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments:"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r329",
      "r337",
      "r341",
      "r343",
      "r681"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "INCOME (LOSS) FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r579",
      "r708"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r575",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r583",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r582",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r236",
      "r709"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r241",
      "r242",
      "r244"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change in unrealized holding gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "totalLabel": "Net change in unrealized holding gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r240",
      "r244"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during the period, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r244",
      "r247"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r244",
      "r247",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Cash Flow Hedging Gains (Losses) Reclassified into Earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "terseLabel": "Reclassifications to net income (loss), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r106",
      "r250",
      "r253",
      "r259",
      "r557",
      "r562",
      "r563",
      "r626",
      "r632",
      "r725",
      "r726"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r250",
      "r253"
     ],
     "calculation": {
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net current period other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r26",
      "r30",
      "r80",
      "r248"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Less: reclassifications to net income (loss), net of tax impact of \u00a0\u00a0$0, $0 and $(127), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r27",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedLabel": "Reclassification, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r149",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Tax effect"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r241",
      "r244"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during the period, net \u00a0\u00a0 of tax impact of $3,247, $1,596 and $(227), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r27",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during the period, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other\u00a0current\u00a0assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "negatedTerseLabel": "Decrease in other long-term liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payments of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r728",
      "r729"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r379",
      "r732"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r44",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition, cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PositionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by position taken for a security.",
        "label": "Position [Axis]",
        "terseLabel": "Position"
       }
      }
     },
     "localname": "PositionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PositionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates position taken for a security.",
        "label": "Position [Domain]",
        "terseLabel": "Position"
       }
      }
     },
     "localname": "PositionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible senior subordinated note offering, net"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from offering debt"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r47",
      "r128"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercises of awards under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r730",
      "r731"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Total net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r653",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, plant and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r95",
      "r227"
     ],
     "calculation": {
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r97",
      "r212",
      "r630",
      "r709"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property Plant and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life, (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitment"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase commitment expected to be paid in 2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "verboseLabel": "Less: gain (loss) reclassified from AOCI"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayments of convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r131",
      "r217",
      "r833"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Restructuring and related cost, expected number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r56",
      "r381",
      "r382",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r112",
      "r210",
      "r641",
      "r646",
      "r709"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r218",
      "r281",
      "r282",
      "r283",
      "r285",
      "r292",
      "r295",
      "r356",
      "r483",
      "r484",
      "r485",
      "r512",
      "r513",
      "r541",
      "r637",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit:"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r323",
      "r324",
      "r336",
      "r339",
      "r340",
      "r344",
      "r345",
      "r347",
      "r430",
      "r431",
      "r621"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r433",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "REVENUES:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r581",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Financing leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r581",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred directly to consumer.",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "terseLabel": "Marketed by Company"
       }
      }
     },
     "localname": "SalesChannelDirectlyToConsumerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred through intermediary.",
        "label": "Sales Channel, Through Intermediary [Member]",
        "terseLabel": "Marketed by Sanofi"
       }
      }
     },
     "localname": "SalesChannelThroughIntermediaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r347",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net Product Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r29",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision for (Benefit From) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r114",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "terseLabel": "Compensation Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r160",
      "r165",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Carrying Amount of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetails",
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofNonMonetaryLongLivedAssetsbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r84",
      "r87",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "terseLabel": "Schedule of Forward Foreign Currency Exchange Contracts Outstanding"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INVENTORYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetails",
      "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r443",
      "r445",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r120",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r706",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r69",
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for not readily marketable securities, valuation methods and significant assumptions used to determine fair value, restrictions on the investment and reasons investments are not readily marketable, including securities that are not registered, investments in nonpublic entities.",
        "label": "Securities Owned Not Readily Marketable, Policy [Policy Text Block]",
        "terseLabel": "Non-Marketable Equity Securities"
       }
      }
     },
     "localname": "SecuritiesOwnedNotReadilyMarketablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorSubordinatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A senior subordinated note is a bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior subordinated debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors. However senior subordinated notes are junior to Senior Notes and Senior bond holders.",
        "label": "Senior Subordinated Notes [Member]",
        "terseLabel": "Senior Subordinated Notes"
       }
      }
     },
     "localname": "SeniorSubordinatedNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award vesting service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period, years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "netLabel": "Granted (in dollars per share)",
        "terseLabel": "Weighted-average fair value per RSU granted (in dollars per share)",
        "verboseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units ending balance (in shares)",
        "periodStartLabel": "Non-vested units beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units ending balance (in dollars per share)",
        "periodStartLabel": "Non-vested units beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of qualified compensation to be used for purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share based awards, authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Expired and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired and forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding ending balance (in shares)",
        "periodStartLabel": "Options outstanding beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r450",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing price of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "The total intrinsic value of restricted stock vested and released"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contractual term of stock option awards, years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofTSRRSUsValuationAssumptionsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Years, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Options unvested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Years, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Options to purchase shares of common stock, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates the sale of a borrowed security or written option.",
        "label": "Short [Member]",
        "terseLabel": "Sell"
       }
      }
     },
     "localname": "ShortMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r62",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r106",
      "r218",
      "r255",
      "r256",
      "r257",
      "r281",
      "r282",
      "r283",
      "r285",
      "r292",
      "r295",
      "r318",
      "r356",
      "r419",
      "r483",
      "r484",
      "r485",
      "r512",
      "r513",
      "r541",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r587",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r318",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Initial equity grant value"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r106",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under the employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r106",
      "r112",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r4",
      "r5",
      "r106",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r106",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r4",
      "r5",
      "r106",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r75",
      "r709",
      "r736",
      "r755",
      "r814"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedTerseLabel": "Stockholders' equity decrease",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetails",
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONScheduleofEmployeeStockPurchasePlanValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r415",
      "r418",
      "r539",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r752",
      "r753",
      "r754",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury stock:"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r678",
      "r697",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r205",
      "r216",
      "r490",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Undistributed earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r491",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "(Deletions) Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "(Deletions) Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect the effective tax rate if recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Provision for Current Period Sales"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Payments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Minority equity ownership"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r299",
      "r311"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r297",
      "r311"
     ],
     "calculation": {
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bmrn.com/role/EARNINGSLOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=123585891&loc=d3e19833-108362",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r719": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001048477-23-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001048477-23-000009-xbrl.zip
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M4JSQU?H]1;CN 6/;(^O+'D-H'')+B57H*NKJY:W[(]2OI#SE[K3.3N407_4
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M^5Q6!7TW^-G98MG?-Q)_UM@%S)(DI@H-FT88C3/9]*=5A< (_=F <%J?CT,
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M<&4RJWT40R!C ]"XQGNWG\-#H4UPF&MDR1(B1"\8JD,$XV*J0F/8@OC3:/,
MS_OU1X(.5_$AY\1  %92,5X?D"_(A#'8$>T(,1"8-K_K ]KD2\V!*S:PH6*E
M4 13WV"PCF(GZ8% >365^41<FV;(K-D+2,DV6'+>^5I#P3(FB_L?X2.%X)8L
M)D?3BQ:L[\2ORP/"-Q:OS[V[VJES:RT/%$1O7-'<%!+;7# Y[TUQKFJXXRW"
M]F VY3?P;B.6)I$-L6^]$CR(M60$I(+"F$LS<00M$&_ICWVIT+V4WZSNX63Q
M_#V1.9N+PGC[53U&=:?=K<ZQ_IEY?O27>#!;3'[/GD?'L_G:/F)@;NA*H@;'
MZ(UD9T(LX)PGKS&^-W!&0\!V!#LZ[]BX:3:N,:?SD$1C6E5'" DR9<WN3(O$
MICH;1[ R:\!LO#=;W_C4<,FX/M=H/'+@6%V5 $(V^]8TIPT-BN421S"VNB/C
MUGC&EK&V(BYC(\A-$SHJJ47C?15(9@0=-M<I_+?! CY&' S&%4+ATH)@M0FX
M2&F4&;'U'0I-BB-85+5CWW6S;YU5'QR]%5,-"1AHQ,I#UG^]:07:SO>-CGT?
M$?V'XOHX0/ F&#(Q 5%#E7^A,8G/V><QS$[NR'?-Y%OCONK9AQ13I((,&'NM
ML@I!-N))+.5=H^%/X\.W>-*W:'MT++*\-ZL?L(7[RV.9WSR;S_57?M2"Y2U(
M4M;G*Y.Q@J5:GRB!YT"YD68M",'VO7+M\'WECJZ#I^L:NY^("347&UID  <8
M;"K)I]2D:L(#.^]Z%715N5$_+\:NL=%NMM**)TRA04WJ6F-HSD6'5+.+XZIY
MVC%VL(Q=GX^ERHFRS0%- ^-8'[!!2)!0W:^/.Q^[)9198\_E J5HTI-=!B P
MY(LOM<4<BK4AC:OWSHXRU[*4QQELWGI/R0'X0-&4!EG#)#!7M]M:8=UQ\4:]
MV-+\ 9XCG<B-*>LK\S/AR[+*B7P&87*-HXS&0PW) .M?LKD4,4VBQT(V:M#<
M^;P=@0?M@0V$$DM(Q=:@B70MD$RUL09?@UC:Y=)7G)E\5K1=8T]G# 6" =O8
M0,L-H^%<JLVYF,)I!!/;.]J.AK9KG!%G3#F9UGQ1VJ+2M@9-D$IN6="Y$>PD
MLI%)R3':RJ>,[@_%JW+-U3MNW'P$B4)-*AIQ3!*<A1&HV1T]!T?/-7;^2MF:
MY I%:!KT+5*2R*D$RPR6=]YS*^BYA@QO*/[4]1[DWB4HQH$K&:L%AB(!J09G
M1M#@=$?8$1!VG>MX0NM;W6)V'FPA8E/(0:[,H1D[IK7(CY9*R?Z>V_\YZZO%
M9Z<O9E-]NO@=>&>G9R>=OM_A9'IOME@<R/(F+H[OG,Q^Z?27!SC_\PQC$&G.
MGWZ)Q7SY]8/YC,_J\O[\D<Q?3JJ\^_&OCZZ?KYM?P-M*JTW3K\8N RNKLZ4<
M6W(J(OK>(RMRVTMR#]HM[\@]8'+;CR>W71NY@=FF4GVO+P'I1:<,GD(LCHNF
M<W5$GOONM,Y.Y0W%_R")>;%JQ#0]NOVJ-S.4=3'X<[2L47KSXHH(-V$J'K)G
M%#:UM+[>LV:3_8B\^8[P(R/\1CR\021VSHF8"A!R+E1C#2%%*RU"&!'AA]1+
M9B-8M@;)$9A6#4-HDC'5F+W30,WZ.'WFT7J4 2G&X"1(5AA5>@'FON0,LF13
MC3,T)OL<(J:;L=-2JF*9^Z8R$$M$9\&CB;F6Z,6[X8\XWQ):_A87WVJ7=\.Z
M\$BFD]G\T1G-YCQ9.=N;L^E+F2\G="('LZ4L;O5!M7T\UY^91C+H&AB;#R$
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M"YQ#T!07035J)A$)(BS55V_<\.>F+GN>O;IQMCR>S?6KO:L;;^G1Q7)2;UZ
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MK<@S5!H9  $DB%3/-"V5,LV- L^DEM% P!JJ7BQ1%0YYB[H^4PU3,U7+C#3
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MA(0W&K&H:*9 K)"IIA-$OF4$.ORW(>L:+4M;]KB8S'6HBT$!#I 5_R*89P?
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MUJ/;%K(>+))5=PP#Y&1/#2W$ **'JD^<$+0ZRPX"AO7 -VHPVP:R+J@?((^
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MG@85MWR[V0WB;70)_ 7$:S>0M_V0!TMZ'!<7R@=")UG>P-Y+W'.&V^#>)M?
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M]QFO12\D21[:&C9Q72]T^S40N.$U6*C<X3?YG+\ !,*2'O%:]8>IJ!D+3VK
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MI/W>&O4+%3D2IT6I*45RNHF<;E%-MU*K"B5D48S*#S=  3>5+6Z4A%P!+G1
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MM@N!9#6#!;]7,N:VF@".V0 UBBR?-4K_DRK]^9S0/"#XDI1R_%R[EOJ8B+#
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M^2H2%L=#ELX2.&*SE*<-[G[^U^FK;:6'^8/T6$S6Y!F3,IF3#!@68+YD"B8
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M=U7X4=85$V4C:X2J($J4B\2OJA;#P31.0G4ZYE)@3>K#:^.PK-(/JMZ\8#]
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MK)F'@RC'L% @-@*6SZ[03_?B6FAP_EB_BB^BAX;9XM-&:8?F<<! ZQMA>>^
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MLQK.1$A4"XBD[+K_!)FG#2<COF"QE34&*R<+R1<D1_NBLIMS+007BB==34/
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M_ONX#K?!W$T^4#T> U;LESQ$PG[=5WA)3BQ'W<L('YO4,R.@LX.%C2N"_Q!
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MWKT,AUZ2;8$;ZQMX;(3 TUOC:HP4Y?64THU&/9?5558(BV[<!)'-*3A^([Y
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MR1*WU&R%7\/=Y#W\+WPW3 ?F#&(=#DG%_E.T/PN\ZV-4'S?H<K&;QS-\0]^
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MFX/\+]$IQX!!R[X[PA.D9Y+>I.1-UF^7AV]&9N?".!/D-@A)E+.NA<3G2=W
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M;6!HM)G!/'DMU$MQ<KO*K\H*[^"BK)N=$+HQOL^Z"CT-U03<6"80R$,Z$/A
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M=1RJ^ML' K^BN !")9#"QR+ W",U>"(8?*O1Q9DP+S<%=;P(MN=]Z_3T;-O
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MA,QK$S75$DXDJG=L49F(>2@!@:\+J5G83PXRWL\4UX1[IDYT1;/9:M?"QT;
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MAPZI "GEGG;.',PAN6>8FG0B5"<@*B@H70TW;<J##N?[0WTF&CAOQOEX%L^
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MM5)P*+1+%P4),\EP9UP6Q;7%H'1"V4@72651#V'+D+ 7' VG586:S@%;TWA
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MY6$HNL70.UQ43A-2^=_UW6+E^>TNUN"F2312BG<5G16+I<W)N4) P<PEI=+
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M?U:YGN_"IPN=WMYA:8&@M:EG<AN0YUJK'Q;-=$H@Q.G!G8SS*+JPHW,A%>H
MV7/$8T1V5W%$&!E6B44$A6#!G[G?MSH!,#(D>,51^X X$9@UW5#S_:Q7;X@E
M"1H!J/:8KZ=;M.%7:E9P=D@9SO!H]9,+CE[E@0KY8%8)/HXAPX2L;5G,R:WL
MR[WG\[;)ET>S>$CTS]KRG,%&491UD^^IS54TQAMB6EWZB0$%W#IB9WEV>)LF
MQ9A5L021'"AO1 N='@=08:,'5 AF^NOE39G_C927,9PNC!/3ZCD:\>GOPEY$
M30?0/Z[!QE\': \);$+-\%^$,:&PQ8Y(*LUF<Q&\RTI@0W6._>J5J+E0@HV6
MD04A,*1PS89O(0% @)90-=ZVX; 1]5"]P#[S6RE341K!P=L5$$:_O: /T#W'
MR(-(_!+!BJ9YRB<0P+U3;RBY#-,[F\7VK%F"NE38!P&8-$1=1F"24\-B@K3H
M4['8P<>>$[/D&<\R8*CB6*-2J'KGJ%S[DCJH@ F::1/)@ JNS"1,B^MP<+GJ
M''<0IBT>S@Z0LJ2?0:P(@_G<#-@EP>&93+R #H/5](3(?=YCF97'IJ1C3TW@
MJ;1SFK"CZ.*0J\%OEUAE<T>,S*.\^A(CZI728_X+5*S]T^Q+96UAS-;664VU
MJD1J*KB%0 XQV=+HK24?DUQ>IVT#!6ZZDV[(I?4\V2BNX0/7/6$B3A4^[,UP
M5/%C=X,/(=H.W/*;JES+[L-:R#_%"O8#'^K3H"V9E[4<1=[LWA@Z&PJ_A'6N
MRV#%"#LI'*+R7T.>[*%OM":?'_&8_&RG[8&X\VCK<T>25-?H8%5$ZKOC\F^8
M,-IF3;M=A1NI&5%&ANGVG_5'ATS>OX5,WD(FKVDS11.!:\_$$XW[&"Z+]RF%
MM!>608PW=<%UC*%0?XO9(6?GX1RM67%3>=U3Q_M=LR[<4:?G "B8X.+GA4%3
MV&XLBS6#@TS[T:D^BDXIHP\+;O>0.S(9KSG)V=7N(XTZQAHG$[Y-1Z$<;W4*
M05;!#M9B%-E:AB_'%<PMJ7J=.F6TLDW\M/0&;W=5$1U^<F6HGJMWD7,(NGVW
M)>8_F'QT)^;<F9(T)ZF/S,B4.!IX2EU81XKFG[Z?O2S@HK_;6C/!JBT*#G1<
M^-L"GCG^A0DI==GV!PU\ ).,Z] WHCF=SD!>+_NQ ":VN^2]W,RPZPK9?2D$
MAV_P(K:!@AM>9 J@AFA#XCB,/\/>0)L$@DMS#3Y!H$I7?&_LO ,LJLN#3\SQ
MI;#AQ[T#)MK>Q+-C)90KP4!*K")/70D=Z& *6/]B*U#C\!TY)16:#3%A\G?!
M-X4'X+T!=^?7X_ZL$GW"1:GRA5J"P1!2CC7OF["U.&3264AAG)K@)"P#AR&$
M_%R8OQU>0)F9LB,4V6N$2L,]"AA5#*6I1[?\)'N/N3&Q:<PE)C($H'B56]4?
M,OM*)D/@[,$R/.8BF)DD)^".(.(+,@WB#O9:'A,^=1M")ML#>& P?4KX?C1[
MDZ8)DOT7(KDBEBY4VX8@Q^TAOG09?Y]ZF4(L2>"\:/QA)SB"#RN)7T_]OKJ?
MIHBBDH)CA^LKC/^BR -J%!:#P/OB+9 T6QG8N6Z<]&>/YE7!]0Z3*[$,4D%Y
MUW#O.)]>1;@P7[*=%5>U :0QN,]6>!L/A+#6 L6F#QP9(F$^B[_OZ(A6A%ED
M *(_^#KV8"QSP/O#X+7#S.(U>H-Q">,T2[UI."AAB.Z;EX98Q0J'!Q\-PTSO
MYT9$6T.1(,X? /D93C4;8_]==FO+72W6E2&)JHUK5 "] /N\X%#&:DX.A1KV
MPI_#B0)!NN5L?TWFV,G@1"XX3MGP?>#+B?KW8M_M/U?] \E=JC'V_+WRTS/Y
M%?;OV(+_2^:L/ULW&.0X9<XU7<PSB6N )4#^):9E_)R^1J0O&?!@RH3&0,5S
M)**(QZ+*+WJ9(A*>ZIFHS*=7B("Z)-WG,H*(>]K#_8QM/XHAJ^#RS?[4<]L!
M_4_+%%*4T;_//_/"7HIX(CN<Q=2P3PH/T]\^[\=2UIHV%0F[KS)W[!)!/@FO
M[O-+W-IM<1U)9N=1D'R:%198\"_)?9)#I*]V=/C#%_>% X/[$.)<(@=('A]N
M8H[R\&2MBZC3\!8;@*H(0R/AMUKP!H%&CP(-V W*OD7_\#Q$D;P%WMK[3\)!
MN?/\[<D!_=7)[I1ZP>_=O7?/['#P ,8W!#O&J%T\*<BGT%?]F>,PFID_(UYZ
M5[3GK.K^YS^_.Z =$RZMAD;.:TM%-<XO2ERKD3DO-H1'5= L.C./7[Z+*]/?
M$K,W%)P^PM_B?SZA 8NZ%V(L,BN'3)53XE9"+; X[(+96!2J2V3.+%L!Y9V$
M,[@-IRH/T_6=5,_N'!_+_Z(?VX@/A&2 /M/<"!K\BF]O3$18"HX%PE(()R!7
M!MY1EQV0OC2S?WZ'.MQ:R# YJ6LI$,2YG?!(<!K@=%<NF8F'L$4;-A6(MM6'
MR"S@TWXI?,/1[&5"Z,_AO_1O^0Z>K0QZ*&2E) Q&E^7C-6;5(D8B?)Q3L;H1
ME]2;\&FM]J*&SQ?51[%@;]K@%B[,V)X0V](2_M%CVIMTYL*BW;M[?!?KDJ^I
M+F)2=G)^'JMY>0IU7SZVU 83PN;<SJX\9W8G?&Y5B-29C.;-R6,ZU]2VV 73
MN^&(%TD[T2NYQ-Z'HT$O3ZXMB2]HW1.EQW!PP^*4I+@5TT^SE$9MD)WA[#\K
M?11A/S6H_7)N+JQZN=SE6NNDH73R''HRG_)RJ8;V*!P3OB[=$9#?)?> NZ35
MB]_I6[04K^9&FWCX>GY7TBCI')HA'5[3=H]FI+I7+K1C.;VO@[=2$<&3> 3R
MNAQD*#90+%=/@Q#_AD ^>N-<Q]^<%165=ZCAB:  ++BVJR&Q-SM#RD*%=-+7
MZZ0@C<.>4GR5<K]%*==$>H:WB/=VU!%S1I)20FAKU'PE/_HB[]1!&>1N_4/X
MOA0HAI=9U5(__6#D_G4[E=*4OIPJ,K7(=FDKL+5*%N)"UQ*N=-MF+3LQ(V6C
MR+.&5*\YCC?-KTX6,AXQ=A"M:Q7W.4\5)2D2F,PF1]]MWY>TZZA(Z9&<2VGY
MK_'43W0>?;$1SD!T"U,OS/6]9/*[R[);5 VL&_N#E#/J:35UT)M%MDH82[V>
M@)Y,'58.^2Y78#6 3^]=B4<<ZR+80J7  J0YU<]*^/6PIY"R08(KCQDW94G4
MM!J<H%WU,83Y;3@NM"+ABC:9M3#O@\R];[M-S6JP#QVX!SD%GRPR$RC-RZ66
M?*W7GOI9N.<Q7 %@3+PDC\<G3YHRVH3#D#HBU4E%C:(G!SE^IF.[[XTX;9%J
MKZS93>MGEC,[2(W<>YI2JLK%GK28VY3]02MGR9GKQY5:Q'=W?<<Q3+=I"+PE
M-T"\_?(M4EB@ZL.2T\6:*F=: IIK4T>SQ_'&3"VXI"VX^(^J7FZGRU58'%'G
M1-HHV4PT?>9[CVF%M2XIU0VSIC$;*KZNKU'AN)U>'9Z620%$,C-,=O5IULPK
M@JV:-,D4%$]P+<&SIO*'AD EF4>-R<+X<=V7BR03/Q#?3:JA!I$"4X$>:)>C
M&%8VHLQN4Q\*"$WMS:ZSQ7*5#7_*?0J:MD+?8'4SH)WO_I"670KDG.\=_\![
MK-HXJY(4-WW;BAD+*KB$WVY+T<5;I7_C!"7_Z$B/;VZ1'K=(CVLCQY(SKYP_
MI+TWIYZ-+6/VD-SJG7.Q!7O$)G8OY(9IC+7FE'RY9TB@"-I1OPYGP?)8+F6(
M1FDEV!Y")'I>9I1X&'!&22Z*$:"2DTL?&^Q;U14@U4A+$E<+(ZZ0C'?>FR=%
M-'KA/M[R\D\SUI,)\=M1:E51'[4$Z^&@=S!Y*8T.BQ/O4VMLNQDQT ?RGL*-
M7&Z,Y](2."X [ON>DFZ- &"EG0*DA\/=E'S-1U.4*P0*OJ]CB61Z6YXV+:7)
M++T2G&'L+7%]?! \BA3@3+O?+FD@RR]EJLW^1HKY94MM"*:$YZV@2"5QCJQW
MP".GPMEHJ^4%@6R8#0P8C3KX,+%[(A4([8JM]R_X=C?02QS>B^(4%D:R1:-P
M LZ?F_LWWW^).Q=+K4DTJ#F#=MVK(XT>YLSE!9S*+4/W.<W#Z5WSVXTV9@!1
MM5UF QOI@! =6NJ^-LX;=M^G:.^)%EJ#6X^^\32KX2"EN^,K.]3C==3G(-?5
MW+383[C992W_.WCC$EL6GYA&B+Z=-EXGB:B4L)W3@.QZ-W*$^CQ,:!Z05B$T
M\DK)8-#@Z^B=-;UFUT/4*Z=*U_)KF_#/$I,G< GAF-Y'9LI(HSW.42D_YU5P
M)1>QK45PGDL-VU3R.L0Q?D$YGR(5E/<H M$+7O.O/*%?.5ELHVHV/5K_IG"H
M(,K#IUNE7$E6U>7*96V#LT.G<8Q,G#(\)(BSQ!-'V+NY/^D"XPRONG?W;A;6
M*+DQGD<4Z"88]5U>&^^E?-=;5[^9F(T4!E2N@%X*FY &&W[=PC?,^'_,[AP?
M>,Q=D7RXEHB697Y:AP"(-0W.)6_0>!(4L)A6Y:HXW)Z! J(6S,GBK&UJ05DM
MBSE'OYQ0,X/)[@>%K8V4FNG+5EQ6GQWS3&V*9E,5,1TQ4W03R%$I#Q!5X>@K
MJ#F+9BF;W;EWP/NKMZZ_]?.R&1TDELQ./HT,#/]$4 N8 O?%[B-JZ5.B,+_9
MD8- %S-JNV%3ER@[JC""+#FE;G==3/Y7Y<<"-[G,2")%FRZNO9>]6KLM'*-*
M6X0S6M/&^SGX$N6*JU.>\XEZ=1ED&G9LB)#/-,GI5H%NM%&"<?8WBD]EARZ@
M8"NW9<><:WLITC.>]"IKPAZLFU7T]S.W/TJXBI3EG.@OT6&#.8%@#:A Y<4\
MK"R=-#76!$EWG(U"W<HG% FZ!"^6;^/(;DCRLH],,=@J5X'+EK 8N X[-LN>
MM3V/YG69V";^X2E%%ZGY%.>T<_NU?TU3.DJ%>NQAN&&W>$]<>W[+ADX=]D\'
M>*34M%^/> +^F+0T"8;[J\@UBTI&3 ,=TU4.BR!\$HPF<2:8:EZ>>[90A"C!
MHU?J)D<(#$ZQ>G Y>_CN1/Z=;@*'F6:-B:2PXZ\Y@WC7[$?R#<',]7Z*IOPC
M&6%'5>>E"62LFATCY^>1BA$-:GB@%<5YE]@(]3[+9\%D'M)RN %(]YI_]QT
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M)4\QE9-SZQH=XI16>XMTJP(8=N?((#0LZEQ8V(=S?#1[Y'2K!"0...4BA#/
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M?&*.>HBWG^>7;SIQIL"M&083KH0%LZ?XW >N:KGXRJZOAAX9^5D94$,4W>D
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MU#]^ 2\_8^_.\GK.,@*/F_9C-GM.F0%:""4P_AV7S*^(+MF(4?4N;V+UI0O
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M. K&%4PKU1+#[T2%V[21FX\X&',&8&Q#?AWU%&Q9S9#6Y(2%MN\P4<2TPV&
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M7["*G!C,2Y,U0##\B >,4N"B=CWH*SB9R#<CB;%/U.<M4S?B\J[1YZE6<=H
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M;G/<!LVCB>_;*T^K@MR-("XT,Y_1#O(@FSHFQF;==,F.$+DOV)*MKW4?1]K
MJV==!"FCXFJ3<SDJ\1I$$W]#IKJ.71&N< DQ-$X#06 F"Z(+8Z4@-B?EP\/L
MC4-:/]XN<]&CU!'E\9GS#5&D(,Z]L85(3&;=1\DKRGJP;\7!=/'R2.5(;8":
MS1<*3"K(P%I,[OL,[:&4V@+.29MSXNM0:Y<OQEW=!/@!SD>GM(!D!T<W))Q&
MMS%L%+)\DJ9'K*_5ZR!65I/\%/SL%_2U8_Z:S6D=T\>OJI)!PMZJP8'MSJE'
MAQJNOR=9"BI;8N%T6J3M5ESAL=,/'37BF4'3-JI"[ E)V"9Z8'@3(^</O 55
M:7B!A\[W#F?\ZF6&^;_!)]-#U[R &C :.Q-4!S6EQJ)79J<5OF#JU,RN&>.>
M-C"IQH7B[8NU![ZM.U^_"#W7R8=G?;V'5Q=6!N#JW"VRL2/'%(NZ*ZKS/N>
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M>=1K.=0Y*5HGV"5\4XS)7XH2^AD6P(GOQ7_W.2].?,98>8CLPFD!CR-H=%*
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M3<";,GGOEBVE[9.#!Y2QW\,BQ66'$2PLW6SF9.84V+PX*3+A,!4J5F0+.\M
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M;3Z\B:;QP_NWW#0^L!9; +'; Q!;K1OXD@KK+=*@OWSYR0KXT24*^.#^UU+
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M\MZ)5T5ZF.OZZD;G&GN8*^[::^XRFOV5C4[%78J[EC4Z6\!>*[M7%6<ISMJ
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MXZ>WRP%5]N"!F=12A8A2-EM,M1G0MBT\NA/(QL?"LI6%#98%8%MFF8>Q7<O
M6QS6CBQ3>UD5G,?EI8;G@-R&=?['^CFC&ON@S^]#GA^V5(T\=FS;9=NLM_E0
MV& K:1#R<A,5R:N,L3:=K2:Y:)+EGV$E)ED\^IJPLZB8K5M&!?+G^<7YM_,+
M!9=U., @G4ZSWE. 1HJ[-L-=1K.N*^Y2W+61!;5;"NI/<=>F%M1JU+N*N11S
M;61!W=XNF6M-'I#R7F0^G+Q[3TW'-^KR,%;;L4+Y*@D_MEJK7P/*!P2TCY1I
M]AI[ "VWEY3IZ_6FHDP)*=-I*I$I)6&.],:.H.;VWG?[\>3]UP_?SO^[">?M
M4JRX[(VB)*QHM%=OTE&^^]U>4J;97;E)E:+,-BBC=W4E,R6EC!*94A*FT]DE
M8?;>T?.?SW^>?%!.GB4/5J/[V):EZEZT6<KTVLK]5DK*M-K=E3WUBC);\26T
M>W6CRK#U>TD4O"(H#\]FLO,N_^_;Y;M+Y>!9\DK4Z>]![M$^4J:]!RT4]Y$N
MA#U@O%*T*2%M]$ZS;BC*E) R.]5F>^_@>7UU_N'-YZL3Y>-94D^T6RHIH9R4
M,7HK!T\49;9"&;VQ\MFJ*+,5OVA'*;-2$D;O[M)?O?>NGK?G5V<G'Z\?E[Y\
M@#:XNKDJVBC:/$*-*Y]"*>FB9*:\M#G25PD[EM37HW?*6.;WB3JT>D4P-KQA
M%V_&%8>;\ 8]]+N'P4(6<FXY=G?E_N)+KKB$,JK7^GKSL;E.RRU[QY=*Q:W[
MQ*V=SNK%YHI;%;?NB%N[C\Y65-RJN'7+95[&RO%9Q:N*5W=SLVS7]95S)S?+
MIGOO:C]Y?_;YBK!"'KYX7IN>/W244W[Y@'?UX;GVDS+&'H ^[B5EF@V5M%Q*
MRK17=B<INFS%:.K6F\H=OV5W_ [][Z)E5A-VSO9C;,!%MN[!WG.>MA\E%&BC
MUF@9C\V47,>F5.-&K^1@S^5 KW5[S97!(Y0<*#G8-SGH-5:OL5%RH.1@O^3
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M3B+]5+R1)X#D7Y0&O&N<PXZY0.:?H@%JFCGV@?M^B42.H18Q:^3!=M],M2B
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MQP=Q".L(J\/,@C)^' )I&*]L9V*C+#3_,ZQ3K"_ JCMVS=B#+?4#^A=I"&!
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MC?-Q&$\F( XP.$P!!@OBB1 YSHTFC<+KNP:.B^H"6,RT1LGY<^.#4-2U\_1
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MD(P:<EY\TEG=Q^E)-^'[[(ED'O -8J&1=R<P,;WD:.ZCYY1@9+JA3\9':L2
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M%N+E<.A8:(\B5E;R?:H&Q/<U::AR[$OX)340%:^S4WI867I,$GIH1X2A-R0
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M,*89@VH(LH?@S,5:>FX&/O9"P"BY R_%KHFO\#O%81OFL/3P :ZY191B9)H
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M?HQ\%T3]Z5>1IQDHO5YYY4:O9X3E%$Q[YH5/L#Z;]6Z[W**1RH*56>W3V+Z
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MZ.1KX.K:1P1@3""[X2>"9;0CQ[.Q9)17YIF8V(A=9)]S1,L!;I%/2.#8*2#
M\G9"4C2IH \H0FDKEN\-'4R.Q MO!%9[))JIRE_*MZ>#\HT+.:@KDVU Q1[6
M5TIB4FIV'6K64&KV\-1LDZO9U37JI17YJ%#UW>O3IM*G2I^63Y\VE3[=5WW:
M[K3:_88.-UNCU6N^&(P##]9D=/[7ZK>X0GWK!"#*9+W>8XWJ!M=G-:G!-F7N
M<JC[F5:8VU7A;]D@(!UN<"7>S2OQSB(E?D\;*:7$E1+?J!)O*M_#_BIQ811W
M01>U]-8+N]5H]MI-,(J;!M?AB0)&]":.J\1X+:#4*P)FZ3Y]N8QQ&WM,'@4Y
MK=BL&SLP;966V;J645?OZFB9<$;-.#__/]NW_EFH;E#-S&D<PVC"V]JH<5H-
M0V_:O1_W^#I?3UWS+ER#EDEL0I+O@]UD0S_L]5/IX&%OP8$O/V]A["(8H2R,
M+5L8+76/J9"%\=A[3+O=[S1!W)O];@/O,2T10WUMAHP 3#QLC28]12?Q31Q&
MFLZ]/]W4^Y-1!F2*?''<,= Z @WP*8"?U+0/-'D$*0U#WW),WB[/#/GWC"UA
MC<R\/:N36DHG'89.4K>> ]1)1M8_?AU/)B[YK^D>LST-A0Y>[/(L$?T1IACO
M6(UZN]__7;MFGN,',#U,^$37.SJ!?(\X:$!J)F*:'3.TI5O/GZKNE)/G(-2=
MB@=61]W-WKZ6TW?H239ZC=X+N]_0#:.3L<'FE!L/P5V84TUOT9V\L4+\[7/]
MNJZ]-KT?BQ5=)$VQO*)[*Q3=.]<?P*](D04,]%?(.'[=@G?7Z.6)9L)RL>74
M9"CU9$[IG>!D A;Y2^C.[!Z5RT[<FO+0E*K>JJIN*56]MZJ:_VEPUNGSW U0
MW'T$L?S)?OYL=;C&SI0A\$KJB1-1-:=O_5@]W6%6=>TBW4'9?%M6)'JCKE._
MD-8KI5 JHU >EPO6:30;3:,G<\'TAOZ_KKCJ"I,+3<"QE_9G2G*W*%DH:?U*
M!IYL\;I*7$_OSR?'(@>N9B3Q$DAUQ:RFNC&4NMES=</_U/O$0=T78AEZ0_C5
M[KTZ%B88@"74T=Z,)ZX_98R;-]K'&&:!40/L'TG723/STT#^]&02.*[,7.HO
M[P83/YA15 O=8/\%.RJ"C9L6JBHPC?ZK=%4%=553Z:H]UU4B"H"I"*U>]X7=
M;QD]'<N.P#IZDKJZAJ<)^!&=5K=9-67[$WQ*N(U(T<#S.,(B)89JB>NQCLR#
M7S)CLRUSZY]B;REO?D755TNIK\-07TV@LM%MO;#;K49+[V;5E[S:I5>YJZ2?
M*6JLP+$(DX_4U6?/B<($Y/]>S7>/DEO.7<Y565-=!0]7/[65?MIS_93Q/#6Z
M.<]39T8]R3)$E/\RZ:K$=Z5<5^O15W-HA3-SW3P@82&RVVY1"CN+40H5WN!A
MX W.0PLJ7+^]PO7;OGW54?95273+AN]_K6:WT>CW7MB]1LN@)-;$VUY<L7>?
MM?3!]_Z*@79#A]JZ@<$14-+4>,*\D,<%BYQ9:9"//%KMASQ:$B^'/][G[>7B
M ).N%OYF-I#8Y)%( 1+!01M:2QAU":Q$B_]D63>_,NKV[Q+:54IRSY7DHO0'
M0UY""W4DCS?2+32]CY(B^3<SO>-_FQ;"J( J99[I@ XPFLU7&?R:5%4UQ<7Q
MR6D2*@G_,#123ZFB?55%W%YKP/\S>D;[!3?4VEP+O7<L,+!81MOP-/Q_Q^Y4
M=-5MD*W46B$-_\QT0-0=[3KV(A^L+?X<:)!Z37L?V?5<Y@1(?NJ'0YU!WJU%
M\_K@WV8Z_G*=U5C&^H(96R/QJXXT%O.:KKT+J*U/8HHCF,Q-8'KX8#% %E\2
M6*83T/8X50MDR(0!)PO0NA2B5J4T<%]IX'W5P W=Z'4;_7ZC88 RSGQTW.\?
M\P_KT4\@J&B@Z]W,FG_OF/<+[$)030G"UE+Y&%*+@\K3^_W9U+)F8Z'*RZED
M,@*OV(T31@+=*VG>E*C#ZV,]HPV;S>9QM]MMZ,KP*[G:T1M*[^RKWA&67Z_1
M:K0Z76[Y-1O<\KLPO7@(BXO!DKNIH7WT@Y'F00ONVG3AFCEK?/':S+P/K5<C
M)%!TNXW]Q762 HVK0(W1;^6O7L@'WK\_7:66J,?GLKQZ*[+HDKQ99=8I_;H^
M_:H@A@Y+O][7H>44 Z@#J?DJKU\7)J*H&[-2K5M0K0HIZ;!4JP@O7Y +<$G[
M](GJLY;^!+X%"]D*Q<,;U*L+@R[*;E7*=5O*5=6A'8:.U0U#[[<0$+?9AC];
MV42>!S*<=0.K]V.+*V&1H".R<[#>@M0;UL$N59W! ]"&"D ?IKY1A6.'HF^:
M3;W3;H*^Z39:AJA[G:D<X_7VEQ-N)^0A01Y?>E'7CLQP4?VLWE@!L=(HU%7Z
MP@OQHEI]397I5U5?J4*R0]97S;7JJR)#ZHFJ:&'W3Z6*]DX5=90.VG,=U&I@
M4\WV"[O3[O8Z7 =U>EP'8;T7KA'U4()0)*.X],>_?0?4RIO0"OP[4#1A%,06
M:2J)NIMF ?-ZAF8MT5S70-$K<V@R-W&+@4ZA:L650A/1*/#C&U B40CJQ'?=
MZ;%_YZ'3)QZ$CNV8P;2FG6()B!]XCCGW,NW$^BMV>+EE#?UL->WZ:OZIC[3Z
M2X^)9V@?%C[WZ6X9I-W47]<I+-WH]!1JY6$H6E6W<2CZMM4VJ$-#KZ5W]?;2
MV$RD'1;ZQ&;5[#*)R_(WW,LO&A?/:B %KG0@"JBG%-">*R!1.-9&7=1JI(5C
MG<;_J".OT=1UH]-9[_6S0&<M5U$A;I^SM12=U3+OE$5468745PKI4!62GE5(
MW4TCOZU?1^TB>TWIJ!V ?S>4CMIS'74/HJY1@/FV5-F]U$NSVN'-3V;%%%*4
MW0BT(Y\01**1Z17?PD8.&\[_\/G3$'559L2!Z"]50;"WBBLUKOJ-MIZ%"3&:
MHD3_FD41;P9*2FN^,GX9[_L%"^""^'=S/'FEG3JLIIT%== /MIUJC?>\,,$/
M'!;6,L7\#SS("_IY&.&:32+AX&HM#1HN2_H7F&DKMS]83QQ39<(J!,X-ZG:.
MP-E5")P[U^P*@5,A<.X7 J>ARJ)VKE4V;"]V&W#1;70+L,TW82W22!_-H+#W
M<;YQ<Z[U57<5ZT] UG67C6P6@$;=:Q&^.%$V8<ELPBKK6%4=M>^J5O@4NQ3D
M:+VP6XUFK\UACEL/!SL^LF (7YN@-T1T]N0.O@(ED^LWGXV)T%-;ZC QTX9Y
M3NVV50#W0!29*KNJG");M;4[UV2&T6BUVWKSA6WT$;W=#GO+);1UM3=_Q4XT
MO:^QH+#[&E*94%(PC[3PKRB$8>BKJ":>)&?D*AOZ_<46X8, =;T9@#JC8_2,
MEE)195=1JM*J<BIJ?;:6L=Y,MX7*;,E0K%%H+JE0[(&H(M7=YH!547.U'+?5
M[W,;TDX+2T&5=MHO[:3*DPY8.Y7%*;4A)=922NPPE)@J<:J<$EO5(<7_- R<
M<;/Y0JSC?\O!CEWSI!545.<PF0EZF4#\SYR 61&HJ&S3P"5T#LGX@>VO:$5X
MB$L_2'H;O4-<-9H1A[ANS/\YO%7/F(N'N 6'27<%<W4H-P/5(:TZ5X+'Y37V
M&XTV2GF2U]CJ_:_=%;7%IP&SG6R%W@KH4W XD.O"#P+_#I&K7IO>#U$/&,!S
M->U#_80_=V*/'4\$DF\Q<Q)>5=.N[]"!\AY6J;W'&T? 7RW^P7&F3IW(&>"X
M.!8.]?[%J78>AK%\ *? ?Q!J$U!/4_PD8)&?3Z),.H5S1.3>2OD\''-YMM-;
M:P,054(OYG2E4I([5I)-U<ZM.DKRD;:0CC,VVM(62I"IWCI!&*6)T5*I(+8Z
M5PN8?R/5P#XKTZ4:8VJ\L[&A+YMQ7B*+LJV4Y5J4I:Y\S573F8]2F6A8PG^Z
M#ZE,*?J%*!'W>J4_^-Y?,:*7.H3S!U(=4+^WU!<]GS1)X2Y>*-U?%>]YUL!;
M66LE78/49;B2JLM0JJMJJNLIKB_=X)=B-%BP8\]/]C/3$>T:WBQ3KK>OQ^ S
M>645:=[[[HB\GQHJZOC !J7>"LXO>^^XOG\[#BQT<?]F- ^=&;9>=W?8^ZVL
MUUU8KTUEME;&;'W"C5O/WKB/FXV03?0^"-]?HD=Z&+(H[5DRYXP<L.@.\0_>
MN([VWG%=_JG0C+6'O)29_KSP$=R!/5HD/)#%+$MLD5YU3)'-4:16"<MT<^O?
M"\-]@P*+M;R'O04'S@&8A''(ZZ]*4N$&.># C\C_G[TO;6ICR=K\*Q6\/3/V
MA!+G5E69OCU$R"#;W$:2#;)]X8LCMP)A+;06V_#KYV25)(0$F$42):B.O@:D
M6G(YY\FSGQRY"U_N'GRZH8S65-&L[JB>EG9&#4&ZA#T"^;'G@DYW$+1A8?T:
M3#S)@_,S?XD:I'_U1J4DO"75E_3J^TV'L^^G[R#7[5TI^O6R=Z)0GY]"?2Z*
M]JR=%KV8N&<T\5PW3M8!>!8]ZV;/OL1I/U6$PMBMQ]?'-K+HI5\/B\BB9_TL
M[""+7I07ES8Y!4 ODO=?4-KD-.#-%MU[ 3[IZQ;BV4>Q7,OH-U@S7N):3"PX
M+W'RUUBM7N(R?'Z)DRXB@M?1*#0ND_I_"ZO06EB%)F;5[^-6;[?5[LH[#LW/
MIM;MH*RSIG.7Y7G6;Q[+*8>V?NM0H/I3H'I4H/JZHGKT5/5B"TY]"DZ-"TY=
M5TZ-5U)D?HV._+@X\I\&2"C9) 6 K > C+-*J,\HH61D/#D8ZG[3-I5OC^W!
MY#:P6%OV*MHY7R&7K)VS*-HY/SGC%NV<BW;.SZB=,V6%.) #5+F?.$ H2Y-,
MX<>H<B&H$6DKNB3XSZ?JAV!O[U/I2O'RK'6=\P%9GX:ZU31!V9CN$%2'SG'P
MO@E:B5<]GJ4DL;:<R0O.7!?.O,-Y3TBXL?7)E[-+375PI/8Z[CQX!;S5&OI
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M3'<[1S;M_]NX0QP5EAM_X&.Q++:-KV7;79COJ-E=M#EU$AYDT?(/@QZRN6(
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M8A[RJ%PM[_\G^'O3N^TJBRJ7LW9@,NY7]U+G7X#I]&I45>]'RA(@C_8+,"W
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M=Z!O=XY3U.@/]6DF99;\$+S9H.5^!Z=#>SSBD70[)E,<\9>Z88=L%\8.:CT
M@__3GT9PJGMI>8IAQ@+N'>!TH'ZXCN=[!<C:;;D,07]EX@F\I^2A8FIT(UBX
M?G IQ91&G)UJ6R!+G"FOD\P-[=H'>+[O3$/;_+9U89Q- .OF8+S+:P(/E1&P
M9OO[$W@I13R_1TT[LDED4TH7N1N4]W:^[)>/#JL5OZ)>$@GZ:KJ%5HX@I=P/
MK.O#INI,3\Z\HB0E)D+OS%HE.-9[8QI+#2VW65BN"+8]9[IPW%W U?\B5(!X
MT6KY%87!3"UDQPTFB]F#4ZDS=)O!%^_[2"U!JM?SDFI[(D4?J$XW:99FW^2
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MS_A9%)Q!OU1M'PPGY_#-5\+#)KI1MV4OI>G,Q.Z-9]EP;IC=R("!1@:,2WG
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MFFW5ZO^_#<3&B3##/CI6ZNRMIYERQ_H?E4N"*0^V5:_G8Q:^JM80--ZT?L4
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MQKAV#XY8Y,E=@-':@U&DE4X("XURC(<15T["GX09@:E)I$G!B!1@E$<P.I^
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MJ*%(1B&)M8UD;/7&EF2X%$?S&2=K;]W(>46A_HW)_$6OK]7[4J9+*U3272C
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MHU5.8+M>.ZCO[>Z4&Y6=X* !/ZJ56N,@J+\/ZI\J^^7&+ERP%C,Y=*K7#RI
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M_52*(M#KS=X1X6%L(SB47,QYS 0U2G.)310YD$WB0EU:._:>49=L(B5A<8@
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M,A%S-"0;6UR4I%R /[4H)O!0/O_4Z_YL]CV# SL$K[3KN*0Y"!)@M]=C7\[
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MMP]2Q>^:S'6'9]QI;Q_S@F*0-PYR00:G[ 2FFS3,XRE<_JF:+>_C07 LH#Z
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MYX0F*HZE14X8"TSJV949@X D$D=C[$Q"O:PM8/?_6E#$9HXBS5\X .1?Y"P
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M6),",E8,&9^O0@;0GP@QCU 2&X ,C2727!F$1:2D)'%,?*P\"TN"L75)42N
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M99D,I1."&TQTI'#L,+=:"BVE_DXX")WDWV_4UA^6;_'@X&MFPK[V7;#=[:3
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M^)!'@7#[(.RP"8' Y/,$,VRLL5P*[#GE,5B;>(8P,07"[8'PSM==&)Y[^?&
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M=K>V.2E0D-RVO#B1V[L8XXED!K1 <"91SKQ,UDO+62CG;-J.Y]D#^4SH( '
M2><D.$(3 J86B)$HC26&LER>X\'G;-J7!]=BB? FCGO#F--%&Q()J^N;6+A(
MV.B'R704(V-1I,3GY((EWK!D,/+&493-1V2I#R@X&RT8D8'AU$;O1?$W+H5<
M*)A^#$S/" >%G38V*.1([GR4S^:#\#=(V@0V)579>BR87E5,-Z ;1G"3\%MC
MX"Y2XJ$(GY427@@B3$!$.9 2D@GD6""(><%T/@A;GX']AI18^I!#^V3$]+F:
MAT07GE6F/9=46EBQ6M2'_H23*7EMG0Y 6/!K4\=JBG'QO=0CY@0#PYQ&(0UR
MFI#<5CR?O(<?4@B'040D*WG37LEVI-@_1H?Q541Y21Q< I3/QAZHY%10T Q1
MXMQ&%2,+A(P8IU@DY:R2KJ"\H+PD&RX5RF=D1."8<X\-,E34[5 \,ES GXX&
MH[CR(#.6"^4K>SPAUZ2P_8NI:L%SY<"^[TC-G<\Q?M=)D[LZ:Y[C%:ZL'F[H
M,,T*1_>#"-;X1%/@CN?N#"1RFUR,N145L_;;1O%?.>?*Z=,%;9[=S].E);:^
M'!C0,EHZBP3' G&G [)8*L24QU(D*0R#S=-TY"V= TN]JN5%;G0X'PY/,4K.
M"6-.4*:<P-[)K)KDMPW=@MPG0FYW&KG1$95""&#L*@UFKTW(DB@0$\XK2ZCE
M7&;D:E:0NTK(90%[3EVTAE@>/"A32Y13C.G@I&'ZVZ=K"G*?"+FS=>2P,IQC
MAZC-@E4+@JRQ%F'AL"62BJCJ/==(T@[DKGX&W2(K5:]ND#[RH"CL-PGXADLG
MC'0R).PB!GM"I;L4JI[AI%+]LB6L=3&G%*SCW&M+D8^,@E+P%FDI-2*"::-,
M,#3ZVRM6EUR<)8<Y"2R"4'0$*TXIMR8*3(4'Z\-CT(=WR*\K,&\MS&=D14BN
M/@J,M+8>8,XI,L3E-E?>:),L#M;=7KZZP'RY80YX9H*!K-0A\5QOE">P2 ,W
MVAN'L;M_REV!>7M@/J-!&)6!4,,0SUDP'"PW 'R,*#$:X2&&I>>WU[(NB7>M
M+&B],M'Z^_A":-($.^QU<HR+Q%URVGEG0R2,:$V_G7I7?"%/P4,SI:VWV$'R
M0L9H@'T,SL5'DD8V>."A"#^]U92D *JBHT4#7LR2F[/4:"_1QJ5#>W<:[=0$
MQ3TQB%%BP>K0%CD+I@<1$<0%21Z[U%BT\?F@?54!7X*42P?X69FA?#*.212D
MXXA[G'*67D#2A$ %T'ATMK$@9?MJ6B]+7MZ&]V<G9\=V'$,U&!_%8<[0.QW&
M(Q#=O4\Y+@)_Q^J'X\%H]&/)SVOK%984O>>1HG>?PVE<F!1Q=N%;GD 3@Y6E
M@J/1>V&Q$*4-3"MV3CHMC+?I@0!E3!VCB/I($9=8Y&*Z!#G/N([.6TGHVCKA
M'<X>[*,K23YMLWPYDP!<89@GB@<2C:(JB"BDDB2!6BJ6;^OPVYW&KQ92"Z(P
MDLH$!':N *EK-7(Q:.-M\(EYP*_LD)*?UWKHW@.Y%@?F*=72>,TI3"Z('*VM
MEE1&P;%LJOAU >Q# 3M; 1L+F*2<!"]\G4\KD#9!(9]"=B\:&YQ96Z>X0R1O
MT8:[^KEYNW\G2)]#5M[]>E'K:+"V"3/.->::LJ"DU(8YJ<'NOW]:WA4IU5.Q
M>7,FMNN)^ VF82>.=].^_5QHJD&:XM.ZH'M^$&FR-@F*=*"Y<D7PR*ID$??.
M,@M3'XP NT)WJ'F(75&R<UIF5Q#,+9B- CMMN5#$"NTB-]3!'A62EO<N<E>P
M_/A8[DYCV=K 1,B.\60=: 0/)D?@$L4@02I(1;$$DX/A#LQWB_)P"J ;V::=
MX#Y@[8U6H/%A:X[,.V4$PQINV:3O+W%7H/WXT)Y1$X1'G(RT"+.4 U]YPX9)
MSO5G<)(R*J8<0%MV&&;MV*97-D;P&-EUJQJ!IP$3RZ*3#*0$!=.#<B.9,Y8(
MAQ,E)<&N740DYO2"%YI[,"50HCXB+JU$ENF$HG%@-0IA6-1 1!TP-Y8@ M^F
MK)NE ?P]\*ZT$E8J16#-<$&]YDGFRI9$<JY88"5<V!:8STJ)8"43PJ*8<O\^
M:CUR)C%DP,3$PMK<WJ#A<&')KVLCV.^54,NU"%8%FVSD. 3K DY,*2I"D(+8
M$F5L'>SG:]\1;7+]#TT#XDP&Y)2("!-&F312&=)@E+$DV#618!=BZOG>>#%I
M=,N=I[84%[FR0OEY)M/=9\.TE#GLJ%,:!VXXU=19CJ727F*A!"TG4%JU8?X^
M4^^NBP]DXBX0V"M-]K9S136R,3B4X#'M6/)@\*RM&RI*Q;L5PV["5'-M!8O*
M<N&=I5(Z@YTFCC OBK';/NQVI[%+77 TEZ:((K>2Y20B[9Q R@CC/'5<Y0P=
M+4E'XH+=5<*NL]BXP/*^2WC*W3ETW<;1&<J58'^15%>P^T38G1&J-EDML+%(
MP:R!4"4>:>8BHDECBYU/0FH0JAU%<4>U!;VKGUMW79RE&L:)/!T/X%Z'PS@!
MY2!5O1. 1<Q?5<7A<# LZ78SF3FY^(0W+EIAN,/1.B^5P4J%$$FDNHB"=I'3
MEVM1<,BZ7P[/#TA*H-\,0T9*EIWG";G<4")B[ABFQF/+U]9%!]^2AE-2ZI87
MN9BZ"#HP.!T\#U193%/D+&G%90"U4"1!ZY#;G4:NY=8Y1AS(>2(1CT$@ZYA%
M3)C M4S&X%B0NQS(O4]:BE'!N<@<,Q%6@+3 TRIBJZ4@PA'?U"&;TJ;I 5!]
M.PW5[",EFFHD281--E"?2TQR%()VQD8-<ZG;V,]Y9=W]$]L?+'XWZ_<O*7+W
M.:I+&3;$)!T%YI)[;3QCWL"2QLY9$8KYWRYFPG/FOP@:MA*OD">1 #/A@*P.
M#($.,,%CAJ/Q:^N&X8Z2\V5OVQ=%+ZDSC^*1](1I0T+B7$9E;(C.*"*T\,R[
MOV@465#_1*B?D0Y@=&2S(^0*=#Z7P=5(1ZT1#0(GICECAN5H@NQ(75"_HJFQ
M]X&\5UXXT)/<*,ZYMTY19P0QF@'B-1,E"-$ZR,]($$]UC))%Y!S\X"I*Y!)U
M""<<F>$^$IH:#4*L5IO8T/MT]=F7'X'RZW\FM&:01P/M3AQ/%P"HKN:E@4L0
M+[2XPU7\XW0PJBO9_US'37J?XC_R+"/V@N2WSPZA'<7\"4 XY'H1P7A^GT=G
M):RM>S"OL0[C1*R5)'"KC E2&!D-C29:I>@="AI,,R^LH.L3D85T%Q-<R5D;
MOY\?$$DIHT&CP(-$W)* C)4!1<V%<U$D+.M"9J0C;NEW]GU^G]886PVZ<5<"
M]/<J8\*=8C3'9W3D6!/G.'%8F]P?3[D[53SXAN%5X/\($9I+^-.40I(*+"TI
M.>($9)95S*$0)#8QV2#S06C)._A!*NLY G]I4'\?D94B6.%6LR 8ETI99HQR
MS"1*' N.WJ$H0L'ZHX=X+I.\!+"PL$P@Y?-6;SP!U*O<8RAP:BS&P<BU=2T
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M5M*415$2@_G.'O[L:W((#JP'OA]^#O%.)+'SF5?C^*BHE';JL4:BH-IQD *
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MO0)ON!<M5(0CG)AEYC987<0-V[1/X]Y&.1.L\KYQ2(7VZ!^KDW,076[E_JZ
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MUT#V-7_OC3H8I8MSVTYA8S.-RUIF?)B?3TU]4@!S<2NXBGM4]JZE$"_Q+SG
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M,H3;?.@NEMPL.R'>6N'UJ_LA>H9C3MYDV1@#@W#.CYX=CGRV+92+-&B!5XX
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M\\A@W7YQRK/U:D:C5@WP_R:SYK)V$\%!+ZRGNFFFP6T>8"^[M%*K4!_='Y:
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MD _L,92B^-PE>1'JWSH(.D%9]"_J8'B 4CJU ?LG OD [ZP!TH9H.0G5>;T
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MX\6<F0C'U,2H^X';YLUNKI.515,O.4.HVD<1VC]^YMR YILR"14"+A<!#R7
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M$;3[$S1-6$Q4Z(884D%JWUWCCK2S]Y/%? ;KW%@_-U\<R]A9Z*(.A,0.8H'
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MPZ)([HSY0B6YCRJYY]<E-Q>8D9XPY%/,;(%+Y)*BR%DB5?3<B!! <@70!;%
MDOMBC0MO>WUXVRU\N?C]>8X*/+3=@QP]TC^S_5#*7IZ 7\N4]W+5EED1B'5H
MZ)?2*;DZ(GU,+/+76<31QK[@-B3,*!)&&<0QO-AD#$J<QL@C#\1'P"):D_C!
MY0,JJ\."B>^L6$0EOG,3W_/KXLLTLQ2S"/)J(N+:"V2\H$A)K# G(7+%EE9D
MC<KG;7AX)OX-[Z,=Q*(S%H*I-'FO7&F9B5]#\S*6:K4;WK:[.0-!.>J7R'->
MX<[,<>=@@C;L[ <,R**]09HH@3B+$EG&&:)6"!E$I)R*G(JGQM0BJ3"5\6$1
M:$,EQT\GQ^?7Y3A&JX)7"?@#-SE?FD,F,(^BE"9JX4RBLI1C+A?)3^DG!.(R
M#0,T-OY8].=UY8NUG:S'%$%.LTOGE]@]_;43EI>K8<W*0+(V-D!]:@\/UTX'
MT.'8GT;*"@SO 88;9QD(1\3&\_K%IM@GE)-$L4&4Z%P)"!/D""A76(? L0K!
MQ+"THDAE"7EI<CHK2\C=Y+1B-+,4XOIU(:8A)1>T1YX!F^%4.>12+BGDM&'6
M&ZDMSR81\_"2'Y5)Y.="6/HL5X:01V$%EZ'D/TV15T'.#"'GZW7>4+_8M\Y+
MZW'*6:<%XM@&9(51B'.FB>-4JF"65G2-ZED%E5?&D$61Y5DQATJ6GTB6Z]=E
MV3NJDY01Z80Q2'!VJ](Y%IL1[8340A"1Z0/F#SY163S?C&=0@\C^*-%:Y[N8
MW)?$_3"]_VO*\C/+\7C>T/YXF<ZJ]#_S /?S":+&]DUTDH?DD5"4(.Z$08XS
M@3 Q(BF3N'< [O E:(</KB0W0T%Z8N-0A9T5=BY,_K0*.^>$G?7KV!E@W_-
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M%RC-8Y:)5,D&3S&"'QQQGAS2 >3:$^>%D"92$@LHS6\E$K-[_\'B\IR<O+5
MC+E$9)8@N2"0W+ZX;<%L?3O$2LID))@LPCK$0\+(1NP0Y9P+3B0)8M9MH,N
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M,Z7_N<2?V5LSW 231+2>*!Y,-,GI8&V2S'*L)"^MF4+ASY@U8V1*7$>#+).
M/U9S9$F"/Z/RFDN5A*5@S9!LS;Q6_W,QZ5KI@'ZU#J"0@F0D8H]=Y)@G%P \
M _QD.!F>2LI6(,CT$Y1-!4=LL 9AFPMK&I=RJQ:+8A+"4Y$BH7QE7:XJ_>R
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M!,HR@K2T 2DEK)-,^) M"K6J<)&J=+S:3GL@0J),SRT<=CW);#CNQ5B"U^S
MJSIA.##JK9%2(2MS,J_,N1C*!"1P2-B#U2!)6%D7!4L&+$6Z2"(]%0L9BG(I
MK8^2UG'3@1@O7&(*N4A!6AV1R+(8D$U:4V6<5 -I?;;E4(KJ*Q/5IUD.I?J=
MN4"/^^VD$,X$A:)3&'$:0/W*X)#S//A(38PAKJS+54R*)-.O^<A!ED<.A4.O
MI]@.?W;/>R5VS0Z[=B;/'#"SAOI\YN!B[FGFD542(YVP]5YBASE96>>K1LTJ
M=[OT9+XVB9Z&A@PEN1361PGKN.6 @^#>@M$ = ,L!Y,\,K!42"6F!?8*WK9
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M :1B6&)LK<=*<4!"1SG17#(2F+=<V$>SX1(@YP.0X\28:H6E4@CS7&.)4X5
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MCZQBS58Q69JPMS(QN@2TYP*:=-8EPH2WD7&@]#8:^),PKS'UR3R5UI> -EM
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MB@1,ML1HJ@CUS#.NK!;C%G4UW-5P]X3@3L406 C6"V$ W]TGSG3.UDLD %E
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M#+/6>4LH388 :#02%!@1H+PLH=<DY8C\5;JR7MB9+*W5I$K O .:!"Y-=A*
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M$"[4:K^D:C\;TP&*S"Y+3K(4F8"(F=@L&*$1<J2(YYRK2V,ZM=8_$JV_F8N
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M3'(NF5&<4(_X!4(:8DJ=1\,R4FO$.%-*FRTV]Z?&LAK+EM_?C&63$/',99>
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M":*91B:2N$2-!_PAK ;I(@_%\Q!-#O/Y%;6^K[:^+SY5HK;I2Z#A,[$%\,*
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ME8V&)4=<")9 5I(X:B+1%A1RCR"3T,]><*6:ABZJ--@217J?N'X;KF(T B7
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M)GN4B_M"<C:(USYT>\.7\G'DAO !)/B_PEDOQP)O3]S&@S6VL[D+/@73#-N
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M_<HHLE2_N:C?F =.JIL;S6!T &M'D?#@.7/+*;(V,92\%3;(X(2Q]U&_UU\
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M]D]KW=-&A,6-KO)^(P?DDBKR$]B(R4Y]%_[>@NALB\)_29,2XUR.NA3F ?%
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M39Z %>4!&:T8LE$2'&/2T8.O'$&53^#>G_9 Z1<ZE6.O'W#E+'N=IUU8_2D
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M%HCGU)H\./@]7ZS$6NE@JEIBK<'&K=*$N,8Q'7OQD!/$I:,(5*R L$\"S(%
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M3!\NS'HQW9MN9@<A9*W>,/RH77B,"YZ%<M6!='I]4[8,AYT=^E4_\/\U3SN
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MFU;$U/G90Z?A1EC MT[1OA=ANRKSDV3I74K<__ =7\!$D2>?J!_,U7<#/E9
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M/&UU6J=;I'DY>]9S^*5U]0FN>X>;5_ZT=?J.'KUMBF;[,XS[\^7^SNYEDWX
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MG'N?"N?"'WOEBOQ=+<CO:3UVKI>CE@CWDPAX6@T\_'+L \_S(#1R$8-$D#2
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MK:D%=LIIJI 3D!8^(A6#(I$81[Q)KN.']T.L_28K@^QEJ1PULI>)[!D-1-A
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M=AF"E5QHKBC745OAHQ:88:M4+@C]B?#L!8*]#M[^>9Q?3N,<=IJP4CBD5<2
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M!5@KPW5#UP@BTWFA"5#F4YC^,J]P5VW&9--:@>#'1N!>JB$@2B:D9'I>"*N
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MI 4H9(V>Y4)N >TJ+L=PO<HYGM*\G$E$*W-@:7 I(!^@($TBJKU$C ,8GVD
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MO7_JV9[O&X&K4Y]1G5#'U/T@C'3N,6&XCN^Z!(OM^.8MLB?Q\D%8Y]@D\,R
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M!K4R8C,6NI;.0@/( C.83IE#=2M@C'/#!/H*1-6RG%N):IM)\S26OUN)7CJ
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M.*< 1<JS3(@R!33B6PKL_W=F_7KYXG\V%@OF3%W\1GQVP(8VXCG^"M]0T>2
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MG>N4"\T#.%<;0[N<@HRQZ.97O1X)D)_[9+L-!VZ_&MM+O!?[?;5&;CWSGA=
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M!<59ABA<;6^J2 J22ZE:MWE<!]=:'.JM0^VS<6A'A75-I>^#%B_ 96DS>F'
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M-'+1Q^"U!90I@(I1@:^^EW92RX11DLEX?DE>PAV2?ST4?M_-(O?#AF9NS!:
M7].WXX^341!>*^<D1$8;F:IILN 3HZV41Y,T!NY;M^C?'NVPDM)_&O)NPX4^
MW)OJI4TG]>;".GMU&_=ENV<V=$\:++J1^_$*"U+XEJ\>=Y%?OT R"E%9KZP
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M2>HQ@HH$>)#,W[K:-Q#CHB297Z:IV7^)O<$(TE]_'0^OX?Z;Z(K"]_%Q;_+
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M2:"3,1KB "WG;+.-A@D?8NUV,@U@[:Q19BMT:+I#K:F6%G:HY:O'#YB%C)M
M;&EF2P-XNYG@4EVU3:FSH5YV1"&5.86 IZ_U"M\B$]'#CA")YU9FGKAU=FM&
M==O4>6'BRSXP9Q5UM,"8#V7R7VE[<G+U=3CX!@_[S'-EG+,02)QTY3))$^_0
M@ /<>9FE*3E=NSKC&3A[9#2OJ[Y!.[)OP;=Z<]WMI6[_"Z[Z]LL%(',05H(N
M/3$E.H E)RBDTIE+11YHXBI7[^_?"-CA4:6^/EJ:*?;U0:*8,6"8D8%07G+0
M9<PD2,](E"EFDX-AU7OFS4$X/")L(N,6^I.5 0;78QC.PXH!8IDJ3BB46;'<
M2>*33TA,82VEU*?<*!=@!=4O@7)X%*@A\Q;:E9WFW(TP#XIG*Z/BG/"(U,2-
MB"(_$6,PVFGJ>=*N]BSWA4 .CP:;R[N%_F0??'^1->.=LDR6P<I<L&+-(#4E
MFC0,$G#(RFI5VU!8C.3P:%!!XK7'OMRG8B2(WI7^1:8T+U=.$R>#(9G*$-!2
M"8I"$[7O:T;85B)8ZXNT]OB7APE.#6 <8&K8*L)?EAJVAN1:3 U#]R $@$0H
MU7A>0-0D<'0[?5:*>6&9=8U"T;M68+/4L KZ6T5@K::&:2EHZ4))4O8(Q,A(
MK.9XW&?@U% :U'R;M=><&K:2V)>FAJTBLU93P[3+6N-#B4*_K0R&0286+X[G
M+(%+4$HUNF1\':EA:RMO;9FUGQKV_N3CT<>W)T<?3CZ>7YQ]_N/XX\6#]*&W
M?G19_BGG_S??*X89VFE'WWRW5PR!/!B6EFOG$*^'DT:BX>9!8OE)_QM,*^[>
M^C%\&0QO-D@:VPG.#=/)=B_;N40S$W@"L!0H3S)Y<(9QDYB+*;F<<NKL!/$F
MC3/N+-8%V(X>8'L_C^W#70J L,GBGHDF; ZAS*+5Q%LJ"9<Z&)/1V>3-FK)5
M +-Q' L?V@DY4RO08\Z6H4UN7"Y9J)($JERTNG3^KAVO+,_==K>8+:O^2?AJ
M55&W<+TQO\9W$,;WZSRZ&@S'W?\JTYA'XS=^A)8CY1[=LU+$XRPZ;CQP8ITK
MH[ED*<</('RC//Q5&E&NB/$'HU&K*FQC;LSS>._GW/P^'(Q&G_M#\+VR@-*8
M[;XI&RC-<PD29::@!!!4&4F!OHR#@&<2!Q]K7]Y7 ?Z3G"TKNX6[G747,==&
M, <N/$4)<A"E&M*@RQ4YH8(Z;82C*M2^ *@"_"=C6U9V"U=0RX7T>#F=(*2*
MMDSOY ;!)BW+#+%(9 S:&3#9J=J67E-L/SCOJJBLA8NM(AD4Q[R T"<;#F^Z
M_2]_][UKZ'@PI4*-D>QC*I(0N&-;2[2/D9D0J<^U9[PU O:#D:J^LEJ8XM.4
M^6]O)]%I&P,$3W"3=40*"L0);8A/-C)!&:.JT65:"WO6V]W,^WDE6]<Z"JPX
M(6A5N ]F&IE2L9-8Z2UC$3&U>)Q#QBV8:DM--"F:VJ4PJZ/\R;J::JP]4.C\
M$AWQ,NKH#S_\)\R:2=]B_,./RU>SR34=FI/W)AB"\J$H%E]>$*5),CH#C?BU
MG<LW7A90;/[0'X0]K>JB]I2@#X/^EX8P4>W,4X,>AO0EUX5RXBF4])G(;08#
M8&PCRC1_YH_$F)8T47%XT(8RFJ;E2!X,GLT(5J<R!05I[P7GQ%#GJ$C*T_EL
MU>HW&5ML(+[3+6B+FMIU1>CCW!.A NZBSN(A7-X/7Z;;^RC0?TU*9R>$G!]A
M]+IRX;:OWH7Y<:N(N<6TJB8P#B\_;B7A+\FO6D=R+2I2\Z1L=*616 EKILB(
M9882%H)AUJMDFC60V+4"&^7'U=#?*@*KG1_W*%V(RW+1YRD>2D+B7J(# G&!
M.,\-R]%)XQO%XEY'BM5*8E^:8K6*S&KGQSU*U*-<<&5YF:$<0ZFZ=6A-!D&\
MBRXKKDJ)P^$D-ZZMO+5EUL(%]WO?'4X"JV]N[K[\6Q>&^)#+FP_P#7K3^072
MZ\"U)51H6N9D*V+Q.V5VNA76<<1>NR-/,V0_C,'4HL):N(6^@_8'^-'U<%KD
M\A3O[:R2!F!;ZH^Q$M#==,IH0^/+2-6:NMK<NAJ!1BLIZ: -40+02M(FX!:+
M+UXRRC %R>AFN=NOBULOM-+8.VJMHJ4V*772_WH]'DTDP&X[I>+:A3&>1!<5
M"B$$$A1D$FDP2G-/)9-M$>@IG.V71+:HR&64V5 ++:2@+H+&9]#0_<HJ4$:D
MLNB,^:"(HXD2%(.(',][)FJ7RSX#YT<CR#I::&,'Z?9]/W9][Z0_&@^O[P:
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MMU>:/<'P"E_X@N'VMNKHJDR>[C@:&"L>KO+*X<ON\7V,^.[KP)0&[U20C5H
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MUJ(),<ND7XRQ-'S67EGIF^MJT)Z@:Z=(7D"\[ ]Z@R\WMWG[=]6"WAM+@?#
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MF4<KO/6R>@7%&N=@6Q<#+$1T0E49@8P'C$S1$&=8)I'S;)UQ@O%F+15?[\7
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M.C28:*G&35KQDJ],%;&):J*TB(KG2/5\LOG&)%D3ZNOGSS9TU()'<2^&:<0
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M:5>7QESVK'7.18H48%K*Y)5U')*.RAD?E10K-)YK!*5^)?W=S-L/=[E16<O
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M$LAL1*#'HGB(LGAODSE''>^M5$9%HJB8M" )Q*-'3XRE(5NE<^"J$4T:/.P
MR%!;I$]5;FM:&P7N1QB?YMNCKR0NC#I!R)R9M@04C[BKH?WL?8ZEM$M*'PW+
MU5-^7D;UNMG1DO2?\L-MG#>"ZSS-;]'\Z98H3FDH?_.'_]Z]NKYZ,Q@.!W]V
M^U_>^J_XD_%-)TEJ>/"6).I$$84FG@.0[%D2U'DAH;;ML0J^P^!,:QI9$&W;
M..#Z$&R'.VF=<)EXPS.1.48TC\ 3II'0QG"CJ]_T/GS^X:E_)8DN4&_E:.IL
MG)X!GE3&#2N7F$O0>*"98$GT"0V8Y%DPM=.'%\#87G?DMAV-U:6Z+UECC]<Q
M[7>$KC-G*1-J2DV51BO7@?5$:!;!JD"%J=\X<A[%[NJM-]3KLSQ96;ZMWZY\
M]%=PVXJL :Z6LL&68=I-(MBF.GN6 AL*?)N$<)E+1A,0L (]70&*.&D\&B;<
MB.#Q;:#M7KBV3807$KZVQ8-5Y%Q1_Q/W]XAQ]30>\B#T/@F-O"OSD__P-Z@O
M,\M*$AJW1?1L2#8"K5;*RZ;H/(%R@R.L#C',^1%+P@SK(MBUJ;BN @?;EG[%
M'(T)Z/\#P\&G <KP?1E6@M94^6<6.&FXF*/K+]>C\<6?@XO+P?7(]]/%G_@?
MW[P?7 ]G"\P9O"K#N(-2JDP_B\1%88GFT24TI"7Z2HWHM0VTAT#%O=-J[9UN
MNHC/_='TIN@,O@UZW] /?X#WN-3[ ?3G'/<I=L:YI;8TC@>;B)1H!3I'-;'1
ML\R=UW0^</)L^'UM((= MFWJHH5$DP^#_I<Q#"?AP O\;Z9S!DI>G(8R!];B
MEBQ<(CXX=#IHB@I<4M[4SBE9A.-0'*>-9;P%O=\.!FF JB7':3&BW;A-FVOL
M!0IL(.X6W*8EZ+)VG!7+S.;HRQ$GB5?E*R<"HY1%4;TR8ILD>,%EVA8'5I%R
M"[I?<H,\.YT,<RIR#D2S<AU$,ZX\E[$SS*;@LO"&UR[&?A;0#@JT*VAMOL-@
M-9%OIT;FON?1L];S:>AUOTQ[-VY80+/^ RM4UU1:[5SI#;BHT:UEB04JE<9-
M _^-'F\T261F:6>S1[=3EZ.SC<E:20)+I64O#22D&(@66G+@+IM4?XKJ%NIR
MGLW\#I%1'R2^?]9F(J.*Q%H:B3$Y&\D90W7]S,-?B1L;Y.&OHHW6*WCFJHL@
M4IZUC23'"--+-^N9)DPPYF/TV83:C7U?1SU7/6YL(/'6KQ<6I&1^&L)5]_KJ
MJ#_)WGV465-&(5,(U HT')7FG$@+K/3X0 D9#V!L2;MK=S]=&?(A<JI=O;7@
MJS\X^B=96X-^O!Z6SJ$=IE12W')BRA^244.\<&@K>JNT<MY[73OY82F8PZ!*
M'5FW4-PS!ZPC@H\&'TF"]!;=CN!(B%D09K(R4B>?0FWG? ["02I\);FV4(XS
M!^>][PXGB;MEI^H-1M=H*'4D*,.4441F[HC4-./"M2 .=R+JJ0U!U0[/-H!U
MD'386/ZM%^5,P]-)1QE]LJ2D=Y<R9R"6>8>&4:8R*4OQX#K\++AZ-L+J4MWC
M+#@G71F $@CU'+<TF7!+DR@@Z[UAOO3^,.VVU]BWRYR5]/IR%MPJ\MUJTE,#
M7#]J%MQ*.FN<_;2&P+=)"&^B0RL6H0E?>KP:P#/+.B)$YH$*;:"ZX;#O67"M
M\& 5.>]-%IR5(4&(GC K&+JVM!0#LD24=(YE1@7-+P;O#R4+;B4%5LF"6T7Z
MKS(+CCO@V?),=!(:;3/G\?05D3  Q9AU7%/?B%X_6!;<VE3<.ZTNW>E:NJR<
MZW!>FMB%3<;7K/#I5:\AFZ]COMV?T.B@JFAX0/^'.T>=!>4T@&"1^M!9X3F;
M9"O.GG Z_X31O>?&C/.J#*O67DP\MQ+81\]-26VBU(S19!OM#@T>MGE_V4<?
M7*1T_#WVKM/TGN)^KD+6(4M?YF8S3TO8F)*0\?VU')3WR:0<ZH^$;89M>QM<
M*Q1XVG>V!96T<)WX$,MIGKQ?CV\@.D9J&\N]EJ<>[8 0$G&<)A*!>B6SAYQK
MF^@O@CHPLM150AOS_!X!G [M*%76DP+]Z)R2GC(25-)EL(-!E)*CW2B=MQ:B
M-;6+WI_#<]#<V$#T+5P#SD]LD<8F\$83.VG_PT&7U A*-*>,(E^IJIZHLK-Y
M.+LX1582<,4;OQ?6.@UA2NHC\VAX@[-XD(4420 OB>%2RL Y];QA"<?S#VH[
MI-^J8JM+<E^"_ MSDTMY0O9.$L?89.X/VC8RZ#++*3O%K6:T]AR]?:C:J*_D
M)N4;JPA[>QG[35#]J.4;*VFL6>K^.N+>'AE$ !884V7F5YDJ'($$;C-1G(-G
M"!RJ)P?M>_E&"QQ81<HMZ'XN7^$V+,<8;FK6$:M2J:G6BEA(F41K==2.6F]J
M]U!;"&1ORC56TM+S*2%KB+C],HVCMV\___'YP]'%\;O3B[\=G[T]_>/3V?'?
MCC^>G_S]^.0C_O7XP^GY@^G5;R]]_PN,NOT'8\K?^%Y)>QP-\M'IVY.3_BR
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M\K[BND@7NTT'H1HZUO<*LGW'NI&A)D-IN;%W?;]PJ7 K/7D8SFA->XA?;A]
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M]-%D_I\XO]K!3P6/.7&)P.MQ16&B#9IK"<YY%GA"6YKW7QUL,"]N.NP'+.X
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M8;7'2)<-LTY%9#&HVBHK2PLJ>P?><08YD5N$N=YT[ WUI??H?DV1_0#./M%
M'QKIF]'W4:;S01WG*9K"42@-NH1(QTE:"#PJA.@="L:"4;EYD_NA!_5K0NP4
M)D,Q*./C XQ]!GB"TZ_\5$OFE4BUH)ZJO+*4(6H;01AT&#G+60R2+SW(:%XF
M\G</C'TB'-XULH^CV;]^FR*^'<]QBK/Y<DZGF$Q,'GBDF:QB9+2W.09%I"("
M*=_A7I\;[AK4RYP >P.3V_- [_T\N#@-6:\Q:N. ^5S)M:S>#1D)3EIF8A;:
M%/;4IL.O0_0>@>;VY##[/SE6YR#)E.$R([@8:!'@0D"DGR%&E :%8T&))S<Y
M?AV?]P<T W2C;M=_)F6I3>T_DVD^@ZJ)-(&T#-;R&(K2(DO;&OTOL!G51J#>
MB;%W3:6?3>>G'^NX%C3%J-$)SB4(3($DITD7; ET8C$D>;32B4ZEBNBIUR!*
M/UW!\Z<7/OW&4KUL/=E4YPUCZ)="K%@A7<3HPU7O H'V))_':>4;*/^F^3;0
MW)"&3+($GEPM36AJ'U\%/C Z;65: TMQ+*IF<WA( ][#KQ[ ?CT4UMANJT/
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MUIUS@I7VPOG"09MZ:QA$+:G":.9YI+.SEZZD05@7+X43+&V0PN4,2G$#*JL
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M0+JA)7>!.(X<G25_B'%.[I&+$?R"":TP.A,#RK2=Y7-HI#W"#'^R0.MCP $
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MRA>Y6Q_O1^-%X:S#_W-.7]^25[+LTOR6]MA4V_6>INC16.: )XN@2E+@K56
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MH9^?NXN67ENPQ:2-(@?P.7\:_NNS,)N-RBB%R[BC\5IY)Q"2)/=#^:C!^Q#
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M$4:)"*+'J#-ZGU$'8[R^OUO>?][[>^^]ZYQU_CEE[V?OO9[UK/,YY_+?Y2*
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MSY;4 =?=1V"5^J)DM!A)T\48NS(B#]NZ[I-SYA?%6<8[=T-*T.$ NF^N$(K
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M/%;90I;B^PL#Z=F3!VT+L]'%VJ[4%@EE$J# @SN5<!S'21U^SP[?6WW^&#J
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M,:PJM2V7@/?WP6K9>>$W?YO?V5EI^B3\PMO_4^SUMY)(@NYWHM8H3)!R#>7
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MIX7Q0V >/1GWK!L>53-S1(2=>D;7D]],IRE$WO,C@Y6<OCW:=4<:'-,V*)\
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M:3&4F5[IEK):3W82]GW&A.C8<AKJ20+-XX^]-BA%%:_PZ.W"?@F._>!+P'0
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MG=EMC,J&HA:9PMH"RJ;=U892?:0'*_QQ81YE#N@>-6#_ZDP%OD>B\&?LXY;
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M+O['HN!]CIJU[%:&5P'^(Q:9]F[DY__H.IQ# =MX[LA0;K*?K7]7PWY4U+V
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M,UH%&C]0)F=PF>QN@KWR2E1BL8,.".&G?<L_X>X<8H>CFT=ATIZ_.>H,0,]
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M1 YMMR88'4_K548[Z6;6IXF/KO_XDR-3VS:F.G7R=2P1R!DZ#;RRE_7GFIU
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M+TPTO&_AR?]=0.-!07HM?2LV0<(D421.FFO%=-SY1#ZB<BOYSW@R4.-L!LF
M;&LG0?X*M2>>^\2KD.3F]WMCJN0RZ21?2 STD66[]BNB%1(-9)>_L _D=S=D
M1]5+"X>0'M(VM7="\]1W[5+S*:>&"83Y*!-,\_CSM_;2=4=<:YL5Z!G@0PO3
M 2Y.)<=?YG;HW3'JC/BQ!MH5_(DCV&8E$A+_8[$HH3/$+&KGX1Q*UE+V=<:.
MT>NMX:4I*$5J[O(Z<DHE/P/1";U6!<,V)+.Q?U7G%%8#!+U04'W>;,0"P<O&
MYFB-5E-E._QD[J38Z(BE"$Z_!LMS3KNTL ZKJ>2=*.K65-O3 =)"T5"*=0EE
MXWF+7P!L]QZR>E!N<$9(^[4('0!5[9LU7 +EL5Q&2A1M5I;=M%T"!V(4:J&#
M-CT9\/:L^HD6.#NYU&3\P^YB>_N%^W2 ?]+1\P865IQS! Q<@_)Q]T\-TGVE
MMC)4+/T)6"A5FEN;\V[I0^")Q; ^?$!J$$+F**<#KEG5%RJ4!0IHYDT&EVZ9
M/9",> IHY0=(N.0V[_;]T^7[G<3ZUL> R_J(=S#5N:0G_I3OI7K(H?9U8(3[
ML/G%OD_O/V]B'53>XZQD.&]FA @6D_J')HMT1V4$M]L::.CYZ=H5CZP.[5-@
M@A#_UX.9V%*O4I@]V9]Y  [-(R_H1/BK=QHQJ[[+JQ_DWF&QF]8(VI!'J<M)
MF$)FK1CY6V>$8O IG17G.FMQ7><MYAL!2#DU"SR26 "Q4K\T">#=BS?17+L:
M8PQ\X^P4-7':,T. /YYN3E8^FU1:TO?U.VC\![D4%Q6A]I)GPXHS:[/LMN?E
M8%$Z !,7274?FCX(&8-)=D-.D>=,B62F5U\;;ZZ/(?6*BL8B4<Z7JSA1UU5D
MJYM7*1GCL-';!<9JK3//[?D?!7?\1@[>@:&71%:#-3CQ<\1/,',BN!\/O&!%
M+N]54IP%OH_Q6G_^1W)H;&XM3/GOIT79?CN1GL@1B]H'^#675['5.8(B$I^&
M2MOL]E7HJ.UAJQ$!(&C+%#I#RU:-@5H27TP7U_3VBC\!>YN!U(;)=0X3L[JG
M$.O\@U$MKS/Q94FW'>W7+VP889.WJIV'13,:+J']BZ;6F6O7)_A2UV+RKH -
MS222^]X]VGF\P>_"?+>B]:FR<'9[KJ&Q3:6YAH128Y%#9@O9$:?W4-3C=.>U
ML:X+\<@N+U,?\-L67N)L_?G20BM=5^\KA!QGOX?U.I\BQ2KD4_#HJ8<X@S#%
M!'^\5D1UK[%RF(<=JV+BMWB%A3$?@8TD(IC03(3@G3L39%M;.$C)[BU"8_'M
M%Z1?>C[2ZHM9@O4-OSU)JL<A#+QL^B.)^\(5NF<SHYH'-B?2)@YKT^:\ZTYT
M.7D:[*;,@JP_3L[UK30,:W!.O/K7]LK_K?U=B'KH5+8,J2BB17#MXGS(2U?>
MB.7/#O6Z4IF/:ZSC?".U;G9Y8OR%2B55T9<=S-N,OW_4UK!-Y?P1PJP!ZX&2
M4KJ/Q[&;VU]<K;8^^L_/<0T)M!0%4C,F#J<^H8IFGG@S<UM;=#PH>Z!:X?!7
MWQ?_H_*:$WV*)G$0B0>R%=9FY#2---G[7GGCY0B(>I2BW6P=[&3,>ZOLND5U
MF/D[+J#H^5,CAE5>=  W30=-1F'XKLB]7K(ED.<H670 ,]+['R5\.=-!$ D:
M+:_GCI>-K)ECT\7O$P=+/=Q=RVVFISO4.[TMIG]7?I=>2+QIN.QXSE!?844L
M>3N:!B9QOX6%%-C\(HONVD&_SCYX-_G;TPDQ4 =RO1!O OMR6XL4;%:]VI<_
M]L?X5 M*I.;0CPZ(&N8W)=TCCMD&I2_9IJ2,3[L4T@$LBLZ5AA#E];D:Q=A[
M7IGH")6$#[1]PMC7Q!:,DWPDIG9\X79/V*9EX$G#1B0=T(,"4%U049T_;4;R
M%!J[KR6?X#/4BIV/3)9Z]Z.+)EO,#W5^'.?&'B6#IS6=C.M:N;E9L[FFK6I?
M(LA<4QD&TU;, 6,#Q.DN55+:U4Q7S>#YF$!*/3H#E;WT+?"U>5F.S$@#W+MB
MR_C]EY[L]R+BAT]3($%FH-3<EN=0QGB8>3% N550K=;CUY'/]RSUK]WV*29P
MW"*0&7<%ZH/F6,OY4[FA(N*UNJ88& 7556@UIW$ZRCY,*[R3((M7!)I@EQ%?
M5M%ITO#Y? A3^:<S,C67V)!RFS_1--4;\GE,%(Z[\X0.<=[$8H[:O\\=5S!O
MO=+S4?/C G,^2H027C)1:(C9$&D-&(DQ;B2B RV2#T/ALH&3. /AGHBP6Y^1
MO*G"/BIZ6UJT^SE./%IT@*S#8>Z$ZQOX#@U,9H#'W5D7-'OXP2A9VHO]>[9R
MW:69LVG^XG"AJS?+K6C8.28H9WRH^JB)1-NNF<4032U<WOUZ9+ I8C:!RSX\
MV Q!.XOY<< KM2(-.9@B3A3 9=*)NQU!=$ GRO**PIH"5. ;'1"D:=L*K_F*
M",I_"7<UB -0"P\?D#7R^L#CT^(M8PI(X^3/"\-Y-RL#UHW\<C_-'9HA0^=B
MPG\4]TY?R=*BCC,DS!M78.<QL%-0;)@B4J1.J_LRZ7(@<5@N6\[.TT.Y&,V)
MR_Z#6DMA;XA; S&/[J.CI^8T:HC4E ;G6<TS2W2 Z\-+)46T'LB5O;CQB= _
M-AK2$VO@3=ALL;%H!%&O8^G R=XNSH'$C.OYZ]8UO9^T#E?/HHO.N9.$AWN_
M<KS)V,S8'VE ZGJU.%I93+:[?U=E]=EN? >9X\@\V1N>;XX/3)]F5 *. Y(V
M'',H0L,%U]EM;__=L_MAGQ?&G\8VYM,Z6_C&T OCH!OD% @Y]4O)(,&*M% +
MW.I$I0(WMX5JI8;!.'>WJ3I>[K :ZRZPG_L/ZQN'O=_!6:]GA<DY>/5;2N,4
M#1S\HL<&4^9!9@$=\)<,A6;:IGL]HEOGEYNIEQ%M4QC;MWY;$=6Q]ZKBH!X5
MH.%?:J3 <$VS.$985[=N;[E /'SC0W+ S;!W/*H6>%Y1]S@\."LO92NPU*HH
MNAK% 22PZ(ST\^,#4UD7]6#]8@AATLM(:97#[FSEESOW&AV<W0P:!7X)+IV#
MC-"ND3>L5%$4N<]D,]&5P?%R7MK*1O4UP=!BJ=6%\*%\U+Z%_0(=8/ E'TNM
M/Z=(_E0QL,/KGLYB%A#GDZ?-<(GYUTMAZHSUOX!X2Q#>06VMC*VLWJRL<Q9;
MU3]%V8@G 0G*T/QMB^K46L;L?TX=Z?KC<"?2@L9QPCJ9L^TPC3>X[M;P7N^P
MK'I)E\]AT\$F/D3.%AU).T^^UM[(V]-AIB>Y(]KP\-7\<?@-)? 34[CC.'P[
M,"[4Q%6<#EC<MYD;2N*D%L26T-;2NYF;W1(-Z ! ?BYF)P>OQ6@V N8LU(/+
MNH,G&9S6D])WBH<W[9RIVS#J(78L !-KLZR?QFG6VN^*[.\^F0O32J5<D5H_
M9YI@:OK@2_RY,P!6'5]7?LRMR#T!\]FR)6,Z0-B#\:?W GPJ%9,0_\JVN/T>
M9N=% >-_DH)L.,BDHD9%0^)&YS%J**8 D5HGM6@=OO4Y&7Z;U<MNIG"M-D/]
MO9D?U]=)JT<*/>>:[-FT/I]Y8^:"?N"[HJ29%LLV):<C9Y<4JPU[]_7791"7
M48D^B%*7XFD46IGR&J[ 8:HZX]2AEV2T=3PU_LN3^5[?6X3--4MLBQIQ(B/V
M,/3FB(=A(F=A<\PI4+BT9;&.M=!/19=RS8V_WZEWR]ZU7,T=-QU@7I:\_E4R
M_M/EY/TL,<(Y8@//K#9(F/Q Z2>7DX??&(#)R.#C2+5%T,@4Z];S!H92[*<#
M<"4MC&@U;$<$TC@F(!2_JG+P2_";B5TU Y)[V]+[^0_[T0+PTSSA9+-2IIA@
MH_3?73\:LSLT CQ6"%U$]FZHC$%L"[]3MS<+-@.3$28%.CF@ ZC9>]1L:!>+
M2-V*X"/O_E'L"V>!X(DXF>Y^MSL,/X<<,6>K#WTN1F?*@N?SD%6I\: 7R&O2
MEM[Q#PMG^^:26_6<&=-\3HF::1\Q$WJC^D?>3:4]]4=W@R]/OSG*&'=4#I]F
M!5/.0Q8%1P2&2L31R1C<&K*JCLJ2OD*;QT(HGI6,;FW" ?#5&VCX/&,%=E=;
MRC#T_[(@G,S,71WEO9DAM= ((4L.M<:M3? %H]ELGDQ.\UO=K>*__ D0(DD'
M4-0VYN<H1!*4=FWWZ<[++N@#B#>KZY65B6KS[XH8H@GD+5>C&DJJ.SVS"BEV
MW[YNHQF[M_<%0]QG?3NW)Q.P2P><=6>D.]>R=#GX#A[R*OBQ/^A[;HM&#1T0
M]I&BU/)6SV-^*/KP:IWV3>+R$C@ZF='(J/<P,!V0PXV'T*Z)T0&))G2  \/%
M5_I9707_KKB;P!@3$-&HX@P.TI4&V!<4B&*B T1=&>---$8PS3QYUT9,QR^.
MU+?W "-Q3F(_3WF;4N,^P(>*R/ /?S>@*[=%EU%-["IF[U'H/<80B2(I2::,
M$<KC8LO--'@#YUF!4=JAE\N>L3X7>3E"Z^D!'_F3T;M_UX]EU,^HA[1]_!G"
MA2$^I ,F389#9P4527<BB/#-?A+0+%W5WXT(=VK+#MC543D.A6?2NGND<5!+
MC="7ZOG!2'M#") .:.^C5E*>@_&&Q)16VKE(@T:QZ/V4( :FQ@6>OQ)BOBX.
M/DL'N".NAV7?(!_AYIA:C^98(V"@.J4%LIUI0@\<+XAY>"*O1:Y9ZZ'-,M+Y
M"$<XLM+Y%^<;/#1:D)MHXF1PE9SR^*?#&2\/_6,I>X1-XZ6C0,Q\=IV=N##Y
M<&&EBY5+RMFW6J5N4CK1*VF)[8\SOQQJH&1WVL6B$W6RGP$(<K:WW#99U\;M
M..O'4HRR<-&'JY\.I[6^]J]1?)=DB1W[*9!W=B&)B"Y(7=W?%S49D^))SLO]
M_9Y0<%W^\FXB2X,2>'$/+4J2I7 PX9@ZBP<*HXBCW7.</)0DA10<4M[[TZNM
MO@U&H+^.+H!)G:A19(B@[I\@ 3)$.U7YFM7:U5O-WLDGBL!.[&?),C=.$\GB
MUJ>W :610K(=O3JIRK4-]<5TP)H<!N]H%(MFTO^B+YMG#HDY&G4NASF-UYC4
MDRU/U .FV[Q4SSM-J!EPQ@> 9\,"VM15N$$?UNP&RFUH8U4!HD)NMWP\+,3O
MZ-0>I.^*,27DA&$H9^%6QWVQA!)D7RD"),BN>Y22<M3;B 33RG$EBK<XEAB2
MTFL*3#[3!-XQWLTS(#+( 7/=37,([TP +X OV%9T6*S1!/2 _ XQ.5YUZT]]
M]M'ZP_#Y3^ +%/>S05'1:M %@UC)'B^D.4GB6T+FF9P8DT3DK-AL2^/XGKIJ
M)U<DUN1K[9@'PL(SQY)[YYG[#WGH)+*#Q0]+$V@8:[I1XFNYEUEH.M20''!@
M5#-*K="I(ZY(LIY\4<,<2<:GTYX85 W>SBQ^+K1;!*8VR#(X64Y-^N0BY10Q
M=.XK[-9/3X4]VEC,/NL0@474'=ND/(^\0@;)2MW_Z3/ KN8Q63C9XRFW]M;0
MSIZ:1<ILQ9 VX 7D$P/]L_YNTN6UU-?G0_KE/0(4%[RP3=K.N 'O]BE,I'PC
M"B_<$.?#SJ'I-RUV'6?P,AB;&=.Q(-4U9MI<;88JL9UNC$?)MLXF^D8=).7%
M%$G>3=&6T-*<33-*F-^?GJU?VS-DX.#>F__XE0?O%C6R/PX1"Q)(OT_R>U-$
M1F@E36A6CJ$F7 X92O:RDOVOQ,#RV%A /Y39!2V8Q.?*Q2*8V'?LEOGB9N];
MI]OV/-1)MJH_I!"IT:MNJ>D=F$NN#;,595,!#EHUX_OO=_;5'_!=2,8?>254
M/>;V"1?XD+'J4J@Z[<#7'LI,//S+QW<$)I?CFLT_DCJE43'R<J'FK[O\56<3
M'BQF%_&/,_^?SX?[_L,Y-9?&X.AU*443XB"B_(6;BFD"60U88RW\D0YH>8.2
ME.@V"F^R_7BMZ%)<FMO&CUV"\0&<'%CFN4N1<A"$KV!],;0X*1O4X6;*?'UJ
M1,)@1?[*.VGH*4BG2MTNVCVW^=Q'!XY  4NE \^-+7^M...;?>NZ6;C/!3,:
M8H>EX,XC_,:!44N-,35UP?*: (.E]1-?AZ*0:Y;<P"I&J-W[W61(AM@ ]\:W
MGGEC*SD-C["C8^8?S1*9KM'VP_*,*2:N<]N&!B05^[#2*#K MPM;0.,=ESY4
M5J(Q?6](;V]^#3QB@4FD/-77RBI8'P87W1!X <[RLD*T8=[&O'+$TCC<>4TZ
M=^4/(U$RU_A75L3S=U/>J;MO'4N).TX*A_)?BJ(&9^G WV=06*CEP:RX9>-T
M*BQ"F0X@5,!CB/? 9^'."<\D.[QQ!)6G<DLV9--GX+CB,_OJZ_O(30.BOTW2
MG#ZR+>A]\J)'XH$+7U(BE\1]X[W3+5/C:LKY&\\2M'2K,$SA!Z4^*73 @_/U
M+,;SP(X9!U'X)8L>Y-$^"Y0.R.V;F)NLAU :T;$%:W;YZ;^7V 7!T4*4Q[C2
MH)&G\"!CD#4#!<.@9-7>^+;Y 5%]T\[:EIOCX;?WSFW);7^"1SC]AK>IJBER
M=&';,MH+;QMU=(W>),T=)O;L4TK7S*CI:A(O=5UY$YL_@Y_Z4/\L9Z5<X#4@
M&X/D1P8)?/C:KSGZIO*ZOHW;OZO@.N!*8]H5;ROP0A5EX6G_"80;>!B?\1[3
M)G+<H-6? :%<$]-K:K#4=4]3H,*R=#M?/_;:C[A/,YUQQ53"&>-]1/M-NH+D
MZ#W\G&S6\,EA=" 0N&-U$$EF+@N(B0O X 7KRX1>3]2*O)P'=9V_3XGP:>$C
ML\Z#F3?=P2R3_9*[*W9G7DWN4W$,&#5+O=,D_7AG63D"]H!FJJP)?+V(H#T>
MR,MROCMZ)JP@RG;)57?+A@XX]@+*;8"N$0UB.3=A?%XD/LO[.V]RNMP]3M,!
MTYJU,LA4+U<&$>QCU3R*F3-/,%==)Y[X!X+^()E@H?$'5R-Z1L\0T3^_V>L&
M3"@E.21H<CY]=FKU'*B1R/GUNB(E]M6K?#H@H[=_>206.GXWA2UJH$KVZ+H3
MIS F37 1?K 6,J+5%\I@N+!@,KBCUEY6WKVWH(?=ZF:4,8TRZ\Y;40YO4Z.P
MX*_14A>  MV8W]7C.7603JW3*R1TB7CYY,K1IYD9O^9;&"%>Y?.6#^R&#8W2
M=W5VT^=$Y_"P5W-$7=:WFYU(]H"]E+$L7SAY7(RB@L$I4B^'JM$!;0S\)'TY
MN1G;?^(N1P<@=TZ&H),/*TB8_Z$,&#=.!US$K#J05FBLW'1 @ODDAR&UY@,=
M,'04LG#P:A/&<,,K:+(>'? 0B  3 S 4-P39%]X./>:A!-(!X5T,"6)ZH,$!
M]W "[](@ <%*?B!UQN(-LX;=K,V$96 3MM)Y=I:QCR'H?AXP2ADSGPH_52X+
M&O6WQS.O73Q'&R[KFR;*A6FR&@2=G(Z%3%LFTF;_^]?\3456H8-S>Q)SC(R^
MOLV("&9%%%79 P;#Y3*:E3K#*)'LOGY)4A#Z 7,4C:0Q(.6'^B=5H!(#A,ZN
M4;.D<8^QN-0D4YYSV]O7,>Q.PC3Y'->3,[2AVJ?1>63;O#LKRA_ZA4)?+F(Q
MPY9J0P+2&T-TP&GX,NCQ@9IFSX$PF:5HFPTF0>S?[H:=W) UT#OJP9FC, YS
M;R:J;I40T]LV^W]JY]V_29/LNT_1"#['F=GS?';?D<'^X%W@K6#!9\C*E;8/
M,[8@-C*;@/Y#V<BR-TQ8JBG#Z]K#R0YTP*.%=@A9B$&?"[ZSAI9JIO[-6H<5
M.^4]4L!V^-F'O+D!BAVKL0I?RM,!@"M_L:3FN<]C6"U:OUJ[J#@V2655=#GS
M%O?VMC)O6-\STT=I-7VPY-RLWM!34-#5M6#($OS7[JO7-OZ2[.(P@7YKCQ7/
M___XG;__%9WB'ZPGW6T/O4YRBL.%6'<&.67AU=W]#SS3O7QBO'RKV?UN**NS
MCI$F<JK(=?,>#SN/TR,),&?<!I+--:FI;NJ12AFKOTM, N'6C<//-O%I9ZY?
M1W\"NR##:;(D)H((CI4]P+AMQ.ZC\&A>XWAYN;3LO9CG=5F+]H'N*H'OM-E[
MA1[*USO=6MA*O=Z&!3M#HAO:R)DYJ[Q.];A^V:N3 7$GF@LVI$?^QTXUOO[B
MP0HU87=8:L_/+[9=-/5H+!0*$9_5V3:((]:TT '->_>6;"8P%C1%S,RA>\D^
M'?"?OEKV"E(U]Q9V/W\#S@;3+B<'&5P4BZEQ=R_58\?C+Q:&*;WT('Q<5-C1
MOBI#K *4]_!YA[=N+(R^J""CG*76N?WC0*E!_9QM>N]HM.DEO2]7E+<,[IL+
MIZ(F0S5U#L8(Q;FQ2?_NZ>K_A^U_[XG__[]/__?[Q+E3FW#RZCI%B^0I;=#N
M->5".U_56+^3-RY$&Y>&"FE5!BN?5KGXW2QF@5UTPO8'\RF("?;-P D_&6)!
MBHJ51[-MS-X@Z=56%<ZZWG8]KOGUSO7@\ 7?VT2/7&>F2U<?;R^]B6CM%K.#
M2H%;IN#6_IM;:@V0AI.&K+^?JQ*;@>B4H!@7N$^=!?&19".W<RLQ555C+/L5
MNQZYWV(6/G1=NRUQ9Y%G+/+LZ]NZ^P8\OZPH3RJ3'V^W#+D7SEKKWED[O)QK
M+%]_20ZH?*%'2"BVGMB(4T>TK_J6W!RO,;BZ/C4^->NFTE)-K!GHR->^_"S:
M(5'>)/'>4TZF)Y^2]?PY\U$%C;(M4S11MX.Q)3H ]\(%LCMR0@><\X=0/!%D
M2UYNRAXC-+398ND OG+&^ON$H=Q*8*8%0>#SY0PMG##\]UN*'] !V>ES9*F&
MO]/4&",D_N\M-"I*3L_58J[D6Q,P285L]N>D)#(=-ZRO?KZBJDO.*;!UK4VQ
M%=E'C;W+ZV<Z\!@-]#3ALCF"S2\Z3Y4QTN[WGYB5@D/:I2T,><:7XRF3[#]6
MZ0/_+U^&VYVD^R3=J#G2 II;&^><!#[P[=U]?>=W(.P9R1S\+V>Y(5;\3#H=
M$)&4 Q_2W:9PSL!)#?_%B[P; XFY<AUPWYF6WN_J]+JKQ7K@\7.VE9T;!+FN
M9DP(%749F7ZT0VVY;GDJ@ ZHDDD<T1("0=PVQ#]?@="X-"/H '59#-'<EP[H
M7OV'VM;_7U!F/0O9)7W'?8-<%'G,<R/)["*FJMS@4P%'"D(V7DZ*;.ZJ 7A-
M!Q K[\D>K84P.+L135/4^I=+!&OX_X(R>HB>@XQ(=('%6NVAO^BZG_9B\F"
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MZD*$IZGN68)PT0VH48SH1;U6CUO?GEV<,IE/C(V-Z<F64>^+K[=*!JM30G#
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MO-! -<A,A5:UQ(4Z1OAGI[?N><%:-W:BN>J]-_;P&0V$,$6:'Y@%,,H8OW)
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M#"BV-P$.C'6(O#"5#GX0<TWN!L_EZV%=C9K5GME#+( 3\FW(/((_FQRE()D
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M0+5U=<ZU9IW-;?NF\(.M*TV[65\JKX&)_J?'$78F?*/F/VR>:X8<@>6AI96
M/&PG$DC++T!U'[']=<9-JB3C0,U,=JFZ=-64RP8PM-RGA0NEX5*,'/H14L6Y
M._W>M=)5-;T5F5T/-.2W_WQ2*6B\:/A:"I6B?MRK]&MJX#!!Z8QLGUN!B^<A
M;'0SIH<99FH-C,],D0GWAL+/L!N<JD(YKP4CURLJBC+/CYG$?T^<L! Y?JP;
M_ND%4<WAA!_N/-P%?!KVI&^[^+)^W[:6YX&TZ!W&6_3E4!!'0<X53@.+1\E-
M:ISB")E  -(C-V=-[="[:!(W_\$J>=7__G8_-P89G\)%"M^HIC%B?%L@^@%!
M@PBK)HC96FR.[3C'IAKA;BSBXC.%._2\8[%HG54RA>ES="G\K-"Y,3>"/7$G
M,M760_"Z VC"^[GGV\9$W1?2CNNV9C=#?2"MZ^I;(5=8@-<TR*X-J!?( B!7
MK'9S/*=U1CNF>R(<!YWZ,&JBU<NVS_K(L*Z2>37+0B,7E_>=$H+/0V,^Y:L'
M*OAVQ/YJ/'2X D3"DL"(QHFY5@V7V*67<IGS7]I)G<Z; L.+GS:#CJ+O%6V>
MY?YP1<0*V6?Z[QW8N/\=C^'@C#W%[X$\3RY'/N2__>/8EX+<V-O__X)G5HAN
MJII5HJL^116U7'X;\@81LG5:]D_[,RK_8%ADD.G8J#[Q$%C,*!J4;??'N+K\
MHF4">KSG\#M$?BV']\94PHG'Z%?^92;;NXA4.]"YP0)\68)/\;$ >^?0*U"S
M_9-@&A_N-Q4>]T\83"^/?HKVB22J9C0(5"Q?Q(ICL%483*2(7"=']76K$]81
M7Z9*Q.KFP57(->$9[@0Q(%4ZAM3UAFLW&J9>8%CJ7DBX]5:C)'--X;FEQ?'\
M3A'>XLZ'E06W.Y%%&/MI+=F.'($ANGHE@=%H,%3A7(U!;8KIJ%[@*ZN<O91Q
M,3GMXK[0O'+/:^T3?0%)?!XH(=Y1#VWI@:G^[=!W"D6&#>@HZ5BI6_"TM/.5
MV_@<I8YC8NT"V1Y\<T(#.XD$U921R=7R]#*7/NW,/5K,0/E(39)TD\(6)K1Q
M"Q[6T B;/KC!_)N!$,"YD?F@H0^IJDFE4$\'XT8$^U+ZN3&CET4=3NH1^O4\
M3(I*"Z1>5]JT]\<+620-3)7M0.&$@6;3N'?:%P>WFNXX#R[TT;6"O_Q0'NNR
M+CHYN6"*BTZ_>DQ_0>^%@TF_\_'3^J%RX.,P?A_W*6,W97UT](\YL^BW@C<-
MO%ZROW%S>6'_P.M)>>2;@(LYGIHMX)HD?,\Q:&887)]R8.NAQ/'U?.C!IXJU
M$UWD>H%ALH0^9%Y-?C;7FVROY+ <'V+P"&=%<&C:7:\+LG980Z'=Q] !X67K
M.'L!K.#!+;H-[75 &.4._!SM#[E=%<<+TPH+"_*$.[D<&:BLZ+]Z][VPVV5M
M<]EJI4Y,A#FGDI^>&:,*J: #Z82),&7ZDEX58%.;>]W<M6K E14B'.J8 '&L
M]2=ZUR-$:LB9>6P$S?5 '7ILFFN[B1CEG_530=[K3_9S0E15:'&<K&-SIO!+
M/^6(XXZE]]OY1,L^3SD^.]"B'8%Q/)O:[KV_**"1NV+96['V(UUSKE[M\I2I
MY&;07C[*>#.%6\1RQ*%?Z4!C:46QO0\BNXT:?A =;J2 I..X0T;0QN3 )"XJ
M"]">=,%0K;V'SY:V3FP9QG%[SU;UP13E*[Y&VZ0331+WG_EOY#U@/@TZ)3]Y
MN30R<=VS@5&@+0N-TV5\6L,X30O'-4G8#+KV85)=1&M'3F58!2Y2VQ6>M-CE
MEW_YJ1JA>VL%A./7<49&(H14N.X<M#D(A38VW=;?::\;]*YP:H1^*%<RXWLL
MYP?TN&>09ET\];(M4$R!9G[(4=^)'8EK9DK'KECUGP4)/ N2RB=+GDGBPT*^
M)R3CVRL^$)1N 5Y:%ZSG[]HAHEO_*14VIIBE O$K1.WBA'W+X$%8<B!L>XJ8
MJ*W4IRW [#4CE76';>..RF586NYC- *P-5QEUG)4Y6H"7BKNYJTL)TE? )_/
M8VC% 9*PL6F&&@QP XH0,B+H6B5+#6*-%<:E^4%5$Q-2WR>XBM]X_8Q:!ZPZ
MOZ/_?G1>/B0J]?"7G#.D),72U<32 @(*:17V 9TJHI8;.^MTY3N\D@V95I])
MU_E@+,"5@_IB19WG/=$:T3$5 4L88/L^.Z22T[C87BI_$W0%%%R$XGWGFG*]
M#&7TZ%-@)??12AW1N;JON\@X\C;17MXUB^:%QN#$H]?WQFJ 06W$NHQ8IB!M
M=^8L53"Z/$"1&^J]8#!0JZFEL.SNO=" )?$'@!ZW:J_]L0J5_E&<>B[5!P]'
M"<8#P4CNTTMPM@!^:G[@2$C<7X^1(%N3BJ$/)T]LRLTW5449V4]./Y3[UO(U
M>?=>'N=D$PDY2OZAK3($-"[VU!">-"-I6LNK6!R$_7YI5RXGQ XL>'^Y^\(Q
MYU^Y^AV<L@+D'2.:%;RHH* CVKL0KD0R0B)L<6HC<#<+F_YY<L_FNE.R4X*M
M>G9?NO+CZU_8(T<Z*A%%>\O,E0#YL:)M!KP9I]<5KA@^(*9!LZ)FM9$A7_$5
M-#T\\U@M5849'1K&_V&XW-O59E*=ESV^>E7_T86 ^#7)6^3O%>%_K0C@>+KN
M,\'7,_64^4B2J* N9DC89M077IMRCJ]J+/@$R,FT])>+PTE=+;92VIM#(@\S
M5T5+%TPOSFD,O\5>P%I72D=*#EA\2O_'<0,:83^/^<5/G7896=V;XNA4B<ZZ
M/4G YA4MCQ2M91SK;JC>8';)\,(:@1^9%BTHXD=54V\!4^"8#+)(BP782A!$
MI'WB;6P$C5%GC>"S(SY=?Q:.S(@3JE?P&@LQE?(P44;!%.+TRG"XR(A*7NDI
M[YF&^@V 9Z@>SSF#J&7 [_[V\.>$"G2.^73/FMJ,B>/R9LNPD#PN$>BI4$.R
M^6)RAZ&<!0I3PC\\ 'JX)$[>Z0_?D'PT]WG#OL-\36AA=7N*FQ?:"RU[V)L)
ML9O0#;M6L?T[,$/M+.!B3JC%>UU@\JM&A[O/[<LBKM\P?L+X&"Z\/"P+D8Y\
MZ8G:V&=XUS)L=_XLN6!\=Y_:Z2G]XK54=\-[W3KF#>#/;+A_,(I$-+KNE@2/
M$AC&$/]U1-=DPT'FBF?9*,A!NF<'E=4NY//:F6+V!F2-HRI&5V(>254B2RHB
M1D?',"]_-0ZK8SKC4R(M %>;I0:M;D[#QS)W6S//1-^BP>2W$;SN!.FOTPSE
M%=V,1X(C7,<[YX./N8[&WJPBC-J)9ZB,P%P9J=.TUX)O+E/2ZURGLN"<UG;N
M@<.>12:2)X>?Z&]L0@(\57LE+L04N(%I)-\C7!2SU9@BJ&$;D;V./>!C@+SL
M=$ZT0EJN+3:[>JDH73D1%%,)[#\/T4.I) 1FR/A95LTM-(YE^2@&TY'K"DW@
M_/MT5.(./6QBA[D+ :[!ORSFQK[^'X(A?N$:5)>%M\KUWN48G6)HHHT43U:8
MNJ[S>9F7.S.BFB-&^NZFC]X.%HFYC.'&G]F>*S%]6*1MHY6=BNY<#.:F*W*?
M90'ZY*EJC /Q:<-_G3HTZ8? 02WPWG_R\0N8KM$,Q$<6H-<?1SD-I\?,ZE P
M0#T6X"ZZE;B["H]T8?:+2=-BG"B[^!!T!"2 H:'N(Y'J('02X0DO'[6IY3W[
M%%7/)5)>$WRI5U:[^\ @6&S.+J@5_C9<@%9U\F..Y+?Z''N%P.]5F&^X^F^-
M=<G)>4ZB;9CD7Z^38[]Q'CL6P?72L;2_@J^X_Z'[;BIN9@\T));.QOT._\OL
MG/V@24"\!6;+F-K4**Y&UZ<ME=MU4J24X3%BES0$8_WM3=</["B&;_7G)@N4
M>4#G\T%7Y15F(XV-I.=.JRYPXH\)R '!U+AV(42S.,<*\^J@M@@TR8'27E'B
M^>;^P*ID6F4%X>]M>X6GG\SG/M2T9P4[*MWHZ,W4:4:<H(4LM)Q;RN13Y9Z6
M-5I5MD"GW#6^]_P);_'#,?"+!"6[&S]EU"4S60 >+!M4CX0J*_ (OX0:_%-0
M@->J*YA,JR"ZI^2;>VWFR7LJNZ1A#N5D4OIWE[+ 92)SPJ<[T%;L@W^L6>[V
M,JXB0-N7*K-V@33A-"7X \YGA%QVX&^@6J(:PAO#INU%580_21B'5J]!O'=V
M):-3)D0@">_,EU(=^@YDH"NM8%YM+AOHFU8UXAA'0%@P(Z.LD_-%=_%2UXL5
MSY=R+TO+?8'/C*_<[? W?Z^IKLT+-3 69QM5B.$4<.#)T<P^,SDZ>7XU_Y[#
M/V5IK_/\7*FK5O^C=*0,>XH&_P*[-4 N!ZH_8V2Y!,-?EG1YUQA).I*"E.[_
MK&PU*)]%M;9$F (ZRQHPQ,"UV2;B1JA;Y2ZN4=%-JD^6!9@EAJ^$V3> P!SU
MM)@9W)GP(8X\:(W#X#^WS.XS(#!-+^4K"OX01]4:KMFL5@:CCO+)U>O^)$@2
M^D0R"GF3@ECS0]J%CZ2ZA?3$.5;37H853[KOZX&M@P6$OAI&#5W\]GZ,W:4Q
MD?*S.O6F?DV:P\H6@?GGD/6GDLY!_[K)J>PT,0=TED9TG ]<T^;"RE9S7$?I
M#(1B]AR9!?"H0L*=DR)MD][E#J_#5( CW\"=I2 #0M/N:/GZI*Y<ZMC8WN23
M,^MJ-^_&6J=^GIV_NCBU4&T9'NHY/]RP-* ?J)&SD2&]/DR'<]5NCSCAF:+T
M9[0\$C)N .2>N1"#T>-'MVJ9WQW<"D5RM0E$.^7>V;SV*S-BM-#U3A6@<&XT
MIMET9I %\/01A>*:*3#5:DK83IU[ !*:K=Q53]<4^+R[^0.BX'*5?9!OK,P[
MY@Q8Y.J%!?X5YEF*0O249I@IU^F.U1L>M@GM%8%8KY3@#//OP?E[?V?\1-;.
M/_I[NIN63$'@P0+RRF5P7I!#%R,-JL)Q86OM\8II/;K^%#6&U]/=Z;UHRJV#
MOWNECVNO=I3.X;*_!V,/M'8AQ%!9B/H?>W$5#+*[:]<>4I?6B$-H"X3W:E_%
M4)#X,3#OY+*5]J5&VIMBJ-ECJ\3^89)4I,)LHF:;M=A5$4,1J822!..SEB9?
MTQI"=0CX)T,JHF++/<UGT6^!NLA)*$A_6'HXT,ZD^+:KQ<VQ4]RIWAN@![GZ
M*8: HX[S33+Z# 2=;7I-#;^CJB$LJ7&F0J'127)DY.8#Q5E>N0S>7QN"V7]-
MI!^4[TVL7N]6VPFFG$R:B:0&%+[M\^29, OCS5I)KXE:?GIWA,?V B?/[ZEO
M[H^O+_@Y;_@YF.WWRVX^1E6.6'W/&IM@UB'V6I@)LN*W:&H[1&H:$H\XF@!N
M?DA#=#A(Q9D/2J#[B \S3U2CZF]X/W,OLKN?:/_6 VLN+>CWJR!BI&P17HM^
M1W<G:9K(XL$<V[)9<1!%XZ&Z%:[G#.5N0U/CD63+6U-IJEV2CA<N#,U&OU+-
M<$*AUW6<B5'G%G<T;!<S(^OJ(MN&VK)&5_83,#L(=_$E'CWE( [)%T:3QY_Q
M,.?<EHDU5GA[SX?]"NM ^>,F!80Q&UT?UY<J=35C8[="W5PC9*PK)6)^.!M9
MM.3<YB,-?YY@ ;C\Z4U!#7]]QR;6:!.>N^ !$[&%>+H@HPCF'C CV0>S*0 M
M[RO4S4SXM>Q[?^=?UO?S@F#V'&,J+">>M$J\16:Z*)A9:)F2UWAFD&+6]$"*
MX%N83!CI9^V:\=W!;8XNG9/X7.%.R2C0DX2NY;*Y=X,/IB(OQ;A,3<T,U?:\
MPA[O6Z\]B-/BZ,PR&_'&&'L1/;,Q37?FG(WFFU.SN^3>//O%-7[E1VN.-DUB
M6B<F_&)_7;>'O*VHJS$Z<[B?!3 806Z5Y$59&B1S$,QX7)R$1%3#%PM$M;*9
MOT9ZQM',-&1A8YI,D+9]SJ0#XY )92F")?[ /5;(YVDZS0UG&J>3WMGN1E4*
M6_<KNZ]5E&]UYF8K^.1&V"!Z:I/??I6\]??7J]<;.7Z_5\0NT1*XU]0AE/VN
MMG#-H5I1'7P#9+M[,@DR/>0GAP[BZ=1:^OZ:/3[?0Y7PY2G?M*]!^%NJ(;[I
M6#M6O+I/I4M=15[CS_SPQOGYABQH)N%).IO[,;(O4JAJW'05-MI94D'G^$J@
MD7;;J-9K5/ZU> WGW1ROZ#",Z89!EIK7>7>[6<[L\=37%L(&1DUA\TP[E#$+
M<+01[2A6Y8F\!M;V1+, KY;\0F*OE)S_?VPL^%][_+<<6''6Z+\!4$L#!!0
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ME[,;</;K]<75W\[.P/NSR[-/YW>WAJ:>Q;73- O?9D6&-B%;\I7LV^@%:L5
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MQV4NO@=11$)(6,)A&(:^2RD*Y4%OUFX$?#@!R5@(K6?[8-=CFX_X6C3P+LU
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MGN&)1Q ,G- -G2CB+F9&=NV>B:9&RZ6<__ZO4L?_H)6TU0]]7(%[P=6T6BU
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M7MNI,$--TN],<,I8JEX3>># *3O//N#'5$KV8?'PL,C*L(099XG'J.-!&N,
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M!8HB$FE%P/>68&H$TB@ &@U I<()D$J 6@O04L.,7LQ72(]W!L5]8$(RAGR
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M1BYW$T$1)$@X$(6!"W$D,(P2[/I"A"%C6ODYYE-/\*2MFLKJ5H[M@;7VZ7D
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M7EDJ10>/M>PJ9??=JBC3%'X$HM$ X+4*QIRINRK:-#D UB,PHY(:7+=A_MS
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M\_7UQ=FO9Y=WIQ?@_>G%Z>6',W#[R]G9'3B__'1U\^OIW?G5I>$1P60Q- \
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M%,H!'9BP.*3"%9$PN^[3G7AJE+,GN'$K"J[>^G'&VF4T#(L<Z2Z,'BL- ??
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MC"+G#TXY-496-NMC+350C]*FA2R3"AC&SA]&7(]O[>(X,'->;\&GQ#T!Y5%
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MQBQR(QBB4#7#B56AXT1U:(Y#)XQ$(/2#R+9&GAHQU,*!2CK],+%MN+K?_:-
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M4OD+J@I/WO.9ZS 2TH1 ![$0JC03B#WBP"")A,>=D 51H,U5P\DY-6XKU2@
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MW%Q]KFG+P(.L"[.&^WT \ 9FI@T%29%!+3,HA0:EU"I]0,I=E4<: %4#%_T
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M(6\J:J=9&$LN20QCGH80JP###"D"B40JC06/$N%$EG-XF+'9^6WE^,R(Z4J
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M^?K&VF>3.1]B#=^7SB.8!UO9^;Q_-RO?(@<KUY'B:KWZOE@:NS.E)-.;TC2
M 0LSJ&VX/G@SC& L,H0P2D48.H7\3HPUPLUIB[ZQIG6D&W&[=[\XA;>=1?6$
M8L]&<I?^L!(4;"7U9_0LX/!DQTZ--*AILE#YK;6QN:0SZ\%R;9A1:GHI67RL
M&[W2# 4R2J0^W5)3)Q$RF"D9P!C'<8Q1DN'4BOGO[$AC,QZUH'H7US"DN28.
M' ?5,C;H ZJ^0X(U2EL./[.-^NB[C>Y9*/RQ"QP99V@J@=/J'N -.'-!1\YJ
M4S5A-BJW:E._=6"[L^TPR9,L82&")*0QQ$D40R*Y/B\&)$@DRG"6.;&^.8X_
M-ANR$;_F$MYGZ.C<\M%Q8NPL3H]P]QU@](&T.W]S-[Q\D3([CCXLTW(W:/;H
MDSO>QLW<%<O5]%?Z(W]:/]5N990&,A:40YQRL^W)&"0)YE $*14D".(HCFP,
MV=Z=QV:B:N'LK,\^3J?MRD7:]VPQ:KD\^LV/:GOJ?=<7M=YU_=/V/=^_WR!O
M\%$UFG?S^!>ZIPJ437[J9RH)4<2$X) F)-6;B$1!&M (LBR,(\ZE"(15F^HC
M]Q_;&_CUZI<O5__YMU^OW>/B;=1.OXD>L.CY?6SBX*5T%^0*M#%QSQ7HB,W
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M+;VV_P3!+$XCR$.J8AZ13,;*K4CH[)ACL_Z?])+[HL_X+[( 8B,^H 7X7BD
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M00;NNGE*T?U&FR>_W;$.>GNGJ[DHFY.9KB-Z.W)=-H"\8L9!R5?3, LQ9BB
M*4D$Q$FH=T_"-!^/]58*XTPF"7&JDK8<>&R[J"\W5Q]NOMP\W%S?@ZNOG\#]
MP^W'?__S[9=/U]_N_]?_R%"8_ANX_H_?;A[^YEAE;3L1=K:D#WA[MBXMD3?I
M,,:#UXCJLVK;$1U?-=VVPPY;\>T(QEX]N.OU'<YR'_+%DSXGSK_)55[U$+BG
MQME4F"2;9G>=JH2$+($Q217$44H@(0&&!"<XQ:D2(;%J2&X[X-@LDQ;Y5R,R
MV,H,:J'+)#.'(XP-W!:G/L\@]FQ_&FF/X=?E+&CUW-J?"CT#.M#Y</-@+K?
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M#F4A#+D4+!()"R*GWO6=\1HL[)E[0,UN$>Z*1>]9'[58GH.8A]3U1@#0NO7
M]?[[2NV7]Q_X3@>7_S5=SE[O5]H\?I(O<K8H2VCOEJ;!U-/MO"&=R5A&661,
M6DRX?F/URTI#I"!+8TZCD+! V#O]K88<F]TKA0:EU* E-JCE!EIP!X>U'>H6
MOG_O6/9L!RQ@[!( L,/3(03@'=>!@@"7/*9N80 GA$X& NSN-%PHP$FSG6"
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MLOIL-S^U-:.6[C_,>/L=8GIL.QP'QQQ9"^;$1-ZOLR42>M?XJ-2Q7['W$_[
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MO\K&^>>WWTK!KY8;^T]=7M0'=))Q0H2] "8T"%0]5P1)*'G'8Z$TS,+ ]X/
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M"75M>BM4A=WU);SP(Y:D7@I#'*':DJ2(IS!*.8EC'F6$&"T$.IU.C>'O+B]
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M9A"G60 S@<,8(1)B:I20SZ&L4Z.GKJ3#4ZX['%M-&V0:(^;:L-D_6-:=U$=
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M3$-DHI"+?16/);O])C^9Q=HN:.ZUFJ/4699%'DLHAB&GL;I1XI!FA,,D"W"
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M$.J.=;56_1NVAJ,ZB%#^XZQ!!+RN(;%;'EW:@(;KW$N+.2KJ7[]BZT:O&SQ
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M1]5K4_UPK?Z>+:])GO^4B[PL\/TH"J&>_7V*_$2MHP,,B112\4W,(4EX"&F
M_0@+BGQ.I^\BIPM3QK&4P.8;:LO1WZ?42 98*35@6FQ0RVW'1+;6X-)CTA,$
MIE@WK ^Q#ZE,(QA&-,3$3UG C-(1!K#%(.ZCT,<@9^#Q?Y'7M__Z7'I&B_Q-
M;P'S?/6R9:!&EWX-9#9Q] A[S]-((WF9"U#)/BE_KL0'6_)/0*.!NWFE(W2.
M9AG;T0>=<SI"\W$&ZOJ8<X^ ->,>V+?62_;;.<_>,[XBLYL?;+;B:IK<V<S6
ME:4>%L4R%\LLKW:\JTAV\>GG<[;4(VT>HZY5_ZHDWS]\E;*8BC# ,DRA$#&#
M"(M 9WK&4/BQ'Z(XPM2NW,/X51X;SV\%"1]%U4E/EP(I.N:DCMX"UB?EQJK(
MB.:N]G&\]3QV,/Y<-D?;Z#H!:]#VQ:6K6H[;R#5Y<VH>I#]!B9X>>O/,\A[]
M*Z7J8:'<)QK_:5X:YR<-1ZOPA8XSCA:/0]'M/X_D'<+>Z[5_N:TXU_G4V[L
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M+=>MN/ZN?[R=7[WJK:U[>:H2DS_U11Q(3R(8)8GRHI#T])%0#C&BL<=(Z*/
M*L8VD-QCHT>]#\!(\1VP4I-"IV[KK.KM@Z9NRM4-]6J84>\(#=XS=S<:@Y;*
MD\/%\-IJJ\M*Q?7K4:FN7XM#MTY<U@&_D+T<S2)#23WH-#2P*3[.8T,/WSEX
MK.,QCXN?9-:.0K(P81'&%&*/!!#A0.I6ADPM_[GT1$P8"X1EC'C?.&.;:)H
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M%$T1 _ZYK%%0'<HKSR%->21D&$H)F1]RB&@00Q)Z(8P(9CA-,6,Q[= LX^3
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M<P1UIY5RL=U+^?%#W<5ZY^1)+)>S\B%%4P+\?EZ7";_YP;[KHR730)$=14A
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MG;G>/]#8EC&UG* 4%#22VAZS/@"JV83@ JJ>V7L_2N!W+:;3@]/'D7!V5/K
M, ,?CCZN[.YQZ!/7=V2$59'-15$HYJ+*#]=/O5ZG\ERW,WGV./'3)!$,XUC
MP"<"HI3YD :,PA@Q@=,@3(5O=3SC+&G&QBU?%_,7J 9Z=90<=9ZI#,EH* /T
MS5BU'J"ER 1L5 %;NAS8]G#(;"Y@=45_9\DR+$>Z@&V'2)T\M!O;5N&X5GB.
M*M>/L.4T#8,T26D(9:I<+Q2D/L1!ZL$TE7X<I90FOF]#I(<&&AM'MJ+,503_
M/^TX\2"@9G3G J:>F:PY\-5"ZO=&3(>^URDD')'/P6$&Y953RGZDC)/7GW=2
M]EY6L;!_*.:YG<M%_EIG'KZ+^4I\4>+K'=%\3F;7JV*Y>%7?Y:>?=0-O7<;K
M2>3O&1/%YAAE*CW=C2B&(8J(KEP30!QZ'!)$L*\/S7HAZW)LUKFD8^.C]A',
MSUE!7E[R<JNS+"15E6JY4TN@IM=\K7@!]#L&&MW!6GF]I55?V^U0K?M7PW"7
M<@P&[YE9:R4,;%>5TFQT&>1\;6_ .SYLZU[.BYR\[0WN0\=P^QNPHV?*V.IU
M-=-1G7(34N]DYN*[CL.]*P&9DD"GNRORNY?/Y,=4LHBBQ--[A3B%*(D8Q%QZ
M,"&Q%], <1%;;1A:CC^V>:,E?MWP@+45T <;E0;@EYD^^6+IXEI:QM#S[0_O
MOAWB%M15 &A+=G!;0UT>,BH+@)5S-_GAT%GN!IXK']IR]&%=ZV[0['C<'1_3
MH2#!@WAY)[.,%.)*.7NB=3HD">/ 3Q"&(A0ET0601"2"@?!%% 6!EWA&B_+C
MPXR-RC:"@K6D%B??#\-YG)C<@=0S_^S#ITN)@,- 690#< +80$?_6\"11EA7
M1_Q/XG#T./_ANX<[NG]2@ZUC^J>O[K@EH3O4M*/8K2H5+")!2D("*<$)1(&D
MD')!(,(D#1.2)L*WZB%S9*RQ<>)M4:S*EO)@-5=@[B]785LWZPC4AHMT-P#V
MS)=[4WI:63_N#RL:X.)J%7QDI&'7L:=5WEF)&MQR3I3CN@X\QAZ-4TXH#()4
MQXC#!!*$0ACX411&)$DC+[ I[KSU="NB&*R:\W9(HTM$X]HJ:ML9DH%B%]>N
MXZE[%78:HKB^1+QSKUK[@Q$?+^I8;.#(VNJ:%-^_S!9__%WP%]&4._@DY"(7
MCX+-U+N=R:S*0]';#L07+)1I"%G,$YT*PB$- PQ#CZ%8HB2-P\"J0H$ST<;F
M3'R;YT+Y;O]2\^'WQ4SWJ08O95F4<G,(D#PK]+_Q55E#1<&@2^1F"SX!RR.;
M&'W;UXR)+F.UGFG,8)=)ZP:T<J#4;JO0S0304DGP4<N)VUTI]]B[*NS@3K!A
MJT$X!W2GA(3[$3KL@"D!7K-ETQ1JG0S#,E&4D:YI3'$2!-R'24(Q1&'D0>I'
M!+(0Q<B+0R](S5O0GQIM;'3=DA<H@<&6Q'4LT&;?YR3:!OMD+C'LF3P'A\]B
M]\PEC -MHK7AU$%IUA;:U6Z:*2Y'-]5./F2XO353?;:VV(QOLF-<+K)I%?I]
M>B6S69.-."5J&9Q*AF% M?\<<033-,+0B\+02R*:1+$1QQYX_MA8M1(1E#*"
M1D@S&CB$X''>=(!+STQI!XGQ%WU"\3T^7B'87U\6[_^A[JS<._7#QJL[]+Q!
M/N<3RC0?\*G+NJV6FVRO=9(IX4'DIQ1!RD,?(BX0)(F?P" EL8^"Q ]BJQWQ
MCP.,[:-]O/GMYN[;S9-EDNX.;F9KR7/0Z/E37>?]]9&*>TAO1ZNQG<</NJ8Z
MI-S'E='!ZSI7B#G4\T!WQ//49TP"[NG>@P%$TE.?-"$$(E_ZD0AEXJ?,9H_Z
M^'!CV[36*3*,Y/E/O=]DT1O,$%SD"R_"*8=>JKNY*ZQA&O$ )J'/)$4A";$5
M2SH$=X@3#@K<^NR>4U3-.-0=5CTSZJE^-T[[.)JAXJY S+'!AJ[Z8J#XGE(N
M)G=US#C(7N;E1M9\^:'5;]9.6P\]SH(4AQ#%3$)$4\7082)@F@0T2A..DX!8
M)1\8#3LV,OGT[>GV[N;I"=S_=O/XV^W-/\#5W6?P=/NWN]LOM]=7=\_@ZOKZ
M_MO=\^W=W\##_=?;Z]N;)\NT!#-[F-&/>Y1[IJ&6P*V^X: 1&?S>3]*_%4RN
M<A?,!ATVC<$*B)V,!KN[N_'5S>O;;/%3B#H!?W_MCV?RXY.8"YDMJTQ^D;.L
M$/>RS+FH:WM,621QQ",*!=>\AF4$"<%ER2@9(AR$<6I5:]"99&-C/>U"+<D/
M0"O!JP,[A188+"J)@:@5.5SKIV=CFO'A14S4-V4>S^^:@$8#G89?B5\&/D&M
MI#L:=8ZN(Z9U)]>@9.P<SH]\[7Z 'BG];C%_%\52\+)R4U$F>K5_?[THEG>+
MY7^+I>X?HB:B?PD^]:.0RX AR#RNO%842TB"E,(H306/11+AQ.H<;F^2CHWR
M=8Y,(UMYE&I=,(XIZ4$NJO,_RP58U<H"4FK; _]WLKS#^:!O>UYZ?ECKUU3Z
MTPJI?UV"GV()-CI-=+?;E<LTPM[A'W("Z23G^":4<^#N-,&<-># -6GK^>Y^
MM2R69*Y3!Q\7L]F71:Y_.4U#$:4\I%"&)(:(I0(2+$*8!MA/L10,!U9G<OL1
M<VQ33:F"[=F-?@QHN*ER<;,,.&-T+!:[+@?;4A;\KM4%M;XNMV]Z-<BE"\ >
M%_+/4>O5"&AG95W-1NLV=?RZ>"_'OIWK9H:51+/9XH_R=-K5G#\*W<Q0%%OS
M@H?3F*88HL!G$*7(T^>8)8SB-(P0Q\0+K#::.L@P.M*_N09-*8X)\ /HX0EH
M]-*5H]>:@8UJ9<)=HYPIFSBSHMGDT+-M^F;^P<QB3?)G .N(P;M(,"@]GP'1
M1^X]YU'G%6,K[N7UHCS76Q6!O)>/6?'/3S_UGU\(4R_))@B&!4G5.^U!',I4
M.=P)@C@5/L1)Y"6>#%.<6IUYZB##Z(BU54#M8+TTL*5= :Z6RSRCJWI'YRO)
M7]2";%.)JUOI-!M#&CK>_9JG;VYMI->FV9)?_X.6?:*=:OT#J+08I-!9!S =
MES"SD> BQ<DZ0'2H[%B71W7C4_7)OXE\^5.?*E\JQE[WR?V<%6RVT"VX-]]?
MC+GTA<=A'+.R:R2&BED9]$@:!T$@D@ 9=8WL,OC8&/3A\?[AYO'YOR?@X6N9
MT7'W&=S\[V^W#[_>W#W;4:&5#<PXL"]D>R:_1FP%JA:\=!DW_;(WLO>4X-$%
M-4<L9S7TH/36!92/O-;I&1VK6KPN\F7VKYHV/PM:CJ$#$@^Y>,U6KU-*4TFY
M6F>G7*^S,>/*'?0)Q$*F*&4>9YY5CMK)$<=&75>,Y:+Q*'@M*RB#=O-W9:8R
MHW.^6-INMYZ&WHR\G +:,V.U92VK$2MI02,N^*46^' M2?N:&J;@N*JS<7*\
M86MOF*J_4X_#^,:+!XMNE=N7S8N,Z46UF"81]7WF"2A0*"#R=#JM7LVF$0UX
M(I($!_&%XD7;DHZ.YYJRX& M9[DS)=:!![#8Z'*QT-('<P\>7>INQ#]G@&GR
M\74898AIOU7&%V7Z(.>?-="T'^X>8TT'!G2\BG]6SZMZMT]]/Q(,20&9Y!PB
MQG7;&A% &:+8]Z*$"KO>-09CCFU".+J\G  MN*.5>POW,Q?LW=#LF9G+GFG5
M(;#GK2-@X/=*UB$6Y;O(]+T6;XTXCB7X+@3&*^\]MW;F'B8$+W3>[Q.9B5_)
M<I5GRY]E-8[93+"*^>1MF;]5%NJ8*KIA"2,I]-+(@RB-"*0^Y="+?4("BM-4
M6KFT'608&S?5(F=UH+0@=0@@VXALS4W6=C'FJC[1[G^/L92^.I^BY9^ 1H,2
M^HT.&O]; _R[<%I7!-UQG+4$0W->5XCV<&#G1]EQ8I$OI[HWX6*6<9WY7A8W
M49]TV6=82!)&#".8*HI3ZWB>JG6\%T*6!C+UI.=S9)3W>6R0L;%:6T[0"'JJ
M([$YI,?YRA50/1-2)XR,*<<$A&.<HNYO\8GZVX9+CCYZ$+(P4:YA Z-KN[E
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M[5H<?#&;D;P ;R*OSE^Z+LOA\!4X)_G@XH8=,&GA4$&/HGM%CP8%4,, &AQ
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MF1 1R%"9;BH)("R/@2 DBZ! C.-LMM&% ,S(\YQ JX7=5JQ'BBQK'+12<<H
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M,BHGGS%UGY_/7=[S9)7J\X!R67:CQOXVOU_1Q9IR'=+]8?E(B\5,A)R%*&>
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M5Y'Q32-;"C,<,0$(@D3MO60(2$01P$BJ;4-*$YQ8N<X[9$V--*KZ [WK,9P
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M@1& "9. X B#E(A8]P'.(Y%9^V;<ZSDU!JJU#9YK;8.?BD6P+E7]N8=GQ</
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MRLE$Z-A+* L@CJRE;.X^Q5#M<?VD_O;G?VE^HWYHK^>?_^7_ %!+ P04
M"  VBUM62PX-5ESW  !-/ L %0   &)M<FXM,C R,C$R,S%?<')E+GAM;.2]
M67<;R7(_^.Y/T=/S.GD[]\7']O]0)"3Q6$W2)-7M.R\XN4KP!0$9 -6B/_U$
M%D 2!#<0E85*>7RNU21(5L7RR\B(R,B(?_D_/Z[&OWR/L_EH.OG77\G?\*^_
MQ(F?AM'DR[_^^OGR/=*__I]_^Z=_^I?_"Z'_?'?^Z9>CJ;^^BI/%+X>S:!<Q
M_/+7:/'UES]#G/_CES2;7OWRYW3VC]%WB]"_-7]T./UV,QM]^;KXA6+*-G\Z
M^V?M@C),2T0DMXA'(9!F)B*-G4C>AA"\^W^^_+,SC*0@,++<*L0Y=TA3J9'$
M D<9N;.*-@\=CR;_^.?\C[/S^ LP-YDWW_[KKU\7BV___-MO?_WUU]]^N-GX
M;]/9E]\HQNRWV]_^=?7K/Q[]_E^L^6UBC/FM^>G=K\Y'3_TB/);\]I^_?[KP
M7^.51:/)?&$G/K]@/OKG>?/AIZFWBT;FK]+UR[._D;]#M[^&\D>(4,3(WW[,
MPZ__]D^__+(4QVPZCN<Q_9+_^_G\^,$KW=5L\C<_O?HM__"WPRE X<Q^R:0V
M?[JX^1;_]=?YZ.K;^.ZSK[.8_O77_(?P2DH)7;[P_[[_X]_NW_UM%N< EX;7
M3_#!ZAGY;6^G(_Y8Q$F(2]YNWS">^@>_-,Z2G<YN_W)L71PWGPY#' V;)Q^X
M^6)F_6+(O-">>8*LTAAQ$3ER.B;XQR8M-=&8IH=L9Y+G0'.CB'GT?_LR_?X;
M//BW+(K\12.31AZ/7K>4RVYTWZZ[2_C=H6,18R\\PEHSQ&FPR"58.2)(*[7'
MT0G;BNSUMSVD>EV?!S/_RW06X@P,Q^WK[,P_TNU#T*Y^X[=O=@8/0O[K:!QN
M_SI;D!*Z6DP+2&ZI%B#WUU^ ZQ1GLQ@^+;7R+',-9PLPI['YS1(:/YA,KNWX
M/'Z;SA9#ZJW10#9*#@NP@YH@HR1!PKEDA;9@.GT1S:^_=2L$T/H1L+,D*T'"
M69R-IF$P"4>P\PZ]#%I:#+LA,P!EQBFR.&"D+.R:+%%B"2T"A0>OW0H+K'XL
M["[+GL%P>#W+DGH_FGL[_GNTLUL>7'(F !O(4^\1MQ),6T@4$2ULM-%$0F*[
MO>R9-V\%"5XO)(I(M!(3<3FSD_DHRWYEYKC&AF.#P:N.&G%%,'(&PU=2!D4X
M.-\QE'$5-MZ\%2I$O:@H(M&>43&8+$:+F_>C<3RYOG)Q-E1 N8S.@1QD #M'
M0"S1)42<P$:#,&00K="P^<:M4"#K14$K"5:A_?/X992%,%F<V*LXE$XPZ1E'
MWCL*#C#&R(B04+"&6,J,D,X40,##MVZ% E4["EI(L@HD'$_\= 8FK!'\!<@_
M'DZO)XO9S>$TQ*'R7B:L"+C"22)N(#RR+#(4M%)&*RL5*V$:7B1B*YSHVG%2
M3LY5P.;2_C@.(+Y1&BU35BM+&+'US(6 :*000"42D8[>((P=!@=:)LIP < \
M\_JMH&)JATH)V58!DH,00 7SU7\^C2:1#&G0&"N?D+4<F,!:(\<=2(H)XR5)
MB2=7 "!/O'J[E!6N'1UMA5H3,@[AR]/9Y?2OR3 1[&*"B$H;E1UH^$<;IE'@
MD6+NC;6TQ$[SZ,7;H:+B3&8)@=:$B69O/)V=S:;?1Q,?AR(Y88.'73%%P+;P
M 6D.IB]R:S&US!I1$!@;;]\.'15G.8N)MB:(G$WG"SO^?T??&M_)<,JBIQH1
MS1GB04IDB9&(,)N\D8Y;7'!'>?#N[>!1<>*SD%C[SGYF'F;1-G239)V-*2%C
M>(0(S ID)$1@-@=?@5LE,&D%A_6W;0> FM.<NXJN9Y7GD_+QV=?IY#8%@X/%
MS$N/K,F!=Z0>&<X$"H9P&:7B5K=3^^8;MU-]Q;G,5B+L6?T7T5_/ +J$NLO1
M8AR'F# P4R $0E(^PK41&0_?2D42X8*")Z1;J7_SC=NIO^(D9BL1]JS^RYG-
MM4@7-U=N.AX2*< V@;'BFBC$@6-D,+8(]BA/"2.,8ME*]P]>MYWB*\Y;[BZ\
M2A;]X(?_:B=?8I-P]9P&HJU%0AK8LR*#W0LKBK #<^:QC2+P(@M__:W;8:#B
MG&1K4581#OP9Q^-_GT"P>Q'M'/:Q<#R?7\-&9GQ0U&"!8E//0V1 )@J.F*#<
M<\T-H26.,YYY_7;@J#X+64*X5:#DC^GX&A0P:P[L9O-A\@%KV-$@S T<<</
MXG&'D58.)^4$,%(BH;#QVNW*I:K//K819A5H6-5U+(_M\S8(2KB>#[G'SECP
M?0'%@&H?&#("@B"J381-D$76,GQXZ>W;8:/Z'&0!T58!D>,)/ W$,?H>C^S"
MKM@:.DZC$<8AXR3P(9A#SF.#I'&.BQ0<$ZP 1)Y^^W80J3X164"T54"DL7Z'
M=A&_3&<W0T4%AM I(N)4=IRX19;@@+"1/IGHB&;MBNR>>.EV@*@^];B[(*O
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MA_&%H;*36"N P]'JM?E>P56\M#_ND#X,(ED<@0E,4D+<:0ZVTTC8EQ5(!/N
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M:J\ JG@A99;/HQ_;^7R41GX)FSL%Y>//@]/#XY4.3].];.X%04 M'D)Q< E
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M<0&RB>&VH^**"\R#I@96"=<89&6I0]I(@P@'"0KA!?RW,+:>IJ3?OO/E@51
MWCVB9CY;Y)&*MZ%N$]IR+(CS4:,$@48>S.&1CAXX\=$[HW228JO[P?#L-9C
M=_<0>>*UE1R%[YX@:BO*>E"P6A5> (4Q,J1=[G:8/$4:6X>"<;G\Q$IEMJJQ
MV!X'?:9]6JOO:1CL(,N>@7#AX\3.1M.S6?P^FE[/QS?G\=MT!AOEK?^5&+')
M<"1$DW*W 1EC#0J86L*%5D9L-;#]%5R\1D<5,-E%O=..9-V[ ?D^FC?3!L^
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M,'F!G/9NSZ-'WX.5!\4L9P2Y%"" </G2JX=]U2:&5<".4%RZI\U+]/0?>)7
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M_>Q\\'%P<M'$,?#MX-/IQ4[NQ+:/;FU!=N*AD)%9%K?='[1X19TT KF@ 0X
M F0)BPB01F ?L$'+TH=O#REH?8]P>@5*^!HG\\9[SG<B3Z:+]0H6+6AD,:%$
MFF9Y3B.7'65#E28F:FED:9?K-9KZ-34M$/#HYE])X==H;<X'?PQ./@\.SP='
MQY>'IR>'@Y.<%3D^/<F)D@^#TP_G!V<?CP];'K_M\IK65J@U;X4LTOEH_H\<
M['X&]W6VL*/)@YI;+*.WD0@4-""3$P[@D> Q^X #.,PB.%PZ8_LB0:T"J,-I
M,_EGV=\OOR8/ (I?<KA_'K]-9XME;\!'(;ZE-BDG(U*1.<039LA%ST$(PDIN
M,:PE_1K&VA#0K\$J!Y ',=0^E%&C3<NEA9=_SSX'.!S-LLY%AWG-7UR>'O[[
MNX.+P='Z3W<Q:&]^1VMKUHZK4A'<'5R:"31WLX]6LY(.I_/%O)F.Y/)TI-N6
MT/?M()377C@"R,J7\/-0;V,31\8$ZHP@6*G2H5 [BEMGMK=]^[OUMZ\M146C
MBC0@92*L?:UTGH+ND!9)6)9(9*1X:-R.Y)ZCS/WA\U&*>X^JKM'J-H'>X/>S
M3Z=_'PS>#4X&[X]WJT9X^D&M[><6]!4RDL]I_SXK*@F11 =DG::(2P-?:< :
MDYP89S +LO04@]=H*A&EWCX_5S2#HJ<W,;Z+DYA&BV;:8Y.SO?QJ)T^/SUN[
MOZI%#!IB->93;M4"#H_V02)J":<J>F-$\<:$Y<CON;](2>P]%0WWH>0:S=TR
MBW5Y\)^[G>RM_WF!TO9G:"E6W+[JQ/5$ M<YB \8@1V+J3RPBW-DO4HH!!N3
M(0 REPHOUA?(*=;G[:FXB &KB@98*R1J@&PNZXG,HL 84]((_JB;41>L5F)H
M2F'BV:YO;350H]$8')R?Y,*CG/P^:]+BOY^>7'P\.!_L%(,^_[3VT>:6E)9*
MVMO99#3YDKO?-QO''91T4HY);)"P>;L*V.:V;0I%336A,NA@2J^YYVAI/;YE
MX[EK2622#(8_0,Q@EPN1,=+61N1Y\(SBJ(CJFLE*K$H1'#P:=%)$\#7:DT_'
MAX.3B\'!R='AZ:=/!^].E^GM@P_G@]VKP5]_:/MZI+?17=4U&6&PD=99I%)D
MB#MAD$Y:P&YDL+!":\E*'RA6<4WF<#J&3Z>SIHKO8#;+4TB>N[/*0C(^S^\*
MQN0C-^&0U@&^2CSYZ#%-MO3EZC>0][_ADLQ;4/@XC.M&DS5:R.RX'%_>%GX?
MGC8=X@8GNW:]>^EQK:WBUK26RU-=C1:WI;AW,V[]T^6_V@7C! &WV^;K$IH*
MY!CWR!H/CKA3DC-2?$V_@< "&:S77W:_,%)4PI'D4#2:(*[ B;#*"L2H3M*D
M$%PH[;.]C<+>\U =8>N)I%17>JO1H+VU"^9M>\!=K-W.[]I[K\^GN>R^YZ=@
M2BFG/-(R&L2CBO"5(<A8K7"4(1%?NGBCNYZ?[^Q\-#]-&R^X6?Y[OX(T\5)C
MCI$4/.1[(+G DN#<R2#%P&PN&"C,\W:45=OS\RTHV31O'2BE@N$(G^?Q- WF
MB]$5>+;S89!)4DL4TM'G<U=ED3,4HR1DBB0([F7IMB$/*>BW=79'T&DAY H@
M\O3 K4W<1^4H5AHC(7,G^B I<B(91(DR@ANE22I]^V\KPK8"%/O) %5>)17@
M['<[^T=<Y/M#]PU1ERP-&6,Z)"<12;E!1&X[:(TT2'BO8J(X6E^Z7.EY:OJ=
M0MT1H@H)OP(8W=-_^M<DAI/IXCS:,!K?W+.X8DR;X#$7&-E(P0XK[!%\8I'R
M&A.F#;:I= )Q:^+ZG<C<$<BZ44T%F+MK!+9I@C&CB6?"-0/#RXG3$.1B@G+'
ML=QDGE-:VD5_CI9^!R1WA*@B@J\ 0,\VHMSDRR<C'&=-)W"&N(D)&<(LX@(X
M(U$9XTO?,=J6MGYG;W8$L$X44P'@EM>ZEW>X-UFAP@BLF4#6XCP90X#QQ8HB
M)8UBU,:D8OG6 <^2T^\HNXY@54K\%2#IA2[BFYPY'@,1*:!@#4C,495+'CGR
M0CJMN26>E![6N3UU6^',_&0XZT@Y%<#N^.J;'<V:(9.SH]'\VW1NQZ<IWT3_
M-/I^.Q_O>.+'UP&$^C3SFR*0F@=CDT#2Y9% -B6DF_Z'08($G%#<E>[$W0$;
MVV5?\4^&Y+[U70/D\^CFB1U_GL>+:5K\!>I8A4L>>_ UN 5&0)S<TH!@Z3(D
MI2.!<"QP\6:HSQ*S'?Q^MNQ_&=E7 *+S"!'3=7P/@LM'M%DP?XX67P^OYXOI
M59QM+I&4VP9)G9 (#"-.I4"Y^1@L$=@M("0/1I<N-G@;A=O![6<[,>A02U5@
M<!Z!@)S"/@)&Q],FHAK\R+=3;I>5T\K#VC'9"<F')'DZE8P246_ , N7HBGM
M*VY!UG9H^]F.$TKKHP*('83O$+:/YB"JYMK5YHHQ6%O'L<^V.K,C%-(4ON5<
MX) XX925OL_["DG;0>MG.U<HJ8<*8+59P?Z('2U\C HCG, /X$;F\0_>(BL(
MM]J[Y(K7V[Y"TG:P^ME.$DKJH0)8/7U'\_3;JAKYN&D? F%.<[-S99"IH9R9
M*)!3TL%Z"0Y,L\Z1NS(QY</=4'P PMO)W Y^/]NQ0]?ZJ@"2=]?_'E45X!@%
MS^EM,-R(YXF .N" &*;.)$V4=J5WSN=HV0Y</]N10Q')5X"@]]-9''V9'%[#
MNR? QPS6 L@&M)/K@YMOQXVR'CD%UA@E?6"(1*_S G'(,1J1D<Y[&K1)M#3$
M=B9V.PS^;.<3^]%=!2"][X?^."&>#"?1:J25:/K Y!,]#N&U#LXX)CPNWK#R
M>6JV@]G/=CQ12/H5X.AN#LG:;;&U#OLK'X!PG[3#'$RVSRUQ,0:F/(8@6M!$
MP$NUMKAAVX:P[:IN?[8C@_(ZJ0!HFWT#GS[9<%S:)"'^ 0.<+_.( /%/TWF5
MJ,24)=*5'ENR%6'; >UG.QPHKY,*@'82_UH3UVPZ@2]]7%LYF_P%'YRE,J#D
M\@U5)3%(D#DD&<7.*2:B*&W<WDKC=O#[V0X+.M74_X:K=\U0BKU<O%N]:>_7
M[I[B< ^7[@A8+44-X B#CV891BX/%:& K^2)(#26KFXM?^FNZ=![X;_&<#T&
M3^'9@K_;^SOA\SRFZ_&G48K+82</)YY0);7&Q".FA(<@'3Q8DWN>*\9IS,&/
MY?@UU)4EJ=[;>&^ SX-^ROUHJT9+^/[XY.#D\/C@T]I<O=VMW0M/:S^#=$M*
M"XZ!GR\OH^>I)"MH+&[NKR#<-TDS3!(>/+(\]YJE7"+;N&E2$$L%EKYXN>OV
MU!6R:OFFV,9M,7CIP7<[&F<=O)_.+NSZU9^-94*\L):I/&*.PTIU1"&G0$3&
M"LN-<)8)]T:CUHZBOEON=0*N9VS<'G57HXD[!G_GY,/QNSPZ[V+0QKP]\Z0"
M73]?I["067NAGO>);AXB,6P-3X@*[1 WW"%-I$9$RAB,8EH4'R3_)@);YT+N
MULC[T62TB$TEZ.9K-Y:#$IQ2SR&\(HGG@H. C-<29"(2B8:0I$H7M.U 9K_V
MK3N4/<J<=*S!"O(H]RP>>+#@0, +K+Z[^=W^UW1V.+;SM8[T*1+K,*=(<$(1
M;\8:.9R0=\&YY#S(HSO,[DIUOYT<^H#P7O1;$:*G+RW:]]>++.&KG!%=]MA;
MU1-NK.:('69>>B2Q%;":(1;3@G$DC/-**\ED\;;5)>GOM[W$_E&^=YW7Z)*>
MG9^>#<XO_Y[G_H#K=Y0G IWEB'9WW_2U1[9V4M]$<R%O]=GLS/U(+<^)!EN'
MK,@3KC@!RY<[EC"L+-'*Y&[EA5?_JT1U=I=[+2:C2BHK"4HFY-D/3B,=I8+E
M2$TD6&$I2Y>)ODY5OSYG6:QL?8U[-YW4:)2.3_Z U7QZ_O<V ?+#1Q2(C%^@
MJ6"FKVD!\=108QH%["4*)7"D$%><(&UI[C%I2;1&,U?\$LD+Y)2+).Y>LBS0
M6FRF?&P@4GF""+,$5@KER&K*P*F,"1-#)"^>T=R6MOX3=R6P\GP,4% S-1J9
MB\]G9Y^:SO 'G]X=@"MQ.+CX.!A<KDUNW=W\;/_PUH9I1SZJZG]OB>$X>8\<
MBR3G02+LC#H@X80T%#9*'$JO\BKZWZ\'W,W9XOS,WF1EY:RX][-K6"8CZT;C
MI[+A0DFNO>/(*9]7N1;(1? I),&&Y@'2PI=N<-F&WO\-'?+?@M.7DBN=ZKK'
MM,K&<<_=R?6*O_/H<M=08#A?TYQ]SP<^^3@H;V&-1)XZUS8J8B\D1TGJF$>M
M@Z\<=4*2$94$=[#9R-?,<0=T]9L3[ _.?:NX1E?B_<'Q^1\'GS[#+GQP\?E\
MT+9VX87'M2]>V);60@["7>7RO9]Z#T ?@HJ<.!2R,>.:6>0(8:!XQHDQ2@A3
M^C3@)7J*5<Z_NWEG(3SW\>)KC(L/L^GUM]'DRYKOK(E.U$DD3 "^/?!MN%.(
MPF>  Y?*3R#;EK9^M^EB:'FV@+ZD:BHXP+CC:\UW^#W:++AP.CG/E10SX*_I
M^/YY,G79)N?%?CSY=KV 'T]A;QB/-N:H\J!8P,&@/" M5_#F'AR*(D<A< PV
M49M*SQ+N@H]^M^CNH=R7RFO<@H\&Y\=_0+#[QV"M*._@Y.CCX.A#GCEY>7YP
M.?C0JH#ZK:]HO56WXJG0]GU_K6WMNA%X=Q]C^ (@._#PHP:!3Z2A0@I)*J.1
M2OF03N$\(#IP%()W!.L03/'=O06Y!2MXEC=.!S_\USP&[;;KT?S. U_SRL^F
M\U&S$A]ZQ$E*'ZV)2&L+]H$DFY/W!$1GHI 6UJ?LL+2G-?W].A'[PNP+%4#[
M14 %?L@][T]*_WCR$NMW.]KZ[!DC"&,4"9L@- U:Y^'R OG M/-.>H*+-[0O
MRT*_WD?_:V#_.*A_&7RPH\FGZ?PY,<19FLZN<G"R-BS30!Q"E$-"1H6XE 99
MF3A20C'PUYA2LOCUU]),]%M95.E2Z!@+-3KIRR;ANWO@#_Z^_<#H9ZDIY#LO
M7W ?\WG8M_/<F91<+HW, RES$R6NM+?"AI0"+;R2'U)0**N_UO!]62L':^G1
MR<5#9R9(0[&-$@69VT3E"VHZV81PS.;=J&BB?TWYK:GHUREM 89G4N\=ZZ&"
MW71I#9<LWG)V\[M=Y-M!-QNL.<<I^,L"8<-B;I,7D9,A( \L6\89<:STT+8W
MD->O,U@ >UVKI *T+=?3Z;>8AYA/OFS%(D1AF%'I$)79/8W@*3CG\JB+Q+UW
M.M+BJ-N!S'[]KX+HZUI%5: 0>,K]93?8X!(<3\(3Q$"Y+[86X(D"[4@PQ:PD
MDD19NB7),Z3T.S2P*)K:B[KO8HN-%0$NP+J%GI\NOL;9\:0))>Z33!N%?$83
M3WE$P>>N44JPY;@G%YFF5F!%TG;.67M:^AT56,I%V[-.:HSTC@;O6MP@6?OK
M H<H3U-2['S$+9[(&W#%C'):(6SS376/)7(L<&25]80)[''Q:NVG*6D],7DZ
M:;J>@P#S"S:3U(KQH%* A:%@1PV>(",\1S%0KA-QUKC2(>V+!/5][M :"X^F
M(Q<3?P6N33-X)LX7RZ[ RXM^S0>KJW7WLMMTX7@4Q GPWF!?AG^< FM(/%(T
M)(HYH7ISARHS$V@'6OO.^A='X%Z45N,6=G!X^/GWSY\.+@='IY<?!^>'I[^?
MG0\^#DXNF@-Y^';PZ?2B13W!VU[0>B-LP4^AO7+96>8.E4Q0:HRPB 9L$,\U
M5YJR@+S6FH&0F(^EJXP>4E"T>O_ZZGJ<ZV ;[RZWTI_%K[ ^FIQ_7CDYU;]9
MU&VXEQXB4VLD+$LF8$5219'VB9$DDK>\^-B#=B3WN[^VP,^+Q?@=JZY&XW8^
M^&-P\GEP>#XX.KX\/#TY')SD:J+CTY-<8/1A</KA_.#LX_%AD<M0N[^LM=$K
MQ&<A W@^FO\C9^D_0RPX6]C1Y$%_+4^2AEW:(1G A^.$<^12TD@Y83".!+.@
M"YN#%PDJ9QX'\-S%S9^C$-?"WK6Y<(,?RXF$MS/AYN]NSF;3<.V;,XV+./L^
M\G&MR8CV-.5.8(B2*,&?H3P?8X"DA"'!B"2T+IT+ZXR9?DUJ.40^;V'[U'X%
M40\XR/;+EUG\LKJ0L^)\TUN.ABAI#<(FL#QIG2(+!A01K$'BC%-EBT]HV(:P
M?N.9[N!97BL50.UVS<U/T^&T&=PTNV4/!/GN)O_['B0WG:W5E&"BK?(&*2*!
M1>XBTC@W(V,,/D@^2E':"]^!S'Y/L+JWDEUIK )0;LRU?G?S(4Z_S.RWKR-_
M,(MVT[/60L$Z"P&!1#7B&.R\B9@AS(%)J[5TFZ4B[<^YWD1AO\=?W4&Q0SW5
M& 'EIE&7?\])D '$ MGQS^VD<E1P<7EZ^._O#BX&1^L_W3W\V?%-K6.?$AR6
M.B6Y2Q)F.W<_9O \-H%W,TZU&43H\B#",WOS\)YRB-Y;Q6#S-80@KHA ^8X4
M\LXH24/@Y6?"MZ.X8.@$")O>Q+AR@Y^>UG@P;AZY<F3\],MD]#] 5)R-IDM*
MUSJ.8J>$!P%RAO/X%B:0!6<&>4U KHS91$H'F9TQT_-IS_XP_4)LU2,\*O M
M[@5Q,FT:F><&!"#@D8>O+A; T>?)"(2^+/'>K P23'/+@+L@@$_.%>R6F# 4
MK7 ^!F\H=9VMA1T([OELJ0:\=ZWFOLMY[CF]7\HK41[\96>KYOQKMPB:G/7E
M5[N:V#O/UV>6D)C/KZ^6GVV6948-OAF32"N?R^"$1_"11);'P)7 C 3RFD^S
M+V)[OCFR?\A7B8*J+/W3>UQC!5;</V,'+.>!BMR5FL<<-U.-M#4*$4.UY-9+
MP4M'ENVI[C?:K,+F[T7AE4)\?=6O<[S% N?&4 G_P&:G(4!702-C6:Z QE$F
MJSCQW7GZ)3CHMQBT,NCO"0@_P3*X"WFR%,ZN9_XK_$9NAKR%*"BW7'/,4>3*
M(YY3^5KJW-R'B8"]B*QX<K%#=K9:(/+_APMD7Q"I,:^YK.2Z//C/-JUN'C^D
M0/_L%^DJUD$[%^Q<VA]/=45.7#,<(C+*Y;FTX/L:@0/ #FL#:B=&E[Y)_P(Y
M)3MHYY>\BVDZB_<OA/_,%R.?+Q\LFY%L[@J<*9JB1R(8\/^SZ^^"2DA9*BV)
MBL7078.-G4CNN]]V&62]U&^[:SU6M;OG/6,Z::+7=,?NJJCX79S$-'I4[BXE
M"WFW<#[FH2_ JG',(&VLH(G'&&AW'NV;R>TW6]<]7+O57U50'2188(N[>E#@
M\QQ<G(U6>@]YE3Q1&KQ&DF+@U<%7UG.=)V82+C3&F'?7G/OM]/:;9^L>K!UK
ML"JT'JT( ":?[PMQWWM96\VI!:DF3!'7FH-'K@C"VLF@K5!:=#6T[(VD]IL*
MZQZCW>FM]U.-ZZLK.[LY3?<W]Z?SS!ZP>@BTC!:'=C:[ <<G1V^/AF12KP/F
M.(_&!$ZC5<"SSM=R0\S]OQSWX;6 ICT9_6:C2J-OSVJIRCY^GLSN#L&!TY6O
M,C^?CL?OEZQN5H'J1"5-'BD>0<#&:O!;*$74&:D4=_!QZ5NNNU/;;U*H>RO9
MJ?9J3.@,#LY/<K???#GOK+FV]_OIR<7'@_-!BY*TUY[9OOCL3527NF!H9Q.P
M8O.S.&L2@VNCZ[W#+GBD%26(BSS$WCF/4L3)4JRC*E[D_!PM!:.2C3?DAM\Y
M3W T&E\OXN8R4-X1)9E'1@/C7.J$'&4:8:HX)C*YP#N\,_,64GN^9%@"0R\$
M(ITIK:H]]F"R&(7,$H1<%[DC?>/"#G[X\34L\WSK)Z</KF^'U&Q*Y5X"7C,2
MA%3(Z=R]"3N+-#"-@I%&XQ"TW)S^4_*.;"$N^DT%=8SH7E1=XT;][O/%\<G@
MXN+TC\'Y'\>#/W.A]?&'D^/WQX=Y3O'AX>GGDTO8$\]./QT?'@\N#D)HNA[;
M\=J]N*.XL*/Q3IMZT?>W=@"ZDT8A9V$UA0VP>#8=C_SZ-8H4",,X=\D(^6Z#
M"PQ9[QURDEGK>*)L,^)L;72>IZ9=Y#T"3SF-?!X5_.@-S68S9 9XXWEN.:48
M\2 26 $F4.[> 5*0A$C\&O2V?%>_.WLAA3\,H<O*M\<]?#Y;#'-1[:H5]<&/
MT7S(#4Z:1(RL5D"Z\&"1*6>P02C*=721B:TV7WCVVAJ [^[Q_\1K^T%))^J<
MEI%M/; XFE[9T60(L7OT' +XY$R.J6'EV ";MM?2<F$@M$Y;942V!\;RQ?U
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M,5MMN<9LS; <SR&8'$+@M [3& AY"(3-U=43%E\MOEY>K#<2XU?[+DA6TMH
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MX]-64_AM!R)@OVS5/NKH&US7F93;6=]MCSR?\1!-I%,*4LB:_"T.?.+T/HA
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M=/UTC[I=3#<;HZ6N@U/KR@IE)9U:M=E6X9/54B76?&#6$+JFO0;'P,->D#M
M.5,'@'ZTB*Y6ZG!TF44&K,1(AU(R<,XSB*(86VH96>*#GL_[?GK/&#E$@??T
MGATNS<GA<"V5K<=5I?+RCG%\E0!2A16E(MD'-M$QP@(AI0PR9\-SR0Z#&0:2
MP=^<ME]V9.B,(_FI ;57I  3,T):#1@S.?6IUAKZ3!>U4,D8(P@YS0J0GE3J
M[1 K:5SQ=V H_;Y;7?%J\?C)?+\\/Z>3]&=8Y9DKV= A#,"13HV2ED&0R0%*
M%8(LTDK3>FS_ 63V;;@?")CE:;77 4 ?9VPGW5D0GLS/VCUBZN(Y&>N,9,T
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M(F]LD?&#J W(.UVHM;4L>PC(&N\\F7Q@N=BD"@QX.@^0A=$UY9;0MQZXVU%
MMFAMM;<<E'#T/#&Z=H+V9&ISHRW=1R[(\0S)IQZ0W0,YOPK([J.'#LR$!\)'
MV=6ZCT)DJSJ"+=D$CJ$#(9CT+!IF2NN&IZ<0D-U+N<,"LOM(NDN\['Q[GHJ,
MP24RCVT!%<CV"=P;8%;X%!W3S+?N1'Y2 =F]]#PT(+N/T#L SY 8H-"J.,81
M8I(!Z-<20C8.&&?12ZY2X:U+19YN0'8O_1\0D-U'&1W@Z[X88> U>DQ'CI?J
M'Z&I*[WIJ3>&J6P=MTFUOI>>3D#V&/P<*^P.\'*?S?A^OO[WYL*.1?/$.0-Z
MV^G!=SZ#$W0 HC:&6#0"F_<P/$9/+]&.XPVA9E+O"D%7GO)'^G]>G:[B,F,E
M0#8R@?)URY)C!EPJL6 @5N1X%4(_T].+*7VLUA^$TY$JZ !.=RJ)KQC:W:Z9
MRQ1<<!"9V*6[HK<.?$E1!J<TEN9CJQXCJ!= ':OWNX6LS930 :+>+=?S:Q_$
MQ:BB90@RU[9%$^NM'1)8B9P.H%)<M"ZSNOW]:3OG6CYA!TNU(T3L3HK,B%EP
M#=9Z,O&E4D#,2%"*!2R*Y6):1WI^I&#:6^1P33X B0/$V@$H/GQ>KJYN.'((
MBB_< ^J2ZCXF!K&H#"Q'DYDQTN76'OBMS_<!AT.TN&PCT@[0\'JY^'158E.D
M#XXE2#K4YTXS\"D5R"(JYSAWGN7&8+CY^K0^3T,L'"C0#J!P7YJ;F\B+]AH"
MFDQ>OJYI;D$7II31^>!+'+'V__5>-4NC=0F/XQ ?)N.N8/)FN>W@.?NRO%Q<
MS)SE=924@.P2$A_!@+?(08: +B8L*;7V61ZBI1=WY4 E/PB:(R3>##E3E(-<
M-QP^#ZO5]YKCW0A@6>Y-!9^B N0PBDY7]-% 8AW4>7A,9$4E"1A]H>?79_#"
M$\"3C4&DZ,F]__O6>>BB@C$H0=0AK*HN-G:V[LK@Z+1#49)KGQ_[F]1Y[(.<
M7]5Y[*.'#A[H![+2VH6L)%FC7G!+7)!LO%06O!%.VIJP;F[*/84ZC[V4.ZS.
M8Q])=XF7G1M$7A!F'A)4LY:L73)Y73 *?#2A>K=2Q-9+E9Y4G<=>>AY:Y[&/
MT#L SY#2 AY0:61TIF)4Q%)A$"5/D$UPT9H@Y0COV%.M\]A+_P?4>>RCC [P
M=5_I04E:.VTB8- )5.&B3C@50#=U-)Z54FQKJ_#IU'D<@Y]CA=T!7F[M]+C^
MY3_GN"*B/G_?;!K;E>@Y(3)Q97CM.ZL3&@(&!&L8YRSHDK%U[^8PROJJ_3C&
M.!I!$SWAZ];HH_7/_%WEIFU1R1D.*6( Q1T#)Z(!AT2:DB30YOF5O0CL9$1W
M0X0,F%351ET]87$[:VLC,;&[MFW!R)1VH(D7$EIEQ:L$J%QQSJDH>&O;_1%R
M.L%9>Q \!+<C-=(!N)Z%\[!(^.$SXL7K^F]?>3TF.IU#E*!-+215O$#P.8&T
MV5AM3(RY=17!0[3T565RS&/91-J=HN9J(H0M/&>&((JO3=5*05#&@>>."Q^4
M=]@Z/?0P-=->2&VT/0!"!XB^ Q!M5IEOVU,OM@NLKWH41"2GA@@W3I-XM-'@
M8LIU8*2(G!693>L"_X=HZ0] A^AZ.8+@>P$0.;/I/E8*,[X4!S;YV@#*(OA$
M)XY.GLM"HXRA]52-1\B9UMT;$T8-Q-\!DLY2JFG3];OPO;[Q9XM,?[*Z)#IN
MS^7=<L:D<2PZP%PY$P7I^<\,.!I9;&#!8>ME,\.IF]92&@EG(RFG ]C=.4$_
M\Q.RYC'R "FP.E[+!HB,F%)"2,>$TY&/\A(^0M.T15JGN<J.4T0'P+JW-,G3
M VZ8A&2, L447<G6>F!>1&0\2Z9:;V[LOL;O&%_N6!EW!9/KB,;;6Y5#FQ=]
MYD6RR9*+(E.JVX(= SH)#(3S67&7@E#CU?L]3%<OY04'*O]!,#721/_HNEX+
M,&/>B.(2/=/.TI6:LR,[L5@H)C//<PFAC#?HYG':>LG3G 1EAVGD25><OB@%
MTY0%IH,(.%T]Z?[RZ*!\5&J7(G<">*A;PPW2O9B+@D*VO\10N,2_9?GHK4]?
MC1=\]GU'P7O<[H)9?YY_??;]U8*@@!\(-INLR)7E_.S[0SW<NW7L0LH<Z=PK
M48M(HN40C)/@,&;+LC.86[<*G8Z[7@R(<?$^9%1#!^CIP%QYH/HO>"<,"@<N
M9/+\HM+@9:2G4)A$;) EEEN[37W7T_:%FV&ENOLHL4LH[F(<GC.5O<D0T*4J
MFKIGACP G6TD4DWQV'J"S9,JU=U+ST-+=?<1>@?@&30%C'N+"A6IVY%][S39
M]YHK(/DYB4)$C?]G1\9!^C]D)-L>RN@ 7_=5C]:]?4H8 YG(KRME/;A$<K(Y
M(7<E9NY:>_!/IU3W&/P<*^P)\;)>7<S>K9;Y,EV\77W U;=YPNU,#I6"CG4$
M(=,5[\5 C$C_X,E8D:QV=I!%11^X!13ZW0U('OIV+^&<+FVH)@KK W#5D]IQ
ML+X:]J"Y"REP,@@8G1HN//CJ.06IM10R2"D'%00,0]W/!$SSN+71Z<\ .5+
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MMR@A%*]!&3I\#C,"#TC'S\HL4^OJU =(F29%?'*\M5!$!\_O?6GO!Z1EI<?
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M*@M5N+H;YFN OPEG\?4,N;V4T3W*'@R0QR#0UY5)I=25-XH5<(&D6C@WK.C
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M-U9:!Z"\[0<,X*Y83P:D$A!B7=MLD),HZ9'PO)!W4!PW9<S13(T .4YWX6D
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M1H'#6#":9.+=?=V-\?08=3T]<F,@K)EFNL/<K<C:]I=K4MK[JCH^(^*9\SR
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MCC*PL-&D1_R".XC%W]VB];GO'K@V;G@X3"OJI@ULW17(NA0LY.@)1P].:&-
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MJ[3:R+W;K++4>-A;6>8Q$X<F)-"8*+>))6%#M+73;L/DWE?E?Q5NRE<;^YX
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M@^40SY0UO/I5PU8!]H"R'B3<XD'Y;O(=Y3N=_1A9[<MB00%41.0DX;EO<@S
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M<,5?V%I\7)9Z1?<):SIDEI(CU+I(I!""! !+F,=O@]8N\+%O6%Z=5!VH[0$
MSV[_QI1&N_ JY&S"!$+*2BI)HJ%0.G])W+HJ3Y++P#3N7WEF[P.OQTG5UF2C
M@F 8Q':42&T__-#/)LNOY0KF-[B#27]3%N;IK+^<^>LOTTUF [/*)L4S42QY
MY)=TQ(?LB;71\ZRH#GI85?Q!PS6)GEWEV^^5V2W#Y_S;IBZ#\!!24(Q0JFTI
MTJ=PMP*4",J"*;T)E1GF00T:KO;=:Q7X[,;L!@S<2\5B=$P"G),D"8,.9HHE
M4ELD$D0,FFOF*!O[=K^ILD[[]Y7&X'RC /JQPDS.*EH0ENC$.2I4FHDUHN0=
M,)F-5 JT> <H_1=4:-I*]%M7:-I&#K4-V_E5-TNG?K;8Q,=FBXR@-!+A-%IE
MI@RQSFA\T2(J7;3KL*/)IT]N#PEOD%H_%@MKR_\7FO?Q%%9(Y4%9CY9<,")I
MDL3SF-"FT\1C#)$^[1.Y_<G0\591OJ-'[NS/#.V'S0T8I-+&^)&2Y>%\T5W[
M!7S)I_B'TNNJ_.#"NB"X 4Z,,8)(,,@\ZRD!*[E3/AADW,A&:=#$VCP9VA$,
M_;XE4U]-;78;FWOE,_#S?HJK<KDAZEG\S@',%JC9O]M$E&+"<'D[*4,M/\1%
M=[=*1"D"@=FJ&T4)^<%?/92L?@C_F5\H%H41I0.@8;B?@83\"ER1S"0%#RR#
M&Q8)U@ Q;?KZ;T-_*[S="B@-Z/'3VUF\\G/X$B;=Y0H#%Y)IH8 #T6;5;2 Y
M$CS51*&FD R8D..'U3R;19N.P#@:^HT\;Q(UO]W"T?0S_+4X_P:3.SA!KEW-
M+ZARG)?L/F=M"?-1CMC,$V&@T3O&[9>F8]O_@5.K$S);"U]OE\[^ R+6?R@O
M 2?_][_]!U!+ P04    "  VBUM6.-U& ?H"   *"   &    &)M<FXM,C R
M,C$R,S%X97AX,C,Q+FAT;<U56T_;,!1^WZ\P18--(O<T:4*I!"UL:, JZ(3V
M-#FVTUBD=N2X+=VOWW'2<AF,/6P:RX-UG'/[SN=CG_[6Z/-P\G5\C H]*]'X
MR]'9Z1!U+,>Y#H:.,YJ,T,?)^1D*;==#$X5%S367 I>.<WS109U"ZRIUG.5R
M:2\#6ZJI,[ET3*C0*:6LF4TU[0SZY@^L#-/!F_Z69:&1)/,9$QH1Q;!F%,UK
M+J;HFK+Z!EG6VFHHJY7BTT(CW_4#="W5#5_@5J^Y+ME@$Z?OM/N^TR3I9Y*N
M!GW*%XC3@P[OTBPBD9]E&>V%V$\RG&5!-\AC2FG@QL$W#T Z8-[ZU'I5LH/.
MC NK8"9_&OIVW*WT_I)37:2>Z[[M-*:#?BZ%AGP*_%NQ#?,DF&:WVL(EGXJT
M*:G3NF[41)92I=MN\^T;C97C&2]7Z>ZAXKC<W:N!?*MFBN>MNN;?69H IF:W
M;''&X%QRP3:X/=\@/;XM>,:!Q<#V'L-\6"U64RA8RRKU>A#V 6 "##/U+Q$/
MI:A->\@<G0K**@8+;"_9E-< !1IF/,]*3M A(7(NM&F>$ZYF?US=,T?YTC'?
MZ?XR*^&SK%PS1-;$:(ETP1 71*I**FQN)<I62+$<Z!'$J!H+U5"V-J@U7#9S
M7VKT[D+:* @"RPNB) KV6CGJ=;O^6NYY41)OY%[DNVLYB>-NTLJ^ZW7=<"-'
M;K*1O5Z4=-=R$/J!MY8CO^>'[Q% .9%JAJZL'L*"OHSU'JKO^4G\R#TP'2+G
M"ER!!2B+-J_)"<O4'*O5SK87N?L^5&$>D#VTY+H T[IBY(Y"PZ@L>>N8<X$%
M@7-Z2!6D..+R'"N .2ZPFF'"YIH3L#H5Q&XJ,)%8GD-<OF""U8T7-XT%CZ7)
MH94LD5PP]2!'"QIZU_Y?.VYG.XSWZV9%G\;G']#9V?@U\5QA.'IEZ*N)W$-#
MN,&Y5(+CUP3U?+?]\BGZ::14LIVIJ6(E-MWS9,AL'#.IM9RE[KT+SJ!UY_JI
MRV_FTGIMIV0SKP<_ %!+ P04    "  VBUM691<OF>T'   1)   &    &)M
M<FXM,C R,C$R,S%X97AX,S$Q+FAT;>U:^V_;.!+^??\*KH/-IH!?\J-.[#1
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MN$$D2SZ12KH%A>?;U-(N\A#SZ D;X(KH1@+IP\%E-:&B- 6BU_IT(HZU$=X
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M+"VOOSLZ=CCQ@_O@+>WI0]+>JI Y<E\A'ZI\Y JY>I87VOIJ_?!O4$L#!!0
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MP,E0PP^I&@&F4(@U<,7L78-J356@$-"91*'TIPI? 1 :F\1I=+='!TS%MMQ
M17R'*U^7$G96,HK B@(IHREKV0VETOK 6J,*-99B#,=N9([8N%5-#?D<?:"U
MF=A?GAP>G7Z12EL8N*D+^?/FX1&IM4SV(N5?[)D4J+F#ARU'5IWX'TY#;4>1
MG)[HA/9/+YW6IP$M>3I6*;F@3I_26?''+LAT=-3<;[4QSI3!^K/03^Q"4$T*
M0>UFX?QG!T?-X^/E'[>:[:6?/3#L4?MQP^[2DGG90!@+ZN)?6_M;,[0C\K::
MSX$<PII(A\*SG7L@,Z/%G[L#.MD;?1+M>J0-!YTCKAFMR"I1[.VMQ-GU"%WG
M:\1-WE<#U\Y+0)UC'3W_ JE(B_\U8K:0E'^?()[@:S2?XEQFZL<XIT*]+9_V
M1SW*KLED)*Z+< HB(O&:X=%G'N[7H.(W.?]=,C)_&<RO\EA^>=)^UCJ=_Q?C
M$71$$PWN)\820UQ=Z9RJ,>:,=%\$0YD,%/F@@1QI/&6;I7F0Y8!<$2Y8#8N5
M*;]A"2Z,4C/6(0]VAQ@-H.UQ%6<\*N50)]=WYC*]V@27Z;T"4B0#<8>AG3Q2
MWW)-B\G D:^2T\:P(N2*?@Z_Z#A6H0;M'TV!9;1)/4SMZQ0>DTF2 [?%2M$F
MZEX1&OCV\U/+P=JAB4"F/4[U4:_2O#1*O M<"=P($"&%H1(8.3>Y!2Y-QSK
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M*Q@9K:+#2NQ4%C#1LPMQL./MB@@@#(-?$^"N@;;,C"06_%!)D$Z H6Q,>8^
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MB&.9P$K$]F2H2%7 O@R0J'!E6'.6XS]E*>92%[^VTA,'/1CD#AQ1&1*K?3<
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M0'#Q57Z/9?ZC1V:IW:1'!\WC9]\*)RY=1^W?G@FG\)]A%D<O_Q]02P,$%
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MZ]9?WIR)/^=<85"5$E449JU,"90-OC,118/R4>4!O P(&B1 @ "+(SJ6#NF
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M.),C%V?B/C37DFI#O&BA^_1U9'+ 4)V'*FO[<]FIPA=J^I$:(BD1Y@A&F81
M2NJ!=O8;TH$$P1,5_%*;',!]5H>DZD?T&E;KFTS5<&S2:O?H6D1,EK2H@P(6
M=>^=!Q!'A.8),HNMS\#/Y_@M*Q<"?K/L$#!N]XW/2KZ5HR5X))1LQ>#6 %4
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MB+PRLQAQMA0_29V*MS+]"%O_14:%XJ!4:. K;(0B;!>BIU.E7>C9F3/)(%!
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MU(!WR*<LT]:F8A$GA0W .^>LZRI$V>4G]KPR+^SB38"H&0PZ<W24EQN/%#F
ML$3?^G(FK?S+"?%"J++ *><0Y8#N%\[$"'%5O\(L+"C(3!0?Z8%B#Z-/0A;8
M_%??4'',=Z]B#'%0U9&K+@,:-F3:> =P? 4GR$"%8TP(PSTD".V)4-(Z_Y,'
M9N@L,1G^EBVO)%+A/7]I.$WP>X&T0$.>'\D8]B(V)T/EH@@&(%MF=%@65^MO
M,1"XY,/MK0JY &0"!RLJ+1[9^@[K(&-@(T/Q=X;A;#H-=Z>[\W0H!-*QV^YX
M>Z8-N87XE+HE.6!M/HQ[H$B'/8WD1[8]66*H\=2&T);8*9-(@,E3_R5H1[G\
MD_!RLE\\2>1[-BK'*J? </R*K(]$Q9FT_70GS\&8P5*@%,<6DC:[-: ,'W_@
M%J#ZVN2HB4#;Q[03H#',9=X[7R* 15()YYB9.%,9,C7+RK.:9KP$Y#>>#V75
MIM7%%)$<<U@(=3$VS!C@Z:#,KA+M-QBF9(?:'IBKZQSM&1OH+!0)[]_&!P.0
M#WV) 40;&_0Z<RB&EI%2YE/5[1:*<$\4'BOSG0]<:O?X>2;<VB(A#+=Y4Z[+
MY]EFM%5K]"&;UP7X.S4C!;N.;" [P[<_8.VBZ/0L75M%RB84JH:@-GVC>09M
MB36WQ,I'><JVR.7*A03Y5]>4"WG\FD=F>YKXA:TQ3-@EWXRDCEC75IY[(UP/
MG(OIG@2L!IR&$6&*BQV3/@Y+==&&AY8D_Y^]'0!/2DT#L1C =UV<P<]==+R\
M1R"Q&MK9W=:CL$M(7 730VD^)88!09"!$0V$AF'3 KR*;.A.Y&+>^%U8?I*2
M@?.4:?NGE8=260%>R%QBZ'\L0>PQN1%1G(.D6<6TMBY/?.*)A^H32G&-!,%A
M,3GJZWNL^8'?!+S#2@-&$8OHCBB</UY:>DB3^'%J8AU4IA<6973*JD+.[V)6
M"X%"#G\6@$7N[/Z:HNSSGD!/HB6- ;!2Y73J7,B&_-D . 9-MXQR AP[ #<Y
MPQF929&B)4VY/JP P3>0A>[RT;:\!)8"*UK>EVY XD;=^,D9JY80D"0TR&J8
M32_1QO+:SI /,8(G I5BZ7H%$ATCK/@ULH]N!KS?\_0[(%-R4GKD?I#DZ%0A
M0["NS:B2'[0?0$@R1!G R:1.6>+9UVD^!.O<!)K>G!4IZ6&7='+8HS)M/=#6
M8G?+@%4/EE!'<*T8^3X=\;OI<]DW!V_K \+0R >+(S=I-M0)BMNH=/7**H%0
M 40BCF" O'3MQ=8)X!WA?G)&'RG]=ETO<>8C>E8!'BO"?W$14J?J]<)#%GEI
M[VG;V#608Q2QCH+^#-V4D[LVUZ_I *71*J=\MK$,24AK ?NN,+6PHC>OTY#Y
M$$=S@I_) 2%+/B5:7.:@*C A5G*889KQ[,I.R; 9F<,ZT11 <W$Q4_K61!@!
MFNM(]5CO%65J@B*T(VJ,7ZY2V;W\%/,]YDU"/8#CX59(!B96,92Q/S"T<^6*
M#[";P7]YMQ5^SB#&"!FFU"7%S"K3 <5#.=,4I8,JHX3@CR-!R\@'@(41H:5/
M:@!<ZKP*C!B<VSPL *IH-L.OT(!*50(_,!K&BC<JBWQH4J"3.G HBVU=G0YL
M 3>4D4[!Z!])15^WE)MY0,DT6#;["V6]'W#EK/\?!7A#>46O5+J -MB%U6RE
M1T=12R9FT4_-1Q2@J/7,!%M<_#!%1>@V2CP9NDJ2=C%7NHOU 'X]AF(W$BIR
M&5783D.T;=?P2M*90E]PD,C@H3,*P"D,HT@N6RE!Z\/58[<'U><"4B:3EIN,
M4+.-M9I8"BAIO*KWFE6<MH H=2U$-OZ#V /85 OIE&-)U;EH;O;(T2@!!="3
MJ@$:/(93FF$J)RXDD-%7O_'ZS;WO]9M/NG[3C6.V463T*<N<?& R8/"Z%JC\
MP\]5"!6[H[DZ46,4AL3XQ&(R\GE,TMAOYX2@&).@.H.<7^HZ?:E S\D859<P
M/[FV0%]$F+AB7G2& Q:LM*C;!2SJWCMO0QR'FJ>*+;0^ SY/V--^O6)/^XBC
M2*_+3.D;.5F!6XU)8(VR-T$CAHU1\.Z(\N+ FHH**3'P;-&:RUL&BCCK6]71
MTKJH[%Q:B].XUIV[ (TRP;2]XUJL/$QMM J#0SF-#"M-TG@ ?G2^;0;;M%Q:
M1 K3.$\ZW_'SRD.9'.ZY DS=L^^Q$AJLT1/**O"7BUQQ5)Y'_H#=6<985#[!
M,B.RFZV'-5M)!6NZ:@:,9A88LU A^A1 K5S&72Z9N4QK4&2<+VA[!VPLL,Q*
M5K/+48PPU9=^H3!\W(K-59=LEL/AYA1LWEQ<_71U?H:3^^<7;*X6B VJM1[+
MR("OK#E2X^ZS\=R"]H(\5OV<7*S7?9-JYCH<UNR>&6,C#?Q&&^RBAV0X1EJ/
MJ/S>5:]$SA+)K-50%BB:/H#0UJZT)?^6NC"KCH#%<P)73/R_K)CV'RA6OKX1
M[ZY>_WPG[F[$^<WUW=7UAYL/[\7[RW>_X+T6RT]?7(B+QQRLZK6[N"!S[.*C
M@V:L&2C/$B0;$OC%^N2%,E)I9M+4; )C [#UY!7X^V9:+ZS(;%-Z2Y:*]E1N
MAHV?V-L^O3:>?2^;0&3O8)S,.27@*U9OX1K@QJT3+<'V6F7'O %#M4A#>ZX<
MK*19SEU_]EPU=QX_U$QP=OZOZYM?WUQ>O,:K[OZ$=EIGZ&/-0O Q-A,L?FK6
M;U+&%VF>U,SB.SS^LM.OU#Y?]4@RS,>6,QU(^&#M7X:3?'6&0S/')BK &4\U
M5_S5,E,ZQV]7#9VV#@CDBIM@V[!9.LYB09&2)6R\F&K$0JW%TY425&*H6#0Y
ML#S [,4PBP>V+$\13XRR5DU:1]Z4,[I J1&"!Q0YZF(]98) 9AR])F_)M3/R
M3;L<A3-8;\8]H*6^+9M?;.1?# JF0,QW9I2:ZJM8#30WQT9:%;@58S.IV#2
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M3$5D:-+RR^H-E'C>LO;%3I_QS^\6G$C"(+M5=<*BX67*V_-3S-B\FKI6YCE
MLCD#&LS3+Q$218Z,O3;-VA7BWC!>,R-]ZP_QF @TZFR/T$B&.)C?N48M[:QM
METSUD6JITMV5/I5YO;(^*NMX!;<=KD-J#L!P]ULA"3-/8NX?3X%_DW5031WD
M&G>3T+C9QAUB7L^./5@)3#<!+A-]';/KA@4JMG4(%QUHBM76XG F;1X'P?.-
MUP+O?Z\%_IQ:X-6*F_HH%QY!#W*?*NR)GDN_W>.AEK03=VA7KJ&-:[A"PWH%
M6$-"M4S0,I5:KL: S)%LK#7(3S314Q3YOZRZ?NS!&IIKGGIT=GM[>7UQ]>\_
M!>-E[C-]W!N*9Z8]^!0V9\9#6T##)GX;DVHQ.8-=56A LDH#$N6.E6QUEUC"
MT1>68R28J-:?'O<B.,)'66=:R8)-K^4*YTJ$..Q/;E&4L-X3]QV&!$._20T=
M PNQCE<%/,>(6[;>]D_?7OPW/K5JZ;UJ\;WW4)'5W=F_Q:]7=S__?//FXNKZ
M-7N ^,NKM[=OYA8&KS_HWU&/ ]?)L+TAK?=9#PM[.3B<C86?KE];M@V<IRMK
MS1:Y_-A2^^]J.<EU"W# 0"X_S0X.P$S.% RPB#^N.EKEIVVR(=&?S]7(6I3E
MU)-%B6Z:_0<XIG+KFO]*5]*M'P[OX+#O[/&N\+ K0Z:-%935AZKJ4,?H%M:Q
MBTB[#KJ!1?#,_NE.:?+&<<:Y*W8'XL! H'W8U;[Y@]AIL)6=7V\'7E)'<?L4
M?D?ZW"$X*%(>8M.V>2_TY2YI\5>@NV)H0%QL:NUUUELG7 &=@_#,;(M4>1DI
M%EZ-/-^E!1CML[@D\THC OI $K@T)GDNA8VXA0MCY/[8TS\;9Z\F -%DOMFY
M&8'M5O>#)Q12*]_NIK!ZER?P2#(WC=E#CO\!WM6HQ_#2.,^\BQ_QKAQ[H51
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M+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  VBUM6AP3]#VVI  #LN@
M%               @ %3_04 8FUR;BTR,#(R,3(S,5]G,2YJ<&=02P$"% ,4
M    "  VBUM6UY("S\B7 0"YIA  %0              @ 'RI@8 8FUR;BTR
M,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ -HM;5DL.#59<]P  33P+ !4
M             ( ![3X( &)M<FXM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( #:+6U8XW48!^@(   H(   8              "  7PV"0!B;7)N+3(P
M,C(Q,C,Q>&5X>#(S,2YH=&U02P$"% ,4    "  VBUM691<OF>T'   1)
M&               @ &L.0D 8FUR;BTR,#(R,3(S,7AE>'@S,3$N:'1M4$L!
M A0#%     @ -HM;5G$6FO7S!P  !R0  !@              ( !ST$) &)M
M<FXM,C R,C$R,S%X97AX,S$R+FAT;5!+ 0(4 Q0    ( #:+6U8A_D<AZP4
M +47   8              "  ?A)"0!B;7)N+3(P,C(Q,C,Q>&5X>#,R,2YH
M=&U02P$"% ,4    "  VBUM6-$C)^E<#   T%   %               @ $9
M4 D 8FUR;BTR,#(R>&5X>#(Q,2YH=&U02P$"% ,4    "  VBUM65Z'.SN\8
M  #4AP  $               @ &B4PD 97AH:6)I=#$P7S,U+FAT;5!+ 0(4
M Q0    ( #:+6U;DDH'; 1X  +NI   0              "  ;]L"0!E>&AI
M8FET,3!?,S8N:'1M4$L! A0#%     @ -HM;5JX]=*24(0  =,4  !
M         ( ![HH) &5X:&EB:70Q,%\S-RYH=&U02P4&      \ #P#@ P
&L*P)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
